This page intentionally left blank
APPLIED PHARMACOLOGY
for Veterinary Technicians
Fourth Edition

Boyce P. Wanamaker, DVM, MS
Director,
Veterinary Technology Program,
Columbia State Community College,
Columbia, Tennessee

Kathy Lockett Massey, LVMT
Veterinary Technology Department,
Columbia State Community College,
Columbia, Tennessee

with 150 illustrations
THIS BOOK IS DEDICATED TO:

Tippy, Mammy, Meghan, Skye, and the other dogs of my past and future for their unswerving loyalty, affection, and companionship.

Doris and Preston, my parents, for a lifetime of encouragement, discipline, and love.

Karen, my wife, for her emotional support and editorial assistance.

The students with whom I have had the pleasure to share knowledge through the years.

B.W.

Thanks to God for the loving miracle of my parents, Harry and Bettie Lockett, who chose me to share their lives with.

To my children, Eric and Darla, you are the light of my life.

Try to give back to the world more than you take.

To Dr. Wannamaker for his patience.

To Dr. Frankie Locklar for teaching me about tolerance and other life lessons.

To all the technicians and students I’ve worked with, don’t ever forget that we are not just helping animals, but people too. If an animal can make a person laugh, our job may have a twofold purpose.

Perhaps mirth is the epitome of human health.

K.M.
Applied Pharmacology for Veterinary Technicians, fourth edition, is designed for both the graduate technician and the student. As a teaching and reference book, its purpose is to help veterinary technicians become familiar with the many veterinary pharmacologic agents and their uses, adverse side effects, and dosage forms. We believe it is very important for the technician to understand the uses of pharmacologic agents and to have the ability to provide client education under the supervision of the attending veterinarian. A key feature of this publication is a format intended to provide easy and quick access to chapter information. Each chapter is introduced with learning objectives, a chapter outline, and key terms with simple definitions. “Technician’s Notes” throughout the text provide helpful hints and important points technicians should be aware of to avoid errors and increase efficiency.

NEW TO THIS EDITION

New features have been added to the fourth edition to aid the student and technician in the study and application of pharmacology. Chapter 2 has new and practical information on performing calculations for constant rate infusion problems. Chapter 16 has new and updated material related to neoplasia and antineoplastic drugs. Chapter 18 has a new section on herbal medicine and Appendix D has updated information on regulations that apply to controlled substances.

NEW TO THE EVOLVE SITE

Evolve Student Learning Resources offer the following new features to reinforce textbook content and help students master key concepts:

- Drug Administration Videos—12 videos demonstrate drug administration techniques (oral, injectable, inhaled) and IV preparation for dogs and cats

- Drug Calculators with Related Exercises—Six drug calculators with accompanying word problems help students perform accurate drug calculations

- Drug Label Image Collection—137 photos of drug labels, divided by chapter and organized alphabetically, help students become familiar with drug information and packaging encountered in practice

- Animations—Animations of pharmacologic processes, such as passive diffusion and receptor interaction, help students visualize and understand key concepts

- Dosage Calculation Exercises—Exercises reinforce calculation skills and provide valuable practice in the areas of:
  - Drug Calculation Methods
  - Oral and Enteral Medication Administration
  - Intravenous Infusion
  - Critical Care Calculations

- Answers to Review Questions—Answers to chapter review questions allow students to gauge comprehension of key topics

Our intent in writing this book has been to combine the comprehensiveness of a veterinary pharmacology textbook with the coverage of pharmacologic fundamentals needed by veterinary technicians. No longer will veterinary technician educators have to draw from two sources for this type of coverage. The scope and organization of the information in this book will make it a useful reference for the practicing technician as well.

Boyce P. Wanamaker, DVM, MS
Kathy Lockett Massey, LVMT
We are inaugurating a set of features and design elements that will be shared with other vet tech titles on the Mosby and Saunders lists. The purpose of the “Vet Tech Threads” is to make it easier for students and instructors to incorporate multiple books into the fast-paced and demanding vet tech curriculum.

The shared features in Applied Pharmacology for Veterinary Technicians, fourth edition, include the following:

- Cover and internal design similarities: the colorful, student-friendly design encourages reading and learning of this core content.
- Lists of Objectives begin each chapter.
- Technician's Notes boxes appear throughout the text to emphasize information particularly relevant to the role of veterinary technicians.
- Key Terms are in bold the first time they appear in the chapter.
- An extensive Glossary of the key terms is at the end of the text.
I would like to acknowledge the editors and staff at Elsevier including Teri Merchant, David Stein, and Shelly Stringer for their support and assistance in making this edition possible.

I would also like to recognize veterinary technicians and veterinary technology students everywhere whose desire for knowledge and dedication to quality animal care have made animal nursing a true profession.

I also want to recognize the technical support and expertise of Stewart Marston in the production of the video clips for the CD-ROM.

**Boyce P. Wanamaker**

I would like to thank: Boyce Wanamaker, DVM, Columbia State Community College; Mary Kirby, LVMT, Columbia State Community College; Bill Henson, DVM, Henson Animal Clinic, Corinth, Mississippi; Jim Jackson, DVM, Jackson Animal Clinic, Corinth, Mississippi; Forrest Cutlip, DVM, Milan Animal Hospital, Milan, Tennessee; C.F. Locklar, Jr., DVM, Maury County Veterinary Hospital, Columbia, Tennessee; Martha Locklar, CPA, Maury County Veterinary Hospital, Columbia, Tennessee; Steve Grubbs, DVM, PhD, Princeton, New Jersey; Robert Myers, DVM, Maury County Veterinary Hospital, Columbia, Tennessee; Christi Cartwright, LVMT, Maury County Veterinary Hospital, Columbia, Tennessee.

**Kathy Lockett Massey**
CONTENTS

1 GENERAL PHARMACOLOGY, 1
Introduction, 2
Drug Sources, 3
Inactive Ingredients, 3
Pharmacotherapeutics, 3
Pharmacokinetics, 5
   Routes of Administration, 6
   Drug Absorption, 8
   Drug Distribution, 10
   Biotransformation, 11
   Drug Excretion, 11
Pharmacodynamics, 13
Drug Interactions, 15
Drug Names, 16
Drug Labels, 17
Development and Approval of New Drugs, 19
   Regulatory Agencies, 19
   Steps in the Development of a New Drug, 21
Federal Laws Related to Drug Development and Use, 21
   The Animal Medicinal Drug Use Clarification Act, 22
   Compounding of Veterinary Drugs, 22
   The Veterinary Feed Directive, 23
   The Minor Use and Minor Species Animal Health Act, 23
Dispensing Versus Prescribing Drugs, 23
Marketing of Drugs, 23

2 ROUTES AND TECHNIQUES OF DRUG ADMINISTRATION, 27
Introduction, 28
Dosage Forms, 28
Drug Preservatives and Solvents, 35
Drug Administration, 35
   Oral Medications, 36
   Parenteral Medications, 38
   Intramuscular Injections, 46
   Subcutaneous Injections, 46
   Inhalation Medications, 46
   Topical Medications, 47
Medication Orders, 48
Controlled Substances, 49
Client Education, 50

3 PRACTICAL CALCULATIONS IN PHARMACOLOGY, 53
Introduction, 54
Mathematics Fundamentals, 54
Systems of Measurement, 55
   Metric System, 55
   Conversion Between Metric Units, 55
   Apothecary and Household Systems, 57
Dosage Calculations, 58
Solutions, 59
Percent Concentrations, 59
   Calculations Involving Concentrations, 60
Milliequivalents, 61
Calculations Involving IV Fluid Administration, 61
   Calculations for Constant Rate Infusion Problems, 61

4 DRUGS USED IN NERVOUS SYSTEM DISORDERS, 69
Introduction, 70
Anatomy and Physiology, 70
Autonomic Nervous System, 75
   How Drugs Affect the Autonomic Nervous System, 78
Classes of Autonomic Nervous System Agents, 78
CHOLINERGIC AGENTS, 78
   Direct-Acting Cholinergics, 78
   Indirect-Acting Cholinergic (Anticholinesterase) Agents, 78
CHOLINERGIC BLOCKING AGENTS (ANTICHOLINERGIC), 79
ADRENERGIC (SYMPATHOMIMETIC) AGENTS, 80
ADRENERGIC BLOCKING AGENTS, 80
   Alpha Blockers, 81
   Beta Blockers, 81
   Ganglionic Blockers, 81
Central Nervous System, 81
TRANQUILIZERS, 82
   Phenothiazine Derivatives, 82
   Benzodiazepine Derivatives, 82
   Xylazine Hydrochloride, 83
   Detomidine Hydrochloride, 83
   Medetomidine, 84
   Romifidine, 84
BARBITURATES, 84
  Long-Acting Barbiturates, 84
  Short-Acting Barbiturates, 85
  Ultrashort-Acting Barbiturates, 85
DISSOCIATIVE AGENTS, 86
OPIOID AGONISTS, 86
  Naturally Occurring Narcotics, 87
  Synthetic Narcotics, 87
OPIOID ANTAGONISTS, 88
NEUROLEPTANALGESICS, 89
DRUGS GIVEN TO PREVENT OR CONTROL SEIZURES, 89
INHALANT ANESTHETICS, 90
MISCELLANEOUS CENTRAL NERVOUS SYSTEM DRUGS, 92
  Propofol, 92
  Glyceryl Guaiacolate or Guaiifenesin (Guainex, Gecolate), 93
  Chloral Hydrate/Magnesium Sulfate, 93
CENTRAL NERVOUS SYSTEM STIMULANTS, 93
  Dextroamphetamine, 94
  Pentylentetrazol (Metrazol), 94
  Caffeine, 94
  Amphetamines, 94
NEUROMUSCULAR BLOCKING DRUGS, 94
Behavioral Pharmacotherapy, 95
  Pharmacotherapeutic Agents, 95
ANTIANXIETY MEDICATIONS, 95
  Benzodiazepines, 95
  Azapirones, 96
ANTIDEPRESSANTS, 96
  Tricyclics, 96
  Serotonin Reuptake Inhibitors, 96
  Monoamine Oxidase-B Inhibitors, 96
  Synthetic Progesterins, 97
EUTHANASIA AGENTS, 97

EXPECTORANTS, 105
  Guaiifenesin (Glycerol Guaiacolate), 105
MUCOLYTICS: ACETYLCYSTEINE, 106
ANTITUSSIVES: CENTRALLY ACTING AGENTS, 106
  Butoxphanol Tartrate, 106
  Hydrocodone Bitartrate, 106
  Codeine, 107
  Dextromethorphan, 108
  Temaril-P, 108
BRONCHODILATORS, 108
  Cholinergic Blockers, 109
  Antihistamines, 109
  Beta-2-Adrenergic Agonists, 109
  Methylxanthines, 109
DECONGESTANTS, 110
ANTIHISTAMINES, 110
CORTICOSTEROIDS, 110
MISCELLANEOUS RESPIRATORY DRUGS, 111
  Respiratory Stimulants, 111

5 DRUGS USED IN RESPIRATORY SYSTEM DISORDERS, 101
Introduction, 102
Respiratory Anatomy and Physiology, 102
Respiratory Defense Mechanisms, 104
Principles of Respiratory Therapeutics, 104
Inhalation Therapy for Respiratory Disease, 105
Categories of Respiratory Drugs, 105

6 DRUGS USED IN RENAL AND URINARY TRACT DISORDERS, 114
Introduction, 115
Physiologic Principles, 116
Renal Failure, 119
Drugs Commonly Used for the Treatment of Renal Dysfunction and Associated Hypertension, 120
DIURETIC DRUGS, 120
  Loop Diuretics, 120
  Osmotic Diuretics, 120
  Thiazide Diuretics, 120
  Potassium-Sparing Diuretics, 120
  Carbonic Anhydrase Inhibitors, 121
CHOLINERGIC AGONISTS, 121
ANTICHOLINERGIC DRUGS, 121
ADRENERGIC ANTAGONISTS, 122
  Alpha-Adrenergic Antagonists, 122
  Beta-Adrenergic Antagonists, 122
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, 123
VASODILATORS AND CALCIUM CHANNEL BLOCKERS, 123
ANTIDIURETIC HORMONE, 123
URINARY ACIDIFIERS, 123
7 DRUGS USED IN CARDIOVASCULAR SYSTEM DISORDERS, 129
Introduction, 130
Anatomy and Physiology of the Heart, 130
Compensatory Mechanisms of the Cardiovascular System, 133
Basic Objectives in the Treatment of Cardiovascular Disease, 135
Categories of Cardiovascular Drugs, 135
POSITIVE INOTROPIC DRUGS, 135
Cardiac Glycosides (Digitalis), 135
Catecholamines, 136
Bipyridine Derivatives, 137
Inotropic, Mixed Dilator, 137
ANTIARRHYTHMIC DRUGS, 138
Class IA, 138
Class IB, 139
Class IC, 139
Class II, 139
Class III, 140
Class IV, 140
Other Class IV Antiarrhythmics, 141
VASODILATOR DRUGS, 141
Hydralazine, 142
Nitroglycerin Ointment, 142
Prazosin, 143
Angiotensin-Converting Enzyme Inhibitors, 143
DIURETICS, 143
Furosemide, 144
Thiazides, 144
Spironolactone, 144
Dietary Management of Heart Disease, 144
Ancillary Treatment of Heart Failure, 145
Bronchodilators, 145
Oxygen Therapy, 145

Sedation, 145
Aspirin, 145
Thoracocentesis and ABDominocentesis, 145

8 DRUGS USED IN GASTROINTESTINAL SYSTEM DISORDERS, 149
Introduction, 150
Anatomy and Physiology, 150
Regulation of the Gastrointestinal System, 153
Vomiting, 154
EMETICS, 154
Centrally Acting Emetics, 154
Locally Acting Emetics, 155
ANTIEMETICS, 155
Phenothiazine Derivatives, 156
Procainamide Derivatives:
Metoclopramide, 156
Antihistamines, 157
Anticholinergics, 157
Butyrophenones, 158
Serotonin Receptor Antagonists, 158
NK-1 Receptor Antagonists, 158
ANTIULCER MEDICATIONS, 158
H2 Receptor Antagonists, 158
Proton Pump Inhibitors, 160
Antacids, 160
Gastronomososal Protectants, 160
Prostaglandin E1 Analogs, 161
Diarrhea, 161
ANTIDIARRHEAL MEDICATIONS, 161
Narcotic Analgesics, 161
Anticholinergics/Antispasmodics, 162
Protectants/Adsorbents, 162
LAXATIVES, 163
Saline/Hyperosmotic Agents, 163
Bulk-Producing Agents, 163
Lubricants, 164
Surfactants/Stool Softeners, 164
Irritants, 164
GASTROINTESTINAL PROKINETIC/S
STIMULANTS, 164
Dopaminergic Antagonists, 165
Serotonergic Drugs, 165
Motilin-like Drugs, 165
Direct Cholinergics, 165
Acetylcholinesterase Inhibitors, 166
DIGESTIVE ENZYMES, 166
MISCELLANEOUS GASTROINTESTINAL DRUGS, 166
  Antibiotics, 166
  Antinflammatory Agents, 167
  Antifoaming Agents, 167
  Weight-Loss Products, 167
  Probiotics, 168
  Appetite Stimulants, 168

ORAL PRODUCTS, 168
  Dentifrice and Cleansing Products, 168
  Fluoride Products, 168
  Perioctic Agents, 169
  Polishing Paste, 169
  disclosing Solution, 169

9 DRUGS USED IN HORMONAL, ENDOCRINE, AND REPRODUCTIVE DISORDERS, 172
  Introduction, 173
  Anatomy and Physiology, 173
    Pituitary Gland, 173
    Control of the Endocrine System, 175
  Hormonal Drugs Associated With Reproduction, 177
  Gonadotropins and Gonadal Hormones, 177
    Gonadotropins, 177
    Estrogens, 178
    Androgens, 178
    Progestins, 179
  Prostaglandins, 180
    Dinoprost Tromethamine, 181
    Fenprostalene, 181
    Flaprosteral, 181
    Cloprosteral Sodium, 182
  Drugs That Affect Uterine Contractility, 182
    Oxytocin, 182
    Ergot, 183
    Prostaglandins, 183
    Corticosteroids, 183

MISCELLANEOUS REPRODUCTIVE DRUGS, 183
  Bromocriptine, 183
  Leuproside, 183
  Melatomin, 183
  Neutersol, 183
  PHEROMONES, 183
  Thyroid Hormones, 184

DRUGS USED TO TREAT HYPOTHYROIDISM, 184
  Levothyroxine Sodium (T₄), 184
  Liothyronine Sodium, 185
  Thyroid-Stimulating Hormone, 185

DRUGS USED TO TREAT HYPERTHYROIDISM, 185
  Methimazole, 185
  Carbimazole, 185
  Iodide, 186
  Propylthiouracil, 186
  Radioactive Iodine, 186
  Propranolol, 186

AGENTS FOR THE TREATMENT OF DIABETES MELLITUS, 186
  Insulin, 186
  Oral Hypoglycemic Agents, 189

HYPERGLYCEMIC AGENTS, 189
  Hormones That Act As Growth Promoters, 190
  Sex Steroids, Synthetic Steroid Analogs, and Nonsteroidal Analogs, 190
  GROWTH HORMONE: BOVINE SOMATOTROPIN, BOVINE GROWTH HORMONE, 191
  Anabolic Steroids, 191
    Stanazolol, 191
    Boldenone Undecylenate, 192
    Nandrolone Decanoate, 192

10 DRUGS USED IN OPHTHALMIC AND OTIC DISORDERS, 195
  Ophthalmic Agents, 196
  MYDRIATICS AND CYCLOPLEGICS, 197
    Phenylephrine Hydrochloride, 197
    Atropine Sulfate, 197
    Homatropine Hydrobromide, 198
    Cyclopentolate Hydrochloride, 198
    Tropicamide, 198
    Epinephrine, 198
  MIOTICS, 198
    Pilocarpine, 198
    Demecarium Bromide, 199
  OTHER AGENTS THAT REDUCE INTRAOCULAR PRESSURE, 199
    Carbonic Anhydrase Inhibitors, 199
    Beta-Adrenergic Antagonists, 199
    Sympathomimetics, 200
Contents

11 DRUGS USED IN SKIN DISORDERS, 210
   Introduction, 211
   Anatomy and Physiology, 211

12 ANTIINFECTIVE DRUGS, 226
   Introduction, 227
   Mechanism of Action, 227
   PENICILLINS, 229
       Pharmacokinetics, 229
       Pharmacodynamics, 229
   CEPHALOSPORINS, 232
       Pharmacokinetics, 232
       Pharmacodynamics, 233
TETRACYCLINES, 234
   Pharmacokinetics, 234
   Pharmacodynamics, 234
AMINOGYCOLSIDES, 236
   Pharmacokinetics, 236
   Pharmacodynamics, 237
FLUOROQUINOLONES, 237
   Pharmacokinetics, 237
   Pharmacodynamics, 237
OTHER ANTIINFECTIVES, 238
   Chloramphenicol, 238
   florfenicol, 238
   Macrolides and Lincomamides, 239
   Vancomycin, 240
   Spectinomycin, 240
   Polymyxin B and Bacitracin, 240
   Sulfonamides, 241
   Nitrofurans, 241
   Rifampin, 241
ANTIFUNGAL DRUGS, 241
   Polyene Antifungal Agents, 242
   Imidazole Antifungal Agents, 242
   Antimetabolic Antifungal Agents, 243
   Superficial Antifungal Agents, 243
   Other Antifungal Agents, 243
ANTIVIRAL DRUGS, 243
   Acyclovir, 244
   Interferon Alfα-2A, Human Recombinant, 244
DISINFECTANTS/ANTISEPTICS, 244
   Alcohols, 244
   Ethylene Oxide, 245
   Formaldehyde, 246
   Chlorines and Iodines, 246
   Phenolics: Saponated Cresol, Semisynthetic Phenols, 246
   Quaternary Ammonium Compounds:
      Cationic Detergents, 247
      Biguanide Compounds, 247
      Other Disinfectants, 247

13 ANTIPARASITIC DRUGS, 250
   Introduction, 251
   Endoparasites, 253
   ANTINEMATODAL, 253
      Benzimidazoles, 253
      Organophosphates, 261
      Tetrahydrothymidines, 261
      Imidazothiazoles, 262
      Avermectins, 262
      Other Agents, 263
   ANTICESTODAL, 263
      Bunamidine (Scolaban), 263
      Epsiprantel (Cestex), 263
   ANTITREMATODAL, 263
      Clorsulon (Curatrem), 263
      Albendazole (Valbaben), 264
      Praziquantel (Droncit), 264
   TOPICAL SOLUTIONS, 264
      Emodedipir/Praziquantel (Profender), 264
   ANTIPROTOZOAL, 264
      Drugs for Treating Coccidia and Other Protozoa, 264
      Drugs for Treating Giardia, 264
      Drugs for Preventing Giardia, 265
      Drugs for Treating Babesia, 265
   Heartworm Disease, 265
   ADULTICIDES, 265
      Melarsomine Dihydrochloride (Immiticide), 265
   MICROFILARICIDES, 267
   PREVENTIVES, 267
      Imidacloprid + Moxidectin
         (Advantage Multi), 267
      Ivermectin (Heartgard, Heartgard Plus,
         Heartgard for Cats), 267
      Milbemycin Oxime (Interceptor, Sentinel), 267
      Moxidectin (ProHeart), 267
      Selamectin (Revolution), 268
      Diethyldicarbamiczin Citrate (Carbam,
         Filaribits, Filaribits Plus), 268
   Ectoparasites, 268
   APPLICATION SYSTEMS, 268
      Prediluted Sprays, 268
      Emulsifiable Concentrates, 270
      Monthly Flea and Tick Products, 271
   INSECTICIDES, 272
      Pyrethrins, 272
      Synthetic Pyrethroids, 273
      Chlorinated Hydrocarbons, 273
      Carbamates, 273
      Organophosphates, 273
      Formamidines, 274
      Nitrothymyl (Capstar), 274
      Synergists, 274
      Repellents, 274
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insect Growth Regulators (IGRs), Insect Growth Hormones</td>
<td>274</td>
</tr>
<tr>
<td>Other Insecticides</td>
<td>274</td>
</tr>
<tr>
<td><strong>14 DRUGS USED TO RELIEVE PAIN AND INFLAMMATION, 277</strong></td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>278</td>
</tr>
<tr>
<td>Anatomy and Physiology</td>
<td>279</td>
</tr>
<tr>
<td>NONSTEROIDAL ANTIINFLAMMATORY DRUGS, 281</td>
<td></td>
</tr>
<tr>
<td>Salicylates, 282</td>
<td></td>
</tr>
<tr>
<td>Pyrazolone Derivatives, 282</td>
<td></td>
</tr>
<tr>
<td>Flunixin Meglumine (Banamine), 283</td>
<td></td>
</tr>
<tr>
<td>Dimethyl Sulfoxide, 283</td>
<td></td>
</tr>
<tr>
<td>Buscopan Composition, 284</td>
<td></td>
</tr>
<tr>
<td>Acetaminophen, 284</td>
<td></td>
</tr>
<tr>
<td>Propionic Acid Derivatives, 284</td>
<td></td>
</tr>
<tr>
<td>OTHER NONSTEROIDAL ANTIINFLAMMATORY DRUGS, 285</td>
<td></td>
</tr>
<tr>
<td>Etodolac, 285</td>
<td></td>
</tr>
<tr>
<td>Deracoxib, 285</td>
<td></td>
</tr>
<tr>
<td>Firocoxib, 286</td>
<td></td>
</tr>
<tr>
<td>Tepoxalin, 286</td>
<td></td>
</tr>
<tr>
<td>Meloxicam, 286</td>
<td></td>
</tr>
<tr>
<td>Polysulfated Glycosaminoglycan (Adequan), 286</td>
<td></td>
</tr>
<tr>
<td>Hyaluronate Sodium (Hyalovet), 286</td>
<td></td>
</tr>
<tr>
<td>Legend, 286</td>
<td></td>
</tr>
<tr>
<td>Meclomenamic Acid (Arquel Granules), 286</td>
<td></td>
</tr>
<tr>
<td>Selenium and Vitamin E (Selenoc), 286</td>
<td></td>
</tr>
<tr>
<td>Ketorolac, 286</td>
<td></td>
</tr>
<tr>
<td>Orgonein (Palosein), 286</td>
<td></td>
</tr>
<tr>
<td><strong>15 THERAPEUTIC NUTRITIONAL, FLUID, AND ELECTROLYTE REPLACEMENTS, 298</strong></td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>299</td>
</tr>
<tr>
<td>Anatomy, Physiology, and Chemistry, 299</td>
<td></td>
</tr>
<tr>
<td>Distribution of Body Water and Electrolytes, 299</td>
<td></td>
</tr>
<tr>
<td>Composition of Body and Therapeutic Fluids, 300</td>
<td></td>
</tr>
<tr>
<td>Osmotic Pressure and Tonicity of Fluids, 301</td>
<td></td>
</tr>
<tr>
<td>Principles of Fluid Therapy, 304</td>
<td></td>
</tr>
<tr>
<td>Indications for Fluid Therapy, 304</td>
<td></td>
</tr>
<tr>
<td>Fluid Balance, 305</td>
<td></td>
</tr>
<tr>
<td>History, Physical Examination, and Laboratory Findings, 305</td>
<td></td>
</tr>
<tr>
<td>Determining the Amount of Fluid to Administer, 305</td>
<td></td>
</tr>
<tr>
<td>Routes of Fluid Administration, 307</td>
<td></td>
</tr>
<tr>
<td>Rate of Administration, 308</td>
<td></td>
</tr>
<tr>
<td>Monitoring Fluid Administration, 309</td>
<td></td>
</tr>
<tr>
<td>Preparing Fluid Administration Equipment, 310</td>
<td></td>
</tr>
<tr>
<td>Types of Solutions Used in Fluid Therapy, 313</td>
<td></td>
</tr>
<tr>
<td>CRYSTALLOID SOLUTIONS, 313</td>
<td></td>
</tr>
<tr>
<td>Physiologic Saline, 313</td>
<td></td>
</tr>
<tr>
<td>Lactated Ringer's Solution, 313</td>
<td></td>
</tr>
<tr>
<td>Dextrose 5% in Water, 313</td>
<td></td>
</tr>
<tr>
<td>Ringer's Solution, 314</td>
<td></td>
</tr>
<tr>
<td>2.5% Dextrose in Half-Strength (0.45%)</td>
<td></td>
</tr>
<tr>
<td>Saline/Potassium Added, 314</td>
<td></td>
</tr>
<tr>
<td>Multisol-R/Normosol-R, 314</td>
<td></td>
</tr>
<tr>
<td>Normosol-M in 5% Dextrose, 314</td>
<td></td>
</tr>
<tr>
<td>Plasma-Lyte/Plasma-Lyte M in 5% Dextrose, 314</td>
<td></td>
</tr>
<tr>
<td>COLLOID SOLUTIONS, 314</td>
<td></td>
</tr>
<tr>
<td>HYPERTONIC SOLUTIONS, 315</td>
<td></td>
</tr>
<tr>
<td>FLUID ADDITIVES, 315</td>
<td></td>
</tr>
<tr>
<td>Sodium Bicarbonate, 315</td>
<td></td>
</tr>
<tr>
<td>Potassium Chloride, 316</td>
<td></td>
</tr>
<tr>
<td>Calcium Supplements, 316</td>
<td></td>
</tr>
<tr>
<td>50% Dextrose, 317</td>
<td></td>
</tr>
<tr>
<td>Vitamin Supplements, 318</td>
<td></td>
</tr>
<tr>
<td>Oral Electrolyte Preparations, 318</td>
<td></td>
</tr>
<tr>
<td>Parenteral Nutrition, 319</td>
<td></td>
</tr>
<tr>
<td>Parenteral Vitamin/Mineral Products, 319</td>
<td></td>
</tr>
</tbody>
</table>
WATER-SOLUBLE VITAMINS, 320
  Vitamin B Complex, 320
  Thiamine Hydrochloride (Vitamin B1), 320
  Vitamin B12 (Cyanocobalamin), 320

FAT-SOLUBLE VITAMINS, 321
  Vitamin A, 321
  Vitamin D, 321
  Vitamin E, 321
  Vitamin K, 321

16 BLOOD-MODIFYING, ANTI NEOPLASTIC, AND IMMUNOSUPPRESSANT DRUGS, 325
  Introduction, 326
  Blood-Modifying Drugs/Agents, 326

HEMATINICS, 326
  Iron Compounds, 327
  Erythropoietin, 328
  Androgens, 328
  Blood Substitutes, 328

ANTICOAGULANTS, 329
  Heparin, 329
  Ethylenediaminetetraacetic Acid (EDTA), 331
  Coumarin Derivatives, 331
  Acid Citrate Dextrose (ACD) Solution and Citrate Phosphate Dextrose Adenine (CPDA-1), 331
  Antiplatelet Drugs, 332

HEMOSTATICS/ANTICOAGULANT ANTAGONISTS, 332
  Topical Agents, 332
  Parenteral Agents, 332

FIBRINOLYTIC (THROMBOLYTIC) DRUGS, 333
  Antineoplastic Drugs, 333
  Principles of Chemotherapy, 334
  ALKYLATING AGENTS, 336
  ANTHRACYCLINES, 336
  ANTIMETABOLITES, 340
  ANTITUBULIN AGENTS, 340

MISCELLANEOUS ANTI NEOPLASTIC DRUGS, 341
  Platinum Drugs, 341
  Asparaginase, 341
  Glucocorticoids, 341

BIOLOGIC RESPONSE MODIFIERS, 342
  Monoclonal Antibodies, 342
  Interferon, 343
  Other Biologic Response Modifiers, 343

IMMUNOSUPPRESSIVE DRUGS, 344
  Azathioprine, 344
  Cyclosporine, 344
  Metronidazole, 345
  Cyclophosphamide, 345
  Corticosteroids, 345
  Other Immunosuppressive Agents, 345

17 IMMUNOLOGIC DRUGS, 348
  Principles of Vaccination, 349
  Common Vaccine Types That Produce Active Immunity, 351
  INACTIVATED, 351
  LIVE, 351
  MODIFIED LIVE, 351
  RECOMBINANT, 352
  TOXOID, 352
  Common Vaccine Types That Produce Passive Immunity, 353
  ANTITOXIN, 353
  ANTISERUM, 353
  Other Types of Vaccines, 353
  AUTOGENOUS VACCINE, 353
  MIXED VACCINE, 353
  Administration of Vaccines, 354
  Biologic Care and Vaccine Failure, 355
  Adverse Vaccination Responses, 355
  Vaccinations for Preventive Health Programs, 356
    Canine, 356
    Equine, 356
    Feline, 356
    Botine, 358
    Others, 364
  Immunotherapeutic Drugs, 365
  IMMUNOSTIMULANTS, 366
  Complex Carbohydrates, 366
  Immunomodulatory Bacterins, 366

18 MISCELLANEOUS THERAPEUTIC AGENTS, 369
  Alternative Medicines, 370
  CHONDROPROTECTIVES, 370
    Polysulfated Glycosaminoglycans, 370
  NUTRACEUTICALS, 370
    Glucosamine and Chondroitin Sulfate, 372
    Fatty Acids, 372
    S-Adenosylmethionine (SAMe), 372
INVENTORY RECORDS, 394
  Reorder Quantity, 397
  Rabies Vaccine, 397
ORGANIZING INVENTORY, 397
  Pharmacy and ICM Office, 397
  Organizing Inventory in the Veterinary Hospital, 399
  Staff Memos, 399
  Special Conditions, 399
PHYSICAL INVENTORY, 399
  Monthly Inventory Versus Rotating Inventory, 399
PURCHASING INFORMATION, 401
  Incoming Freight, 401
  FOB Rules and Shipment Contracts, 402
  Receiving Freight, 402
  Stocking Shelves, 403
  Vendors, 403
  Communicating With Sales Representatives, 404
  DEA Forms, 404
  Special Orders, 404
  Human Pharmacy, 404
COMPUTERS AND INVENTORY, 404
THE JOB OF ICM, 405

19 INVENTORY: THE VETERINARY TECHNICIAN’S ROLE, 385
  Introduction, 386
  Inventory, 387
THE TIME EQUATION, 388
  Calculating Turnover Rate, 390
TURNOVER, 390
  Controlling Inventory, 390
PROACTIVE INVENTORY CONTROL SYSTEM, 391
KEEPING ACCURATE RECORDS, 391

APPENDIX A
  COMMON ABBREVIATIONS USED IN VETERINARY MEDICINE, 409
APPENDIX B
  WEIGHTS AND MEASURES, 411
APPENDIX C
  RESOURCE INFORMATION, 413
APPENDIX D
  CONTROLLED SUBSTANCES INFORMATION SUMMARY, 417

BIBLIOGRAPHY, 421

REVIEW QUESTION ANSWERS, 425

GLOSSARY, 439
APPLIED PHARMACOLOGY
for Veterinary Technicians
Fourth Edition
This page intentionally left blank
CHAPTER 1

General Pharmacology

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Define terms related to general pharmacology.
2. List common sources of drugs used in veterinary medicine.
3. Outline the basic principles of pharmacotherapeutics.
4. Define the difference between prescription and over-the-counter drugs.
5. Describe the events that occur after a drug is administered to a patient.
6. List and describe the routes used for administration of drugs.
7. Define biotransformation, and list common chemical reactions involved in this process.
8. List the routes of drug excretion.
9. Discuss in basic terms the mechanisms by which drugs produce their effects in the body.
10. Discuss the mechanisms of clinically important drug interactions.
11. Discuss the different names that a particular drug is given.
12. List the items that should be included on a drug label.
13. List the steps and discuss the processes involved in gaining approval for a new drug.
14. List the government agencies involved in the regulation of animal health products.
15. Describe reasons for dispensing rather than prescribing drugs in veterinary medicine.
16. Discuss the primary methods of drug marketing.
INTRODUCTION

Veterinary technicians are an essential component of the efficient health care delivery team in veterinary medicine. One of the important tasks that veterinary technicians carry out is administration of drugs to animals on the order of a veterinarian. Because this task may have serious consequences in terms of the outcome of a case, it is mandatory that technicians have a thorough knowledge of the types and actions of drugs used in veterinary medicine. They should have an understanding of the reasons for using drugs, called indications, and the reasons for not using drugs, called contraindications (pharmacotherapeutics). They also should know what happens to drugs once they enter the body (pharmacokinetics), how drugs exert their effects (pharmacodynamics), and how adverse drug reactions manifest themselves (toxicity). Because veterinarians dispense a large number of drugs, technicians also must be well versed in the components of a valid veterinarian-client-patient relationship, the importance of proper labeling of dispensed products, and methods of client education on the proper use of products to avoid toxic effects or residue. Finally, technicians should have a basic understanding of the laws that apply to drug use in veterinary medicine and the concept of the marketing of veterinary drugs. In short, veterinary technicians must have a working knowledge of the science of veterinary pharmacology.
DRUG SOURCES

Traditional sources of drugs are plants (botanical) and minerals. Plants have long been a source of drugs. The active components of plants that are useful as drugs include alkaloids, glycosides, gums, resins, and oils. The names of alkaloids usually end in -ine, and the names of glycosides end in -in (Williams and Bagay, 1990). Examples of alkaloids include atropine, caffeine, and nicotine. Digoxin and digitoxin are examples of glycosides. Bacteria and molds (e.g., Penicillium) produce many of the antibiotics (penicillin) and anthelmintics (ivermectin) in use today. Animals once were important as a source of hormones such as insulin, and as a source of anticoagulants such as heparin. Today, most hormones are synthesized in a laboratory. Mineral sources of drugs include electrolytes (sodium, potassium, and chloride), iron, selenium, and others. Laboratories are one of the most important sources of currently used drugs because chemists are finding methods of reproducing drugs previously obtained through plant and animal sources. Advances in recombinant deoxyribonucleic acid (DNA) technology have made it possible for animal and human products (e.g., insulin) in bacteria to be produced in large quantities.

INACTIVE INGREDIENTS

Veterinary pharmaceutic products and supplements may contain substances in addition to active ingredients. Inactive ingredients are classified as binders, coatings, coloring agents, disintegrants, emulsifiers, fillers, flavorings, flow agents, humectants, preservatives, sweeteners, and thickeners (Table 1-1).

PHARMACOTHERAPEUTICS

Veterinarians are challenged by the task of assessing a patient to determine a diagnosis and arrive at a plan of treatment. If the plan of treatment includes the use of drugs, the veterinarian must choose an appropriate drug and a drug regimen. The drug is selected through the use of one or more broadly defined methods called diagnostic, empirical, or symptomatic. The diagnostic method involves assessment of a patient, including a history, physical examination, laboratory tests, and other diagnostic procedures, to arrive at a specific diagnosis. Once the diagnosis has been determined, the causative microorganism or altered physiologic state is revealed to allow selection of the appropriate drug. The empirical method calls on the use of practical experience and common sense when the drug choice is made. In other instances, drugs are chosen to treat the symptoms or signs of a disease if a specific diagnosis cannot be determined. In veterinary medicine, the comparative cost of a drug also may be an important consideration in selection of an appropriate drug. Once the drug to be used in treatment has been decided, the next step for the veterinarian is to design the plan for administering the drug. This plan, called a regimen, includes details about the following:

- The route of administration
- The amount to be given (dosage)
- How often the drug is to be given (frequency)
- How long the drug will be given (duration)

Every drug has the potential to cause harmful effects if it is given to the wrong patient or according to the wrong regimen. Some medications have greater potential than others for producing harmful outcomes. According to the U.S. Food and Drug Administration (FDA), when a drug has potential toxic effects or must be administered in a way that requires the services of trained personnel, that drug cannot be approved for animal use except when given under the supervision of a veterinarian. In such a case, the drug is classified as a prescription drug and must be labeled with the following statement: “Caution: Federal law restricts the use of this drug to use by or on the order of a licensed veterinarian.” This statement sometimes is referred to as the legend, and the drug is called a legend (prescription) drug. Labels that state “For veterinary use only” or “Sold to veterinarians only” do not designate prescription drugs. Technicians should be aware that prescription drugs often have been approved by the FDA for use in specific species or for particular diseases or conditions. Veterinarians have some discretion to use a drug in ways not indicated...
Table 1-1 Inactive Ingredients

<table>
<thead>
<tr>
<th>Inactive Ingredient</th>
<th>Function</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Binder</td>
<td>Holds tablet together</td>
<td>Cellulose, lactose, methylcellulose, sorbitol, starch, xylitol, and others</td>
</tr>
<tr>
<td>Coating</td>
<td>Protects tablet from breaking, absorbing moisture, and early disintegration</td>
<td>Beeswax, carob extract, methylcellulose, cellulose acetate, acrylic resin, and others</td>
</tr>
<tr>
<td>Coloring agents</td>
<td>Provide color and enhance appearance</td>
<td>Yellow No. 5, annatto, caramel color, titanium oxide, FD&amp;C Blue No. 1, FD&amp;C Red No. 3, and others</td>
</tr>
<tr>
<td>Disintegrants</td>
<td>Expand when exposed to liquid, allowing tablets and capsules to dissolve and disperse their active ingredients</td>
<td>Cellulose products, crospovidone, sodium starch glycolate, and starch</td>
</tr>
<tr>
<td>Emulsifiers</td>
<td>Allow fat-soluble and water-soluble agents to mix, so they do not separate</td>
<td>Stearic acid, xanthan gum, lethicin, and vegetable oils</td>
</tr>
<tr>
<td>Fillers/diluents</td>
<td>Increase bulk or volume</td>
<td>Calcium carbonate, calcium sulfate, cellulose lactose, mannitol, sorbitol, starch, sucrose, and vegetable oils</td>
</tr>
<tr>
<td>Flavor agents</td>
<td>Create a desired taste or mask an undesired taste</td>
<td>Beeswax, carob extract, glycercyl triacetate, and natural orange</td>
</tr>
<tr>
<td>Flow agents</td>
<td>Prevent powders from sticking together</td>
<td>Calcium state, glycercyl triacetate, polyethylene glycol, silica, sodium benzoate, and talc</td>
</tr>
<tr>
<td>Humectants</td>
<td>Hold moisture in a product</td>
<td>Glycerin, glycerol, glycercyl triacetate, and sorbitol</td>
</tr>
<tr>
<td>Preservatives</td>
<td>Prevent degradation and extend the shelf life of a product</td>
<td>Citric acid, glycerol, potassium benzoate, sodium benzoate, and others</td>
</tr>
<tr>
<td>Sweetening agents</td>
<td>Improve taste</td>
<td>Aspartate, fructose, glycercin, sorbitol, sucrose, and xylitol</td>
</tr>
<tr>
<td>Thickening agents</td>
<td>Increase the viscosity of a product</td>
<td>Methylcellulose, povidone, sorbitol, and others</td>
</tr>
</tbody>
</table>


by the label, if they take responsibility for the outcome of use. Use of a drug in a way not specified by the label is called extralabel use.

Federal law and sound medical practices dictate that prescription drugs should not be dispensed indiscriminately. Before prescription drugs are issued or extralabel use is undertaken, a valid veterinarian-client-patient relationship must exist. For this relationship to occur, several conditions must be met. These include, but are not limited to, the following:

- The veterinarian has assumed responsibility for making clinical judgments about the health of the animal(s) and the need for treatment, and the client has agreed to follow the veterinarian’s instructions.
- The veterinarian has sufficient knowledge of the animal(s) to issue a diagnosis. The veterinarian must have seen the animal recently and must be acquainted with its husbandry.
- The veterinarian must be available for follow-up evaluation of the patient.

Drugs that do not have enough potential to be toxic or that do not require administration in special ways do not require the supervision of a veterinarian for administration. These drugs are called over-the-counter drugs because they may be purchased without a prescription. Drugs that have the
potential for abuse or dependence have been classified as controlled substances. Careful records of the inventory and use of these drugs must be maintained, and some of them must be kept in a locked storage area.

When a drug and its regimen have been selected, veterinary technicians often are directed through verbal or written orders to administer the drug. Technicians have several important responsibilities in carrying out these orders:

1. Making sure that the correct drug is being administered
2. Administering the drug by the correct route and at the correct time
3. Carefully observing the animal’s response to the drug
4. Questioning any medication orders that are not clear

5. Creating and affixing labels to medication containers accurately
6. Explaining administration instructions to clients
7. Recording appropriate information in the medical record

Technicians should be aware that even when the correct drug is administered in a correct manner, an unexpected adverse reaction might occur in a patient. All adverse reactions should be reported immediately to the veterinarian.

**PHARMACOKINETICS**

Pharmacokinetics is the complex sequence of events that occurs after a drug is administered to a patient (Figure 1-1). Once a drug has been given,
it is available for absorption into the bloodstream and delivery to the site where it will exert its action. After a drug is absorbed, it is distributed to various fluids and tissues in the body. It is not enough for the drug simply to reach the desired area, however. It also must accumulate in that fluid or tissue at the required concentration to be effective. Because the body immediately begins to break down and excrete the drug, the amount available to the target tissue becomes less and less over time. The veterinarian then must administer the drug repeatedly and at fixed time intervals to maintain the drug at the site of action in the desired concentration. Some drugs are administered at a high dose (loading dose) until an appropriate blood level is reached. Then the dose is reduced to an amount that replaces the amount lost through elimination. Doses of other drugs are at the replacement level throughout the regimen. The point at which drug accumulation equals drug elimination is called the steady state. Underdosing leads to less-than-effective levels in tissue, and overdosing may result in toxic levels (Figure 1-2). Drug levels can be measured in blood, urine, cerebrospinal fluid, and other appropriate body fluids to help a veterinarian determine whether an appropriate level has been achieved. This procedure, which is called therapeutic drug monitoring, is being used increasingly in veterinary practice. Nonsteroidal antiinflammatory drugs (NSAIDs), cardiac drugs, anticonvulsants, and thyroid drugs are commonly monitored.

The primary factors that influence blood concentration levels of a drug and a patient’s response to it include the following:

1. Rate of drug absorption
2. Amount of drug absorbed
3. Distribution of the drug throughout the body
4. Drug metabolism or biotransformation
5. Rate and route of excretion

These factors are explored after the drug administration routes have been discussed.

**Routes of Administration**

A drug is of no use unless it can be delivered to the patient in an appropriate form at an appropriate site. The way in which a drug is administered to an animal patient is influenced by several factors:

- Available pharmacological form of the drug
- Physical or chemical properties (irritation) of the drug
- How quickly onset of action should occur
- Use of restraint or behavioral characteristics of the patient
- Nature of the condition being treated

The routes of administration of drugs to animal patients are discussed next.

---

**Figure 1-2**

ORAL
In veterinary medicine, drugs commonly are administered through the oral route. Medications given by this route may be placed directly in the mouth or may be given via a tube passed through the nasal passages (nasogastric tube) or through the mouth (orogastric tube). The mucosa of the digestive tract is a large absorptive surface area with a rich blood supply. Drugs given by this route, however, are not absorbed as quickly as drugs administered by injection, and their effects are subject to species (e.g., ruminants vs. animals with a simple stomach) and individual differences. Many factors may influence the absorption of drugs from the digestive tract, including the pH of the drug, its solubility (fat vs. water), the size and shape of the molecule, the presence or absence of food in the digestive tract, the degree of gastrointestinal (GI) motility, and the presence and nature of disease processes. This route is not suitable for animals that are vomiting or have diarrhea. Drugs given by this route generally produce a longer-lasting effect than those given by injection.

PARENTERAL
Drugs that are given by injection are called parenteral drugs. A drug can be injected via many different routes:

- Intravenous (IV)
- Intramuscular (IM)
- Subcutaneous (SC)
- Intradermal (ID)
- Intraperitoneal (IP)
- Intraarterial (IA)
- Intrarticular
- Intracardiac
- Intramedullary
- Epidural/subdural

Drugs given by the intravenous route produce the most rapid onset of action, accompanied by the shortest duration. Medications that are irritating to tissue generally are given by this route because of the diluting effect of blood. Intravenous medications should be administered slowly to lessen the possibility of a toxic or allergic reaction. Unless a product is specifically labeled for intravenous use, it should never be given by this route. Oil-based drugs and those with suspended particles (i.e., those that look cloudy or thick) generally should not be given intravenously because of the possibility of an embolism. Special care should be taken to ensure that irritating drugs are injected into the vein and not around it, to avoid causing phlebitis.

The intramuscular route of administration produces a slower onset of action than the intravenous route but usually provides a longer duration of action. The onset of action by this route can be relatively fast with a water-based form (aqueous) and is slower with other diluents (vehicles) such as oil or with other forms such as microfine crystals. When an injectable drug is placed in a substance that delays its absorption, this may be referred to as a depot preparation. Altering the molecule of the drug itself can influence its onset or duration of action. Onset of action usually is inversely related to duration of action. Irritating drugs should not be given by the intramuscular route, and back pressure always should be applied to the syringe plunger before intramuscular administration of a drug to ensure that the injection is not directed into a blood vessel.

In some texts, the subcutaneous route has been called hypodermoclysis. It produces a slower onset of action but a slightly longer duration than the intramuscular route. Irritating or hypertonic solutions (i.e., those with a greater number of suspended particles than are found in body fluid) should not be given by this route.

Quantities of medications that are appropriate for the species or individual being treated should be used to prevent possible dissection of the skin from underlying tissue, which could lead to death and loss (sloughing) of surface skin. Adding an enzyme called hyaluronidase to a drug that is given subcutaneously may speed its absorption.

The intradermal route involves injecting a drug into the skin. This route is used in veterinary medicine primarily for testing for tuberculosis and allergic conditions.

The intraperitoneal route is used to deliver drugs into the abdominal cavity. The onset and duration of action of drugs given by this route are variable. This route is used to administer fluids, blood, and other medications when normal routes are not
available or are not practical. Problems such as adhesions and puncture of abdominal organs may be caused by this method.

The intraarterial route involves injecting a drug directly into an artery. This route seldom is used intentionally, but this may happen by mistake. Administration of drugs into the jugular vein of a horse must be done with caution to avoid injection into the underlying carotid artery. Intracarotid injection into an animal results in delivery of a high concentration of the drug directly to the brain, and seizures or death may result.

Through the intraarticular route, a drug is injected directly into a joint. This method is used primarily to treat inflammatory conditions of the joint. Extreme care must be exercised to ensure that sterile technique is used when an intraarticular injection is given. Technicians usually do not use this route.

The intracardiac route is used to inject drugs through the chest wall directly into the chambers of the heart. This provides immediate access to the bloodstream and ensures that the drug is delivered quickly to all tissue in the body. This method is often used in cases of cardiopulmonary resuscitation and in euthanasia.

The intramedullary route is another route that is seldom used in veterinary medicine. It involves injection of the substance directly into the bone marrow. The bones used most often are the femur and the humerus. The intramedullary route usually is used to provide blood or fluids to animals with very small or damaged veins, or for treatment of animals with very low blood pressure.

When spinal anesthesia is provided, drugs may be injected into the epidural or subdural space. The epidural space is outside the dura mater (meninges) but inside the spinal canal. The subdural space is inside the dura mater. Injection of drugs into the subdural space (cerebrospinal fluid) is also called the intrathecal route. A veterinarian usually carries out these methods of drug delivery.

**Inhalation**

Medications may be delivered to a patient in inspired air by converting a liquid form into a gaseous form through the use of a vaporizer or nebulizer. Examples of drugs that may be given by this route include anesthetics, antibiotics, and bronchodilators.

**Topical**

Drugs that are administered topically are placed on the skin or on mucous membranes. Drugs generally are absorbed more slowly through the skin than through other body membranes. The rate of absorption may be increased or absorption facilitated by placement of the drug in a vehicle such as dimethyl sulfoxide (DMSO). Medication also may be applied to the mucosa of the oral cavity (sublingual), the rectum (suppositories), the uterus, the vagina, the mammary glands, the eyes, and the ears. In horses, caustic materials may be applied topically to inhibit the growth of exuberant granulation tissue (proud flesh).

Transdermal drug administration is a form of topical administration that involves the use of a patch applied to the skin to deliver a drug through intact skin directly into the blood. This method is used most commonly to administer an analgesic in a slow, continuous manner or to administer compounded drugs to animals when oral administration may be difficult (e.g., cats).

**Drug Absorption**

Before drugs can reach their site of action, they must pass across a series of cellular membranes that make up the absorptive surfaces of the sites of administration. The degree to which a drug is absorbed and reaches the general circulation is called bioavailability.

The manufacturing process can have a significant effect on the physical and chemical characteristics of drug molecules that influence their bioavailability. Because of manufacturing differences, the generic form of a drug may differ somewhat from a trademark form in overall efficacy. Bioavailability often is demonstrated with the use of a blood level curve (Figure 1-3). Factors that may affect the absorption process include the following (Upson, 1988; Boothe, 2001):

- Mechanism of absorption
- pH and ionization status of the drug
- Absorptive surface area
Blood supply to the area
- Solubility of the drug
- Dosage form
- Status of the GI tract (motility, permeability, and thickness of the mucosal epithelium)
- Interaction with other medications

Drugs pass across cellular membranes through three common methods. Passive absorption (transport) occurs by simple diffusion of a drug molecule from an area of high concentration of drug on one side of the membrane to an area of lower concentration on the other side. This method requires no expenditure of energy by the cell. The drug may pass through small pores in the cell membrane or may dissolve into the cell membrane on one side, pass through the membrane, and exit on the other side. For example, a disintegrated tablet or capsule results in a high concentration of drug in the GI tract. This concentration then passes through the cellular membranes of intestinal villi and adjacent capillaries, and the drug then appears in lesser concentration in the bloodstream. Alternatively, a drug may cross a membrane passively with the help of a carrier.

Some small drug molecules such as electrolytes may simply move with fluid through pores in cell membranes. Active transport of drugs across cell membranes moves molecules from an area of lower concentration to an area of higher concentration and requires that the cell use energy. This is the usual mechanism for the absorption of sodium, potassium, and other electrolytes. In pinocytosis, a third method of passive transport, cells engulf drug molecules by invaginating their cell membrane to form a vesicle that then breaks off from the membrane in the interior of the cell. The method of absorption that occurs in a particular situation depends on whether the drug is fat soluble or water soluble, the size and shape of the drug molecule, and the degree of ionization of the drug.

Many drugs can pass through a cell membrane only if they are nonionized (i.e., not positively or negatively charged). Most drugs exist in the body in a state that consists of both ionized and nonionized forms. The pH of a drug and the pH of the area in which the drug is located can determine the degree to which a drug becomes ionized and thus is absorbed. Weakly acidic drugs in an acidic environment do not ionize readily and therefore are absorbed well. The absorption of basic drugs is more favorable in an alkaline environment. If a drug is placed in an environment in which it readily ionizes such as a mildly acidic drug in an alkaline environment or a mildly alkaline drug in an acidic environment, it does not diffuse and may become trapped in that environment.

As the absorptive surface of the area of drug placement increases, so does the rate of absorption. One of the largest absorptive surfaces in the body is found in the small intestine because the efficient design of the villi maximizes the surface area.

At any site of drug administration, as the blood supply to an area increases, so does the rate of absorption of the drug. Drugs are absorbed from an intramuscular site at a faster rate than from a subcutaneous site because of the proportionately greater blood supply to the muscle. Initiating the fight-or-flight response increases blood flow to the muscle but decreases blood flow to the intestines. Heat and massage also increase blood flow to an area. Poor circulation, which may occur during shock or cardiac failure, decreases blood flow, as does cooling or elevation of a body part. These factors then can positively or negatively influence drug absorption.

Another important factor that determines the rate at which drugs pass across cell membranes is the solubility of the drug. The lipid (fat) solubility of a drug tends to be directly proportional to the degree of drug ionization. As was stated previously, the nonionized form is the one that usually is
absorbed. The degree of lipid solubility of a drug often is expressed as its lipid partition coefficient. A high lipid partition coefficient indicates enhanced drug absorption.

Drug absorption rates often depend on the formulation of the drug. Various inert ingredients, such as carriers (vehicles), binding agents, and coatings, are used to prepare dosage forms. These substances have major effects on the rate at which formulations dissolve. Depot and sparsus are terms that are associated with prolonged- or sustained-release formulations in veterinary medicine. Subcutaneous implants that contain growth stimulants that break down slowly and release their products over prolonged periods are used in some situations.

When drugs are given orally, the condition of the GI tract can have a major influence on the rate and extent of drug absorption. Factors such as degree of intestinal motility, emptying time of the stomach, irritation or inflammation of the mucosa (e.g., gastritis, enteritis), damage to or loss of villi (e.g., viral diseases), composition and amount of food material, and changes in intestinal microorganisms can affect the rate and extent of absorbance of medications. Another consideration regarding drugs that are absorbed from the GI tract is the first-pass effect (see Figure 1-6). This refers to the fact that substances are absorbed from the GI tract into the portal venous system, which delivers the drug to the liver before it enters the general circulation. In some instances, a drug then is metabolized in the liver to altered forms; this process may make the drug inactive or less active.

The process of combining some drugs with other drugs or with certain foods can negatively affect drug absorption. The availability of tetracycline is reduced if it is administered with milk or milk products. Antacids may reduce the absorption of phenylbutazone or iron products. Technicians always should consult appropriate references about potential interactions before administering new drugs.

**Drug Distribution**

Drug distribution is the process by which a drug is carried from its site of absorption to its site of action. Drugs move from the absorption site into the plasma of the bloodstream, out of the plasma into the interstitial fluid that surrounds cells, and from the interstitial fluid into the cells, where they combine with cellular receptors to create an action. Equilibrium soon is established between these three compartments while the drug moves out of the blood into the tissue and then out of the tissue back into the blood (Figure 1-4). How well a drug is distributed throughout the body depends on several factors.

The rate of movement of drug molecules from one of the previously listed compartments to the other is proportional to the differences between the amounts of drug in all areas. The difference between the amounts of drug in two compartments is called the concentration gradient, and as the gradient increases (difference), so does the tendency of the drug to move from the area of higher concentration to the area of lower concentration.

A drug within the plasma comes into contact with various proteins (e.g., albumin) and binds with them or remains free. When a drug is bound to a protein, it becomes inactive and is unavailable for binding with cell receptors or for metabolism. A bound drug may be regarded as a storage site of a drug because a bound drug eventually frees itself from the protein. Low levels of plasma proteins may occur in malnutrition or in certain diseases, and plasma binding may be reduced.

![Figure 1-4](Image)

**Figure 1-4**

Drug distribution establishes an equilibrium between the amount of drug at the site of absorption, the amount in the plasma, and the amount at the cellular receptor sites.
Drugs that are highly lipid soluble tend to move readily out of the plasma and into the interstitial fluid. Drugs in the nonionized form follow a similar pattern. Once a drug is present in a tissue, it may become bound or stored there. Tissues such as fat, liver, kidney, and bone may act as storage sites for drugs such as barbiturates, inhalation anesthetics, and others. When a drug moves out of the storage tissue back into the blood, and additional doses are given, an exaggerated or prolonged effect may result because of the additive effects.

Barriers that exist in particular tissues tend to retard the movement of all or certain classes of drugs into them. The exact nature of these barriers has not been well explained in the literature. The placenta acts as a barrier to some drugs that could be toxic to a fetus and permits the passage of others. Anesthetics that do not excessively depress a fetus must be chosen when a cesarean section is performed. The so-called blood-brain barrier is generally minimally permeable to all drugs, although it becomes relatively permeable to many antibiotics upon inflammation. A defect in the p-glycoprotein drug transporter in the blood-brain barrier has been identified in individuals of several dog breeds including collies, Old English sheepdogs, Australian shepherds, Shetland sheepdogs, and English shepherds. The eye also has a barrier that impedes some drugs from diffusing into its tissue.

Disease processes can interfere with drug distribution. Antibiotics usually do not diffuse well into abscesses or exudates. Heart failure and shock can reduce normal blood flow to tissue and thus impede drug distribution. Kidney failure (uremia) can alter the plasma binding of some drugs such as furosemide and phenylbutazone. Liver failure can cause a reduction in the amount of protein (albumin) available for protein binding.

Some clinicians believe that reptiles have a renal-portal system that can distribute potentially toxic levels of a drug to the kidney if the drug is injected into the posterior one third of the body.

**Biotransformation**

Biotransformation, or metabolism, is the body's ability to change a drug chemically from the form in which it was administered into a form that can be eliminated from the body. Most biotransformation occurs in the liver because of the action of microsomal enzymes found in liver cells. These enzymes induce chemical reactions that render a drug water soluble, allowing its subsequent elimination in the urine. Once a drug has been biotransformed, it is called a metabolite. Metabolites are usually inactive but in some cases may be active. A few highly lipid-soluble drugs are incorporated into bile and are eliminated through the biliary system. Some biotransformation does occur in other tissues such as the kidney, lung, and nervous system.

The following four chemical reactions are induced by microsomal enzymes in the liver to biotransform drugs:

1. **Oxidation**—loss of electrons
2. **Reduction**—gain of electrons
3. **Hydrolysis**—splitting of the drug molecule with the addition of a water molecule to each of the split portions
4. **Conjugation**—the addition of glucuronic acid to the drug molecule; when glucuronic acid is attached to a drug molecule, the drug becomes much more water soluble

Many factors, including species, age, nutritional status, tissue storage, and health status, can alter drug metabolism. Cats have limited ability to metabolize aspirin, narcotics, and barbiturates because of their reduced ability to form glucuronic acid. Young animals usually have poor ability to biotransform drugs because their liver enzyme systems are not fully developed. Old animals have a decreased capacity to biotransform because their ability to synthesize needed liver enzymes is impaired. Malnourished animals have fewer protein raw materials available for use in manufacturing enzymes for biotransformation, and animals with liver disease are not able to process the raw materials available for enzyme production. Drugs present in storage compartments such as fat or plasma proteins are not available to be metabolized.

**Drug Excretion**

Most drugs are metabolized by the liver and then are eliminated from the body by the kidneys via the urine. They can be excreted, however, by the liver
(bile), mammary glands, lungs, intestinal tract, sweat glands, salivary glands, and skin. An understanding of the route of excretion of drugs is very important because alterations or diseases of a particular organ can cause a reduced capacity to excrete the drug, and toxic accumulation may result. For example, the anesthetic agent ketamine can cause serious central nervous system (CNS) depression in cats with urinary obstruction because the kidneys excrete this drug.

Kidneys excrete drugs by two principal mechanisms. The first method is called glomerular filtration. A glomerulus and its corresponding tubule make up the individual functional unit of the kidney, called a nephron. A glomerulus acts like a sieve to filter drug molecules (metabolites) out of the blood into the glomerular filtrate, which is then eliminated as urine (Figure 1-5). The second mechanism that kidneys use to excrete drugs is called tubular secretion. Kidney tubule cells secrete metabolites out of the capillaries surrounding the tubule and into the glomerular filtrate, which becomes urine as it exits the kidneys. In some instances, drug molecules may be reabsorbed out of the glomerular filtrate and back into the blood through tubular reabsorption.

It is important that the nephrons (glomerulus and corresponding tubule) are healthy and that they have an adequate blood supply, so they can do an effective job of excreting metabolites. The lower urinary tract (bladder and urethra) also must be functioning normally, so filtered or secreted metabolites can be eliminated. If any part of this system from the glomerulus to the urethra is compromised or diseased, toxic levels of a drug may accumulate.

The liver excretes drugs by first incorporating them into bile, which is eliminated into the small intestine. In the small intestine, the drug then may become a part of the feces and be eliminated from the body, or it may be reabsorbed into the bloodstream (Figure 1-6).

**Figure 1-5**
The kidneys eliminate or conserve drug metabolites by glomerular filtration (1), tubular reabsorption (2), and tubular secretion (3).
Some drugs or their metabolites may pass directly out of the blood and into the milk via the mammary glands. This is an important consideration because of the potential effects of the drug on nursing offspring or on people who drink the milk. Quantities of drug that remain in animal products when they are consumed are called residues. Residues found in milk, eggs, or meat products are potentially dangerous to people for the following reasons:

- People may be allergic to the drug.
- Prolonged exposure to antibiotic residues can result in resistant strains of bacteria.
- Residue of some drugs may cause cancer in humans.

Drugs that convert readily between a liquid and a gaseous state (gas anesthetics) may be eliminated from the blood via the lungs. These gas molecules move out of the blood and into the alveoli of the lungs to be eliminated in expired air.

Drugs that are given orally and are not absorbed readily out of the intestinal tract may pass through the tract and be eliminated through feces. As was mentioned previously, some drugs are excreted through the bile into the intestinal tract, and a few may be actively secreted across the intestinal mucosa into the intestine for elimination.

Some drugs are eliminated through sweat and saliva, although these routes usually are not clinically important. The rate of drug loss from the body can be estimated by calculating the drug's half-life. The half-life is the time required for the amount of drug present in the body to be reduced by one half (Figure 1-7).

**PHARMACODYNAMICS**

Pharmacodynamics is the study of the mechanisms by which drugs produce physiologic changes in the body. Drugs may enhance or depress the physiologic activity of a cell or a tissue. Drug molecules combine with components of the cell membrane or with internal components of the cell to cause alterations in cell function. The way in which drugs combine with structures (receptors) on or in a cell...
can be compared with a lock-and-key model. The geometric match of a drug molecule and a cellular receptor must be exact for the appropriate action to occur (Figure 1-8). The tendency of a drug to combine with a receptor is called affinity, and the degree to which the drug binds with its receptor helps to determine drug efficacy. A drug with a high level of affinity and efficacy causes a specific action and is an agonist. A drug with less affinity and efficacy is a partial agonist. A drug that blocks another drug from combining with a receptor is an antagonist. The combining of a drug with its receptor causes a particular drug action, and this interaction produces a particular drug effect. Examples of drug effects include stimulation, depression, irritation, and cell death. Sometimes, a drug replaces a substance that is missing or is in short supply in the body.

A dose-response curve displays the relationship between the dose of a drug and the body's response. The dose-response curve shows that as a dose increases, an increase in response occurs until a maximum response or plateau is achieved. No drug produces a single effect. Low doses of a narcotic may be used to treat patients with diarrhea. Higher doses may be used for pain relief, and even higher doses may depress the respiratory system. The potency of a drug is described as the amount of a drug needed to produce a desired response and is represented by a position along the dose-response curve.

The efficacy of a drug represents the degree to which a drug produces its desired response in a patient. Once the efficacy level of a drug has been reached, increasing the dose does not improve the effect.

The therapeutic index is the relationship between a drug's ability to achieve the desired effect and its tendency to produce toxic effects. The therapeutic index, which is expressed as the ratio between the LD₅₀ and the ED₅₀, quantitates the drug's margin of safety. The LD₅₀ is the dose of a drug that is lethal to 50% of the animals in a dose-related trial. The ED₅₀ is the dose of a drug that produces the desired effect in 50% of the animals in a dose-related trial. The index is calculated as follows: Therapeutic index = LD₅₀/ED₅₀.

The larger the number that is produced by dividing the LD₅₀ by the ED₅₀, the greater is the level of safety. Drugs with a narrow margin of safety (low therapeutic index) must be administered with caution to prevent toxic or fatal effects. The drugs used to treat cancer often have a low therapeutic index.

An adverse drug reaction is an undesirable response to a drug that can range from mild to life threatening. Adverse reactions can be related to the characteristics of the drug itself, the quality or purity of the drug, or the amount of drug used. Phenobarbital is potentially toxic to the liver, and amphotericin
B may damage the kidneys. Drugs can have carriers or vehicles that are toxic to some individuals. Some adverse reactions are allergic and can cause a range of reactions from dermatitis to anaphylactic shock. Drugs can cause changes in the skin that make it very sensitive to sunlight. This type of reaction is called photosensitivity.

Other types of adverse responses include abortion, liver or kidney damage, infertility, vomiting or diarrhea, and cancer. An unusual or unexpected reaction is called an idiosyncratic drug reaction. All adverse reactions should be reported to the drug manufacturer or the FDA. If the report is made to the drug company, the company is obligated to report the incident to the FDA.

**DRUG INTERACTIONS**

An altered pharmacologic response to a drug that is caused by the presence of a second drug is called a drug interaction. The normal response to the drug may be increased or decreased as a consequence of this interaction. The interaction may be beneficial or harmful to the patient.

Drug interactions can be classified as pharmacokinetic, pharmacodynamic, or pharmaceutic. A pharmacokinetic interaction is one in which plasma or tissue levels of a drug are altered by the presence of another. This alteration may be due to changes in absorption, distribution, metabolism, or excretion of the other drug. Metoclopramide hastens
gastric emptying and promotes the delivery of a drug to the small intestine for absorption. When calcium and tetracycline are administered at the same time orally, calcium binds the tetracycline and the complex is not absorbed. Displacement of albumin-bound drugs by other drugs with a greater binding affinity may result in an increase in the free drug, leading to an increased response. Many drugs are metabolized by the cytochrome P-450 enzyme system found in the liver, and several drugs can alter the activity (increase or decrease) of the P-450 system, causing drug interaction.

A pharmacodynamic interaction is one in which the action or effect of one drug is altered by another. These reactions occur at the site of drug action. These actions may be antagonistic (reversal of an alpha agonist with yohimbine), additive (CNS depression with combinations of preanesthetics), or synergistic (sulfonamide-trimethoprim combinations).

A pharmacokinetic interaction occurs when physical or chemical reactions take place as a result of mixing of drugs in a syringe or other container. Amphotericin B may form a precipitate when mixed with electrolyte solutions other than 5% dextrose. Diazepam may precipitate if mixed with certain drugs. Ampicillin and furosemide may be chemically inactivated if mixed with an acid medium (Ahrens, 1996).

Drug interactions are described as involving an object drug (the one being acted upon) and a precipitant drug (the one that influences the other) (Mealey, 2002). Table 1-2 lists selected drug combinations that may have undesired consequences.

---

**Technician's Notes**

1. It generally is recommended that mixing of drugs in the same syringe or fluid administration system should be avoided unless the drugs are known to be compatible.
2. When two drugs metabolized by the liver are given, one should anticipate a drug interaction.
3. Concurrent use of drugs from the "behavior modifying" category can cause serious problems such as serotonin syndrome or hypertensive reactions.

---

**DRUG NAMES**

During the course of its testing, development, and marketing, a drug may be assigned several different names. These multiple names can be a source of

---

**Table 1-2 Drug Combinations That May Have Undesired Consequences**

<table>
<thead>
<tr>
<th>Precipitant Drug</th>
<th>Object Drug</th>
<th>Consequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antacids</td>
<td>Tetracycline</td>
<td>Reduced absorption of tetracycline</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Digoxin, cyclosporine, tricyclic antidepressants</td>
<td>Decreased metabolism of object drugs</td>
</tr>
<tr>
<td>Sucralfate</td>
<td>Fluoroquinolones</td>
<td>Decreased metabolism of fluoroquinolones</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>Theophylline</td>
<td>Decreased metabolism of theophylline</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>Ketoconazole/itraconazole</td>
<td>Decreased oral absorption of object drugs</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>Theophylline, doxycycline, beta blockers</td>
<td>Increased metabolism of object drugs (cytochrome P-450 induction)</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>Diazepam and theophylline</td>
<td>Decreased metabolism of object drugs (cytochrome P-450 inhibition)</td>
</tr>
<tr>
<td>MAO Inhibitors</td>
<td>Amitraz, selective serotonin reuptake inhibitors, tricyclic antidepressants, other MAOs</td>
<td>Dangerous accumulation of biogenic amines leading to serotonin syndrome or hypertensive state</td>
</tr>
<tr>
<td>Tetracyclines</td>
<td>Penicillins</td>
<td>Tetracyclines slow bacterial growth and inhibit penicillins that are most effective against rapidly growing bacteria</td>
</tr>
</tbody>
</table>
confusion. For practical purposes, drugs are given the following types of names:

1. Chemical—the name that describes the molecular structure of a drug. These names are scientifically very accurate, but they are complex and are impractical for use in clinical settings.
2. Code or laboratory—the name given to a drug by the research and development investigators. It is used for communication between research teams and consists of abbreviations and code numbers.
3. Compendial—the name listed in the United States Pharmacopoeia (USP). The USP is the legally accepted compendium that lists drugs and standards for their quality and purity.
4. Official—usually the same as the compendial or generic name.
5. Proprietary or trade—the name chosen by the manufacturing company. When it is registered, it is the exclusive property of the company. A name that is short and can be easily recalled is usually selected for the proprietary name. Federal copyright and trademark laws protect this name. On drug container labels, in package inserts, and in drug references, the proprietary name can be distinguished by a superscript R with a circle around it after the name.
6. Generic—the common name chosen by the company. It is not the exclusive right of the company. It may be the same as the official or compendial name. These are drugs with patents that have expired, or they were never patented.

The following illustration illustrates use of the various name categories. Ketaset, Ketamject, Ketavet, and Vetalar are proprietary names for ketamine, which is the generic and compendial name for 2-(o-chlorophenyl)-2-methylaminocyclohexanone (chemical name). Code or laboratory names for this drug include CI-581 and CI-369 (Webb and Aeschbach, 1993).

In textbooks and other scholarly works, generic names begin with a lowercase letter, and proprietary names begin with a capital letter. This practice is followed throughout this text (e.g., ketamine [Ketaset]).

**DRUG LABELS**

The Center for Veterinary Medicine (CVM) of the FDA requires that drug container labels must list the following items (Webb and Aeschbach, 1993):

- Drug names (both generic and trade names)
- Drug concentration and quantity
- Name and address of the manufacturer
- Controlled substance status
- Manufacturer's control or lot number
- Drug's expiration date

The labeling is also required to list instructions for use of the drug and warnings of possible adverse effects of the drug. Because the label on the container usually has limited space, many manufacturers list this added information in an insert. An insert is a small folder that is placed inside the box with the drug container or is provided as a tear-off portion of the label.

The trade name usually is placed first on a drug label and is scripted in bold letters (Figure 1-9). The generic name typically follows in smaller print. The label must display the concentration (strength) of a drug and the total quantity in the container. Drug strength often is expressed as milligrams or units per dosage unit (mg/ml, mg/capsule, and so forth). Some drugs are sold in different concentrations with similar labels, and underdosing or overdosing can result. When the same drug is marketed in different strengths with similar labels, some companies use different sizes of bottles for the different strengths and display the concentrations in bold print. Atropine and xylazine are examples of drugs that are marketed in different concentrations for large and small animals.

The label must include the name and address of the manufacturer of the drug. This is important so that one can know whom to contact if adverse drug reactions occur, or if other problems with the drug arise.

Drugs that have potential for abuse by humans are controlled under the Comprehensive Drug Abuse Prevention and Control Act of 1970. The Drug Enforcement Administration places drugs into categories or schedules according to their
FIGURE 1-9
A label showing the components of a drug as required by the U.S. Food and Drug Administration (FDA). (Courtesy Pfizer Animal Health, Exton, Pa.)

Potential for abuse and requires that the label of a container for a controlled substance must be identified with a capital C, followed by a Roman numeral that identifies which of the five categories is appropriate. This labeling must be placed on the upper right side of the container label.

Drug labels are required to list an expiration date for the product. This is to ensure that dispensed drugs have the intended safety and efficacy. Drugs are tested during development to determine the effective shelf life and proper storage conditions. Some drugs must be stored in refrigeration, and others must be stored in light-resistant (amber) containers to ensure that the shelf life is not shortened.

Storage instructions on the label should be followed carefully to validate the expiration date.

All drugs must have a lot or batch number on the label. The purpose of the lot number is to allow the manufacturer to know the exact time and date of production of the product and the quality and quantity of the ingredients. The lot number is determined by the manufacturer and may consist of numbers, or numbers and letters.

Another feature that is often found on a drug label but is not required by the FDA is the national drug code (NDC) number. The NDC is a 10-digit number that identifies the manufacturer or distributor, the drug formulation, and the package size.
The development of new animal health products begins in the research and development department of the manufacturing company. The company wants to ensure that the drug not only is safe and effective for animals but also is safe for the environment and for the people who will consume products from animals treated with the drug. The company wants to be certain that a market is available for the product, that it will be produced at a cost that is reasonable for consumers, and that the product will be profitable for the company.

**Regulatory Agencies**

The three agencies of the U.S. government that regulate animal health products are the FDA, the Environmental Protection Agency (EPA), and the U.S. Department of Agriculture (USDA). The FDA
regulates the development and approval of animal drugs and feed additives through its Center for Veterinary Medicine. The EPA regulates the development and approval of animal topical pesticides, and the USDA regulates the development and approval of biologics (vaccines, serums, antitoxins, and similar products).

**THE FOOD ANIMAL RESIDUE AVOIDANCE DATABASE**

The Food Animal Residue Avoidance Databank (FARAD), a project sponsored by the USDA Extension Service, serves as a repository of residue avoidance information and educational materials. FARAD provides expert advice concerning the
avoidance of drug residues in an effort to achieve its
goal of producing "safe foods of animal origin." FARAD produces a compendium of FDA-approved
drugs and provides information about withholding
times for milk and pre-slaughter withdrawal times
for meat. The information in this compendium is
available online (www.farad.org), and direct tele-
phone access is provided for situations in which
online information is not sufficient.

Steps in the Development of a New Drug
Preliminary Trials
When a new drug or product shows the potential
for development by a company, it is first subjected
to a series of preliminary trials. The company wants
to know whether the product will actually perform
as expected, whether it has potentially harmful ad-
verse effects, and whether it will be profitable to
market. If these concerns are satisfactorily an-
swered, testing begins. First, the product is tested in
a laboratory on simple organisms such as bacteria,
yeasts, or molds. Computer models may be used to
simulate animal models at this time.

Preclinical (Animal Safety) Trials
If preliminary trial findings prove satisfactory, the
next step involves preclinical trials. These trials
usually are carried out with the use of laboratory
animals to gather information about appropriate
doses of the drug. A few target (intended species)
animals may be used as well. If the results of the
preclinical trials are satisfactory, the company then
notifies the appropriate government agency that a
new drug is under investigation. It does this by fil-
ing an Investigational New Animal Drug (INAD)
application with the FDA. If the product is a pesti-
cide, the company files for an Experimental Use
Permit (EUP) from the EPA. If a biologic is in-
volved, the company contacts the Animal and
Plant Health Inspection Service of the USDA.

Clinical Trials
By this time, the manufacturer has compiled enough
information to decide whether the product should
be tested in the target species. These tests must
prove that the drug is safe and effective. Potential
toxic and adverse effects must be identified. Tissue
residue and withdrawal time information must be
accumulated if the product will be used in food-
producing animals. Possible toxic effects on preg-
nant animals are explored, along with information
about the potential for birth defects (teratogenesis).
Shelf life studies also must be conducted to estab-
lish expiration date data. Results of these studies
are validated through the use of statistical analysis.

Submission of a New Animal Drug
Application
If the manufacturing company decides to market
the drug, it then must file with the FDA a New
Animal Drug Application (NADA). Procedures for
pesticides and biologics are similar.

Final Review by the FDA
Volumes of research are submitted to the FDA,
EPA, or USDA for review. Approval and a license
for manufacture are granted if the appropriate
agency validates the information.

Product Monitoring
As long as a product is marketed, it is monitored
constantly by the company and the government to
ensure its continuing safety and efficacy.

The Green Book
The Green Book is a list of all animal drug products
that have been approved by the FDA for safety and
effectiveness. This list was first published in 1989 as a
cooperative, nonprofit effort between the USDA and
Virginia Polytechnic Institute and State University.
It is funded through an interagency agreement be-
tween the USDA and the FDA. Monthly updates are
made to the list, and the entire list is published each
January. The Green Book is available electronically at
the FDA-CVM World Wide Web site (http://www.
fda.gov/cvm/greenbook/greenbook.html).

Federal Laws Related to Drug
Development and Use
In 1906, Congress passed the first legislation de-
digned to regulate the manufacture, use, and sale of
drugs. Table 1-3 provides a list of the major acts of
Table 1-3  Federal Laws Regulating the Use of Pharmaceutics

<table>
<thead>
<tr>
<th>Date</th>
<th>Legislation</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>1958</td>
<td>Food additives amendment</td>
<td>Regulation of substances added to food for human consumption. Delaney clause provided that no additive may be added if it causes cancer in humans or animals.</td>
</tr>
<tr>
<td>1962</td>
<td>Kefauver-Harris amendment</td>
<td>Provided for safety and effectiveness of drugs by strict control of manufacturing for new animal drugs.</td>
</tr>
<tr>
<td>1968</td>
<td>Animal drug amendment</td>
<td>Provided regulations for new animal drugs. Placed controlled substances into schedules according to their potential for abuse. Called for registration of veterinarians.</td>
</tr>
<tr>
<td>1970</td>
<td>Comprehensive drug abuse and control act</td>
<td></td>
</tr>
</tbody>
</table>

legislation passed before the 1990s and describes the significance of each.

**The Animal Medicinal Drug Use Clarification Act**

In 1994, Congress passed the Animal Medicinal Drug Use Clarification Act (AMDUCA). This legislation made extralabel use of approved veterinary drugs legal under specific well-defined conditions. This act came about because of the lobbying efforts of the American Veterinary Medical Association (AVMA) and other groups in response to the FDA, which had tightened its policies on extralabel use of veterinary drugs. Previously, veterinarians had been permitted to use any drug as long as it could be legally obtained, was used according to sound professional practice, and left no residue in food products (Coppoc, 2003). However, public concerns over food safety issues related to residues of substances such as diethylstilbestrol, chloramphenicol, and antibiotics caused the FDA to issue compliance policy guidelines (CPGs) that made extralabel use illegal. Even though the FDA would not routinely prosecute veterinarians for extralabel use after issuance of the CPGs, practitioners nonetheless were placed in the position of breaking federal law to meet their obligations to animals and their owners. The AMDUCA allows veterinarians to legally select the most efficacious drugs for their patients. The AVMA issued an AMDUCA Guidance Brochure in 1998. This brochure outlines requirements of the act and provides an algorithm that can be used to determine when extralabel use is appropriate.

A section of the AMDUCA states that the FDA may prohibit an extralabel use in animals if the agency finds that such use presents a risk to the public health. The following drugs and substances are prohibited for extralabel use in all food-producing animals:

- Chloramphenicol
- Clenbuterol
- Diethylstilbestrol
- Dimetridazole
- Ipromidazole
- Other nitroimidazoles
- Furazolidone
- Sulfonamide drugs in lactating dairy cattle
- Sulfadimethoxine, sulfabromomethazine, and sulfathioxypyridazine
- Fluoroquinolones
- Glycopeptides
- Phenylbutazone in dairy cattle 20 months of age and older

**Compounding of Veterinary Drugs**

FDA-approved drugs are labeled for specific therapeutic uses in defined species. Because veterinarians must treat a variety of animal species that may vary greatly in size, it is not always possible to use an
approved drug for every clinical situation; therefore, veterinarians may have to dilute or combine (compound) existing medications. For example, it may be in the best interest of a horse to combine more than one drug in a single syringe to minimize the number of injections. It also may be essential to dilute an injectable agent to obtain an appropriate concentration for a bird or mouse, or to prepare an antidote (e.g., sodium sulfate) that is not commercially available. None of these activities would be permitted under a strict interpretation of FDA regulations, which traditionally have not distinguished the act of diluting or combining drugs from the act of manufacturing. Any alteration of a drug by a veterinarian or his or her employee that changes the concentration of the active ingredient, the preservatives, or the vehicles results in a new animal drug that is subject to the FDA approval process (Davidson, 1997). Recognizing the difficulties imposed by these regulations, the FDA issued a CPG (608.400) in 1996 to better define the conditions for which compounding is permitted. These conditions include but may not be limited to (1) identification of a legitimate veterinary medical need; (2) the need for an appropriate regimen for a particular species, size, gender, or medical condition; (3) lack of an approved animal or human drug that when used as labeled will treat the condition; and (4) too long a time interval for securing the drug to treat the condition.

The Minor Use and Minor Species Animal Health Act

There is a shortage in the United States of approved animal drugs intended for use in less common animal species or those with less common conditions. The drugs that do exist may not be used legally in the animals that need the treatment. The Minor Use and Minor Species (MUMS) Animal Health Act of 2001 is intended as a mechanism to provide FDA-authorized drugs for those less common species and indications, similarly to the human Orphan Drug Act of 1983. MUMS specifically defines the provision of labeled drugs for minor species, including sheep, goats, game birds, emus, ranched deer, alpacas, llamas, deer, elk, rabbits, guinea pigs, pet birds, reptiles, ornamental and other fish, shellfish, wildlife, zoo, and aquarium animals. MUMS is also designed to provide major species (e.g., cats, dogs, horses, cattle, swine, turkeys, chickens) with needed drugs for uncommon indications (minor uses).

DISPENSING VERSUS PRESCRIBING DRUGS

Although most physicians prescribe drugs, most veterinarians prescribe and dispense them. The primary reason why veterinarians maintain a pharmacy in their hospitals is that drug sales represent an important source of income. Food animal practitioners in particular use profit from drug sales to supplement their income because it may be difficult for them to charge sufficiently for their time. Another reason why veterinarians dispense drugs from their hospitals is that human pharmacies usually do not stock veterinary drugs. A few drugs are available only from human pharmacies, and others are used so infrequently that veterinarians find it more practical and economical to write a prescription for them.

MARKETING OF DRUGS

Pharmaceutical products are purchased by veterinarians from various sources. Some products are purchased directly from the manufacturer by telephone...
or by mail; others are obtained from sales representatives (detail persons) who call on veterinary clinics. Distributors (wholesalers) are companies that buy products from many different manufacturers and then resell the products to veterinarians through sales representatives or by phone. Generic drug companies sell generic products under their own label, usually by mail order.

Most of the pharmaceutic manufacturers are large companies that have separate divisions. One division sells products to veterinarians only, and the other sells over-the-counter products. It should be noted that the statement "sold to graduate veterinarians only" on a drug label does not mean that the product is a prescription drug. It only indicates a sales policy of the company. In a few instances, the same product is sold under different labels to veterinarians only and to over-the-counter markets. Some feed stores and cooperatives are able to sell over-the-counter products (similar to products sold by veterinarians) to consumers at prices lower than veterinarians can charge because of the quantity purchasing power of the stores. This can be a source of tension between veterinarians and retail markets.

In recent years, Internet pharmacies have emerged on the marketing scene. Many clients attempt to use these resources because of the reduced cost of some products. The primary concern in the veterinary community is that some Internet pharmacies are supplying prescription drugs to consumers without the authorization of a veterinarian with a veterinarian-client-patient-relationship. The prescription may be issued by an out-of-state veterinarian who responds to client questionnaire information, rather than through actual patient and client contact. Solving these problems may be difficult because the FDA regulates the drug products themselves, not the practice of the pharmacy. The board of pharmacy in the individual states where the Internet pharmacy is located and registered regulates the practice of pharmacy. The board of pharmacy in states where consumers are given prescriptions enforces requirements for out-of-state pharmacies. The AVMA advocates a program called "VIPPS" to validate the legitimacy of online pharmacies. VIPPS (Anonymous, 2007) is a voluntary certification program that was created by the National Association of Boards of Pharmacy. The VIPPS seal of approval validates that the online pharmacy is appropriately licensed and is conducting business legitimately. A related issue is the sale of "ethical products" by these Internet companies. These are products for which the manufacturer has voluntarily limited their sale to veterinarians as a marketing decision. Some flea and tick control products are ethical products registered with the EPA or the FDA in the over-the-counter category. Improper sale of these ethical products may then be an ethical rather than a legal issue.

REFERENCES
Ahrens AA: Pharmacology, the national veterinary medical series for independent study, Philadelphia, 1996, Lippincott Williams & Wilkins.
REVIEW QUESTIONS

1. Define the following terms:
   a. Agonist ______________________
   b. Contraindication ______________
   c. Efficacy ______________________
   d. Over-the-counter drug ___________
   e. Prescription drug ______________
   f. Receptor ______________________
   g. Therapeutic index _______________
   h. Withdrawal time __________________
   i. Veterinarian-client-patient relationship _______________________

2. List four sources of drugs used in veterinary medicine. ______________________

3. What are four components of a drug regimen? ______________________

4. Discuss the conditions that must be met before a valid veterinarian-client-patient relationship can be shown to exist. ______________________

5. Discuss the responsibilities of a veterinary technician in the administration of drug orders. ______________________

6. Describe the sequence of events that a drug undergoes from administration to excretion. ______________________

7. List 11 possible routes for administering a drug to a patient, and discuss the advantages and/or disadvantages of each. ______________________

8. List some of the factors that influence drug absorption. ______________________

9. Most biotransformation of drugs occurs in which of the following?
   a. Kidney
   b. Liver
   c. Spleen
   d. Pancreas

10. Most drug excretion occurs via which of the following?
    a. Kidneys
    b. Liver
    c. Spleen
    d. Intestine

11. Drugs usually produce their effects by combining with specific cellular ______________________.

12. The drug name that is chosen by the manufacturer and that is the exclusive property of that company is called ______________________.

13. What are six items that must be included on a drug label? ______________________

14. What are three government agencies that regulate the development, approval, and use of animal health products? ______________________

15. Why do many veterinary clinics dispense rather than prescribe most of the drugs that they use? ______________________

16. Describe the marketing of animal health products. ______________________

17. All FDA-approved veterinary drugs are listed in the publication entitled ______________________.

18. What is the purpose of FARAD? ______________________

19. Extralabel veterinary drug use was made legal (under prescribed circumstances) by what act of Congress? ______________________

20. Define compounding. ______________________

21. What are the potential dangers of residues in animal products? ______________________

22. List three classes of drug interactions.
    1. ______________________
    2. ______________________
    3. ______________________

23. Drug interaction can be anticipated when two drugs are given that are both metabolized by the ______________________.

24. Define "ethical product." ______________________

25. Once a drug has been biotransformed, it is called a ______________________.

26. An(a) ______________________ is a reason to use a drug.
    a. contraindication
    b. indication
27. The diagnostic method of choosing a drug is based on all of the following except _____.
   a. practical experience
   b. assessment of the patient
   c. obtaining a history
   d. performing laboratory tests

28. Extralabel use means _____________.
   a. sold over the counter (OTC)
   b. using a drug in a way not specified by the label
   c. using a drug according to the empirical method
   d. deciding how long the drug should be given

29. All the following are true about a veterinarian-client-patient relationship except:
   a. The veterinarian has seen and treated all the client's pets except a dog for which the owner would like to buy heartworm preventative.
   b. The veterinarian has assumed responsibility for making clinical judgments about the health of the animal(s) and the need for treatment, and the client has agreed to follow the veterinarian's instructions.
   c. The veterinarian has sufficient knowledge of the animal(s) to issue a diagnosis. The veterinarian must have recently seen the animal and must be acquainted with its husbandry.
   d. The veterinarian must be available for follow-up evaluation of the patient.

30. _______ is the complex sequence of events that occurs after a drug is administered to a patient.
   a. Half-life
   b. Metabolism (biotransformation)
   c. Pharmacokinetics
   d. Residue

31. Parenteral drugs are administered _______.
   a. orally
   b. by injection
   c. SC
   d. ID

32. _______ is the body's ability to change a drug chemically from the form in which it was administered into a form that can be eliminated from the body.
   a. Half-life
   b. Metabolism (biotransformation)
   c. Pharmacokinetics
   d. Residue

33. The _______ of a drug represents the degree to which a drug produces its desired response in a patient.
   a. pharmacodynamics
   b. pharmacokinetics
   c. efficacy
   d. metabolism

34. An adverse drug reaction is always life threatening.
   a. True.
   b. False.

35. All the following agencies regulate animal health products except _________.
   a. FDA
   b. EPA
   c. AVMA
   d. USDA
CHAPTER 2

Routes and Techniques of Drug Administration

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Discuss the many types of available drug forms.
2. List and explain the five rights of administering medication.
3. Name available types of syringes and needles, and describe their common uses.
4. Correctly read doses in a syringe.
5. Explain the techniques available for administering medications, the routes commonly used, and how the treatment should be documented.
6. Describe what is involved in preparing a prescription and explain how the prescription is posted to the medical record.
7. List the U.S. Drug Enforcement Administration (DEA) requirements for keeping inventory and dispensing controlled substances.
**KEY TERMS**

**CERUMEN** A waxy secretion of the glands of the external ear canal.

**COUNTERIRRITANT** An agent that produces superficial irritation that is intended to relieve some other irritation.

**CREAM** A semisolid preparation of oil, water, and a medicinal agent.

**ELIXIR** A hydroalcoholic liquid that contains sweeteners, flavoring, and a medicinal agent.

**EMULSION** A medicinal agent that consists of oily substances dispersed in an aqueous medium with an additive to stabilize the dispersion.

**LINIMENT** A medicine in an oily, soapy, or alcoholic vehicle to be rubbed on the skin to relieve pain or to act as a counterirritant.

**OINTMENT** A semisolid preparation that contains medicinal agents for application to the skin or eyes.

**PARENTERAL** Administration by a route other than the alimentary canal (e.g., intramuscular, subcutaneous, intravenous).

**SPECULUM** An instrument for dilating a body orifice or cavity to allow visual inspection.

**SUSPENSION** A preparation of solid particles dispersed in a liquid but not dissolved in it.

**INTRODUCTION**

In a busy veterinary practice, a veterinary technician often administers treatments ordered by the veterinarian. Proper administration techniques should be used along with accurate documentation on the medical record. Additionally, a veterinary technician must be knowledgeable about dosage forms, syringe construction, and hatch marks and must be able to draw correct amounts of medication within a syringe, know the five rights of drug administration, be capable of administering medication by all available routes, be knowledgeable in the area of client education regarding drugs, and know how to properly handle controlled substances. Proper documentation of administered treatments is of utmost importance and ensures that the same treatment is not repeated by other veterinary personnel. Knowledge of adverse reactions that animals may have to particular medications is also crucial. The veterinary technician is the veterinarian's most important employee in a busy practice. Through observation of the patient during treatments, the technician is able to provide the veterinarian with information regarding the patient's response. The doctor, thus informed, can easily reach decisions regarding adjustment of the treatment regimen. The technician who recognizes the importance of administering proper treatment to the patient and who uses observation skills in assessing patient response to that treatment is an invaluable asset to the practice.

**DOSAGE FORMS**

Pharmaceutic companies manufacture drugs in various forms. Some drugs are available in a variety of forms; others may be available for administration in only one form. Most pharmaceutic companies endeavor to provide comfort to the patient and to ensure ease of administration when formulating their drugs. Some common drug preparations may be administered orally, parenterally, through inhalation, intrarectally, and topically. The most common type of preparation is an oral medication. Oral preparations are usually easy to administer, have extended expiration dates, and are manufactured uniformly with respect to the content of the drug.

Tablets are the most commonly used oral form (Figure 2-1). A tablet may be scored or unscored. A scored tablet has indentations that have been made into its surface, allowing it to be broken into halves or quarters. Therefore, a scored tablet provides a way of administering a smaller dose to the patient. A tablet that is unscored may be cut into a smaller size with the use of a pill cutter device. However, scored tablets break more readily and are less likely to fragment. Some tablets whose drug type may be irritating to the gastrointestinal tract
may be enteric-coated. Capsules are containers that house medication. The capsule itself may be made of gelatin and glycerin. The contents of a capsule may be in powder or liquid form. Capsules may be advantageous to use because they allow a patient to be treated without an unpalatable taste coming into contact with the oral mucosa. Unfortunately, capsules cannot be broken down the way a scored tablet can to provide a smaller dose. Boluses are large rectangular tablets that may be scored or un-scored. Boluses are used in the treatment of large animals (e.g., cattle, horses, sheep). Boluses usually are administered to bovines with the aid of a special instrument called a balling gun.

Liquid preparations for oral administration may be purchased in several different forms (e.g., mixtures, emulsions, syrups, elixirs). Mixtures consist of aqueous solutions (i.e., water) and suspensions for oral administration. A suspension usually separates after long periods of shelf life and must be shaken well before it is used, to provide a uniform dose. Syrups often are used as cough remedies; they contain the drug and a flavoring in a concentrated solution of sugar water or other aqueous liquid. In veterinary medicine, an antitussive (e.g., Torbugesic) may be mixed with a liquid vitamin (e.g., Lixotinic) to ensure a more palatable taste for the patient. Elixirs usually consist of a hydroalcoholic liquid that contains sweeteners, flavoring, and a medicinal agent. Emulsions consist of oily substances dispersed in an aqueous medium with an additive that stabilizes the mixture. All liquid oral medications should be administered slowly to allow the patient to swallow before more liquid is given. Rapid administration of oral medication can result in aspiration into the lungs, thereby causing pulmonary problems.

### Technician's Notes
Rapid administration of oral medication can cause the liquid to be aspirated into the lungs, thereby causing pulmonary problems.

Two forms of parenteral injection are available: injections and implants.

Two forms of parenteral injection that are available are injections and implants. Injections are available as single-dose vials, multidose vials, ampules, or large-volume bottles, which may be used to administer intravenous infusions (Figure 2-2). A vial is a bottle that is sealed with a rubber diaphragm. A vial may contain a single dose or multiple doses. A single-dose vial must be discarded after one use (dose). Multidose vials usually contain preservatives that enable them to have a longer shelf life; thus they may be used for more than one dose. Ampules contain a single dose of medication in a small glass container with a thin neck, which is usually scored so that it can be snapped off easily. Some drugs may be unstable in solution and may require reconstitution with sterile water or another diluent; these may be used immediately for injection (Procedure 2-1).

### Technician’s Notes
It is a good idea to place a paper towel over the neck of an ampule before breaking it, to protect the fingers from glass cuts.

Syringes and needles are used for parenteral administration of drugs (Box 2-1). This equipment must be sterile. Drugs should never be stored in syringes for a long time before administration occurs because some drugs may be absorbed into the plastic makeup of the syringe, resulting in an inadequate dose.
Parenteral medications are supplied in single-dose vials (A), multidose vials (B), ampules (C), and large-volume bottles or bags used for intravenous administration (D).

<table>
<thead>
<tr>
<th>Animal</th>
<th>Needle Gauge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swine</td>
<td>16, 18</td>
</tr>
<tr>
<td>Cattle</td>
<td>16, 18</td>
</tr>
<tr>
<td>Horses</td>
<td>16, 18, 20</td>
</tr>
<tr>
<td>Dogs</td>
<td>20, 21, 22, 25</td>
</tr>
<tr>
<td>Cats</td>
<td>22, 25</td>
</tr>
<tr>
<td>Small exotics</td>
<td>23, 25, 27</td>
</tr>
</tbody>
</table>
PROCEDURE 2-1

Reconstitution of a Medication

Materials Needed
Syringe of adequate size for the amount of diluent with a needle attached
70% isopropyl alcohol
Cotton swab

Procedure
1. Clean the rubber diaphragm of the medication vial and the diluent vial with an alcohol swab (Figure 2-3, A).
2. Remove the needle cap and pull back on the plunger to fill the barrel with air equal to the desired amount of diluent. Inject the air into the vial of diluent to create positive pressure and to ease withdrawal (Figure 2-3, B). Invert the diluent vial and withdraw the desired amount of diluent.
3. Inject the diluent into the medication vial and withdraw the syringe and needle. Shake the vial to mix well (Figure 2-3, C).
4. Positive pressure may be created in the freshly mixed medication vial before the desired amount of medication has been withdrawn. Once the medication has been withdrawn (Figure 2-3, D), label the syringe if needed, or administer the drug to the patient. After withdrawing the patient’s medication, dispose of the vial, or store it according to the label.
**BOX 2-1  Syringes and Needles**

**Syringes**

Syringes are available in various sizes and styles. The most commonly used sizes are 3 ml, 6 ml, 12 ml, 20 ml, 35 ml, and 60 ml. Syringes may be ordered from the manufacturer with or without an attached needle. The tip of the syringe, where the needle attaches, can be one of four types: Luer-lok tip (Figure 2-4, A), slip tip (Figure 2-4, B), eccentric tip (Figure 2-4, C), or catheter tip (Figure 2-4, D). Each type of tip has its own advantages and disadvantages and is often chosen because of personal preference. A complete syringe consists of a plunger, barrel, hub, needle, and dead space (Figure 2-5). The area in which fluid remains when the plunger is completely depressed is called dead space.

**Tuberculin syringe**

A tuberculin syringe (Figure 2-6) holds up to 1 ml of medication. It usually is available with a 25-gauge or smaller attached needle. This syringe is commonly used for injections of less than 1 ml. Some tuberculin syringes have a dead space. Although the patient receives the proper amount of medicine, some liquid remains in this dead space, thus wasting the drug and costing the practice money. This is also important to remember when a tuberculin syringe is used to draw up controlled substances. The dead space will cause the controlled substance log book to reflect more of the controlled substance than is actually in the vial. Thus, the dead space should be considered when...
amounts used are documented. Some tuberculin syringes are manufactured with low dead space or no dead space at all. In the case of syringes with no dead space, the needle screws into the TB syringe instead of attaching to the tip.

**Multidose syringe**

A multidose syringe (Figure 2-7) is commonly used for large animals when several animals require the same injection. It allows the user to set the dose and to give repeated injections until the barrel is empty of medication. This type of syringe may be disassembled and disinfected for reuse.

**Insulin syringe**

An insulin syringe (Figure 2-8) usually is supplied with a 25-gauge needle and, different from other syringes, it has no dead space. The syringe is divided into units instead of milliliters and should be used only for insulin injection.

Figure 2-9 illustrates the importance of being familiar with the different types of syringes and the units of measurement found on each. This is necessary to ensure that one can draw up an accurate amount of medication.

**Figure 2-7**
A multidose syringe.

**Figure 2-8**
An insulin syringe with needle attached. (Courtesy Sherwood Medical, St. Louis, Mo.)

**Figure 2-9**
Examples of how to read amounts of medication contained in a syringe.

Continued
Syringes and Needles (cont'd)

Needles

Needles are available in various sizes and styles, but all needles have the following three parts: hub, shaft, and bevel (Figure 2-10). Needle sizes vary by gauge and by length (Table 2-1). The gauge refers to the inside diameter of the shaft; the larger the gauge number, the smaller the diameter. The length of the needle is measured from the tip of the hub to the end of the shaft. Lengths longer than 1 inch usually are used in large animals and occasionally for biopsy. The bevel is the angle of the opening at the needle tip. It is often helpful when venipuncture is performed to have the beveled side of the needle facing up before the needle is inserted into the patient.

Bleeding needles (Figure 2-11) may be up to 3 inches long, are large gauge (14 to 16 gauge), and usually are used for obtaining blood from cattle and swine. These needles are made of stainless steel and are reusable after proper cleaning and disinfecting. Biopsy needles (Figure 2-12) are used for obtaining bone marrow or soft tissue and organ specimens. These needles vary in size and style.

**Figure 2-9** (cont'd)

**Figure 2-10**
A needle consists of three parts: hub, shaft, and bevel.

**Figure 2-11**
A 3-inch stainless steel bleeding needle.

**Figure 2-12**
A stainless steel biopsy needle.
Implants are very hard sterile pellets that contain a chemical or a hormonal agent. Implants are inserted subcutaneously and are absorbed by the body over an extended time. Growth hormones are commonly manufactured in this form for use in cattle and are implanted in the subcutaneous dorsal aspect of the ear.

Topical medications are available in several forms. Liniments are medicinal preparations for use on the skin as a counterirritant or to relieve pain. Lotions are liquid suspensions or solutions with soothing substances that may be applied to the skin. An ointment is a semisolid preparation of oil and water, plus a medicinal agent. The water in an ointment evaporates after application and leaves the drug behind on the skin’s surface. Dusting powders (e.g., flea powder) are mixtures of drugs in powder form for topical application. Additionally, powders may have adsorbent (corn starch) or lubricant (talcum) properties. Aerosols are drugs that have been incorporated into a suitable solvent and packaged under pressure with a propellant. Dusting powders and aerosols are common forms for some topical insecticides and wound dressings.

Microencapsulation is a drug form that stabilizes substances commonly considered unstable. Microencapsulation also may be used for drugs intended to be released slowly over a period of time (e.g., moxidectin [ProHeart injection]). (Note: ProHeart has been taken off the market.) When the drug’s active ingredients are microencapsulated, a protective environment is formed against harmful substances and the stability of the product is improved. Microencapsulation completely masks the flavor of a drug and allows oral treatments to be administered with greater ease because the patient is unable to taste or smell the ingredients.

**DRUG PRESERVATIVES AND SOLVENTS**

In addition to the active ingredient, many drugs contain organic or inorganic agents as additives or pharmaceutic aids. These inactive (or inert) ingredients facilitate tablet administration, improve solubility, or increase stability. Although the quantity of inert ingredients is usually small, these ingredients can cause adverse effects, or a patient may be sensitive to or may smell the ingredients.

Parenterally administered drugs often contain chemical preservatives that are used to prevent destruction and loss of potency through oxidation or hydrolysis. The amount of preservative in the formulation of parenterally administered drugs is an optimal concentration and the reconstituted medication should be used immediately to prevent the possibility of fungal or bacterial growth. Dilution of the drug reduces the effectiveness of the preservatives. Most drugs are water soluble, although some may need additives to increase solubility. Glycols are one example of additives used to increase solubility. Generally, propylene glycol and polyethylene glycols are preferred.

**Technician’s Notes**

Some vaccines may contain antibiotic preservatives. Care should be taken by personnel during reconstitution of these vaccines because liquid that escapes from the rubber seal of the vial could be sprayed inadvertently into an allergic person’s eye (e.g., those persons with hypersensitivity to penicillin).

**DRUG ADMINISTRATION**

A veterinarian initiates administration of drugs for therapeutic purposes. (It is unlawful for a veterinary technician to prescribe drugs for an animal patient.) The role of the technician is to administer drugs to the patient on the order of a veterinarian. When doing this, a technician must always follow the five rights:

1. Right patient
2. Right drug—check label three times before administering the drug
3. Right dose  
4. Right route  
5. Right time and frequency

By following these rules, a technician will efficiently and effectively medicate a patient.

**Oral Medications**
The most common forms of drug therapy are tablets and capsules. These are easily administered (Procedure 2-2) and are sometimes used in conjunction with other drug forms.

### PROCEDURE 2-2

**Oral Administration of Tablets or Capsules for Dogs and Cats**

**Materials Needed**
- Medication in tablet or capsule form
- Pilling gun (optional) (Figure 2-13)

**Procedure**
1. Hold the animal's upper jaw with one hand and apply pressure against the upper premolars to cause the mouth to open.
2. Push the medication over the tongue of the animal with the other hand or with the pilling gun (Figure 2-14).
3. Close the animal's mouth.
4. Initiate swallowing by blowing into the animal's nose and/or rubbing its throat (Figure 2-15).

**Figure 2-13**
Example of a small-animal pilling gun.
PROCEDURE 2-2
Oral Administration of Tablets or Capsules for Dogs and Cats—cont’d

Technician’s Notes
Coating the tablet or capsule with a palatable substance such as Cat Lax, peanut butter, or canned food may help in pilling difficult animals.

Copyrighted image

Figure 2-15

Copyrighted image

Figure 2-16
A balling gun used to administer a bolus to large animals.

In large animals, a balling gun (Figure 2-16) is used to administer boluses. With proper restraint, this is usually not too difficult.

Liquid oral medications may be administered to small animals through a syringe with the needle removed (Procedure 2-3 and Figure 2-17) or, in some instances, through an orogastric or nasogastric tube. Most liquid medications are made palatable to ease administration. Oral liquid medications are used commonly in exotics and may be administered through the drinking water or an orogastric tube. In large animals, a stomach tube usually is used to administer oral liquid medications (Figure 2-18). In cattle, the stomach tube is passed through a Frick speculum (Figure 2-19).

Technician’s Notes
Oral Medications
1. Remember when administering oral medications, that it takes longer for a drug to be absorbed into the bloodstream by this route as compared with parenteral injection.
2. Do not use oral administration in animals that are vomiting.

Copyrighted material
PROCEDURE 2-3

Oral Administration of Oral Liquid Medication With a Syringe for Dogs and Cats

Materials Needed
Syringe with the needle removed or oral dose syringe
Oral medication in liquid form

Procedure
1. Fill syringe with the calculated amount of medication.
2. Tilt the animal's head up slightly.
3. Insert the tip of the syringe into the animal's cheek pouch (Figure 2-20).
4. Administer the medication slowly.

Technician's Notes
Attachment of a J-12 Teat Infusion Cannula (Jorgensen Laboratories, Loveland, Colorado) is handy for administering oral liquid medications.

Parenteral Medications

Parenteral administration (i.e., injection) of liquid medications may be used alone or in conjunction with other forms of medication. Some conditions are unfavorable for oral administration (e.g., in vomiting patients), and some drugs are available only for parenteral administration.

Approximately 10 routes are used commonly for parenteral administration of drugs; the most commonly used are the intramuscular, subcutaneous, and intravenous routes (Figures 2-21 to 2-23). A veterinary technician must be aware of the proper route of administration for each drug. For those in doubt, the route of administration usually is listed.
Figure 2-21
Intramuscular injections in the pelvic limb should be given in an area that avoids the large sciatic nerve, labeled as M.
on the drug label or the package insert. Sometimes, complications may result after parenteral administration of a drug. Common complications include irritation, necrosis, and infection of the injection site. Sometimes, allergic reactions to medications may occur. Clinical signs of an allergic reaction after a parenteral drug has been administered include swelling around the face or extremities, raised bumps or swellings on the skin's surface, edema, and salivation. If any complications are observed, these should be reported immediately to the veterinarian. Care should be exercised when an intramuscular injection is administered, so that nerve damage or accidental injection into a vein or artery can be avoided. Negative pressure should be applied to the plunger of the syringe before an intramuscular (or subcutaneous) injection is performed. Should any blood be observed in the hub of the needle, the needle should be redirected or removed. Care should also be exercised when intraperitoneal injections are provided, so that peritonitis does not develop and damage to the abdominal viscera does not occur. Proper administration involves knowing (1) what equipment is needed, (2) how the dose should be calculated, and (3) the proper method for withdrawing and administering medication (Procedure 2-4).

Intravenous (IV) administration allows the most rapid and effective drug administration (Procedure 2-5). IV therapy is used most commonly to maintain and restore fluid and electrolyte balance, to administer drugs, and to transfuse blood. IV administration also is used when the medication is contraindicated for other routes of administration. Sites for IV administration include the cephalic vein, the jugular vein, the lateral saphenous vein, and sometimes the femoral veins. Long-term IV therapy is best achieved with the cephalic or jugular veins.

In some cases, an animal may need repeated IV injections. The veterinarian may order the placement of an indwelling IV catheter in an effort to lessen vein damage and pain for the animal (Procedures 2-6 and 2-7).

**Technician’s Notes**
An IV catheter must be removed after 72 hours and replaced with a new one. Time can be accounted for by writing (e.g., use a permanent marker) placement time on the adhesive bandage that secures the IV catheter in the animal’s vein. Additionally, IV tubing should be changed after a 24- to 48-hour period.
PROCEDURE 2-4

Parenteral Administration of Medications—Intramuscular or Subcutaneous

Materials Needed
Syringe and needle (Figure 2-24)
Parenteral medication
Cotton swabs
70% isopropyl alcohol

Procedure
1. If the syringe is not supplied ready-to-use, firmly attach the needle to the syringe.
2. Swab the bottle's rubber diaphragm with cotton that is saturated with alcohol.
3. Remove the needle cap, insert the needle at an angle into the rubber diaphragm, and withdraw the calculated amount of the drug.
4. Hold the syringe with the needle pointing upward, and remove the large air bubbles by briskly tapping the barrel of the syringe.
5. Release the air bubbles by slightly pushing on the syringe plunger. Carefully replace the needle cap if the medication is not to be given immediately. Avoid contamination.
6. Swab the injection site with another cotton swab that is saturated with alcohol.
7. Insert the needle into the appropriate site and pull slightly on the plunger. If no blood is seen, inject the medication and remove the needle from the site. Blood indicates that a vessel has been entered. Withdraw the needle and continue with the same procedure at a different site.
8. Massage the injection site to aid distribution and decrease pain.
9. Properly dispose of the syringe and needle.

Guidelines for Parenteral Doses
- Round up to the nearest tenth if the amount is greater than 1 ml, and measure in a 3-ml syringe.
- Measure amounts less than 1 ml in a tuberculin (TB) syringe.
- In cats weighing less than 9 lb, 0.5 to 1.0 ml is an appropriate amount for intramuscular (IM) injection.
- In cats weighing more than 9 lb, 1 to 1.5 ml is an appropriate amount for IM injection.
- In dogs weighing up to 10 lb, 0.5 to 1 ml is an appropriate amount for IM injection.
- In dogs weighing 10 to 30 lb, 1 to 2 ml is an appropriate amount for IM injection.
- In dogs weighing more than 30 lb, 2 to 4 ml is an appropriate amount for IM injection.

Figure 2-24
(Courtesy Shenwood Medical, St. Louis, Mo.)

Technician's Notes
Injecting multidose vials with air sometimes allows easier withdrawal of medication.
**PROCEDURE 2-5**

Parenteral Administration of Medication—Intravenous Direct Bolus

**Materials Needed**
Syringe containing calculated dose with needle attached
Cotton swabs
70% isopropyl alcohol or surgical scrub
Butterfly catheter (scalp vein needle, Figure 2-25) —optional
Syringe containing 3 ml of flushing solution (e.g., heparinized saline: 500 IU sodium heparin in 250 ml of normal saline)
Tape (optional)

**Procedure Without Catheter**
1. Clip the area over the venipuncture site, if desired.
2. Prepare the area with alcohol swabs or surgical scrub.
3. Have the restraint person hold pressure on the vein or use a tourniquet.
4. Perform venipuncture with the medication syringe and needle. If blood enters the hub of the needle, the venipuncture is successful.
5. Release pressure from the vein and proceed to inject the medication over the recommended time interval.
6. Remove the needle and apply pressure to the site to stop bleeding.
7. A bandage made of tape and cotton may be applied, if needed.

**Procedure With a Butterfly Catheter**
Proceed with steps 1 through 3 as described in the previous section (McCumin and Bassert, 2006).
1. Remove the cap from the catheter tubing and needle cover.
2. Perform venipuncture with the catheter. If this is successful, blood will return into the catheter tubing.
3. Release pressure from the vein, and allow the blood to fill the catheter tubing.
4. Remove the needle from the medication syringe and attach the syringe hub to the catheter tubing.
5. Administer the medication at the recommended time interval.
6. Remove the needle from the syringe containing the flushing solution. Remove the medication syringe from the catheter and attach the syringe containing the flushing solution.
7. Flush the catheter with 1 to 2 ml of solution to ensure administration of all medication.
8. Remove the catheter and apply pressure to the site to stop the bleeding.
9. A bandage may be applied as described earlier.
10. Properly dispose of all syringes and needles in an approved sharps container.

**Figure 2-25**
Butterfly catheter.

**Technician's Notes**
Watch for swelling at the injection site. Swelling may signal extravascular injection. Notify the veterinarian immediately if this should occur.
Administration by Bolus With an Indwelling Intravenous Catheter

Materials Needed
- Syringe containing flushing solution (about 3 ml)
- 70% isopropyl alcohol
- Cotton swabs
- Syringe with medication and attached needle

Procedure
1. Clean the cap of the indwelling catheter with an alcohol swab.
2. Insert into the catheter cap the needle of the syringe containing the flushing solution. (Use the smallest-gauge needle possible to help prevent a leak in the catheter cap.)
3. Gently aspirate to determine correct placement of the catheter (blood entering the hub shows proper placement).
4. Inject half the flushing solution into the catheter. Observe the area over the vein for swelling.
5. Remove the syringe and needle, and carefully replace the cap to prevent contamination.
6. Insert into the catheter cap the needle of the syringe containing the medication, and inject the medication over the recommended time interval.
7. Remove the syringe and needle from the catheter.
8. Flush the catheter with the remaining flushing solution.
9. Observe the area for swelling and look for signs of discomfort. Report any abnormal observations to the veterinarian.
10. Properly dispose of syringes and needles.

Technician's Notes
Some hospitals may require that with flushing solution, two syringes should be used instead of the same syringe and needle for both flushes. Keep additional male adapter plugs (catheter caps) (Figure 2-26) in stock to replace a leaky cap.

Figure 2-26
Examples of a male adapter plug. (Manufactured by Abbott Laboratories, Abbott Park, Ill.)
**PROCEDURE 2-7**

**Administration of Intravenous Fluids**

**Materials Needed**
- Indwelling catheter (Figure 2-27)
- Tape
- 70% isopropyl alcohol or surgical scrub
- Infusion set
- IV fluids
- Clippers

**Procedure**

1. Remove the IV tubing from the container and the protective covering from the medication bottle or bag.
2. Remove the covering of the diaphragm of the medication bag or bottle.
3. Close the clamp on the IV tubing. Remove the cap of the IV tubing spike and insert it into the diaphragm of the medication bag or bottle.
4. Squeeze the drip chamber to allow fluid to collect in the chamber. Fill to the designated line or about half full.
5. Remove the protective cap from the end of the IV tubing and slowly open the roller clamp to allow the fluid to clear the tubing of air. Replace the protective cap and hang the medication bag or bottle on the IV pole near the patient.
6. Clip and scrub the chosen site for catheter placement.
7. After successful catheter placement, cap the catheter, wipe away any blood, and quickly tape in place. The time of placement should be recorded on the adhesive tape with a permanent marker.
8. Remove the catheter cap and the protective cap of the IV tubing and insert the end of the tubing directly into the end of the catheter. Or, if desired, a needle may be placed on the end of the tubing and inserted into the catheter cap.
9. Open the clamp to begin a slow drip and lower the medication bag or bottle to below the IV site to confirm correct placement.
10. Return the bottle or bag to the IV pole and set at desired flow rate.
11. Tape the tubing to the patient at the catheter site.

**Technician’s Notes**

1. Mark the fluid level and time on tape placed on the bag with a permanent marker (tape can be used on bottles). Use this procedure each time the patient is checked.
2. If any medications are added to the fluids, write the medication, time, and amount on the medication bag or tape.
3. Tape the catheter cap to the bag or bottle so that it will be ready when needed.

---

**Figure 2-27**

A 14-gauge indwelling catheter. (ABBOCATH is a registered trademark of Abbott Laboratories, Abbott Park, Ill.)
**PROCEDURE 2-8**

**Administration by Bolus Using the Y-Injection Site**

**Materials Needed**
- Syringe with medication and the needle attached
- Cotton swabs
- 70% isopropyl alcohol

**Procedure**
1. Close the clamp on the infusion set.
2. Clean the Y-injection site (Figure 2-28) with an alcohol swab.
3. Insert the needle of the medication syringe into the Y-injection site.
4. Inject the medication over the recommended time interval.
5. Remove the medication syringe and needle.
6. Open the clamp on the infusion set. Allow enough fluid to flow through the infusion set to ensure that all medication is received. Then return to the desired flow rate.
7. Properly dispose of the syringe and needle.
8. Note: No flushing solution is required for this procedure.

![Figure 2-28 Intravenous set with Cari clamp and Y-injection site.](image)

**Technician’s Notes**

To check for proper placement of the IV catheter, remove the bag of fluids from the IV pole and hold the bag and tubing below the level of the catheter (do not close the clamp on the infusion set). If blood returns into the tubing, the catheter is properly placed. Return the bag to the IV pole and continue fluid administration.

If the patient is receiving IV fluids, the Y-injection site (see Figure 2-28)—located on the IV tubing—may be used to administer medications by direct bolus (see Procedure 2-8). When medications are to be administered continuously and for long periods, the IV tubing must be changed after a 24- to 48-hour period. Once the medication bottle or bag has been emptied, replacement is necessary to facilitate care of the patient. An indwelling catheter must be removed after 72 hours and replaced with a new one in a different vein location (McCurnin, 2006). If the IV catheter is not used continuously, it should be flushed with heparinized saline every 8 to 12 hours.

A simplex (i.e., gravity set) IV set is used to administer medications or fluids intravenously to large animals (Figure 2-29). This administration set may be disinfected and reused. Disposable IV sets and large-volume fluid bags are available for large animals that require continuous IV therapy.

In pediatric patients and small exotics, IV medications may be administered by intraosseous cannulation. This route also may be used in larger patients when rapid administration of fluids or drugs is necessary and a vein is not readily available. If needed, large volumes of fluid may be administered in this manner.
Technician's Notes

Parenteral Medications
1. Some liquid medications for parenteral administration may "settle out" or precipitate (e.g., penicillin, Vetalog). Therefore these medications should be shaken gently to mix the solution before it is injected into the patient.
2. Drugs that may cause tissue irritation are administered by the intravenous route (e.g., pentothal, vincristine). Therefore, one should be sure to check the drug's package insert to identify the correct way to administer the drug.

Intramuscular Injections
1. Ketaset can be administered by intramuscular injection. Ketaset has a tendency to burn upon injection, and careful restraint methods, along with rapid injection of this drug, should be used in cats.
2. Upon insertion of the needle into the chosen muscle, always apply negative pressure to the syringe's plunger to be certain that the needle has not entered a blood vessel. If blood is seen in the hub of the syringe, remove and redirect the needle.

Subcutaneous Injections
1. Most vaccines can be administered subcutaneously. However, the intrascapular area should always be avoided when subcutaneous injections are given.

Inhalation Medications
In veterinary medicine, inhalation is used primarily to produce anesthesia. The inhalant gas is placed into the anesthetic machine in liquid form and then is vaporized through the machine and delivered to the patient via an endotracheal tube, an anesthetic gas mask, or an induction chamber (Figures 2-30 to 2-32). Medications occasionally may be nebulized to treat an upper respiratory tract (URT) problem, and oxygen may be delivered to a patient with dyspnea with the use of inhalation techniques.

In some veterinary hospitals, use of an infusion pump may facilitate continuous IV administration. Once the necessary flow rate is known (the rate is ordered by the veterinarian), the technician can set the infusion pump to deliver a constant amount of solution per minute or hour. To determine the pump settings, the technician considers the total amount of solution to be given and the time interval for infusion. The operating instructions for the infusion pump should be followed because each model may operate in a slightly different manner.

Technician's Notes
It should be remembered that any patient on IV fluid therapy should be monitored every 15 to 30 minutes.

Monitoring involves evaluating drip rate; ensuring that the IV catheter is properly placed in the vein; making sure the patient has not moved around in the cage to such an extent that the IV tubing has become kinked; and, most important, ensuring that the patient has not chewed the IV catheter out. Animals can do surprising things, and it is up to the technician to provide an excellent level of nursing to ensure that no harm comes to the patient.
Topical Medications

Topical administration of medicine involves application of drugs (creams, ointments, and drops) to the body’s surface. Topical preparations usually provide local effects instead of systemic ones. Clipping hair from the affected area provides better visualization during treatment and makes application easier and absorption faster. The technician should observe the area after treatment and should report adverse reactions to the veterinarian. The technician should provide client education regarding skin medications, including information on frequency and number of applications. Many clients apply too much medication, which not only is unnecessary but can be quite costly with some medications.

Ophthalmic drugs are supplied as an ointment or a solution. The eyes have the ability to remove foreign substances rapidly. Therefore, these preparations usually are applied several times a day. Application frequency depends on the disease or disorder, the drug, and the type of formulation. When ophthalmic preparations are applied, the hand that is holding the medication should rest on the animal’s head above
the affected eye (Figure 2-33). Drops should be placed at the inner canthus of the eye. If application of ointment is necessary, a small strip should be applied along the lower palpebral border, with assurance that the applicator tip does not come into contact with the eye or conjunctiva. When you are demonstrating to a client how to apply eye medications, point out that the applicators have blunt tips. Therefore, should the applicator tip inadvertently touch the eye, no harm should occur.

Drugs may be applied topically to the ears for local effect to soften cerumen and ease its removal, or to treat a superficial infection or ear mites. Cleaning of the ears before otic medication is applied aids the effectiveness of treatment. The veterinary technician should provide instruction to the client regarding the correct ways to clean ears and to apply ear medication. By explaining the ear’s anatomy, the technician can assure the client that it is difficult to reach the animal’s eardrum when one is swabbing the ear clean.

**MEDICATION ORDERS**

In a veterinary hospital, most medication orders are written or verbal. A written order may be provided in prescription form or may be noted in the medical record. Verbal orders are given directly to the technician by the veterinarian. When filling a prescription, the technician must be familiar with abbreviations frequently applied to the medical record to describe drug therapy. Appendix A lists abbreviations commonly used in veterinary medicine. The technician must know the patient being treated, the route of administration used, and the frequency of administration. This information is described in the medication order. After the medication has been administered to the patient, a notation should be made in the medical record describing when, what, how, and by whom the medication was administered. Observations of the patient’s progress should be noted in the medical record (Figure 2-34). If the medication order is a prescription (Figure 2-35) to be filled, the order should be dated and noted in the medical record (Figure 2-36). If the owner picks up the prescription at the veterinary hospital, the medical record should be retrieved and presented to the veterinarian for approval of the refill. The same procedure as described earlier should be followed for dispensing medication.

![Figure 2-33](image)

**Figure 2-33**
Ointment is applied to the dog’s eye on the lower palpebral border.

---

**6-18-95**

**9:30 AM patient B&A**

**T-102°**

**250 mg Amoxi PO, flushed IV catheter with heparinized saline, continue IV LR at 15 gtt/min C. Smith, LVT**

**Figure 2-34**

After medication is administered to a patient, a notation should be made in the patient’s medical record.
CONTROLLLED SUBSTANCES

Substances that have the ability to become habit-forming for humans are labeled as controlled substances. The Drug Enforcement Agency (DEA) requires that the upper right corner of the original container should show a code containing a capital C (controlled), followed by a Roman numeral indicating one of the five schedules defined by the Code of Federal Regulations. Because some of these drugs may be misused, the DEA requires that they be kept in an unmovable locked area, and that an inventory log be kept to report amounts used and on hand (Figure 2-37). Each time a controlled drug is administered or dispensed to a patient, this must be reported in the controlled substance inventory log, as well in the patient's medical record. This documentation should include the following: (1) date, (2) owner's name, (3) patient's name, (4) drug name, (5) amount administered or dispensed, and (6) the names of veterinary personnel who dispensed the drug. If the drug is to be dispensed, the label must bear the following warning: "Caution: Federal law prohibits the transfer of this drug to any
Drug: diazepam

<table>
<thead>
<tr>
<th>Patient</th>
<th>Owner</th>
<th>Beginning</th>
<th>Administered</th>
<th>On hand</th>
<th>Initials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toby</td>
<td>Smith</td>
<td>5 ml</td>
<td>0.2 ml</td>
<td>4.8 ml</td>
<td>BD/JC</td>
</tr>
<tr>
<td>Frisky</td>
<td>Potto</td>
<td>4.6 ml</td>
<td>0.15 ml</td>
<td>4.65 ml</td>
<td>LW/RW</td>
</tr>
<tr>
<td>Gilbert</td>
<td>Pettes</td>
<td>4.85 ml</td>
<td>0.5 ml</td>
<td>4.15</td>
<td>LW/RW</td>
</tr>
<tr>
<td>T.J.</td>
<td>Curtis</td>
<td>4.15 ml</td>
<td>0.2 ml</td>
<td>3.95</td>
<td>BD/JC</td>
</tr>
</tbody>
</table>

**Figure 2-37**
Example of a controlled substance inventory log.

person other than the patient for whom it was prescribed" (Webb and Aeschbacher, 1993). A list of the controlled substances most commonly used in veterinary medicine is available in Appendix D.

**Technician’s Notes**

**Drug Storage**
1. The manufacturer’s instructions should be followed closely to facilitate safe storage.
2. Some drugs are sensitive to light and humidity.
3. The location of the pharmacy in a veterinary hospital should not be accessible to the public.

**CLIENT EDUCATION**

Veterinary technicians should make themselves familiar with all administered and dispensed drugs. Often, it is the technician’s duty to educate clients about how a medication should be administered and why it has been prescribed, and about any adverse reactions that may occur. The technician should consult the veterinarian to gather information about any questions that he or she cannot answer. If needed, written information about the medication should be available for the client’s reference purposes.

**REFERENCES**
REVIEW QUESTIONS

1. Name four common drug preparations.

2. Boluses are used in the treatment of ___________________ animals and are administered with a ___________________.

3. Name two types of parenteral injection forms.

4. Vials may be either ___________________ dose or ___________________ dose.

5. All used needles should be discarded in a ___________________.

6. Name the five rights of drug administration.

7. Oral drugs should never be administered in animals that are ___________________.

8. Intravenous administration of drugs allows the most ___________________ and effective drug administration.

9. An indwelling catheter should be replaced with a new one every ___________________ hours.

10. A simplex (i.e., gravity set) IV system is used to administer fluids to ___________________ animals.

11. Name six items that should be recorded in the controlled substance log.

12. Why should drugs given by injection not be stored in syringes for any length of time before administration? ___________________.

13. List four types of syringe tips that are available for use. ___________________.

14. A tuberculin syringe holds up to ___________________ ml of medication.

15. What type of syringe is divided into units rather than milliliters?

16. A(n) ___________________ is an agent that produces superficial irritation that is intended to relieve some other irritation.
   a. elixir
   b. emulsion
   c. liniment
   d. counterirritant

17. A(n) _________ will usually separate after long periods of shelf life and must be shaken well before use to provide a uniform dose.
   a. elixir
   b. antimicrobial
   c. suspension
   d. anthelmintic

18. This type of syringe is constructed in such a way that the needle screws onto the tip of the syringe.
   a. slip tip
   b. eccentric tip
   c. catheter tip
   d. Luer-lok tip

19. All the following are sites for IV administration in small animals, except:
   a. jugular vein
   b. carotid artery
   c. lateral saphenous vein
   d. phalic vein

20. An indwelling catheter must be replaced every ___ hours.
   a. 48
   b. 24
   c. 60
   d. 72

21. If an IV catheter is not used continuously, it should be flushed with heparinized saline every ___ to ___ hours.
   a. 6; 12
   b. 4; 18
   c. 8; 12
   d. 8; 10

22. Cerumen is a substance that is commonly found in what anatomic part of the body?
   a. urinary bladder
   b. ear
   c. rectum
   d. crown of the tooth
23. Any patient on IV fluid therapy should be monitored every ___ to ___ minutes.
   a. 1; 2
   b. 15; 30
   c. 90; 120
   d. 60; 120
24. IV tubing should be changed after a ___- to ___-hour period.
   a. 12; 24
   b. 12; 48
   c. 12; 36
   d. 24; 48
25. When an intramuscular injection is given in the pelvic limb of a dog or cat, the area near the ____ nerve should be avoided.
   a. radial
   b. sciatic
   c. ischiatic
   d. both b and c
CHAPTER 3

Practical Calculations in Pharmacology

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Exhibit an understanding of the systems of measurement.
2. Explain how to perform conversions while using the metric system and other systems of measurement.
3. Demonstrate how to perform dosage calculations.
4. Explain how percent concentrations are prepared.
**KEY TERMS**

**EQUIVALENT WEIGHT** 1 g molecular weight (from periodic chart) divided by the total positive valence of the material.

**MILLIEQUIVALENT** 1/1000 of an equivalent weight. A term used to express the concentration of electrolytes in a solution.

---

**INTRODUCTION**

Veterinary technicians often are called on to prepare and administer medications to animal patients. A veterinarian’s orders may call for administration of a specific number of milligrams or units of medication (dose). The technician then must determine the quantity (in milliliters, tablets, and so forth) of the preparation that contains the appropriate dose. In other instances, the technician may be called on to calculate the dose on the basis of a dosage rate (found in the insert or in reference books) and the animal’s weight. In either case, an error in calculation can seriously affect the health of a patient. This chapter provides the background information and applications needed by the veterinary technician to accurately carry out a veterinarian’s medication orders.

---

**MATHEMATICS FUNDAMENTALS**

It is assumed that the student who uses this text has a basic understanding of fractions and decimals. With these fundamentals as a background, the concepts of percent, ratio, and proportion should be reviewed before the practice problems are solved.

Percent is defined as parts per hundred. Percent is a fraction with the percent as the numerator and 100 the denominator (e.g., 5% = 5/100). Percents may be written as decimals, fractions, or whole numbers.

**Example 1:**
- Decimal: 0.3%
  (three-tenths percent [3/10 ÷ 100])
- Fraction: 1/5%
  (one-fifth percent [1/5 ÷ 100])
- Whole number: 5%
  (five percent [5 ÷ 100])

Percent may be changed to fractions or decimals.

**Example 2:** Change to a fraction:
5% = 5/100 = 1/20
Change to a decimal:
5% = 5/100 = 0.05

Note that a percent can be changed to a decimal quickly by dropping the percent sign and moving the decimal two places to the left.

**Example 3:** 5% = 0.05

A ratio is a way of expressing the relationship of a number, quantity, substance, or degree between two components. In reality, ratios are fractions, with the first number in the ratio the numerator and the second number the denominator. The numbers may be placed side by side, separated by a colon, or they may be set up as a numerator/denominator (e.g., 1:5, 1/5). In mathematics, a ratio may be expressed as a quotient, a fraction, or a decimal, per the following:

**Example 4:** 1 ÷ 5, 1/5, 5/1.0 = 0.2

A proportion shows the relationship between two ratios. When a proportion is set up, the two ratios usually are separated by an = (equals) sign.

**Example 5:** 8:16 1:2 or \[
\frac{8}{16} = \frac{1}{2}
\]

The proportions above read “8 is to 16 as 1 is to 2.” The two inner numbers in the first example (16 and 1) are called the means, and the two outer numbers (8 and 2) are called the extremes. In a true proportion, the product of the means equals the product of the extremes (16 × 1 = 16; 8 × 2 = 16). This fact makes the proportion a useful mathematical tool. When a part of the
problem is unknown, “X” can be substituted for the unknown part in the proportion and the equation solved for “X.” Care must be taken to ensure that the proportion is set up correctly, and that the same unit of measure is used on both sides of the equation.

**Example 6:** \( \frac{8}{16} = \frac{1}{X} \) or \( \frac{8}{16} = \frac{1}{8X} \)

\( 8X = 16 \)

\( X = 2 \)

**Example 7:** To convert 0.2 g to milligrams, calculate the following:

\[
\begin{align*}
1000 \text{ mg} : 1 \text{ g} &= X \text{ mg} : 0.2 \text{ g} \\
1000 \text{ mg} &= X \text{ mg} \\
\frac{X \text{ mg}}{0.2 \text{ g}} &= \frac{1000 \text{ mg}}{1 \text{ g}} \\
X &= 200 \left( 1000 \times 0.2 \right)
\end{align*}
\]

**SYSTEMS OF MEASUREMENT**

The first step in the successful calculation of doses is to develop an understanding of the units of measure used to carry out the calculations. These units are components of the following three separate systems:

1. Metric system
2. Apothecary system
3. Household system

All three systems are expressed in the fundamental units of weight, volume, and length. Technicians should be able to convert values within each system and between the three systems.

**Metric System**

The fundamental units of measurement in the metric system are the gram (weight), the liter (volume), and the meter (length). Gram is abbreviated g or gm, liter is abbreviated L or l, and meter is abbreviated m. The usefulness of the metric system is that all units are powers of the fundamental units. Prefixes are used in combination with fundamental units to denote smaller or larger quantities. Table 3-1 illustrates the units of measurement used in the biologic sciences.

The units that are used most commonly in dosage calculations include the gram, the kilogram (kg; 1000 g), the milligram (mg; 1/1000 g), and the milliliter (ml; 1/1000 L). It should be noted that a milliliter is equivalent to the quantity of water contained in 1 cubic centimeter (cc), which is also equivalent to 1 g of weight. Therefore, for practical purposes, it may be said that 1 ml = 1 cc = 1 g.

On occasion, the microgram (μg) may be used. (It should be noted that this unit also may be abbreviated as mcg.) Care should be taken to differentiate this abbreviation from mg, which looks very similar when written orders are used.

**Conversion Between Metric Units**

The most fundamental way to convert between metric units is to multiply the units given by the conversion factor involving the units desired. If the desired

<table>
<thead>
<tr>
<th>Table 3-1 Units of Measure for the Biologic Sciences</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Weight</strong></td>
</tr>
<tr>
<td>Gram (g)</td>
</tr>
<tr>
<td>Kilogram (kg)</td>
</tr>
<tr>
<td>Decigram (dg)</td>
</tr>
<tr>
<td>Centigram (cg)</td>
</tr>
<tr>
<td>Milligram (mg)</td>
</tr>
<tr>
<td>Microgram (μg)</td>
</tr>
<tr>
<td>Nanogram (ng)</td>
</tr>
<tr>
<td>Picogram (pg)</td>
</tr>
</tbody>
</table>
conversion is from milligrams (mg) to grams (g), the number of milligrams given should be multiplied by the factor 1 g/1000 mg because 1 g = 1000 mg. The following steps would be involved in this conversion:

1. Write down the number of milligrams to be converted to grams.
2. To the right of that number, write down the number of milligrams in 1 g, with the milligrams as the denominator. (The numerator should always contain the unit to which you wish to convert.)
3. Multiply the two numbers together.

**Example 1:** Convert 3000 mg to grams.

1. 3000 mg
2. \[ \frac{1 g}{1000 mg} \]
3. \[ 3000 mg \times \frac{1 g}{1000 mg} = 3 g \]

Figure 3-1 illustrates the stairstep method of converting from one unit to another within the metric system. When converting measurements in the metric system via the stairstep method, divide by 10 for each step up to the desired measurement, and multiply by 10 for each step down to the desired measurement.

You also may think of converting measurements with this method by remembering that for each step up, the decimal point is moved one place to the left. For each step down, the decimal point is moved one place to the right.

**Example 2:** 500 ml = _____ L

Conversion of milliliters to liters requires three steps upward. Therefore, divide 500 by 10 three times (or 500 ÷ 1000). This moves the decimal point three places to the left, and the answer is 500 ml = 0.5 L.

**Example 3:** 2 g = _____ mg
To convert grams to milligrams, go down three steps. Multiply 2 by 10 three times (or $2 \times 1000$). This moves the decimal point three places to the right, and the answer is $2 \text{ g} = 2000 \text{ mg}$.

A second method for performing conversions in the metric system can be called the arrow method. When this method is used, it is paramount to remember which units of measure are larger. Conversions between the commonly used units of kilograms, grams, milligrams, and micrograms are illustrated in the following text.

A kilogram is 1000 times larger than a gram (g), a gram is 1000 times larger than a milligram (mg), and a milligram is 1000 times larger than a microgram (mcg). This relationship can be abbreviated as follows with the use of the "greater than" symbol ($>$):

$$\text{kg} > \text{g} > \text{mg} > \text{mcg}$$

Many times, the technician will have to calculate the amount of drug to be given when the supply on hand is not measured in the same units as the order calls for. For example, the order is for $0.3 \text{ g}$ of drug A, and the supply on hand is 150-mg tablets. Before it can be determined how many tablets should be given, $0.3 \text{ g}$ must be converted to milligrams. Because it is known that $1 \text{ g} = 1000 \text{ mg}$, $0.3 \text{ g}$ can be changed to milligrams by multiplying $0.3 \text{ g}$ by $1000 \text{ mg/g}$ ($0.3 \times 1000 = 300 \text{ mg}$). The decimal point is moved three places to the right ($0.3 \rightarrow 3_{123}$).

The conversion could have been made very quickly by simply moving the decimal point three places to the right. To know which direction to move the decimal, one should determine which way the arrow is pointing (e.g., $\text{kg} > \text{g} > \text{mg} > \text{mcg}$).

Any time the conversion is made between two adjacent units in the relationship of $\text{kg} > \text{g} > \text{mg} > \text{mcg}$, the decimal point will be moved three places.

The steps for converting grams to milligrams with the use of this method are as follows:

1. Write down the order first, using the units called for ($0.3 \text{ g}$).
2. Write down the equivalent units (on hand) needed next to the order units ($0.3 \text{ g} = \_ \text{ mg}$).
3. Place an arrow between the two units, with the closed part of the arrow pointing toward the smaller unit ($\text{g} \rightarrow \text{mg}$).
4. Move the decimal point three places to the right in the direction the arrow points ($0.3 \rightarrow 3_{123}$).

In the previous problem, it would take two 150-mg tablets to fill the 300-mg order.

If the order had been for $300,000 \text{ mcg}$ of drug A, and the supply on hand had consisted of 150-mg tablets, micrograms would have to be converted to milligrams through the following steps:

1. Write the order ($300,000 \text{ mcg}$).
2. Write down the equivalent units needed next to the order units ($300,000 \text{ mcg} = \_ \text{ mg}$).
3. Place an arrow between the two units, with the closed part of the arrow pointing toward the smaller units ($\text{mcg} \rightarrow \text{mg}$).
4. Move the decimal three places to the right in the direction the arrow points ($300 \rightarrow 300_{123}$).

In this problem, it would take two 150-mg (150,000 mcg) tablets to fill the 300,000-mcg order.

Additional problems for converting within the metric system are provided at the end of this chapter.

**Apothecary and Household Systems**

The apothecary and household systems of measurement are older systems than the metric system. The apothecary system is seldom used, but the household system is used for giving clients instructions about dosage.

The units most often encountered in the apothecary system are the minim, abbreviated m or min; the dram, abbreviated dr; the ounce, abbreviated oz; and the grain, abbreviated gr. A minim is equal to 1 drop, a dram is equal to 4 ml, an ounce is equal to 30 ml, and a grain is equal to 65 mg (64.8, sometimes rounded off to 65). When quantities related to grains are written, the symbol gr should be placed before the number, and common fractions are used when appropriate (e.g., gr $1/50$). The apothecary pound (12 oz) is not used when doses are calculated. Instead, the avoirdupois pound (16 oz) is used.

Units commonly used in the household system include the drop, abbreviated gt; the tablespoon,
abbreviated T or Tbsp; and the teaspoon, abbreviated t or tsp. One drop is equivalent to 1 min, 1 Tbsp is equivalent to 15 ml, and 1 tsp is equivalent to 5 ml. The pint, quart, and gallon are other units that are sometimes encountered. Boxes 3-1 and 3-2 illustrate equivalent values that are useful in dosage calculations. Problems on converting within and between the apothecary and household systems are found at the end of this chapter.

**DOSAGE CALCULATIONS**

The quantity of drug to be delivered to a patient is called the dose. A dosage rate expressed in milligrams per kilogram (or milligrams per pound) is multiplied by the animal's weight in kilograms (or pounds) to determine the dose. The dose then is divided by the amount (concentration) of the drug in the pharmaceutic form (tablet, solution, and so forth) to determine the actual amount of the pharmaceutic form to be administered. The formula for dosage calculation, which should be committed to memory, is as follows:

\[ \text{Dose} = \frac{\text{Animal's weight} \times \text{dosage rate}}{\text{Concentration of drug}} \]

**Example 1:** If a 20-kg dog is to be given amoxicillin at the rate of 10 mg/kg, and injectable amoxicillin at a concentration of 100 mg/ml is available, the dosage calculation would be as follows:

\[ \text{Dose} = \frac{20 \text{ kg} \times 10 \text{ mg/kg}}{100 \text{ mg/ml}} = \frac{200 \text{ mg}}{100 \text{ mg/ml}} = 2 \text{ ml} \]

Note that in the first step of the calculation, kilograms cancel out to leave only milligrams in the numerator. In the second step, milligrams cancel out to leave milliliters. If 100-mg amoxicillin tablets are available, the formula becomes as follows:

\[ \text{Dose} = \frac{20 \text{ kg} \times 10 \text{ mg/kg}}{100 \text{ mg/tablet}} = \frac{200 \text{ mg}}{100 \text{ mg/tablet}} = 2 \text{ tablets} \]

Because most scales used to weigh animals for drug dosage calculation provide the weight in pounds, a conversion must be made from pounds to kilograms. To do this, divide the weight in pounds by 2.2.

**Example 2:** The dog in the previous problem weighed 44 lb, and 44 divided by 2.2 equals 20 kg. To convert kilograms to pounds (if the dose is provided in milligrams per pound), multiply the weight in kilograms by 2.2 (e.g., 20 kg × 2.2 = 44 lb).

If the order to the technician is to “give a dog 300 mg of amoxicillin,” then the ordered amount is simply divided by the concentration of the drug to determine the amount to be administered.

**Example 3:** If the order is to give a dog 300 mg of amoxicillin (concentration 100 mg/ml), the calculation would be as follows:

\[ \frac{300 \text{ mg}}{100 \text{ mg/ml}} = 3 \text{ ml} \]

---

**BOX 3-1 Weight Equivalents**

<table>
<thead>
<tr>
<th>1 kg = 1000 g = 2.2 lb</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 g = 1000 mg</td>
</tr>
<tr>
<td>1 mg = 1000 μg = 0.001 g</td>
</tr>
<tr>
<td>65 mg = 1 g</td>
</tr>
<tr>
<td>1 μg = 0.001 mg = 0.000001 g</td>
</tr>
<tr>
<td>1 lb = 453.6 g = 0.4536 kg = 16 oz</td>
</tr>
<tr>
<td>1 oz = 28.35 g</td>
</tr>
</tbody>
</table>

**BOX 3-2 Volume Equivalents**

<table>
<thead>
<tr>
<th>1 L = 1000 ml = 1 qt (946.4 ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>500 ml = 1 pt (473 ml) = 2 cups (equivalent to 1 lb of water)</td>
</tr>
<tr>
<td>15 ml = 1 Tbsp</td>
</tr>
<tr>
<td>5 ml = 1 tsp</td>
</tr>
<tr>
<td>30 ml = 1 oz</td>
</tr>
<tr>
<td>240 ml = 1 cup/glass</td>
</tr>
<tr>
<td>4 ml = 1 dram</td>
</tr>
<tr>
<td>1 ml = 15gtt/min*</td>
</tr>
</tbody>
</table>

*The number of drops/min in 1 ml depends on the size of the dropper. With a standard-size dropper, 1 ml equals 15 drops.*
It should be noted that the dose of most drugs used to treat neoplasms is calculated according to the total body surface area of the patient. Body surface area is correlated with the weight of the animal. A table is available in Chapter 16 (see Table 16-2) for converting an animal’s weight to surface area in square meters (sq M or m²). In these cases, the formula for dosage calculation becomes the following:

$$\text{Dose} = \text{mg/m}^2 \, (\text{from insert}) \times \text{m}^2 \, (\text{from table})$$

Dosage calculation problems are provided at the end of this chapter.

**SOLUTIONS**

To understand dosage calculation problems and how to prepare dilutions of substances (e.g., formalin and dextrose), a technician must have a basic understanding of solutions. Solutions are mixtures of substances that usually are not chemically combined with each other. Solutions are made up of a dissolving substance, called the solvent, and a dissolved substance, called the solute. Not all substances form solutions with each other. Those that form solutions are called miscible, and those that do not are called immiscible. A solution is referred to as saturated if it contains the maximum amount of solute at a particular temperature and pressure. Under some circumstances, a solution can become supersaturated. Mixtures of substances in which the solute is made up of very large particles are called suspensions. The particles in suspensions settle upon standing, and the mixture must be agitated before it is administered. True solutions do not settle out and remain mixed without agitation. All parts of solutions contain equal parts of the solute.

When working with solutions, it is important to know the amount of solute in the solvent or to be able to measure it. The amount of solute dissolved in the solvent is referred to as the concentration of the substance. Concentrations may be expressed in a number of ways, including the following:

1. Parts
2. Weight per volume (w/v) for liquids
3. Volume per volume (v/v) for liquids
4. Weight per weight (w/w) for solids

Solutions can be described in terms of parts without any reference to units of measurement. The parts simply refer to the relationship between the solvent and the solute. For example, instructions may call for a 1-to-30 (1:30) dilution of a disinfectant.

One unit that describes the relationship of parts is called parts per million (ppm). Parts per million is equal to 1 mg of a solute in a kilogram or liter of solvent. One part per million is also equivalent to 1 μg in a gram or milliliter. Upson (1988) reports that 1 ppm is equivalent to 1 minute in approximately 2 years or 1 oz of sand in approximately 31 tons of cement. Parts per billion is a unit that is used occasionally. It is equivalent to 1 μg in a kilogram or liter, or 1 nanogram in a gram or milliliter.

The most common way of expressing drug concentration when the solute is a solid and the solvent is a liquid is weight per volume (w/v). For example, the concentration of most pharmaceutical preparations is expressed as milligrams per milliliter (mg/ml); the concentration for Ketaset is 100 mg/ml. The weight-per-weight (w/w) and the volume-per-volume (v/v) solutions are not used as often in veterinary pharmaceutical preparations as the w/v preparations.

**PERCENT CONCENTRATIONS**

The term percent concentration may be used when w/v, w/w, or v/v concentrations are described. Percent (percentage) means parts of solute per 100 parts of the solution. Percent w/v means the number of grams of solute in 100 ml of solution; percent w/w describes the number of grams of solute in 100 g of solution; and v/v expresses the number of milliliters of solute in 100 ml of the solution.

A 100% solution (w/v) contains 100 g of solute per 100 ml of solution. Another way to say this is that it contains 1 g (1000 mg) of solute per 1 ml of solution (1000 mg/ml). To convert from a percent
solution to mg/ml, multiply the percentage by 10 (e.g., a 5% Lasix solution contains 50 mg/ml). To convert milligrams per milliliter to a percent, divide the milligrams per milliliter by 10 (e.g., a Lasix solution containing 50 mg/ml is a 5% solution). Sometimes, the term milligrams percent (mg%) is encountered. This term is used to refer to the number of milligrams in 100 ml of solution. It is an expression of concentration but not of percent concentration (g/100 ml). A more accurate description of mg% would be milligrams per deciliter (mg/dl), because a deciliter is equal to 100 ml.

A 100% solution (w/w) contains 100 g of solute in 100 g of solution. A 5% solution (w/w) of sodium chloride would contain 5 g of sodium in 100 g of solution. To make this preparation, weigh out 5 g of sodium chloride and mix it with 95 g of water.

A 100% solution (v/v) would simply be pure drug or chemical. A 10% solution would contain 10 ml of the chemical in 100 ml of solution. When a w/v solution or a v/v solution is prepared, the desired amount of solute is added to a container, and enough solvent is added to create the desired volume. This process is called diluting up, or it may be said that you q.s. to the desired volume. The abbreviation q.s. means to add a "quantity sufficient" to arrive at the desired volume. For example, to make 100 ml of a 10% formalin solution, place 10 ml of formaldehyde (100% formalin) in a container and q.s. (quantity sufficient) to 100 ml (10 ml formalin, 90 ml distilled water).

**Calculations Involving Concentrations**

To determine the amount of solute needed to make a desired amount of solution, you may use the following formula:

\[
\text{Grams of solute to q.s. to desired volume} = \frac{\% \times \text{desired volume}}{100}
\]

**Example 1:** How many grams of sodium chloride are needed to make 1 L of 0.9% sodium chloride?

**Answer** Grams needed = \( \frac{0.9 \times 1000 \text{ ml}}{100} = 9 \text{ g} \)

Nine grams of sodium chloride are added to a container and is diluted up to 1000 ml.

When the amount of solute and the volume of solution are known, the percent solution may be calculated as follows:

\[
\text{Percent solution} = \frac{\text{grams of solute} \times 100}{\text{volume of solution}}
\]

**Example 2:** What percentage is a solution that contains 9 g of sodium chloride?

**Answer** Percent solution = \( \frac{9 \times 100}{1000} = \frac{900}{1000} = 0.9\% \)

To solve problems involving a change in concentration of the solution, the following formula may be used:

\[
\text{Volume one} \times \text{Concentration one} = \text{Volume two} \times \text{Concentration two}
\]

**Example 3:** How would you prepare 100 ml of a 5% dextrose solution from a 50% dextrose solution?

**Answer** \( V_1 \times C_1 = V_2 \times C_2 \)

\[
100 \times 5 = V_2 \times 50
\]

\[
500 = 50V_2
\]

\[
10 = V_2
\]

This formula demonstrates that you would take 10 ml of the 50% dextrose solution and add q.s. to 100 ml to prepare the 5% solution.

Another formula that may be used to solve problems in which a change in concentration is involved is as follows:

\[
\frac{\text{Desired strength}}{\text{Available strength}} = \frac{\text{amount to use}}{\text{amount to make}}
\]

**Example 4:** In solving the foregoing problem, the desired strength is 5%, the available strength is 50%, the amount to make is 100 ml, and the amount to use is the unknown.

**Answer** \( \frac{5}{50} = \frac{X}{100} \)

\[
50X = 500
\]

\[
X = 10 \text{ ml}
\]
**MILLIEQUIVALENTS**

When electrolytes are involved, the concentration of a solution is often expressed in terms of milliequivalents (mEq). One milliequivalent is equal to 1/1000 of an equivalent. An equivalent weight is equal to (for practical applications) 1 g molecular weight divided by the total positive valence of the material in question (Blankenship and Campbell, 1976). The concentration of an electrolyte solution is expressed as milliequivalents per liter (mEq/L), which can be calculated when the concentration of the solution is known by using the following formula:

\[
\text{mEq/L} = \frac{\text{mg/dl} \times 10}{\text{eq wt}}
\]

**Example 1:** How many milliequivalents per liter is found in a sodium chloride solution that contains 700 mg/dl?

\[
\text{mEq/L} = \frac{700 \times 10}{58.5} = 119.66
\]

The number of milligrams per deciliter also can be calculated when the number of milliequivalents per liter is known by manipulating the previous formula as follows:

\[
\text{mg/dl} = \frac{\text{mEq/L} \times \text{eq wt}}{10}
\]

**Example 2:** How many milligrams per deciliter is contained in a solution that has 119.66 mEq/L?

**Answer**

\[
\text{mg/dl} = \frac{119.66 \times 58.5}{10} = \frac{7000}{10} = 700 \text{ mg/dl}
\]

**CALCULATIONS INVOLVING IV FLUID ADMINISTRATION**

Calculations for determining the volume of fluid to administer are covered in Chapter 15. The rate at which to run intravenous fluids (in drops per minute) can be determined by dividing the volume of fluids to be given by the time in minutes during administration, and then multiplying that number by the drops per milliliter delivered by the administration set.

\[
\frac{\text{Volume of infusion (ml)}}{\text{Time of infusion (min)}} \times \text{drop factor (gtt/ml)} = \text{drops per minute}
\]

The drip rate in drops per minute can be divided by 60 to determine the rate in drops per second—a number that is easier to work with when one is actually adjusting the flow.

**Example 1:** Give 480 ml of lactated Ringer’s solution to Dog A over a 4-hour period using a standard 15 gtt/ml administration set.

\[
\frac{480 \text{ ml}}{240 \text{ min}} = \frac{2 \text{ ml}}{1 \text{ min}} \times \frac{15 \text{ gtt}}{\text{ ml}} = \frac{30 \text{ gtt}}{\text{ ml}} \times \frac{1 \text{ min}}{60 \text{ sec}} = \frac{1 \text{ gtt}}{2 \text{ sec}}
\]

Giving one drop every 2 seconds will deliver 30 drops in a minute.

**Calculations for Constant Rate Infusion Problems**

Sometimes, medications given by intravenous infusion have to be administered at a dose delivered at a constant rate over a specified period of time. The dosage is often ordered in micrograms per kilogram per minute.

This dosage can be confusing because most drugs are available in a concentration expressed as milligrams/milliliter (mg/ml) and are delivered through infusion pumps at a rate expressed as milliliters/hour (ml/hr). The following example problem illustrates a method for solving these problems without the use of an infusion pump.

**Example 1:** A 44-lb dog in acute heart failure is ordered to receive 10 mcg/kg/min of dopamine. You will add a 200-mg vial of dopamine to a 1-L bag of D5W (dextrose 5% in water) solution (0.2 mg/ml). At what rate in drops per minute will you administer this solution to deliver the correct dosage?

**Step 1:** Convert to the same units. The dose is expressed in mcg/kg, so the patient’s weight
must be converted from pounds to kilograms, and the drug concentration must be expressed in mcg/ml.

\[
\frac{44 \text{ lbs} \times \frac{1 \text{ kg}}{2.2 \text{ lbs}} = 20 \text{ kg}}{2.2}
\]

\[
\frac{0.2 \text{ mg} \times \frac{1000 \text{ mcg}}{1 \text{ mg}} = 200 \text{ mcg}}{1 \text{ ml} \times \frac{1 \text{ mg}}{1 \text{ mg}} = \frac{1 \text{ ml}}{1 \text{ ml}}}
\]

Step 2: Determine the number of mcg/min.

\[
\frac{20 \text{ kg} \times \frac{10 \text{ mcg}}{\text{kg/min}} = \frac{200 \text{ mcg}}{\text{min}}}{20 \text{ kg}}
\]

Step 3: Determine the number of ml per minute.

\[
\frac{200 \text{ mcg}}{1 \text{ min} \times \frac{1 \text{ ml}}{200 \text{ mcg}} = \frac{1 \text{ ml}}{1 \text{ min}}}{1 \text{ ml}}
\]

Step 4: Determine the number of drops per minute using a minidrip (60 gtt/ml) administration set.

\[
\frac{1 \text{ ml}}{\text{min} \times \frac{60 \text{ gtt}}{1 \text{ ml}} = \frac{60 \text{ gtt}}{1 \text{ min}} = 1 \text{ gtt/sec}}{1 \text{ ml}}
\]

Formulas and recipes have been devised to simplify the constant rate infusion (CRI) calculations (Macintire and Tefend, 2004). The following formula can be used to determine the number of milligrams of drug that must be added to a bag of fluids to deliver a predetermined dosage rate to a patient. A volume of the delivery fluid equal to the volume of the drug added should be removed before the drug is added, to keep the dose and volume accurate.

\[
M = \frac{(D) (W) (V)}{(R) (16.67)}
\]

M = number of mg of drug to add to delivery fluid
D = dosage of drug in mcg/kg/min
W = patient body weight in kg
V = volume in ml of delivery fluid
R = rate of delivery in ml/hr
16.67 = conversion factor

The next formula can be used to adjust the dosage (mcg/kg/min) in accordance with the response of the animal.

\[
R = \frac{(D) (W) (V)}{(M) (16.67)}
\]

Another formula allows rapid calculation of the amount of drug to be added to a standard volume of 250 ml of fluid at a standard delivery rate of 15 ml/hr.

Drug dosage (mcg/kg/min) \times Body weight (kg) =
mg of drug to add to 250 ml fluid and run
at 15 ml/hr

Some CRI drugs are dosed in milligrams (mg)/
kg/hr rather than mcg/kg/min. The following formula determines the amount of drug (mg) to be
added to 250 ml of fluid for a delivery rate of
10 ml/hr.

\[
\text{Dose (mg/kg/hr)} \times \text{Body weight (BW) (kg) } \times 25 \text{ hr} = \frac{\text{Drug concentration (mg/ml)}}{	ext{Number of ml of drug to add to 250 ml delivery fluid and administer at 10 ml/hr}}
\]

A combination of morphine and ketamine (MK)
sometimes is delivered as a CRI for pain control in
dogs and cats. A recipe (Ortel, 2006) for this combination calls for adding to a single 500-ml bag of
fluids the following:

60 mg of ketamine (100 mg/ml)
60 mg of morphine (15 mg/ml)

When the two drugs are added, the patient’s weight in kilograms becomes the infusion rate in
ml/hr that is set on the infusion pump. The delivery dose is 1 ml/kg/hr or 2 mcg/kg/min ketamine and
2 mcg/kg/min morphine.

For dogs, lidocaine (500 mg of a 20 mg/ml concentration) can be added to the MK recipe above to make the MLK mixture. The MLK mixture also is run at a delivery rate of 1 ml/kg/hr, delivering
17 mcg/kg/min of lidocaine, in addition to the ketamine and morphine.
REFERENCES


REVIEW QUESTIONS

PROBLEMS USING RATIOS AND PROPORTIONS
Ratios
1. Express 1/4 as a ratio and as a decimal.
2. Express 0.75 as a ratio and as a fraction.
3. Express 0.004 as a ratio and as a fraction.
4. Express 1:80 as a fraction and as a decimal.
5. Express 9/1000 as a ratio and as a decimal.
6. Express 1:32 as a fraction and as a decimal.

Proportions (Solve for X.)
1. \(25:X = 5:10\)
2. \(\frac{4}{5} = \frac{X}{10}\)
3. \(\frac{1}{2}:100 = X:500\)
4. \(\frac{1}{4} = \frac{20}{X}\)
5. Convert 0.2 g to milligrams using a proportion.
\[
\frac{1000 \text{ mg}}{1 \text{ g}} = \frac{X \text{ mg}}{0.2 \text{ g}}
\]
6. If a drug concentration is labeled 5 ml = 250 mg, how many mg are in three fourths of a milliliter?
\[
\frac{250 \text{ mg}}{5 \text{ ml}} = \frac{X}{\frac{3}{4} \text{ ml}}
\]
7. How much bleach would you use to prepare 1000 ml of a 1:32 solution?
\[1:32 = X:1000\]
8. How much bleach would you use to prepare 1 gallon (3784 ml) of a 1:32 solution?
\[1:32 = X:3784\]
9. If you were to give a horse 1 ml per 250 lb of body weight of an anthelmintic, how many milliliters would you give to a horse that weighs 1250 lb?
\[
\frac{1}{250} = \frac{X}{1250}
\]
10. If a 10-lb dog gets one fourth of a tablet of an antibiotic, how many tablets will a 50-lb dog get?
\[
\frac{1}{4:10} = X:50
\]

PROBLEMS USING THE METRIC SYSTEM
1. 150 mg = \underline{\underline{\underline{}}} g
2. 2 L = \underline{\underline{\underline{}}} ml
3. 2250 mg = \underline{\underline{\underline{}}} g
4. 5 g = \underline{\underline{\underline{}}} mg
5. 3000 ml = \underline{\underline{\underline{}}} L
6. 2 kg = \underline{\underline{\underline{}}} g
7. 0.5 kg = \underline{\underline{\underline{}}} g
8. 5000 mg = \underline{\underline{\underline{}}} kg
9. 1.25 mg = \underline{\underline{\underline{}}} g
10. 0.004 g = \underline{\underline{\underline{}}} mg
11. 2050 μg = _________________ mg
12. How many grams would you administer if the veterinarian ordered 10 mg of acepromazine?

13. If the medical order is for 0.5 L of sodium chloride 0.9%, how many milliliters would be administered?

14. How many liters would you give to the patient if the order called for 750 ml to be administered?

15. If the veterinarian orders 300 μg of vitamin B₁₂, how much is this in milligrams?

16. If the order is for 2.5 mg of vitamin B₁₂, how many micrograms are administered?

PROBLEMS USING THE APOTHECARY AND HOUSEHOLD SYSTEMS
1. 1.5 qt = _________________ pt
2. 12 pt = _________________ gal
3. 3 tsp = _________________ Tbsp
4. 3 qt = _________________ cups
5. 12 cups = _________________ pt
6. 2 oz = _________________ Tbsp
7. 1 gal = _________________ oz
8. 1 pt = _________________ oz
9. 6 pt = _________________ qt

PROBLEMS COMBINING THE TWO SYSTEMS
1. 1 pt = _________________ ml
2. 2 Tbsp = _________________ ml
3. 15 ml = _________________ cc
4. 2 cups = _________________ oz
5. 6.5 ml = _________________ pt
6. 125 ml = _________________ tsp
7. 1.5 cc = _________________ ml
8. 15 kg = _________________ lb
9. 250 ml = _________________ pt
10. 5 oz = _________________ ml
11. 15 lb = _________________ kg

PROBLEMS MEASURING ORAL MEDICATIONS
1. The order is for 500 mg of amoxicillin, and tablets on hand are 250 mg. How many tablets will be administered?

2. The order is for 15 mg of prednisone, and 10-mg (scored) tablets are on hand. How many tablets will be administered?

3. The order is for 960 mg of SMZ-TMP. Tablets on hand are 240 mg. How many tablets will be administered?

4. The order is for enrofloxin to be given once daily at 5 mg/kg to a 10-lb cat for 7 days. How many 22.7-mg tablets should be dispensed to the client?

5. The veterinarian prescribes 15 mg of prednisone every other day for 10 days. The tablets on hand are 10 mg. How many tablets will be administered? How many tablets will be dispensed?

6. The veterinarian prescribes 100 mg of cephalaxin twice a day (b.i.d.) for 10 days. You have 100-mg tablets on hand. How many will be dispensed?

7. The veterinarian prescribes Albon for Coccidia. Your patient is a puppy that weighs 8 lb and needs treatment for 21 days. The dose for Albon is 25 mg/lb loading dose and 12.5 mg/lb maintenance dose to be given once daily (s.i.d.). The drug is supplied at 250 mg/5 ml. How many milligrams does your patient need for a loading dose?

A maintenance dose?

How many mg/ml are there in Albon?

How many milliliters does your patient need for a loading dose?

A maintenance dose?

How many milliliters will be dispensed?

8. The veterinarian orders 4.4 mg/kg of carprofen for pain control divided into two equal daily doses for a 50-lb dog. On hand are 100-mg scored tablets. How many tablets are administered each morning and afternoon?

9. The order is for 0.5 mg/kg enalapril twice daily for a 20-kg dog for 30 days. On hand are 10-mg scored tablets. How many tablets should be dispensed?
10. The veterinarian prescribes 2.5 mg of acepromazine t.i.d. for 3 days, and tablets on hand are 5 mg (scored). How many tablets will be administered? __________________________
How many will be dispensed? __________________________

11. The veterinarian prescribes aminophylline to be given three times daily for 14 days to a 15-lb dog. The dose for aminophylline is 10 mg/kg. How many kilograms does your patient weigh? __________________________
How many milligrams have to be administered to your patient? __________________________
Because the tablets on hand are 100 mg (scored), how many tablets will you give to the patient? __________________________
How many tablets will be dispensed? __________________________

12. The veterinarian has ordered 5 mg/kg ponazuril once daily for a 1200-lb horse for 28 days. Tubes of 127 g of ponazuril paste are available; these contain 150 mg ponazuril per gram. How many tubes of the medication are needed for the 28-day treatment? __________________________

13. A farmer has 10 calves that weigh approximately 100 lb each. A microscopic fecal examination reveals Coccidia. The veterinarian chooses to treat all 10 calves with Corid powder (20% amprolium) by drenching daily for 10 days. To make a drench solution, mix 3 oz of Corid powder in 1 qt of water (1 oz of powder = 3.5 Tbsp). The dose of Corid for drenching is 1 oz of solution per 100 lb of body weight. How much solution should be mixed to drench these 10 calves for 10 days? __________________________

14. Doxycycline has been chosen as a treatment for a 1-kg Amazon parrot at the rate of 25 mg/kg b.i.d. for 7 days. The tablets on hand are 50 mg (scored). How many tablets will be given for each treatment? __________________________
How many tablets will be dispensed? __________________________

15. The veterinarian orders clenbuterol syrup for a 200-lb foal. The dosage is 0.8 micrograms/kg twice daily for 3 days. The syrup contains 72.5 micrograms/ml. How many milliliters is given at each dose? __________________________

PROBLEMS MEASURING PARENTERAL MEDICATIONS

1. The veterinarian orders prednisone, 20 mg intramuscularly (IM). The vial is labeled 50 mg/ml. How many milliliters will be administered? __________________________

2. The veterinarian orders an injection of Percorten-V for a 20-lb dog at the dosage rate of 2.2 mg/kg. The concentration of Percorten-V is 25 mg/ml. How much of the drug should be injected? __________________________

3. The veterinarian orders phenylbutazone to be administered to a 1500-lb horse at a dose of 5 mg/kg intravenously. The vial is labeled 200 mg/ml. How many milliliters will be administered? __________________________

4. The veterinarian orders penicillin G procaine for a 25-lb dog to be administered at a dose of 40,000 U/kg IM. The vial is labeled 300,000 U/ml. How many milliliters will be administered? __________________________

5. The veterinarian orders cefazolin to be given to a 23-lb dog at a dosage of 20 mg/kg IV for surgical prophylaxis. The concentration of cefazolin on hand is 100 mg/ml. How much of the drug should be given? __________________________
How many milliliters will be administered at each treatment? __________________________

6. A 78-lb dog is to be administered ampicillin trihydrate at a dose of 5 mg/lb subcutaneously. The antibiotic has been reconstituted, and the concentration is 200 mg/ml. How many milliliters will be administered to the patient? __________________________

7. A microscopic fecal examination reveals a Giardia infection in a 500-g African gray parrot. The veterinarian chooses to treat the infection with metronidazole injectable at a dosage of 30 mg/kg daily for 3 days. How many milligrams will the parrot receive at each treatment? __________________________

8. A 45-lb dog is to be treated for lymphosarcoma with vincristine sulfate, 1 mg/ml. The dose is 0.5 mg/m². How many square meters of body surface area does this patient have? __________________________
How many milligrams will be given to the patient? __________________________
9. The veterinarian orders lincomycin HCl for a 500-lb Yorkshire boar. The dosage to be administered is 5 mg/lb/day IM for 5 days. The medication on hand is 100 mg/ml in a 50-ml multidose vial. How many milligrams will be administered to the boar each day? ____________

How many milliliters will be administered to the boar each day? ____________

How many bottles of medication does the owner have to purchase to treat the boar for 5 days? ____________

10. A cat weighing 8 lb that has a small laceration on its left hip is to be administered ketamine HCl to produce anesthesia. The veterinarian orders 15 mg/kg IM. The vial is labeled 100 mg/ml. How many milligrams will be administered to the cat? ____________

How many milliliters will be administered? ____________

11. The veterinarian orders 7 mEq of potassium chloride to be added to the IV fluids. The vial is labeled 20 mEq in 10 ml. How many milliliters will be added to the fluids? ____________

12. The veterinarian orders 4 U of regular insulin to be administered to a diabetic cat. The regular insulin is labeled 40 U/ml. How many milliliters will be administered? ____________

13. The veterinarian orders testosterone propionate for a 475-lb Landrace boar. The dose to be administered is 1 mg/10 lb. The label on the vial is 25 mg/ml. How many milligrams will be administered? ____________

How many milliliters will be administered? ____________

14. The veterinarian orders dexamethasone 60 mg IV to be given to a patient. The vial is labeled 2 mg/ml. How many milliliters will be administered? ____________

15. The veterinarian orders 15 mg of vitamin K₁. The vial is labeled 10 mg/ml. How many milliliters will be administered? ____________

16. The order is for meloxicam at 0.2 mg/kg to control postsurgical pain in a 45-kg cat. The concentration of the drug is 5 mg/ml. What volume of the drug should be given? ____________

17. A rabbit weighing 12 lb is to be given 0.02 mg/kg of buprenorphine subcutaneously for pain control. The concentration of the drug is 0.3 mg/ml. How much of the drug should be given? ____________

18. Atropine (0.5 mg/ml) is ordered at 0.01 mg/lb to control bradycardia in a 75-lb dog. How much of the drug should be given? ____________

19. The veterinarian orders enrofloxacin at 5 mg/kg IM for a 7-kg python with respiratory disease. The product contains 100 mg/ml. How much should be injected? ____________

20. The order is for an injection of metoclopramide at 0.4 mg/kg for a 15-kg dog. The concentration of available product is 5 mg/ml. How much should be injected? ____________
## INJECTION PROBLEMS

<table>
<thead>
<tr>
<th>Order</th>
<th>Give</th>
<th>Stock</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>0.5 g IM</td>
<td>250 mg/ml</td>
</tr>
<tr>
<td>2.</td>
<td>20 mEq IV</td>
<td>40 mEq/10 ml</td>
</tr>
<tr>
<td>3.</td>
<td>0.75 mg IM</td>
<td>0.50 mg/ml</td>
</tr>
<tr>
<td>4.</td>
<td>150 mg IM</td>
<td>0.2 g/5 ml</td>
</tr>
<tr>
<td>5.</td>
<td>25 mg IM</td>
<td>100 mg/ml</td>
</tr>
<tr>
<td>6.</td>
<td>0.5 mg IM</td>
<td>0.5 mg/2 ml</td>
</tr>
<tr>
<td>7.</td>
<td>0.3 mg IV</td>
<td>0.4 mg/ml</td>
</tr>
<tr>
<td>8.</td>
<td>300,000 U SC</td>
<td>40,000 U/ml</td>
</tr>
<tr>
<td>9.</td>
<td>0.3 mg IM</td>
<td>0.5 mg/ml</td>
</tr>
<tr>
<td>10.</td>
<td>55 mg SC</td>
<td>250 mg/ml</td>
</tr>
</tbody>
</table>

### PREPARING SOLUTIONS

1. **Order:** 100 ml of 10% formalin solution  
   On hand: formaldehyde 37% (considered as 100% formalin) and water  
   Amount needed: _______________

2. **Order:** 1000 ml 0.9% NaCl and 5% dextrose  
   On hand: 1000 ml 0.9% NaCl and 500 ml 50% dextrose  
   Amount of each needed: _______________

3. **Order:** 100 ml 50% dextrose  
   On hand: 500 ml 50% dextrose and 250 ml sterile water for injection  
   Amount needed: _______________

4. **Order:** 500 ml 0.45% NaCl and 5% dextrose  
   On hand: 500 ml 0.9% NaCl and 500 ml 5% dextrose  
   Amount of each needed: _______________

5. **Order:** 2000 ml lactated Ringer's solution and 2.5% dextrose  
   On hand: 2 containers of 1000 ml lactated Ringer's solution and 250 ml 50% dextrose  
   Amount of each needed: _______________

6. **Order:** 50 ml 5% dextrose  
   On hand: 1000 ml sterile water for injection and 250 ml 50% dextrose  
   Amount of each needed: _______________

7. **Order:** 500 ml 2.5% dextrose and 0.45% NaCl  
   On hand: 1000 ml 0.45% NaCl and 500 ml 50% dextrose  
   Amount of each needed: _______________

8. **Order:** 1000 ml of 10% glyceryl guaiacolate solution  
   On hand: packets containing 50 g guaifenesin (GG) powder and 1000 ml sterile water for injection  
   Amount of each needed: _______________

9. **Order:** 8% thiamylal sodium solution  
   On hand: One 5-g vial of powder and sterile water for injection  
   Amount of sterile water needed: _______________

10. **Order:** 5 ml of 2% cyclosporine ophthalmic solution  
    On hand: 50 ml Sandimmune Oral Solution (cyclosporine) 100 mg/ml and 16 oz of extra virgin olive oil  
    Amount of each needed: _______________

11. **Order:** 50 ml of 2% formalin for Knott's heartworm test  
     On hand: 37% formaldehyde and water  
     Amount of each needed: _______________

### PROBLEMS CALCULATING IV DRIP RATES

1. What drip rate will you use to administer 500 ml of lactated Ringer's solution over a 3-hour period with a standard (15 gtt/ml) administration set?  
2. What drip rate would you use to deliver 120 ml of 0.9% NaCl over a 2-hour period using a microdrip (60 gtt/ml) administration set?  
3. What drip rate would you use to deliver 1.2 L of Normosol over a 10-hour period using a standard (15 gtt/ml) administration set?  
4. What drip rate would you use to deliver 8 mcg/kg/min of drug C (500 mg/250 ml) to
an 83-lb dog using a microdrip (60 gtt/ml) administration set?

5. What drip rate would you use to deliver 10 mcg/kg/min of dopamine (0.2 mg/ml) to a 22-lb dog using the microdrip (60 gtt/ml) administration set?

6. Using the formula \( M = \frac{(D)(W)(V)}{R(16.67)} \), how much nitroprusside (25 mg/ml) would you add to 1000 ml of 5% dextrose to deliver 2 mcg/kg/min of nitroprusside at a delivery rate of 12 ml/hr to a 3.8-kg dog?

7. Using the formula \( R = \frac{(D)(W)(V)}{M(16.67)} \), calculate the new fluid delivery rate needed to increase the dosage of nitroprusside in problem 6 to 3 mcg/kg/min.

8. Using the formula \( M = \frac{(D)(W)(V)}{R(16.67)} \), how much dobutamine (12.5 mg/ml) would you add to 100 ml of a 5% dextrose solution to administer 15 mcg/kg/min to a 28-kg dog at a delivery rate of 10 ml/hr?

9. How much furosemide (10 mg/ml) would you add to a 250-ml fluid bag to deliver 3 mcg/kg/min to a 5-kg patient with the fluid pump set at 15 ml/hr?

10. How much morphine (15 mg/kg) would you add to a 250-ml fluid bag to deliver 0.2 mg/kg/hr to a 10-kg animal with the pump set on 10 ml/hr?
CHAPTER 4

Drugs Used in Nervous System Disorders

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Define terms related to the pharmacology of the nervous system.
2. Develop a basic understanding of the anatomy and physiology of the nervous system.
3. Describe the subdivisions, functions, and primary neurotransmitters of the autonomic nervous system (ANS).
4. Describe how drugs affect the ANS.
5. List the different classes of ANS drugs.
6. List the two major classification schemes of barbiturates.
7. List indications and precautions for the use of barbiturates.
8. Describe dissociative anesthesia, and list three dissociative agents.
9. List the opiate receptors and the basic function of each.
10. List the indications for the use of narcotics.
11. List potential side effects of narcotic use or overdose.
12. Describe how opioid antagonists exert their effects, and list three examples of this category of drug.
13. Define neuroleptanalgesic and give an example.
14. List examples of drugs used to control seizures.
15. List commonly used inhalant anesthetic agents and compare their characteristics.
16. Describe the primary uses of central nervous system (CNS) stimulants.
17. List drugs used in behavioral pharmacotherapy.
18. Describe the characteristics of a good euthanasia agent.
**KEY TERMS**

**ACETYLCHOLINE** A neurotransmitter that allows a nerve impulse to cross the synaptic junction (gap) between two nerve fibers or between a nerve fiber and an organ (e.g., muscle, gland).

**ACETYLCHOLINESTERASE** An enzyme that brings about the breakdown of acetylcholine in the synaptic gap.

**ADRENERGIC** A term used to describe an action or a receptor that is activated by epinephrine or norepinephrine.

**ANALGESIA** Loss of pain sensation (other sensations may be present).

**ANESTHESIA** The loss of all sensation. May be described as local (affecting a small area), regional, or surgical (accompanied by unconsciousness).

**AUTONOMIC NERVOUS SYSTEM** That portion of the nervous system that controls involuntary activities.

**CATALEPSY** A state of involuntary muscle rigidity that is accompanied by immobility, amnesia, and variable amounts of analgesia. Some reflexes may be preserved.

**CATECHOLAMINE** The class of neurotransmitters that includes dopamine, epinephrine, and norepinephrine. When given therapeutically, catecholamines mimic the effects of stimulating the sympathetic nervous system.

**CHOLINERGIC** A term used to describe an action or receptor that is activated by acetylcholine.

**EFFECOR** A gland, organ, or tissue that responds to nerve stimulation with a specific action.

**GANGLIONIC SYNAPSE** The site of the synapse between neuron one and neuron two of the autonomic nervous system.

**MUSCARINIC RECEPTORS** Receptors activated by acetylcholine and muscarine that are found in glands, the heart, and smooth muscle. An acronym for remembering muscarinic effects is "SLUD": S = salivation; L = lacrimation; U = urination; D = defecation.

**NICOTINIC RECEPTORS** Receptors activated by acetylcholine and nicotine found at the neuromuscular junction of the skeletal muscle and at the ganglionic synapses.

**PARASYMPATHETIC NERVOUS SYSTEM** That portion of the autonomic nervous system that arises from the craniosacral portion of the spinal cord, is mediated by the neurotransmitter acetylcholine, and is concerned primarily with conserving and restoring a steady state in the body.

**PARASYMPATHOMIMETIC** A drug that mimics the effects of stimulating the parasympathetic nervous system.

**SYMPATHETIC NERVOUS SYSTEM** That portion of the autonomic nervous system that arises from the thoracolumbar spinal cord, is mediated by catecholamines, and is concerned with the fight-or-flight response.

**SYMPATHOMIMETIC** A drug that mimics the effects of stimulating the sympathetic nervous system.

---

**INTRODUCTION**

The nervous system is the body’s primary communication and control center. It functions in harmony with the endocrine system to allow an animal to respond and adapt to its environment and to maintain a relatively constant internal environment (homeostasis) through control of the many internal organ systems. In broad terms, the nervous system serves three functions: (1) sensory, (2) integrative (analysis), and (3) motor (action). It senses changes within the environment and within the body, interprets the information, and responds to the interpretation by bringing about an appropriate action. The nervous system carries out this complex activity very rapidly by sending electric-like messages over a network of nerve fibers. The endocrine system works much more slowly by sending chemical messengers (hormones) through the bloodstream to target structures. The two systems are very closely interrelated functionally and anatomically. The nervous system exerts control over the endocrine system through the influence of the hypothalamus (brain) on the pituitary gland.

**ANATOMY AND PHYSIOLOGY**

The nervous system has two main divisions, the central nervous system (CNS) and the peripheral nervous system, as well as their related subdivisions.
Figure 4-1). The CNS is composed of the brain and the spinal cord and serves as the control center of the entire nervous system. All sensory information must be relayed to the CNS before it can be interpreted and acted on. Most impulses that stimulate glands to act and muscles to contract originate in the CNS.

The nerve processes that connect the CNS with the various glands, muscles, and receptors in the body make up the peripheral nervous system. Functionally, the peripheral nervous system is divided into afferent and efferent portions. The afferent portion is composed of nerve cells that carry information from receptors in the periphery of the body to the CNS. The efferent system consists of nerve cells that carry impulses from the CNS to muscles and glands. Anatomically, the peripheral nervous system is composed of cranial nerves and spinal nerves.

The peripheral nervous system is also subdivided into a somatic nervous system and an autonomic nervous system (ANS). The somatic nervous system consists of efferent nerves that carry impulses from the CNS to skeletal muscle tissue. It is under conscious control and is therefore called voluntary. The ANS consists of efferent nerve cells that carry information from the CNS to cardiac muscle, glands, and smooth muscle. It is under unconscious control and is

**FIGURE 4-1**
Organization of the nervous system.
called involuntary. The ANS has two subdivisions, the **sympathetic nervous system** and the **parasympathetic nervous system**. Most tissues innervated by the ANS receive both sympathetic and parasympathetic fibers. In general, one division stimulates an activity by a receptor and the other inhibits the activity to serve as a method of checks and balances.

The fundamental unit of all branches and divisions of the nervous system is the neuron (nerve cell). Neurons have the amazing ability to transmit information from point to point. The second point may be nearby or at a great distance. Similar to all cells in the body, neurons have a nucleus surrounded by cytoplasm. Different from other cells, however, neurons have cellular extensions or processes called **axons** and **dendrites**. Axons carry electric-like messages away from the nerve cell, and dendrites carry electric-like messages toward the nerve cell (Figure 4-2). Transmission of these messages along nerve fibers occurs through a wave of charge reversal that moves down the fiber (Figure 4-3). The resting (polarized) fiber has positive charges lined up on the outside of its membrane and negative charges lined up on the inside of its membrane. When a stimulus of sufficient magnitude reaches the fiber, depolarization or charge reversal (positive in, negative out) occurs in a progressive wave down the fiber toward the synapse. Repolarization is the movement of charges back to their original positions.

Axons may be short or long (up to 4 feet in humans), and they end, or terminate, in as many as 10,000 nerve endings called **telodendra** (Snyder, 1986). The large number of nerve endings allows for great variety in the number and type of connections made with other neurons. The synaptic end bulbs of the telodendra pass nerve impulses to an adjacent structure (another neuron, gland, or muscle) by emitting a chemical messenger called a neurotransmitter into the gap or junction (synapse) between the nerve ending and the adjacent structure (Figure 4-4). Neurotransmitters then combine with receptors on the dendritic side of the synapse and cause a stimulatory or inhibitory effect. Dendrites may respond to neurotransmitters by generating a nerve impulse, which is conducted.

**Figure 4-2**
Impulse transmission through the neuron.

**Figure 4-3**
Electrical impulse transmission along a nerve fiber.
via the axon to the adjacent structure (neuron, gland, or muscle). Neurotransmitters can be mimicked or blocked by the use of appropriate drugs (Figure 4-5).

Nerve fibers (nerves) may have a large diameter (A fibers), a medium diameter (B fibers), or a small diameter (C fibers) (Boothe, 2001). Fibers with large diameters conduct nerve impulses faster than those with small diameters. Fibers that are surrounded by the insulating substance called myelin also transmit impulses faster than nonmyelinated fibers. Type A and B fibers are generally myelinated fibers.

The most basic impulse conduction system through the nervous system is the reflex arc (Figure 4-6). The reflex arc is composed of the following:

1. A receptor
2. A sensory neuron
3. A center in the CNS for a synapse
4. A motor neuron
5. An effector

The receptor of the reflex arc may be located in a peripheral site—such as the skin—or in a central area—such as a muscle, tendon, or visceral organ. The sensory neuron carries the impulse from the receptor to the CNS. In the CNS, the sensory neuron synapses with interneurons in the spinal cord. These interneurons send the impulse to the brain for interpretation or send the impulse to a motor neuron. The motor neuron carries the message to an effector organ. If the impulse travels around the arc without going to the brain for analysis, the sequence of events is called a spinal reflex (see Figure 4-6). A spinal reflex can occur even if the spinal cord is completely severed. For example, a hemostat applied to the toe of a dog with a severed cord can cause the dog to withdraw its leg by means of the spinal reflex.
Areas of the brain that have importance to an understanding of the pharmacology of the CNS are illustrated in Figure 4-7. The cerebrum is responsible for higher functions of the brain, such as learning, memory, and interpretation of sensory input (vision, pain recognition, and so forth). The thalamus serves as a relay center for sensory impulses from the spinal cord, brain stem, and cerebellum to the cerebrum. The thalamus also may be involved in pain interpretation. The hypothalamus serves as the primary mediator between the nervous system and the endocrine system through its control of the pituitary gland. The hypothalamus also controls and regulates the ANS. The medulla carries both sensory and motor impulses between the spinal cord and the brain. It contains centers that control vital physiologic activities, such as breathing, heartbeat, blood pressure, vomiting, swallowing, coughing, body temperature, hunger, thirst, and others. The reticular formation is a network of nerve cells scattered through bundles of fibers that begin in the medulla and extend upward through the brain.
The reticular activating system is a part of the reticular formation, which functions to arouse the cerebral cortex and is responsible for consciousness, sleep, and wakefulness (DeLahunta, 1983).

In summary, nerve activity is usually described as the generation of nerve impulses that occurs in a dendrite or cell body and then travels down an axon by electric-like activity, which is similar to the passage of an electric current down a wire. When this current reaches a synapse, a chemical "bridge" or neurotransmitter allows the message to be passed to one or as many as thousands of other neurons. Neurotransmitter substances include acetylcholine, norepinephrine, dopamine, serotonin, and gamma-aminobutyric acid (GABA). These other neurons then carry the message to an interpretation center or a structure that takes appropriate action. CNS drugs act by mimicking or blocking the effects of neurotransmitters.

**AUTONOMIC NERVOUS SYSTEM**

The ANS is that portion of the nervous system that controls unconscious body activities. ANS fibers innervate smooth muscle, heart muscle, salivary glands, and other viscera. This system operates automatically and involuntarily to control visceral functions, such as gastrointestinal (GI) motility, rate and force of the heartbeat, secretion by glands, sizes of the pupils, and various other involuntary functions and characteristics. In contrast to the somatic nervous system, the ANS has two subdivisions: parasympathetic (cholinergic) and sympathetic (adrenergic). The sympathetic division regulates energy-expending activities (fight-or-flight responses), and the parasympathetic division regulates energy-conserving activities.

The ANS has two neurons that carry impulses to target structures (in contrast to the somatic nervous system, which has only one). The cell body of the first neuron arises in the CNS—in the thoracolumbar cord for the sympathetic nervous system and in the craniosacral cord for the parasympathetic nervous system (Figure 4-8). The axon of the first neuron leaves the CNS and travels to a ganglion, where it synapses with dendrites of the second neuron. This second neuron then travels to the target structure (Figure 4-9). Axons of the first neuron are called preganglionic, and those of the second are called postganglionic. The synapse between the preganglionic neuron and the postganglionic neuron is called the **ganglionic synapse**.

Preganglionic fibers of the sympathetic nervous system are short. They end in ganglia adjacent to the spinal cord. The only exception is the preganglionic fiber to the adrenal medulla. The adrenal medulla itself is analogous to a postganglionic fiber because it releases epinephrine and norepinephrine directly into the bloodstream when stimulated by preganglionic fibers. Postganglionic sympathetic fibers are long.

Preganglionic fibers of the parasympathetic nervous system are generally long. They travel to ganglia located in the wall of the target organ. Postganglionic fibers are consequently short.

Normally, target sites of the ANS have both sympathetic and parasympathetic innervation. The physiologic functions of the two systems usually oppose each other and thereby bring about a state of balance. When this balance is disrupted, drug therapy may be indicated to restore the balance. The adrenal medulla, sweat glands, and hair follicles have only sympathetic fibers.

Stimulation of the sympathetic nervous system causes an increase in heart rate and respiratory rate, a decrease in GI activity, dilation of the pupils, constriction of blood vessels in smooth muscle, dilation of blood vessels in skeletal muscle, dilation of bronchioles, and an increase in blood glucose levels. These actions prepare an animal to fight or to flee. On the other hand, stimulation of the parasympathetic nervous system causes a decrease in heart rate and respiratory rate, an increase in GI activity, constriction of the pupils, and constriction of the bronchioles.

Receptors of the sympathetic (adrenergic) nervous system are subdivided as follows (Figure 4-10):

1. Alpha-1
2. Alpha-2
3. Beta-1
4. Beta-2
5. Dopaminergic
Figure 4-8
Schematic of the autonomic nervous system. (From Thibodeau JA: Anatomy and physiology, St. Louis, 1987, Mosby.)
Generally, alpha receptors are stimulatory and beta receptors are inhibitory (Table 4-1). The parasympathetic (cholinergic) nervous system has nicotinic and muscarinic receptors. Effector organs have one or a combination of these receptors. A drug’s effect is determined by the number of receptors in the effector and the drug’s specificity for the receptor (Williams and Baer, 1990).

The primary neurotransmitters for adrenergic sites are norepinephrine, epinephrine, and dopamine. Epinephrine equally stimulates alpha and beta receptors and is therefore a potent stimulator of the heart and an equally powerful dilator of bronchioles. Acetylcholine is the neurotransmitter at sympathetic postganglionic fibers to sweat glands and the smooth muscle of blood vessels (muscarinic sites).
**Table 4-1** Adrenergic Receptor Responses

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Target Organ</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-1</td>
<td>Arterioles</td>
<td>Constriction</td>
</tr>
<tr>
<td></td>
<td>Urethra</td>
<td>Increased tone</td>
</tr>
<tr>
<td></td>
<td>Eye</td>
<td>Dilation of pupil</td>
</tr>
<tr>
<td>Alpha-2</td>
<td>Skeletal muscle</td>
<td>Constriction</td>
</tr>
<tr>
<td>Beta-1</td>
<td>Heart</td>
<td>Increased rate, conduction,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and contractility</td>
</tr>
<tr>
<td>Beta-2</td>
<td>Kidneys</td>
<td>Renin release</td>
</tr>
<tr>
<td>Dopaminergic</td>
<td>Bronchioles</td>
<td>Dilation</td>
</tr>
<tr>
<td></td>
<td>Kidneys</td>
<td>Dilation of blood vessels</td>
</tr>
<tr>
<td></td>
<td>Heart</td>
<td>Dilation of coronary vessels</td>
</tr>
<tr>
<td></td>
<td>Mesenteric blood vessels</td>
<td></td>
</tr>
</tbody>
</table>

The neurotransmitter for cholinergic sites is **acetylcholine**. Acetylcholine combines with both nicotinic and muscarinic receptors.

Cholinergic sites are found in both the sympathetic and parasympathetic nervous systems. Nicotinic receptors are found in all autonomic ganglia, in the adrenal medulla, and at the neuromuscular junction of the somatic nervous system. Muscarinic receptors are found at the synapse of postganglionic fibers of the parasympathetic nervous system and at a few of the sympathetic postganglionic fibers.

**How Drugs Affect the Autonomic Nervous System**

Autonomic drugs bring about their effects by influencing the sequence of events that involve neurotransmitters. Most autonomic drugs bring about this alteration of events by doing the following:

1. Mimicking neurotransmitters
2. Interfering with neurotransmitter release
3. Blocking the attachment of neurotransmitters to receptors
4. Interfering with the breakdown or reuptake of neurotransmitters at the synapse

**CLASSES OF AUTONOMIC NERVOUS SYSTEM AGENTS**

**Cholinergic Agents**

Cholinergic agents are drugs that stimulate receptor sites mediated by acetylcholine. They achieve these effects by mimicking the action of acetylcholine (direct acting) or by inhibiting its breakdown (indirect acting). Cholinergic agents are also called parasympathomimetic because their effects resemble those produced by stimulating parasympathetic nerves.

**Clinical Uses**

Cholinergic agents do the following:

1. Aid in the diagnosis of myasthenia gravis
2. Reduce the intraocular pressure of glaucoma
3. Stimulate GI motility
4. Treat urinary retention
5. Control vomiting
6. Act as an antidote for neuromuscular blockers

**Direct-Acting Cholinergics**

1. Acetylcholine. Acetylcholine is seldom used clinically because it is broken down so rapidly by acetylcholinesterase.
2. Carbamylcholine. This product has been used to treat atony of the GI tract and to stimulate uterine contractions in swine.
3. Bethanechol (Urecholine). Bethanechol is used to treat GI and urinary tract atony.
5. Metoclopramide (Reglan). Metoclopramide is used to control vomiting and to promote gastric tract emptying.

**Indirect-Acting Cholinergic (Anticholinesterase) Agents**

1. Edrophonium (Tensilon). Edrophonium is used to diagnose myasthenia gravis.
2. Neostigmine (Prostigmine, Stiglyn). These products are used to treat urine retention and
GI atony and as an antidote to neuromuscular blocking agents.
3. Physostigmine (Antilinium, Eserine). Uses of this product are similar to those of neostigmine.
4. Organophosphate compounds. These are commonly used as insecticide dips and may result in toxicity if used inappropriately. See Pralidoxime below.
5. Demecarium (Humorsol). This drug is used in the preventive management of glaucoma.
6. Pyridostigmine (Mestinon). This drug is used for the treatment of myasthenia gravis.

**Adverse Side Effects**
Adverse side effects of the cholinergic drugs may include bradycardia, hypotension, heart block, lacrimation, diarrhea, vomiting, increased intestinal activity, intestinal rupture, and increased bronchial secretions.

---

**Cholinergic Blocking Agents (Anticholinergic)**

Cholinergic blocking agents are drugs that block the action of acetylcholine at muscarinic receptors of the parasympathetic nervous system.

**Clinical Uses**
Clinical uses of these drugs are as follows:

1. Treatment of diarrhea and vomiting by decreasing GI motility
2. As a preanesthetic to dry secretions and prevent bradycardia
3. To dilate the pupils for ophthalmic examination
4. To relieve ciliary spasm of the eye
5. To treat sinus bradycardia

The belladonna alkaloids of the deadly nightshade family of plants have been used as drugs for centuries and represent the prototype for this category of agents.

**Dosage Forms**
1. Atropine. Numerous generic and trade name products are available for parenteral or ophthalmic administration. Atropine is used as a preanesthetic to dry secretions and to prevent bradycardia; as an antidote to organophosphate poisoning; to dilate the pupils for ophthalmic examination; to control ciliary spasms of the eye; to treat sinus bradycardia; and to slow a hypermotile gut.
2. Scopolamine. This is used in antidiarrheal medications.
3. Methscopolamine is an ingredient of Biosol-M. Methscopolamine is used to control diarrhea.
4. Glycopyrrolate (Robinul-V). Glycopyrrolate is a quaternary ammonium compound with actions similar to atropine. It provides longer action than atropine and is used primarily as a preanesthetic.
5. Aminopentamide (Centrine). Aminopentamide is used to control vomiting and diarrhea in dogs and cats.
6. Propantheline (Pro-Banthine). Propantheline is used to treat diarrhea, urinary incontinence, and bradycardia, and to reduce colonic peristalsis in horses to allow rectal examination. Propantheline, similar to glycopyrrolate, is a quaternary ammonium compound.
7. Pralidoxime (Protosan, 2-PAM). A cholinesterase reactivator used to treat organophosphate intoxication.

**Adverse Side Effects**
Adverse side effects of the cholinergic blockers are dose related. Overdose can cause drowsiness, disorientation, tachycardia, photophobia, constipation, anxiety, and burning at the injection site.

---

**Technician's Notes**
1. Atropine administered as a preanesthetic causes dilation of the pupils. It dries secretions and prevents bradycardia.
2. Atropine is packaged in small-animal and large-animal concentrations. Care should be taken not to confuse the two preparations.
Adrenergic (sympathomimetic) agents bring about action at receptors mediated by epinephrine or norepinephrine. Adrenergic agents may be classified as catecholamines or noncatecholamines, and either category can also be classified according to the specific receptor types activated (alpha-1, alpha-2, beta-1, beta-2). In most cases, alpha receptor activity causes an excitatory response (except in the GI tract), and beta stimulation causes an inhibitory response (except in the heart). Adrenergic activity is a complex subject, and more advanced texts should be consulted for a thorough explanation.

Clinical Uses
Adrenergic agents are used for the following purposes:

1. To stimulate the heart to beat during cardiac arrest
2. To reverse the hypotension and bronchospasm of anaphylactic shock
3. To strengthen the heart during congestive heart failure
4. To correct hypotension through vasoconstriction
5. To reduce capillary bleeding through vasoconstriction
6. To treat urinary incontinence
7. To reduce mucous membrane congestion (vasoconstriction) in allergic conditions
8. To prolong the effects of local anesthetic agents by causing vasoconstriction of blood vessels at the injection site, thereby prolonging their absorption
9. To treat glaucoma (alpha stimulation increases the outflow of and beta stimulation decreases the production of aqueous humor)

Dosage Forms
1. Epinephrine (Adrenalin). Epinephrine stimulates all receptors to cause an increase in heart rate and cardiac output, constriction of the blood vessels in the skin, dilation of the blood vessels in muscle, dilation of the bronchioles, and an increase in metabolic rate.
2. Norepinephrine (Levophed, Noradrenalin). Norepinephrine is mostly an alpha stimulator with some beta stimulation. Its primary influence is that of a vasopressor (to raise blood pressure).
3. Isoproterenol (Isuprel). Isoproterenol is a pure beta stimulator. Its primary use is for bronchodilation.
4. Phenylephrine (Neo-Synephrine). Phenylephrine is an alpha stimulator that is used as a nasal vasoconstrictor.
5. Dopamine (Intropin). Dopamine is a precursor of epinephrine and norepinephrine. Its action is dose dependent. It is used to treat shock and congestive heart failure and to increase renal perfusion.
6. Phenylpropanolamine (Ormeade, Prolamine, Dextran). Phenylpropanolamine is used to treat urinary incontinence in dogs.
7. Dobutamine (Dobutrex). Dobutamine is a beta-1 agonist that is used for short-term treatment of heart failure.
8. Ephedrine (Vatroynol), terbutaline (Brethine), and albuterol (Proventil). These products are beta agonists and their main use is bronchodilation.

Adverse Side Effects
These may include tachycardia, hypertension, nervousness, and cardiac arrhythmias. Hypertension, arrhythmia, and pulmonary edema may occur with an overdose.

Technician's Notes
Epinephrine is normally packaged as a 1:1000 dilution. Many clinicians prefer a 1:10,000 dilution for treating cardiac arrest. Mix 1 ml of the original dilution with 9 ml of sterile water to prepare a 1:10,000 dilution. Epinephrine is stored under refrigeration. A note should be placed in the emergency crash cart noting the location of this drug.

Adrenergic Blocking Agents
Adrenergic blocking agents are used to disrupt the activity of the sympathetic nervous system. They are classified according to the site of their action as an
alpha blocker, beta blocker, or ganglionic blocker. Drugs usually block only one category of receptor.

**Alpha Blockers**
Alpha blockers have had limited use in veterinary medicine. Phenoxybenzamine has been advocated by some clinicians for the treatment of laminitis in horses and urethral obstruction in cats. Yohimbine is used for xylazine antagonism.

**Clinical Uses**
See Dosage Forms.

**Dosage Forms**
1. Phenoxybenzamine (Dibenzyline). Phenoxybenzamine is a hypotensive (vasodilator) agent.
2. Tranquilizers (acepromazine, droperidol). These tranquilizers act as alpha blockers and cause vasodilation.
3. Prazosin (Minipress). Prazosin is a hypotensive agent.
4. Yohimbine (Yobine). Yohimbine is used as an antidote for xylazine toxicity.
5. Atipamezole (Antisedan). Atipamezole is a reversal agent for medetomidine.

**Adverse Side Effects**
Adverse side effects may include hypotension (phenoxybenzamine, tranquilizers, prazosin), tachycardia (phenoxybenzamine), muscle tremors (yohimbine), and seizures (acepromazine).

**Beta Blockers**
Beta blockers are used to treat glaucoma, arrhythmias, and hypertrophic cardiomyopathy.

**Clinical Uses**
See Dosage Forms.

**Dosage Forms**
1. Propranolol (Inderal). Propranolol is used to treat cardiac arrhythmias and hypertrophic cardiomyopathy.
2. Timolol (Timoptic). Timolol is an ophthalmic preparation that is used to treat glaucoma.
3. Atenolol. Used in a similar way to propranolol.

**Adverse Side Effects**
These include bradycardia, hypotension, worsening of heart failure, bronchoconstriction, heart block, and syncope.

**Ganglionic Blockers**
Ganglionic blockers are seldom used in veterinary medicine.

**CENTRAL NERVOUS SYSTEM**
CNS drugs have various uses in veterinary medicine. Depressant drugs are used to tranquilize or sedate animals to facilitate restraint or anesthetic procedures. They are also used to control pain, to induce anesthesia, and to prevent or control seizures. CNS drugs are also available to antagonize (reverse) the effects of some depressant drugs. Another group of CNS agents is used to stimulate the CNS to treat cardiac or respiratory depression or arrest. Euthanasia drugs allow veterinarians to provide a quick and painless end to hopeless medical situations.

Drugs that affect the CNS generally cause depression or stimulation. They are thought to generate these changes by altering nerve impulse transmissions between the spinal cord and the brain or within the brain itself. Altering impulse transmissions within the thalamus could prevent messages regarding painful stimuli from reaching interpretation centers within the cerebrum. Interfering with impulses within the reticular activating system could alter levels of consciousness or wakefulness (Ganong, 2003). The changes that occur in the transmission of nerve impulses as a result of administration of CNS drugs are probably brought about by altered neurotransmitter activity.

The categories of CNS drugs that are covered in this chapter include the following:

1. Tranquilizers
2. Barbiturates
3. Dissociatives
4. Opioid/antagonists
5. Neuroleptanalgesics/antagonists  
6. Drugs to prevent or control seizures  
7. Inhalants  
8. Miscellaneous CNS drugs  
9. CNS stimulants  
10. Euthanasia agents

**Phenothiazine Derivatives**

The mechanism of action of the phenothiazine derivatives on the CNS is not well understood. However, it has been proposed that they are dopamine blockers (Muir and Hubbell, 2007). The effects on the cardiovascular system are a result of alpha-adrenergic blockade.

Phenothiazine derivative tranquilizers produce sedation and allay fear and anxiety without producing significant analgesia. Sudden painful stimuli arouse the animal. Phenothiazine derivative tranquilizers produce an antiemetic effect by depressing the chemoreceptor trigger zone in the brain and have a mild antipruritic effect. These agents also reduce the tendency of epinephrine to induce cardiac arrhythmias.

**Clinical Uses**

Phenothiazine derivatives are used for prevention or treatment of vomiting, relief of mild pruritus, and sedation/tranquilization.

**Dosage Forms**

1. Acepromazine maleate (Acepromazine, Promace)  
2. Chlorpromazine hydrochloride (Thorazine)  
3. Promazine HCl (Sparine)  
4. Prochlorperazine/isopropanide (Darbazine, Compazine)

**Adverse Side Effects**

Phenothiazine derivative tranquilizers can cause hypotension and hypothermia through their vasodilator effects (alpha blockade). They also can induce seizures (by lowering the seizure threshold) in epileptic animals.

---

**Technician’s Notes**

1. Phenothiazine derivatives should not be used within 1 month of worming with an organophosphate anthelmintic.  
2. The tranquilizing effect may be reduced in an excited animal.

Phenothiazine derivative tranquilizers are approved for use in a wide variety of animals and for administration by almost any route. They generally are relatively safe drugs to use when administered appropriately. They should be given with care when used with other CNS depressants because of the additive effect. Most phenothiazine derivative tranquilizers are metabolized by the liver and excreted by the kidneys.

**Benzodiazepine Derivatives**

The mechanism of action of diazepam occurs through depression of the thalamic and hypothalamic areas of the brain. This drug produces sedation, muscle relaxation, appetite stimulation (especially in cats), and anticonvulsant activity. Diazepam also produces minimal depression of the cardiovascular and respiratory systems when compared with other CNS depressants. It sometimes is used in combination with ketamine to induce short-term anesthesia. Diazepam is very useful for treating seizures in progress.

Several potential drug interactions can occur when diazepam is administered simultaneously with other drugs, and appropriate references should be consulted.

**Clinical Uses**

Clinical uses include sedation, relief of anxiety and behavioral disorders, treatment of seizures, and appetite stimulation. Diazepam can be used as an injectable anesthetic.

**Dosage Forms**

1. Diazepam (Valium, Vazepam)  
2. Midazolam (Versed)  
3. Alprazolam (Xanax)
Adverse Side Effects
These are limited when used as directed. Dogs can exhibit excitement. Overdose may cause excessive CNS depression.

Technician's Notes
1. Diazepam should be stored at room temperature and protected from light.
2. Diazepam should not be stored in plastic syringes or in solution bags because it can be absorbed into the plastic.
3. Manufacturers recommend that it not be mixed with other medications or solutions.
4. Diazepam is metabolized by the liver and eliminated by the kidneys.
5. Alprazolam is also used as an appetite stimulant.

Xylazine Hydrochloride
Xylazine is an alpha-2 agonist with sedative, analgesic, and muscle relaxant properties. It is approved for use in dogs, cats, horses, deer, and elk. This agent causes vomiting in a large percentage of cats and in some dogs. Xylazine is antagonized by yohimbine. It produces effective analgesia in horses and is often used for treating the pain associated with colic and for sedation for minor procedures. It is also used in combination with ketamine for short-term field procedures in horses, such as castration and suturing of extensive wounds, because this combination usually produces 15 to 20 minutes of recumbency. Extralabel use of xylazine for cesarean sections in cattle and other surgical procedures is common. Xylazine is used in cats and dogs as a tranquilizer and in combination with other injectable agents for surgical procedures.

Clinical Uses
Clinical uses include sedation, analgesia, short-term anesthesia (when combined with other agents), and induction of vomiting.

Dosage Forms
1. Rompun
2. AnaSed
3. Gemini
4. Sedazine

Adverse Side Effects
These include bradycardia, hypotension, respiratory depression, and increased sensitivity to epinephrine, resulting in cardiac arrhythmias. An overdose increases the potential for these effects.

Technician's Notes
1. Because of the potential of xylazine to cause bradycardia or heart block in dogs, atropine should be used as a premedicant in this species.
2. Xylazine is used in cattle at one tenth of the equine dose.
3. Horses may appear heavily sedated with xylazine and still respond to painful stimuli by kicking.
4. Small-animal (20 mg/ml) and large-animal (100 mg/ml) concentrations are available. Care should be taken not to confuse them when administering a drug dose to an animal.

Detomidine Hydrochloride
Detomidine, similar to xylazine, is an alpha-2 agonist. It is approved as a sedative/analgesic for horses, and clinicians often report excellent analgesic properties in their patients when using this product. It is used for procedures in horses when sedation and analgesia are needed and reportedly produces better analgesia of the rear limbs than does xylazine.

Clinical Uses
Detomidine is used for sedation and analgesia in horses.

Dosage Form
Dormosedan

Adverse Side Effects
These may include sweating, muscle tremors, penile prolapse, bradycardia, and heart block.

Technician's Notes
The manufacturer warns that detomidine should be used very carefully with other sedative drugs, and that it should not be used with potentiated sulfa drugs such as trimethoprim/sulfa.
**Medetomidine**

Medetomidine is an alpha-2-adrenergic agonist labeled for use as a sedative and analgesic in dogs older than 12 weeks of age. Atipamezole (Antisedan) is the reversal agent for this drug.

**Clinical Uses**

Uses include facilitating clinical examination, minor surgical procedures, and minor dental procedures that do not require intubation.

**Dosage Form**

Domitor

**Adverse Side Effects**

Side effects include bradycardia (product insert states that hemodynamics are maintained), atrioventricular (AV) heart block, decreased respirations, hypothermia, urination, vomiting, hyperglycemia, and pain at the injection site.

---

**Technician's Notes**

1. Treatment of medetomidine-induced bradycardia with anticholinergic drugs (atropine or glycopyrrolate) is not recommended because of the potential for more serious arrhythmias.
2. Antisedan is recommended for treatment of medetomidine-induced effects.
3. Before the use of medetomidine in combination with other sedatives is attempted, references should be consulted for potential side effects and dosages.

---

**Romifidine**

Romifidine is an alpha-2-adrenergic agonist labeled for use in horses.

**Clinical Uses**

Romifidine is used as a sedative to facilitate handling, examination, and treatment, and as a premedication prior to general anesthesia.

**Dosage Form**

Sedivet

---

**Barbiturates**

The barbiturates are one of the oldest categories of CNS depressants used in veterinary medicine. They are derived from the parent compound barbituric acid and cause various responses ranging from sedation to death, depending on the dose and the circumstances of use. Barbiturates are used in veterinary medicine as sedatives, anticonvulsants, general anesthetics, and euthanasia agents. They are easy and cheap to administer. They have great potential for complications because of their potent depressing effects on the cardiac and pulmonary systems (especially in cats), and because they are nonreversible and must be metabolized by the liver before elimination can occur. Individual patients with poor liver function, little body fat, or preexisting illnesses that cause acidosis may be at risk when receiving barbiturates. Because of their alkalinity, the ultrashort-acting barbiturates can cause necrosis of the tissue if administered outside the vein in the subcutaneous space. Barbiturates are metabolized by the liver and are potent depressors of the respiratory system.

Barbiturates are classified according to their duration of action as long-acting, short-acting, and ultrashort-acting. Or they are classified according to the chemical side chain on the barbituric acid molecule as an oxybarbiturate or a thio-barbiturate (Table 4-2). The long- and short-acting barbiturates have a side chain that is connected by oxygen; they are therefore called oxybarbiturates. The thio-barbiturates have a side chain connected by a sulfur. The thio-barbiturates are highly soluble in fat and tend to move rapidly out of the CNS into the fat stores of the body, thus accounting for their ultrashort activity.

**Clinical Uses**

Clinical uses include the prevention and treatment of seizures, as well as sedation, anesthesia, and euthanasia.

**Long-Acting Barbiturates (Oxybarbiturates, 8 to 12 Hours)**

Phenobarbital. Numerous proprietary and generic products are available. Phenobarbital is used primarily as an anticonvulsant to prevent epileptic
seizures. It is administered by the oral route. Phenobarbital is a Class IV controlled substance.

**Short-Acting Barbiturates (Oxybarbiturates, 45 Minutes to 1.5 Hours)**
Pentobarbital sodium (Nembutal and numerous generic products). Pentobarbital is given by intravenous injection (the intraperitoneal route also may be used) and provides 1 to 2 hours of general anesthesia. In the early days of veterinary anesthesia, it was the general anesthetic that was routinely used in dogs. Today, pentobarbital is used primarily to control seizures in progress and as a euthanasia agent. Intravenous administration of glucose or concurrent use of chloramphenicol may prolong the recovery period. Pentobarbital is a Class II controlled substance.

**Ultrashort-Acting Barbiturates (Thiobarbiturates, 5 to 30 Minutes)**
Thiobarbiturates are very alkaline (especially at the higher concentrations) and must be given intravenously to avoid necrosis and subsequent sloughing of tissue. Thiobarbiturates are redistributed into the fat stores of the body within 5 to 30 minutes.

Extreme care should be taken when a thiobarbiturate is administered to a thin animal because of the lack of fat stores. Thiobarbiturates are prepared as a sterile powder in vials for dilution up to the desired concentration. They are stable for long periods in undiluted form. Sterile water for injection should be used as the diluent because solutions with electrolytes hasten precipitate formation. Solutions should not be administered if precipitates are present.

Thiobarbiturates can cause a period of apnea when they are rapidly administered intravenously. If spontaneous respirations do not resume in a short time, controlled respirations should be started. Barbiturates can also cause a period of CNS excitement when administered intravenously if they are given too slowly. It is often recommended to give one third to one half of the calculated dose rapidly to avoid the excitement phase. The remainder of the dose is administered in increments until the desired effect is achieved.

**Dosage Forms**
1. Thiopental (Pentothal). Thiopental is used as an intravenous agent to induce general anesthesia.
2. Methohexital (Brevane). Methohexital is an ultrashort-acting barbiturate that produces 5 to 10 minutes of anesthesia. It has been recommended for use in sight hounds because of its rapid redistribution and metabolism by the liver.

**Adverse Side Effects**
These include excessive CNS depression, paradoxical CNS excitement, severe respiratory depression, and cardiovascular depression. Tissue irritation may occur when barbiturates are injected perivascularly.

**Technician’s Notes**
1. Recovery from pentobarbital is often prolonged, and dogs exhibit padding limb movements during this time.
2. Thiobarbiturates should not be used in sight hounds or in any very thin animal.
3. Giving additional doses of thiobarbiturates may prolong recovery.
4. Barbiturates are potent depressors of the respiratory system.
The dissociative agents belong to the cyclohexylamine family, which includes phencyclidine, ketamine, and tiletamine. Involuntary muscle rigidity (catalepsy), amnesia, and analgesia characterize dissociative anesthesia. Pharyngeal/laryngeal reflexes are maintained, and muscle tone is increased. Because deep abdominal pain is not eliminated (surgical stage III is not usually reached) with dissociative anesthesia, it is recommended only for restraint, diagnostic procedures, and minor surgery. Dissociative agents often are combined with other agents for abdominal surgery, however. Dissociative drugs produce minor cardiac stimulation, and respiratory depression can occur with higher doses. These agents act by altering neurotransmitter activity, causing depression of the thalamus and cerebral cortex, and activating the limbic system (Plumb, 2005).

Some species are often ataxic and hyperresponsive during induction and recovery with dissociative agents (Muir and Hubbell, 2007). Tremors, spasticity, and convulsions can occur at higher doses. Hallucinations have been reported in humans and are suspected in cats.

**Clinical Uses**
Dissociative agents are used for sedation, restraint, and anesthesia.

**Dosage Forms**
1. Ketamine HCl (Ketaset, Vetalar, Ketalar). Ketamine is approved for use in humans, primates, and cats but has extralabel uses in various species, including dogs, horses, birds, small ruminants, and reptiles. Tranquilizers, such as acepromazine, xylazine, and diazepam, are often used concurrently with ketamine to enhance muscle relaxation and to deepen the level of anesthesia. Oral, ocular, and laryngeal reflexes are maintained when ketamine is used alone (except at high doses). Occasional spastic jerking movements can occur in cats that are administered ketamine. Ketamine produces good somatic analgesia but poor visceral analgesia.

Increased salivation may accompany administration of this drug and can be controlled or prevented with the use of atropine or glycopyrrolate. An ophthalmic lubricant should be used because cats’ eyes remain open after administration of ketamine. Ketamine is a Class III controlled substance.

2. Tiletamine HCl (Telazol—tiletamine plus zolazepam HCl). Telazol is an injectable anesthetic that consists of a combination of tiletamine (chemically related to ketamine) and zolazepam (a tranquilizer). Telazol is approved for use in dogs and cats. The pharmacokinetics and pharmacotherapeutics of tiletamine are similar to those of ketamine. Because of the zolazepam in this product, additional agents are not needed for muscle relaxation. Ocular lubrication should be used in cats receiving Telazol. Telazol is a Class III controlled substance.

3. Phencyclidine (Serrylan). This dissociative agent is no longer available. It was originally used as an immobilizing agent for nonhuman primates. Its street name is “PCP” or “angel dust” (Upson, 1988).

**Adverse Side Effects**
These are usually associated with high doses and include spastic jerking movement, convulsions, respiratory depression, burning at the intramuscular injection site, and drying of the cornea.

---

**Technician’s Notes**
1. Both ketamine and tiletamine may cause burning at the injection site. Adequate restraint should be used to ensure injection of all medication.
2. Metabolites of the dissociative agents are excreted through the kidneys. These drugs may be contraindicated in animals with compromised kidney function.

---

**Opioid Agonists**
An opioid is any compound derived from opium poppy alkaloids and synthetic drugs with similar pharmacologic properties. These drugs produce analgesia and sedation (hypnosis) while reducing
anxiety and fear. Narcotic effects are produced in combination with opiate receptors at deep levels of the brain (e.g., thalamus, hypothalamus, limbic system). Opioid receptors are grouped into the following four classes (Paddleford, 1999):

1. Mu—found in pain-regulating areas of the brain; contribute to analgesia, euphoria, respiratory depression, physical dependence, and hypothermic actions
2. Kappa—found in the cerebral cortex and spinal cord; contribute to analgesia, sedation, and miosis
3. Sigma—may be responsible for struggling, whining, hallucinations, and mydriatic effects
4. Delta—modify mu receptor activity

Opioids are used as preanesthetics or postanesthetics because of their sedative and analgesic properties. Sedation is more pronounced at higher doses. They are sometimes used alone or in combination with tranquilizers as anesthetics for surgical procedures, for relief of colic pain in horses, and for restraint/capture of wild/zoological animals. At low doses, the opioids have antitussive (cough suppression) properties owing to depression of the cough center in the brain and antidiarrheal action because they cause a reduction in peristalsis or segmental contractions. Several potential adverse side effects are associated with narcotics. Opioids are potent respiratory depressants. Because they affect the thermoregulatory centers in the brain (the body’s thermostat), they may cause panting, defecation, flatulence, and vomiting. Sound sensitivity may also occur. Excitement may occur in dogs if the narcotic is rapidly given intravenously. Cats and horses are reported to be sensitive to the opioids and may exhibit excitatory effects at high doses. Because opioids pass the placenta fairly slowly and their effects can be antagonized, they can be useful when cesarean section is performed. The liver metabolizes opioids, and resultant metabolites are eliminated in the urine. Most opioid preparations are Class II controlled substances, and narcotic antagonists can antagonize them.

**Clinical Uses**

Opioid agonists are used for analgesia, sedation, restraint, anesthesia, treatment of coughing, and treatment of diarrhea.

**Naturally Occurring Narcotics**

1. Opium (laudanum—10% opium), paregoric. Opium is derived from the seed capsule of the opium poppy. Paregoric, also called camphorated tincture of opium, has been used for longer than 100 years for the treatment of diarrhea. It has been used in veterinary medicine for treating diarrhea, primarily in calves and foals.

2. Morphine sulfate (Duramorph). Morphine is an opium derivative used to treat severe pain. Occasionally, it is used as a preanesthetic or anesthetic agent (e.g., cesarean section in dogs). It is also used to relieve anxiety associated with acute congestive heart failure. It exerts its effects primarily on mu receptors. Morphine is a Class II controlled substance that should be used under strict supervision because of its potential for abuse. It is the standard opioid with which all others are compared in terms of analgesic effect.

**Synthetic Narcotics**

1. Meperidine (Demerol). Meperidine is a mu agonist that is approximately one eighth as potent an analgesic as morphine. It is used for relief of acute pain, such as that occurring after orthopedic procedures. It also may be combined with a tranquilizer for use as an anesthetic agent (neuroleptanalgesic). No meperidine products carry a veterinary label. However, human products often have extralabel uses in animals. Naloxone is the preferred antagonist.

2. Oxymorphone (Numorphan). Oxymorphone is a semisynthetic opioid that is a mu agonist. It is approximately 10 times more potent an analgesic than morphine. This drug is used primarily in dogs for restraint, for diagnostic procedures, and for minor surgical procedures. It may be combined with tranquilizers to produce neuroleptanalgesia; naloxone is the antagonist.

3. Butorphanol tartrate (Torbutrol, Torbugesic). Butorphanol is a synthetic, partial opioid agonist. Its narcotic activity is exerted on kappa and sigma receptors. It is a Class IV controlled substance. Butorphanol has 4 to 7 times the analgesic properties of morphine and significant antitussive effects (Plumb, 2005). Torbutrol is a product that is approved as an antitussive agent.
in dogs. It is also used in dogs and cats as an analgesic and preanesthetic. Torbugesic is approved for the treatment of pain associated with colic in horses. It is also used in combination with other sedatives/tranquilizers in horses, dogs, and cats as a preanesthetic or for minor surgical procedures.

4. Fentanyl (Sublimaze). Fentanyl is an opioid agonist that is found in the neuroleptanalgesic Innovar-Vet. It has approximately 100 times the analgesic properties of morphine. Fentanyl is a Class II controlled substance. Fentanyl transdermal patches are sometimes used in animals to control chronic pain (see Chapter 14).

5. Hydrocodone bitartrate (Hycodan, Tussigon). Hydrocodone is an opioid agonist that is used as an antitussive agent in dogs. It is a Class III controlled substance.

6. Etorphine (M-99). Etorphine is an opioid that produces analgesic effects 1000 times those of morphine. It is restricted to use by veterinarians in zoo or exotic animal practice (Upson, 1988). It is lethal to people who accidentally inject themselves (it also can be absorbed through intact skin) if the antagonist (diprenorphine) is not administered immediately. Etorphine is a Class II controlled substance.

7. Pentazocine (Talwin, Talwin-V). Pentazocine is a partial opioid agonist that is approved for pain relief in horses and dogs. It is a Class IV controlled substance.

8. Diphenoxylate (Lomotil). Diphenoxylate is a synthetic opioid agonist that is combined with atropine for use as an antidiarrheal agent. This drug is a Class V controlled substance.

9. Apomorphine—generic labeling. Apomorphine is an opioid with the principal effect of inducing vomiting by stimulating the chemoreceptor trigger zone in the brain. This drug is often administered by placing a portion of a tablet in the conjunctival sac for absorption (see Chapter 8).

10. Methadone (Dolophine). Methadone is a synthetic opioid that was developed as a treatment for morphine and heroin addiction in humans. Its primary use in veterinary medicine is in the treatment of colic pain in horses. Methadone is a Class II controlled substance.

11. Codeine—generic labeling or in combination. Codeine is an opioid that is available in human label products for use as an antitussive in dogs.

12. Carfentanil (Wildnil). Carfentanil is used to induce wildlife anesthesia. It has 10,000 times the potency of morphine.

13. Buprenorphine (Buprenex). Buprenorphine is a human label, partial mu agonist-antagonist. It is a potent analgesic that is used in several small animal species.

**Adverse Side Effects**

These can include respiratory depression, excitement (cats and horses), nausea, vomiting, diarrhea, defecation, panting, and convulsions. Overdose causes profound respiratory depression.

**Opioid Antagonists**

Opioid antagonists block the effects of opioids by binding with opiate receptors, displacing narcotic molecules already present, and preventing further narcotic binding at the sites. These antagonists are classified as pure antagonists or as partial antagonists. The partial antagonists may have some agonist activity (analgesic and respiratory depressant effects).

These drugs usually are administered by the intravenous route and exert their effects very rapidly (15 to 60 seconds).

**Clinical Uses**

Opioid antagonists are used to antagonize the effects of opioid agonists.

**Dosage Forms**

1. Naloxone (naloxone HCl injection, Narcan). Naloxone is a pure opioid antagonist that is chemically similar to oxymorphone, with high affinity for mu receptors. It has no agonist activity.

2. Nalorphine (Nalline). Nalorphine is a partial antagonist that may produce untoward analgesic and respiratory depressant effects.
Adverse Side Effects
Nalorphine may induce respiratory depression. Naloxone usually has few adverse effects if given in the correct dose.

Neuroleptanalgesics
A neuroleptanalgesic agent consists of an opioid and a tranquilizer. Animals that receive neuroleptanalgesics may or may not remain conscious (Muir and Hubbell, 2007). They often defecate and are highly responsive to sound stimuli. The opioid effects of the neuroleptanalgesics can be antagonized with the opioid antagonists.

Clinical Uses
Neuroleptanalgesics are used for sedation and restraint, and to produce anesthesia.

Dosage Forms
1. Fentanyl and droperidol (Innovar-Vet). Innovar-Vet is the only commercially available neuroleptanalgesic. It may be used for restraint, for diagnostic procedures, as a preanesthetic, and for minor surgical procedures.
2. Other neuroleptanalgesics may be prepared by a clinician and include the following:
   - Acepromazine and morphine
   - Acepromazine and oxymorphone
   - Xylazine and butorphanol

Adverse Side Effects
These can include panting, flatulence, personality changes, increased sound sensitivity, and bradycardia. Overdose may cause severe depression of the CNS, respiratory system, and cardiovascular system.

Drugs Given to Prevent or Control Seizures
Seizures occur in animals for various reasons, which include but are not limited to unknown (idiopathic), infectious (postdistemper), traumatic (head injury), toxicity (strychnine poisoning), and metabolic (heatstroke) factors. Prolonged seizures in progress require emergency action with intravenous therapy. Periodic, recurring seizures require preventive oral medication. Oral preventive therapy often must be titrated to the individual patient and reviewed regularly for the appropriate dose adjustment that controls seizure activity.

Clinical Uses
These drugs are used to prevent seizures or to control seizures in progress.

Dosage Forms
1. Diazepam (Valium). Diazepam is a tranquilizer with potent antiseizure properties. It is administered intravenously and has a 3- to 4-hour duration of action.
2. Pentobarbital—generic products. Pentobarbital is a short-acting barbiturate that is effective for controlling seizures. It is administered intravenously and has a 1- to 3-hour duration.
3. Phenobarbital (Luminal, Solfoton, generic formulations). Phenobarbital is an effective antiseizure drug that is available in oral and parenteral formulations. The oral route is the usual means of administering this drug to dogs and cats. The injectable form is used in horses (foals) by some clinicians. Drowsiness is a potential side effect of phenobarbital. Phenobarbital is a Class IV controlled substance.
4. Primidone (Mylepsin). Primidone is similar chemically to phenobarbital, and a portion of the primidone dose is metabolized to phenobarbital by the liver. It is administered orally to dogs and cats, although its use in cats is controversial. Adverse side effects may include agitation, anxiety, polyuria, polydipsia, and dermatitis.
5. Phenytoin sodium (Dilantin). The use of phenytoin has declined considerably through the years because of its variable pharmacokinetics in dogs and cats (Plumb, 2005). It may occasionally be used in combination with other antiseizure medications.
6. Bromide is an old anticonvulsant that has sparked renewed interest, mainly as an adjunct to phenobarbital or primidone therapy.
7. Clorazepate
8. Felbamate
Adverse Side Effects
These may include drowsiness, CNS depression, anxiety, agitation, polyuria, polydipsia, and hepatotoxicity (phenobarbital and primidone). Consult product inserts or appropriate references for specific effects.

Technician’s Notes
1. Inadequate client compliance is a frequent cause of failure of anticonvulsant therapy. Clients should be advised about the importance of following medication instructions carefully.
2. Reserpine and phenothiazine drugs should not be given to epileptic animals.

Inhalant Anesthetics
Inhalant anesthetic agents are used to produce general anesthesia. They are converted from a liquid to a gaseous phase by an anesthetic vaporizer and are delivered to the lungs with the use of an oxygen source and a patient breathing circuit. From the alveoli of the lungs, they are absorbed into the bloodstream and delivered to the CNS, where they produce unconsciousness, analgesia, and muscle relaxation through mechanisms not fully understood.

Inhalants generally require little biotransformation for elimination from the body. They enter and exit the body through the lungs, and this facilitates a rapid induction and recovery from the effects of the agent compared with injectable anesthetic agents. It also permits a quicker alteration of the depth of anesthesia.

The amount (partial pressure) of inhalant anesthetic in the brain is proportionate to the alveolar concentration of the agent. Alveolar concentration depends on the amount of agent delivered to the lungs compared with the amount removed from the lungs. Delivery of the agent to the lungs can be increased by increasing the vaporizer setting, increasing the fresh gas (oxygen) flow, increasing minute ventilation, or decreasing mechanical and physiologic dead space. Factors that influence removal of the agent from the lungs include the solubility (blood-gas partition coefficient) of the agent, the molecular weight of the agent, the partial pressure difference between the agent in the alveolus and the agent in the blood, the amount of alveolar surface available for exchange (absence of lung pathology), and cardiac output.

Uptake by tissue of an anesthetic agent depends mainly on the degree of tissue perfusion and the solubility of the agent in the tissue. Vessel-rich tissue (brain, heart, lungs, liver, kidneys, intestine, and endocrine glands) receives the greatest percentage of cardiac output and is consequently the first to reach equilibrium during uptake of an anesthetic gas and the first to download an agent. Lipid-rich cells, similar to brain cells, absorb more agent than do lipid-poor cells.

Characteristics important to the understanding of inhalant agents include MAC (minimum alveolar concentration), partition coefficient, and vapor pressure (Table 4-3). The MAC value of an anesthetic agent is a measure of potency and is the alveolar concentration that prevents gross purposeful movement in 50% of patients in response to a standardized painful stimulus. Lower numbers indicate more potent agents, and values may vary slightly between species. The partition coefficient is the ratio of the number of molecules of an anesthetic gas that exist in two phases (blood/gas). It indicates the solubility of an agent in a tissue like blood and correlates with the speed of induction and recovery. Lower numbers indicate faster agents. Vapor pressure of an agent indicates how volatile it is and the maximum concentration that can be achieved. Higher numbers indicate greater volatility and the need for a precision vaporizer.

Exposure to anesthetic waste gases can pose a health hazard to the veterinary technician if improper scavenging of waste is not carried out. Reproductive, hepatic, and renal effects have been noted. Toxicity is likely due to the biotransformation of by-products of the agents. Inhalant agents are biodegraded to various degrees (methoxyflurane, 50%; halothane, 25%; isoflurane, 0.2%; sevoflurane, 3%; nitrous oxide, 0.0004%).

Clinical Uses
Inhalant anesthetics are used to induce and maintain general anesthesia in animal patients.
### Table 4-3  Physical Properties of Currently Used Inhalation Anesthetics

<table>
<thead>
<tr>
<th>Property</th>
<th>Sevoflurane</th>
<th>Desflurane</th>
<th>Isoflurane</th>
<th>Halothane</th>
<th>Methoxyflurane</th>
<th>Nitrous Oxide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formula</td>
<td></td>
<td>F</td>
<td>F H F</td>
<td>Br F</td>
<td>Cl F</td>
<td>H</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>O</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>200</td>
<td>168</td>
<td>184.5</td>
<td>197.4</td>
<td>165.3</td>
<td>44</td>
</tr>
<tr>
<td>Specific gravity (20°C C)</td>
<td>1.52</td>
<td>1.47</td>
<td>1.49</td>
<td>1.86</td>
<td>1.41</td>
<td>-</td>
</tr>
<tr>
<td>Bolling point (°C)</td>
<td>59</td>
<td>23.5</td>
<td>48.5</td>
<td>50.2</td>
<td>104.7</td>
<td>-</td>
</tr>
<tr>
<td>Vapor pressure at 20°C (mm Hg)</td>
<td>160</td>
<td>664</td>
<td>239.5</td>
<td>244.1</td>
<td>22.8</td>
<td>-</td>
</tr>
<tr>
<td>ml Vapor/ml liquid at 20°C</td>
<td>182.7</td>
<td>209.7</td>
<td>194.7</td>
<td>227</td>
<td>207</td>
<td>-</td>
</tr>
<tr>
<td>Preservative</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>0.01% thymol</td>
<td>0.01% butyl hydroxytoluene</td>
<td>None</td>
</tr>
<tr>
<td>Stability</td>
<td></td>
<td></td>
<td></td>
<td>Decomposes</td>
<td>Decomposes</td>
<td>Stable</td>
</tr>
<tr>
<td>Soda lime</td>
<td>No?</td>
<td>Stable</td>
<td>Stable</td>
<td>Decomposes</td>
<td>Decomposes</td>
<td>Stable</td>
</tr>
<tr>
<td>UV light</td>
<td>-</td>
<td>-</td>
<td>Stable</td>
<td>Decomposes</td>
<td>Decomposes</td>
<td>-</td>
</tr>
</tbody>
</table>

Dosage Forms
The inhalant agents discussed in this section include isoflurane, sevoflurane, halothane, methoxyflurane, and nitrous oxide.

1. Isoflurane (Forane, Isolene). Isoflurane was synthesized in 1968 and was used clinically in people by 1970. Isoflurane is a colorless liquid with a pungent odor. It is stable and does not require a preservative. A halogenated ether, it is one of the least soluble of the inhalant agents. It is less potent than halothane and methoxyflurane but has very rapid induction and recovery times. Isoflurane allows a stable heart rhythm and does not decrease cardiac output at clinically used levels. It is metabolized at a very low rate (<0.2%) This agent is used in a wide variety of species.

2. Sevoflurane (SevoFlo). Sevoflurane is a halogenated ether with little odor, which makes it a good choice for mask induction. This agent is characterized by very rapid induction and recovery times. Its cardiovascular and respiratory effects are similar to those of isoflurane. Sevoflurane is often used in high-risk, small-animal patients because of its safety and rapid, smooth induction. Only 3% of sevoflurane is metabolized. The disadvantage of the use of this agent is its cost compared with that of isoflurane.

3. Halothane (Halothane). Halothane is a halogenated hydrocarbon that was first used clinically in human anesthesia in 1956. Halothane decomposes when exposed to ultraviolet light and for this reason has thymol added as an antioxidant. Halothane sensitizes the heart to the catecholamines; this may result in cardiac dysrhythmias. Similar to isoflurane and sevoflurane, halothane has a high vapor pressure and must be used in precision vaporizers. "Halothane hepatitis" has been reported in humans but is a very rare occurrence. This agent is metabolized at the rate of 25%, a considerably higher rate than that of the previous two agents.

4. Methoxyflurane (Metofane). Methoxyflurane has been used since 1959. It is a methyl-ethyl-ether that is highly soluble in blood and other tissues. It consequently has a very slow induction and recovery time. Methoxyflurane is the most potent (MAC = 0.23% to 0.27%) of the agents considered in this section. It has a relatively low vapor pressure, making 3% the maximum level that can be vaporized. Also, because of this low vapor pressure, it can be used in nonprecision, in-circuit vaporizers or precision, out-of-circuit vaporizers. Methoxyflurane undergoes the greatest biotransformation (50%) of any of the inhalants. It has been associated with renal toxicity in human patients.

5. Nitrous oxide. Nitrous oxide is a colorless inorganic gas. It was discovered to have anesthetic properties in the late 1700s. Nitrous oxide may be used as an adjuct to more potent agents during mask induction to speed the induction of anesthesia. General anesthesia cannot be produced with nitrous oxide alone. It is compressed to form a liquid and is supplied in blue cylinders. It has the lowest solubility coefficient of any of the inhalants, which means that it enters and exits the blood and tissue rapidly. Because nitrous oxide is 30 times more soluble than nitrogen, it displaces nitrogen from the alveoli, blood, and gas-filled cavities of the body. This means that it will diffuse into and potentially cause distention of the intestines and other gas-filled areas (e.g., the pneumothorax). Nitrous oxide is delivered through a flowmeter and must always be given with oxygen to prevent hypoxia. Oxygen should always be administered for several minutes after the nitrous oxide is turned off to prevent diffusion hypoxia. (The rapid exit of nitrous oxide from the blood will dilute the oxygen in the alveoli.)

Miscellaneous Central Nervous System Drugs

Propofol
Propofol is a short-acting hypnotic that is unrelated to other general anesthetic agents. Its mechanism of action is not well understood. Chemically, it is an alkylphenol derivative. The product that is commercially available is an emulsion that contains soybean oil, glycerol, and egg lecithin. Because of its
white color, some clinicians have called this product "milk of amnesia." Propofol produces a rapid and smooth anesthetic induction in dogs when given slowly intravenously. It produces sedation, restraint, or unconsciousness, depending on the dose. A single bolus lasts 2 to 5 minutes, making it particularly useful when rapid recovery is important.

**Clinical Uses**
Propofol is useful for anesthetic induction before administration of an inhalant anesthetic, for outpatient procedures, as a substitute for barbiturates in sight hounds, and for patients with preexisting cardiac arrhythmia. It is also useful as an anesthetic agent for dogs undergoing a cesarean section since it does not cross the placental barrier.

**Dosage Forms**
1. Rapinovet
2. PropoFlo
3. Diprivan (human label)

**Adverse Side Effects**
Apnea may occur if propofol is given too rapidly intravenously. Occasional seizure-like signs may be seen. Prolonged recovery and/or Heinz body production may be seen in cats with repeated use.

**Technician's Notes**
Propofol is an expensive agent that contains no preservatives. Opened bottles should be stored under refrigeration.

**Glyceryl Guaiacolate or Guaiifenesin (Guailaxin, Gecolate)**
Guaiifenesin is a skeletal muscle relaxant that exerts its effects on the connecting neurons of the spinal cord and brain stem (Plumb, 2005). It is used primarily in equine medicine to induce general anesthesia or to extend the anesthetic activity of other injectable field anesthetics (i.e., ketamine and xylazine). It may be used as a 5% or 10% solution in 5% dextrose. Some clinicians add an ultrashort-acting barbiturate to the solution before administering it intravenously. Relatively large amounts are required to induce general anesthesia, and small increments are given to maintain or extend the anesthetic effects of other agents.

**Clinical Uses**
These include induction or prolongation of general anesthesia in large animals and occasional use as an expectorant.

**Dosage Forms**
1. Guailaxin
2. Gecolate

**Adverse Side Effects**
Adverse side effects are limited. Hemolysis has been reported when greater than 5% solutions are used.

**Chloral Hydrate/Magnesium Sulfate**
This combination has been used as an intravenous agent to produce anesthesia in large animals. Because of the potential for severe irritation of tissue if administered outside of the vein, and because of the advent of more efficacious agents, this combination is seldom used.

**Central Nervous System Stimulants**
The primary medical use of the CNS stimulants is for treatment of respiratory depression or arrest. Many of the other uses of CNS stimulants are
illegal or unethical (e.g., to enhance athletic performance).

**Doxapram**

Doxapram activates the respiratory system by stimulating respiratory centers in the medulla. It is labeled for use in dogs, cats, and horses. Its main indications are to stimulate respirations during or after general anesthesia; it is used in newborns and in cases of cardiopulmonary arrest. It is labeled for intravenous use, but it may be administered under the tongue (1 to 2 drops) or into the umbilical vein of the newborn.

**Clinical Uses**

These include use to stimulate respiration in newborns and use during or after anesthesia.

**Dosage Forms**

1. Dopram-V

**Adverse Side Effects**

Adverse side effects are rare and usually are associated with overdose. Hypertension, seizures, and hyperventilation may occur.

---

**Technician’s Notes**

One to two drops of doxapram may be placed under the tongue or injected into the umbilical vein of the newborn to stimulate respirations.

---

**Pentylenetetrazol (Metrazol)**

Pentylenetetrazol is a generalized stimulant of the CNS that has been used to stimulate respirations and to hasten recovery from anesthesia. It has limited use in veterinary medicine.

**Caffeine**

Caffeine is a general CNS stimulant that promotes wakefulness.

---

**Amphetamines**

Amphetamines, which are potent stimulants of the cerebral cortex, are similar chemically to epinephrine. They have no legitimate medical indications in veterinary medicine.

---

**Neuromuscular Blocking Drugs**

Neuromuscular blocking drugs, sometimes called muscle relaxants, interfere with neuromuscular transmission of impulses and are used as an adjunct to general anesthesia. These drugs provide no analgesia or sedation. However, they do stop ventilation, and this makes ventilation and constant patient monitoring necessary (Muir and Hubbell, 2007).

Neuromuscular blocking drugs are classified as depolarizing agents or nondepolarizing agents. Depolarizing agents act in a way that is similar to that of acetylcholine at the neuromuscular synapse, but the effects last longer, leading to muscle paralysis (Phase I block). These drugs are not broken down by acetylcholinesterase and have no antagonist. Nondepolarizing agents prevent (competitive inhibition) acetylcholine from binding to receptor sites (Phase II block). These drugs are not degraded by cholinesterase, but they can be antagonized by edrophonium or neostigmine.

**Clinical Uses**

Neuromuscular blocking agents are used as an adjunct to general anesthesia (e.g., ophthalmic/orthopedic) and to facilitate endotracheal intubation.

**Dosage Forms**

Depolarizing
1. Succinylcholine chloride (Sucostrin, Anectine)
2. Decamethonium (Syncurene)

Nondepolarizing
1. d-Tubocurarine chloride (Curare)
2. Gallamine (Flaxedil)
3. Pancuronium bromide (Pavulon)
4. Vecuronium bromide (Norcuron)
5. Atracurium (Tracrium)
BEHAVIORAL PHARMACOTHERAPY

The use of drugs to treat behavioral problems in animals is a relatively new but rapidly growing area of veterinary medicine. Behavior problems—such as separation anxiety, fears and phobias, unruliness, hyperactivity, compulsive disorders, cognitive dysfunction in older dogs, and inappropriate elimination in cats—are being diagnosed in increasing numbers. Many animals with behavioral disorders are taken in desperation to animal shelters, but a growing number of clients are willing to attempt to correct these conditions with environmental management, behavior modification, and/or pharmacotherapy.

Informed consent should be obtained from the client before these drugs are used (Shull, 1998) because many of the drugs used in behavioral pharmacotherapy are human psychiatric drugs that have not been approved for use in animals. The technician or veterinarian should explain to the animal owner the extralabel status of the drug, its possible side effects or precautions, and the medical effects to be expected in the pet. Owners should also be aware that pharmacotherapy may not be a cure-all for problems of behavior, and that these problems may return after therapy is discontinued.

All drugs used in psychotherapy are thought to produce their effects through alteration of neurotransmitter activity in the brain (Simpson and Simpson, 1996a, 1996b). The five neurotransmitters of clinical importance in behavioral pharmacotherapy are acetylcholine, dopamine, norepinephrine, serotonin, and GABA.

Dopamine, norepinephrine, and serotonin are called monoamine neurotransmitters because they have similar chemical structures. Monoamines are found in large quantities in areas of the brain often associated with expression and control of emotions. The primary method by which monoamines are inactivated is through their reuptake from the synapse back into synaptic vesicles in nerve endings (see Figure 4-4). Drugs that block or inhibit their reuptake increase their activity. Acetylcholine is the most widely distributed neurotransmitter in the body. It is associated with a variety of behavioral effects and is inactivated by cholinesterase at the synapse. Some of the most common side effects of drugs used in behavioral psychotherapy are related to their anticholinergic effects, such as dry mouth, increased heart rate, urine retention, and constipation. GABA is considered to be an inhibitory neurotransmitter and is widely distributed in the brain.

Pharmacotherapeutic Agents

Drugs most commonly used in treating behavioral problems in veterinary medicine include antianxiety medications, antidepressants, and miscellaneous agents—such as synthetic progestins. All drugs listed in the following section carry a human label, except those that are otherwise indicated.

Antianxiety Medications

Benzodiazepines

The benzodiazepines most commonly used in veterinary medicine include diazepam, alprazolam, and lorazepam. All the benzodiazepines are similar in structure and mechanism of action. They are thought to bind with and promote GABA activity in the cerebral cortex and in subcortical areas, such as the limbic system.

Clinical Uses

Behavioral uses of benzodiazepines include the treatment of fears and phobias, separation anxiety, aggression, anxiety-induced stereotypes, urine marking in cats, and appetite stimulation.

Dosage Forms

1. Diazepam (Valium)
2. Alprazolam (Xanax)
3. Lorazepam (Ativan)

Adverse Side Effects

These may include lethargy, ataxia, polyuria and polydipsia (PUPD), hyperexcitability, and hepatic necrosis (cats).
**Azapirones**
Buspirone is the azapirone agent that is used in behavioral pharmacotherapy. In contrast to the benzodiazepines, it possesses no muscle relaxant, anticonvulsant, or sedative effects. Its antianxiety effect is thought to be caused by blocking serotonin receptors.

**Clinical Uses**
Veterinary uses include the control of urine spraying/marking and the control of fearfulness and anxiety.

**Dosage Form**
Buspirone (BuSpar)

**Adverse Side Effects**
Few serious side effects appear to exist.

**Antidepressants**

**Tricyclics**
Tricyclics used commonly in veterinary medicine include amitriptyline, imipramine, and clomipramine. These drugs are thought to exert their effects by preventing reuptake of norepinephrine and serotonin. Clomipramine is apparently a selective inhibitor of serotonin reuptake. The tricyclic group is often used on a long-term basis and may take several weeks of use to become effective. Some of the tricyclics are available in the generic form and are relatively inexpensive to use.

**Clinical Uses**
Uses include the treatment of separation anxiety, obsessive disorders (e.g., lick granuloma, tail chasing), fearful aggression, hyperactivity, hypervocalization, and urine marking.

**Dosage Forms**
1. Amitriptyline (Elavil, generic forms)
2. Imipramine (Tofranil)
3. Clomipramine (Anafranil, Clomicalm [veterinary label])

**Adverse Side Effects**
Side effects may include sedation, tachycardia, heart block, mydriasis, dry mouth, reduced tear production, urine retention, and constipation.

**Serotonin Reuptake Inhibitors**
Serotonin reuptake inhibitors include fluoxetine, sertraline, paroxetine, and fluvoxamine. As their name indicates, these drugs increase the amount of serotonin in the synapse by inhibiting its reuptake back into the nerve terminal. Serotonin reuptake inhibitors have fewer potential side effects than the tricyclics but are usually more expensive.

**Clinical Uses**
Used for a variety of behavioral syndromes, including obsessive disorders, phobias, aggression, and separation anxiety.

**Dosage Forms**
1. Fluoxetine (Prozac, human label) (Reconcile, labeled for use in dogs)
2. Sertraline (Zoloft)
3. Paroxetine (Paxil)
4. Fluvoxamine (Luvox)

**Adverse Side Effects**
Side effects are relatively few but include anorexia, nausea, lethargy, anxiety, and diarrhea.

**Monoamine Oxidase-B Inhibitors**
The neurotransmitter dopamine is broken down by the enzyme monoamine oxidase-B (MAO-B). Substances such as selegiline (a MAO-B inhibitor) block or inhibit MAO-B and allow dopamine levels to increase. Decreased dopamine levels may be associated with certain types of dementia that are seen in older dogs (canine cognitive dysfunction). Canine cognitive dysfunction is characterized by disorientation, decreased activity level, abnormal sleep-wake cycles, loss of house training, decreased or altered responsiveness, and decreased or altered greeting behavior.

**Clinical Uses**
Uses include treatment of old-dog dementia and treatment of canine Cushing’s disease.

**Dosage Form**
Selegiline (Eldepryl, Atapryl, Anipryl [veterinary label])
**Adverse Side Effects**
Side effects include vomiting, diarrhea, anorexia, restlessness, lethargy, salivation, shaking, and deafness.

**Synthetic Progestins**
Synthetic progestins are sometimes used to treat behavioral problems through mechanisms associated with changing hormonal levels (reduced gonadotropins) or through some direct effect on the cerebral cortex.

**Clinical Uses**
Uses include the treatment of urine spraying/ marking, intermale aggression, and dominance aggression.

**Dosage Forms**
1. Megestrol acetate (Megace, Ovaban [veterinary label])
2. Medroxyprogesterone (Depo-Provera)

**Adverse Side Effects**
Transient diabetes mellitus (cats), PUPD, increased weight gain, personality changes, endometritis, endometrial hyperplasia, mammary hypertrophy, mammary tumor, adrenal atrophy, and lactation are side effects.

---

**Euthanasia Agents**
Euthanasia agents should have several properties that make them effective medically and aesthetically for this emotion-laden procedure. These drugs should rapidly produce unconsciousness without struggling, vocalizations, or excessive involuntary movement. Death should follow quickly owing to the cessation of all vital functions, such as respiratory and cardiac functions.

The main component of most of the euthanasia agents is pentobarbital. Pentobarbital may also be combined with other agents, such as propylene glycol and alcohol. Pentobarbital alone is a Class II controlled substance, and pentobarbital combinations usually are Class III controlled substances.

**Clinical Uses**
These agents are used to produce a rapid, humane death.

**Dosage Forms**
1. Pentobarbital sodium (Sleepaway, pentobarbital generic). These products are Class II controlled substances for intravenous use.
2. Pentobarbital sodium (Beuthanasia-D). This drug is a Class III controlled substance for intravenous use. This product is different from the pentobarbital sodium described previously in that it contains rhodamine B, a bluish-red dye that helps to distinguish it from other parenteral pentobarbital solutions, as well as phenytoin and preservatives.
3. Euthanasia-6. This product contains pentobarbital only.
4. T-61. T-61 is a nonnarcotic, nonbarbiturate agent that contains a general anesthetic, a local anesthetic, and a muscle paralyzer. It is not a controlled substance. It must be administered according to manufacturer instructions (first two thirds slowly) to avoid apparent anxiety or pain.
5. Fatal-Plus. Contains pentobarbital sodium and is available as a sterile powder for dilution or as a prepared solution. The solution contains a stabilizer, a solvent, and a preservative.
6. Euthasol-C III.

**Adverse Side Effects**
These may include muscle twitching; death may be delayed if the drug is injected outside the vein.

**REFERENCES**
Shull EA: Psychopharmacology in veterinary behavioral medicine, Annual Conference for Veterinarians and Technicians, Knoxville, Tenn, 1998, UT-CVM.
Williams BR, Baer C: Drugs affecting the autonomic nervous system. In Williams BR, Baer C, editors: Essentials of clinical pharmacology in nursing, Springhouse, Pa, 1990, Springhouse Corp.
REVIEW QUESTIONS

1. Define the difference between an agonist and an opioid antagonist. ________________________________
2. Define neurotransmitter. ________________________________
3. The area of the brain that serves to relay information from the spinal cord and brain stem to the interpretation center in the cerebrum is the
   a. Cerebellum
   b. Thalamus
   c. Hypothalamus
   d. Hippocampus
4. Most CNS drugs act by ________________________________
or ________________________________ the effects of neurotransmitters.
5. What are the primary neurotransmitters for adrenergic receptors?
   ________________________________
6. List the four primary ways in which drugs affect the ANS. ________________________________
7. List five indications for the use of cholinergic agents. ________________________________
8. Atropine, scopolamine, glycopyrrolate, and aminopyrine are examples of what specific drug class?
   ________________________________
9. What category of drug is used to treat cardiac arrest and anaphylactic shock?
   ________________________________
10. Propranolol is an example of what category of drug?
    a. Alpha agonist
    b. Beta agonist
    c. Alpha blocker
    d. Beta blocker
11. What are some adverse side effects of xylazine, and what drug may be used to antagonize its effects?
    ________________________________
12. Why would you be concerned about using a thiobarbiturate to induce anesthesia in a very thin dog?
    ________________________________
13. What are some of the characteristics of a cat anesthetized with ketamine?
    ________________________________
14. List some of the signs of a narcotic overdose.
    ________________________________
15. List two narcotic antagonists.
    ________________________________
16. Why should glyceryl guaiacolate not be mixed until just before use?
    ________________________________
17. You are assisting in the delivery of a litter of puppies and you deliver one that is not breathing adequately. What drug would the veterinarian instruct to give, and by what route?
    ________________________________
18. Why are euthanasia solutions that contain only pentobarbital classified as Class II controlled substances, whereas those that contain pentobarbital and other substances are classified as Class III controlled substances?
    ________________________________
19. All psychotherapy drugs are thought to produce their effects by altering ________________________________ activity in the brain.
20. Dissociative agents, such as ketamine and tiletamine, may cause ________________________________ at the injection site.
21. A hypnotic (anesthetic) known for its very short duration and its white color is
    ________________________________
22. An inhibitory neurotransmitter that is widely distributed in the brain is
    ________________________________
23. A benzodiazepine that is used as an antianxiety medication and as an appetite stimulant in cats is
    ________________________________
24. An example of a tricyclic antidepressant used in veterinary medicine for separation anxiety in dogs is
    ________________________________
25. ________________ is used to treat old-dog dementia.

26. The nervous system carries out activity very rapidly by sending electric-like messages over a network of nerve fibers. The ______ system works much more slowly by sending chemical messengers through the bloodstream to target structures.
   a. hematopoietic
   b. endocrine
   c. exocrine
   d. cytokine

27. The _____ nervous system is under voluntary control.
   a. somatic
   b. autonomic

28. The _____ is the fundamental unit of the nervous system.
   a. hepatocyte
   b. nephron
   c. beta cell
   d. neuron

29. Axons carry electric-like messages _____ (from) the nerve cell, and dendrites carry electric-like messages _____ (from) the nerve cell.
   a. away; toward
   b. toward; away

30. Neurotransmitters cannot be mimicked or blocked by the use of appropriate drugs, and that is why patients with nervous system disorders do not have a very good prognosis.
   a. True
   b. False

31. The ANS is that portion of the nervous system that controls _____ body activities.
   a. conscious
   b. unconscious

32. The neurotransmitter for cholinergic sites is ______.
   a. atropine
   b. scopolamine
   c. pralidoxime
   d. acetylcholine

33. Epinephrine (adrenaline) is responsible for all of the following except ______.
   a. can cause an increase in metabolic rate
   b. can cause an increase in heart rate and cardiac output
   c. communication with stem cells in the bone marrow
   d. can constrict blood vessels in the skin

34. Xylazine is antagonized by ______.
   a. hemp
   b. detomidine HCl
   c. Valium
   d. yohimbine

35. All the following are benzodiazepines except ______.
   a. yohimbine
   b. diazepam
   c. alprazolam
   d. lorazepam
CHAPTER 5

Drugs Used in Respiratory System Disorders

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Describe the basic anatomy and physiology of the respiratory system.
2. List the protective mechanisms of the respiratory system.
3. Describe the fundamental principles of treatment of the respiratory system.
4. List the differences between the actions of expectorants, antitusives, and mucolytics.
5. Describe the action of bronchodilators.
6. Describe the use of antihistamines and decongestants in respiratory disease.
7. List potential uses for respiratory stimulants.
8. List the advantages and disadvantages of inhalant therapy.
INTRODUCTION

Veterinary references list a wide variety of diseases of the respiratory system. A partial listing of general origins includes the following:

1. Allergy
2. Aspiration
3. Bacteria
4. Congenital defects
5. Fungi
6. Immunologic factors
7. Neoplasia
8. Neurologic conditions
9. Parasites
10. Trauma
11. Viruses

The respiratory system has a series of defense mechanisms by which it protects itself from disease. These natural defenses can be damaged by management practices such as those that cause a buildup of ammonia in enclosed, poorly ventilated housing. They can also be suppressed by inappropriate therapy, such as the use of cough suppressants for a productive cough. Because it is essential that these defense mechanisms function optimally for prompt recovery from respiratory disease, it is very important that technicians have a basic understanding of respiratory anatomy and physiology, respiratory defense mechanisms, and respiratory therapeutics.

RESPIRATORY ANATOMY AND PHYSIOLOGY

The respiratory system consists of the lungs and the passageways that carry air into and out of the lungs (Figure 5-1). These passageways include the nostrils, nasal cavity, pharynx, larynx, trachea, bronchi, and bronchioles.

The passageways that lead to the lungs are referred to as the upper respiratory system. The upper respiratory system begins with the nostrils, which open into the nasal cavity. The nasal cavity contains turbinates that are covered with mucous membranes. These turbinates increase the surface
area of the nasal cavity to allow **humidification** and warming of inspired air. Air that passes out of the nasal cavity moves in turn through the pharynx and the larynx into the trachea. The trachea bifurcates into right and left bronchi, which lead to right and left lungs, respectively. Each bronchus then divides into a series of passageways of decreasing size, called bronchioles. Smooth muscle fibers are found in the walls of the bronchioles. Contraction of smooth muscle fibers decreases the diameter of the bronchioles, and relaxation of fibers allows the diameter to return to normal size (Figure 5-2).

The upper respiratory tract is lined with ciliated, pseudostratified columnar epithelial cells. Interspersed between the epithelial cells are goblet cells capable of secreting mucus. Mucus is secreted onto the surface of the epithelial cells and is moved toward the pharynx by movement of the cilia (mucociliary apparatus).

Sympathetic stimulation results in decreased production of mucus by the goblet cells and relaxation of smooth muscle in the walls of the bronchioles, leading to **bronchodilation**.

Parasympathetic stimulation causes increased secretion of mucus and constriction of smooth muscle (**bronchoconstriction**) (Figure 5-3).

The bronchioles terminate in small, sac-like structures called **alveoli**. The alveoli are arranged in grape-like clusters and are lined with a chemical
**RESPIRATORY DEFENSE MECHANISMS**

The respiratory system has several effective methods of defense against disease processes, including the following:

1. Nasal cavity: The turbinates of the nasal cavity provide a large surface area for warming and humidifying inspired air. Hair in the nasal passages also may help to filter out larger particulate matter.

2. Protective reflexes: The cough, the sneeze, and perhaps the reverse sneeze respond to stimulation of receptors on the surfaces of air passages to forcefully expel foreign material. Laryngospasm and bronchospasm also help to prevent introduction of materials into the lung tissue.

3. Mucociliary clearance: The layer of mucus secreted onto the surface of the epithelial lining of the respiratory tract helps to trap foreign debris that enters the respiratory passages. Wave-like actions of the cilia then move the debris up the passages ("escalator" action) to the pharynx, where it can be swallowed or expelled. Macrophages and immunoglobulin (IgA) also contribute to the defensive qualities of the mucociliary apparatus by immobilizing or phagocytizing foreign material.

**PRINCIPLES OF RESPIRATORY THERAPEUTICS**

It is important that a specific diagnosis be made through radiology, cytology, or appropriate culture before treatment of respiratory disease is initiated because the correct treatment for one type of disease may be contraindicated for another. Once the diagnosis has been made, treatment for respiratory disease is divided into the following three general goals (McKiernan, 1988):

1. Control of secretions: Secretions may be reduced by decreasing their production or increasing their elimination. Removing the cause of the secretions by means of antibiotic, antifungal, antiparasitic, or other appropriate therapy is
of vital concern. Methods are also aimed at making the secretions less **viscid** through the use of expectorants or through nebulization of **mucolytics** (aerosol therapy).

2. Control of reflexes: Coughing may be suppressed through the use of antitussives or bronchodilators if the cough is **nonproductive**. Sneezing is controlled by removal of the offending agent or through the use of vasoconstrictors. Bronchospasms may be controlled with bronchodilators and corticosteroids.

3. Maintaining normal airflow to the alveoli: Airflow to the alveoli may be maintained by reversing bronchoconstriction, by removing edema or mucus from alveoli and air passages, and by providing oxygen therapy. Intermittent positive-pressure ventilation and other ventilation strategies are often used in humans and may have application in selected animal cases.

## INHALATION THERAPY FOR RESPIRATORY DISEASE

Although drugs used to treat respiratory disease are often administered by the oral or parenteral route, inhalant therapy may also be useful. **Aerosolization** (nebulization) of drugs allows their delivery at high concentrations directly into the airways while minimizing their blood levels—a feature that may reduce the chance of toxic reaction. The efficacy of an inhaled drug depends on the dose and on how well it is distributed in the lungs. Distribution of an aerosol depends on several factors such as the size, shape, and pattern of the airways and the breathing pattern of the animal. The size of the inhaled particle plays a significant role in its distribution. The optimum particle size for entry into the peripheral airways is 1 to 5 microns (Lavoie, 2001). Particles smaller than 0.5 micron are likely to be exhaled, and those larger than 5 microns could be deposited in the upper airways. Airway pathology (e.g., excessive mucus or exudate) can interfere with distribution of the drug, causing some clinicians to assert that inhalant therapy should always be accompanied by systemic treatment (Booth, 2001). Concurrent use of a bronchodilator and/or a mucolytic may be a helpful adjunct to inhalant therapy. Relatively inexpensive infant units for inhalation therapy are available for use in small animals (Opti-Chamber, Aero-Chamber) and horses (Aero-Mask).

## CATEGORIES OF RESPIRATORY DRUGS

### Expectorants

**Expectorants** are drugs that liquefy and dilute viscid secretions of the respiratory tract, thereby helping in evacuation of those secretions. Most expectorants are administered orally, although a few are given by inhalation or parenterally. Expectorants are thought to act directly on the mucus-secreting glands or by reducing the adhesiveness of mucus. Expectorants are indicated when a **productive cough** is present and are often combined with other substances, such as ammonium chloride, antihistamines, or dextromethorphan.

**Guaifenesin** (Glyceryl Guaiacolate)

Guaifenesin is found in a few veterinary label products and in many human label over-the-counter cough preparations. Guaifenesin is more commonly used in equine practice to induce or maintain general anesthesia.

### Clinical Uses

These include relief of cough symptoms related to upper respiratory tract conditions.

### Dosage Forms

These are primarily liquid (syrup) and tablet preparations.

1. Antitussive syrup
2. Cough syrup
3. Cough tablets
4. Robitussin-AC
5. Triaminic Expectorant

### Adverse Side Effects

Adverse side effects of guaifenesin are rare, although mild drowsiness or nausea may occur.
Mucolytics: Acetylcysteine

Mucolytics, such as acetylcysteine, decrease the viscosity of respiratory secretions by altering the chemical composition of the mucus through the breakdown of chemical (disulfide) bonds. Acetylcysteine is the only mucolytic of clinical significance in veterinary medicine. It is administered by nebulization for pulmonary uses. This drug is also administered orally as an antidote for acetaminophen toxicity.

Clinical Uses
Acetylcysteine is used to break down thick or inspissated respiratory mucus and to treat acetaminophen toxicity.

Dosage Forms
Dosage forms with a human label include a 10% solution and a 20% solution in 4-ml, 10-ml, and 30-ml vials. A veterinary labeled product for horses is available in powder form for oral administration.

1. Mucomyst
2. Mucosil-10
3. Mucosil-20
4. Dembrexine (Sputlosin)—veterinary label

Adverse Side Effects
Adverse side effects are few when acetylcysteine is nebulized. However, the drug may cause nausea or vomiting when administered orally.

Butorphanol Tartrate
Butorphanol is a synthetic opiate, partial agonist with significant antitussive activity. It is a Class IV controlled substance. It is also used as a preanesthetic and as an analgesic.

Clinical Uses
Butorphanol tartrate is used for the relief of chronic nonproductive cough in dogs and for analgesia and preanesthesia in dogs and cats.

Dosage Forms
Dosage forms include injectable and tablet forms.

1. Butorphanol (Torbutrol) injection (0.5 mg/ml, 10-ml vial); approved for use in dogs
2. Butorphanol (Torbugesic) injection (10 mg/ml, 50 ml); approved for use in horses
3. Butorphanol (Torbutrol) tablets (1 mg, 5 mg, and 10 mg; 100/bottle)

Adverse Side Effects
Adverse side effects may include sedation and ataxia.

Hydrocodone Bitartrate
Hydrocodone is a schedule III opiate agonist used for the treatment of nonproductive cough in dogs.

Clinical Uses
Hydrocodone is used primarily as an antitussive for harsh, nonproductive cough.

Dosage Forms
Dosage forms include several human label combination products in syrup and tablet form.

1. Hycodan (hydrocodone and homatropine) tablets
2. Tussigon (hydrocodone and homatropine) tablets
3. Hycodan (hydrocodone and homatropine) syrup
4. Hydrome (hydrocodone and homatropine) syrup
5. Codan syrup (hydrocodone and homatropine)
6. Generic hydrocodone syrup

Antitussives: Centrally Acting Agents

Antitussives are drugs that inhibit or suppress coughing. Antitussives are classified as centrally acting or peripherally acting (Figure 5-4). Centrally acting agents suppress cough by depressing the cough center in the brain, whereas peripherally acting agents depress cough receptors in the airways. Peripherally acting antitussives are seldom used in veterinary medicine because they are usually prepared as cough drops or lozenges, which are not practical to administer to animal patients.
**Adverse Side Effects**
These include potential sedation, constipation, and gastrointestinal upset.

**Codeine**
Codeine is a schedule V opiate agonist that is used as an antitussive in human label combination products.

**Clinical Uses**
Clinical uses of codeine are similar to those of hydrocodone.

**Dosage Forms**
These include combination human label products primarily in syrup form.

1. Codeine phosphate oral tablets, 30 mg and 60 mg
2. Codeine sulfate oral tablets, 15 mg, 30 mg, and 60 mg
3. Codeine phosphate with aspirin (Empirin with codeine)

**Adverse Side Effects**
Adverse side effects include sedation and constipation.

**Technician's Notes**
1. Codeine-only products are Class II (C-II).
2. Codeine with aspirin or acetaminophen is C-III.
3. Codeine syrups are C-III or C-V (by state).
**Dextromethorphan**

Dextromethorphan is a nonnarcotic antitussive that is chemically similar to codeine. It has no analgesic or addictive properties. It acts centrally and elevates the cough threshold. Similar to the two drugs previously mentioned, it is available primarily in human label combination products.

**Clinical Uses**

Dextromethorphan is used to suppress a nonproductive cough.

**Dosage Forms**

The primary dosage form is the syrup product.

1. Phenergan with dextromethorphan
2. Dimetapp DM (dextromethorphan, phenylpropanolamine, and brompheniramine)
3. Robitussin DM (dextromethorphan and guaifenesin)

**Adverse Side Effects**

Adverse side effects are rare when this drug is given in the correct dose but can include drowsiness and gastrointestinal upset.

---

**Technician's Notes**

Technicians who administer combination products to cats should take special precautions to ensure that the product does not contain acetaminophen.

---

**Temaril-P**

Temaril-P is a combination product that contains a centrally acting antitussive (trimeprazine tartrate) and a corticosteroid (prednisolone).

**Clinical Uses**

Temaril-P is used as an antitussive and as an antipruritic.

**Dosage Forms**

Dosage forms include tablets. Temaril-P tablets (5 mg trimeprazine tartrate, 2 mg prednisolone).

---

**Adverse Side Effects**

These include sedation, depression, hypotension, and minor central nervous system signs.

---

**Bronchodilators**

Contraction of the smooth muscle fibers that surround the bronchioles results in bronchoconstriction and often corresponding dyspnea. Contraction of these smooth muscle fibers can result from the following three basic mechanisms (Bill, 2006) (Figure 5-5):

1. Release of acetylcholine at parasympathetic nerve endings or inhibition of acetylcholinesterase. Increased acetylcholine levels also tend to increase secretions of the respiratory tract, thus reducing airflow and adding to the level of dyspnea.
2. Release of histamine through allergic or inflammatory mechanisms. Histamine combines with H₁ receptors on smooth muscle fibers to cause bronchoconstriction. Histamine also increases the inflammatory response in the airways, further leading to increased levels of secretion and viscosity.
3. Blockade of beta-2-adrenergic receptors by drugs such as propranolol results in bronchoconstriction. Stimulation of beta-2-adrenergic receptors, however, produces bronchodilation.

Drugs that cause bronchodilation are of four basic categories. Those categories include the cholinergic blockers, the antihistamines, the beta-2 adrenergics, and the methylxanthines (Boothe, 2001).

---

**Figure 5-5**

Bronchoconstriction may result from (1) acetylcholine release at parasympathetic nerve endings, (2) stimulation of H₁ histamine receptors, and (3) blockade of beta-2-adrenergic receptors.
Cholinergic Blockers
Cholinergic blockers produce bronchodilation by combining with acetylcholine receptors on smooth muscle fibers and preventing the bronchoconstrictive effects of acetylcholine. Cholinergic blockers such as atropine, aminopentamide (Centrine), and glycopyrrolate (Robinul-V) have limited use in treating bronchoconstriction, except in cases of organophosphate or carbamate toxicity. Ipratropium bromide, a synthetic anticholinergic, may be of some value in treating equine pulmonary obstructive disease (Hoffman, 2001).

Antihistamines
Antihistamines are discussed later in this chapter.

Beta-2–Adrenergic Agonists
Beta-2–adrenergic agonists combine with appropriate receptors on the smooth muscle fibers and effect relaxation of those fibers. They also stabilize mast cells and reduce the amount of histamine released (Bill, 2006). It is preferred that these drugs have limited beta-1 activity because beta-1 stimulation can produce tachycardia.

Clinical Uses
Beta-2–adrenergic agonists are used as bronchodilators.

Dosage Forms
1. Epinephrine. This drug is a potent bronchodilator that is used only in life-threatening situations (e.g., anaphylactic shock) because it also produces significant tachycardia.
2. Isoproterenol (Isuprel). Also causes beta-1 stimulation and has limited use as a bronchodilator in veterinary medicine.
3. Albuterol (Ventolin, Proventil), clenbuterol (Ventipulmin syrup and clenbuterol HCl oral syrup), terbutaline (Brethine), and metaproterenol (Alupent). These beta-2 agonists have little stimulatory influence on the heart. Clenbuterol is veterinary approved for horses and is not intended for food. None of the other products carry a veterinary label.
4. Salmeterol (Serevent).

Adverse Side Effects
These include tachycardia and hypertension.

Methylxanthines
Methylxanthine derivatives that are used therapeutically include aminophylline and theophylline. These two products are very similar in their chemistry and pharmacologic effects. Both inhibit an enzyme in smooth muscle cells called phosphodiesterase. When beta-2 receptors are stimulated, a chemical messenger called cyclic adenosine monophosphate (cyclic AMP) that is released in the smooth muscle cell completes the relaxation response to allow dilation. Phosphodiesterase inhibits cyclic AMP in the cell, thereby tending to promote bronchoconstriction. By inhibiting the inhibitor (phosphodiesterase) and allowing cyclic AMP to accumulate, the methylxanthines tend to promote bronchodilation.

Methylxanthines also cause mild stimulation of the heart and respiratory muscles and minor diuresis.

Caffeine and theobromine (found in chocolate) are methylxanthines.

Aminophylline is an ethylenediamine salt of theophylline. It is available in various human label products. One hundred milligrams of aminophylline contains approximately 79 mg of theophylline (Plumb, 2005). Injectable forms are available, as are immediate- and sustained-release oral forms.

Clinical Uses
Methylxanthines are used for bronchodilation in respiratory and cardiac conditions and for mild heart stimulation (positive inotropic effect).

Dosage Forms
1. Theo-Dur
2. Slo-bid
3. Choledyl SA
4. Aminophylline (generic)

Adverse Side Effects
These may include gastrointestinal upset, central nervous system stimulation, tachycardia, ataxia, and arrhythmia.
Generic names for antihistamines often are easily recognized because most end in the suffix “-amine” (e.g., pyrilamine, diphenhydramine, chlorpheniramine). Veterinary label antihistamines for treating respiratory conditions are available in injectable and oral preparations.

Clinical Uses
Antihistamines are used in the treatment of allergic and respiratory conditions. They also may be used for their antiemetic effects.

Dosage Forms
1. Pyrilamine (Histavet-P)
2. Tripeleamine (Re-Covr)
3. Probahist Syrup
4. Antihistamine Injection
5. Diphenhydramine (Benadryl). Human approved
6. Doxylamine (A-H, injection or tablets)
7. Hydroxyzine (Atarax)
8. Terfenadine (Seldane). Human approved
9. Clemastine (Tavist)
10. Cyproheptadine (Periactin). May be used in cats to block bronchoconstriction and also as an appetite stimulant.

Adverse Side Effects
These include sedation and, occasionally, gastrointestinal effects.

Corticosteroids
Corticosteroids are used primarily in the treatment of allergic respiratory conditions. They are considered the most effective drugs in the treatment of equine chronic obstructive pulmonary disease (Lavoie, 2001). Corticosteroids prepared for inhalation therapy have strong antiinflammatory effects locally in the lungs and are rapidly biodegraded when absorbed into the general circulation. Oral corticosteroids (prednisone or prednisolone) are considered the drugs of choice in the treatment of chronic airway inflammation in dogs and cats (Dowling, 2001). Corticosteroid therapy controls the signs of respiratory disease, not the cause; good
short-term effects often ensue with few residual effects that may require long-term use.

**Clinical Uses**
Corticosteroids are used in the treatment of equine heaves, feline asthma, acute respiratory distress syndrome, and allergic pneumonia.

**Dosage Forms**
1. Prednisolone sodium succinate (Solu-Delta-Cortef, Delta-Cortef)
2. Prednisolone (Delta Albaplex, Temaril-P, generic forms)
3. Dexamethasone (Dexasone, Dexamethasone Solution, Azium)
4. Beclomethasone dipropionate (Vanceril) (For inhalation)
5. Fluticasone propionate (Flo Vent) (For inhalation)
6. Triamcinolone (Vetalog, Aristocort)

**Adverse Side Effects**
Few adverse side effects are noted if these products are used according to recommendations.

**Miscellaneous Respiratory Drugs**

Many other drugs are used to treat respiratory disorders. These include antimicrobials, mast cell stabilizers, and diuretics. Antimicrobials are used in cases of bacterial infection of the respiratory tract and may be administered parenterally or by nebulization. Mast cell stabilizers, such as cromolyn, are most effective if used before inflammatory activation. Diuretics are used to treat respiratory disease in which pulmonary edema is a major problem.

**Respiratory Stimulants**

**DOXAPRAM HYDROCHLORIDE**
Doxapram is a general central nervous system stimulant that is used primarily as a stimulant for the respiratory system.

**Clinical Uses**
Doxapram is used for stimulation of respiration during and after anesthesia and to speed awakening and restoration of reflexes after anesthesia. In neonatal animals, doxapram is used to stimulate respiration after dystocia or cesarean section.

**Dosage Form**
An injectable form is Dopram-V for injection (20 mg/ml, 20-ml vial)

**Adverse Side Effects**
These include hypertension, arrhythmia, hyperventilation, central nervous system excitation, and seizures. These effects are most likely to occur at high doses (Plumb, 2005). The safety of doxapram in pregnant animals has not been established.

**NALOXONE**
Naloxone is used to stimulate respirations in narcotic overdose.

**YOBINE**
Yobine is used to stimulate respirations in xylazine overdose.

**REFERENCES**
Tilley LP, Smith WK: The 5-minute veterinary consult: canine and feline, ed 2, Baltimore, 2000, Lippincott Williams & Wilkins.
REVIEW QUESTIONS

1. What structures would a molecule of oxygen pass over or through as it travels from the environment to the alveoli?

2. What are the four primary functions of the respiratory system?

3. Describe the function of the three basic defense mechanisms of the respiratory system.

4. What are three important principles of respiratory therapeutics?

5. Expectorants are indicated when what type of cough is present?

6. Mucolytics decrease the viscosity of respiratory mucus by what mechanism?

7. Acetylcysteine is administered by what method for pulmonary uses?

8. What is the mechanism of action of most antitussives used in veterinary medicine?

9. Codeine is classified in what category of controlled substances?

10. List three mechanisms that can cause smooth muscle contraction in the bronchioles.

11. List two bronchodilators that are beta-2-adrenergic agonists.

12. The methylxanthines bring about bronchodilation by inhibiting what cellular enzyme?

13. List two potential uses for antihistamines in veterinary medicine.

14. What suffix is found at the end of many antihistamine names?

15. List two potential uses for Dopramp.

16. Use your textbook and formulary to answer the following questions.

Maxi Jones is being treated for canine infectious tracheobronchitis. Dr. Ladd has instructed you to dispense Hycodan tablets at 0.22 mg/kg b.i.d. for 7 days. Maxi weighs 50 lb. What dose of Hycodan does Maxi require?

How many tablets will you dispense?

Create a label for this prescription.

17. List two uses of acetylcysteine in veterinary medicine. 1. 2. 

18. Which of the following is not an example of a methylxanthine?
   a. Aminophylline
   b. Theophylline
   c. Caffeine
   d. Theobromine
   e. These are all examples of methylxanthines.

19. Particles of what size are capable of reaching the alveoli?

20. Give an example of a beta-2-adrenergic agonist bronchodilator.

21. All of the following are functions of the respiratory system, except ________.
   a. oxygen–carbon dioxide exchange
   b. regulation of acid-base balance
   c. production of sodium bicarbonate to aid in regulation of acid-base balance
   d. body temperature regulation

22. ________ are drugs that liquefy and dilute viscid secretions of the respiratory tract and thereby help in evacuating those secretions.
   a. Antitussives
   b. Decongestants
   c. Bronchodilators
   d. Expectorants
23. _____ are drugs that inhibit or suppress coughing.
   a. Antitussives
   b. Decongestants
   c. Bronchodilators
   d. Expectorants

24. _______ _______ is used for the relief of chronic nonproductive cough in dogs and for analgesia and preanesthesia in dogs and cats.
   a. Hydrocodone bitartrate
   b. Butorphanol tartrate
   c. Temaril P
   d. Doxapram HCl

25. Drug products with codeine alone are in what schedule of controlled substances?
   a. Class I
   b. Class III
   c. Class V
   d. Class II

26. Temaril-P is a combination product that contains a centrally acting antitussive (trimeprazine tartrate) and _______.
   a. prednisolone
   b. aminophylline
   c. furosemide
   d. theophylline

27. Aminophylline and theophylline are _______ derivatives.
   a. adrenergic
   b. cholinergic
   c. methylxanthine
   d. acetylcysteine

28. _______ are drugs that reduce the congestion of nasal membranes by reducing associated swelling.
   a. Antihistamines
   b. Decongestants
   c. Bronchodilators
   d. Expectorants

29. _______ are substances that are used to block the effects of histamine.
   a. Antihistamines
   b. Decongestants
   c. Bronchodilators
   d. Expectorants

30. Solu-Delta-Cortef is a brand name for _______.
   a. prednisolone
   b. dexamethasone
   c. prednisolone Na succinate
   d. fluticasone propionate
CHAPTER 6

Drugs Used in Renal and Urinary Tract Disorders

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Identify the anatomic features of the urinary system.
2. Discuss the formation of urine through glomerular filtration, tubular reabsorption, and tubular secretion.
3. Compare the different classes of drugs and describe the indications for each class.
4. Explain how renal dysfunction can affect the metabolism and excretion of many drugs and their metabolites.
KEY TERMS

**AGONIST** A drug that competes for the same receptor site as another drug or natural substance and that enhances or stimulates the receptor's functional properties.

**ANTAGONIST** A drug that competes for the same receptor site as another drug or natural substance but does not produce a physiologic effect by itself.

**ATONY** The absence or lack of normal tone or strength.

**CATECHOLAMINE** A group of sympathomimetic amines, including dopamine, norepinephrine, and epinephrine.

**DETRUSOR** The smooth muscle of the urinary bladder that is mainly responsible for emptying the bladder during urination.

**DETRUSOR AREFLEXIA** The absence of detrusor contractions.

**ERYTHROPOIESIS** The formation of erythrocytes.

**ERYTHROPOIETIN** A glycoprotein hormone secreted mainly by the kidney; it acts on stem cells of the bone marrow to stimulate red blood cell production.

**HEMATURIA** Blood in the urine.

**HYPERTENSION** Persistently high blood pressure.

**HYPERTONUS** The state characterized by an increased tonicity or tension.

**HYPOKALEMIA** Abnormally low potassium concentration in the blood.

**LOWER MOTOR NEURONS** Peripheral neurons whose cell bodies lie in the central gray columns of the spinal cord and whose terminations lie in skeletal muscle. A sufficient number of lesions of lower motor neurons cause muscles supplied by the nerve to atrophy, resulting in weak reflexes and flaccid paralysis.

**NEPHROLOGY** The study of the urinary (renal) system.

**NEPHRON** The basic functional unit of the kidney.

**POLYDIPSIA** Excessive thirst manifested by increased water consumption.

**POLYURIA** Excessive urination.

**UPPER MOTOR NEURONS** Neurons in the cerebral cortex that conduct impulses from the motor cortex to the motor nuclei of the cerebral nerves or to the ventral gray columns of the spinal cord. A sufficient number of lesions of upper motor neurons interrupt the inhibitory effect that upper motor neurons have on lower motor neurons, resulting in exaggerated or hyperactive reflexes.

**UREMIA** Abnormally high concentrations of urea, creatinine, and other nitrogenous end products of protein and amino acid metabolism in the blood.

**URINARY INCONTINENCE** Lack of voluntary control over the normal excretion of urine.

**URINARY TRACT INFECTION** Infection of the urinary tract. Infection may be localized or may affect the entire urinary tract.

INTRODUCTION

The urinary system (the renal system) is composed of two kidneys, two ureters, a urinary bladder, and a urethra (Figures 6-1 to 6-4). The medical study of the renal system is known as nephrology, because the basic functional unit of the kidney is the nephron. The kidneys act in the body the way a filter acts in a fish aquarium. All water in the aquarium is sent through the filter to capture waste products in the water to keep it clean. Thus, the kidneys filter all waste products out of the bloodstream but allow those elements needed by the body to stay in the bloodstream. The kidneys are bean-shaped and lie on each side of the spine. They are also retroperitoneal.

**Figure 6-1** Side view of the urogenital system of a female dog.
and regulation of blood pressure. The kidneys communicate with other organs in the body through hormones that are secreted into the bloodstream.

Veterinary technicians should educate clients regarding the importance of nutrition, especially in those dog breeds predisposed to developing bladder stones (e.g., dalmatians, miniature schnauzers). Fresh water should be available for animals at all times. Companion animals observed straining to urinate or with bloody urine (i.e., *hematuria*) should be brought to the veterinary hospital immediately.

### PHYSIOLOGIC PRINCIPLES

The formation of urine is a rather complex process that involves glomerular filtration, tubular reabsorption, and tubular secretion (Figure 6-5). The glomerular filtrate is composed of water and dissolved substances, which pass from the plasma into the glomerular capsule. The formation of glomerular filtrate is controlled by effective filtration pressure (EFP = arterial blood pressure – [plasma osmotic pressure + capsule pressure]). The amount of glomerular filtrate is directly proportional to the effective filtration pressure (Figure 6-6). Changes in blood

---

**Figure 6-2**
Side view of the urogenital system of a male dog.

**Figure 6-3**
Side view of the urogenital system of a male cat.

**Figure 6-4**
Side view of the urogenital system of a bull.
**Figure 6-5**
Shown are the direction and location of glomerular filtration: 1, tubular reabsorption; 2, tubular secretion; and 3, as they would occur in the glomerulus and the proximal tubule.

**Figure 6-6**
Filtration occurs through the glomerular membrane within Bowman's capsule. The amount of filtrate produced is determined by the difference between the pressures favoring filtration and those opposing filtration. This diagram shows that filtration occurs because $60 - (32 + 18) = 10$ mm Hg. Values greater than or less than 10 mm Hg would correlate with more or less filtration, respectively. Pressure values (60, 32, 18) are measured in mm Hg. BP, Blood pressure; CTP, capsular tissue pressure; POP, plasma osmotic pressure.
flow through the glomerulus, glomerular blood pressure, plasma osmotic pressure, and capsule pressure affect glomerular filtration.

The kidney tubules are responsible for the reabsorption, or the secretion, of specific substances. Substances needed by the body are reabsorbed from the filtrate, pass through the tubular cell wall, and reenter the plasma. This process filters needed substances and returns them to the body. Reabsorbed materials include water, glucose, amino acids, urea, and ions such as Na⁺, K⁺, Ca²⁺, Cl⁻, HCO₃⁻, and HPO₄²⁻. Any excess of these substances or of substances that are not useful remains in the filtrate and is excreted in the urine.

Tubular secretion occurs when substances are carried to the tubular lumen. This involves the active transport of certain endogenous substances and many exogenous substances. These secreted substances include potassium and hydrogen ions, ammonia, creatinine, and some drugs. The main effects of tubular secretion are to rid the body of certain materials and to help control blood pH (Figure 6-7). The kidneys are active in the metabolism and excretion of many drugs and their metabolites. Therefore, it is very important to remember that these actions may be inhibited in cases of renal failure or dysfunction. Drug therapy in animals with renal dysfunction has increased risks. Renal failure can impair a drug's absorption from an administration site or can affect a drug's distribution in the body.

If the kidneys' functionality is decreased, erythropoiesis may not occur correctly. Erythropoiesis is the formation of erythrocytes. Erythropoietin is a hormone secreted by the healthy kidney that communicates with the bone marrow to make more red blood cells. In diseased kidneys, this hormone is secreted in reduced amounts or not at all, and the animal may develop a nonregenerative anemia as a

---

**Figure 6-7**

Tubular reabsorption and secretion. A. Cross-section of nephron tubules and peritubular capillaries. Interstitial fluid occupies the interstitial space. Reabsorption is represented by substance X going from tubule to capillary, and secretion is represented by substance Y going from capillary to tubule. B. Longitudinal section of nephron tubule. Shown is the relationship among the tubular lumen, epithelial cell, and capillary.
result. Injections of human recombinant erythropoietin may be given to animals to treat this anemia.

**Uremia** can increase the sensitivity of some tissues to certain drugs. For example, sensitivity to central nervous system depressants is increased, and therefore the dose of opiates, barbiturates, and tranquilizers should be reduced, in uremic patients. Xylazine (Rompun) and ketamine hydrochloride (Ketaset) are contraindicated in uremic patients. Impaired renal excretion or biotransformation causes delayed elimination of many drugs and enhances their toxicity and duration of action.

Box 6-1 lists drugs that commonly require dosage modification in renal insufficiency. Modification can be made by measuring the plasma concentrations of drugs and adjusting the dose accordingly. Because this is impractical in most clinical settings, a veterinarian may use the normal dose but lengthen the time intervals at which it is administered, or give a smaller dose at normal time intervals. Technicians may be responsible for administering anesthesia, and it is important to remember that patients with renal failure are at greater anesthetic risk and require even closer monitoring than patients with normal renal function.

### RENAL FAILURE

Renal failure is among the major causes of nonaccidental death in dogs and cats. Although the disease is most common in older animals, it may be diagnosed in younger animals. Renal damage may stem from many causes, including infectious disease, diabetes mellitus, toxins, neoplasia, congenital

---

**BOX 6-1 Dosage Modification in Renal Insufficiency**

<table>
<thead>
<tr>
<th>Drugs That Require Dosage Modification or That Are Contraindicated in Renal Insufficiency</th>
<th>Drugs That Do Not Require Dosage Modification or That Are Not Contraindicated in Renal Insufficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetazolamide</td>
<td>Nitrofurantoin</td>
</tr>
<tr>
<td>Antimonials</td>
<td>Ouabain</td>
</tr>
<tr>
<td>Aspirin</td>
<td>Penicillins</td>
</tr>
<tr>
<td>Atropine</td>
<td>Phenazopyridine</td>
</tr>
<tr>
<td>Barbital</td>
<td>Procainamide</td>
</tr>
<tr>
<td>Bendroflumethiazide</td>
<td>Spiromedone</td>
</tr>
<tr>
<td>Cephalothins</td>
<td>Streptomycin</td>
</tr>
<tr>
<td>Chelating agents</td>
<td>Sulfonamides</td>
</tr>
<tr>
<td>Chlorothiazide</td>
<td>Tetracyclines</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>Tetraethyl-ammonium</td>
</tr>
<tr>
<td>Colistin and polymyxin</td>
<td>Tubocurarine, gallamine</td>
</tr>
<tr>
<td>Decamethonium</td>
<td>Vancomycin</td>
</tr>
<tr>
<td>Digoxin</td>
<td>Nitrofurantoin</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>Ouabain</td>
</tr>
<tr>
<td>Furosemide (increased dose)</td>
<td>Penicillins</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>Phenazopyridine</td>
</tr>
<tr>
<td>Iodide</td>
<td>Procainamide</td>
</tr>
<tr>
<td>Kanamycin</td>
<td>Pentobarbital</td>
</tr>
<tr>
<td>Lincomycin</td>
<td>Phenobarbital</td>
</tr>
<tr>
<td>Mannitol</td>
<td>Phenothiazine</td>
</tr>
<tr>
<td>Mercurials</td>
<td>Phenytoin</td>
</tr>
<tr>
<td>Methenamine</td>
<td>Procaine</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Propranolol</td>
</tr>
<tr>
<td>Neomycin</td>
<td>Neostigmine</td>
</tr>
</tbody>
</table>

disorders, immunologic problems, and amyloidosis. Diets with excessive protein, phosphorus, and sodium are other factors that may cause renal damage. Renal damage may be categorized as prerenal, renal, or postrenal. Renal failure may be differentiated as acute, chronic, or end-stage, according to parameters common to each stage.

**DRUGS COMMONLY USED FOR THE TREATMENT OF RENAL DYSFUNCTION AND ASSOCIATED HYPERTENSION**

**Diuretic Drugs**

Diuretics are used to remove excess extracellular fluid by increasing urine flow and sodium excretion and reducing hypertension. A number of conditions may indicate the need for a diuretic drug. Classifications of commonly used diuretics include loop diuretics, osmotic diuretics, thiazide and thiazide-like diuretics, potassium-sparing diuretics, and carbonic anhydrase inhibitors.

**Loop Diuretics**

Loop diuretics are highly potent diuretics that inhibit the tubular reabsorption of sodium. Once administered, their actions are generally rapid. Additionally, loop diuretics promote the excretion of chloride, potassium, and water. Some patients on long-term loop diuretic therapy may have to be placed on potassium supplementation.

**Dosage Forms**
1. Furosemide (Lasix, Disal, Diuride)
2. Ethacryninc acid (Edecrin—human label)

**Adverse Side Effects**
These include hypokalemia because of the increased excretion of potassium.

**Osmotic Diuretics**

Osmotic diuretics can be administered intravenously to promote diuresis by exerting high osmotic pressure in the kidney tubules and limiting tubular reabsorption. Water is drawn into the glomerular filtrate, reducing its reabsorption and increasing the excretion of water. These drugs may be used to treat oliguric acute renal failure and to reduce intracranial pressure.

**Dosage Forms**
1. Mannitol 20%
2. Glucose

**Adverse Side Effects**
These are uncommon.

**Technician’s Notes**
These drugs are administered over a 10- to 15-minute period.

**Thiazide Diuretics**

Thiazide diuretics reduce edema by inhibiting reabsorption of sodium, chloride, and water. Their duration of action is longer than that of loop diuretics.

**Dosage Forms**
1. Chlorothiazide (Diuril—human label)
2. Hydrochlorothiazide (HydroDIURIL—human label)

**Adverse Side Effects**
These include hypokalemia if therapy is prolonged.

**Technician’s Notes**
1. Similar to loop diuretics, thiazide diuretics cause an increase in potassium excretion. A potassium supplement may be necessary to prevent hypokalemia.
2. These drugs cross the placental border.

**Potassium-Sparing Diuretics**

Potassium-sparing diuretics have weaker diuretic and antihypertensive effects than other diuretics, but they have the ability to conserve potassium.
These agents are also referred to as aldosterone antagonists. They work by antagonizing aldosterone, an adrenal mineralocorticoid. This action enhances the excretion of sodium and water and reduces the excretion of potassium. Aldosterone secretion may be a factor in edema associated with heart failure.

**Dosage Forms**
1. Spironolactone (Aldactone—human label)
2. Triamterene (Diazide, Dyrenium—human label)

**Adverse Side Effects**
These are uncommon, but hyperkalemia may result if these drugs are administered concurrently with potassium supplements or angiotensin-converting enzyme (ACE) inhibitors, such as captopril or enalapril.

**Technician’s Notes**
These drugs may be used alone or with other diuretic agents.

**Carbonic Anhydrase Inhibitors**
A carbonic anhydrase inhibitor is a substance that decreases the rate of carbonic acid and H⁺ production in the kidney, thereby promoting the excretion of solutes and increasing the rate of urinary output (Mosby, 1998). These drugs also reduce intraocular pressure by reducing the production of aqueous humor and may be used in the treatment of glaucoma.

**Dosage Forms**
1. Acetazolamide (Diamox—human label)
2. Dichlorphenamide (Daranide—human label)

**Adverse Side Effects**
These include the ability to cause hypokalemia.

**Technician’s Notes**
Carbonic anhydrase inhibitors have the least efficacy when compared with the other tubular inhibitors and are not commonly used to treat edema.

**Cholinergic Agonists**
Cholinergic agents act directly or indirectly to promote the function of acetylcholine. Cholinergic agents also may be referred to as parasympathomimetic agents because their effects mimic stimulation of the parasympathetic nervous system. Cholinergic agonists mimic the action of natural acetylcholine by directly stimulating cholinergic receptors. Once the cholinergic agonist binds with receptors on the cell membrane of smooth muscles, the permeability of the cell membrane changes, permitting calcium and sodium to enter into the cells. Depolarization of the cell membrane occurs, and muscle contraction is achieved.

**Clinical Uses**
Cholinergic agents are used to help void the urinary bladder. Their action increases the tone of the detrusor muscle of the bladder and decreases bladder capacity.

**Dosage Form**
Bethanechol (Urecholine—human label)

**Adverse Side Effects**
These include the potential for cholinergic toxicity.

**Technician’s Notes**
1. Observe the patient for signs of cholinergic toxicity (e.g., vomiting, defecation, dyspnea, tremors).
2. Atropine is antidotal.

**Anticholinergic Drugs**
The action of anticholinergic drugs is the opposite of that of cholinergic agents. They block the action of acetylcholine at receptor sites in the parasympathetic nervous system. These drugs may also be described as parasympatholytic because of their ability to block the passage of impulses through the parasympathetic nerves. Their action produces muscle relaxation.
Clinical Uses
Anticholinergic drugs can be used for treating urge incontinence by promoting the retention of urine in the urinary bladder.

Dosage Forms
1. Propantheline (Pro-Banthine—human label)
2. Butyl hyoscine (Buscopan)

Adverse Side Effects
These include decreased gastric motility and delayed gastric emptying, which may decrease the absorption of other medications.

Adrenergic Antagonists
Adrenergic blocking agents disrupt the sympathetic nervous system by blocking impulse transmission at adrenergic neurons, adrenergic receptor sites, or adrenergic ganglia. These agents also may be described as sympatholytic agents because of their ability to block sympathetic nervous system stimulation. The classification of adrenergic antagonists is based on their site of action (i.e., alpha blockers, beta blockers, or autonomic ganglionic blockers).

Alpha-Adrenergic Antagonists
Alpha-adrenergic antagonists relax vascular smooth muscle, enhance peripheral vasodilation, and decrease blood pressure by interrupting the actions of sympathomimetic agents at alpha-adrenergic receptor sites.

Clinical Uses
In the urinary system, these drugs reduce internal sphincter tone when the urethral sphincter is in hypertonus. This action is useful in the treatment of urinary retention because of detrusor areflexia or functional urethral obstruction. Prazosin is effective in controlling moderate to severe hypertension, which may be a complicating factor in chronic renal failure.

Dosage Forms
1. Phenoxybenzamine (Dibenzyline—human label)
2. Nicergoline (Sermion)

3. Moxisylyte (Carlytene)
4. Prazosin (Minipress—human label)

Adverse Side Effects
These include rapid decrease in blood pressure, resulting in weakness or syncope after the first dose of prazosin. This is usually self-limiting.

Technician’s Notes
1. Prazosin may be used alone or combined with a diuretic to produce the desired effect.
2. Because alpha-adrenergic antagonists are metabolized by the liver, dosage modification is not necessary in patients with renal dysfunction.

Beta-Adrenergic Antagonists
Beta-adrenergic antagonists inhibit the action of catecholamines and other sympathomimetic agents at beta-adrenergic receptor sites and thereby inhibit stimulation of the sympathetic nervous system.

Clinical Uses
These include control of mild to moderate hypertension associated with chronic renal failure.

Dosage Form
Propranolol (Inderal—human label)

Adverse Side Effects
These include decreased cardiac output and the promotion of bronchospasm. Therefore, caution should be exercised with their use in patients with cardiac or pulmonary disease (Cowgill, 1991).

Technician’s Notes
Combination with a diuretic is common because of the tendency of beta-adrenergic antagonists to cause salt and fluid retention.
Angiotensin-Converting Enzyme Inhibitors

ACE inhibitors block the conversion of angiotensin I to angiotensin II, decrease aldosterone secretion, reduce peripheral arterial resistance, and alleviate vasoconstriction.

Clinical Uses
ACE inhibitors are used to treat nonresponding hypertension or moderate to severe hypertension.

Dosage Forms
1. Benazepril
   a. Fortekor (veterinary label)
   b. Benazepril Lotensin (human label)
2. Captopril (Capoten—human label)
3. Enalapril (Enacard)

Adverse Side Effects
These include complications in patients with renal insufficiency caused by excretion by the kidneys.

Vasodilators and Calcium Channel Blockers

A vasodilator or calcium channel blocker may be substituted for or used in combination with other medications if previous drug therapy to control hypertension fails.

Clinical Uses
These drugs are used to treat nonresponding hypertension. Dopamine may be used to promote diuresis in patients unresponsive to loop or osmotic diuretics.

Dosage Forms
1. Vasodilators
   a. Hydralazine (Apresoline—human label)
   b. Dopamine (Intropin—human label)
2. Calcium channel blockers
   a. Diltiazem (Cardizem—human label)
   b. Verapamil (Isoptin—human label)
   c. Amlodipine (Norvasc and Besylate—human label)

Adverse Side Effects
These include hypotension, edema, conduction disturbances, heart failure, and bradycardia (Cowgill, 1991). Hydralazine is excreted by the kidneys and requires dosage modification when used to treat hypertension in patients with renal failure.

Antidiuretic Hormone

Antidiuretic hormone (ADH) is normally secreted by the posterior pituitary gland. This secretion regulates fluid balance in the body. In some conditions, such as pituitary diabetes insipidus, this hormone fails to be synthesized or excreted properly, and polyuria and polydipsia occur.

Clinical Uses
ADH is used to treat diabetes insipidus.

Dosage Form
Vasopressin (Pitressin—human label)

Adverse Side Effects
These are uncommon.

Technician’s Notes
Chlorpropamide (Diabinese, Glucamide) is a human product that is used to control type II diabetes mellitus. It potentiates the action of ADH and may be used to treat mild diabetes insipidus.

Urinary Acidifiers

Urinary acidifiers are used to produce acid urine, which assists in dissolving and preventing formation of struvite uroliths. Since the introduction of urinary acidifying diets, urinary acidifiers have not been routinely prescribed.

Dosage Forms
1. Methionine (Methigel, Methio-Tabs)
2. Ammonium chloride (Uroze)

Adverse Side Effects
These include gastrointestinal disturbances. These products should not be administered to patients with severe liver, kidney, or pancreatic disease or to those who exhibit acidosis.

Technician’s Notes
It is very important to inform clients who may change from using an acidifier to one of the available acidifying diets that while the diet is being administered, no acidifiers, salt, vitamin or mineral supplements, or any other food items—other than what is allowed in the diet—should be given to the patient.

Dosage Forms
1. Potassium citrate (Urocit-K—human label)
2. Sodium bicarbonate, administered orally
3. Tiopronin tablets (Thiola—human label)

Adverse Side Effects
These include possible fluid and electrolyte imbalance with the use of sodium bicarbonate.

PHARMACOTHERAPY OF RENAL FAILURE COMPLICATIONS

Because the renal cortex produces erythropoietin, chronic renal failure can cause an absolute or relative deficiency in its production. The resultant complication is normocytic, normochromic anemia that is classified as nonregenerative. Parenteral androgens, such as nandrolone (Durabolin) and testosterone enanthate, are capable of stimulating the production of red blood cell precursors and may increase the level of erythropoietin. Injections of recombinant human erythropoietin (Epogen, Procrit) have been shown to correct anemia associated with chronic renal failure (Ettinger, 2000). When a regimen of erythropoietin is administered, packed cell volume (PCV) values should be monitored on a weekly basis until improvement is reached and until after the dose has been decreased. It also may be advisable to place animals on supplemental iron as an adjunct in supporting RBC production (Merck, 2006). Vitamin D supplements may be used in the control of renal secondary hyperparathyroidism. Rocaltrol (calcitrol) and dihydrotachysterol (Hytakerol) may be used for this purpose. Serum calcium, creatinine, and phosphate levels should be monitored in patients receiving this therapy because hypercalcemia, hyperphosphatemia, or deteriorating renal function can occur (Ettinger, 2000).

EPOETIN ALPHA (EPOGEN, PROCRIT)
Adverse Side Effects
These include local or systemic allergic reaction in animals and pain occurring at the injection site. Headaches, along with seizures, have occurred in humans.

Xanthine Oxidase Inhibitors
Xanthine oxidase inhibitors decrease the production of uric acid and are used in combination with a urate calculolytic diet for the dissolution of ammonium acid urate uroliths. Once dissolution occurs, a urine-alkalizing, low-protein, low-purine, low-oxalate diet is usually prescribed to prevent recurrence of uroliths.

Dosage Form
Allopurinol (Zyloprim—human label)

Adverse Side Effects
These are uncommon, but because excretion occurs via the kidneys, the dosage may be altered in patients with renal insufficiency.

Technician’s Notes
In cases of recurrence, allopurinol may once again be prescribed.

Urinary Alkalizers
Urinary alkalizers may be used in the management of ammonium acid urate, calcium oxalate, and cystine urolithiasis.
PHARMACOTHERAPY OF URINARY INCONTINENCE

Erringer (2000) states: “Pharmacologic agents are selected for management of urinary incontinence when urinary tract infection, morphologic abnormalities, and mechanical types of excessive outlet resistance have been excluded as possible causes of the problem.” Urinary incontinence may be described as a neurogenic disorder or a nonneurogenic disorder. A neurogenic disorder is evidenced by a neurologic lesion that affects the upper motor neuron segments or the lower motor neuron segments. When upper motor neuron segments are affected, the result is a spastic neuropathic bladder.

Detrusor muscle contractions are normal, but bladder and urethral functions are abnormal. Therefore, as the bladder fills with urine, contractions occur more frequently (hypercontractility) and bladder capacity decreases. Also, contraction of the detrusor muscle and relaxation of the urethral sphincter often are not coordinated. This results in interrupted, incomplete, and involuntary urination.

Functional urinary obstruction and urinary retention may also be present. When lower motor neuron segments are affected, the result is an atonic, neuropathic bladder. With this disorder, detrusor muscle contractions are abnormal and the sensation of fullness is absent when the bladder fills (hypocontractility). This causes the bladder to distend, and eventually, bladder capacity increases. Bladder distention may cause damage to the tight junctions between smooth muscle fibers. Urination eventually occurs when pressure inside the bladder exceeds urethral outlet resistance.

Nonneurogenic disorders occur as a result of some type of anatomic anomaly of the lower urinary tract. In the young dog, this is usually a congenital anomaly. A congenital anomaly seen in young female dogs is ectopic ureter, which causes constant dribbling of urine. This occurs when the ureters end in abnormal places rather than at normal sphincters. In the older dog, acquired anatomic anomalies are usually responsible for nonneurogenic disorders. Conditions that commonly cause such problems include chronic cystitis, chronic urethritis, neoplasia, urolithiasis, and postsurgical adhesions. Other nonneurogenic disorders include functional abnormalities such as urethral incompetence and partial urethral obstruction. One type of nonneurogenic urethral incompetence is often seen in spayed female dogs and is usually responsive to hormonal therapy. Once the cause of the urinary incontinence has been identified, medical or surgical management begins. If a morphologic abnormality is causing urinary incontinence, surgical correction of the problem is necessary.

Medical management may include treatment for infection, if present, and treatment for the cause of the urinary incontinence (e.g., urethral incompetence, bladder hypercontractility or hypocontractility). Drugs used in the medical management of urinary incontinence include the previously mentioned cholinergic agonists, anticholinergics, alpha-adrenergic antagonists, smooth muscle relaxants, skeletal muscle relaxants, tranquilizers, alpha-adrenergic agonists, and hormones such as estrogen and testosterone. Table 6-1 outlines these drugs for easy reference.

Miscellaneous Renal Drugs

Urinary Tract Analgesics

Phenazopyridine

Phenazopyridine is used in humans as a urinary tract analgesic. It can be bought over-the-counter. It can be used alone or with sulfa drugs. Its use is contraindicated in felines because they are quite susceptible to dose-related methemoglobinemia, and oxidative changes in hemoglobin may be irreversible, causing formation of Heinz bodies and anemia (Osborne, 2001).

Tricyclic Antidepressants

Amitriptyline

Dosage Form
Amitriptyline (Elavil)

Amitriptyline has many properties and has been used in treating interstitial cystitis in humans. Its mechanism is not fully understood. Amitriptyline is a tricyclic antidepressant and anxiolytic drug with anticholinergic, antihistaminic, anti-alpha-adrenergic, antiinflammatory, and analgesic properties. It has
### Table 6-1  Pharmacotherapy of Urinary Incontinence

<table>
<thead>
<tr>
<th>Drug</th>
<th>Action</th>
<th>Examples of Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bethanechol (Urecholine)</td>
<td>Cholinergic agonist</td>
<td>Bladder hypotonicity</td>
</tr>
<tr>
<td>Propantheline (Pro-Banthine)</td>
<td>Anticholinergic agent</td>
<td>Urge incontinence, bladder hypercontractility</td>
</tr>
<tr>
<td>Butyl hyoscine (Buscopan)</td>
<td>Anticholinergic agent</td>
<td>Urge incontinence, bladder hypercontractility</td>
</tr>
<tr>
<td>Phenoxybenzamine (Dibenzyline)</td>
<td>Alpha-adrenergic antagonist</td>
<td>Urethral hyperreflexia</td>
</tr>
<tr>
<td>Nicergoline (Sermion)</td>
<td>Alpha-adrenergic antagonist</td>
<td>Urethral hyperreflexia</td>
</tr>
<tr>
<td>Moxisylyte (Carlytene)</td>
<td>Smooth muscle relaxant</td>
<td>Urge incontinence, bladder hypercontractility</td>
</tr>
<tr>
<td>Aminopropazine (Jenotone)</td>
<td>Skeletal muscle relaxant</td>
<td>Urethral hyperreflexia</td>
</tr>
<tr>
<td>Dantrolene (Dantrium)</td>
<td>Tranquilizer/skeletal muscle relaxant</td>
<td>Urethral hyperreflexia</td>
</tr>
<tr>
<td>Diazepam (Valium)</td>
<td>Alpha-adrenergic agonist</td>
<td>Urethral incompetence</td>
</tr>
<tr>
<td>Phenylpropanolamine</td>
<td>Antineoplastic, estrogen (hormone)</td>
<td>Hormone-responsive urethral incompetence</td>
</tr>
<tr>
<td>Diethylstilbestrol (DES)</td>
<td>Hormone</td>
<td>Hormone-responsive urethral incompetence</td>
</tr>
<tr>
<td>Testosterone cypionate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone propionate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

been used extensively for the treatment of interstitial cystitis in humans. Although it is a popular drug, its exact mechanism of action and therapeutic value in managing patients with interstitial cystitis remain unknown. This drug has been used recently for symptomatic treatment of idiopathic feline lower urinary tract disease (LUTD) (Osborne, 2001).

**Adverse Side Effects**

Many side effects such as dry mouth, rapid heart rate, and sedation (i.e., antihistamine effects) are associated with this drug. High doses can cause heart toxicity. Sometimes it may cause cats to be less interested in grooming themselves. Additionally, weight gain may occur (Papich, 2002).

**Glycosaminoglycans**

Glycosaminoglycans (GAGs) are found covering the transitional epithelium of the urinary tract. These urothelial GAGs have the ability to keep microorganisms and crystals from adhering to the bladder wall and limit the transepithelial movement of urine proteins and solutes (ionic or nonionic). Defects in surface GAGs and subsequent urothelial permeability are believed to be a factor in the pathogenesis of feline idiopathic LUTD (Osborne, 2001).

**PENTOSAN POLYSULFATE SODIUM (ELMIRON)**

**Clinical Uses**

Often used to manage human interstitial cystitis. Used to reinforce urothelial GAGs and to reduce transitional cell injury.

**Adverse Side Effects**

The safety and efficacy of pentosan polysulfate or other GAGs for the treatment of feline LUTD have not been reported. This treatment remains a logical choice, but it is not possible to make recommendations at this time (Osborne, 2001).

**Other Agents**

**Epakitin**

Epakitin is a chitosan-based nutritional supplement made from a polysaccharide extracted from crab and shrimp shells.

**Clinical Uses**

Product information states that Epakitin binds phosphorus in the intestine, causing phosphorus to be eliminated through the intestinal tract. Reducing the amount of phosphorus absorbed then helps to lower the elevated levels of phosphorus noted in renal failure.
AZODYL
Azodyl product information claims that this product has the potential to reduce the azotemia of renal failure through “enteric dialysis.”

TECHNICIAN’S ROLE
Veterinary technicians have a vital role in the care of patients with problems that affect the urinary system. This role includes providing client support and education, carrying out patient nursing care, performing necessary laboratory or radiologic examinations, giving surgical assistance, and understanding the various drugs and diets available for the treatment of renal disease.

REFERENCES

REVIEW QUESTIONS

1. What structures constitute the urinary system? ________________________________

2. Name two drugs that are contraindicated in uremic patients. ____________________

3. Renal damage may be categorized as ____________________________, ____________________________, or ____________________________.

4. Explain how diuretics work. ________________________________________________

5. What supplement may be administered in conjunction with loop diuretics? ______

6. ACE inhibitors block the conversion of angiotensin I to ________________________.

7. Urinary acidifiers are used to produce acid urine, which assists in dissolving and preventing the formation of __________________ uroliths.

8. The renal cortex produces __________________; thus chronic renal failure can cause an absolute or relative ____________________________ in its production.

9. Why is furosemide referred to as a loop diuretic? ______________________________

10. Where is ADH secreted? ____________________________

11. The ureters ____________.
   a. originate from the urinary bladder and lead to the outside of the body
   b. originate from the kidneys and connect with the urinary bladder
   c. are found inside the nephrons
   d. are found inside the glomerulus

12. Persistently high blood pressure is known as ______.
   a. hypertonus
   b. hyperkalemia
   c. hypertension
   d. atony

13. Diuretics are used to remove ______ fluid.
   a. intracellular
   b. extracellular

14. Antidiuretic hormone (ADH) is normally secreted by the ______ pituitary gland.
   a. anterior
   b. posterior
15. What supplement may be administered in conjunction with loop diuretics?
   a. Calcium
   b. Phosphorus
   c. Aluminum hydrochloride
   d. Potassium

16. Urinary acidifiers are used to produce acid urine, which assists in dissolving and preventing the formation of _____.
   a. calcium
   b. uroliths
   c. urinary casts
   d. bacteria

17. _____. is a medical term for bloody urine.
   a. Hematuria
   b. Hemolysis
   c. Hematopoiesis
   d. Uremia

18. What part of the kidney is responsible for the reabsorption, or the secretion, of certain substances?
   a. Nephrons
   b. Tubules
   c. Glomerular filtrate
   d. Extracellular fluid

19. Patients with renal failure are at a lesser anesthetic risk than patients with normal renal function.
   a. True
   b. False

20. Loop diuretics inhibit the tubular reabsorption of _____.
   a. calcium
   b. phosphorus
   c. sodium
   d. potassium
CHAPTER 7

Drugs Used in Cardiovascular System Disorders

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Describe the basic anatomy and physiology of the cardiovascular system.
2. List four compensatory mechanisms of the cardiovascular system.
3. List five basic objectives of the treatment of cardiovascular disease.
4. Differentiate between an inotropic and a chronotropic drug.
5. List and describe the indications, physiologic effects, and toxic effects of the cardiac glycosides.
6. List the four categories of antiarrhythmic drugs and give an example from each category.
7. List potential adverse side effects of the antiarrhythmic drugs.
8. Describe the actions and potential side effects of the vasodilator drugs.
9. Describe the actions and potential side effects of the angiotensin-converting enzyme (ACE) inhibitors.
10. Describe the actions and potential side effects of the diuretics used to treat cardiovascular disease.
11. Describe the purpose of dietary sodium restriction in the therapy of cardiovascular disease.
12. List ancillary drugs or procedures that may be used in the treatment of cardiovascular disease.
KEY TERMS

**AFTERLOAD** The resistance (pressure) in arteries that must be overcome to empty blood from the ventricle.

**ARRHYTHMIA (DYSRHYTHMIA)** A variation from the normal rhythm.

**AUTOMATICITY** The ability of cardiac muscle to generate impulses.

**BRADYARRHYTHMIA** Bradycardia associated with an irregularity of heart rhythm.

**BRADYCARDIA** A slower-than-normal heart rate.

**CHRONOTROPIC** Affecting the heart rate.

**DEPOLARIZATION** Neutralizing of the polarity of a cardiac cell by an influx of sodium ions. Depolarization results in contraction of the cardiac cell and renders it incapable of further contraction until repolarization occurs.

**INOTROPIC** Affecting the force of cardiac muscle contraction.

**PRELOAD** The volume of blood in the ventricles at the end of diastole.

**PREMATURE VENTRICULAR CONTRACTION (PVC)** Contraction of the ventricles without a corresponding contraction of the atria. PVCs arise from an irritable focus or foci in the ventricles.

**REPOLARIZATION** The return of the cell membrane to its resting polarity after depolarization.

**STROKE VOLUME** The amount of blood ejected by the left ventricle with each beat.

**TACHYARRHYTHMIA** Tachycardia associated with an irregularity in normal heart rhythm.

**TACHYCARDIA** A faster-than-normal heart rate.

INTRODUCTION

Heart disease has a relatively high incidence in veterinary medicine. Studies have found that approximately 11% of all dogs presented to veterinary clinics exhibited some degree of heart disease (Roudebush et al, 2000). Heart disease may be congenital or acquired. However, the acquired form accounts for most cases. The incidence and cause may vary from location to location. Heartworm disease accounts for a large percentage of heart disease in some parts of the country, whereas acquired disease of the atrioventricular valves or myocardium has a more uniform distribution. Acquired disease is encountered more often in older animals, and congenital disease is more prevalent in younger ones.

Whatever the cause, treatment of heart disease is often individualized to the particular patient according to cause, degree of progression, and owner cooperation. The response to treatment must be monitored carefully and adjusted while the disease progresses, causing poor liver or kidney function, or while toxic side effects develop. Some cardiovascular drugs have a narrow margin of safety (i.e., they are potentially toxic at low doses), and failing liver and kidney function may reduce the body’s ability to metabolize or eliminate these drugs.

Because veterinary technicians are often the persons who monitor the progress of hospitalized patients, they must be aware of the signs of cardiovascular disease and of normal and abnormal responses to drugs used to treat this disease.

ANATOMY AND PHYSIOLOGY OF THE HEART

The heart is a four-chambered pump that is responsible for moving blood through the vascular system. The two dorsal chambers are called atria, and the two ventral chambers are called ventricles (Figure 7-1). Each of the chambers is composed primarily of strong muscle tissue called myocardium, which contracts to eject the blood. Even though the heart is considered one organ, it functions as two pumps (Spinelli and Enos, 1978).

The right atrium and ventricle constitute the “right-side pump,” and the left atrium and ventricle make up the “left-side pump.” Blood from the general circulation returns by way of the vena cava to the right atrium, enters the right ventricle through the right atrioventricular valve (tricuspid valve), and is pumped through the pulmonary artery to the lungs. In the lungs, the blood gives up carbon dioxide and
Chapter 7 Drugs Used in Cardiovascular System Disorders

![Diagram of the heart and its conduction system](image)

FIGURE 7-1  Schematic of the heart and its conduction system.

...picks up oxygen. The oxygenated blood returns to the heart via the pulmonary veins, where it fills the left atrium, passes through the left atrioventricular valve (mitral valve), and enters the left ventricle. The mitral and tricuspid valves swing open when the atria contract and snap shut when the ventricles contract. The closing of the valves as the ventricles contract prevents blood from flowing back into the atria. The left ventricle then contracts and ejects the oxygenated blood through the aorta out into the branching arteries. These arteries divide into arterioles and end in the thin-walled capillaries throughout the body, where carbon dioxide is loaded to the blood and oxygen is unloaded to the tissue. Because the left ventricle must work harder to pump blood throughout the body than the right ventricle must work to pump blood to the lungs, the left ventricular wall is thicker than the right ventricular wall.

The pumping action of the heart is divided into two phases—systole and diastole. Systole is the period of contraction of the chambers, and diastole represents the relaxation phase when the chambers are filling with blood. Because each cell in the heart is capable of contracting spontaneously, the interaction of these two phases must be carefully coordinated to create an efficient pumping action. Diastolic time must be adequate to allow the atria to fill completely, and atrial systole must occur shortly before ventricular systole to allow the ventricles to fill maximally. Coordination of these two phases is achieved primarily through a wave of electric activity that arises in a specialized group of cells in the right atrium and then is conducted throughout the myocardium by a special conduction system.

The structures that make up the cardiac conduction system (see Figure 7-1) include the sinoatrial node, the atrioventricular node, the bundle of His and its branches, and the Purkinje system. Under abnormal conditions, parts of the myocardium and conduction system are capable of spontaneous discharge. Normally, however, the sinoatrial node discharges most rapidly and spreads a wave of depolarization over remaining areas of the heart before they can depolarize spontaneously. The rate of discharge of this node therefore controls the heart rate and is called the cardiac pacemaker. Impulses generated by the sinoatrial node travel over the atria to the atrioventricular node, face a brief delay (about 0.1 second) in the atrioventricular node, travel down the bundle of His to its left and right branches, and pass into the ventricular muscle via the Purkinje fibers. Myocardial cells are joined together by structures called intercalated disks and by fusing of cell membranes into an interconnected mass of cells called a syncytium. The syncytium of cells in the atria is separate and is insulated from the...
syncytium in the ventricles (Ganong, 2003). An electric stimulus from the sinoatrial node is transmitted over the entire atrial mass by the syncytial arrangement of cells. The impulse is not, however, transmitted directly into the ventricular syncytium. The impulse first must be picked up and transmitted by the atroventricular node through its conduction system to the ventricular syncytium. Stimulation of a single atrial or ventricular muscle fiber causes the entire atrial or ventricular muscle mass to contract as a unit. When situations cause spontaneous depolarization of cardiac muscle or abnormalities of the conduction system, arrhythmias may occur.

When a cardiac cell is stimulated by electric activity that arises in the sinoatrial node, it undergoes depolarization and contracts. Depolarization is characterized by the rapid influx of sodium ions into the cell through channels or “gates,” the slower influx of calcium ions, and the outflow of potassium ions (Figure 7-2). Until the sodium, potassium, and calcium ions have returned to the positions they had before depolarization, the cell is in a refractory period (Figure 7-3). A cell in an absolute refractory state cannot normally depolarize. In a relative refractory period, however, a cardiac cell can depolarize again, but the stimulus must be stronger than normal (Bill, 2006). A refractory period is essential for a cardiac cell to prevent it from remaining in a constant state of contraction as the result of stimulation by recycling impulses. The return of the ions to their original positions is brought about in part by the sodium-potassium pump and is an essential part of the repolarization process. Summed electric activity arising from the contraction of all heart cells represents the electrocardiogram (Figure 7-4), with each of its waves signifying activity in a particular area.

Even though the heart establishes its own inherent rate of beating, this rate is subject to outside influences through the autonomic nervous system. The sympathetic portion of the autonomic nervous system, through beta-1 receptors, produces positive chronotropic and inotropic effects on the heart. The parasympathetic branch of the autonomic nervous system causes negative chronotropic effects through cholinergic receptors.

![Figure 7-2](image_url)

**Figure 7-2**
Depolarization and repolarization of a cardiac cell. Repolarization: The sodium-potassium-ATPase pump restores electrolytes to their resting sites.

![Figure 7-3](image_url)

**Figure 7-3**
Schematic of the refractory period of a cardiac cell. After depolarization (contraction), cardiac muscle cells are unable to contract again until they have undergone repolarization. The time during which they are unable to contract is the refractory period.

The heart pumps blood through a series of arteries (arterial tree) to deliver it to the tissues. The larger of these arteries have elastic properties, which
allow them to stretch and recover when blood is pumped into them—thereby serving as a second pump (Upson, 1988). The smaller arteries are capable of changing their diameter (constricting or dilating) through the action of smooth muscle in their walls to increase or decrease the resistance that the heart must pump against. Stimulation of alpha-1 receptors causes vessels to constrict, and stimulation of beta-2 receptors causes vessels to dilate.

The amount of blood that the heart is capable of pumping per minute is called cardiac output; this value is calculated by multiplying the heart rate by the stroke volume. The stroke volume is determined in part by the amount of blood that fills the ventricle during diastole, called the preload, and the arterial resistance that the ventricle must pump against, called the afterload.

**COMPENSATORY MECHANISMS OF THE CARDIOVASCULAR SYSTEM**

The cardiovascular system has a built-in reserve capacity, which allows it to increase its output during times of need (e.g., athletic performance) and to compensate for cardiac disease. The four basic factors of cardiac reserve or compensation are described in the following (Bill, 1994):

1. Increasing heart rate. Increasing the rate of contraction increases cardiac output up to the point at which the rate is so fast that there is inadequate time for ventricular filling.
2. Increasing the stroke volume. Up to a point, an increased force of contraction results in an increase in the amount of blood that is pumped.
3. Increasing the efficiency of the heart muscle.
4. Physiologic heart enlargement. The heart is composed of muscle that responds to work by increasing its size and becoming stronger.

Many disorders can result in cardiac disease. However, most that respond to pharmacologic therapy fall into one of the following categories:

1. Valvular disease. Valvular insufficiency, a backflow or leakage of blood backward through the valve, is a relatively common acquired heart disorder of dogs. If the tricuspid valve is affected, ascites may occur. If the mitral valve
is involved, pulmonary edema may result. Valvular disease may result from progressive bacterial endocarditis. Inadequate opening of valves may also occur and cause disease. Insufficiency or stenosis may be accompanied by a murmur.

2. Cardiac arrhythmias. If a focus of cardiac tissue depolarizes out of sequence with the sinoatrial node, an arrhythmia may result. Various types of arrhythmias, including tachyarrhythmias (arrhythmias with a rapid rate) and bradyarrhythmias (arrhythmias with a slow rate), may occur. Arrhythmias may occur in the atria (supraventricular) or in the ventricles (ventricular). Several categories of drugs (catecholamines, thiobarbiturates, xylazine, digoxin, and others) predispose the heart to arrhythmias.

3. Myocardial disease. Cardiomyopathy, a disease of the myocardium, primarily affects dogs and cats. It may be classified as congestive (the myocardium becomes thin and ineffective in its pumping action) or hypertrophic (the myocardium becomes thickened and restricts ventricular filling). Each type is often accompanied by various arrhythmias.

4. Other potential causes of cardiac disease include congenital defects (right-to-left shunts), abnormalities of cardiac innervation, vascular disease (hypertension), and heartworm disease.

Cardiovascular diseases with the greatest prevalence include mitral disease in dogs, hypertrophic cardiomyopathy in cats, dilated cardiomyopathy in dogs, “Boxer” cardiomyopathy, and heartworms (Hamlin, 2003).

Congestive heart failure (CHF) (Figure 7-5) occurs when the pumping ability of the heart is impaired to the extent that sodium and water are retained in an effort to compensate for inadequate cardiac output. It is associated with exercise.

**Figure 7-5**
Pathophysiology of congestive heart failure.
Table 7-1 Stages and Treatment of Cardiac Disease

<table>
<thead>
<tr>
<th>Stage</th>
<th>Signs</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>None/murmur</td>
<td>None</td>
</tr>
<tr>
<td>II</td>
<td>Cough</td>
<td>Restricted sodium diet</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diuretic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bronchodilator</td>
</tr>
<tr>
<td>III</td>
<td>Cough</td>
<td>Digitalis</td>
</tr>
<tr>
<td></td>
<td>Reduced exercise</td>
<td>Diuretic</td>
</tr>
<tr>
<td></td>
<td>tolerance</td>
<td>Vasodilators</td>
</tr>
<tr>
<td>IV</td>
<td>Dyspnea at rest</td>
<td>Oxygen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Diuretics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sedatives</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vasodilators</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Others</td>
</tr>
</tbody>
</table>

5. Ancillary treatment
   a. Narcotics/sedatives
   b. Oxygen

CATEGORIES OF CARDIOVASCULAR DRUGS

Positive Inotropic Drugs

The general principle involved in the use of drugs that improve the strength of contraction is that the heart, even in the presence of disease, has reserve capacity for contraction that can be called on to improve cardiac output. Some clinicians advise cautious use of positive inotropic drugs because these can increase the oxygen demand of cardiac muscle, can potentially damage the contractile apparatus, and can increase the tendency for arrhythmias. Proof of clinical efficacy of positive inotropic drugs is lacking, and their use is controversial (Booth, 2001). Their popularity has waxed and waned through the years as newer, more effective products have come into use.

Cardiac Glycosides (Digitalis)

The digitalis compounds (digoxin and digitoxin) are obtained from the dried leaves of the plant Digitalis purpurea. The beneficial effects of these compounds have been known for hundreds of years and include (1) improved cardiac contractility, (2) decreased heart rate, (3) antiarrhythmic effects, and (4) decreased signs of dyspnea.

Digitalis increases the strength of contraction by increasing the level of calcium ions available in the contractile filaments within cardiac muscle cells. This action occurs as a result of inhibition of sodium-potassium-adenosine triphosphatase (Figure 7-6). The heart rate is slowed by prolonging atrioventricular conduction time and by increasing parasympathetic, autonomic stimulation. The primary actions of the digitalis drugs are to (1) increase the force of contraction, (2) decrease the rate of contraction, and (3) improve baroreceptor function (Hamlín, 2003).

Digitalis use is indicated in patients with cardiac disease that results from impaired cardiac contraction or atrial arrhythmias as suggested by clinical

intolerance, pulmonary edema, and ascites. The heart usually becomes enlarged in this condition.

Cardiac disease has been divided into four phases according to degree of severity. Table 7-1 lists these phases with corresponding clinical signs and treatments.

BASIC OBJECTIVES IN THE TREATMENT OF CARDIOVASCULAR DISEASE

Basic objectives in the treatment of cardiovascular disease include the following (Ettinger, 2000):

1. Control rhythm disturbances
2. Maintain or increase cardiac output
   a. Increase the strength of contraction
   b. Decrease the afterload
      (1) Arteriolar dilator
   c. Decrease the preload
      (1) Venodilator
3. Relieve fluid accumulations
   a. Diuretics
   b. Dietary salt restriction
4. Increase the oxygenation of the blood
   a. Bronchodilation
adversely affected when given concurrently with many drugs (cimetidine, metoclopramide, diazepam, anticholinergics, and others). Consult appropriate references for suitability.

**Technician’s Notes**
1. The bioavailability of digoxin varies from 60% in tablet form to 75% in elixir form, and adjustments are probably needed if the dosage form is changed.
2. Clients should be advised to monitor their pets carefully for signs of toxicity and to advise the veterinarian if any arise.

**Catecholamines**
Catecholamines include a group of sympathomimetic (adrenergic) compounds that (1) increase the force and rate of muscular contraction of the heart (increase in cardiac output), (2) constrict peripheral blood vessels (increase blood pressure), and (3) elevate blood glucose levels. Catecholamines increase cardiac contractility primarily by stimulating beta-1 receptors. Because of their short serum half-lives, catecholamines are used mainly for short-term management of severe heart failure.

**Epinephrine**
Epinephrine is the preferred drug for providing stimulation for contraction of the heart and for supporting the circulatory system after cardiac arrest. It may be administered by the intracardiac, intratracheal, or intravenous route, and a 1:10,000 solution is preferred. Most products provide a 1:1000 solution. Because epinephrine greatly increases the workload of the heart and increases the tendency for arrhythmias, it is not used for therapy of chronic heart failure.

**Clinical Uses**
Epinephrine is used in veterinary medicine for cardiac resuscitation and for the treatment of anaphylaxis.

**Dosage Forms**
Human label forms of epinephrine are used.

---

**Clinical Uses**
Clinical uses of the digitalis compounds include the treatment of CHF, atrial fibrillation, and supraventricular tachycardia.

**Dosage Forms**
Dosage forms include tablets and elixirs. Veterinary and human label products are available for digoxin, but digitoxin is no longer marketed.

1. Veterinary approved
   a. Digoxin elixir (Cardoxin LS, 0.05 mg/ml; Cardoxin, 0.15 mg/ml)
   b. Digitoxin—not available
2. Human approved
   a. Digoxin for injection (Lanoxin, 0.25 mg/ml or 0.1 mg/ml in ampules and vials)
   b. Digoxin tablets (Lanoxin, 0.125, 0.25, and 0.5 mg)
   c. Digoxin capsules (Lanoxicaps, 0.05, 0.1, and 0.2 mg)
   d. Digoxin elixir (Lanoxin, 0.05 mg/ml, 60-ml bottle)

**Adverse Side Effects**
Adverse side effects from the use of digitalis compounds are often associated with high or toxic serum levels of drugs and can include anorexia, vomiting, diarrhea, and various arrhythmias. Cats are relatively more sensitive than dogs to toxic effects (Plumb, 2005). Digitalis compounds are
1. Epinephrine HCl for injection, 0.1 mg/ml (1:10,000) in 10-ml syringes
2. Epinephrine HCl for injection (Adrenalin Chloride, 1 mg/ml [1:1000] in ampules and vials)

**Adverse Side Effects**
These include hypertension, arrhythmias, anxiety, and excitability.

**Technician's Notes**
1. A 1:10,000 solution can be prepared from a 1:1000 solution by mixing 1 ml of the drug with 9 ml of sterile water for injection. Alternatively, 0.5 ml of drug can be mixed with 4.5 ml of sterile water for injection.
2. Epinephrine is stored under refrigeration.

**ISOPROTERENOL**
Isoproterenol is seldom used in the treatment of cardiac disease. It is indicated in atropine-resistant bradycardia.

**DOPAMINE**
Dopamine is a biosynthetic precursor of norepinephrine. It stimulates dopaminergic receptors in coronary, mesenteric, renal, and cerebral vascular beds. It also is capable of stimulating alpha- and beta-adrenergic receptors to increase heart contractility, heart rate, and blood pressure. Dopamine use in cardiac cases is mainly limited to heart failure associated with anesthetic emergencies or after cardiac resuscitation.

**Clinical Uses**
Dopamine is used for adjunctive treatment of acute heart failure and oliguric renal failure and for the supportive treatment of shock.

**Dosage Forms**
1. Intropin
2. Dopamine HCl
3. Dopamine HCl in 5% dextrose

**Adverse Side Effects**
These include vomiting, tachycardia, dyspnea, and blood pressure variations (hypotension or hypertension).

**DOBUTAMINE**
Dobutamine is a synthetic inotropic agent related structurally to dopamine. It causes increased cardiac contractility, as does dopamine, but does not produce dilation of selected vascular beds. Dobutamine is a direct beta-1-adrenergic agent. It produces increased cardiac output with little tendency to cause arrhythmias or increased heart rate. It is available only as a human label product (Dobutrex solution) and is administered in diluted form by intravenous infusion. Consult the Veterinary Drug Handbook (Plumb, 2005) for directions on preparation of the solution for infusion.

**Bipyridine Derivatives**
Amrinone and milrinone are representatives of a new class of positive inotropic drugs that appear to work by inhibiting enzymes that ultimately lead to an increase in cellular calcium. Amrinone (Inocor) is given intravenously and is limited to short-term inpatient use, whereas milrinone is given orally and has potential for long-term use.

**Inotropic, Mixed Dilator**

**PIMOBENDAN**
Pimobendan was approved for use in veterinary medicine in April, 2007. It is a positive inotropic drug that increases the calcium sensitivity of cardiac myofilaments and inhibits the enzyme phosphodiesterase.

**Clinical Uses**
Pimobendan is labeled for the treatment of atrioventricular insufficiency or dilated cardiomyopathy in dogs.

**Dosage Form**
Vetmedin Chewable Tablets in 1.25, 2.5, or 5 mg sizes

**Adverse Side Effects**
Side effects may include anorexia, lethargy, diarrhea, and others.

**Contraindication**
Pimobendan is contraindicated in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other condition when cardiac augmentation is inappropriate for anatomical reasons.
Antiarrhythmic Drugs

An arrhythmia is a variation from the normal rhythm of the heart. Such a variation may result from an abnormality of impulse generation (increased automaticity) or from abnormalities of impulse conduction. Many arrhythmias arise when a local group of cells begins to depolarize faster than the sinoatrial node (pacemaker), causing disruption of the normal depolarization pattern of the heart. The location of this group of cells is called an ectopic focus (foci if more than one location is involved). Arrhythmias usually result in reduced cardiac output caused by poorly coordinated pumping activity. Some arrhythmias may be auscultated by an experienced ear, but arrhythmias more often are diagnosed through their production of abnormal waveforms seen on an electrocardiogram.

Factors that may cause or predispose the heart to arrhythmias include the following:

1. Conditions that cause hypoxemia
2. Electrolyte imbalances
3. Increased levels of or increased sensitivity to catecholamines
4. Drugs such as digitalis compounds, thiobarbiturates, inhalant anesthetics (halothane), xylazine, and others
5. Cardiac trauma or disease that results in altered cardiac cells

Arrhythmias are classified in relation to heart rate as tachyarrhythmias or bradyarrhythmias. Tachyarrhythmias are further classified into ventricular or atrial, depending on their location, and can lead to rapid contraction rates in corresponding chambers. At these rapid rates, pumping efficiency is greatly reduced because of decreased filling time. Rapid, uncoordinated activity called flutter or fibrillation may also result.

Pharmacologists classify antiarrhythmic drugs into the following four basic categories (Boothe, 2001):

1. Class IA includes quinidine, procainamide, and others.
2. Class II includes the beta-adrenergic blockers (propranolol).
3. Class III includes bretylium and amiodarone.
4. Class IV includes the calcium channel blockers (verapamil, nifedipine, amlodipine, and diltiazem).

Class IA
Drugs in Class IA depress myocardial excitability, prolong the refractory period, decrease automaticity, and increase conduction times. Class IA drugs are used to treat atrial and ventricular arrhythmias and may be given orally on a long-term basis.

Quinidine
Quinidine is an alkaloid that is obtained from cinchona plants or is prepared from quinine (Plumb, 2002).

Clinical Uses
Quinidine is used to treat ventricular arrhythmias, ventricular tachycardia, and atrial fibrillation.

Dosage Forms
Human label forms are used.

1. Quinidine sulfate
   a. Tablets, 200 and 300 mg (Quinora)
   b. Sustained-release tablets, 300 mg (Quinidex Extentabs)
2. Quinidine gluconate
   a. Sustained-release tablets (Quinaglude DuraTabs [324 mg])
   b. Injection, 80 mg/ml
3. Quinidine polygalacturonate
   a. Tablets, 275 mg (Cardioquin)

Adverse Side Effects
These include anorexia, vomiting, diarrhea, weakness, and laminitis (horses).

Technician's Notes
Quinidine doses must be reduced in animals who are being treated concurrently with digoxin.
**Procainamide**

Procainamide is an antiarrhythmic that is chemically related to procaine.

**Clinical Uses**

Procainamide is used to treat premature ventricular contractions (PVCs), ventricular tachycardia, and some forms of atrial tachycardia.

**Dosage Forms**

Human label procainamide hydrochloride is used.

1. Injection, 100 mg/ml in 10-ml vials and 500 mg/ml in 2-ml vials (Pronestyl)
2. Tablets or capsules, 250, 375, and 500 mg (Pronestyl)

**Adverse Side Effects**

These include anorexia, vomiting, diarrhea, hypotension, and others. However, these effects are generally dose related.

**Class IB**

Drugs in this category exert their influence by stabilizing myocardial cell membranes. By blocking the influx of sodium into the cell, these drugs prevent depolarization and decrease cell automaticity (Figure 7-7). They are used to treat ventricular arrhythmias, but they have not been approved for this use by the U.S. Food and Drug Administration (FDA).

**Lidocaine**

Lidocaine is a local anesthetic and antiarrhythmic. It is prepared only in injectable form and is administered intravenously. It is used frequently in emergency medicine and acute care.

**Clinical Uses**

Lidocaine is primarily used for the control of PVCs and for the treatment of ventricular tachycardia.

**Dosage Forms**

Various veterinary brand name forms are available in 1% and 2% solutions.

**Adverse Side Effects**

These are rare but may include drowsiness, depression, ataxia, and muscle tremors. Cats are potentially sensitive to the central nervous system effects of lidocaine. These should be monitored carefully when a patient is receiving this drug.

---

**Technician’s Notes**

When administering lidocaine for an arrhythmia, make certain that it is lidocaine without epinephrine. Epinephrine (a catecholamine) predisposes the heart to arrhythmia.

**Tocainide And Mexiletine**

Tocainide and mexiletine are other class IB agents that may be given orally.

**Class IC**

Class IC agents are seldom used in veterinary medicine.

**Class II**

Class II antiarrhythmics are the beta-adrenergic blockers. Propranolol has been the most widely used agent in this class for veterinary therapeutics, although atenolol and other agents are now used as well. Beta blockers may block only beta-1 receptors or only beta-2 receptors (selective), or they may block both types (nonselective). They also are thought to “upregulate” or increase adrenergic receptors to improve cardiac efficiency (Hamlin, 2003). These drugs may be used to treat atrial or ventricular arrhythmias, decrease cardiac conduction, reduce cardiac output, and decrease blood pressure.
PROPRANOLOL
Propranolol reduces automaticity of cardiac conduction cells by blocking beta-1 and beta-2 receptor sites. Myocardial oxygen demand is reduced by propranolol. Reducing myocardial oxygen demand reduces the tendency for ischemia, in turn reducing automaticity (Williams and Baer, 1990). Propranolol reduces heart rate, cardiac output, and blood pressure. It also may improve cardiac performance in animals with hypertrophic cardiomyopathy.

Clinical Uses
In veterinary medicine, propranolol is used to treat hypertrophic cardiomyopathy and various atrial and ventricular arrhythmias. It is used in cats to treat systemic hypertension and hyperthyroidism (Plumb, 2005).

Dosage Forms
1. Propranolol HCl tablets, 10, 20, 40, 60, 80, and 90 mg (Inderal)
2. Propranolol HCl extended-release capsules, 60, 80, 120, and 160 mg (Inderal LA)
3. Propranolol for injection, 1 mg/ml in 1-ml ampules or vials (Inderal)
4. Propranolol oral solution, 4, 8, and 80 mg/ml concentrate (Intensol)

Adverse Side Effects
These include bradycardia, hypotension, worsening of heart failure, lethargy, bronchospasm, and depression.

Technician’s Notes
1. Propranolol is contraindicated in patients with overt heart failure, greater than first-degree heart block, and sinus bradycardia (Plumb, 2005).
2. Do not discontinue therapy abruptly because tachycardia or hypertension may occur.

ATENOLOL
Atenolol is a selective beta-1 blocker (Papich, 2002). Atenolol decreases heart rate, slows cardiac conduction, decreases myocardial oxygen demand, reduces blood pressure, and diminishes cardiac output. Because of its selective beta-1 effect, atenolol may be safer to use in animals prone to bronchospasm.

Clinical Uses
Atenolol is used in the treatment of supraventricular tachyarrhythmias, premature ventricular contractions, hypertension, and cardiomyopathy.

Dosage Forms
1. Atenolol tablets, 25, 50, and 100 mg (Tenormin)
2. Atenolol injection, 5 mg/ml (Tenormin)
3. Atenolol (Tenormin)
4. Atenolol (Anseolol)

Adverse Side Effects
Bradycardia, lethargy and depression, hypotension, syncope, or heart failure is most commonly reported in older animals.

Other Beta Blockers
1. Carvedilol (Dilatrend)
2. Sotalol (Betapace, Cardol). Nonselective with action similar to propranolol. This drug is replacing quinidine as the antiarrhythmic drug of choice by some clinicians.
4. Metoprolol (Lopressor, Betaloc). Beta-1 blocker otherwise similar to propranolol.
5. Pindolol (Barbloc)

Class III
The Class III antiarrhythmics bretylium (Bretylol) and amiodarone (Cordarone) are not in common use in veterinary medicine. Some clinicians have reported that Bretylol has promise for treating ventricular fibrillation in the absence of a defibrillation unit. These drugs are used in human medicine to treat ventricular arrhythmias.

Class IV
Class IV antiarrhythmic drugs work by blocking the channels that permit entry of calcium ions through the cardiac cell membrane. This effect causes depression of the contractile mechanism in myocardial and
smooth muscle cells and depresses automaticity and impulse transmission (Williams and Baer, 1990).

**VERAPAMIL HYDROCHLORIDE**
Verapamil is a channel-blocking agent and is available in oral and injectable forms. It has had limited use in veterinary medicine.

**Clinical Uses**
Verapamil is used to treat supraventricular tachycardia, atrial flutter, and atrial fibrillation.

**Dosage Forms**
Human label products are used.

1. Verapamil HCl tablets, 40, 80, and 120 mg (Calan, Isoptin)
2. Verapamil HCl sustained-release tablets, 120, 180, 240, and 360 mg (Calan SR, Isoptin SR)
3. Verapamil HCl for injection, 5 mg/2ml in ampules, vials, and syringes (Isoptin)

**Adverse Side Effects**
These include hypotension, bradycardia, tachycardia, pulmonary edema, and worsening of CHF.

**DILTIAZEM**
Diltiazem is a channel-blocking agent that is similar in action to verapamil.

**Clinical Uses**
Diltiazem is used for supraventricular tachyarrhythmias in dogs and cats and for hypertrophic cardiomyopathy in cats.

**Dosage Forms**
1. Diltiazem tablets, 30, 60, 90, and 120 mg (Cardizem)
2. Diltiazem oral capsules extended/sustained release, 60, 90, 120, 180, 240, 300, 360, and 420 mg (Cardizem SR, Cardizem CD, Dilacor XR)

**Other Class IV Antiarrhythmics**
Other channel blockers include nifedipine (Adalat) and amlodipine (Norvasc). These agents are used primarily for the treatment of hypertension rather than as antiarrhythmics.

---

**Vasodilator Drugs**

When heart failure occurs, cardiac output is reduced, resulting in hypotension and poor perfusion of tissue. As a reaction to this poor perfusion of tissue, the body activates compensatory mechanisms to increase blood pressure and improve blood supply to tissue. The first compensatory activity is stimulation of the sympathetic nervous system to increase heart rate and to cause constriction of small arteries, which in turn raises blood pressure. Next, the renin-angiotensin system is activated by the release of renin from poorly perfused kidneys (Figure 7-8). Renin causes angiotensinogen to be converted to angiotensin I. Angiotensin I then is converted by angiotensin-converting enzyme (ACE) inhibition to angiotensin II. Angiotensin II causes further vasoconstriction and stimulates the adrenal glands to release aldosterone. Aldosterone acts on the kidney tubules to cause reabsorption of sodium ions and osmotic retention of water. The water that is retained helps to expand the circulating blood volume to improve tissue perfusion.

In the short term, these compensatory mechanisms are beneficial. In the long term, however, they become harmful because the heart must work harder to pump blood through vessels constricted by sympathetic nervous stimulation and by the effects of angiotensin II (increased afterload). The ever-increasing blood volume (increased preload) caused by aldosterone release and water retention also necessitates more strenuous activity by the heart, which in a weakened state initiates the preceding chain of events.

Vasodilator drugs act by dilating arteries (arteriolar dilator), veins (venodilator), or both (combined vasodilator). Dilatory activity may be brought about by direct action on vessel smooth muscle, through blockage of sympathetic stimulation, or by preventing conversion of angiotensin I to angiotensin II. Dilation of constricted arteries tends to decrease afterload and improve cardiac output. Preload is also reduced because of pooling of blood in dilated veins.

Many forms of CHF are improved by the use of vasodilators, which can be used in conjunction with other heart medications.
**Hydralazine**

Hydralazine is primarily an arteriolar dilator. It acts directly on smooth muscle in the arterial wall by interfering with calcium movement and inhibiting the contractile state (Plumb, 2002). The net result is that peripheral resistance is reduced and cardiac output is often greatly improved in animals with CHF. Some clinicians recommend that hydralazine be used with a diuretic because it may activate the renin-angiotensin system and cause water retention (Bill, 2006).

**Clinical Uses**

Hydralazine is used for afterload reduction associated with CHF, especially CHF caused by mitral valve insufficiency.

**Dosage Forms**

Human forms are used.

1. Hydralazine HCl tablets, 10, 25, 50, and 100 mg (Apresoline)
2. Hydralazine for injection, 20 mg/ml in ampules or vials (Apresoline)

**Adverse Side Effects**

Adverse side effects in small animals include hypotension, vomiting, diarrhea, sodium and water retention, and tachycardia.

**Nitroglycerin Ointment**

Nitroglycerin is primarily a venodilator that reduces preload as the result of pooling of blood in peripheral vessels and decreased venous return to the heart. Some arteriolar dilation may occur at higher doses. Nitroglycerin is applied topically in hairless areas of small animal patients. The medical vehicle of nitroglycerin causes it not to be explosive.
Clinical Uses
In small-animal medicine, nitroglycerin is used as a vasodilator to improve cardiac output and reduce associated pulmonary edema. In equine medicine, nitroglycerin is used as a leg sweat to reduce swelling and to treat laminitis.

Dosage Forms
Human forms, such as nitroglycerin topical ointment, 2% in 20-, 30-, and 60-g tubes (Nitro-Bid, Nitrol), are used.

Adverse Side Effects
Adverse side effects are minimal and may include rashes at the application site and hypotension.

Technician’s Notes
1. Gloves should be worn when nitroglycerin is applied.
2. Rotate application sites.
3. Do not pet animals at application sites.
4. The dose is measured in inches by application of a strip of ointment to measuring paper that is supplied with the product.
5. The veterinarian should be contacted if a rash appears at the application site.

Prazosin
Prazosin is a combined vasodilator. It reduces blood pressure and peripheral vasoconstriction by blocking alpha-1-adrenergic receptor sites. Prazosin apparently does not activate the renin-angiotensin system.

Clinical Uses
Prazosin is used for adjunctive treatment of CHF, dilated cardiomyopathy in dogs, systemic hypertension, and pulmonary hypertension.

Dosage Forms
Human forms are used; prazosin capsules, 1, 2, and 5 mg (Minipress).

Adverse Side Effects
These include hypotension, syncope, vomiting, and diarrhea.

Angiotensin-Converting Enzyme Inhibitors
Captopril and enalapril are combined vasodilators that exert their effects on blood vessels by preventing formation of the potent vasoconstrictor angiotensin II. They prevent the conversion of angiotensin I to angiotensin II by inhibiting ACEs. Drugs in this category are sometimes called ACE inhibitors. Both products may be administered with cardiac glycosides and furosemide.

Clinical Uses
ACE inhibitors act as vasodilators in the treatment of Class II, III, and IV heart failure (see Table 7-1).

Dosage Forms
1. Veterinary approved: enalapril tablets, 1, 2.5, 5, 10, and 20 mg (Enacard)
2. Human approved: captopril tablets, 12.5, 25, 50, and 100 mg (Capoten)
3. Human approved: Vasotec tablets, 2.5, 5, 10, and 20 mg
4. Human approved: Vasotec injection for IV use, 1.25 mg/ml

Adverse Side Effects
These include hypotension, azotemia, vomiting, diarrhea, hyperkalemia, and others. The safety of enalapril in breeding dogs has not been established.

Technician’s Notes
1. Care should be taken when captopril or enalapril is administered with other vasodilators and certain diuretics because of potential hypotension.
2. Concurrent use of nonsteroidal antiinflammatory drugs may reduce the effectiveness of captopril.
3. Captopril may cause a false-positive urine acetone finding.

Diuretics
Diuretics have been some of the most commonly used drugs in the treatment of heart failure because of their ability to promote the reduction of preload.
through diuresis. Diuretics reduce the harmful effects of CHF (pulmonary edema, ascites, and increased cardiac work) by reducing plasma volume through various mechanisms.

Many different diuretics are available, and most work by inhibiting reabsorption of sodium and water in the loop of Henle or the distal tubules. If sodium ions remain in the tubules, they exert an increased osmotic “pull” on water molecules to cause them to remain in the tubules and be excreted as urine. The diuretics used most in veterinary medicine include furosemide, the thiazides, and spironolactone.

**Furosemide**
Furosemide is very powerful and is the most important and efficacious diuretic for removing edema from animals with heart failure (Hamlin, 2003). Furosemide may be administered intravenously, intramuscularly, subcutaneously, or orally and works rapidly to reduce pulmonary edema and other signs of CHF. It causes diuresis by reducing reabsorption of sodium and other electrolytes in the kidney tubules. Because much of the reabsorption occurs in the loop of Henle, furosemide is sometimes called a loop diuretic.

**Clinical Uses**
Furosemide is used for diuretic therapy (in CHF and other conditions) in all species.

**Dosage Forms**
Injectable and oral (solution, tablet, and bolus) human label products are used.

1. Lasix
   a. Tablets, 12.5 and 50 mg
   b. Bolus, 2 g
   c. Oral solution, 10 mg/ml
   d. Injection, 5% (50 mg/ml)
2. Furosemide injection, generic 5%
3. Furosemide tablets, generic, 12.5 and 50 mg

**Adverse Side Effects**
These include low blood potassium (hypokalemia), dehydration, low blood sodium (hyponatremia), ototoxicity (cats), weakness, and shock.

**Technician’s Notes**
1. Furosemide should be administered carefully to animals that are dehydrated or in shock.
2. Furosemide can cause hypokalemia that can increase the chances of digoxin toxicity (anorexia increases the chances of hypokalemia). Potassium supplementation may be required.
3. Animals who are receiving diuretics such as furosemide should always have free access to water.
4. Administer the dose at convenient times for the client because urination follows within 20 to 30 minutes.

**Thiazides**
Thiazide diuretics such as (chlorothiazide) Diuril act on the loop of Henle and distal tubules to inhibit reabsorption of sodium. Thiazides are seldom used in veterinary medicine.

**Spironolactone**
Spironolactone is a potassium-sparing diuretic (it does not normally cause hypokalemia) and an antagonist of aldosterone. By inhibiting aldosterone, it reduces the amount of sodium reabsorbed from the kidney tubules. Spironolactone (Aldactone) usually is not used alone but is combined with a loop diuretic or a thiazide (Plumb, 2005). Similar to the thiazides, it has limited use in veterinary medicine.

**DIETARY MANAGEMENT OF HEART DISEASE**

Dietary management is an important part of the overall treatment of patients with heart disease. Dietary measures often are instituted early in the pathogenesis of heart disease (before clinical signs are observed or drug therapy is begun). Two of the primary goals of dietary management of heart disease are sodium restriction and maintenance of good body weight and condition (reduction of obesity or cachexia). Specific nutrient deficiencies (taurine or carnitine), concurrent disease (chronic renal failure), and electrolyte disorders also may have to be addressed (Roudebusch et al, 2000).
Sodium restriction has long been recognized as an important part of the management of CHF. As was previously mentioned, increased sodium levels in the body lead to water retention, increased plasma volume, and exacerbation of the clinical signs of heart failure. The primary source of sodium is food. However, water and treats also must be considered when dietary intake is limited. Prescription diets (Hill’s and Purina) provide sodium-restricted nutrition for dogs and cats. These diets may also be restricted in chloride and phosphorus. They may have added taurine and/or carnitine, B-complex vitamins, and normal or added levels of potassium. Sometimes it is difficult to get an animal to accept a sodium-reduced diet because of palatability issues. These foods may be made more palatable by adding flavor enhancers or warming the food.

Because heart failure may impair other internal organs, such as the kidneys, gastrointestinal tract, and liver, cardiac diets should be highly digestible and easily metabolized. They are balanced with adequate (but not excessive) levels of high-biologic-value protein to address potential renal failure. The energy level may need to decrease or increase on the basis of individual animal type and the cardiac condition of the animal. Improvements in cachexia in dogs with congestive failure have been seen with dietary supplementation of fish oils, which are high in omega-3 fatty acids (Ware, 2002).

**Bronchodilators**

Bronchodilators such as aminophylline and theophylline are sometimes used in the treatment of heart failure. These agents increase the size of lung passageways to allow more efficient oxygenation of blood, to exert a mild positive inotropic effect on heart muscle, and to obtain a mild diuretic effect.

**Oxygen Therapy**

Oxygen therapy can be crucial in treating animals in the advanced stages of CHF. Animals with pulmonary edema benefit greatly from the administration of 40% to 50% oxygen via cage, mask, or nasal cannula.

**Sedation**

Animals with pulmonary edema caused by heart failure often experience a great deal of anxiety because of the dyspnea that they encounter. This anxiety often leads to hyperventilation and even greater oxygen demand and anxiety. To break the cycle and calm the animal, sedative drugs are often administered. The clinician may choose morphine, meperidine, diazepam, or other drugs.

**Aspirin**

Aspirin is known for its ability to reduce pain and inflammation, fever, and platelet aggregation. It is sometimes used in heart disease when clot formation may be a potential problem. It is used by some veterinarians to reduce the tendency for clot formation in heartworm treatment and for the same purpose in congestive cardiomyopathy in cats.

**Thoracocentesis and Abdominocentesis**

When heart failure is accompanied by excessive fluid (effusion) in the thoracic cavity, drawing fluid from the cavity may be lifesaving. Removal of ascitic fluid is controversial but may relieve pressure on the diaphragm and improve ventilation.

**REFERENCES**


**REVIEW QUESTIONS**

1. Why is the heart considered to be two pumps functionally?

2. Cardiac cells are connected by intercalated disks and a fusion of cell membranes to form a __________.

3. Depolarization of cardiac cells is characterized by a rapid influx of __________ ions, a slower influx of __________ ions, and the outflow of __________ ions.

4. A relatively long __________ is important to cardiac cells to prevent a constant state of contraction from recycling impulses.

5. Define chronotropic and inotropic effects in relation to the heart.

6. Define preload and afterload in relation to the pumping mechanism of the heart.

7. List the four basic compensatory mechanisms of the cardiovascular system.

8. List five objectives of treatment for heart failure.

9. List four beneficial effects and one potential toxic effect of the use of the cardiac glycosides.

10. Catecholamines such as epinephrine are used in veterinary cardiology primarily for __________.

11. List five factors that may predispose the heart to arrhythmias.

12. List six categories of antiarrhythmic drugs and give an example of each.

13. List four vasodilator drugs and classify each as arteriodilator, venodilator, or mixed.

14. Why is Lasix sometimes called a loop diuretic?

15. The use of many diuretics can lead to a dangerous loss of what electrolyte?

17. _________________ is characterized by the rapid influx of sodium ions into the cell through channels, the slower influx of calcium ions, and the outflow of potassium ions.

18. The amount of blood that the heart is capable of pumping per minute is called _________________.

19. _________________ results when the pumping ability of the heart is impaired to the extent that sodium and water are retained in an effort to compensate for inadequate cardiac output.

20. ACE causes the conversion of _________________ to _________________.

21. Nitroglycerin is supplied as an ointment. List the precautions that should be taken when applying. _________________

22. What diuretic is used most commonly in the treatment of heart failure?

23. What is hypokalemia?

24. What are the primary goals of the dietary management of heart disease?

25. List three effects of administration of catecholamines.
   1. _________________
   2. _________________
   3. _________________

26. The heart is a ______-chambered pump that is responsible for moving blood through the vascular system.
   a. two
   b. four
   c. three
   d. five

27. ______ is a faster-than-normal heart rate.
   a. Bradycardia
   b. Arrhythmia
   c. Tachycardia
   d. Automaticity

28. When situations cause spontaneous depolarization of cardiac muscle or abnormalities of the conduction system, ______ may occur.
   a. bradycardia
   b. arrhythmia
   c. tachycardia
   d. automaticity

29. All of the following (except one) are ways by which the cardiovascular system may increase its output during times of need, such as during athletic performance or to compensate for cardiac disease. _________________
   a. decreasing heart rate to such an extent that the myocardium is protected from damage caused by the increased workload
   b. increasing the stroke volume
   c. increasing the efficiency of the heart muscle
   d. physiologic heart enlargement; the heart is composed of muscle that responds to work by increasing its size and becoming stronger

30. CHF (congestive heart failure) results when the pumping ability of the heart is impaired to the extent that Na and H2O are retained in an effort to compensate for inadequate cardiac output. It is associated with all of the following, except ______.
   a. exercise intolerance
   b. pulmonary edema
   c. ascites
   d. diaphragmatic hernia

31. Digitalis is a (an) _________________. It is obtained from the dried leaves of the plant Digitalis purpurea.
   a. catecholamine drug
   b. bipyridine derivative
   c. cardiac glycoside
   d. antiarrhythmic drug

32. Quinidine is an alkaloid that is obtained from cinchona plants or is prepared from quinine. It is used to treat ventricular arrhythmias, ventricular tachycardia, and atrial fibrillation. Quinidine doses must be ______ in patients who are being treated concurrently with digoxin.
   a. decreased
   b. increased
33. Gloves do not have to be worn when applying nitroglycerin.
   a. True
   b. False

34. Concurrent use of nonsteroidal antiinflammatory drugs may _____ the effectiveness of captopril.
   a. increase
   b. decrease

35. Furosemide may cause _____ in patients.
   a. hypoadrenocorticism
   b. hypokalemia
   c. hypocalcemia
   d. hypothyroidism
CHAPTER 8

Drugs Used in Gastrointestinal System Disorders

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Exhibit a basic understanding of the anatomy and physiology of the gastrointestinal (GI) system.
2. Describe the various mechanisms of control of the GI system.
3. Explain the difference between vomiting and diarrhea.
4. Exhibit a working knowledge of drugs that induce vomiting and those that inhibit it.
5. List and describe antiulcer medications used in veterinary medicine.
6. Explain the pathophysiology of diarrhea and list the medications used to control this condition.
7. List the different categories of laxatives and explain their respective mechanisms of action.
8. List the two basic categories of GI prokinetics and stimulants.
9. Explain why digestive enzymes are used.
10. Discuss the use of antibiotics and antiinflammatory agents in GI disease.
11. List the categories of oral products and give an example from each category.
**KEY TERMS**

**ADSORBENT** A drug that inhibits GI absorption of drugs, toxins, or chemicals by attracting and holding them to its surface.

**ANTICHOLINERGIC** Blocking nerve impulse transmission through the parasympathetic nervous system; also called parasympatholytic. Anticholinergic drugs may be used for the treatment of diarrhea or vomiting.

**CHEMORECEPTOR TRIGGER ZONE (CRTZ)** An area in the brain that activates the vomiting center when stimulated by toxic substances in the blood.

**CHOLINERGIC** Activated by or transmitted through acetylcholine; also called parasympathomimetic. Cholinergic drugs increase activity in the GI tract.

**DENTIFRICE** A preparation for cleansing teeth that is available in a powder, paste, or liquid.

**EMESIS** The act of vomiting.

**HEMATEMESIS** Vomiting of blood (the vomitus often resembles coffee grounds).

**MELENA** Dark or black stools that result from blood staining. Bleeding has occurred in the anterior part of the GI tract.

**MOTILIN** A hormone secreted by cells in the duodenal mucosa that causes contraction of intestinal smooth muscle.

**PARITIAL CELL** A cell located in the gastric mucosa that secretes hydrochloric acid.

**PERISTALSIS** A wave of smooth muscle contraction that passes along a tubular structure (GI or other) and moves the contents of that structure forward.

**REGURGITATION** Casting up of undigested or semidigested (ruminant) foodstuff from the esophagus or rumen.

**SEGMENTATION** Periodic constriction of segments of the intestine without movement backward or forward; a mixing rather than a propulsive movement.

**VOMITING CENTER** An area in the medulla that may be stimulated by the CRTZ, the cerebrum, or peripheral receptors to induce vomiting.

**INTRODUCTION**

Problems of the gastrointestinal (GI) system are common reasons for visits to a veterinary practice. These problems include regurgitation, vomiting, diarrhea, weight loss, colic, bloat, flatulence, abnormal stools, and constipation. Because veterinary technicians are expected to answer clients' questions about the GI tract, administer therapeutic GI medications, and monitor the response to GI medications, they must be knowledgeable about this system. They should have a basic knowledge of GI anatomy, physiology, pathophysicsiology, therapeutic principles, and medications.

**ANATOMY AND PHYSIOLOGY**

Anatomic and physiologic differences between the GI systems of different animal species are greater than for any other organ system (Bill, 2006). Despite these differences, the functions are basically the same in each species: (1) intake of food and fluid into the body, (2) absorption of nutrients and fluid, and (3) excretion of waste products. A discussion of the anatomy and physiology of the GI tract with an emphasis on similarities and differences between species follows.

The basic structures of the GI tract include (depending on the species) the mouth, teeth, tongue, salivary glands, esophagus, outpocketings of the esophagus (crop, reticulum, rumen, and omasum), stomach, liver, pancreas, duodenum, jejunum, ileum, cecum, colon, rectum, and anus.

Carnivorous or omnivorous species (cats, dogs, and primates) often are described as monogastric or simple-stomach animals because they have no outpocketings or forestomachs arising from the basic configuration (Figure 8-1). The function of the stomach in these monogastric animals is primarily to store ingested material and to begin some enzymatic breakdown of protein. The salivary glands begin enzymatic digestion by producing enzymes that break down starch into simpler carbohydrates. Pancreatic enzymes delivered to the duodenum break down fats, carbohydrates, and proteins, and
sodium bicarbonate from the pancreas neutralizes hydrochloric acid from the stomach. Bile salts, produced in the liver and delivered to the duodenum, aid in digestion by emulsifying fats. Bile is stored in the gallbladder, which is absent in some animals (horses and rats). Digestion and its control mechanisms are complex, and students should consult an appropriate text for further information.

Ruminant animals are herbivorous and have a GI system characterized by three forestomachs, the reticulum, rumen, omasum, and a “true” stomach—the abomasum (Figure 8-2). The reticulum receives ingested material and passes it to the rumen, where it is mixed and acted on by microorganisms to digest cellulose and other coarse plant material (roughage). Some refer to the rumen as a “fermentation vat,” where microorganisms break down coarse feeds into forms that can be used by the simple stomach portion of the GI system in ruminants. Partially digested material (cud) in the rumen is regurgitated and remasticated to further facilitate digestion. In an immature ruminant, an esophageal groove allows milk to bypass the rumen and flow directly into the abomasum, and the rumen gains full function only after several months.

Equines, rabbits, and some rodents are chiefly herbivorous animals that have a monogastric GI configuration. They possess, however, a large cecum, which is capable of limited roughage digestion (hindgut fermentation) (Figure 8-3).

Birds have an outpocketing of the esophagus called the crop, which is used for food storage. They also have a ventriculus, or gizzard, which serves to grind coarse food material (Figure 8-4).

The small intestine comprises three sections: the duodenum, which has a sharp bend and in which the pancreas is located; the long and highly coiled jejunum; and the short ileum, which connects to the large intestine. In the small intestine, contents
passing from the stomach are mixed with intestinal secretions, pancreatic juice, and bile. The digestive process that began in the mouth and stomach is completed in the small intestine. Products of this process are absorbed together with most of the vitamins and a great deal of fluid. Villi and microvilli protrude from the mucosal surface into the lumen of the small intestine and greatly enhance the absorptive process.

Movements of the small intestine mix the intestinal contents, called chyme, and move them toward the large intestine. Normal intestinal motility includes two different patterns—peristalsis and segmentation (Figure 8-5). **Peristalsis** is a wave of contractions that propels contents along the digestive tract. **Segmentation** is a periodic, repeating pattern of intestinal constrictions that serves to mix and churn the contents.

The colon has a considerably larger diameter than the small intestine. The colon is connected to the ileum and the cecum through the ileoceccolic valve. The surface of the colon may exhibit one or more longitudinal bands (depending on the species) called *teniae*. The wall of the colon may also form outpocketings, called *haustra*. The colon of monogastric animals has an ascending portion, a transverse portion, and a descending portion that leads into the rectum. Functions of the colon...
include absorption of water, synthesis of certain vitamins, and storage of waste material.

Movements of the colon include peristalsis and segmentation (as in the small intestine), as well as a third type called mass action contraction (Ganong, 2003). Mass action contraction is a result of simultaneous contraction of smooth muscle over a large area and serves to move fecal material from one portion of the colon to another and from the colon into the rectum.

**REGULATION OF THE GASTROINTESTINAL SYSTEM**

Regulation of GI system activity is complex but can be said to be under the influence of the following three basic control systems:

1. The autonomic nervous system (ANS).
   a. Stimulation of the parasympathetic portion of the ANS increases intestinal motility and tone, increases intestinal secretions, and stimulates relaxation of sphincters. Drugs that mimic parasympathetic stimulation (cholinergic or parasympathomimetic) cause similar results. Anticholinergic, or parasympatholytic, drugs inhibit these ANS actions.
   b. Stimulation of the sympathetic branch of the ANS decreases intestinal motility and tone, decreases intestinal secretions, and inhibits sphincters.
   c. Stimulation of various intrinsic receptors in the GI tract, such as the myenteric plexus (stretch receptor), also may increase peristaltic activity. Some physiologists consider the intrinsic receptors (myenteric plexus and Meissner's plexus) to be a third portion of the ANS called the enteric nervous system (Ganong, 2003).

2. GI hormones such as gastrin, secretin, and cholecystokinin, when released from intestinal cells, exert control over many functions such as gastric secretion, emptying of the gallbladder, and gastric emptying.
3. Substances such as histamine, serotonin, and prostaglandin are released from specialized cells of the GI tract. Histamine attaches to H₂ receptors in gastric parietal cells to cause increased release of hydrochloric acid in the stomach. The influences of serotonin and prostaglandin are not as well defined.

Another factor that can have a major influence on GI activity is the presence of bacterial endotoxins. Endotoxins are components of the bacterial cell wall of certain bacteria (often gram-negative bacteria) that may increase the permeability of intestinal blood vessels and cause increased fluid loss and fever.

**VOMITING**

Vomiting is forceful ejection of the contents of the stomach, and sometimes the contents of the proximal small intestine, through the mouth. Vomiting is initiated by activation of the vomiting (emetic) center in the medulla of the brain. The vomiting center is connected by nerve pathways to the chemoreceptor trigger zone (CRTZ), the cerebral cortex, and peripheral receptors in the pharynx, GI tract, urinary system, and heart. Impulses from any of these areas activate the vomiting reflex; this requires a coordinated effort of the GI, musculoskeletal, respiratory, and nervous systems (Figure 8-6). Impulses may be generated by (1) pain, excitement, or fear (cortex); (2) disturbances of the inner ear (CRTZ); (3) drugs such as apomorphine and digoxin (CRTZ); (4) metabolic conditions such as uremia, ketonemia, or endotoxemia (CRTZ); and (5) irritation of peripheral receptors.

Occasional vomiting by a dog or cat is considered normal. However, persistent vomiting is not normal. Horses and rats do not normally vomit. Persistent vomiting can cause serious problems such as resultant dehydration, electrolyte disturbances, and acid-base imbalances. Sizable quantities of sodium, potassium, and chloride are lost in vomit. However, potassium loss is usually the most significant abnormality.

![Figure 8-6](image)
The vomiting center/chemoreceptor trigger zone.

**Emetics**

Emetics are drugs that induce vomiting. Emetics are administered to animals that have ingested toxins, but they must be used carefully to avoid serious complications. Emetics should not be used in animals that (1) are comatose or are having a seizure; (2) have depressed pharyngeal reflexes; (3) are in shock or dyspnea; or (4) have ingested strong acid, alkali, or other caustic substances. Obviously, emetics should not be given to animals that do not normally vomit, such as rabbits, some rodents, and horses. Emetics usually remove about 80% of the stomach contents. Therefore, the animal should be closely monitored for signs of toxicity after induced vomiting (Plumb, 2005).

Emetics are classified according to their site of action. Those acting on the CRTZ are categorized as centrally acting, and those that act on peripheral receptors are locally acting.

**Centrally Acting Emetics**

**APOMORPHINE**

Apomorphine is a morphine derivative that stimulates dopamine receptors in the CRTZ, which then activates the vomiting center. This drug
is poorly absorbed after oral administration and is therefore usually administered topically in the conjunctival sac or parenterally. Vomiting follows rapidly after intravenous administration, 5 to 10 minutes after intramuscular injection, and variably (10 to 20 minutes) after conjunctival administration.

**Clinical Uses**
Apopomorphine is used primarily for induction of vomiting in dogs. It is considered by many to be the emetic of choice for dogs. Its use in cats is controversial and possibly is contraindicated. Xylazine, which is safer than apomorphine, is effective as an emetic in most cats.

**Dosage Form**
Apopomorphine HCl soluble tablets, 6 mg (human label), are commonly used. Apomorphine is a Class II controlled substance.

**Adverse Side Effects**
These include protracted vomiting, restlessness, and depression.

---

**Technician’s Notes**
1. Whole or divided apomorphine tablets may be placed in the conjunctival sac of the eye. These tablets or portions can also be crushed or dissolved in saline and placed in the conjunctiva. Once vomiting has occurred, the remaining apomorphine should be rinsed out of the conjunctiva to prevent protracted vomiting.
2. Naloxone may be used to treat an overdose or toxicity.
3. Intravenous cephalozin may cause vomiting.

---

**Locally Acting Emetics**
Syrup of ipecac is the primary agent. Other locally acting emetics that have been used with various degrees of effectiveness include mustard and water, hydrogen peroxide, and warm salt water.

**Syrup of Ipecac**
Ipecac, which is obtained from plant roots, contains alkaloids that irritate the gastric mucosa and induce vomiting within 10 to 30 minutes. Stimulation of the CRTZ is also thought to occur. This agent may be used in dogs and cats. Some veterinarians question the efficacy of this emetic.

**Clinical Uses**
Ipecac is used to induce emesis in dogs and cats.

**Dosage Form**
Ipecac oral syrup in 15- and 30-ml, pint, and gallon bottles (generic) is an over-the-counter product.

**Adverse Side Effects**
These include cardiotoxicity (high doses), lacrimation, and salivation.

---

**Technician’s Notes**
1. Ipecac should be administered with caution to animals with an existing heart condition. It is a cardiotoxic drug when given in high doses.
2. Extract of ipecac should never be substituted for syrup of ipecac because it is several times more potent than the syrup.

---

**Antiemetics**
Antiemetics are drugs that are used to prevent or control vomiting. The use of antiemetics is a form of symptomatic treatment because these drugs do not necessarily correct the underlying cause of the vomiting. Many cases of vomiting in small animals are self-limiting or can be controlled by withholding food and water for 24 to 48 hours. Other cases are more difficult to control and necessitate the use of antiemetic agents and careful attention to determining the underlying
cause. Antiemetics usually are given parenterally because vomiting precludes use of the oral route.

**Phenothiazine Derivatives**
Phenothiazine derivative antiemetics act centrally by blocking dopamine receptors in the CRTZ and possibly by direct inhibition of the vomiting center. These agents are in widespread use. They are very useful in preventing motion sickness in dogs and cats but may be less effective against irritant emetics (Upson, 1988). Common side effects include hypotension and sedation.

**Chlorpromazine**
Chlorpromazine is a phenothiazine derivative tranquilizer that has little popularity as a tranquilizer in veterinary medicine and is more often used as an antiemetic.

**Clinical Uses**
Chlorpromazine is used as an antiemetic in dogs and cats. It is more effective in dogs than in cats.

**Dosage Forms**
1. Chlorpromazine tablets (Thorazine), various sizes
2. Chlorpromazine extended-release capsules (Thorazine Spansule), various sizes
3. Chlorpromazine oral solution (Thorazine), 2 mg/ml, 30 mg/ml, and 100 mg/ml
4. Rectal suppositories (Thorazine), 25 mg and 100 mg
5. Chlorpromazine injection (Thorazine), 25 mg/ml in ampules and vials

**Adverse Side Effects**
These are primarily limited to sedation, ataxia, and hypotension.

**Prochlorperazine**
Prochlorperazine is a phenothiazine derivative agent with moderate sedative effects and strong antiemetic effects. The approved form of this drug is a combination product that contains an anticholinergic agent (Darbazine). Prochlorperazine is available singly as Compazine (human label).

**Clinical Uses**
These include control of vomiting (prochlorperazine alone) in dogs and cats and treatment of vomiting, gastroenteritis, diarrhea, spastic colitis, and motion sickness (combination product).

**Dosage Forms**
1. Prochlorperazine—injection, oral syrup, sustained-release capsules, and suppositories (Compazine)
2. Prochlorperazine/isopropamide—injectable and capsule (Darbazine)

**Adverse Side Effects**
These are similar to those of chlorpromazine but may also include dry mucous membranes, dilated pupils, and urinary retention caused by the effects of the anticholinergic in the combination product.

**Procainamide Derivatives: Metoclopramide**
Metoclopramide is a derivative of procainamide that has central and peripheral antiemetic activities. Centrally, it blocks dopamine receptors in the CRTZ, whereas peripherally, it increases gastric contraction, speeds gastric emptying, and strengthens cardiac sphincter tone. Metoclopramide has a limited influence on GI secretions. This drug has a short half-life and may have to be administered often or in a continuous drip in severe cases of vomiting (Plumb, 2005).

**Clinical Uses**
1. As an antiemetic (especially for parvoviral enteritis, uremic vomiting, and vomiting associated with chemotherapy)
2. For the treatment of gastric motility disorders

**Dosage Forms**
1. Metoclopramide HCl tablets (Reglan), 5 and 10 mg
2. Metoclopramide HCl oral solution (Reglan), 1 mg/ml in containers of various sizes
3. Metoclopramide HCl injection (Reglan), 5 mg/ml

**Adverse Side Effects**
The most common side effects in horses, dogs, and cats are behavioral or other disorders associated with the central nervous system (CNS). Constipation also may occur.

**Technician’s Notes**
1. Reglan is contraindicated if GI obstruction is suspected.
2. Atropine and the opioid analgesics may antagonize the actions of metoclopramide.

**Antihistamines**
Antihistamines are most effective as antiemetics in dogs and cats when vomiting is a result of motion sickness or inner ear abnormalities. Antihistamines block vomiting at the level of the CRTZ. All antihistamines may cause sedation.

**Dosage Forms**
1. Trimethobenzamide HCl (Tigan). Trimethobenzamide is an antiemetic for use in dogs only.
2. Dimenhydrinate (Dramamine). Dimenhydrinate is an antihistamine labeled for treatment of motion sickness in dogs and cats. It is available in tablet, liquid, and injectable forms.
3. Diphenhydramine (Benadryl). Diphenhydramine is used in veterinary medicine as an antiemetic and for the treatment of motion sickness, pruritus, and allergic reactions. It is available in tablet, capsule, oral elixir, and injectable forms.
4. Meclizine (Antivert). Meclizine is used mainly in small animals for the treatment of motion sickness.
5. Promethazine (Phenergan)

**Anticholinergics**
Anticholinergic or parasympatholytic drugs block the effects of acetylcholine at parasympathetic nerve endings. The result is reduced GI spasms, intestinal motility, and intestinal secretions. These drugs act peripherally—except for atropine sulfate and aminopentamide, which have some capacity to cross the blood-brain barrier and block the CRTZ. Many clinicians believe that these drugs have a limited ability to reduce vomiting. Gastric emptying is slowed by anticholinergics, which may actually increase the tendency for vomiting.

**Aminopentamide Hydrogen Sulfate**
Aminopentamide is an anticholinergic, antispasmodic agent for use in dogs and cats.

**Clinical Uses**
These include the treatment of acute abdominal spasm and associated nausea, vomiting, and diarrhea.

**Dosage Forms**
1. Aminopentamide hydrogen sulfate tablets (Centrine), 0.2 mg
2. Aminopentamide hydrogen sulfate injection (Centrine), 0.5 mg/ml, 10-ml vials

**Adverse Side Effects**
These include dry mucous membranes and urinary retention.

**Propantheline**
Propantheline is a quaternary ammonium compound with anticholinergic activity similar to that of atropine.

**Clinical Uses**
The antispasmodic and antisecretory activities of propantheline are useful in the treatment of vomiting and diarrhea.

**Dosage Form**
Propantheline bromide tablets, 7.5 and 15 mg (Pro-Banthine)

**Adverse Side Effects**
These are similar to those of atropine and include dry mucous membranes, tachycardia, urinary retention, and constipation.
Butyrophenones
The butyrophenones are a group of tranquilizers that are capable of blocking the CRTZ and the vomiting center. These drugs are relatively effective antiemetics but are seldom used for this purpose in veterinary medicine. Domperidone has been used in Europe but has seldom been used as an antiemetic in the United States.

Dosage Forms
1. Droperidol/fentanyl (Innovar-Vet)
2. Haloperidol (Haldol)
3. Pimozide (Orap)

Serotonin Receptor Antagonists
Serotonin receptors are found on vagal nerve terminals and in the CRTZ (Plumb, 2005). Blockade of these receptors consists of antiemetic activity.

Dosage Form
Ondansetron (Zofran). Zofran is used mainly as an antiemetic during chemotherapy and is noted for its special effectiveness during this application.

NK-1 Receptor Antagonists
NK-1 antagonists block the binding of substance P (a neurotransmitter involved in vomiting) to NK-1 receptors in the CRTZ.

Clinical Uses
Uses include the prevention and treatment of vomiting in dogs caused by motion sickness or other causes.

Dosage Form
Maropitant citrate (CERENIA) tablets in 16, 24, 60, or 160 mg. Injection in 10 mg/ml.

Adverse Side Effects
Side effects noted in a field study included diarrhea, bloody stool, anorexia, endotoxic shock, and otitis.

Antiulcer Medications

Gastric ulcers may occur in animals for various reasons, including stress, metabolic disease, gastric hyperacidity, and drug therapy (corticosteroids or nonsteroidal antiinflammatory agents) (Hall, 2001). Anorexia, hematemesis, pain, and melena are common signs of gastric ulcer. Most cases of gastric ulceration involve increased gastric acid production and require treatment of the underlying cause and symptomatic therapy. Five classes of drugs are most commonly used to treat gastric ulcers: (1) H₂ receptor antagonists, (2) proton pump inhibitors, (3) antacids, (4) gastromucosal protectants, and (5) prostaglandin E-1 analogs.

H₂ Receptor Antagonists
One of the primary stimuli for secretion of hydrochloric acid by gastric parietal cells is activation of H₂ receptors by histamine. By blocking H₂ receptors, H₂ receptor antagonists reduce the release of hydrochloric acid, thus decreasing irritation of the eroded mucosa and promoting healing (Figure 8-7). H₂ blockers in current use include cimetidine, ranitidine, famotidine, and nizatidine. These are all available as over-the-counter products.

Cimetidine
Cimetidine competitively inhibits histamine at H₂ receptors of gastric parietal cells, thereby reducing hydrochloric acid secretion by these cells. Cimetidine, the least potent of the H₂ receptors, must be given 3 to 4 times daily to be effective (DeNovo, 2002).

![Diagram of H₂ receptor blockade and gastric acid production](image-url)
Clinical Uses
Cimetidine is used for the treatment or prevention of gastric, abomasal, or duodenal ulcers; hypersecretory conditions of the stomach; esophagitis; gastric reflux; and experimentally as an immunomodulator.

Dosage Forms
Products approved for use in humans are also used in animals.
1. Cimetidine tablets (Tagamet), 100, 200, 300, 400, and 800 mg
2. Cimetidine oral solution (Tagamet), 60 mg/ml
3. Cimetidine HCl for injection (Tagamet)

Adverse Side Effects
These are rare in animals; however, cimetidine does inhibit microsomal enzymes in the liver and thus may alter the rate of metabolism of other drugs.

Technician’s Notes
1. Because of its inhibition of liver microsomal enzymes, cimetidine may prolong the effects of drugs that are highly metabolized by the liver (lidocaine, propranolol, metronidazole, diazepam, and others). References should be checked before cimetidine is used in combination with other drugs.
2. If cimetidine is used with antacids, metoclopramide, digoxin, sulfonamide, or ketoconazole, doses should be separated by at least 2 hours.

RANITIDINE
Ranitidine is also an H₂ receptor antagonist that competitively inhibits histamine at parietal cell receptors and reduces hydrochloric acid secretion. Ranitidine has little effect on hepatic microenzymes and is unlikely to cause drug interactions. Ranitidine is the H₂ receptor antagonist that is preferred by many clinicians because of its greater potency (five times that of cimetidine) and duration of action. Ranitidine also has prokinetic activity in that it promotes gastric emptying (DeNovo, 2002).

Clinical Uses
Clinical uses are identical to those of cimetidine.

Dosage Forms
1. Ranitidine HCl tablets (Zantac), 75, 150, and 300 mg
2. Ranitidine HCl oral syrup (Zantac), 15 mg/ml
3. Ranitidine injection (Zantac), 25 mg/ml

Adverse Side Effects
Adverse side effects are rare in animals.

Technician’s Notes
A practical advantage of ranitidine over cimetidine is its reduced frequency of dosing (twice a day rather than three or four times daily).

FAMOTIDINE
Famotidine is an H₂ receptor antagonist that is considerably more potent than cimetidine. It is administered once a day and may have fewer drug interactions than cimetidine or ranitidine.

Clinical Uses
Clinical uses are similar to those of cimetidine and ranitidine.

Dosage Forms
1. Famotidine film-coated tablets (Pepcid or Pepcid AC), 10, 20, and 40 mg
2. Famotidine oral powder (Pepcid)
3. Famotidine injection (Pepcid IV)

Adverse Side Effects
Because of limited use, side effects have not been determined.

NIZATIDINE
Nizatidine is an H₂ receptor antagonist that also has prokinetic activity, similar to ranitidine.

Clinical Uses
Even though nizatidine is an H₂ receptor blocker, it is used primarily in small-animal medicine as a prokinetic agent for the treatment of constipation and delayed gastric emptying (Plumb, 2002).

Dosage Forms
1. Axd tablets
2. Axd capsules
Proton Pump Inhibitors
Omeprazole and lansoprazole are benzimidazoles that act as proton pump inhibitors. These agents bind irreversibly at the secretory surface of the parietal cell to the enzyme Na-K-ATPase. This enzyme is responsible for “pumping” hydrogen ions into the stomach against a concentration gradient. When bound in this way, the enzyme is inactivated and the cell is unable to secrete acid until a new enzyme is synthesized.

Clinical Uses
These agents are used to treat gastric or duodenal ulcer and esophagitis and may be useful in treating parietal hypersecretion associated with gastrinoma and mastocytosis (DeNovo, 2002). Omeprazole has a veterinary-approved label for the treatment and prevention of recurrence of gastric ulcers in horses and foals (Foushee, 2000).

Dosage Forms
1. Omeprazole oral sustained-release capsules
   (Prilosec), 10 and 20 mg
2. Omeprazole (Losec) (Canada)
3. Omeprazole Oral Paste
4. Gastroguard (Equine product)
5. Lansoprazole (Prevacid)

Adverse Side Effects
These include constipation, sedation, ileus, pancreatitis, and CNS effects.

Antacids
Antacids used in veterinary medicine are (relatively) nonabsorbable salts of aluminium, calcium, or magnesium. Antacids are used to decrease hydrochloric acid levels in the stomach as an aid in the treatment of gastric ulcers. In ruminants, antacids such as magnesium hydroxide are used to treat rumen acidosis (rumen overload syndrome) and are used as a laxative. Antacids also may be used in patients with renal failure to bind with (chelate) intestinal phosphorus and reduce hyperphosphatemia.

Clinical Uses
These include treatment of gastric ulcer, gastritis, esophagitis, and hyperphosphatemia in small animals. In ruminants, they are used to treat rumen overload.

Dosage Forms
1. Human label
   a. Aluminum/magnesium hydroxide (Maalox, Mylanta, WinGel)
   b. Aluminum carbonate (Basaljel)
   c. Aluminum hydroxide (Amphojel)
   d. Magnesium hydroxide (milk of magnesia)
2. Veterinary label: magnesium hydroxide
   (Magnalax, Rulax II)

Adverse Side Effects
Adverse side effects in monogastric animals include constipation (with aluminium- and calcium-containing products) and diarrhea (with magnesium-containing products).

Technician’s Notes
1. Generally, do not give oral antacids within 1 to 2 hours of other oral medications because of their ability to decrease the absorption of drugs such as tetracycline, cinemidine, ranitidine, digoxin, captopril, corticosteroids, and ketoconazole.
2. Magnesium-containing antacids are contraindicated in animals with renal disease.

Gastromucosal Protectants
Sucralfate is the only gastromucosal protectant in common use in veterinary medicine. This drug is a disaccharide that, when administered orally, forms a paste-like substance in the stomach that binds to the surfaces of gastric ulcers. This paste-like material forms a barrier over the ulcer to protect it from further damage and to promote healing. Because sucralfate binds better to ulcers in an acidic environment, it should be administered 30 minutes to 1 hour before H₂ receptor antagonists are given. It also may reduce the availability of some other drugs.

Clinical Uses
Sucralfate is used in the treatment of oral, esophageal, gastric, and duodenal ulcers.

Dosage Form
Sucralfate (Carafate), 1-g tablets
Adverse Side Effects
These usually are limited to constipation. However, drug interactions may be notable.

Technician’s Notes
1. Sucralfate should be given 2 hours before cimetidine, tetracycline, phenytoin, fluoroquinolones, or digoxin is administered.
2. Sucralfate should be given a half hour before H₂ receptor antagonists or antacids are given because it requires an acid environment to be effective.

Prostaglandin E-1 Analogs
Misoprostol is a prostaglandin E-1 analog that directly inhibits the parietal cell from secreting hydrogen ions into the stomach. It also protects the gastric mucosa by increasing the production of mucus and bicarbonate.

Clinical Uses
Prostaglandin E-1 analogs are used primarily to prevent or treat gastric ulcers associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs).

Dosage Form
Misoprostol oral tablets (Cytotec), 100 and 200g

Adverse Side Effects
Side effects include diarrhea, vomiting, flatulence, and abdominal pain.

Technician’s Notes
Misoprostol causes abortion and should not be used in pregnant animals.

DIARRHEA

Diarrhea is the passage of loose or liquid stools, often with increased frequency. Diarrhea can result from primary disease of the intestinal tract or may accompany non-GI disease. Explanation of the pathophysiology of diarrhea is beyond the scope of this text. However, categories of mechanisms described in veterinary references include hypersecretion, increased permeability, osmotic overload, and altered intestinal motility. Parasitism is a common cause of diarrhea in all domestic animal species; it results in diarrhea through a combination of previously described mechanisms. Parasitism always should be ruled out when a diagnosis is determined.

Increased secretion of fluid from the intestine may result from the actions of bacterial endotoxins from microorganisms such as Escherichia coli, Clostridium perfringens, Clostridium difficile, Campylobacter jejuni, and Helicobacter. Intestinal epithelium damaged by viruses or other organisms may lose fluid as the result of increased permeability. Osmotic overload may occur because of poorly digestible foods, a rapid change in diet, or malabsorption. Although diarrhea has often been associated with hypomotility of the GI tract, the current belief is that most patients with diarrhea actually have hypermotility.

Decreased segmental contractions (hypomotility) increase the diameter of the lumen and allow rapid passage of contents, resulting in diarrhea. Normal segmental constrictions narrow the diameter of the intestinal lumen and actually slow the passage of contents. Diarrhea, if not controlled, can result in substantial fluid and electrolyte (sodium, chloride, potassium, and bicarbonate) losses. Dehydration, acidosis, weakness, and anorexia may follow.

Acute diarrhea, similar to acute vomiting, in dogs and cats often responds to dietary management and conservative treatment. In cases that do not respond to conservative management, symptomatic and specific treatments are essential. A discussion of the medications used in the treatment of diarrhea follows.

Antidiarrheal Medications

Narcotic Analgesics
Narcotic analgesics (opiates) are effective agents in the control of diarrhea because of their ability to (1) increase segmental contractions, (2) decrease intestinal secretions, and (3) enhance intestinal absorption. Many clinicians consider opiates to be the drugs of choice for the control of diarrhea in dogs. They also are used for the treatment of
diarrhea in calves, but their use in cats and horses is controversial because of their tendency to cause CNS stimulation. Narcotic agents are sometimes prepared as combination products with other classes of antidiarrheals.

**Clinical Uses**
The opiates are used in GI therapy for the control of diarrhea.

**Dosage Forms**
1. Diphenoxylate (Lomotil). Diphenoxylate is a synthetic narcotic agent (Class V) that is structurally similar to meperidine. Atropine sulfate is added to commercial preparations to discourage substance abuse.
2. Loperamide (Imodium). Loperamide is a synthetic narcotic that is available in a nonprescription preparation. Loperamide poorly penetrates the CNS in cats and is acceptable in this species (Willard, 1998).
3. Paregoric/kaolin/pectin (Parepectolin)
4. Opium/kaolin/pectin/anticholinergics (Donnagel)

**Adverse Side Effects**
Adverse side effects of all the opiates include constipation, ileus, sedation, and CNS excitement (cats and horses).

**Anticholinergics/Antispasmodics**
Anticholinergics and antispasmodics have been widely used in veterinary medicine for the treatment of diarrhea. Because hypomotility rather than hypermotility is now considered to be associated with most cases of diarrhea, anticholinergics and antispasmodics should be used with caution for the treatment of diarrhea. A few commercial antidiarrheal preparations contain an anticholinergic plus a CNS depressant.

**Clinical Uses**
Anticholinergics/antispasmodics are used for the treatment of diarrhea.

**Dosage Forms**
1. Aminopentamide (Centrine)
2. Methscopolamine (Pamine)
3. Hyoscyamine (Levsin)
4. Propantheline (Pro-Banthine)
5. Clidinium/chlordiazepoxide (Librax)
6. Hyoscyamine/phenobarbital (Donnagel)

**Adverse Side Effects**
Adverse side effects are addressed in the section on antiemetics.

**Protectants/Adsorbents**
Products in this category may have protectant or adsorbent qualities in the GI tract. The coating action of these drugs protects inflamed mucosa from further irritation. Their adsorbent activity binds bacteria or their toxins to protect against the harmful effects of these organisms. Kaolin and pectin are two ingredients often used in protectant compounds. The ability of protectants to control diarrhea has been questioned by some clinicians.

Bismuth subsalicylate is a compound found in products such as Corrective Suspension and Pepto-Bismol. Bismuth subsalicylate is converted to bismuth carbonate and salicylate in the small intestine. The bismuth has a coating and antibacterial effect, and the salicylate (an aspirin-like compound) has an antiinflammatory effect and reduces secretion by inhibiting prostaglandins (Boothe, 2001).

Activated charcoal is an adsorbent that is used primarily to treat poisoning.

**Clinical Uses**
These agents are used to control diarrhea and act as an adsorbent.

**Dosage Forms**
1. Bismuth subsalicylate
   a. Corrective Mixture (veterinary approved)
   b. Pepto-Bismol (human label)
2. Kaolin/pectin
   a. Kaopectolin
   b. Kao-Forte
   c. K-Pek
3. Activated charcoal
   a. Toxiban Suspension and Granules
   b. SuperChar-Vet Powder and Liquid
4. DL-Tri-Octahedral Smectite
   a. Bio-Sponge
Adverse Side Effects
Adverse side effects are rare and usually are limited to constipation.

Technician's Notes
1. Bismuth subsalicylate compounds should be used with caution in cats because of the conversion to aspirin.
2. Bismuth may appear opaque on radiographs.
3. Administration of bismuth subsalicylate can result in black stools that resemble melena.

Laxatives
Laxatives are substances that loosen bowel contents and encourage their evacuation. Laxatives with a strong or harsh effect are called cathartics, or purgatives. Categories of laxatives include saline/hyperosmotic agents, bulk-producing agents, lubricants, surfactants/stool softeners, irritants, and miscellaneous agents.

Saline/Hyperosmotic Agents
Saline or hyperosmotic laxatives contain magnesium or phosphate anions that are very poorly absorbed from the GI tract. It generally is believed that these anions hold water in the tract osmotically. Increased water in the GI tract then softens the stool and stimulates stretch receptors in the gut wall to enhance peristalsis.

Clinical Uses
These agents are used for the relief of constipation.

Dosage Forms
Dosage forms include suspensions, crystals, powders, and boluses.

1. Lactulose (Cephulac, Constulose, or Enulose).
   Lactulose also reduces blood ammonia levels in some hepatic diseases.
2. Magnesium hydroxide
   a. Milk of magnesia is a suspension for use in dogs and cats.
   b. Carmilax Powder and Bolets is for use in cattle (laxative/antacid).
   c. Magnalax Bolus and Powder is for use in cattle.
   d. Poly Ox II Bolus is for use in cattle.
3. Magnesium sulfate
   a. Epsom Salts has been used in horses and birds.
4. Sodium phosphate salts
   a. Fleet Enema is for use in dogs and foals.
   b. Gent-L-Tip Enema is for dog and foal use.

Adverse Side Effects
These are rare but may include cramping or nausea. Overdose or overuse may result in hyperphosphatemia or hypocalcemia. Cats are especially susceptible to these electrolyte imbalances.

Technician's Notes
Phosphate enemas should not be used in cats because cats are especially sensitive to electrolyte imbalances that may occur.

Bulk-Producing Agents
Bulk-producing agents are often indigestible plant materials (cellulose or hemicellulose) that act by absorbing water and swelling to increase the bulk of intestinal contents, thereby stimulating peristalsis.

Clinical Uses
Bulk-producing agents are used for relief of constipation and for relief of some types of impaction (sand primarily) in horses.

Dosage Forms
Dosage forms primarily consist of psyllium preparations. Psyllium is obtained from the ripe seed of a species of Plantago (Plumb, 2005).

1. Metamucil
2. Equine Psyllium
3. Equi-Phar Sweet Psyllium
4. Equine Laxative
5. Bran—a bulk-producing agent often used in horses (bran mash)
Adverse Side Effects
Adverse side effects are rare.

Lubricants
Lubricants are typically oils or other hydrocarbon derivatives (petrolatum) that soften the fecal mass and make it easier to move through the GI tract.

Clinical Uses
These include treatment of constipation and fecal impaction.

Dosage Forms
Dosage forms include liquids (mineral oil) and a jelly-like mass (petrolatum).

1. Mineral oil. Mineral oil is used in horses for the treatment of constipation, colic, and impaction. This substance is also used as a laxative in other species. Heavy mineral oil is preferred over light mineral oil.
2. Petrolatum. This is a jelly-like mass that is insoluble in water and is only slightly soluble in alcohol. Petrolatum is the principal ingredient in many of the oral laxatives for hairball treatment in cats.
   a. Laxatone
   b. Felaxin
   c. Kat-A-Lax

Adverse Side Effects
These are minimal when used appropriately.

Clinical Uses
Clinical uses include the treatment of hard, dry feces in small animals; impaction in horses; and occasionally digestive upset in cattle.

Dosage Forms
These products are available in liquid, syrup, capsule, tablet, and enema forms. Docusate sodium, also called dioctyl sodium sulfosuccinate, is the main ingredient.

1. Docusate Sodium (Colase)
2. Docusate Calcium (Surfak)
3. Disposable Enema

Adverse Side Effects
Adverse side effects are rare.

Technician’s Notes
Docusate sodium given with mineral oil may result in some absorption of mineral oil.

Irritants
Irritants act by irritating the gut wall, causing stimulation of GI smooth muscle and increased peristalsis. These drugs are seldom used in veterinary medicine. This category includes several agents that are sometimes used in the treatment of constipation in humans.

1. Bisacodyl (Dulcolax)
2. Castor oil
3. Emodin

Gastrointestinal Prokinetics/Stimulants
Prokinetic/stimulant drugs increase the motility of a part or parts of the gastrointestinal tract and by doing this enhance the transit of material through the tract. Several classes of drugs, including dopaminergic antagonists, serotonergic drugs, motilin-like drugs, direct cholinergics, and acetylcholinesterase
inhibitors, have the ability to enhance gastrointestinal motility. As was previously noted, some H₂ receptor antagonists exhibit prokinetic activity (see ranitidine earlier).

**Dopaminergic Antagonists**

Dopaminergic antagonists used as prokinetics in veterinary medicine include metoclopramide and domperidone (Hall and Washabau, 1997). These agents stimulate motility of the gastroesophageal sphincter, stomach, and small intestine. Domperidone has had limited use as a prokinetic in the United States but is approved in Europe for the treatment of nausea, vomiting, and gastric reflux in humans (Parker, 2001).

**Clinical Uses**

Metoclopramide is used to treat gastroesophageal reflux and delayed gastric emptying, to stimulate the gastrointestinal tract in foals, and for gastrointestinal motility disorders in dogs and cats. Metoclopramide has been shown to enhance gastric emptying. The use of metoclopramide as an antiemetic is discussed in a previous section.

**Dosage Forms**

1. Metoclopramide (Reglan) tablets, syrup, and injection
2. Domperidone (Motilium, Equidone). Domperidone may have use in regulating gastrointestinal motility in horses, cats, and dogs.

**Adverse Side Effects**

Side effects include behavioral changes in dogs, cats, and adult horses. Cats have shown frenzied behavior (Plumb, 2005), and adult horses have exhibited alternating periods of sedation and excitement.

**Serotonergic Drugs**

Cisapride is the serotonergic prokinetic that is used frequently in veterinary medicine. Cisapride stimulates motility of the proximal and distal gastrointestinal tract, including the gastroesophageal sphincter, stomach, small intestine, and colon (Boothe, 2001). Cisapride is not effective as an antiemetic but may be better than metoclopramide in treating some motility disorders and in promoting gastric emptying of solid material. Cisapride is not currently commercially available. However, compounding pharmacies may be able to make the product available.

**Clinical Uses**

Uses include the treatment of constipation (along with dietary and/or surgical considerations) in cats and gastroesophageal reflux and gastrointestinal stasis in dogs, cats, and horses.

**Dosage Form**

Cisapride (Propulsid), 10- and 20-mg tablets or 1-mg/ml suspension

**Adverse Side Effects**

Side effects may include diarrhea and abdominal pain.

**Motilin-like Drugs**

Erythromycin has been used by veterinarians to treat bacterial and mycoplasmal infections for many years. This drug has been shown to stimulate gastrointestinal motility by mimicking the effect of the hormone motilin (Hall and Washabau, 2000). Erythromycin stimulates motility in the esophageal sphincter, stomach, and small intestine at microbiologically ineffective doses.

**Clinical Uses**

Uses may include increasing lower esophageal sphincter pressure, accelerating gastric emptying, and facilitating intestinal transit time.

**Dosage Form**

Erythromycin (Erythro)

**Adverse Side Effects**

Side effects may include anorexia, vomiting, diarrhea, and abdominal pain.

**Direct Cholinergics**

**Clinical Uses**

These include postoperative treatment of ileus—or retention of flatus or feces—and equine colic (without obstruction).
Dosage Forms
1. Veterinary approved: dextenan (d-Panthenol Injectable, d-Panthenol Injection)
2. Human approved: dextenan (llopan injection)

Adverse Side Effects
Adverse side effects are rare but may include cramping and diarrhea.

Technician’s Notes
Dextenan should not be used within 12 hours of the use of neostigmine, parasympathomimetic agents, or succinylcholine.

Acetylcholinesterase Inhibitors
These drugs increase the amount of acetylcholine available to bind smooth muscle receptors.

Clinical Uses
These agents are used to treat rumen atony, to enhance gastric emptying (ranitidine), to stimulate peristalsis, to empty the bladder of large animals, and to aid in the diagnosis of myasthenia gravis (neostigmine) in dogs. They also may be used to treat curare overdose.

Dosage Forms
1. Neostigmine methylsulfate (Stiglyn injection)
2. Ranitidine (Zantac)

Adverse Side Effects
Adverse side effects are cholinergic and may include nausea, vomiting, diarrhea, drooling, sweating, lacrimation, bradycardia, and various others.

Technician’s Notes
Ranitidine and nizatidine, H₂ receptor antagonists, increase acetylcholine by inhibiting acetylcholinesterase. The increase in acetylcholine stimulates smooth muscle in the stomach and promotes gastric emptying to reduce vomiting in patients with gastritis and related disorders.

Digestive Enzymes
Pancrelipase is a product that contains pancreatic enzymes that aid in the digestion of fats, proteins, and carbohydrates. The powder that contains the enzymes is mixed with the animal’s food, which is allowed to stand for 15 to 20 minutes before feeding.

Clinical Uses
This product is used to treat pancreatic exocrine insufficiency.

Dosage Form
Pancrelipase (Vioke-V powder, Pancrezyme powder). Both are approved for use in dogs and cats.

Adverse Side Effects
Adverse side effects of high doses include cramping, nausea, and diarrhea.

Technician’s Notes
1. Powder spilled onto the skin should be washed off to prevent irritation.
2. Inhaled powder can cause nasal irritation or can precipitate an asthma attack.

Miscellaneous Gastrointestinal Drugs
Drugs discussed in this section include antibiotics, antiinflammatory agents, and antifoaming agents.

Antibiotics
Antibiotics are not routinely used in the treatment of GI tract disease in small animals because these agents may destroy normal inhabitants of the GI tract and allow pathogenic bacteria (Salmonella species, C. jejuni, C. perfringens, C. difficile, Helicobacter, and others) to grow on the mucosal surface. Bloody diarrhea or signs of sepsis may indicate the need for antibiotic therapy. Antibiotics that are often used for treating bacterial overgrowth and other GI conditions include metronidazole, amoxicillin, clavamox, and tylosin.
Chapter 8 Drugs Used in Gastrointestinal System Disorders

METRONIDAZOLE
Metronidazole is a synthetic antibacterial and anti-protozoal agent.

Clinical Uses
1. Treatment of giardiasis, trichomoniasis, balanitis, trichomoniasis, balanitis, plasmacytic/lymphocytic enteritis, ulcerative colitis, hepatic encephalopathy, and anaerobic infection in dogs
2. Treatment of giardiasis and anaerobic infection in cats
3. Treatment of anaerobic infection in horses

Dosage Form
Metronidazole (Flagyl tablets, Flagyl IV powder for reconstitution, and Flagyl IV RTU injection)

Adverse Side Effects
These include anorexia, hepatotoxicity, neutropenia, vomiting, and diarrhea.

Technician's Notes
1. Metronidazole should not be given to debilitated, pregnant, or nursing animals.
2. Tylosin is a macrolide antibiotic that is sometimes used to treat chronic colitis in animals.

Antiinflammatory Agents
Antiinflammatory agents are used in the treatment of idiopathic inflammatory bowel disease in animals. Increased numbers of lymphocytes, macrophages, plasma cells, or eosinophils in the intestinal wall characterize these diseases. Treatment often involves the use of hypoallergenic diets and antiinflammatory agents.

Dosage Forms
Antiinflammatory agents used in the treatment of inflammatory bowel disease include prednisone, azathioprine, sulfasalazine, and olsalazine.

1. Prednisone—Many generic and trade name products are available.
2. Azathioprine (Imuran)—A purine antagonist antimetabolite that may be used in the treatment of inflammatory bowel disease because of its immunosuppressive effects.
3. Sulfasalazine (Azulfidine)—A drug that is converted by intestinal bacteria to a sulfa drug (sulfapyridine) and aspirin (salicylic acid). Aspirin is the active component that has an antiinflammatory effect and is useful in many cases of colitis in dogs and cats. It should be used with care in cats because of their poor ability to metabolize aspirin.
4. Olsalazine (Dipentum)—Olsalazine is used for the treatment of dogs with chronic colitis that cannot tolerate sulfasalazine or respond poorly to the product.

Antifoaming Agents
Antifoaming agents are used to treat frothy bloat in ruminants. In this condition, gas bubbles form and become trapped in the rumen fluid as a result of consumption of wheat pasture or legumes, such as alfalfa or clover. The trapped bubbles cause a form of bloat that cannot be relieved by usual means.

Antifoaming agents act as surfactants (reduce surface tension) and cause bubbles to break down so that gas can be relieved by eructation or by the stomach tube. These products are given orally.

Clinical Uses
Antifoaming agents are used for the treatment of frothy bloat in ruminants.

Dosage Forms
1. Bloat Guard
2. Bloat Treatment
3. Bloat-Pac
4. Therabloat

Adverse Side Effects
These are rare if the products are given as directed.

Weight-Loss Products
DIRLOTOAPIDE
Dirlotapide is a selective microsomal triglyceride transfer protein inhibitor that blocks the assembly and release of lipoprotein particles into the bloodstream in dogs.
Clinical Uses
Dirlotapide is indicated for the management of obesity in dogs.

Dosage Form
SELENTROL solution containing 5 mg/ml for oral administration.

Adverse Side Effects
Side effects include vomiting, diarrhea, lethargy, anorexia, constipation, and dehydration.

Probiotics
Probiotics are substances that competitively inhibit enteropathogens. They are used to treat diarrhea, inflammatory bowel disease, and food allergy, as well as for long-term antibiotic use. Controversy regarding the effectiveness of these substances is ongoing.

Dosage Forms
1. FortiFlora
2. Culturelle
3. G.I. Conditioner
4. Propanion
5. Prolacis Paste
6. T.D.N. Mini Rockets
7. T.D.N. Rockets
8. Advance Power Freshen
9. Others

Appetite Stimulants
Stimulating an animal to eat can be an important component of a therapy regimen. Proper nutrition is essential for optimal functioning of the immune system as well as for proper organ function. Cats who do not eat adequately for a period of time may develop a “fatty liver” syndrome that can be life threatening. The following is a partial list of appetite stimulants:

1. Diazepam—Medication that produces a transient appetite stimulation when given intravenously
2. Alprazolam—Medication given orally as an appetite stimulant in cats
3. Cyproheptadine—Antihistamine used as an appetite stimulant primarily in cats

Oral Products
An increased emphasis on dentistry in veterinary practice in recent years has fueled a demand for products that promote and maintain oral health. Many of these products help to remove food particles and plaque and assist in the maintenance of pleasant-smelling breath. Some are labeled as a dentifrice, and others may be applied as an oral rinse or with a toothbrush. They are prepared as solutions, gels, and premoistened gauze sponges. Various flavors are available, as are products with fluoride. These products should not be considered a substitute for veterinary dental treatment.

Other oral products include grit impregnated in paste for polishing teeth and smoothing rough surfaces left by scaling, as well as disclosing solution used to help identify plaque.

Dentifrice and Cleansing Products
1. C.E.T. Enzymatic Toothpaste.
2. Novaldent oral cleansing solution. Chlorhexidine acetate is the active ingredient; also contains a peppermint flavor; may be used with a toothbrush or as a rinse
3. OraVet Plaque Prevention Gel
4. OraVet Barrier Sealant
5. C.E.T. Oral Hygiene Rinse
6. C.E.T. HEXtra Premium Chews for Dogs
7. Friskies ChewEEz Beefhide treats
8. C.E.T. Oral Hygiene Chews for Cats
9. Hills t/d Diets
10. Hartz Flavor Infused Oral Chews
11. Friskies Feline Dental Diet
12. C.E.T. Dental Reward
13. Royal Canin Veterinary Diet
14. Purina Veterinary Diets DH
15. CHX Guard

Fluoride Products
1. SF04 Stannous Fluoride Gel
2. Fluorofom
3. C.E.T. Oral Hygiene Spray with Fluoride
**Perioceutic Agents**

**Doxirobe**

Doxirobe is placed in the periodontal pocket after dental cleansing with the use of a cannula. Upon contact with the aqueous environment, the product coagulates and releases doxycycline for several weeks.

**Bioactive Ceramic Agent**

Consil Dental is a substance used to promote the regeneration of bone lost as the result of periodontal disease or tooth extraction.

**Polishing Paste**

C.E.T. prophypaste

Human Products

**Disclosing Solution**

Duo 128 Disclosing Solution

**REFERENCES**


1. List three general functions of the GI tract.

2. List three examples of monogastric animals.

3. What is the GI configuration of ruminant animals?

4. What is the difference between vomiting and regurgitation?

5. Ruminants are animals that use _____________ to digest coarse plant material.

6. What are the three basic control mechanisms of the GI tract?

7. What is the significance of the presence of bacterial endotoxins in the GI tract?

8. The CRTZ stimulates vomiting when activated by _____________.

9. List two examples of centrally acting emetics and two examples of peripherally acting emetics.

10. Drugs that inhibit vomiting are called _____________.

11. H₂ receptor antagonists promote the healing of GI ulcers by _____________.

12. List two H₂ receptor antagonists.

13. What are the two types of intestinal motility patterns?

14. Acute vomiting and diarrhea in dogs and cats often respond to conservative management such as _____________.

15. List two species that do not vomit.

16. What is the mechanism of action of saline/hyperosmotic laxatives?

17. What is the active ingredient of Metamucil?

18. Direct cholinergic drugs stimulate the GI tract by what mechanism?

19. A synthetic antibiotic/antiinflammatory agent used to treat giardiasis and anaerobic bacterial infection in animals is called

20. List four products used as dentifrice/oral cleansing agents.

21. What is the difference between peristalsis and segmentation?

22. Stimulation of the parasympathetic portion of the ANS decreases intestinal motility.

a. True
b. False

23. About what percent of the stomach’s contents do emetics usually remove?

24. How does sucralfate work to treat/prevent gastric ulcers?

25. Bismuth subsalicylate compounds should be used with caution in what species?

26. All the following are basic functions of the GI system, except ________.

   a. intake of food and fluid into the body
   b. absorption of nutrients and fluid
   c. excretion of waste products
   d. excretion of urine

27. Which of the following species has no gall-bladder?

   a. canines
   b. equines
   c. felines
   d. ovines
28. Ruminants remasticate food to facilitate the digestion process.
   a. True
   b. False

29. The crop in birds is used for _______.
   a. a stomach
   b. food storage
   c. feces storage
   d. a place where food goes to mix with hydrochloric acid to aid in the breakdown of foodstuffs

30. All of the following are parts of the small intestine, except the _________.
   a. ilium
   b. duodenum
   c. jejunum
   d. ileum

31. ________ is an emetic.
   a. Tigan
   b. Meclizine
   c. Promethazine
   d. Apomorphine

32. Cimetidine is _________.
   a. a proton pump inhibitor
   b. an antacid
   c. a gastromucosal protectant
   d. an H₂ receptor antagonist

33. ________ are substances that loosen bowel contents and encourage their evacuation.
   a. Protectants
   b. Adsorbents
   c. Antispasmodics
   d. Laxatives

34. Mg sulfate is found in _________.
   a. Magnalax boluses
   b. Fleet Enemas
   c. Epsom Salts
   d. milk of magnesia

35. Viokase-V powder is _________.
   a. an anticholinergic substance
   b. a digestive enzyme
   c. approved for use in dogs and cats
   d. both b and c
CHAPTER 9

Drugs Used in Hormonal, Endocrine, and Reproductive Disorders

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Discuss the control mechanisms (physiology) of the endocrine system.
2. List the endocrine glands.
3. List the reasons why hormones are clinically used.
4. Describe the difference between an endogenous and an exogenous hormone.
5. Describe the location and functions of the pituitary gland.
6. Differentiate between a positive and a negative feedback control mechanism.
7. Describe a neurohormonal reflex.
8. Discuss the uses and classes of gonadotropins, gonadal hormones, progestins, and prostaglandins used in veterinary medicine.
9. Describe the uses and classes of drugs that affect uterine contractility.
10. Define pheromone and give an example.
11. Describe the location, function, and hormonal products of the thyroid gland.
12. Describe the hormonal treatment of hypothyroidism and hyperthyroidism.
13. List the endogenous source of insulin and its metabolic effects.
14. List the classes of insulin products and their general characteristics.
15. Describe the method of action of the growth promoters.
16. List the clinical uses for the anabolic steroids.
INTRODUCTION

The traditional definition of the endocrine system states that it is composed of organs (glands) or groups of cells that secrete regulatory substances (hormones) directly into the bloodstream. This definition has now been extended to include regulatory substances that are distributed by diffusion across cell membranes.

The endocrine system and the nervous system constitute the two major control mechanisms of the body. These two control mechanisms are linked together through the complex integrating action of the hypothalamus (Figure 9-1). Coordination of these two systems allows an individual to adapt its reproductive and survival strategies to changes in the environment.

Endocrine glands include the pituitary, adrenals, thyroid, ovaries, testicles, pancreas, and kidneys. These glands produce hormones that are carried to target organs, where they influence the physiologic activity of these structures.

Hormones generally are administered to animals for one of two reasons: (1) to correct a deficiency of that hormone, or (2) to obtain a desired effect (e.g., to postpone estrus). Hormones that are administered to an animal are called exogenous hormones, whereas those produced naturally in the body are endogenous hormones.

ANATOMY AND PHYSIOLOGY

Pituitary Gland

The pituitary gland has been called the master gland of the endocrine system because of the control it exerts over the regulation of this system. It is located at the base of the brain just ventral to the hypothalamus and is connected to the brain by a stalk. It is divided into two main lobes—an anterior lobe (adenohypophysis), which arises from the embryologic pharynx, and a posterior
lobe (neurohypophysis), which arises from the brain (Figure 9-2).

The hypothalamus exerts control over the anterior pituitary through the transport of releasing hormones, or factors, down the hypophyseal portal system. In the anterior pituitary, these releasing factors cause the secretion of trophic hormones into the circulation. Trophic hormones produced by the anterior pituitary include thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin (LTH), and growth hormone (GH or somatotropin). These trophic hormones are sometimes called indirect-acting hormones because they cause their target organ to produce a second hormone, which in turn influences a second target organ or tissue (Table 9-1). For example, TSH stimulates
Table 9-1 Pituitary Hormones

<table>
<thead>
<tr>
<th>Source and Name</th>
<th>Target and Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anterior Lobe</strong></td>
<td></td>
</tr>
<tr>
<td>Thyroid-stimulating hormone (TSH)</td>
<td>Stimulates the thyroid to produce T&lt;sub&gt;3&lt;/sub&gt;/T&lt;sub&gt;4&lt;/sub&gt;</td>
</tr>
<tr>
<td>Follicle-stimulating (FSH)</td>
<td>Stimulates ovarian follicle growth (female) and spermatogenesis (male)</td>
</tr>
<tr>
<td>Luteinizing hormone (LH)</td>
<td>Stimulates ovulation (female) and testosterone production (male)</td>
</tr>
<tr>
<td>Growth hormone (somatotropin)</td>
<td>Accelerates body growth and increases milk production</td>
</tr>
<tr>
<td>Adrenocorticotropic hormone (ACTH)</td>
<td>Stimulates production of corticosteroids by adrenal cortex</td>
</tr>
<tr>
<td><strong>Posterior Lobe</strong></td>
<td></td>
</tr>
<tr>
<td>Oxytocin</td>
<td>Stimulates uterine contraction and milk letdown</td>
</tr>
<tr>
<td>Vasopressin (antidiuretic hormone, ADH)</td>
<td>Stimulates water retention</td>
</tr>
</tbody>
</table>

the thyroid gland to produce triiodothyronine (T<sub>3</sub>) and tetraiodothyronine (T<sub>4</sub>), which are hormones that in turn influence the metabolic rate of all tissues in the body.

The two hormones of the posterior pituitary are vasopressin (antidiuretic hormone) and oxytocin. These hormones are produced in the hypothalamus and subsequently travel down nerve fibers to the posterior pituitary, where they are stored for release into the circulation. The hormones of the posterior pituitary are called direct-acting hormones because they produce the desired activity (e.g., contraction of the uterus) directly in the target organ.

**Control of the Endocrine System**

**FEEDBACK MECHANISM**

The nervous system is sensitive to levels of hormones through a mechanism called the feedback mechanism. By this mechanism, the plasma level of a particular hormone controls the activity of the gland that produces it. The feedback may be negative or positive (Figure 9-3).

With negative feedback, high plasma levels of a hormone are sensed by the hypothalamus, which then reduces the amount of the appropriate releasing factor (or hormone). A decreased amount of releasing factor reduces the amount of trophic hormone released from the pituitary, causing less activity in the organ that is producing the hormone in question. The overall effect is to lower the amount of the hormone in the plasma.

![Feedback control mechanisms](image)

**FIGURE 9-3** Feedback control mechanisms. Positive and negative feedback mechanisms control the quantity of a particular hormone.

In the positive feedback scheme, low levels of a hormone are sensed by the hypothalamus, and release of the appropriate releasing factor increases. Increased amounts of the corresponding trophic hormone are then secreted, causing increased
activity in the target organ and a corresponding rise in the plasma levels of the hormone.

**NEUROHORMONAL REFLEX**
The neurohormonal reflex applies to the release of oxytocin by the posterior pituitary. The first step in this reflex can be initiated by (1) stimulation of the udder by a nursing calf or by preparation of the udder for milking, (2) stimulation of the uterus and vagina in parturition, or (3) stimulation of the cerebral cortex by sensory stimuli associated with nursing or milking.

**CONTROL OF THE REPRODUCTIVE SYSTEM**
The reproductive (estrus) cycle in animals traditionally has been divided into four stages called proestrus, estrus, diestrus, and anestrus. The cycle also may be divided into a follicular phase and a luteal phase. In the follicular phase, the cycle is under the influence of estrogen produced by a developing follicle, and in the luteal phase, it is under the influence of progesterone made by the corpus luteum.

Control of the reproductive system is coordinated in the hypothalamus, where the gonadotropin-releasing hormone (GnRH) is produced in response to various stimuli (Figure 9-4). These stimuli can include day-night length (photoperiod), pheromones, and positive and negative internal feedback mechanisms. GnRH causes the release of FSH and LH from the anterior pituitary.

FSH causes the growth and maturation of a follicle, which begins to produce increasing amounts of estrogen as it matures. Estrogen causes the changes that occur in proestrus and estrus, including the behavioral characteristics associated with estrus (e.g., standing to be mounted). The follicle also produces inhibin, which—along with estrogen—serves as negative feedback to the hypothalamus to inhibit the release of GnRH.

![Figure 9-4](image)
Control of the reproductive system is achieved primarily through feedback mechanisms and the photoperiod. FSH, Follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone.
LH release causes ovulation of the mature follicle and the formation of a corpus luteum in its place. This event signals the beginning of diestrus and the beginning of the luteal phase of the cycle. The corpus luteum produces progesterone, which prepares the uterus for pregnancy. Once pregnancy occurs, the corpus luteum maintains a uterine environment conducive to normal progression of the pregnancy. Progesterone levels in the blood serve as negative feedback to prevent the release of GnRH and the development of new follicles during pregnancy.

When the gestation period nears its end, the fetus begins to produce increasing amounts of ACTH. ACTH causes increased amounts of cortisol to be produced by the adrenal glands. The increased cortisol levels result in increased production of estrogen and prostaglandin by the uterus. These two substances sensitize the uterus to the contraction-producing effects of oxytocin and allow parturition to begin. Prostaglandin also causes the breakdown (lysis) of the corpus luteum at the end of pregnancy and at the end of diestrus if pregnancy does not occur.

**HORMONAL DRUGS ASSOCIATED WITH REPRODUCTION**

**Gonadotropins and Gonadal Hormones**

Products in this category are used in veterinary medicine for various reasons. Some of these include synchronization of estrus, suppression of estrus, induction of estrus, treatment of cystic ovaries, and termination of pregnancy.

**Gonadotropins**

Gonadotropins are drugs that act similarly to GnRH, LH, or FSH. Gonadotropins cause the release of LH and FSH or cause activity like that of LH or FSH. LH may be prepared from the pituitary glands of slaughtered animals or obtained from the urine of pregnant women in the form of human chorionic gonadotropin (hCG). FSH may be obtained from pituitary glands (FSH-P) and from the serum of pregnant mares (PMS) between the 40th and 140th days of pregnancy. GnRH is prepared synthetically.

FSH that is released endogenously by the anterior pituitary causes growth and maturation of the ovarian follicle in females and spermatogenesis in males. LH, also released by the anterior pituitary, causes ovulation in females and production of testosterone in males.

**Gonadorelin**

Gonadorelin (GnRH) is produced endogenously by the hypothalamus. Gonadorelin causes the release of FSH and LH by the anterior pituitary.

**Clinical Uses**

Gonadorelin is used to treat cystic (follicular) ovaries in dairy cattle. It has also been used in cats and horses (with limited success) to induce estrus.

**Dosage Forms**

1. Cystorelin. Gonadorelin for injection
2. Factrel. Gonadorelin for injection
3. Fertagyl. Gonadorelin for injection

**Adverse Side Effects**

These are minimal with the use of this product.

**Chorionic Gonadotropin**

Chorionic gonadotropin (hCG) is a hormone secreted by the uterus and obtained from the urine of pregnant women. It mimics the effects of LH, although it has limited FSH activity. In males, it stimulates the production of male hormones by the testicles and may facilitate descent of the testicles.

**Clinical Uses**

Chorionic gonadotropin is used to treat cystic ovaries (nymphomania) in dairy cattle. In males, it has been used to treat cryptorchidism and infertility caused by low testosterone levels.

**Dosage Forms**

1. Follurein. hCG injection
2. PG. 600. Combination of hCG and PMS; contains both LH and FSH activity
3. Chorulon. hCG injection
4. Chorionic gonadotropin injection (generic)
5. APL, Human label

**Adverse Side Effects**
These are limited but may include hypersensitivity reaction and abortion in mares if given before the 35th day of pregnancy.

**Follicle-Stimulating Hormone—Pituitary**
FSH-P is obtained from the pituitary glands of slaughtered animals. FSH causes growth and maturation of the ovarian follicle.

**Clinical Uses**
FSH-P is used in veterinary medicine to induce superovulation and for out-of-season breeding.

**Dosage Form**
FSH-P

**Adverse Side Effects**
These include endometrial hyperplasia, superovulation, and follicular cysts.

**Estrogens**
Estrogens are a group of hormones synthesized by the ovaries and—to a lesser extent—by the testicles, adrenal cortex, and placenta. Estrogens are classified as sex steroids and are synthesized from a cholesterol precursor. Estrogens are necessary for normal growth and development of the female gonads. They cause secondary female characteristics and are responsible for female sex drive. These hormones inhibit ovulation, increase uterine tone, and cause proliferation of the endometrium.

**Clinical Uses**
In cattle, estrogens are used to treat persistent corpus luteum, to expel purulent material from the uterus, to expel retained placentas and mummified fetuses, and to promote weight gain. In dogs, estrogens are used to induce abortion and to control urinary incontinence. In horses, they may be used for induction of estrus in the nonbreeding season.

**Dosage Forms**
1. Estradiol cypionate (ECP) injection
2. Estradiol cypionate (generic)
3. Diethylstilbestrol (DES) compounded capsules and tablets
4. Implants to promote weight gain (discussed in a later section)

**Adverse Side Effects**
These include severe anemia, prolonged estrus, genital irritation, and follicular cysts.

**Technician’s Notes**
1. Estrogens should not be given during pregnancy.
2. Estrogen administration can cause severe anemia.
3. Synthetic DES has been banned from use in food-producing animals because of its possible link with cervical cancer in women.

**Androgens**
Androgens are male sex hormones produced in the testicles, the ovaries, and the adrenal cortex. Similar to the other gonadal hormones, they have a steroidal parent molecule. These hormones are necessary for growth and development of the male sex organs. They cause secondary male sex characteristics and produce male libido. The androgens promote tissue anabolism, weight gain, and red blood cell formation.

**Testosterone Cypionate, Testosterone Enanthate, and Testosterone Propionate**
These injectable testosterone products are available under a human label.

**Clinical Uses**
These androgens are used to treat urinary incontinence in male dogs and to increase libido and fertility in domestic animals (with generally poor results).

**Dosage Forms**
1. Danocrine (Danazol—synthetic derivative of ethinyl testosterone) (human label)
2. Testosterone cypionate injection (generic)
3. Testosterone enanthate (generic)
4. Testosterone propionate injection (generic)
5. Depo-Testosterone
6. Combination products with estradiol as growth-promoting implants
**Adverse Side Effects**
These are uncommon when used as directed.

---

**Technician’s Notes**
Testosterone products are now Class III controlled substances.

---

**Mibolerone**
Mibolerone is an androgen used for prevention of estrus in dogs. Mibolerone blocks the release of LH by the pituitary and prevents complete development of the follicle. Ovulation does not occur.

**Clinical Uses**
This product is used for prevention of estrus in adult female dogs and for treatment of pseudopregnancy.

**Dosage Forms**
2. Implants to promote weight gain (discussed later)

---

**Adverse Side Effects**
Adverse side effects reported in the product insert include premature epiphyseal closure and vaginitis in immature females. In mature females, vulvovaginitis, clitoral hypertrophy, riding behavior, increased body odor, and various other side effects have been reported. It is further reported that side effects usually resolve with discontinuation of therapy.

---

**Technician’s Notes**
Mibolerone should not be used in cats because of a very low margin of safety in this species.

---

**Progestins**
Progestins are a group of compounds that are similar in effect to progesterone. Endogenous progestins are produced by the corpus luteum. They cause increased secretions by the endometrium, decreased motility in the uterus, and increased secretory development in the mammary glands. They also inhibit the release of gonadotropins by the pituitary to produce an inactive ovary. In some situations, they can cause elevated blood glucose levels (antiinsulin effect) or serious suppression of the adrenal glands. These hormones are used clinically to suppress estrus and to treat false pregnancy, behavioral disorders, and progestin-responsive dermatitis. The root “gest” often allows name recognition of the progestins.

---

**Megestrol Acetate**
Megestrol acetate is a synthetic progestin labeled for use in dogs. It is used, however, in cats for some behavioral and dermatologic conditions.

**Clinical Uses**
Megestrol acetate is labeled for use in dogs to control estrus, treat false pregnancy, prevent vaginal hyperplasia, treat severe galactorrhea, and control unacceptable male behavior. Megestrol acetate has been used in cats for various dermatologic and behavioral problems, and for suppression of estrus.

**Dosage Forms**
1. Ovabon. Megestrol acetate tablets in bottles or foil strips

---

**Adverse Side Effects**
These can include hyperglycemia, adrenal suppression, endometrial hyperplasia, and increased appetite.

---

**Technician’s Notes**
Clients should be made aware of the potential dangers associated with the use of this drug and should be asked to report any changes in their pet’s health status that occur after initiation of therapy.

---

**Medroxyprogesterone Acetate**
Medroxyprogesterone acetate (MPA) is a human label progestin that has been used to treat certain behavioral and dermatologic problems and to suppress estrus in dogs and cats.

**Clinical Uses**
MPA is used for (1) treatment of behavioral problems, such as aggression, roaming, spraying, or
mounting in males, and (2) treatment of certain dermatologic conditions.

**Dosage Forms**
1. Depo-Provera. MPA for injection (human label)
2. Provera tablets (human label)
3. Cyclin tablets (human label)

**Adverse Side Effects**
These are potentially numerous and include pyometra, personality changes, depression, lethargy, mammary changes, and increased appetite.

**NORGESTOMET**
Norgestomet is a synthetic progestin that is used in combination with an estrogen (estradiol valerate) for synchronization of estrus in beef cows and nonlactating dairy cows. A treatment consists of one implant and an injection at the time of implantation.

**Clinical Uses**
Norgestomet is used for synchronization of estrus in cattle.

**Dosage Form**
Syncro-Mate-B

**Adverse Side Effects**
Adverse side effects are not reported in the insert.

**MELENGESTROL ACETATE**
Melengestrol acetate is a progestin used in implants that promotes weight gain (discussed in a separate section).

**Technician's Notes**
Progestins should be administered with strict adherence to accepted protocol to minimize side effects such as pyometra.

**ALTERNOGEST**
Alternogest is an oral progestin labeled for use in horses. This drug is used to suppress estrus in mares. (Mares stop cycling within 3 days of treatment and begin cycling again 4 to 5 days after treatment is stopped.) It is also used to manage other reproductive conditions that are listed later.

**Clinical Uses**
1. To suppress estrus for synchronization
2. To suppress estrus for long periods
3. To maintain pregnancy in mares with low levels of progesterone

**Dosage Form**
Regu-Mate. Alternogest in oil oral solution

**Adverse Side Effects**
These have been reported as minimal when used correctly.

**Prostaglandins**
Prostaglandins consist of a group of naturally occurring, long-chain fatty acids that mediate various physiologic events in the body. The primary use of prostaglandins in veterinary medicine is for regulation of activity in and treatment of conditions of the female reproductive tract. Of the six classes (A, B, C, D, E, and F), only prostaglandin F\(_{2\alpha}\) has significant clinical application in the reproductive system.

Prostaglandin F\(_{2\alpha}\) causes lysis of the corpus luteum, contraction of uterine muscle, and relaxation of the cervix. Lysis of the corpus luteum results in a decline in plasma levels of progesterone and, through the negative feedback mechanism, initiation of a new estrus cycle. Contraction of uterine muscle can facilitate evacuation of uterine contents (pus or a mummified fetus) or produce an abortion.

Bronchoconstriction, increased blood pressure, and smooth muscle contraction have been reported in other species, including humans. For these reasons, pregnant women and asthmatic individuals should handle prostaglandin products with extreme caution; exposure (through injection or skin contact) can cause abortion or an asthma attack.

**Technician's Notes**
Alternogest can be absorbed through the skin and should be used with great caution by pregnant women or anyone with vascular disorders. Read the label carefully before using.
Name recognition of the prostaglandins is made easier by looking for "prost" in the drug name.

**Dinoprost Tromethamine**
Dinoprost tromethamine is a salt of the naturally occurring prostaglandin F₂₀₀₀₀₀ and is labeled for use in cattle, horses, and swine. It also has accepted clinical uses in dogs, cats, sheep, and goats. It is effective only in animals with a corpus luteum.

**Clinical Uses**
Labeled clinical uses are as follows:

1. For estrus synchronization, treatment of silent estrus and pyometra in cattle
2. For abortion of feedlot and other nonlactating cattle
3. For induction of parturition in swine
4. For controlling the timing of estrus in cycling mares and in anestrous mares that have a corpus luteum
5. For treatment of pyometra and endometrial hyperplasia and as an abortion-producing agent in dogs and cats
6. In sheep and goats, basically has the same uses as in cattle

**Dosage Forms**
1. Lutalyse. Dinoprost tromethamine for injection
2. AmTech ProstaMate
3. In Synch
4. ProstaMate

**Adverse Side Effects**
These can include sweating (horses), abdominal pain (horses, dogs, cats, and swine), urination/defecation (dogs, cats, and swine), dyspnea and panting (dogs and cats), tachycardia (dogs), and increased vocalization (cats and swine). Most of the side effects are self-limiting and disappear within a short time.

**Fenprostalene**
Fenprostalene is a synthetic analog of prostaglandin F₂₀₀₀₀₀. Fenprostalene produces effects similar to those of dinoprost and the other class F prostaglandins. It is labeled for synchronization of estrus and as an agent to induce abortion (at 150 days or fewer of gestation) in cattle.

**Clinical Uses**
Fenprostalene is used for induction of abortion in feedlot heifers and for synchronization of estrus in beef and nonlactating dairy cows. It should be administered subcutaneously.

**Dosage Form**
BoviTene. Fenprostalene for injection

**Adverse Side Effects**
These can include infection at the injection site and abortion (when not an indication for use).

**Technician's Notes**
1. Do not administer by intravenous injection.
2. Skin that is exposed should be washed off immediately.
3. Pregnant women, asthmatic individuals, and those with bronchial disease should handle this product with great caution.

**Fluprostenedol**
Fluprostenedol is a synthetic analog of prostaglandin F₂₀₀₀₀₀ for use in mares.

**Clinical Uses**
1. Estrus synchronization in cycling mares
2. To establish estrus cycles in anestrus mares
3. To induce parturition in mares
4. To treat lactational anestrus
5. For facilitation of postpartum (after foal-heat) breeding

**Dosage Form**
Equimate. Fluprostenedol for injection

**Adverse Side Effects**
These can include sweating, increased respiration, abdominal discomfort, and defecation.
**Technician's Notes**
See the sections on dinoprost and fenprostalene.

**Cloprostenol Sodium**
Cloprostenol sodium is an analog of prostaglandin \( \text{F}_2\alpha \) for use in cattle. This product is chemically very similar to dinoprost and fenprostalene and is labeled for use in cattle that are very similar to those of dinoprost and fenprostalene. The same precautions should be taken when this drug is used as are taken with the other prostaglandins.

**Clinical Uses**
This drug is used for treatment of luteal cysts and mummified fetuses, termination of pregnancy, and estrus synchronization.

**Dosage Form**
1. Estrumate. Cloprostenol for injection

**Adverse Side Effects**
At high doses, adverse side effects may include uneasiness, frothing at the mouth, and milk letdown.

---

**Drugs That Affect Uterine Contractility**

Several drugs have the ability to increase the contractility of uterine muscle. Some are used during pregnancy to cause abortion, and others are used at term to induce parturition, to aid in delivery of the fetus or the placenta, and to cause involution of the uterus after delivery. Great care should be taken to ensure that the cervix is dilated before these drugs are administered.

One of these drugs, oxytocin, also causes contraction of the myoepithelial cells in the mammary glands to facilitate milk letdown.

**Oxytocin**
Oxytocin is a polypeptide made in the hypothalamus and stored in the posterior pituitary for release in response to appropriate stimuli from the reproductive tract or mammary glands. This hormone causes stronger uterine contractions by increasing the contractility of uterine myofibrils. The uterus must be primed for a period by progesterone and estrogen before oxytocin is effective in stimulating the uterus.

Oxytocin is used clinically to cause more forceful uterine contractions as an aid in delivery of a fetus. It is also used to assist delivery of the placenta, to cause uterine involution, and to reduce bleeding of the uterus after delivery. It should be used only when the cervix is sufficiently dilated and when it can be determined that the fetus can be delivered normally through the pelvic canal.

This hormone is responsible for milk letdown from the mammary glands through its stimulation of myoepithelial cells in the alveolar wall of the glands. It is released endogenously after stimulation of the udder or in response to environmental stimuli, such as the sound of milking machines or other sights, sounds, or smells associated with nursing/milking.

**Clinical Uses**
1. To augment the force of uterine contractions during delivery
2. To aid in delivery of the placenta
3. To facilitate involution of the uterus (to reduce bleeding or to facilitate replacement of a prolapse)
4. To induce milk letdown
5. To assist in the treatment of agalactia in sows

**Dosage Form**
Oxytocin injection is available in generic form from many sources.

**Adverse Side Effects**
These are minimal when used according to recommendations.

---

**Technician's Notes**
1. Oxytocin should be used in dystocia only when the reproductive tract has been adequately examined. Inappropriate use can result in uterine torsion or rupture, and can lead to death.
2. A single dose of oxytocin lasts approximately 15 minutes.
3. Oxytocin is stored under refrigeration.
**Ergot**

Ergot is a fungus that grows on rye grass and possibly on some pasture grasses. It causes smooth muscle contraction and can cause intense vasoconstriction. If the vasoconstriction is severe enough, gangrene and sloughing may occur.

Ergonovine maleate has been used in veterinary medicine because it produces uterine contractions similarly to oxytocin. It results in very little vasoconstrictive action, however. This product is not commonly used.

**Prostaglandins**

Prostaglandins, as mentioned in a previous section, stimulate uterine smooth muscle and can be used to induce parturition or abortion.

**Corticosteroids**

Corticosteroids comprise a group of hormones produced by the adrenal cortex that are used primarily for their antiinflammatory effect but can cause induction of parturition in the last trimester of pregnancy. This effect occurs because exogenous administration of the drug mimics the natural rise in production of corticosteroids by the fetus as the time for delivery draws near. Induction of parturition or abortion is not a labeled use for the corticosteroids, but they have been applied clinically for this purpose.

**Miscellaneous Reproductive Drugs**

**Bromocriptine**

Bromocriptine is a dopamine agonist and prolactin inhibitor that has been used mainly in dogs for pregnancy termination after mismating or for the treatment of pseudopregnancy.

**Leuprolide**

Leuprolide is a synthetic analog of gonadotropin-releasing hormone that is used for the treatment of adrenal endocrinopathy in ferrets and for the treatment of inappropriate egg laying in cockatiels.

**Melatonin**

Melatonin is a naturally occurring hormone that is produced in the pineal gland. In addition to its use in the treatment of alopecia in dogs and sleep disorders in cats and dogs, melatonin has been used to improve early breeding and ovulation in sheep and goats.

**Neutersol**

Neutersol is a U.S. Food and Drug Administration (FDA)-approved product that contains the amino acid l-arginine and a zinc salt; it is administered directly into the testicles of puppies to cause permanent sterility. It reportedly does not eliminate testosterone production and its associated behavioral characteristics, however.

**Pheromones**

Pheromones are odors released by animals that influence the behavior of other animals of the same species. Although pheromones do not fit exactly into the endocrine category, they are considered in this section.

The first pheromone made commercially available was a boar odor aerosol called SOA/Sex. This product is a synthetic version of the natural pheromone that causes the typical boar odor and is used for heat detection in sows and gilts. Label instructions call for spraying the pheromone directly at the nostrils of the sow or gilt for 2 seconds. If the sow or gilt is in heat, she will demonstrate mating reflexes—such as rigid posture, deviations of the tail, and erect ears.

Another pheromone product is Feliway. Feliway is an analog of the feline facial pheromone. It is labeled for use in stopping or preventing urinary marking by the cat and to comfort the cat in an unknown or stressful environment. Cats deposit facial pheromones by rubbing an object with the side of the face. The manufacturer recommends spraying this product directly onto the places soiled by the cat and also on prominent objects that could be attractive to the cat. The product should be applied daily at a height of 8 inches from the floor until the cat is seen rubbing the area with its head. Feliway can also be used to familiarize cats with new environments, such as carriers and cages. It may be dispensed over a large area with the use of a plug-in diffuser.
Another pheromone available in the veterinary market is called D.A.P. (dog-appeasing hormone). The manufacturer indicates that this product mimics the appeasement pheromones, which female dogs secrete to comfort and reassure their nursing puppies. Label indications for use include calming dogs during stressful situations, such as thunderstorms, fireworks, visits by strangers, or moving the dog to a new environment. It is dispensed via a plug-in diffuser.

**THYROID HORMONES**

The thyroid gland is made up of two lobes (one on each side of the trachea) and is located near the thyroid cartilage of the larynx. Microscopically, the thyroid is composed of follicles that, on stimulation by TSH from the anterior pituitary, produce two metabolically active hormones. The thyroid synthesizes these hormones by first trapping iodide from the blood and then oxidizing the iodide to iodine. The iodine is combined with the amino acid tyrosine to form (through several intermediary steps) T3 and T4. T3 is considered to be the active form at the cellular level. Although both T3 and T4 are released from the thyroid gland, some of the T4 is converted to T3 after release. T4, also called thyroxine, is found in higher levels than T3 in euthyroid animals.

Thyroid hormones control many events in the body, including metabolic rate, growth and development, body temperature, heart rate, metabolism of nutrients, skin condition, resistance to infection, and others. Two abnormalities of thyroid function that are encountered in veterinary medicine are hypothyroidism and hyperthyroidism.

Hypothyroidism is noted most often in dogs and is characterized by lethargy, cold intolerance, dry haircoat, and bradycardia. Hyperthyroidism is encountered more often in older cats and is accompanied by weight loss, increased appetite, restlessness, hyperexcitability, and tachycardia. Diagnosis of thyroid conditions is made by observing clinical signs and by measuring serum levels of T3 and T4 before and after TSH administration.

Goiter is a condition that is caused by inadequate levels of iodide in the diet. Lack of iodide causes the thyroid to be unable to produce T3 or T4.

The thyroid attempts to increase its output by enlarging, often to a size that can be palpated and visualized. Goiter is almost nonexistent in animals receiving a commercial diet.

**Drugs Used to Treat Hypothyroidism**

Treatment of hypothyroidism consists of supplementation of thyroid hormones on a daily basis. Clinical signs usually resolve within a short time of treatment initiation, but lifelong therapy is required.

Thyroid hormones can be extracted from thyroid glands or can be prepared synthetically. Purification of the animal source hormones is difficult and has led to the common use of synthetic products. Synthetic thyroxine (T4) is considered to be the compound of choice in the treatment of hypothyroidism. T3 products are recommended only when a poor response to T4 occurs.

**Levothyroxine Sodium (T4)**

Levothyroxine is a synthetic levo isomer of T4. It is the compound of choice for the treatment of hypothyroidism in all species.

**Clinical Uses**

Levothyroxine is used for the treatment of hypothyroid conditions.

**Dosage Forms**

1. Soloxine. Levothyroxine tablets, approved for dogs
2. Thyro-Form. Levothyroxine chewable tablets, approved for dogs
3. Thyro-L. Levothyroxine powder, approved for horses
4. NutriVed T-4 Chewables. Levothyroxine chewable tablets, approved for dogs
5. Thyro-Tab. Levothyroxine tablets for dogs
6. Equine Thyroid Supplement
7. Thyroxine Tablets. Levothyroxine tablets for dogs
8. Synthroid. Levothyroxine tablets approved for humans
9. Leventa. Levothyroxine in a small-volume liquid form
Adverse Side Effects
These are rare when used according to recommendations.

Liothyronine Sodium
Liothyronine sodium (T₃) is a synthetic salt of endogenous T₃. T₃ is not the compound of choice for the treatment of hypothyroidism. It may be useful, however, in cases that do not respond well to T₄.

Clinical Uses
T₃ is used for the treatment of hypothyroidism in cases that respond poorly to T₄.

Dosage Forms
1. Cytobin Tablets. Liothyronine sodium tablets, approved for dogs
2. Cytomel. Human label

Adverse Side Effects
These are probably minimal with careful use.

Thyroid-Stimulating Hormone
Thyrotropin is a purified form of TSH obtained from the anterior pituitary in cattle. It is used as an aid in the diagnosis of hypothyroidism.

Clinical Uses
In veterinary medicine, thyrotropin is used for diagnosis of primary hypothyroidism in the TSH stimulation test.

Dosage Forms
1. Dermathycin. TSH approved for use in dogs
2. Thytopar. TSH approved for use in humans

Adverse Side Effects
Allergic reactions may occur in animals sensitive to bovine protein.

Methimazole
Methimazole is a compound that interferes with incorporation of iodine into the precursor molecules of T₃ and T₄. It does not alter thyroid hormones already released into the bloodstream.

Clinical Uses
Methimazole is used for the treatment of feline hyperthyroidism.

Dosage Form
Tapazole. Methimazole tablets (human approved)

Adverse Side Effects
These include anorexia, vomiting, and skin eruptions. Kittens should be placed on a milk replacement after receiving colostrum from mothers on methimazole.

Carbimazole
Carbimazole is a product similar to methimazole that is used in Canada and other countries. Most of this drug is converted to methimazole after administration to the cat. It inhibits the synthesis of thyroid hormones.

Clinical Uses
Carbimazole is used for the treatment of feline hyperthyroidism.

Dosage Forms
1. Carbazole. Human label
2. Neo-Carbazole. Human label

Adverse Side Effects
Side effects are similar to those of methimazole.
Iopodate
Iopodate is an orally administered, radiopaque, organic iodine compound that is thought to inhibit the conversion of \( T_4 \) to \( T_3 \).

Clinical Uses
Iopodate may be helpful in the treatment of hyperthyroidism in cats that are not tolerant of methimazole or carbimazole.

Dosage Form
Oragrafin. Human label

Propylthiouracil
Propylthiouracil has been used as an antithyroid drug but is considered dangerous for use in cats because of potential hematologic complications.

Radioactive Iodine
Radioactive iodine (I-131) may be given intravenously to destroy overproductive thyroid tissue. I-131 concentrates in the thyroid, where it remains and destroys thyroid tissue. This method has appeal because it is performed only once and is not especially stressful to patients. However, it must be done at facilities that can handle radioactive materials.

Propranolol
Propranolol (Inderal) may be used preoperatively to treat the tachycardia associated with hyperthyroidism in cats.

Agents for the Treatment of Diabetes Mellitus

Insulin
The pancreas produces two principal hormones in special cells of the islets of Langerhans: insulin and glucagon. Insulin is produced by beta cells, and glucagon is produced by alpha cells. Insulin causes a decrease in blood glucose levels, and glucagon promotes an increase. Only insulin is used clinically.

Insulin facilitates cellular uptake of glucose and its storage in the form of glycogen and fat. It inhibits the breakdown of fat, protein, and glycogen into forms that may be used as energy sources. Further, it promotes synthesis of protein, fatty acids, and glycogen. In the absence of insulin, the body cannot use glucose and must break down its own fat and protein that can be used for energy.

Diabetes mellitus is a complex disease that results from inability of the beta cells of the pancreas to produce enough insulin or from altered insulin action within cells. Diabetes mellitus that results from inadequate secretion of insulin is called type I, or insulin-dependent, diabetes mellitus. This is the most common type of diabetes mellitus in dogs and cats. Diabetes mellitus that results from resistance of tissue to the action of insulin is called type II, or noninsulin-dependent, diabetes mellitus (NIDDM). NIDDM is rare in dogs but is occasionally encountered in cats.

Both forms of diabetes mellitus eventually cause polydipsia, polyuria, polyphagia, and weight loss. Untreated diabetes mellitus proceeds to the condition called diabetic ketoacidosis, in which body fat is metabolized as a substitute energy source. Metabolism of body fat results in accumulation of byproducts of this process called ketone bodies, which promote a metabolic acidosis that can lead to death.

Because blood glucose levels can be increased by corticosteroids, epinephrine, and progesterone, these drugs should be given with caution to diabetic animals. Sudden changes in diet and exercise level should also be avoided because they can alter blood glucose levels and cause an imbalance in the ratio of insulin to glucose.

Insulin is not effective when given orally because the digestive tract breaks down the protein molecule before it can be absorbed. Insulin usually is administered by subcutaneous injection. However, some forms may be given intravenously or intramuscularly.

Sources of insulin have traditionally included beef or pork pancreas and preparations consisting of a purified (pure beef source or pure pork source) form or a combination beef/pork form. The beef/pork form is best suited to the treatment of diabetes mellitus in dogs and cats. Pork insulin is very close in structure to dog and human insulins, whereas beef insulin is very similar to cat insulin.

Most human insulin products are now prepared through recombinant DNA or synthetic processes.
Only one animal labeled product is currently approved for use in the United States. The availability of insulin products is subject to change, and technicians should always consult current information when dealing with diabetic patients.

Insulin concentration is measured in units of insulin per milliliter. It is available in concentrations of 40 (U-40), 100 (U-100), and 500 (U-500) U/ml. All products for human use are U-100 concentrations.

A U-40 concentration makes administering the small amounts of insulin needed for cats and small dogs much easier. When insulin is drawn into the syringe, each mark on the syringe barrel denotes 1 U of insulin. Drawing up 5 U on a scale of 40, for example, is easier than drawing up 5 U on a scale of 100. Small-volume U-100 syringes are available, however, to facilitate administration of small doses of U-100 insulin.

U-40 syringes must be used with U-40 insulin, and U-100 syringes must be used with U-100 insulin. Table 9-2 lists the available insulin syringes.

**Table 9-2 Insulin Syringes**

<table>
<thead>
<tr>
<th>Name and Manufacturer</th>
<th>Insulin</th>
<th>Needle Gauge</th>
<th>Needle Size</th>
<th>Packaging</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1-ml Syringes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-D Microfine IV</td>
<td>U-100</td>
<td>28</td>
<td>½ inch</td>
<td>100 (10 packs of 10)</td>
</tr>
<tr>
<td>B-D Microfine</td>
<td>U-100</td>
<td>27</td>
<td>⅝ inch</td>
<td>100 (10 packs of 10)</td>
</tr>
<tr>
<td>B-D Microfine IV</td>
<td>U-40</td>
<td>28</td>
<td>⅝ inch</td>
<td>100 (10 packs of 10)</td>
</tr>
<tr>
<td>Can-Am E-Z Ject</td>
<td>U-100</td>
<td>27</td>
<td>½ inch</td>
<td>100 (individually wrapped)</td>
</tr>
<tr>
<td>Can-Am E-Z Ject</td>
<td>U-100</td>
<td>28</td>
<td>½ inch</td>
<td>100 (individually wrapped)</td>
</tr>
<tr>
<td>Monoject Ultra Comfort 28</td>
<td>U-100</td>
<td>28</td>
<td>½ inch</td>
<td>100 or 30 (individually wrapped)</td>
</tr>
<tr>
<td>Pharma-Plast</td>
<td>U-100</td>
<td>28</td>
<td>½ inch</td>
<td>100 (10 packs of 10)</td>
</tr>
<tr>
<td>Terumo</td>
<td>U-100</td>
<td>29</td>
<td>½ inch</td>
<td>100 (individually wrapped)</td>
</tr>
<tr>
<td>Terumo</td>
<td>U-100</td>
<td>27</td>
<td>½ inch</td>
<td>100 (individually wrapped)</td>
</tr>
<tr>
<td><strong>0.25-ml Syringes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Terumo</td>
<td>U-100</td>
<td>29</td>
<td>½ inch</td>
<td>100 (individually wrapped)</td>
</tr>
<tr>
<td><strong>0.5-ml Syringes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-D Microfine IV</td>
<td>U-100</td>
<td>28</td>
<td>½ inch</td>
<td>100 (10 packs of 10)</td>
</tr>
<tr>
<td>Can-Am E-Z Ject</td>
<td>U-150</td>
<td>28</td>
<td>½ inch</td>
<td>100 (individually wrapped)</td>
</tr>
<tr>
<td>Monoject Ultra Comfort 28</td>
<td>U-100</td>
<td>28</td>
<td>½ inch</td>
<td>100 or 30 (individually wrapped)</td>
</tr>
<tr>
<td>Pharma-Plast</td>
<td>U-100</td>
<td>28</td>
<td>½ inch</td>
<td>100 (10 packs of 10)</td>
</tr>
<tr>
<td>Terumo</td>
<td>U-100</td>
<td>29</td>
<td>½ inch</td>
<td>100 (individually wrapped)</td>
</tr>
<tr>
<td>Terumo</td>
<td>U-100</td>
<td>27</td>
<td>½ inch</td>
<td>100 (individually wrapped)</td>
</tr>
<tr>
<td><strong>0.3-ml Syringes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-D Microfine IV</td>
<td>U-100</td>
<td>28</td>
<td>½ inch</td>
<td>100 (10 packs of 10)</td>
</tr>
</tbody>
</table>

### Table 9-3 Insulin Products Commonly Used in Dogs and Cats

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Source</th>
<th>Duration</th>
<th>Manufacturer</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humulin R</td>
<td>Regular insulin</td>
<td>Human recombinant</td>
<td>Short</td>
<td>Eli Lilly</td>
<td>U-100</td>
</tr>
<tr>
<td>Novolin R</td>
<td></td>
<td></td>
<td></td>
<td>Novo Nordisk</td>
<td></td>
</tr>
<tr>
<td>Humulin N</td>
<td>NPH</td>
<td>Human recombinant</td>
<td>Intermediate</td>
<td>Eli Lilly</td>
<td>U-100</td>
</tr>
<tr>
<td>Novolin N</td>
<td></td>
<td></td>
<td></td>
<td>Novo Nordisk</td>
<td></td>
</tr>
<tr>
<td>Vetsulin</td>
<td>Lente</td>
<td>Pork</td>
<td>Intermediate</td>
<td>Intervet</td>
<td>U-40</td>
</tr>
<tr>
<td>PZI Vet</td>
<td>PZI</td>
<td>Beef 90%, pork 10%</td>
<td>Intermediate</td>
<td>IDEXX</td>
<td>U-40</td>
</tr>
<tr>
<td>Lantus</td>
<td>Glargine</td>
<td>Human recombinant</td>
<td>Intermediate to long</td>
<td>Aventis</td>
<td>U-100</td>
</tr>
</tbody>
</table>

Preparations to be considered. For an in-depth discussion of insulin forms and characteristics, other references should be consulted.

**SHORT-ACTING INSULIN**

Regular insulin/lispro/aspart. Regular insulin is a fast-acting insulin that is made from zinc insulin crystals; it is a clear solution that may be administered intravenously, intramuscularly, or subcutaneously. It is used mainly to treat diabetic ketoacidosis until blood glucose levels are reduced and the animal is metabolically stable. At that time, the animal is usually switched to a longer-acting form. Lispro and aspart insulins are not used in dogs and cats at this time.

**Clinical Uses**

Regular, lispro, and aspart insulins are used primarily for the treatment of diabetic ketoacidosis.

**Dosage Forms**

Many products approved for humans are available. Following is a partial listing:

1. Humulin R
2. Novolin R
3. Humalog
4. NovoLog
5. Apidra

**Adverse Side Effects**

These usually are related to overdose and may include weakness, ataxia, shaking, and seizures.

---

**Technician's Notes**

1. Although not required by label on the newer products, refrigeration probably enhances storage life. Do not freeze.
2. Do not use regular insulin preparations if discoloration or precipitates are present.

**INTERMEDIATE-ACTING INSULIN**

NPH (Neutral Protamine Hagedorn) Insulin/PZI (Protamine Zinc Insulin)/Lente. NPH insulin is a cloudy suspension of zinc insulin crystals and protamine zinc. Protamine (a fish protein) and zinc prolong the absorption and activity of the product. These insulins are longer acting than regular insulin. They are commonly used for the control of uncomplicated diabetes in dogs and cats. Lente insulin is similar in activity to NPH insulin but is made without the use of protamine.

**Clinical Uses**

NPH insulin is used in the treatment of uncomplicated diabetes mellitus.

**Dosage Forms**

A partial listing follows:

1. Humulin N
2. Novolin N
3. Vetsulin
4. PZI Vet
Adverse Side Effects
These are similar to those of regular insulin.

Technician’s Notes
1. Resuspension, by gently rolling the bottle, is required before the product is withdrawn from the bottle.
2. Store in the manner of regular insulin. Do not freeze.
3. NPH insulin is usually administered once a day.

Long-Acting Insulin
Glargine (Lantus) and detemir (Levemir) insulin are long-acting insulins with a human label. Lantus is marketed as a peakless insulin. Care should be taken to avoid confusing Lantus and Levemir with other clear insulins.

Clinical Uses
Glargine is used for the treatment of uncomplicated diabetes mellitus.

Dosage Forms
Lantus. Clear, long-acting glargine insulin
Levemir. Clear, detemir insulin.

Adverse Side Effects
These are similar to those of regular and intermediate-acting insulins.

Technician’s Notes
Humulin L, Humulin U, lletin II regular pork insulin, and Iletin II NPH pork insulin were discontinued by Eli Lilly in 2005.

Use of Insulin Products
Technicians who are counseling clients about the use of insulin products should take great care to become thoroughly familiar with the products they are using. The onset of action of various insulin products can vary from a few minutes to a few hours. Peak activity time and duration of activity can also vary greatly between products. Exercise levels and eating patterns may influence insulin activity. An overdose of insulin can lead to various degrees of hypoglycemia that produce clinical signs ranging from mild weakness to coma. Clients should be shown how to give subcutaneous injections of insulin, and they should be given written instructions about monitoring insulin response and making appropriate adjustments. Tips regarding the use of insulin products follow as Technician’s Notes.

Technician’s Notes
1. It is usually best to feed the animal 30 minutes before giving the insulin injection.
2. Roll “cloudy” insulins between your palms; do not shake.
3. NPH insulin should not be mixed with any Lente insulin.
4. It is the opinion of some people that insulin should be disposed of after 30 days or 100 injections.
5. Injection sites should be rotated.
6. Clients should be advised to use insulin syringes only once.
7. Mild to moderate hypoglycemia resulting from an overdose can be treated by feeding the animal or administering Karo syrup.

Oral Hypoglycemic Agents
Oral hypoglycemic agents such as the sulfonylureas are extensively used in human diabetic patients to control type II diabetes mellitus (NIDDM). They have little apparent effectiveness in diabetic dogs but may be useful in some cats with type II diabetes. Drugs in this category include glipizide (Glucotrol) and metformin (Glucophage XR).

Hyperglycemic Agents
Several drugs such as corticosteroids, epinephrine, and progesterone incidentally elevate blood glucose levels. Two products that are marketed for this purpose, however, are diazoxide (Proglycem) and octreotide (Sandostatin). These are used to treat the low blood glucose levels associated with hypersecretion of insulin that occurs in tumors of the beta cells
of the pancreas (insulinoma) in dogs and ferrets (Plumb, 2005). These products act by inhibiting the release of insulin from beta cells of the pancreas.

HORMONES THAT ACT AS GROWTH PROMOTERS

Sex Steroids, Synthetic Steroid Analogs, and Nonsteroidal Analogs

The factors that control growth, feed efficiency, and carcass composition in animals involve a complex interrelationship between genetic, metabolic, and hormonal mechanisms that are not always totally understood. It is possible, however, to increase growth (weight gain) in ruminants by administering sex steroid hormones (estrogen, testosterone, or progesterone), synthetic steroid hormone analogs (trenbolone), or certain nonsteroidal hormone analogs (zeranol).

The primary sex steroid used to promote weight gain is estrogen (estradiol). The mechanisms by which estradiol promotes weight gain include (1) increased water retention, (2) increased protein synthesis, (3) increased fat deposition, and (4) possible increased release of growth hormone (bovine somatotropin).

Testosterone is used as an adjunct to estradiol in some growth-promotion products because it is an anabolic agent in itself, and because a second component in the compound slows down the release of estradiol and prolongs its effective life span.

Progesterone is also added to growth promoters to slow the release of estradiol. It apparently has little anabolic effect of its own.

Trenbolone is a synthetic anabolic agent that improves feed efficiency and promotes weight gain in steers. It is used as the sole agent in some growth-promoting preparations.

Zeranol is an analog of a naturally occurring plant estrogen that increases feed efficiency, protein synthesis, and growth rate.

All of the growth-promoting products for use in cattle and sheep are prepared as compressed pellets that are implanted in the subcutaneous tissue of the dorsal, middle third of the ear (Figure 9-5). These pellets are designed for use with corresponding needle devices and should be implanted with close adherence to product instructions (failure to do so is a violation of federal law in some cases).

The growth-promotion products are considered here as a group, and minimal information is provided about each product.

Clinical Uses
These drugs are used to promote feed efficiency and weight gain in calves, steers, heifers, or sheep (depending on the product).

Dosage Forms
1. Synovex C. Estradiol/progesterone implant for use in calves older than 45 days
2. Synovex H. Estradiol/testosterone implant for use in heifers
3. Synovex S. Estradiol/testosterone implant for use in steers
5. Implus-H. Estradiol/testosterone implant for use in heifers
6. Implus-S. Estradiol/progesterone for use in steers
7. CALF oid Implant. Progesterone/estradiol implant for calves older than 45 days
9. Finaplix-S. Trenbolone implant for steers
10. Revalor-S. Trenbolone and estradiol implant for use in feedlot steers
11. Raigro beef cattle implant. Zeranol implant for use in growing cattle, feedlot heifers, feedlot steers, and suckling and weaned calves
12. Raigro feedlot lamb implant. Zeranol implant for feedlot lambs

Adverse Side Effects
These may include mounting, elevated tail heads, rectal prolapse, and udder development.

Technician’s Notes
1. Most growth-promoting implants should not be given to animals intended for breeding purposes or to dairy cattle.
2. Product insert instructions for these products should be read and followed carefully.

Growth Hormone: Bovine Somatotropin, Bovine Growth Hormone

Growth hormone, also called somatotropin, is a hormone produced by the anterior pituitary. Its function before the onset of puberty is to stimulate growth. It is released throughout life to promote anabolic activity (e.g., to increase protein synthesis). It has been shown to increase growth rate and feed efficiency in farm animals. Many of the growth-promoting agents listed in the previous section may work by stimulating the release of somatotropin. Somatotropin is a potent stimulator of milk production as well. Claims of a 20% boost in milk production in dairy cows have been made after administration of somatotropin.

The FDA approved a recombinant (genetically engineered) bovine somatotropin (BST) for commercial production in 1993. This product, Posilac, is manufactured by the Monsanto Co. Its market availability has sparked intense debate among certain groups. Some dairy producers have opposed its use because of their fear that increased production would drive milk prices down and reduce their overall income. Other groups have resisted the use of BST because of their concerns about residues of the hormone in milk products, even though the FDA has stated that milk from cows receiving BST is completely safe. People who advocate the use of “organic” food products may oppose the use of this product.

ANABOLIC STEROIDS

Anabolic steroids are steroids that produce a tissue-building (anabolic) effect. Testosterone is a naturally occurring anabolic steroid that produces masculinization in addition to its anabolic effects. Synthetic anabolic steroids are designed to prevent most masculinizing effects.

Anabolic steroid administration causes positive nitrogen balance and reverses processes that break down tissue. An increase in appetite, weight gain, improved overall condition, and recovery are promoted. These products are labeled for clinical use in dogs, cats, and horses for anorexia, weight loss, and debilitation. In working animals, they may be used in cases of overwork or overtraining. Anabolic steroids also promote red blood cell formation and are used to treat some forms of anemia. The product insert for a commonly used product states that “anabolic therapy is intended primarily as an adjunct to other specific and supportive therapy, including nutritional therapy.”

Because of the potential for abuse by bodybuilders and other athletes, the FDA has now classified anabolic steroids as C-III controlled substances.

Stanozolol
Stanozolol is an anabolic steroid that has been found to have an unusual pattern of biologic activity in that its anabolic effect far outweighs its weak androgenic influence.

Clinical Uses
Stanozolol is used for the treatment of anorexia, debilitation, weight loss, overwork, and anemia.

Dosage Forms
1. Winstrol-V. Stanozolol sterile suspension for injection in dogs, cats, and horses
2. Winstrol-V. Stanozolol tablets for use in dogs and cats
Adverse Side Effects
These may include mild androgenic effects after prolonged use or overdose.

**Technician’s Notes**
1. Winstrol-V should not be used in pregnant dogs, mares, or stallions.
2. Winstrol-V should not be given to horses intended for food uses.

**Boldenone Undecylenate**
Boldenone undecylenate is a steroid ester that possesses marked anabolic activity and a minimal amount of androgenic activity. It is labeled for use in horses.

**Clinical Uses**
Boldenone undecylenate acts as an aid in the treatment of debilitated horses.

**Dosage Form**
Equipoise. Boldenone injection for horses

**Adverse Side Effects**
These include androgenic effects such as overaggressiveness.

**Nandrolone Decanoate**
Nandrolone decanoate is an injectable anabolic steroid sold under the human label Deca-Durabolin. It exhibits activity similar to that of the other anabolic agents.

**REFERENCES**
REVIEW QUESTIONS

1. Describe the relationship between hormonal releasing factors, trophic hormones, and the hormones produced by specific tissues or glands.

2. List the major endocrine glands.

3. What are the reasons for using hormonal therapy in veterinary medicine?

4. Endogenous hormones are those that are produced ________________, whereas exogenous hormones come from ________________ sources.

5. Where is the pituitary gland located, and what is its function? ________________

6. Describe the difference between a negative and a positive feedback control mechanism in the endocrine system.

7. The release of oxytocin by the posterior pituitary is controlled through the ________________ mechanism.

8. GnRH is classified as a/an ________________.

9. Hormonal products with “gest” in their name are classified as ________________.

10. List three potential uses of the prostaglandins in veterinary medicine.

11. Human skin contact or injection with prostaglandins can be a serious health risk to ________________ women and ________________.

12. Before oxytocin can exert its effects on the uterus, the uterus must first be primed by ________________ and ________________.

13. What precautions should be taken before oxytocin is administered?

14. What two active hormones are produced by the thyroid gland?

15. List two drugs used in the treatment of hypothyroidism.

16. List the three major classes of insulin.

17. Which form of insulin is used in the treatment of diabetic ketoacidosis?

18. Which form(s) of insulin must be resuspended before administration?

19. What are some signs of insulin overdose?

20. Growth promoters generally should not be used in animals intended for ________________.

21. Why are anabolic steroids classified as controlled substances?

22. ________________ are odors released by animals that influence the behavior of other animals of the same species.

23. What precautions should be taken by pregnant women when Regu-Mate is administered?

24. Why was synthetic DES banned from use in food-producing animals?

25. Prostaglandin causes lysis of the ________________ at the end of pregnancy or at the end of diestrus if pregnancy does not occur.

26. Endometrium lines the ________________.
   a. kidney
   b. stomach
   c. intestines
   d. uterus
27. A _______________ hormone is one that results in the production of a second hormone within a target gland.
   a. gonadotropin
   b. euthyroid
   c. trophic
   d. myofibril

28. GnRH is produced in the _______________.
   a. pancreas
   b. thymus
   c. thyroid gland
   d. hypothalamus

29. All the following drugs are gonadotropins, except _______________.
   a. estradiol cypionate
   b. Cystorelin
   c. Factrel
   d. Fertagyl

30. Androgens are female sex hormones produced in the ovaries, adrenal cortex, and testicles.
   a. True
   b. False

31. Prostaglandins are a group of naturally occurring, long-chain fatty acids that mediate various physiologic events in the body.
   a. True
   b. False

32. _______________ causes uterine contractions.
   a. Regu-Mate
   b. Bovilene
   c. Oxytocin
   d. Cystorelin

33. Corticosteroids are produced by _______________.
   a. the thyroid gland
   b. the adrenal cortex
   c. the kidneys
   d. the hypothalamus

34. Pheromones are _______________ released by an animal that influence the behavior of other animals of the same species.
   a. hormones
   b. gonadotropins
   c. steroids
   d. odors

35. Levothyroxine is used in the treatment of _______________ in all species.
   a. hypoglycemia
   b. hypothyroidism
   c. hypokalemia
   d. hypocalcemia
CHAPTER 10

Drugs Used in Ophthalmic and Otic Disorders

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Describe the clinical indications for common ophthalmic and otic agents.
2. Identify the different classes of ophthalmic and otic agents.
3. Identify the possible adverse reactions and contraindications of many commonly used agents.
KEY TERMS

**CLOSED-ANGLE GLAUCOMA** A type of primary glaucoma of the eye that is characterized by a shallow anterior chamber and a narrow angle that compromises filtration because the iris is blocking the angle and is causing an increase in intraocular pressure.

**CONJUNCTIVITIS** Inflammation of the conjunctiva.

**CYCLOPLEGIA** Paralysis of the ciliary muscle.

**ECTROPION** A rolling outward (i.e., away from the eye) or sagging of the eyelid. Many times, the conjunctiva is plainly visible.

**ENTROPION** A rolling inward (i.e., toward the cornea) of the eyelid.

**GLAUCOMA** A group of eye diseases characterized by increased intraocular pressure that results in damage to the retina and the optic nerve.

**KERATITIS** Inflammation of the cornea.

**MYDRIASIS** Dilation of the pupil.

**OPEN-ANGLE GLAUCOMA** A type of primary glaucoma of the eye in which the angle of the anterior chamber remains open, but filtration of the aqueous humor is gradually reduced, causing an increase in intraocular pressure.

**UVEA** The vascular layer of the eye that comprises the iris, ciliary body, and choroid.

**UVEITIS** Inflammation of the uvea.

OPHTHALMIC AGENTS

Although the sense of smell is highly developed in many animals, the sense of sight plays an important role in an animal’s health and well-being. Cats rely on excellent eyesight because they are animals of prey. This prey trait provides many cat owners with amusement and laughter when a string or a feather toy is pulled around the house with a cat running behind in rapid pursuit. Horses rely on good eyesight to perform their best for human companions. Police dogs, hunting dogs, seeing-eye dogs, and herding dogs rely on their eyesight to interpret owners’ hand signals when working in the field.

A good ocular examination includes an examination of the external ocular features (eyelids, sclera, cornea, third eyelid [nictitating membrane]) and the internal ocular features (anterior chamber, iris, lens), all of which can be seen without highly specialized equipment (McCurmin, 2006). Some dog breeds (Shar-Pei, cocker spaniels, English bulldogs, and others) are genetically predisposed to conditions that may require surgery. Two of these conditions are known as entropion and ectropion.

Topical administration of eye drops or ointment is the most common method of treatment involving disorders of the eye. It is the veterinary technician’s duty to educate the client by demonstrating the proper way to administer eye medication. Products for ocular treatment are usually available as solutions or ointments. Drug penetration is one factor that veterinarians must consider when choosing a topical ophthalmic agent. Topical agents are more readily absorbed into the anterior chamber than the posterior chamber. For this reason, these agents have limited use in posterior eye disorders. Systemic agents may be more effective. Lipid-soluble agents readily penetrate the corneal epithelium and endothelial layers. Water-soluble agents readily penetrate the corneal stroma layer (Figure 10-1). Most topical ophthalmic medications require several applications per day because the eye continuously secretes tears that wash away the medication. Ointments tend to necessitate less frequent applications than do drops. However, ointments may blur an animal’s vision for a short period after application. Client education is invaluable during treatment of an eye disorder.

Clients placing telephone calls to the veterinary hospital to discuss a potential eye problem in a patient should be made to realize that these situations may be considered an emergency. Unfortunately, some clients tend to let an ocular problem progress to severe stages before treatment is sought. Veterinary technicians should remind clients that animals
have only two eyes, and the importance of vision should not be minimized.

**Mydriatics and Cycloplegics**

Mydriatic agents are used to dilate the pupils (Figure 10-2). This action facilitates examination of the posterior segment and the fundus of the eye. Cycloplegic agents paralyze the accommodative muscle of the ciliary body. In some cases, this action can minimize pain associated with ciliary spasms. These agents often are used before and after ophthalmic surgery.

*Phenylephrine Hydrochloride*

Phenylephrine hydrochloride is used to produce mydriasis but does not produce cycloplegia.

**Clinical Uses**

Phenylephrine HCl is used in the evaluation of uveitis, glaucoma, or scleritis. It also may be used before conjunctival surgery to reduce hemorrhage or may be used in combination with atropine before cataract or intraocular surgery. It can be used to detect the presence of Horner’s syndrome.

**Dosage Forms**

1. Mydfrin (human label)
2. Neo-Synephrine

**Adverse Side Effects**

These include local discomfort after application. Frequent use may lead to inflammation.

**Technician’s Notes**

Phenylephrine HCl is also used in cough preparations but at a higher concentration.

**Atropine Sulfate**

Atropine sulfate is one of the ophthalmic agents that is most commonly used to produce mydriasis and cycloplegia.
Clinical Uses
Atropine sulfate is used for refraction or for the treatment of acute inflammatory conditions of the anterior uveal tract.

Dosage Forms
1. Atrop shake
2. Atropine sulfate

Adverse Side Effects
These include salivation. Atropine is contraindicated in glaucoma and keratoconjunctivitis sicca (KCS or dry eye).

Homatropine Hydrobromide
Homatropine hydrobromide produces mydriasis and cycloplegia but is less potent than atropine.

Clinical Uses
Homatropine hydrobromide is used for refraction and for the treatment of uveitis.

Dosage Forms
1. Homatropel Ophthalmic (human label)
2. Isopto Homatropine (human label)

Adverse Side Effects
These are the same as for atropine.

Cyclopentolate Hydrochloride
Cyclopentolate hydrochloride produces mydriasis and cycloplegia.

Clinical Uses
Cyclopentolate hydrochloride is used for refraction.

Dosage Forms
1. Cyclogyl (human label)
2. Pentolair

Adverse Side Effects
These are the same as for atropine.

Tropicamide
Tropicamide is a rapid-acting mydriatic that has less cycloplegic effect than the previously mentioned drugs.

Clinical Uses
Tropicamide is used for ocular fundus examination.

Dosage Forms
1. Mydriacyl (human label)
2. Opticyl
3. Tropicacyl

Adverse Side Effects
These include local discomfort after application and salivation. Contraindications are the same as for atropine.

Epinephrine
Epinephrine is administered topically and is available as epinephrine and dipivalyl epinephrine. Dipivalyl epinephrine readily penetrates the corneal barrier and is converted to epinephrine in the cornea.

Clinical Uses
Epinephrine is used to reduce intraocular pressure, produce mydriasis, or aid in the diagnosis of Horner's syndrome.

Dosage Forms
1. Epitrin (human label)
2. Epinal
3. Glaucoun

Adverse Side Effects
These include local irritation. Epinephrine is contraindicated in closed-angle glaucoma.

Miotics
Miotics produce pupillary constriction. These drugs are commonly used in the treatment of chronic open-angle glaucoma, acute and chronic closed-angle glaucoma, and some cases of secondary glaucoma. Miotics reduce intraocular pressure by increasing the outflow of aqueous humor.

Pilocarpine
Pilocarpine is a cholinergic drug that is commonly used to treat chronic open-angle glaucoma.
Clinical Uses
These include stimulation of tear production in some cases of keratoconjunctivitis sicca, as well as the treatment of glaucoma.

Dosage Forms
1. Piloptic
2. Isopto Carpine
3. Pilostat

Adverse Side Effects
These include local irritation and discomfort. Repeated use may cause vomiting, diarrhea, and salivation.

Demecarium Bromide
Demecarium bromide is a potent carbamate inhibitor that can reduce intraocular pressure in dogs for up to 48 hours.

Clinical Uses
Preventive management of the contralateral eye after diagnosis of acute glaucoma in the other eye.

Dosage Form
Humorsol

Adverse Side Effects
Local irritation of the eye and/or salivation, vomiting, and diarrhea.

Other Agents That Reduce Intraocular Pressure

Carbonic Anhydrase Inhibitors
Carbonic anhydrase inhibitors reduce intraocular pressure by decreasing the production of aqueous humor. These products, similarly to those previously mentioned, are used to control glaucoma. However, some are administered orally or intravenously rather than topically.

Dosage Forms
1. Dichlorphenamide (Daranide—human label)
2. Acetazolamide (Diamox—human label)—available in injectable and oral forms
3. Methazolamide (Neptazane—human label)
4. Dorzolamide (Trusopt—human label)
5. Brinzolamide (Azopt)—topical agent
6. Dorzolamide (Trusopt)—topical agent

Adverse Side Effects
These include vomiting, diarrhea, panting, and weakness.

Beta-Adrenergic Antagonists
The beta-adrenergic blocking agents used to treat glaucoma include timolol, betaxolol, carteolol, levobunolol, and metipranolol.

Timolol Maleate
Timolol maleate is an ophthalmic beta blocker with action that results in decreased production of aqueous humor.

Clinical Uses
Timolol maleate is used in the contralateral eye of a dog with primary glaucoma to prevent the development of bilateral disease. It reduces intraocular pressure to some extent, but it is not as effective in the treatment of glaucoma.

Dosage Forms
1. Timoptic (human label)
2. Cosopt

Adverse Side Effects
Adverse side effects are uncommon. See the Technician's Notes below.

Technician's Notes
Timolol may be contraindicated in some patients with cardiovascular disease or bronchoconstrictive disease.

Betaxolol
Betaxolol is a specific beta-1 adrenergic blocking agent that reduces aqueous humor production by decreasing cyclic adenosine monophosphate (cAMP) production in the ciliary body.
Clinical Uses
It is used for the treatment of glaucoma, especially in animals with respiratory disease or asthma.

Dosage Form
Betopin

Adverse Side Effects
Similar to those of timolol.

CARTEOLOL
Carteolol is a nonspecific adrenergic blocking agent that reduces aqueous humor production similarly to betaxolol.

Clinical Uses
This drug is primarily used for the control of primary glaucoma in cats.

Dosage Form
Ocupress

Adverse Side Effects
Similar to those of timolol.

LEVOBUNOLOL
Levobunolol is a beta-1 and beta-2 blocker similar to timolol but without the potential for myocardial depression or airway constriction.

Clinical Uses
This drug may be used to treat glaucoma in feline patients with asthma.

Dosage Form
Betagan

METIPRANOLOL
Metipranolol is a nonselective beta blocking agent.

Clinical Uses
This drug has been used for the management of primary open-angle glaucoma in cats.

Dosage Form
OptiPranolol

Sympathomimetics
The sympathomimetics used to control glaucoma include apraclonidine and brimonidine.

APRACLONIDINE
Apcalonidine is a alpha-2 adrenergic agonist that is used to reduce aqueous humor production.

Clinical Uses
This drug is used for the treatment of glaucoma.

Dosage Form
Iopidine

Adverse Side Effects
May cause vomiting and diarrhea in dogs and cats.

BRIMONIDINE
Brimonidine is an alpha-adrenergic agonist that reduces aqueous humor production and increases aqueous humor outflow.

Clinical Uses
It is used for the treatment of glaucoma.

Dosage Form
Alphagan

Topical Prostaglandins
Prostaglandin analogs decrease intraocular pressure by increasing the outflow of aqueous humor through the uveal and scleral pathways.

Dosage Forms
1. Latanoprost-Xalantan
2. Bimatoprost-Lumigan
3. Travoprost-Travatan

Osmotic Diuretics
MANNITOL
Mannitol is an osmotic diuretic that is administered intravenously in emergency situations to reduce intraocular pressure.

Dosage Form
Mannitol injection
Adverse Side Effects
These include fluid and electrolyte imbalance, nausea, vomiting, pulmonary edema, congestive heart failure, and tachycardia.

GLYCEROL
Glycerol (glycerin) is an osmotic diuretic that is administered orally to reduce intraocular pressure in emergency situations.

Dosage Form
Osmoglyn (human label)

Adverse Side Effects
Vomiting may occur after administration.

Technician’s Notes
Glycerol acts more slowly than mannitol.

Topical Anesthetics

Topical anesthetics anesthetize the corneal surface and are commonly used to facilitate removal of a foreign body or sutures, to allow the use of instruments to measure intraocular pressure, or to aid in the application of a hydrophilic contact lens.

Proparacaine Hydrochloride
Proparacaine hydrochloride is a commonly used topical anesthetic. Anesthesia lasts 5 to 10 minutes.

Dosage Form
Ophthaine

Adverse Side Effects
These are very uncommon.

Technician’s Notes
Unopened bottles may be stored at room temperature, but opened bottles should be refrigerated. Any discolored solutions should be discarded.

Ophthalmic solutions should be warmed (i.e., those stored in the refrigerator) to room temperature before administration into the patient’s eye. This can be facilitated by rolling the bottle between the palms of the hands or by placing the bottle under the arm, until the desired temperature is achieved.

Tetracaine and Tetracaine Hydrochloride
Tetracaine and tetracaine hydrochloride are also used for anesthetizing the cornea.

Dosage Forms
1. Pontocaine (human label)
2. Pontocaine hydrochloride (human label)

Adverse Side Effects
These include irritation, which usually is resolved within a short period after administration.

Ophthalmic Stains

Ophthalmic stains are used as diagnostic aids for detecting disease in the anterior and posterior segments and in the nasolacrimal system. Fluorescein stain (i.e., strips) is the most commonly used dye for the detection of corneal epithelial defects. Through wetting of the strip with sterile water or saline, the stain is allowed to cover the eye. The strip should not be allowed to touch the cornea. Excess dye is rinsed from the eye with sterile eye wash. Fluorescein stain is a water-soluble agent. The outer (epithelial) layer of the cornea is a fat-soluble layer, and the stroma just beneath the epithelium is a water-soluble layer. If the epithelium is intact, the stain does not adhere because of differences in solubility. If the epithelium is eroded, as in the case of a corneal ulcer, the stain gains access to the water-soluble stroma, where it adheres and remains after the eye is rinsed. Appearance of fluorescein stain at the nostril
opening indicates functional patency of the nasolacrimal drainage system.

Phenol red is another stain used in the eye. The Phenol Red Thread (PRT) test is used to measure tear production in the eye. The PRT test makes use of a 75-mm-long, yellow thread that is impregnated with phenol red. The thread is inserted into the conjunctival sac for 15 seconds. Tears traveling up the thread turn the thread red. The distance at which the color change occurs is measured and is compared with normal values, as in the Schirmer Tear test.

Rose bengal is another stain that is used in the eye. It is used to detect dead epithelial cells and mucus. It has been found by some clinicians to be useful for detecting dendritic lesions associated with viral keratitis in cats.

**Dosage Form**

Vet-Shield 72

**Technician’s Notes**

1. Do not allow the fluorescein strip to touch the cornea because this could potentially produce a paper cut on the cornea.
2. A good idea is to obtain a sterile 6-cc syringe and place the fluorescein strip into the syringe barrel. Fill the syringe with sterile water and replace the plunger. Invert the syringe several times until the water turns yellow. Simply administer this solution into the eye for the staining procedure.
3. Horses have strong palpebral muscles. If stain is to be used in this species, it may be necessary to have another person keep the eyelids spread apart while the stain is introduced into the eye.
4. Fluorescein stains the hair if allowed to drain onto the face. Use cotton to wipe away excess fluorescein stain because it is softer than a paper towel.

**Topical Ophthalmic Antiinfectives**

**Antiviral Agents**

Antiviral agents may be used to treat viral infections of the eye, such as herpes simplex keratitis (e.g., feline ocular herpes).

**Dosage Forms**

1. Idoxuridine (Stoxil—human label)
2. Trifluridine (Viroptic ophthalmic solution—human label)
3. Acyclovir (Acyclovir ophthalmic ointment available in the United States as a compounded product)

**Antifungal Agents**

Antifungal agents are used to treat ophthalmic fungal infections such as mycotic keratitis, mycotic endophthalmitis, and blepharodermatomycosis. Mycotic keratitis occurs most commonly in horses.

**Dosage Forms**

1. Natamycin (Natacyn—human label)
2. Itraconazole—may be compounded with dimethyl sulfoxide (DMSO)
3. Povidone iodine—compounded to a 0.5% to 1.0% solution
4. Miconazole—1% solution compounded without alcohol

**Antibacterial Agents**

Antibacterial agents are used to treat superficial ocular infections resulting from bacterial organisms.
These drugs are often used in combination with each other to provide broad-spectrum activity.

1. Bacitracin is used topically to treat superficial ocular infections that result primarily from gram-positive bacteria; it is often combined with other antibacterial agents such as neomycin and polymyxin B.
2. Chloramphenicol is available for topical ophthalmic administration and provides broad-spectrum activity. This agent is antagonistic with aminoglycosides.
3. Gentamicin is used topically to treat conjunctivitis caused by susceptible bacterial agents.
4. Polymyxin B sulfate is effective against gram-negative organisms and may be combined with other antibacterial agents to provide broad-spectrum activity.
5. Oxytetracycline is used to treat superficial ocular infections and provides broad-spectrum activity. It may be used in combination with other agents such as polymyxin B.
6. Neomycin provides broad-spectrum activity and is often used in combination with other topical ophthalmic antibacterials.
7. Fluoroquinolone ophthalmic antibiotics are used to treat established gram-negative corneal infections.
8. Tobramycin is used for conditions for which gentamicin is used.
9. Sulfacetamide
10. Ciprofloxacin, norfloxacin, moxifloxacin, and ofloxacin are available as human products.

3. Diclofenac sodium (Voltaren—human label)
4. Suprofen (Profenal—human label)

**Adverse Side Effects**
These are uncommon, but flurbiprofen can cause immunosuppression.

**Topical Corticosteroid Agents**
Corticosteroid agents are used to treat inflammatory conditions of the cornea, iris, conjunctiva, sclera, and anterior uvea. Topical corticosteroids have poor penetration into the eyelid and the posterior segment of the eye (Plumb, 2005). They may be combined with antibacterial agents to manage ocular infections. They are prepared as ointments or solutions. Common corticosteroid agents for ophthalmic use include prednisolone, hydrocortisone, dexamethasone, betamethasone, fluorometholone, and flumethasone.

**Dosage Forms (Partial List)**
1. Prednisolone acetate drops—human label
2. Prednisolone sodium phosphate drops—human label
3. Gentocin Durafilm solution (combination)
4. Anaprine ophthalmic solution
5. Neo-Pred (combination)
6. Pred Forte prednisolone
7. Vetropolycin (combination)
8. Chlorasone (combination)
9. Maxitrol (combination)

**Adverse Side Effects**
Topical corticosteroids can cause problems similar to those caused by systemic corticosteroids. These include delayed healing, steroid dependency, and corneal complications such as ulcerative keratitis.

**Technician’s Notes**
Ophthalmic products that contain corticosteroids are contraindicated in the treatment of deep corneal ulcers, fungal infections, and viral infections.
Agents for the Treatment of Keratoconjunctivitis Sicca

Keratoconjunctivitis sicca (KCS) is a common ocular disorder in dogs. With this disorder, secretion of the lacrimal glands is reduced, resulting in corneal dryness. If left untreated, corneal ulceration and eventual perforation may occur (Tizard, 2000).

Cyclosporine

Cyclosporine is used for the management of KCS and chronic superficial keratitis (CSK, or German Shepherd pannus). It stimulates increased tear production, although its mechanism of action is not fully understood.

Dosage Forms
1. Optimmune Ophthalmic Ointment
2. Cyclosporin A
3. Neoral
4. Sandimmune

Adverse Side Effects
Adverse side effects are uncommon.

Miscellaneous Ophthalmic Agents

Anticollagenase Agents

Anticollagenase agents are used to protect against the melting effects of collagenase and protease enzymes on the cornea.

Dosage Forms
1. Acetylcysteine ophthalmic
2. Edetate disodium ophthalmic

Viscoelastic Substances

Viscoelastic substances are used in ophthalmic surgery to minimize the loss of fluid from the anterior chamber and to maintain ocular space during surgery (Plumb, 2005). Hyaluronic acid and other viscoelastic substances are used as an aid in cataract extraction, ocular implantation surgery, retinal attachment surgery, and others. Ophthalmic texts should be consulted for detailed explanations of the use of these agents.

OTIC DRUGS

When a client obtains a new puppy, the veterinary technician should educate the client regarding the proper way to clean the pup’s ears. Performance of the ear cleaning process at an early age will allow the puppy to submit more readily to the task as an adult dog. Unfortunately, those breeds with pendulous ears may tend to have otic problems. Long ear flaps (i.e., pinnae) tend to keep air from circulating into the ear canal; consequently, the ear canal remains moist, creating a perfect environment for yeast formation. Yeast is not the only problem that veterinarians encounter in dogs and cats. External parasites such as Otodectes cynotis and Otodectes procyonis (i.e., ear mites) can cause extreme
discomfort in animals that are parasitized by these creatures. Patients whose ears remain untreated often experience aural hematoma caused by extreme shaking of the head.

Generally, ear problems are treated with topical medications. Sometimes, ear infections must be treated with systemic medications as well. Topical preparations used to treat ear infections are often a combination of different types of drugs, such as antibacterial, antifungal, antipruritic, and antiinflammatory agents. Still other preparations are cleansers, drying agents, and parasiticides. When a ruptured eardrum is suspected or confirmed, oil-based or irritating external ear preparations (e.g., chlorhexidine) and aminoglycosides should be avoided.

When educating clients about cleaning ears and using otic medications, the veterinary technician should demonstrate how to clean the ear canal. Assure the client that because of the anatomy of the ear, the eardrum is difficult to reach. Emphasize that it is much easier to provide preventive care than to treat infections continually, especially in those dog breeds that are predisposed to ear problems (Figure 10-3).

**Topical Otic Antiinfective Agents**

Many topical otic preparations with antibacterial or antifungal properties are manufactured and available for placement in inventory. Topical otic preparations often contain antiinflammatory agents that reduce inflammation and decrease pruritus. A good idea involves clipping the hair on the inside of the pinna along with any hair that may block the external ear canal. It is also a good idea to use a cleanser before medicating the ear. By cleansing the ear first, the technician removes cerumen and debris from the external canal and allows medicine to work effectively. After the ear is cleaned, it should be dried before treatment is provided.

**Gentamicin Sulfate**

Gentamicin sulfate is an antibacterial agent found in otic preparations. It is commonly combined with a corticosteroid such as betamethasone valerate. Some products also have antifungal properties because of the addition of clotrimazole.

*Figure 10-3*

Structures of the ear.
Clinical Uses
These include the treatment of acute and chronic otitis in dogs. In cats, it may be used to treat superficial infected lesions caused by bacteria susceptible to gentamicin.

Dosage Forms
1. GentaVed Otic Solution
2. Gentocin Otic Solution
3. Otomax (twice-daily treatment)
4. Mometamax (once-a-day treatment)
5. Tri-Otic

Adverse Side Effects
These include possible ototoxicity because gentamicin is an aminoglycoside.

**Technician’s Notes**
1. Patients should be carefully monitored for signs of ototoxicity. Products that lower the pH or produce an acidic environment in the ear can reduce the efficacy of gentamicin.
2. Do not use these products with other agents that may cause ototoxicity.
3. Do not use in the presence of a ruptured eardrum.

Chloramphenicol
Chloramphenicol is an antibacterial agent that is often combined with a corticosteroid such as prednisolone. Products may also contain an anesthetic (tetracaine) and squalane (Cerumene). Squalane enhances the product by speeding up percutaneous penetration of the active ingredients.

Clinical Uses
These include treatment for acute otitis externa and pyoderma in dogs and cats.

Dosage Forms
1. Liquichlor
2. Chlora-Otic

**Technician’s Notes**
Products that contain chloramphenicol cannot be used in animals raised for food production.

Neomycin Sulfate
Neomycin sulfate is an antibacterial agent that is often combined with drugs such as corticosteroids, antifungals, and/or anesthetics.

Clinical Uses
Clinical uses of this antibacterial, antifungal/anti-parasitic, and antiinflammatory combination include the treatment of otitis externa and certain bacterial, fungal, and inflammatory skin disorders.

Dosage Forms
1. Tresaderm
2. Tritop
3. Panalog

Adverse Side Effects
These include sensitivity resulting from the use of neomycin. If such signs (e.g., erythema) develop after treatment, the medication should be discontinued. Ototoxicity is also a potential side effect.

**Technician’s Notes**
1. Do not use in the presence of a ruptured tympanic membrane (i.e., eardrum).
2. Observe the patient for signs of ototoxicity.

Enrofloxacin
Enrofloxacin is available in a combination otic product with silver sulfadiazine (Baytril Otic) and in a combination product with ketoconazole and triamcinolone (BNT).

Dosage Forms
1. Baytril Otic
2. BNT

**Antiparasitics**
Ear mites are ubiquitous in the environment. They are the most common parasite affecting the ears of dogs, cats, and rabbits. These mites are macroscopic, white, and freely motile. Although they occur primarily in the external ear canal, ear mites may be found on any area of the body.
Ear mites can be identified with an otoscope and appear as white, motile creatures within the external ear canal. Ear mites also can be observed microscopically by placing exudate, which can be removed from the ear canal with a cotton-tipped applicator stick, into mineral oil on a microscope slide.

The spinose ear tick (*Otothius megnini*) affects the external ear canal of cattle and horses, and occasionally of dogs and cats. These immature ticks pack the ear canal, which causes discomfort, and should be removed. Periodic treatment of the animal with an insecticide, such as a flea and tick spray, prevents reinfection. Cattle and horses can be treated with topical sprays such as Catron IV. This product should not be used in lactating dairy animals or in household pets.

---

**Technician’s Notes**

Ticks should not be removed with bare hands. Technicians should educate clients not to remove ticks without wearing gloves. Donning a pair of exam gloves (or Playtex gloves for clients at home) and then extracting ticks is better. A pair of thumb forceps can also be employed.

---

**Pyrethrins**

Some products containing pyrethrins are indicated for the treatment of ticks and mites in the ears of dogs and cats.

**Dosage Forms**

1. Cerumite
2. Aurimite
3. Mita-Clear
4. Tresaderm
5. Nolvamite

---

**Rotenone**

Rotenone is an effective agent for the treatment of ear mites in dogs, cats, and rabbits.

**Dosage Forms**

1. Ear miticide
2. Mitaplex-R

---

**Ivermectin/Milbemycin**

Ivermectin has been indicated as an effective treatment for ear mites in dogs and cats. This is an extra-label use of the bovine injectable product Ivermectin. The dose is most often given by subcutaneous injection, although some practitioners place it directly into the external ear canal. In recent years, a product that contains .01% Ivermectin (Acarexx) has been developed for the treatment of ear mites. Milbemycin is available in a 0.1% solution for the treatment of ear mites in cats.

**Dosage Forms**

1. Acarexx (0.01% Ivermectin)
2. MilbeMite (0.1% Milbemycin)

---

**Drying Agents**

Drying agents are used to reduce moisture in the ears. Excess moisture provides a warm, moist environment that is ideal for the growth of certain bacterial and yeast agents, which can cause infection or inflammation. These preparations may also contain an antimicrobial or a corticosteroid. Tannic acid, salicylic acid, acetic acid, and boric acid are commonly used in drying solutions.

**Dosage Forms**

1. Dermal Dry
2. Ace-Otic Cleanser
3. CleaRx

---

**Technician’s Notes**

1. It is recommended that the ears be cleaned before a drying agent or other medication is applied.
2. Some ear-cleansing products also contain drying agents.

---

**Cleaning Agents**

Ear cleansers are used to clean the ears and provide odor control. In the presence of otitis externa, they help to remove necrotic tissue, debris, and wax. Many breeds, as mentioned before, are predisposed to ear
problems, and routine cleaning can often reduce or prevent these problems. These cleansers may also contain an antimicrobial agent, an anesthetic, or a drying agent. Many cleansers contain an agent such as squalane (Cerumene), which helps to break up and soften wax and debris and facilitates cleaning. If wax and debris are impacted in the horizontal canal, it may be necessary to flush the ear canal to remove the wax and debris before starting routine cleaning. The ears may be too painful for the patient to undergo this type of cleaning without general anesthesia. A common solution for flushing the ear canal is a mixture of warm water and chlorhexidine surgical solution diluted 1:100. Flushing may be accomplished with the use of a bulb syringe, a soft rubber feeding tube, or a regular-tipped syringe. It is very important to use gentle pressure when flushing the ear canal to reduce the possibility of damaging the eardrum. Thorough drying of the canal after flushing provides better visualization of the eardrum.

**Dosage Forms (Partial Listing)**
1. Epi-Otic ear cleanser
2. Fresh-Ear
3. Oti-Cleans
4. AloCetic
5. Cerumene
6. Oti-Calm
7. Cerulytic
8. Oti-Clear
9. Xenodyne

---

**Miscellaneous Otic Agents**

**Tris-EDTA**

Tris-EDTA (Ethylendiaminetetraacetic acid) is a topically applied buffer that contains a chelating agent (EDTA); this agent removes calcium and magnesium ions from the lipopolysaccharide covering of gram-negative organisms and the cell walls of gram-negative and gram-positive organisms (Boothe, 2001), and this action facilitates the penetration of antiinfectives. Treatment with tris-EDTA should be carried out before treatment with antibacterials is provided.

**Silver Sulfadiazine**

Silver sulfadiazine is a broad-spectrum agent that is effective against gram-positive and gram-negative bacteria and fungi. It has been used extensively in treating people with skin burns. It is available in one veterinary labeled product (Baytril Otic) and is used off-label in formulated products by some clinicians.

**Dosage Forms**
1. Baytril Otic
2. Silvadene

---

**REFERENCES**


REVIEW QUESTIONS

1. Mydriatic agents are used to _____ the pupils.
2. Atropine is contraindicated in _____ and _____.
3. Miotic agents produce _____ constriction.
4. Why are ophthalmic stains used?
5. _____ stain is the most commonly used dye for the detection of corneal epithelial defects.
6. Patients with ear mites, whose ears are left untreated, often experience _____ hematomas caused by excessive shaking of the head.
7. What type of administration is the most common method of treating disorders of the eye?
8. Why do most topical ophthalmic medications require several applications per day?
9. What is Ophthaine used for?
10. The appearance of fluorescein stain at the nostril opening is an abnormal finding when a fluorescein stain test is performed.
   a. True
   b. False
11. The nictitating membrane is also known as _____.
   a. sclera
   b. cornea
   c. third eyelid
   d. ciliary body
12. Mydriatic agents are used to _____ the pupils.
   a. dilate
   b. constrict
   c. hydrate
   d. teach
13. Atropine ophthalmic agents are used to produce _____.
   a. miosis
   b. mydriasis
14. Epinephrine is contraindicated in _____-angle glaucoma.
   a. closed
   b. open
15. Mannitol is a loop diuretic.
   a. True
   b. False
16. The local anesthesia provided by proparacaine HCl usually lasts ___ to ___ minutes.
   a. 5; 10
   b. 30; 60
   c. 60; 90
   d. 90; 120
17. Fluorescein stain is used commonly to diagnose _____.
   a. glaucoma
   b. corneal ulcers
   c. entropion
   d. ectropion
18. _____ have very strong palpebral muscles, and it may be necessary to have another person assist when one is applying ophthalmic drugs.
   a. Canines
   b. Felines
   c. Equines
   d. Caprines
19. It is acceptable to use corticosteroid-type ointments in patients with corneal ulcers.
   a. True
   b. False
20. _____ has been developed for the treatment of Otodectes spp.
   a. Chloramphenicol
   b. Enrofloxacin
   c. Optimmune
   d. Acarexx
CHAPTER 11

Drugs Used in Skin Disorders

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Exhibit a basic understanding of the anatomy and physiology of the skin.
2. List the common ingredients of topical antiseborrheics.
3. Describe the use of topical antipruritics.
4. Explain the use of fatty acid supplements.
5. Explain the use of astringents.
6. Explain the use of skin antiseptics.
7. Exhibit a basic understanding of wound healing.
8. Describe the use of topical wound dressings.
9. Discuss the use of irritants.
**KEY TERMS**

**ANGIOGENESIS** The development of blood vessels.

**ASTRINGENT** An agent that causes contraction after application to tissue.

**CALLUS** Hypertrophy of the horny layer of the epidermis in a localized area as a result of pressure or friction.

**COLLAGEN** A fibrous substance found in skin, tendon, bone, cartilage, and all other connective tissues.

**COMEDO (PL. COMEDONES)** A plug of keratin and sebum within a hair follicle of the skin.

**DERMATITIS** Inflammation of the skin.

**ERYTHEMA** Redness of the skin caused by congestion of the capillaries.

**EXUDATION** Leakage of fluid, cells, or cellular debris from blood vessels and their deposition in or on the tissue.

**GRANULATION TISSUE** New tissue formed in the healing of wounds of the soft tissue, consisting of connective tissue cells and ingrown young vessels; it ultimately forms a scar.

**INTEGUMENTARY SYSTEM** Pertaining to, or composed of, skin.

**KERATOLYTIC** An agent that promotes loosening or separation of the horny layer of the epidermis.

**KERATOPLASTIC** An agent that promotes normalization of the development of keratin.

**PRURITUS** Itching.

**PYODERMA** Any skin disease characterized by the presence or formation of pus.

**SEBORRHEA** An increase in scaling of the skin; sebum production may or may not be increased.

**SEBORRHEA OLEOSA** Condition characterized by scaling and excess lipid production that forms brownish yellow clumps, which adhere to the hair and skin.

**SEBORRHEA SICCA** Characterized by dry skin and white to gray scales that do not adhere to the hair or skin.

**SEBORRHEIC DERMATITIS** An inflammatory type of seborrhea characterized by scaling and greasiness.

**INTRODUCTION**

Dermatologic conditions are frequently seen in veterinary practice. From ectoparasitic problems to allergies, veterinarians are continually combating companion animal skin problems. As a veterinary technician, this is one area in which your expertise will be used because clients will ask many questions about shampoos, dips, conditioners, soaks, lotions, creams, ointments, sprays, and powders. Each of these products may be used to treat a full spectrum of dermatologic problems from parasites to pyoderma. Patients are often presented for examination of a skin disease when in reality they have an underlying systemic illness. Veterinarians use various diagnostic procedures (e.g., skin scrapings, allergy testing, dermatophyte tests) to determine the cause of skin disease. Technicians play a vital role by obtaining a complete history, knowing how to perform the diagnostic procedures used in a dermatologic workup, and providing client education.

Client education is essential when skin disease is treated because clients must understand the purpose of medications and how they are properly used.

**ANATOMY AND PHYSIOLOGY**

The skin is a part of the integumentary system and constitutes the largest organ in the body. It is made up of three layers (Figure 11-1) and serves multiple functions. It provides a barrier against the outside world by preventing entry of pathogenic microorganisms and by protecting against physical and chemical insults. It senses heat, cold, pain, touch, pressure, and other sensations like pruritus and helps to regulate body temperature through mechanisms related to cutaneous blood flow, sweating, and the haircoat. The skin plays a role in immunologic defense through the actions of Langerhans (dendritic or antigen-presenting) cells and keratinocytes, produces vitamin D, from
precursors in the skin, and acts as a reservoir for electrolytes and other substances. This organ may also play a limited role in the excretion of some substances from the body.

The three primary layers of the skin are the epidermis, the dermis or corium, and the hypodermis or subcutis (also called the panniculus). The dermis provides most of the thickness of the skin. The epidermis is made up of keratinocytes, melanocytes, Langerhans cells, and Merkel cells (Yaphe, 2004). The epidermis is comprised of five distinct layers. These layers are the basal (deepest), spinous, granular, clear, and horny/cornified (superficial) layers. Epidermal cells are replenished in the basal layer and are pushed outward by newly forming layers. As these cells reach the surface, they are flattened and hardened to form a protective barrier. It normally takes 21 to 22 days for cells to reach the outer layer; this process is called the epidermal turnover rate. The epidermal turnover rate may be speeded up in some disease processes. Continual shedding of these cells is called desquamation. When the process becomes excessive, scale or dandruff is seen. The epidermis includes a population of normal microorganisms that help to prevent overgrowth of pathogenic microorganisms.

The dermis or corium is located directly beneath the epidermis and is separated from and attached to it by the basement membrane. The dermis is a thick layer that comprises collagen fibers, blood vessels, nerves, lymphatics, and other structures such as hair follicles, sebaceous glands, and sweat glands. Sebaceous glands are found throughout haired skin, and their ducts empty into hair shafts. One type of sweat gland (eccrine) is found only in footpads and may play a role in body temperature regulation. The dermis gives stability and flexibility to the skin and acts to maintain and repair the skin.

The hypodermis is the deepest layer of the skin. It is made up of fat and connective tissue. Its functions are to provide padding and insulation and to serve as an energy store.

The skin produces hair and other keratinized structures like nail, horn, nasal pads, and footpads. Hair grows from follicles found in the dermis. In contrast to humans, who have one hair per follicle,
dogs and cats have multiple hairs per follicle. Individual hair follicles have associated glandular structures (see earlier) and arrector pili muscles that are responsible for piloerection (hair standing on end). The hair follicle is frequently involved in bacterial, fungal, and demodectic infections. If a hair follicle loses the hair and becomes plugged with sebaceous secretion and keratin, a comedo (blackhead) results. There are three stages or phases of hair growth called anagen (growth), telogen (rest), and catagen (intermediate). Hair grows until it reaches a predetermined length, enters a resting phase, and then is shed. The hair cycle is controlled by day-night length (photoperiod), environmental temperature, hormones, and nutritional status. General illness, skin disorders, poor nutrition, overbathing, and stress are conditions that may result in excessive shedding.

**Topical Antiseborrheics**

Keratolytics and keratoplastics are known as antiseborrheic drugs. These drugs are most often found in medicated shampoos and are available in combinations. Table 11-1 compares products and their uses.

**Sulfur**

Sulfur is commonly found in shampoos and is also available in ointments. It is nonirritating, nonstaining, and safe for cats. Primarily, it is keratolytic and keratoplastic. It is also antipruritic, antibacterial, antifungal, and antiparasitic. It is a mild follicular flusher but is not degreasing.

Client education consists of making sure the client understands the importance of lathering the shampoo well and letting it (the lather) stay on the pet’s body for at least 5 to 10 minutes before rinsing. In this manner, the medication in these shampoos has a greater therapeutic effect. Technicians can bring this to the client’s attention most notably by advising the use of a timer set for a 5- to 10-minute time span.

**Clinical Uses**

Sulfur is used to treat seborrhea sicca.

**Dosage Forms**

1. SebaLyt Shampoo
2. NuSal-T Shampoo
3. Sebolux Shampoo
4. Allerseb-T Shampoo

**Adverse Side Effects**

These include local irritation, which results from excessive and prolonged treatment. Sulfur is not recommended for routine bathing.

**Technician’s Notes**

1. Products that contain sulfur are not recommended for routine bathing.
2. Manufacturers of most products recommend allowing the shampoo to remain on the coat for 5 to 10 minutes before rinsing. Before using this or any other therapeutic shampoo on very dirty pets, it is best to bathe them first in a good cleansing type of shampoo and rinse well. Then, the therapeutic shampoo (sulfur or other) is applied. In this manner, the sulfur does not need to compete with dirt, grease, or parasites to penetrate to the skin to do its job.

**Salicylic Acid**

Salicylic acid is a common ingredient that is found in many antiseborrheic products. It is nonirritating, nonstaining, and safe for cats. It is primarily keratoplastic, but it also has keratolytic, antipruritic, and antibacterial properties.

**Clinical Uses**

These include its combination with sulfur to treat seborrhea sicca. It also may be used to treat hyperkeratotic skin disorders, such as calluses, thickened footpads, and planum nasale. It is an ingredient in many otic preparations.

**Dosage Forms**

1. SebaLyt Shampoo
2. Micro Pearls Advantage Seba-Moist Shampoo
3. KeraSolv Gel

**Adverse Side Effects**

Adverse side effects are uncommon.
### Table 11-1 Common Skin Disorders With Suggested Treatments and Various Products Available

<table>
<thead>
<tr>
<th>Disease</th>
<th>Sulfur</th>
<th>Salicylic Acid</th>
<th>Coal Tar</th>
<th>Benzoyl Peroxide</th>
<th>Chlorhexidine</th>
<th>Hydrocortisone</th>
<th>Therapeutic Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seborrhea sicca</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sebalyt Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sebolux Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Allerseb-T Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LyTar Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pyoben Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sulf/OxyDex Shampoo</td>
</tr>
<tr>
<td>Seborrhea oleosa</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td>Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ChlortHex Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pyoben Gel</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gentocin Topical Spray</td>
</tr>
<tr>
<td>Hot spots</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skinfold dermatitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OxyDex Gel</td>
</tr>
<tr>
<td>Deep pyoderma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pyoben Gel</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pyoben Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sulf/OxyDex Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Systemic antibiotics</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Superficial pustular dermatitis</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pyoben Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>OxyDex Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sulf/OxyDex Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Superficial folliculitis</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ChlorHex Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pyoben Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sulf/OxyDex Shampoo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atopy/ allergic contact dermatitis</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schnauzer comedo syndrome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Technician’s Notes
Products that contain salicylic acid as an active ingredient are not recommended for routine bathing.

Coal Tar
Coal tar is potentially irritating and may stain some light-colored haircoats. It is primarily keratolytic and keratoplastic and is mildly degreasing. The refining process used to produce coal tar solutions helps to decrease the staining effect, strong odor, and potential carcinogenic effect.

Clinical Uses
Coal tar is used to treat seborrhea sicca.

Dosage Forms
1. LyTar Shampoo
2. LyTar Therapeutic Spray
3. Mycodex Tar and Sulfur Shampoo

Adverse Side Effects
These include toxicity in cats.

Technician’s Notes
1. Manufacturers of most products recommend allowing the shampoo to remain on the haircoat for 5 to 10 minutes before rinsing.
2. Benzoyl peroxide may bleach colored fabrics.

Selenium Sulfide
Selenium sulfide is primarily keratolytic, keratoplastic, and degreasing. It is also antifungal.

Clinical Uses
Selenium sulfide is used to treat dry eczema and seborrhea.

Dosage Forms
1. Selsun Plus Medicated Shampoo
2. Selsun Blue Shampoo (human label)
3. Selsun Shampoo (human label)

Adverse Side Effects
These include possible rash or irritation after use.

Technician’s Notes
1. Selenium sulfide can be irritating and may stain.
2. Do not use selenium sulfide on cats.
3. Manufacturers of most products recommend allowing the shampoo to remain on the haircoat for 5 to 10 minutes before rinsing.
4. Human label products tend to be less irritating and tend to stain less.

Topical Medications Mixed With Water

These products may be used in baths or applied with compresses. They possess a number of uses in veterinary medicines.
**Aluminum Acetate**

Aluminum acetate (Burrow’s solution [USP]) is drying, astringent, and mildly antiseptic.

**Clinical Uses**

Aluminum acetate is used in cool water soaks to prevent exudation that may result from inflammation and to relieve itching.

**Dosage Forms**

1. Domeboro powder
2. Domeboro tablets

**Adverse Side Effects**

Adverse side effects are uncommon.

**Technician’s Notes**

One pack of powder or one tablet is mixed with ½ to 1 L of water.

---

**Magnesium Sulfate**

Magnesium sulfate is mixed with water to produce a mildly hypertonic solution for wet dressings.

**Clinical Uses**

Wet dressings that contain magnesium sulfate are used to dehydrate or “draw” water from tissues.

**Dosage Form**

Epsom Salts

**Adverse Side Effects**

Adverse side effects are uncommon.

**Technician’s Notes**

To produce a 1:65 solution, mix 1 tbsp of magnesium sulfate with 1 L of water.

---

**Bath Oils**

Bath oils may be used to manage seborrhea sicca by normalizing keratinization. These may be applied as sprays or diluted and used as a bath rinse. They contain ingredients such as sodium lactate, lanolin, and mineral oil.

**Clinical Uses**

Bath oils are used in the treatment of dry skin and haircoat.

**Dosage Forms**

1. HyLyte efa Bath Oil/Coat Conditioner
2. Alpha Keri Therapeutic Bath Oil (human label)
3. Humilac

**Adverse Side Effects**

Adverse side effects are uncommon.

**Technician’s Notes**

1. Excessive use makes the haircoat greasy and causes it to collect dirt.
2. Humilac is an oil-free humectant that does not cause the haircoat to become greasy.

---

**Topical Antipruritics**

**Nonsteroidal Antipruritics**

Topical antipruritics provide only temporary relief of itching. They are often used in conjunction with systemic or topical corticosteroids or systemic antihistamines. Colloidal oatmeal provides a soothing effect and may be beneficial for a few hours to days. Pramoxine HCl is also used topically as a palliative treatment for itching. These products provide safe and often effective alternatives to corticosteroids.

**Clinical Uses**

Topical antipruritics are used to provide relief of itching discomfort.

**Dosage Forms**

1. Epi-Soothe Shampoo
2. Epi-Soothe Bath Treatment
3. Relief Shampoo
4. Relief Spray
5. Relief Lotion
6. ResiSOOTHE
7. Histacalm
Chapter 11 \ Drugs Used in Skin Disorders

8. ResiHIST
9. ResiPROX

**Adverse Side Effects**
Adverse side effects are uncommon.

**Topical Corticosteroids**
Topical corticosteroids provide relief from itching, burning, and inflammation. They are often combined with other ingredients, such as antimicrobial agents and astringents. Hydrocortisone, triamcinolone, fluocinolone, and betamethasone are corticosteroids that are commonly used in topical preparations. These steroids differ in their potency and duration of action.

**Clinical Uses**
They are used in the treatment of inflammation and pruritus associated with conditions such as moist dermatosis (hot spots) and allergic dermatitis.

**Dosage Forms**
1. Gentocin Topical Spray
2. DermaCool-HC
3. Vetalog Cream
4. Betamethasone dipropionate (Diprosone, Diprolene)
5. Fluocinolone acetonide cream
6. Genesis

**Adverse Side Effects**
Adverse side effects are uncommon.

**Astringents**
Astringents have very little penetration and act to precipitate proteins. They may be used alone or combined with other ingredients. Tannic acid, iodine, alcohol, and phenol are common astringents used in veterinary medicine.

**Clinical Uses**
These include the treatment of moist dermatitis in dogs and cats and weeping skin wounds in large animals. They also are used to toughen the footpads of dogs.

**Dosage Forms**
1. Tanisol
2. Tanni-Gel
3. Stanisol

**Adverse Side Effects**
Astringents may cause irritation.

**Antiseptics for the Skin**
Antiseptics inhibit the growth of bacteria and are found in many dermatologic preparations. They are used in the cleansing and treatment of wounds and may be found in products such as surgical scrubs and shampoos.

**Alcohols**
Alcohols are bactericidal, astringent, cooling, and rubefacient.

**Dosage Forms**
1. 70% ethyl alcohol
2. 70% to 90% isopropyl alcohol

**Adverse Side Effects**
Alcohols may cause irritation of denuded skin surfaces.

**Propylene Glycol**
Propylene glycol is antibacterial and antifungal. Concentrations greater than 50% are keratolytic. Propylene glycol is primarily used as a solvent and a vehicle for other drugs.

**Dosage Forms**
1. Propylene glycol
2. Topical preparations

**Adverse Side Effects**
Erythema can result when propylene glycol concentrations greater than 50% are used.

**Chlorhexidine**
Chlorhexidine is bactericidal, fungicidal, and effective against many viruses. It is nonirritating, is not affected by organic debris, and is safe for cats.
Concentrations of 0.5% to 2% may be found in forms such as shampoos, ointments, surgical scrubs, and solutions.

**Dosage Forms**
1. ChlorhexiDerm Maximum Shampoo
2. Nolvasan Antiseptic Ointment
3. ResiCHLOR
4. KetoChlor

**Adverse Side Effects**
Adverse side effects are uncommon.

**Acetic Acid**
Acetic acid may be found in many otic preparations. It is effective against superficial *Pseudomonas* spp infections of the skin and ears.

**Dosage Forms**
1. Fresh-Ear
2. Clear Ear Cleansing Solution and Drying Solution

**Adverse Side Effects**
Adverse side effects are uncommon.

**Iodine**
Iodine is bactericidal, fungicidal, virucidal, and sporicidal. It may be found in shampoos, surgical scrubs, surgical preparations, ointments, and sprays.

**Dosage Forms**
1. Iodine Tincture
2. Lugol’s Solution
3. Betadine
4. Xenodine Spray

**Adverse Side Effects**
Iodine can be irritating and sensitizing, especially in cats. Most products stain.

**Technician’s Notes**
1. Povidone-iodine is nonstaining.
2. Xenodine is not as irritating as other iodines.

**Benzalkonium Chloride**
Benzalkonium chloride is antifungal and antibacterial but is not effective against *Pseudomonas* spp. Soap and other anionic compounds inactivate it.

**Dosage Forms**
1. Topical wound spray
2. Myosan Cream
3. Dermacid

**Adverse Side Effects**
Toxicity can occur in cats.

---

**WOUND HEALING**

A wound is created when an insult—either purposeful, such as surgery, or incidental, such as trauma—disrupts the normal integrity of the tissue (McCurmin and Bassert, 2002). Normal wound healing can be divided into four stages: inflammation, debridement, repair, and maturation. However, more than one phase of wound healing usually is occurring at any time (McCurmin and Bassert, 2006). The inflammatory phase usually begins with hemorrhage and is limited by vessel contraction and constriction. Serum leakage into the wound deposits fibrinogen and other clotting elements. Later, this serum provides enzymes, proteins, antibodies, and complement. The debridement phase begins about 6 hours after injury and is facilitated by the appearance of neutrophils and monocytes that migrate to the wound. Neutrophils phagocytize bacteria and then die. Monocytes become macrophages and phagocytize necrotic debris. The repair phase is marked by the formation of a blood clot and is usually active by 3 to 5 days post-injury. During the repair phase, fibroblasts produce collagen and other connective tissue proteins. Capillaries infiltrate the wound to provide blood supply and oxygen. This process forms granulation tissue. Epithelial cells proliferate beneath the scab, and the
wound begins to contract. The maturation phase is the end of wound healing and is a period of remodeling. During this time, the wound consolidates and strengthens. Many factors contribute to proper wound healing. These include patient factors (e.g., the age of the patient, nutritional status, rest, environment, and general health); wound factors—including wound characteristics (i.e., contaminated wounds versus noncontaminated wounds); external factors (e.g., temperature regulation [i.e., bandage]); whether or not lavage is performed; and how the wound is closed (e.g., primary, secondary). A veterinarian must consider all these factors when determining how to treat a wound and anticipating how well it will heal.

**Topical Wound Dressings**

The treatment of wounds may involve systemic therapy, bandages, topical medications, or a combination of treatments. Topical dressings are commonly used in the treatment of wounds. These wound dressings are available as ointments, solutions, gels, creams, lotions, sprays, powders, and dressing sheets. The type of dressing and the length of therapy are dependent on the previously mentioned factors that affect wound healing. For example, a degloving injury will take weeks to months for complete healing to occur, whereas a small abrasion may heal in a few days.

**Healing Stimulators**

Some dressings stimulate the activities of wound healing. These products may be used on simple wounds or may be most helpful during the later stages of large wound healing, when less exudate is produced. Some products may be used alone or in combination with other products. Depending on the wound, a bandage may be applied. Many times, a bandage is applied to keep a wound warm because warmth advances the healing process. Advances in products that stimulate healing include the addition of products that contain acemannan or bovine collagen. Acemannan promotes fibroblast proliferation, collagen deposition, angiogenesis, and epithelialization. Products that contain bovine collagen also promote fibroblast proliferation and collagen deposition (Swaim and Gillette, 1998).

**Dosage Forms**

1. Scarlet Oil
2. Zinc Oxide
3. Carravet Wound Dressing
4. BioDres
5. Collamend

**Adverse Side Effects**

Adverse side effects are uncommon.

**Technician’s Notes**

1. It is very important to follow manufacturer recommendations regarding application frequency.
2. Keep bandages dry and clean.
3. Some products may not be suitable for deep or puncture wounds.

**Wound Cleansers**

Wound cleansers are used during the lavage of wounds in an effort to remove necrotic tissue, debris, and bacteria. Some products also act as healing stimulants. These products may be used in the initial cleansing of a wound before a wound dressing is applied. (It should be noted that great benefit is given to the healing process when warm water lavage lasting 15 minutes or longer is performed on the wound.) More extensive wounds will require cleansing at every treatment because of the large amounts of exudate that may be produced during the early stages of healing. It is important that necrotic tissue and purulent debris be removed during cleansing. Some products are applied directly to the wound after cleansing or removal of necrotic tissue. A nonadherent bandage may be applied, and these products will absorb exudate and stimulate the healing process.

**Dosage Forms**

1. Oti-Cleans
2. C-Stat
3. Intracell
4. Dakin’s solution—a 0.5% solution of sodium hypochlorite (bleach)
5. Granulex-V
Adverse Side Effects
These are uncommon, but some products may cause temporary stinging after application.

**Technician’s Notes**
1. These products should not be used on fresh arterial clots.
2. Keep bandages dry and clean.
3. Some products may not be suitable for deep or puncture wounds.

Protectants
Protectants provide a protective environment to assist the healing of noninfected wounds. Some products protect the skin from irritation caused by urine, feces, and tape. They act as a barrier to prevent irritation and allow healing of previously irritated intact skin.

**Dosage Forms**
1. Dermal Wound Gel
2. Thuja-Zinc Oxide Ointment
3. Nexaband
4. Tissuemend
5. No Sting Barrier Film

Adverse Side Effects
Adverse side effects are numerous. Many occur with misuse and long-term use. Side effects most commonly seen with doses used in the treatment of skin inflammation and pruritus include polyuria, polydipsia, and polyphagia, which may result in weight gain.

**Technician’s Notes**
The technician should alert clients to the side effects seen with systemic corticosteroids. Polyuria and polydipsia may be problematic for some household pets. Technicians should always consult the veterinarian when refilling each prescription of systemic corticosteroids and should note the doctor’s approval of the refill on the medical record.

Systemic Corticosteroids
Sometimes it may be necessary to use systemic corticosteroids in the treatment of some dermatosis and dermatitis conditions. These drugs affect immunologic and inflammatory activity. Systemic steroids are available for oral and parenteral administration. The effects of systemic steroids may last from a few hours up to several weeks depending on the type of steroid used. Chapter 9 provides an in-depth discussion of systemic corticosteroids and their effects on the body.

Clinical Uses
In the treatment of dermatologic conditions, systemic corticosteroids are indicated for allergic reactions (e.g., flea bite hypersensitivity, atopy), moist dermatosis (hot spot), seborrheic dermatitis, and acral lick dermatitis.

**Dosage Forms**
1. Dexamethasone injection
2. Depo-Medrol injection
3. Prednisone generic tablets
4. Medrol tablets
5. Vetalog

Topical Antibacterial Agents
Topical antibacterial agents are used in the treatment and prevention of superficial bacterial infections of wounds. These products may contain corticosteroids and antifungal agents. They may require frequent application (i.e., 2 to 3 times daily) and can be used under bandages.
Dosage Forms
1. Bactoderm
2. Nitrofurazone dressing
3. Forte-Topical
4. Prodine solution
5. Furazolidone spray
6. Gentamicin sulfate/betamethasone valerate ointment and spray
7. Gentamicin sulfate/betamethasone valerate/clotrimazole ointment

Technician’s Notes
To achieve good contact with the skin surface, clipping the hair before application is often necessary.

Topical Antifungal Agents
Topical antifungal agents are used in the treatment of superficial fungal infections. They are effective in the treatment of ringworm and for thrush in equines. They are often found in combination with antibacterial agents and corticosteroids. They may necessitate frequent application (i.e., 2 to 3 times daily) and can be used under bandages. Local treatment of fungal infections is not always effective, and the use of systemic antifungal agents may be necessary.

Dosage Forms
1. Conofite
2. Kopertox
3. Miconazole
4. Panalog
5. Iodine Shampoo
6. Clotrimazole cream
7. Cuprimycin cream
8. Tolnaftate cream

Technician’s Notes
1. To achieve good contact with the skin surface, clipping the hair before application is often necessary.
2. Kopertox and products that contain iodine will stain clothes and light-colored hair.

Fatty Acid Supplements
Fatty acids consist of long chains of carbon atoms with a methyl group (−CH₃) at one end. Polyunsaturated fatty acids have varying numbers of double bonds that connect the carbon atoms. Formulas used to identify fatty acids give the number of carbon atoms, followed by the number of double bonds, and finally the distance of the first double bond from the methyl group. The formula for arachidonic acid, (20:4N-6), indicates that this fatty acid has 20 carbon atoms and four double bonds and that the first double bond is six carbon atoms from the methyl group.

Fatty acids that have the first double-bond six-carbon atoms away from the methyl group are called omega-6 (N-6) fatty acids. Those that have the first double-bond three-carbon atoms away are called the omega-3 (N-3) fatty acids (Scott, Miller, and Griffin, 1995). Linoleic acid (18:2N-6) and linolenic acid (18:3N-3) cannot be synthesized by the dog and must be supplied in the diet. For this reason, linoleic and linolenic acids are called essential fatty acids. Arachidonic acid is an essential fatty acid in the cat.

Fatty acids are responsible for the shine of the haircoat and the smooth texture of the skin. It has also been well documented that fatty acid supplementation can play an important role in managing the itching dog or cat. The exact mechanism by which fatty acids help to control itching is not known, but it has been proposed that fatty acids may tie up cyclooxygenase and/or phospholipase (see Chapter 14), thereby inhibiting prostaglandin formation in the skin. A synergistic effect may be achieved by combining fatty acid therapy with the administration of antihistamines or glucocorticosteroids.

Fatty acid supplements are usually derived from fish oil or vegetable oil and may be combined with antioxidant vitamins such as A and E.

Clinical Uses
Fatty acid supplements are used to control itching (pruritus) associated with certain dermatologic conditions of dogs and cats. They also may be used to improve the luster of the skin (Boothe, 2001).
Dosage Forms
1. Dermcaps
2. Dermcaps ES
3. Dermcaps ES liquid
4. EFA-Caps
5. Pet Tabs FA liquid

Adverse Side Effects
Side effects may include vomiting, diarrhea, or increased bleeding times.

Counterirritants
Counterirritants are substances that are applied to the skin of horses to produce local irritation and inflammation. These compounds are sometimes used to treat chronic inflammatory conditions of bone, joints, ligaments, tendons, or other tissues below the surface. The rationale for their use is that creating an acute inflammatory condition promotes blood supply to the inflamed area and adjacent tissue. This increased blood supply brings with it more oxygen, white blood cells, antibodies, complement, and other factors to promote healing. The proper use of counterirritants is complicated because underuse may have little effect and overuse may cause severe tissue damage. The beneficial effects of using counterirritants are controversial, and many clinicians claim that the period of enforced rest (1 to 3 months) for treated animals is actually responsible for the healing effect.

When counterirritants are applied to the skin, three stages of irritation result, depending on the agent applied, the quantity applied, and the way in which it is applied. The three stages are listed below.
1. Rubefaction
2. Vescication
3. Blistering

Rubefaction (reddening) indicates mild irritation accompanied by an increase in blood congestion in the skin. Liniments and “braces” are alcohol-based products that produce a rubefacient effect when massaged into the skin. Liniments and braces usually have alcohol as the primary ingredient and may include oil of wintergreen, camphor, turpentine, thymol, menthol, or ammonia. The major benefits of these products may result from the massage used in their application rather than the medicinal effect. A tightener is a rubefacient compound, similar to a liniment or a brace, that is applied under a cotton leg wrap in an effort to reduce edema around tendons or joints. A sweat usually contains alcohol and glycerin and is applied under a moisture-proof bandage to reduce edema.

Clinical Uses
Counterirritants are used for reducing “filling” (edema) around joints or tendons and associated soreness.

Dosage Forms
1. White Liniment
2. Isopropyl alcohol
3. Lin-O-Gel
4. Shin-O-Gel
5. Absorbine Veterinary Liniment
6. Equ-Lin
7. BIGEOIL
8. SU-PER Sweat
9. Antiphlogistine Poultice
10. SU-PER Poultice

Adverse Side Effects
Tissue irritation may be caused by counterirritants.

Vescication
Vescication, the second stage of counterirritation, is achieved by applying irritating substances under a bandage. Severe irritation accompanied by capillary damage results in vescication or blister formation. Mercuric oxide and cantharide ointments are commonly used as blistering agents. Since the application of vesicants is a painful process that can lead to self-mutilation, they should be applied only under the supervision of a veterinarian.

Clinical Uses
Vescication is used in the treatment of chronic inflammatory musculoskeletal conditions in horses.

Dosage Forms
1. Mercuric oxide
2. Cantharide
Adverse Side Effects
These may include severe tissue damage, worsening of the original condition, and self-mutilation.

Technician’s Notes
Petroleum jelly should not be applied around the site where a vesicant is applied. To do so may damage adjacent tissue.

Caustics
Caustics are substances that destroy tissue at the application site. They are used to destroy excessive granulation tissue (proud flesh), superficial tumors (warts), or horn buds. They should be applied by knowledgeable persons because they can cause damage to adjacent tissue.

Clinical Uses
Caustics are used for the control of proud flesh, the removal of warts, and the removal of horn buds in calves.

Dosage Forms
1. Copper sulfate
2. Silver nitrate
3. Proudsoff
4. Wartsoff
5. Caustic Powder
6. Acidified Copper Sulfate
7. Caustic Dressing Powder
8. Equi-Phar Proud Blue Liquid
9. Dehorning Paste

Adverse Side Effects
These may include damage to adjacent tissue, especially the eye when used on the horn buds.

Miscellaneous Drugs
Some drugs used for behavior modification in cats and dogs can be used in dermatologic conditions such as feline psychogenic alopecia and canine acral lick dermatitis (Merck, CD-ROM, ed. 8). These conditions occur because of excessive self-licking. Tricyclic antidepressants are potent H₁ blockers that also inhibit the uptake of serotonin and norepinephrine.

Clinical Uses
These drugs are used to modify behavior in such a way that excessive self-licking may be decreased. They may be used in the treatment of feline psychogenic alopecia and canine acral lick dermatitis.

Dosage Forms
1. Phenobarbital
2. Diazepam (Valium)
3. Amitriptyline
4. Fluoxetine
5. Naloxone
6. Naltrexone

Adverse Side Effects
Side effects include sedation, idiosyncratic fatal hepatic necrosis in cats, dry mouth, hypersalivation, vomiting, constipation, urinary retention, ataxia, disorientation, depression, and anorexia.

Selective Immunosuppressors
Cyclosporine A (ATCvet code QL04A A01) is used as a selective immunosuppressors in the treatment of atopic dermatitis. It is a cyclic polypeptide that acts specifically and reversibly on T-lymphocytes. It has antiinflammatory and antipruritic activities that aid in the treatment of atopic dermatitis. Cyclosporine inhibits the antigen-triggered release of lymphokines by activated T-lymphocytes and by activated T-cells. It also inhibits activation of eosinophils, keratinocyte cytokine production, Langerhans cell function, and degranulation of mastocytes. Cyclosporine does not interrupt hemopoiesis and does not interfere with the function of phagocytic cells (Novartis, 2007).

Dosage Forms
Cyclosporine (Atopica)
Adverse Side Effects
The most frequently observed undesirable effects are gastrointestinal disturbances such as vomiting, mucoid or soft stools, and diarrhea. These effects are usually mild and generally do not require cessation of treatment with Atopica (Novartis Animal Health Inc., New London, Connecticut, USA). Sometimes (very rarely), muscle cramps, muscle weakness, anorexia, gingival hypertrophy, verruciform lesions, or changes in haircoat have been observed (Novartis, 2007).

REFERENCES

REVIEW QUESTIONS

1. The skin consists of ________________ layers and is part of the ________________ system.

2. ________________ is essential for healthy skin.

3. Name seven functions of the skin.
   ________________

4. Shampoos are more effective if left on the skin about _________ to _________ minutes before rinsing.

5. Keratolytics and keratoplastics are known as ________________ agents.

6. Name the four stages of wound healing.
   ________________

7. What does an astringent do to the skin?
   ________________

8. Tissue irritation may be caused by counterirritants.
   a. True
   b. False

9. Patients are commonly presented for skin problems when in reality they may have a ________________ illness.

10. Why are behavioral-type drugs used in treating skin illness? ________________

11. All patients presented for dermatologic problems have an underlying systemic illness.
    a. True
    b. False

12. The ____ is the largest organ in the body.
    a. liver
    b. spleen
    c. skin
    d. stomach
    e. intestinal tract

13. Increased skin irritation may result in hyperpigmentation of the skin.
    a. True
    b. False

14. Humans have multiple hairs per follicle, but animals have one hair per follicle.
    a. True
    b. False

15. Shampoos should be left on the animal's skin for 5 to 10 minutes before rinsing.
    a. True
    b. False

16. The debridement stage of wound healing usually begins to occur about ___ hour(s) after injury.
    a. 2
    b. 3
    c. 1
    d. 6

17. During the repair phase of wound healing, fibroblasts produce _______ and other connective tissue proteins.
    a. angiogenesis
    b. collagen
    c. comedones
    d. hyperpigmentation

18. The maturation phase marks the beginning of wound healing.
    a. True
    b. False

19. _______ tissue is formed during healing of wounds of the soft tissue that consists of connective tissue cells and ingrown young vessels, which ultimately form a scar.
    a. Collagen
    b. Keratolytic
    c. Callus
    d. Granulation

20. _______ is a product that is used in horses to treat thrush.
    a. Conofite
    b. Miconazole
    c. Kopertox
    d. Panalog
CHAPTER 12
Antiinfective Drugs

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Identify the classes of antiinfective drugs.
2. Describe the adverse side effects of antiinfective drugs.
3. Explain the clinical uses of antiinfective drugs.
4. Discuss antiviral drugs.
5. Explain how disinfectants and antiseptics are used.
**KEY TERMS**

**Antibacterial** An agent that inhibits bacterial growth, impedes replication of bacteria, or kills bacteria.

**Antibiotic** An agent produced by a microorganism or semisynthetically that has the ability to inhibit the growth of or kill microorganisms.

**Antimicrobial** An agent that kills microorganisms or suppresses their multiplication or growth.

**Bacteria** Single-celled microorganisms that usually have a rigid cell wall and a round, rod-like, or spiral shape.

**Bactericidal** An agent with the capability to kill bacteria.

**Bacteriostatic** An agent that inhibits the growth or reproduction of bacteria.

**Beta-Lactamase** Enzymes that reduce the effectiveness of certain antibiotics; beta-lactamase I is penicillinase; beta-lactamase II is cephalosporinase.

**Dermatophytosis** A fungal skin infection.

**Detergent** An agent that cleanses.

**Disinfect** To make free of pathogens or make them inactive.

**Fungicidal** An agent that kills fungi.

**Fungistatic** An agent that inhibits the growth of fungi.

**In Vitro** Within an artificial environment.

**In Vivo** Within the living body.

**Iodophor** An iodine compound with a longer activity period that results from the combination of iodine and a carrier molecule that releases iodine over time.

**Microorganism** An organism that is microscopic (e.g., bacterium, protozoan, Rickettsia, virus, and fungus).

**Sporicidal** An agent capable of killing spores.

---

**INTRODUCTION**

Microorganisms are ubiquitous in the environment. Some microorganisms have pathogenic potential, but others do not. Animals usually make initial contact with an infectious agent somewhere on the body's surface (e.g., mucous membranes, skin, respiratory tract, digestive tract). In the fight against infection, several hundred antimicrobial drugs have been developed since the early 1900s. These drugs have been used to fight disease in both humans and animals.

Not all antimicrobials have the same degree of effectiveness against microorganisms. A determination can be made to distinguish different types of bacteria with the use of a Gram stain. The Gram stain is a laboratory procedure in which dyes are used to stain bacteria (Figure 12-1). Gram-positive bacteria stain dark blue to purple. Gram-negative bacteria stain pink to red. However, some bacteria cannot be identified through the Gram stain technique. To differentiate acid-fast bacilli, carbol fuchsin stain can be used and then decolorized with ethyl alcohol and hydrochloric acid. Other bacteria must be identified by special techniques such as dark-field examination or Gimenez stain. Giemsa and Wright stains may be used to identify parasites and intracellular microorganisms. Bacteria with similar staining properties tend to respond to the same antimicrobial therapy. Still other bacteria are classified by their ability to survive with or without oxygen. Aerobes are bacteria that must have oxygen to live and replicate. Other bacteria are able to live and multiply without oxygen; these are known as anaerobes. Anaerobes may be hardy and difficult to eradicate.

**MECHANISM OF ACTION**

Through analysis of the effects that a drug's action has on bacteria, antimicrobial drugs can be divided into two categories: bactericidal and bacteriostatic. However, some strains of mutant bacteria have greater resistance to some antimicrobials. Resistant strains of bacteria can make antimicrobial therapy difficult. Therefore, to prevent mutant strains from developing, antimicrobial drugs must not be used indiscriminately. Sometimes, it may be necessary to use two different types of antimicrobial drugs to treat patients with infections caused by two or more different organisms.
After a laboratory has identified the type of organism that is causing an infection, a sensitivity test may be performed. Several tests are available for testing the susceptibility of an organism to a specific antimicrobial drug. Most commonly, the disk susceptibility test is used in small laboratories (Figure 12-2). With this test, an agar plate with a standard amount of cultured organism is used. With the use of a dispenser, paper disks impregnated with various antimicrobial drugs are placed within the agar plate. Incubation is carried out, along with measurement of the zones of inhibition. These zones show which antimicrobial agents are susceptible or resistant to each particular antimicrobial, and how effectively they may perform in vitro. The Kirby-Bauer procedure is commonly used in many laboratories.

The broth dilution susceptibility test is used in many laboratories (Figure 12-3). An organism is inoculated into a series of tubes or wells in a microculture plate. These tubes or wells contain different concentrations of antimicrobials. The lowest concentration that macroscopically inhibits the growth of an organism is the minimum inhibitory concentration (MIC). The MIC represents the degree of susceptibility of an organism to a specific concentration of a particular antimicrobial drug. The antimicrobials that are effective in vitro may not always be the best choice for use in vivo. A clinician chooses which agent to use by considering the diagnosis and assessing each agent's pharmacodynamics and pharmacokinetics. This process allows a clinician to choose the most efficient and efficacious drug to treat a specific condition.
today's arsenal of drugs. Researchers have developed natural and semisynthetic compounds that display varied antimicrobial spectra (Table 12-1).

Many penicillin formulations may “settle out” (i.e., precipitate) during nonuse and must be shaken well before use. Additionally, when oral preparations are reconstituted, it is important to add appropriate amounts of water so that dilution does not occur (e.g., when amoxicillin oral preparations are mixed). Many oral preparations are stable for only 7 to 14 days. Most penicillin formulations must be stored in the refrigerator, and the veterinary technician must tell clients that oral prescriptions for pets should be administered until the entire therapeutic time frame has been completed.

**Pharmacokinetics**

Absorption of most orally administered penicillins takes place in the stomach and small intestine (i.e., the duodenum). Most injected penicillins are absorbed rapidly at the injection site and are distributed rapidly through the tissue. The kidneys are the primary organs for excretion of penicillins, although the liver metabolizes other penicillins. Withdrawal times for dairy cows must be adhered to because penicillins are excreted through the milk. Veterinary technicians should be aware of the withdrawal rates of penicillin and should ensure that proper directions are included on the prescription label, especially for clients who are beef and dairy producers.

**Pharmacodynamics**

Research has shown that penicillins bind reversibly with enzymes outside the bacterial cytoplasmic membrane. These enzymes, called penicillin-binding proteins (PBP5), are involved in cell wall synthesis and cell division; when this binding occurs, it increases internal osmotic pressure and ruptures the cell. Some bacteria produce beta-lactamase (penicillinase), which increases the resistance of bacteria by converting penicillin to inactive penicillic acid. Some penicillins are more resistant to beta-lactamase hydrolysis and are referred to as beta-lactamase-resistant or penicillinase-resistant penicillins. Penicillins are usually very effective against gram-positive bacteria, but gram-negative bacteria have an outer membrane

---

**Technician's Notes**

*Special Considerations When Antimicrobial Drugs Are Used*

1. Do not use antimicrobial drugs for mild infection.
2. Antimicrobials should be used only for individuals at risk of severe infection.
3. Do not dismiss the principles of asepsis just because there are many antibiotics from which to choose.
4. The use of antimicrobials should be based on a definitive diagnosis.
5. Do not use a broad-spectrum antibiotic if the infecting organism is sensitive to a specific antibiotic.
6. Antimicrobial drugs should be administered in full therapeutic doses.
7. If an antimicrobial can be used topically or locally, do so. This reserves the use of systemic drugs for serious disease.
8. Be careful regarding antibiotic withdrawal times in animals to be slaughtered for human consumption and antibiotic withdrawal times in dairy cows.
   a. Penicillin G benzathine is long-acting (48 hours) and is not approved for use in dairy animals.

---

**Penicillins**

Penicillin was developed during the 1940s and remains very important as an antimicrobial drug, even though many other antimicrobials are available in
## Table 12-1 Penicillin Preparations, Indications, and Antagonistic Drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications</th>
<th>Antagonist</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Narrow-Spectrum Penicillins</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillin G sodium</td>
<td>Infections caused by penicillin-sensitive organisms: bacterial pneumonia, upper respiratory tract infections, equine stranggles, blackleg, infected wounds, urinary tract infections (at high doses)</td>
<td>Tetracyclines, chloramphenicol, and paromomycin</td>
<td>May add to sodium load</td>
</tr>
<tr>
<td>Penicillin G potassium</td>
<td>Same as for penicillin G sodium</td>
<td>Same as for penicillin G sodium</td>
<td>May produce hyperkalemia (IV); delayed absorption in horses (IM); unreliable absorption</td>
</tr>
<tr>
<td>Penicillin G procaine</td>
<td>Same as for penicillin G sodium</td>
<td>Same as for penicillin G sodium</td>
<td>Never give IV; contraindicated in some exotics and horses that race; pre-slaughter withdrawal and milk withholding periods</td>
</tr>
<tr>
<td>Penicillin G benzathine</td>
<td>Same as for penicillin G sodium</td>
<td>Same as for penicillin G sodium</td>
<td>Never give IV; pre-slaughter withdrawal required, and may persist in dairy cattle milk for 2 weeks</td>
</tr>
<tr>
<td><strong>Narrow-Spectrum, Acid-Resistant Penicillins</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillin V</td>
<td>Mild infections already controlled by parenteral therapy</td>
<td>Same as for penicillin G sodium</td>
<td>Should not be administered with food; less active against gram-negative bacteria than penicillin G</td>
</tr>
<tr>
<td><strong>Beta-Lactamase-Resistant Penicillins</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methicillin</td>
<td>Pyodermaatitis, otitis externa, and other conditions caused by <em>Staphylococcus aureus</em></td>
<td>Same as for penicillin G sodium</td>
<td>Not stable in solution; many incompatibilities in vitro</td>
</tr>
<tr>
<td>Cloxacillin</td>
<td>Same as for methicillin</td>
<td>Same as for penicillin G sodium</td>
<td>Frequently used in dry-cow intramammary preparations</td>
</tr>
<tr>
<td>Dicloxacillin and floxacinil</td>
<td>Same as for methicillin</td>
<td>Same as for penicillin G sodium</td>
<td>Absorbed from GI tract better than cloxacillin</td>
</tr>
<tr>
<td>Oxaclillin</td>
<td>Same as for methicillin</td>
<td>Sulfonamides</td>
<td>Not absorbed as well as cloxacillin</td>
</tr>
<tr>
<td><strong>Broad-Spectrum Penicillins</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ampicillin and metacillin</td>
<td>Infection of organs and tissues caused by ampicillin-sensitive bacteria</td>
<td>Chloramphenicol, erythromycin, tetracyclines, cephaloridine</td>
<td>Incompatible with many drugs and solutions; food impairs absorption; milk withholding and pre-slaughter withdrawal times</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>Same as for ampicillin</td>
<td>Same as for ampicillin</td>
<td>Absorbed from GI tract better than ampicillin</td>
</tr>
<tr>
<td>Drug</td>
<td>Indications</td>
<td>Antagonist</td>
<td>Comments</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Piperacillin Carbenicillin sodium</td>
<td>Same as for ampicillin Same as for ampicillin, but especially <em>Pseudomonas</em> infections</td>
<td>Aminoglycosides</td>
<td>Freshly mixed solutions should be used</td>
</tr>
<tr>
<td>Broad-Spectrum Penicillins</td>
<td></td>
<td>Same as for ampicillin</td>
<td>Absorbed rapidly from the GI tract</td>
</tr>
<tr>
<td>Carbenicillin indanyl</td>
<td>Same as for carbenicillin sodium</td>
<td>Same as for ampicillin</td>
<td>Used as an intrauterine infusion in mares</td>
</tr>
<tr>
<td>Ticarcillin</td>
<td>Same as for carbenicillin sodium</td>
<td>Same as for ampicillin</td>
<td>Capsules/tablets that are not kept in air-tight containers lose activity; do not give to patients allergic to penicillins or cephalosporins</td>
</tr>
<tr>
<td>Potentiated Penicillins</td>
<td>Amoxicillin-potassium clavulanate (4:1) Wide range of infections when used in combination</td>
<td>Same as for ampicillin</td>
<td>Same as for ampicillin</td>
</tr>
<tr>
<td>Inhibitor of Tubular Secretion of Penicillins</td>
<td>Probenecid Prolongs blood levels of penicillins that have very short plasma half-lives or that are extremely costly</td>
<td>Same as for ampicillin</td>
<td></td>
</tr>
</tbody>
</table>

around the cell wall that limits PBP permeability. Some penicillins have an increased ability to penetrate this outer membrane and may be more effective against gram-negative bacteria.

**Clinical Uses**

Penicillins are used to treat individuals with bacterial infections resulting from penicillin-susceptible microorganisms.

**Dosage Forms**

1. Amoxicillin (tablets and oral liquids for dogs and cats)
   a. Amoxicillin
e   b. Amoxi-Tabs
e   c. Amoxi-Drops
e   d. Amoxi-Inject
e   e. Robamox
e   f. Biomox
g. Amoxicillin trihydrate
   i. Many brands are available
2. Amoxicillin (Veterinary)
a. Amp-Equine
   b. Amoxicillin trihydrate (Polyflex)
c. Withdrawal times (at 6 mg/kg)
   i. Meat = 6 days
   ii. Milk = 48 hours
3. Carbenicillin
   a. Geopen
   b. Pyopen
4. Cloxacillin
   a. Cloxapen
   b. Orbenin
c. Tegopen
5. Dicloxacillin
   a. Dynapen
6. Penicillin G
   a. Many brands available
   b. Penicillin G, potassium or sodium
c. Penicillin G, benzathine: Benza-Pen, Benzylpenicillin (many brands available)
d. Penicillin G, procaine
   i. Many brands available
e. Penicillin V: Pen-Vee
f. Amoxicillin trihydrate
   i. Many brands available
g. Withdrawal time (cattle)
   i. Meat = 4 days
   ii. Milk = 48 hours
   iii. Calves = 7 days
h. Withdrawal time (sheep)
   i. 8 days
   i. Withdrawal time (swine)
   i. 6 days
j. Withdrawal time at higher doses (i.e., off-label doses)
   i. Meat = 21 days

7. Ticarcillin
   a. Ticar
   b. Ticillin

Adverse Side Effects
Allergic reactions, vomiting and diarrhea, or enteritis may occur in cattle and horses when treatment is administered orally. Hives or respiratory distress also may occur because of possible sensitivity reactions to penicillin. Epinephrine should be administered STAT if respiratory distress is severe.

Technician’s Notes
1. Subcutaneous (SC) administration of penicillin G or benzathine penicillin should be avoided because of potential tissue injury and residue potential in food animals.
2. Penicillin should not be used in horses intended for food.
3. Carefully read labels concerning milk withholding times and the treatment of animals to be slaughtered for food.
4. Penicillin G benzathine is long-acting (48 hours) and is not approved for use in dairy cattle.

Amoxicillin + Clavulanate Potassium
Known as Augmentin in human medicine, Clavamox (veterinary) is a beta-lactam antibiotic + beta-lactamase inhibitor. Clavamox is a broad-spectrum antibiotic that is used to treat skin infection, urinary tract infection, wound infection, and respiratory infection. Clavamox is supplied in tablet and liquid forms for oral administration.

Dosage Form
1. Amoxicillin + clavulanate potassium
   a. Clavamox tablets
   b. Clavamox liquid

Adverse Side Effects
Although allergic reactions may occur, this drug usually is well tolerated. Vomiting and diarrhea may occur in some animals when this drug is administered orally.

Technician’s Notes
Use with caution in animals with allergies to penicillin.

Cephalosporins
Cephalosporins are used primarily in small-animal medicine. However, a few have been developed for use in large-animal medicine. This group of drugs is classified into generations according to spectrum of activity (Table 12-2).

Pharmacokinetics
Most cephalosporins are administered parenterally because they lack the ability to be well absorbed by the gastrointestinal (GI) tract. Once absorbed, cephalosporins are distributed to tissues and fluids, with the exception of the central nervous system (CNS). Some cephalosporins are absorbed into the cerebrospinal fluid, but this absorption is limited. Metabolism occurs in the liver, with elimination occurring in the kidneys by glomerular filtration and tubular secretion into the urine. Therefore, doses must be modified for patients in renal failure. With a few exceptions, cephalosporins are excreted through the feces via the biliary system.
### Table 12-2 Cephalosporin Preparations, Indications, and Antagonistic Drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications</th>
<th>Antagonist</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefadroxil</td>
<td>Infections caused by sensitive organisms in the respiratory tract, skin, urinary tract, soft tissue, bones, joints, etc.</td>
<td>All cephalosporins: gentamicin</td>
<td>Ingestion of food does not impair absorption</td>
</tr>
<tr>
<td>Cephalexin</td>
<td>Urinary tract infections</td>
<td></td>
<td>Ingestion of food may delay absorption</td>
</tr>
<tr>
<td>Cephalothin</td>
<td>Infections caused by sensitive organisms in the respiratory tract, skin, urinary tract, soft tissue, bones, joints, etc.</td>
<td></td>
<td>IM injection painful; inactivated in liver</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>Same as for cephalothin</td>
<td></td>
<td>Highly protein bound; very rarely nephrotoxic</td>
</tr>
<tr>
<td>Cephamycin</td>
<td>Same as for cephalothin</td>
<td></td>
<td>Intramammary infusion for mastitis</td>
</tr>
<tr>
<td>Cefamandole</td>
<td>Life-threatening, gram-negative infections</td>
<td></td>
<td>Dose should be reduced in patients with renal failure</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>Treatment of susceptible infections</td>
<td></td>
<td>Local reaction may occur at injection site</td>
</tr>
<tr>
<td>(a cephamycin)</td>
<td></td>
<td></td>
<td>May be used in lactating dairy animals</td>
</tr>
<tr>
<td>Cefiotur HCl</td>
<td>Treatment of respiratory disease in cattle and swine; broad spectrum against gram-positive and gram-negative bacteria including beta-lactamase—producing strains</td>
<td></td>
<td>May be used in lactating dairy animals</td>
</tr>
<tr>
<td>Cefiotur sodium</td>
<td>Treatment of respiratory disease in cattle, sheep, horses, and swine; urinary tract infections in dogs; and for control of early mortality associated with E. coli organisms in day-old chicks and day-old turkey poults; broad spectrum against gram-positive and gram-negative bacteria including beta-lactamase—producing strains</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Pharmacodynamics

Similar to penicillins, cephalosporins interfere with cell wall synthesis by binding to the bacterial enzymes (PBPs). The spectrum of activity of a cephalosporin is revealed by the drug’s ability to penetrate the bacterial cell wall and bind with proteins within the cytoplasmic membrane. Another similarity between cephalosporins and penicillins is the susceptibility of cephalosporins to beta-lactamases (cephalosporinases), which can be produced by certain bacteria. Some cephalosporins are more effective in treating individuals with infection caused by bacteria that produce beta-lactamase II.

### Technician’s Notes

1. Naxcel is approved for use in lactating dairy animals.
2. Remember to read package inserts regarding milk withholding time and withholding time in animals to be slaughtered.
Clinical Uses
Cephalosporins are used to treat cystitis, skin and soft tissue infections in dogs and cats, bovine mastitis, shipping fever, and other respiratory infections in cattle, horses, sheep, and swine. Ceftiofur sodium (Naxcel) also is approved for use in day-old chicks and day-old turkey pouls for control of early mortality associated with Escherichia coli organisms.

Dosage Forms
1. Cefaclor (second-generation cephalosporin antibiotic)
   a. Cefclor
2. Cefadroxil (first-generation cephalosporin antibiotic)
   a. Cefa-Tabs
   b. Cefa-Drops
3. Cefazolin (first-generation cephalosporin antibiotic)
   a. Ancef
   b. Kezol
   c. Many other brands available
4. Cefepime (fourth-generation cephalosporin antibiotic)
   a. Maxipime
5. Cefotaxime (third-generation cephalosporin antibiotic)
   a. Claforan
6. Cefotetan (second-generation cephalosporin antibiotic)
   a. Ceforan
7. Cefoxitin (second-generation cephalosporin antibiotic)
   a. Mefoxin
8. Ceftazidime (third-generation cephalosporin antibiotic)
   a. Fortaz
   b. Ceptaz
   c. Tazicef
   d. Tazidime
9. Ceftiofur (third-generation cephalosporin antibiotic)
   a. Naxcel
   b. Excenel
10. Cephalexin (first-generation cephalosporin antibiotic)
    a. Keflex and generic forms

11. Cephalothin (first-generation cephalosporin antibiotic)
    a. Kellin
12. Cephradine (first-generation cephalosporin antibiotic)
    a. Velosef
13. Cefodoxime (third-generation cephalosporin)
    a. Simplicef, administered once daily

Adverse Side Effects
Cephalosporins are usually safe for use in animals. However, allergic reactions can occur. Rare bleeding disorders have been reported with some cephalosporins. Others have caused seizures, although this occurrence is rare. Vomiting and diarrhea have been reported in some individuals.

Technician’s Notes
1. Carefully read labels regarding milk withholding time after mastitis treatment and use in animals to be slaughtered.
2. Naxcel is approved for use in lactating dairy animals.

Tetracyclines
Tetracyclines can be administered parenterally or orally. The tetracyclines most commonly used in clinical practice are tetracycline, oxytetracycline, doxycycline, and minocycline (Table 12-3).

Pharmacokinetics
When tetracyclines are administered, they are distributed quickly throughout the tissue and sometimes penetrate into the CNS. Decreased metabolism occurs with most tetracyclines; thus, they are eliminated from the body in active form. Elimination occurs most often by glomerular filtration but sometimes may be achieved through biliary excretion routes.

Pharmacodynamics
Tetracyclines work by inhibiting protein synthesis, thereby impeding bacterial cell division. They offer a broad spectrum of activity against gram-positive
Table 12-3 Tetracycline Preparations, Indications, and Antagonistic Drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications</th>
<th>Antagonist</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytetracycline</td>
<td>Infections of organs or tissues caused by tetracycline-sensitive strains; anaplasmosis; often ineffective for endocarditis, empyema, meningitis, septic arthritis, and osteomyelitis</td>
<td>Antacids, milk, diuretics, methoxyflurane, penicillins, ferrous sulfate</td>
<td>Long withdrawal times in cattle; shock reaction may occur when given intravenously in horses; diarrhea also common in horses</td>
</tr>
<tr>
<td>Chlortetracycline</td>
<td>Same as for oxytetracycline</td>
<td>Antacids, milk, diuretics, methoxyflurane, penicillins</td>
<td></td>
</tr>
<tr>
<td>Tetracycline</td>
<td>Same as for oxytetracycline</td>
<td>Same as for oxytetracycline</td>
<td>These drugs are potent broad-spectrum tetracyclines</td>
</tr>
<tr>
<td>Doxycycline, minocycline</td>
<td>Same as for oxytetracycline, but much better tissue penetration; doxycycline is especially useful for canine ehrlichiosis</td>
<td>Minocycline—same as for chlortetracycline; doxycycline—same as for oxytetracycline, barbiturates, and carbamazepine</td>
<td></td>
</tr>
</tbody>
</table>

and gram-negative bacteria. They are bacteriostatic, although at high dose concentrations they may become bactericidal.

Clinical Uses

Tetracyclines are used to treat respiratory tract infection, bacterial enteritis, and urinary tract infection caused by tetracycline-susceptible microorganisms. Tetracyclines also are used to treat rickettsial diseases (e.g., borreliosis [i.e., Lyme disease], Rocky Mountain spotted-tick fever).

Dosage Forms

1. Chlortetracycline
   a. Anaplasmosis block
   b. Aureomycin soluble powder
   c. Aureomycin tablets
   d. Aureomycin soluble calf oblets
   e. Calf scour bolus
   f. Fermycin
2. Doxycycline
   a. Vibramycin
   b. Monodox
   c. Doxy caps
   d. Many other brands available
3. Minocycline
   a. Minocin
4. Oxytetracycline
   a. Biomycin
   b. Oxybiotic
   c. Oxy-Tet
   d. Terramycin
   e. Terramycin scour tablets
   f. Terramycin soluble powder
   g. Long-acting formulations include the following:
      i. Liquamycin-LA 200
      ii. Biomycin 200
5. Tetracycline
   a. Panmycin
   b. Duramycin powder

Adverse Side Effects

Tetracyclines may cause renal problems when administered at high doses, can affect formation of bones and teeth (cause staining of teeth) in young animals, should never be given to horses intravenously, and may cause drug fever in cats; some hepatotoxicity may occur at increased doses, especially in susceptible individuals.
Hidden page
high concentrations in renal cortical tissue, adequate renal function is necessary for their use. Ettinger (2001) recommends monitoring nephrotoxicity by obtaining a pretreatment serum creatinine level and comparing that with values from samples taken during treatment. Any significant change in the serum creatinine level could indicate the need for termination of treatment. Another area of concentration is the inner ear, in which concentration levels do not diminish until treatment has been completed. The ototoxicity that occurs may be vestibular or auditory.

**Pharmacodynamics**

Aminoglycosides work similarly to tetracyclines by inhibiting protein synthesis and impeding bacterial cell division. Aminoglycosides have a broad spectrum of activity but should be used only in specific cases of gram-negative infection. Streptococcal bacteria species do not show much sensitivity to aminoglycosides (Ettinger, 2001). They are most often effective against anaerobic bacteria.

**Clinical Uses**

Aminoglycosides are used to treat patients with pneumonia, endometritis, urinary tract infection, bacterial enteritis, conjunctivitis, and skin and soft tissue infections caused by aminoglycoside-susceptible microorganisms.

**Dosage Forms**

1. Amikacin
   a. Amiglyde-V
2. Gentamicin
   a. Gentocin
3. Kanamycin
   a. Kantrim
4. Neomycin
   a. Biosol

**Adverse Side Effects**

Because intestinal bacterial flora may be disrupted during therapy with this drug, diarrhea may occur. Other side effects include neuromuscular blockage (when used with anesthetic agents), nephrotoxicity, and ototoxicity.

---

**Fluoroquinolones**

Fluoroquinolones are relatively new to veterinary medicine and have been approved for use in dogs, cats, turkeys, chickens, and cattle. Their use in horses continues to be controversial and is not approved (Plumb, 2005). Fluoroquinolones approved for use in veterinary medicine include enrofloxacin, difloxacin hydrochloride, orbifloxacin, sarafloxacin, and marbofloxacin. Fluoroquinolones exhibit broad-spectrum activity against gram-positive and gram-negative bacteria.

**Pharmacokinetics**

Fluoroquinolones are available for oral and parenteral administration. After administration, they are readily absorbed into tissue and body fluids. Metabolism occurs in the liver, and elimination occurs via the kidneys into urine or through bile into the intestines.

**Pharmacodynamics**

The broad spectrum of activity offered by the fluoroquinolones is bactericidal against many different pathogens. The effect of fluoroquinolones is achieved through inhibition of or interference with the bacterial enzyme DNA-gyrase.
Hidden page
body and can reach therapeutic levels in the cerebrospinal fluid (Plumb, 2005).

**Clinical Uses**
Florfenicol is approved for the treatment of patients with bovine respiratory disease associated with *Pasteurella haemolytica*, *P. multocida*, and *Haemophilus somnus*.

**Dosage Form**
Nuflor injectable solution

**Adverse Side Effects**
Adverse side effects include transient inappetence, decreased water consumption, and diarrhea.

---

**Technician’s Notes**
1. Florfenicol is not approved for use in female dairy cattle 20 months of age or older and should not be used in veal calves, calves younger than 1 month old, or calves receiving an all-milk diet.
2. Florfenicol is for intramuscular injection only. Injections should be administered into the neck with no more than 10 ml given per site.

---

**Macrolides and Lincosamides**
Macrolides and lincosamides are primarily effective against gram-positive organisms. The macrolides most commonly used in veterinary medicine include tilmicosin phosphate, erythromycin, and tylosin. The lincosamides include lincomycin, clindamycin, and pirlimycin. Clindamycin is also effective in treating anaerobic infection and is used to treat patients with deep pyodermas, wounds, abscesses, and osteomyelitis.

---

**Lincosamides**
**Clinical Uses**
Lincosamides are used to treat upper respiratory tract infection and skin infection in dogs, cats, and swine, as well as mastitis in cattle. Lincomycin may be found in combination with other agents for use in chickens. Clindamycin is approved for use in dogs and cats to treat deep pyoderma, wound infection, abscess, dental infection, and osteomyelitis.

**Dosage Forms**
1. Clindamycin
   a. Antirobe (capsules, oral liquid)
2. Lincomycin
   a. Lincocein (capsules, oral liquid)
   b. Lincocein Sterile Solution (swine)
   c. Lincomix
d. Pirsue Aqueous Gel
**Adverse Side Effects**
These include occasional vomiting and diarrhea.

**Technician's Notes**
1. Lincomycin is not for use in avians used for egg laying, breeders, or turkeys.
2. Carefully read label about use in animals for slaughter.
3. Lincosamides should not be administered to rabbits, hamsters, guinea pigs, or horses.

**Vancomycin**
Vancomycin is not commonly used in veterinary medicine. It is very effective against gram-positive pathogens, particularly coccus organisms. It is administered intravenously or orally. Vancomycin is administered orally (not absorbed) only to control Clostridium difficile.

**Clinical Uses**
Vancomycin is used to treat resistant staphylococcal and streptococcal infections.

**Dosage Forms**
1. Vancocin Powder
2. Vancocin Injection

**Adverse Side Effects**
These include possible thrombophlebitis and febrile reactions (Beech et al, 1987). Ototoxicity, nephrotoxicity, and hypersensitivity are other possible side effects.

**Spectinomycin**
Spectinomycin is an aminocyclitol antibiotic that is primarily effective against gram-negative bacteria, some mycoplasma, and some gram-positive bacteria. Its action inhibits protein synthesis in susceptible bacteria. It is not generally effective against anaerobic bacteria.

**Clinical Uses**
These include control of air sacculitis and chronic respiratory disease in turkey poults and chicks caused by organisms sensitive to spectinomycin. In baby pigs, it is used to control and treat infectious diarrhea caused by *E. coli*. In cattle, it is indicated for the treatment of bovine respiratory disease associated with *P. haemolytica*, *P. multocida*, and *H. somnus*.

**Dosage Forms**
1. Spectam Injectable (turkey poults and chicks)
2. Spectam Scour-Halt (swine)
3. Adspect Sterile Solution (cattle)

**Adverse Side Effects**
These are uncommon. In cattle, mild swelling may be noted at the injection site.

**Technician's Notes**
1. Do not use in female dairy cattle 20 months of age or older.
2. Do not use in veal calves.
3. Carefully read labels about use in animals for slaughter.
4. Approved only for use in swine younger than 4 weeks of age or weighing less than 15 lb.

**Polymyxin B and Bacitracin**
Polymyxin B and bacitracin are restricted to topical skin and ophthalmic applications. These drugs are often combined with other drugs (e.g., neomycin) in topical skin and ophthalmic ointments.

**Clinical Uses**
These include treatment of superficial bacterial infections of the eye, conjunctiva, and skin.

**Dosage Forms**
1. Mycitracic Sterile Ointment
2. Forte Topical
3. Neobacimyxy Ophthalmic Solution

**Adverse Side Effects**
Adverse side effects of polymyxin B include nephrotoxicity and neurotoxicity if administered parenterally (Beech et al, 1987). Bacitracin is limited to topical application because it causes nephrotoxicity.
Clinical Uses
These include treatment of superficial bacterial infections of wounds, necrotic enteritis in swine, coccidiosis in chickens, and bacterial enteritis in pigs younger than 4 weeks old. Nitrofurazone also may be used to treat pinkeye in cattle, sheep, and goats, as well as eye and ear infections in dogs and cats.

Dosage Forms
1. NFZ Puffer
2. Nitrofurazone Soluble Dressing
3. Nitrofurazone 0.2% Solution

Adverse Side Effects
Adverse side effects are uncommon.

Technician's Notes
1. Except for approved topical use, nitrofurans have been prohibited in food-producing animals.
2. Nitrofurans should not be used in veal calves.

Rifampin
Rifampin is a large complex antimicrobial that is derived from rifamycin B and produced by Nocardia mediterria; it usually is used in combination with other antibiotics to avoid the development of resistant strains of bacteria.

Clinical Uses
This drug is used primarily to treat young horses with Rhodococcus equi infection.

Dosage Forms
1. Rifadin Powder for injection
2. Rifampin Capsules

Adverse Side Effects
May cause red-orange-colored urine.

Antifungal Drugs
Fungal infections (mycoses) are classified into two types: topical (superficial), which affect the skin and mucous membranes, and systemic, which affect
such areas as the blood, lungs, or CNS. A topical fungal infection may be diagnosed by direct microscopic examination for the presence of delicate hyphae in skin cells or the presence of spores on the surface of an infected hair. Dermatophyte test medium is available for topical fungal identification at in-hospital laboratories (Figure 12-4). Systemic mycosis usually is diagnosed in large laboratories through serologic testing. Patients with fungal infection are treated with oral, topical, or parenteral drugs that are suitable for these infections. The antifungal, or antimycotic, drugs are divided into four classes: (1) polyene, (2) imidazole, (3) antimetabolic, and (4) superficial agents.

**Polyene Antifungal Agents**  
**AMPHOTERICIN B**  
Amphotericin B is an antifungal drug that may be fungistatic or fungicidal.

**Clinical Uses**  
These drugs are used to treat dogs and cats with systemic mycotic infection.

**Dosage Form**  
Fungizone (human label)

**Figure 12-4**  
Dermatophyte test medium may be used to culture topical fungal infections. This medium contains a phenol red indicator that turns red as a dermatophyte grows and produces alkaline metabolic products.

**Adverse Side Effects**  
Numerous toxicities such as anorexia, vomiting, seizures, anemia, and cardiac arrest have been reported with the use of amphotericin B. Nephrotoxicity also occurs in most patients that are given this drug (Beech et al, 1987).

**Technician's Notes**  
1. Amphotericin B is administered intravenously through dilution in 5% dextrose.  
2. Renal function should be monitored closely during treatment.

**Nystatin**  
Nystatin may be fungistatic or fungicidal. It often is combined with other drugs such as neomycin, thiostrepton, and triamcinolone acetonide.

**Clinical Uses**  
Nystatin is used to treat dogs and cats with candidiasis infection of the skin, mucous membranes, and intestinal tract.

**Dosage Forms**  
1. Animax Ointment  
2. Dermalone Ointment  
3. Panalog Cream

**Adverse Side Effects**  
Adverse side effects are uncommon.

**Imidazole Antifungal Agents**  
**KETOCONAZOLE AND MICONAZOLE**  
Ketoconazole and miconazole are two of the most commonly used drugs in this class. Ketoconazole is available in oral and topical preparations, and miconazole is available in parenteral and topical preparations.

**Clinical Uses**  
These include the treatment of some systemic mycotic infections and some dermatophytoses, as well as Candida infection in dogs and cats.

**Dosage Forms**  
1. Nizoral Tablets (human label)—ketoconazole  
2. Nizoral Cream (human label)—ketoconazole
3. Monistat (human label)—miconazole
4. Conofite Lotion or Spray—miconazole

**Adverse Side Effects**
Adverse side effects are not as severe as those of amphotericin B and are uncommon. Ketoconazole may produce hepatotoxicity. Miconazole may produce tachycardia, arrhythmia, fever, nausea, and thrombophlebitis after intravenous administration.

---

**Technician’s Notes**
Ketoconazole may cause infertility in male dogs.

---

**ITRACONAZOLE**
Itraconazole is the most recently available imidazole for use in veterinary medicine.

**Clinical Uses**
Itraconazole is used to treat dogs and cats with systemic mycotic infection.

**Dosage Form**
Sporanox Capsules (human label)

**Adverse Side Effects**
These include anorexia associated with hepatotoxicity, ulcerative dermatitis resulting from vasculitis, and possible cardiotoxicity. Severe adverse reactions are uncommon.

---

**Antimetabolic Antifungal Agents**

**FLUCYTOSINE**
Flucytosine is a fungistatic oral antifungal agent. This drug may be used in combination with other antifungal agents for the treatment of some yeast infections.

**Clinical Uses**
Flucytosine is used to treat cryptococcal infection, but it inhibits the growth of other fungi as well.

**Dosage Form**
Ancobon (human label)

---

**Adverse Side Effects**
These include bone marrow depression, anemia, leukopenia, and thrombocytopenia. Severe reactions may occur in patients with renal insufficiency.

---

**Superficial Antifungal Agents**

**GRISEOFULVIN**
Griseofulvin is used primarily in dogs, cats, and horses as an antifungal. It is administered orally in the form of a tablet or powder.

**Clinical Uses**
Griseofulvin is used to treat dermatophytosis.

**Dosage Forms**
1. Fulvicin-U/F Tablets
2. Fulvicin-U/F Powder

**Adverse Side Effects**
Adverse side effects are uncommon.

---

**Technician’s Notes**
1. Griseofulvin should not be administered to pregnant or breeding animals.
2. Absorption of griseofulvin is enhanced by administration with a fatty meal.

---

**Other Antifungal Agents**
Several agents that have other uses are also effective as topical antifungal drugs. A topical preparation often is used in conjunction with systemic antifungal drugs. Commonly used topical preparations include chlorhexidine, iodine, tolnaftate, benzoic acid, salicylic acid, and thiabendazole.

---

**Antiviral Drugs**
Antiviral drugs are used to treat patients with viral infection. Their use in veterinary medicine is still limited, but research is increasing the use of these drugs for treatment of animals with viral infection. Because no antiviral agents are veterinary-approved, human-approved antiviral agents are used. Antivirals may be used for the treatment
of optic viral infection and nonneoplastic feline leukemia virus (FeLV)-associated disease. Antiviral drugs are available for topical and systemic use. Other antiviral drugs that may be beneficial in veterinary medicine include amantadine, ganciclovir, idoxuridine, and azidothymidine.

**Acyclovir**

**Clinical Uses**

In veterinary medicine, acyclovir may be used in birds for the treatment of Pacheco's disease and in cats for confirmed feline herpes virus infection of the conjunctiva or cornea, when other treatments have failed (Plumb, 2005).

**Dosage Forms**

1. Zovirax tablets and capsules (human label)
2. Zovirax Suspension (human label)
3. Zovirax Injectable (human label)
4. Valacyclovir (human label)

**Adverse Side Effects**

Adverse side effects include leukopenia and anemia in treated cats. In birds, tissue necrosis can occur at the injection site if this agent is used parenterally for longer than 72 hours (Oglesbee and Bishop, 2000).

**Interferon Alfa-2A, Human Recombinant**

**Clinical Uses**

In veterinary medicine, interferon alfa-2A is administered orally to treat cats with nonneoplastic FeLV disease.

**Dosage Form**

Roferon-A

**Adverse Side Effects**

No adverse side effects have been noted (Plumb, 2005).

---

**Disinfectants/Antiseptics**

The use of disinfectants in a veterinary hospital ranges from table sprays to premise cleaners (Figure 12-5). A disinfectant destroys disease-producing microorganisms or inactivates viruses.

![Figure 12-5](image)

**Figure 12-5**

The concentrations of disinfectants vary from dilutions that are used for disinfecting kennels, floors, and so forth, to dilutions that are used as table sprays.

It is used primarily on inanimate objects. Disinfection time is the time required for a particular agent to produce its maximum effect. This time varies with different agents but can be affected by a range of factors such as the type of material that is being disinfected, the amount of soil and microbial contamination involved, and the concentration of the disinfectant and its germicidal potency. Antiseptics are used on live tissue to destroy microorganisms. The terms disinfectant and antiseptic commonly are used interchangeably, although disinfectants should be used on inanimate surfaces (e.g., countertops, feed bowls), whereas antiseptics are used on living tissue (e.g., skin). Table 12-5 lists common products and their uses.

**Alcohols**

Alcohols such as ethyl and isopropyl work through protein coagulation and dissociation of membrane lipids. They are bactericidal, tuberculocidal, and active against some viruses, but they are not sporicidal or active against fungi. Alcohols do not penetrate organic material.
### Table 12-5 Disinfectant Preparations and Their Activity

<table>
<thead>
<tr>
<th>Disinfectant Group</th>
<th>Proprietary Products</th>
<th>Recommendations</th>
<th>Bactericidal</th>
<th>General Virucide</th>
<th>Fungicidal</th>
<th>Sporicidal at Room Temperature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quatammonium Phenolics</td>
<td>Q-Cide, Roccal-D Plus D-128, Panteck Cleanser, Lysol I.C. Disinfectant Spray, Beaucoup Chlorines: Clorox Purex Iodophors: Betadine Povidine Iosan</td>
<td>Instruments, dairy equipment, rubber goods Laundry rinse, floors, walls, equipment</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>N</td>
</tr>
<tr>
<td>Halogens</td>
<td>Floors, spot disinfection Presurgical skin preparation, thermometers, daily operation</td>
<td>M</td>
<td>H</td>
<td>H</td>
<td>S</td>
<td></td>
</tr>
<tr>
<td>Glutaraldehyde</td>
<td>Instruments</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Chlorhexidine</td>
<td>Instruments, surgical scrub, daily operation</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>Alcohols</td>
<td>Instruments, thermometers, skin preparation</td>
<td>H</td>
<td>N</td>
<td>S</td>
<td>N</td>
<td></td>
</tr>
</tbody>
</table>

M, Moderate activity; N, no activity; H, high activity; S, slight activity.

**Clinical Uses**
These include disinfection of thermometers and instruments for skin preparation and for spot disinfection.

**Adverse Side Effects**
Alcohols can corrode metal and may be drying to the skin.

**Ethylene Oxide**
Ethylene oxide works via substitution of cell alkyl groups for labile hydrogen atoms. It sterilizes against bacteria, fungi, and viruses. This gas, which should be handled carefully when used by veterinary personnel, may irritate the lungs and cause chemical burns if skin contact occurs. The gas is flammable and is considered to be a human carcinogen. When inanimate objects are sterilized, this gas must be used with proper ventilation and according to proper Occupational Safety and Health Administration (OSHA) standards.

**Clinical Uses**
Ethylene oxide is used to sterilize inanimate objects such as blankets, pillows, mattresses, instruments with lenses, rubber goods, thermostable plastics, books, and papers.
Adverse Side Effects
Adverse side effects are uncommon if ethylene oxide is used according to proper OSHA standards and with good ventilation.

Technician’s Notes
Special equipment is required when ethylene oxide is used as a sterilization gas.
1. After rubber boots are sterilized with this gas, it is best to let them “air” for several hours before donning them, to prevent chemical burns to the skin of the feet.
2. Proper ventilation (refer to OSHA standards) must be employed when this gas is used.

Formaldehyde
The mode of action for formaldehyde is the same as for ethylene oxide. It is noncorrosive and is effective against bacteria, fungi, spores, and viruses. It is considered to be carcinogenic to humans and must be used only in diluted amounts.

Clinical Uses
Formaldehyde is used as a disinfecting gas or solution. The gas can be used to disinfect large areas, such as a cabinet or incubator. The solution is appropriate for instrument disinfection. Delicate instruments may be vapor disinfected.

Technician’s Notes
1. For adequate disinfection, formaldehyde requires long contact time.
2. Organic material inactivates its effectiveness.

Adverse Side Effects
These include toxicity to skin and mucous membranes because of its strong odor.

Chlorines and Iodines
Chlorines and iodines are halogens that inactivate pathogens by oxidizing free sulfhydryl groups on bacterial enzymes. Chlorines are bactericidal, exhibit high levels of activity against viruses, and are fungicidal and tuberculocidal unless highly diluted. Iodines and iodophors are bactericidal, exhibit high levels of activity against viruses, are fungicidal and tuberculocidal, and are effective against bacterial spores.

Clinical Uses
Chlorines are recommended for floors, plumbing fixtures, spot disinfection, and fabrics not harmed by bleaching. Iodine tincture is used for skin preparations and thermometers. Iodophors are used to disinfect thermometers, utensils, rubber goods, and dishes, and for presurgical skin preparation.

Dosage Forms
1. Sodium hypochlorite
   a. Clorox bleach
2. Iodine tincture (7%)
3. Betadine surgical scrub
4. Povidone solution

Adverse Side Effects
The strong vapor of chlorines may irritate the eyes and mucous membranes. Skin irritation may result from failure to rinse a chlorine-disinfected surface. Chlorine bleaches colored fabrics and is corrosive to most metals. Tinctures of iodine contain alcohol and are drying to the skin. They stain and may corrode metal. Iodophors may corrode metal; iodine solutions stain and may corrode metal, and high concentrations (3.5%) may irritate living tissue.

Technician’s Notes
1. These compounds are inactivated by organic material.
2. Always check labels for dilution requirements (more is not better).
3. Iodophors are less staining and irritating than other iodine compounds.

Phenolics: Saponated Cresol, Semisynthetic Phenols
The mode of action of phenolics is protein coagulation. They destroy selective permeability of cell membranes; leakage of cell constituents results.
They are effective against bacteria, fungi, and some viruses, but they are not sporicidal and are only weakly effective against nonenveloped viruses (e.g., parvovirus). Cresol must be used in soft water and is slow-acting. Organic matter, soap, or hard water (except cresol) does not inactivate phenolics. They have high detergency and a residual effect if allowed to dry on surfaces.

Clinical Uses
These include use as a general disinfectant for laundry, floors, walls, and equipment.

Dosage Forms
1. Pantec Disinfectant
2. Beaucoup
3. Lysol L.C. Disinfectant Spray

Adverse Side Effects
Adverse side effects are uncommon, but repeated and prolonged skin exposure may result in accumulation in tissue and eventual toxic effects such as neurotoxicity or teratogenicity.

Technician’s Notes
Some phenolics have objectionable odors.

Quaternary Ammonium Compounds: Cationic Detergents
Cationic detergents concentrate at the cell membrane and are thought to act by dissolving lipids in cell walls and membranes. They are more active against gram-positive than against gram-negative organisms. They are bacteriostatic at high dilutions, but spores, viruses, mycobacteria, and Pseudomonas aeruginosa are relatively resistant. Organic debris, hard water, and anionic soaps and detergents inactivate quaternary ammonium compounds.

Clinical Uses
These include cleaning of instruments, utensils, inanimate objects, and rubber goods. They may be used for instrument soaks except for instruments with cemented lenses.

Dosage Forms
1. Rocal-D Plus
2. Q-Cide
3. D-128

Adverse Side Effects
Adverse side effects are uncommon.

Technician’s Notes
Read labels carefully because some quaternary ammonium compounds do not effectively disinfect against some common viruses (e.g., parvovirus).

Biguanide Compounds
Chlorhexidine is the most common disinfectant in this group. In high dilutions, it is bactericidal, fungicidal, and active against enveloped viruses (e.g., feline infectious peritonitis virus, feline leukemia virus). Other viruses, spores, and mycobacteria are relatively resistant.

Clinical Uses
These include disinfecting surgical instruments, anesthetic equipment, and kennels. It is also available as a surgical scrub and a tear dip.

Dosage Forms
1. Nolvasan cap tabs
2. Nolvadent oral solution
3. Nolvalube (lubricating jelly)
4. Nolvasan solution
5. Nolvasan surgical scrub
6. Virosan solution

Adverse Side Effects
Adverse side effects are uncommon.

Other Disinfectants
Soaps
Soaps, or anionic detergents, have only slight bactericidal activity but are effective in the mechanical removal of organisms. They are not sporicidal or tuberculocidal and have limited virucidal activity. They often contain germicides, such as triclosan, that decrease the number of resident flora after
Hidden page
REVIEW QUESTIONS

1. Different types of bacteria can be distinguished with the use of a ________________ stain.
2. Gram-positive bacteria will stain what color? ____________
3. Gram-negative bacteria will stain what color? ________________
4. ________________ is approved for use in lactating dairy animals.
5. ________________ can cause staining of teeth in young animals.
6. ________________ should never be given intravenously to horses.
7. Some aminoglycosides may be ________________-toxic and/or ________________-toxic.
8. Griseofulvin is used to treat ________________.
9. A drug's ________________ of activity is the range of bacteria affected by its action.
10. Aerobes are bacteria that require oxygen to live.
    a. True
    b. False
11. A fungicidal agent inhibits the growth of fungi.
    a. True
    b. False
12. A bacteriostatic agent inhibits the growth of bacteria.
    a. True
    b. False
13. Dermatophytosis is a(n) ________________ skin infection.
    a. fungal
    b. bacterial
    c. parasitic
    d. immune-mediated
14. Penicillin-G benzathine is a long-acting antibiotic that is approved for use in dairy animals.
    a. True
    b. False
15. All the following drugs are classified as penicillins, except ________________.
    a. cephalaxin
    b. amoxicillin
    c. ampicillin
    d. cloxacillin
16. Naxcel is not approved for use in lactating dairy animals.
    a. True
    b. False
17. Panmycin is classified as a(n) ________________.
    a. penicillin
    b. cephalosporin
    c. aminoglycoside
    d. tetracycline
18. Veterinarians commonly dispense aminoglycosides to patients with renal insufficiency.
    a. True
    b. False
19. Enrofloxacin is a ________________.
    a. penicillin
    b. cephalosporin
    c. fluoroquinolone
    d. tetracycline
20. Amphotericin B may be used in the treatment of mycotic fungal infection.
    a. True
    b. False
Hidden page
Hidden page
rumen provides a warm, liquid environment in which to live. Commensalism is a type of symbiotic relationship in which one symbiont benefits, but the other symbiont is not harmed. An example of commensalism is mistletoe growing in the top of a tree. Lastly, parasitism occurs when one species lives at the expense of another. An example of parasitism is *Trichuris vulpis* that live in the cecum of the canine.

Sometimes, an animal may harbor a parasite on or within its body that is potentially pathogenic, but the animal does not exhibit any outward signs (i.e., clinical disease) of parasitism. This is known as **parasitiasis**. If, however, the animal harbors a parasite on or within its body, and injury occurs to the animal because of the parasite, this is known as **parasitosis**. Parasites living on the outside of an animal’s body are known as **ectoparasites** (e.g., fleas, ticks), and parasites living on the inside of an animal’s body are known as **endoparasites** (e.g., canine heartworms). An animal with ectoparasites is said to be infested, and an animal with endoparasites is said to be infected. Sometimes, a parasite may wander from its normal location in the host’s body to another location where it does not normally live. These parasites are said to be aberrant (erratic). Although most veterinary personnel use the lay term given to parasites when speaking with a client, it is important for veterinary technicians to know the genus and species name of the most common parasites as well. The Linnaean classification scheme is fundamental in keeping parasites organized (i.e., kingdom, phylum, class, order, family, genus, and species).

Each parasite has its own individual life cycle, which may consist of several stages. Every parasite has at least a definitive host and, depending on the species, may have one or more intermediate hosts. The host that contains the adult (sexually mature) stage of the parasite is known as the definitive host, and the host that contains the immature (not sexually mature) stage of the parasite is known as the intermediate host. Knowing the life cycle of parasites helps veterinarians determine which drugs to use and how many doses will be needed to eradicate the parasite from the host animal’s body.

Some parasites have zoonotic potential. This means they may be transmissible from animals to humans. Veterinary technicians should be familiar with which parasites have this ability so they can properly educate clients. Examples of parasites with zoonotic potential include *Toxoplasma gondii*, *Trichinella spiralis*, *Ancylostoma caninum*, and *Toxocara canis* (Hendrix, 2006).

The Companion Animal Parasite Council recommends fecal centrifugation techniques to accurately diagnose endoparasitism. Additionally, the amount of feces collected for evaluation is important and should consist of at least 1 gram. The specific gravity of flotation solution is equally important, in that ideally it should be 1.18 to 1.20 (Companion Animal Parasite Council@capcvet.org/default.asp?p=Home).

---

**Technician's Notes**

Educating clients about how to collect a freshly voided fecal sample from a pet will result in more accurate fecal evaluations. (Tell them to bring a sample in a zip-loc bag to each appointment their pet has.)

Ectoparasites represent an ongoing problem faced by companion animal and livestock owners. Numerous products are manufactured for the removal of fleas and ticks from an animal's body. Since so many products are available, veterinary technicians play an important role in educating clients about the effectiveness of each product. Client education is important in the area of ectoparasites because misuse of over-the-counter insecticides can be fatal. Clients should be taught to ask veterinary personnel about the correct use of shampoos, dips, sprays, powders, and topical parasiticides (e.g., fipronil, imidacloprid) before a purchase is made.

Parasitology is a fascinating subject. However, for most clients, it is not fascinating at all because they just want their pet to be free of worms and bugs. It is up to veterinary personnel to have knowledge about available products and to remember that—as technology evolves—lifelong learning must be pursued so that professionals can remain current with how each drug or parasiticide works. Veterinary personnel have a double responsibility because it is up to us to protect both pets and their owners from those parasites with...
zoonotic potential, and to educate clients accordingly. Veterinary medicine truly has a twofold purpose: the medical treatment of animals and protection of the public from health risks associated with zoonotic diseases and parasites. In some ways, veterinary medicine is more important than human medicine when it is considered from this standpoint, because it represents the first defense in the protection of human health. Reading package inserts helps veterinary personnel to understand how a particular drug works. Tables 13-1 to 13-9 list products and their uses for various species.

**ENDOPARASITES**

Endoparasites found in the gastrointestinal (GI) tracts of animals benefit not only from the foodstuffs the animal ingests, but from body fluids (e.g., blood) as well. Horses with increased numbers of endoparasites in the GI tract may develop colic. Puppies and kittens with increased numbers of intestinal parasites may develop fatal anemia if not treated early. Adult heartworms can cause disruption to the normal movement of blood within the heart chambers, resulting in clinical signs similar to congestive heart failure. Without treatment, a dog with active heartworm infection will die.

In the following section, some of the most common *anthelmintics* used in veterinary practice today are discussed. As a veterinary technician, you may come into contact with products not mentioned in this section. The charts in this section list various products, their trade names, and their effectiveness. Since anthelmintics are so numerous, many veterinarians keep only a few products to meet their needs and to limit inventory. Some products are available under many different names. Experience will provide familiarity with various available brands.

**Antinematodal**

**Benzimidazoles**

Benzimidazoles interfere with the worm's energy level on a cellular basis. They bind to beta tubulin and prevent its entry into microtubules that are needed for energy metabolism. Without energy, the worm dies.

**Dosage Forms**

This class includes the following products:

1. Thiabendazole (Equizole, TBZ, Omnizole)
2. Oxibendazole (Anthelcide EQ)
3. Mebendazole (Telmin, Telmintonic)
4. Fenbendazole (Panacur, Safeguard)
5. Cambendazole (Camvet)
6. Oxendazole (Benzelmin, Synanthric)
7. Albendazole (Valbazen)

**Clinical Uses**

Benzimidazoles are used in the following species:

1. Horses. Effective against strongyles, pinworms, and ascarids
2. Cattle. Ascarids, several species of strongyles and other stomach worms; albendazole is also effective against adult liver flukes and tape-worms; fenbendazole is also effective against lungworms
3. Sheep and goats. Ascarids, several species of strongyles and other stomach worms; Panacur is also effective against lungworms
4. Dogs. Hookworms, roundworms, and whipworms; some are effective against *Taenia pisiformis* but not *D. caninum*
5. Swine. Strongyloides and lungworms
6. Many of the benzimidazoles are used as anthelmintics for exotics such as snakes and birds.

**Adverse Side Effects**

These are uncommon but include vomiting and diarrhea. Mebendazole has clinically produced hepatotoxicity in dogs.

**Technician’s Notes**

1. Read labels carefully regarding use in lactating dairy animals and animals to be slaughtered.
2. None of these products is approved for use in cats.

_text continued on p. 261_

## Table 13-2  Parasiticides Used to Treat Internal Parasites in Horses

<table>
<thead>
<tr>
<th>Drug</th>
<th><em>Gasterophilus</em></th>
<th><em>Ascarids</em></th>
<th><em>Strongylus vulgaris</em></th>
<th><em>Strongylus edentatus</em></th>
<th><em>Small Strongyles</em></th>
<th><em>Pinworms</em></th>
<th><em>Strongyloides</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clobendazole</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Dichlorvos</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Febantel</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Fenbendazole</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Moxidectin</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Oxibendazole</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Oxidentazole</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Phenothiazine</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Piperazine salts</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pyrantel salts</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Thiabendazole</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Thiabendazole/piperazine</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Thiabendazole/trichlorfon</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Trichlorfon</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Trichlorfon/phenothiazine/</td>
<td></td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>piperazine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*, Indicated for use; -, not indicated for use.

Table 13-3  Parasiticides Used to Treat Internal Parasites in Cattle, Sheep, and Goats

<table>
<thead>
<tr>
<th>Drug</th>
<th>Haemonchus</th>
<th>Oster-</th>
<th>Tricho-</th>
<th>Cooperia</th>
<th>Nematodi-rus</th>
<th>Strongy-</th>
<th>Bunostomum</th>
<th>Trichuris</th>
<th>Oesophagostomum</th>
<th>Che-</th>
<th>Dictyocaulus</th>
<th>Monezia</th>
<th>Fasciola</th>
<th>Coccidia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albendazole</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Amprolium</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chlorpheniramine</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Dicloquinol</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fenbendazole</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Haloxan</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lasalocid</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Levamisole</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>oxendine</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Monezol</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Morantel</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Tetratrate</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Phenothiazine</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sulphonamides</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thiabendazole</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

+, Indicated for use; -, not indicated for use.

Hidden page
<table>
<thead>
<tr>
<th></th>
<th>Ectoparasites</th>
<th>Nematodes</th>
<th>Trematodes</th>
<th>Cestodes</th>
<th>Cryptosporidium</th>
<th>Coccidia</th>
<th>Amoebae and Trichomonads</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metronidazole (Flagyl)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Humatin 400 (Paromomycin)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Praziquantel (Droncit)</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Febantel plus Praziquantel (Vercom)</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Dichlorvos (Tekt)</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Levamisole (Trimisol, Ripercol)</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thiabendazole (Thibendazole)</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fenbendazole (Panacur)</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Mebendazole (Telmin)</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ivermectin* (Ivomec)</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Dithiazanine iodoide (Dizan)</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vapona Strip</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sulfadiazine (many trade names)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Sulfamerazine (many trade names)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Sulfamethazine (many trade names)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Sulfadimethoxine (Albon)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Trimethoprim plus Sulfadiazine (Di-Trim, Tribissen)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

+, Effective; -, not effective.

* Do not use in chelonians. Contraindicated in animals that have been given diazepam or will receive diazepam within 10 days of administration of ivermectin.

### Table 13-6 Parasiticides Used for Control of External Parasites on Dogs and Cats

<table>
<thead>
<tr>
<th>Drug</th>
<th>Fleas</th>
<th>Lice</th>
<th>Mites</th>
<th>Ticks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allethrin</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Amaitraz</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Carbaril</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Chlorpyrifos</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Cythioate</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>d-Limonene</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Diazinon</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Fenthion</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Fipronil</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Imidacloprid</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Lime-sulfur</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Lindane (not legal in United States)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Fleas</th>
<th>Lice</th>
<th>Mites</th>
<th>Ticks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linalool</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Lufenuron</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Malathion</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Methylcarbamate</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Permethrin</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Phosmet</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pyrethrins</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Resmethrin</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Rotenone</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Selamectin</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

+, Indicated for use; −, not indicated for use.


### Table 13-7 Parasiticides Used for Control of External Parasites on Horses

<table>
<thead>
<tr>
<th>Drug</th>
<th>Lice</th>
<th>Flies</th>
<th>Mites</th>
<th>Ticks</th>
<th>Maggots</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coumaphos</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Malathion</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Permethrin</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Pyrethrins</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>

+, Indicated for use; −, not indicated for use.

**Table 13-8** Parasiticides Used for Control of External Parasites on Cattle, Sheep, and Goats

<table>
<thead>
<tr>
<th>Drug</th>
<th>Cattle Grub</th>
<th>Horn Fly</th>
<th>Face Fly</th>
<th>Other Flies</th>
<th>Maggots</th>
<th>Chewing Lice</th>
<th>Sucking Lice</th>
<th>Psoroptic Mite</th>
<th>Other Mites</th>
<th>Ear Ticks</th>
<th>Other Ticks</th>
<th>Sheep Ked</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbaryl</td>
<td>-</td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Coumaphos</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Chlorpyrifos</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Dichlorvos</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Endosulfan</td>
<td>+</td>
<td></td>
<td>-</td>
<td></td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Domerprin</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fenthion</td>
<td>+</td>
<td></td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Fenvatranate</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>+</td>
<td></td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Methoxychlor</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Moxidectin</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Permethrin</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pyrethrin</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Rotenone</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Trichloran</td>
<td>+</td>
<td></td>
<td>-</td>
<td></td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

+, Indicated for use; -, not indicated for use.

### Table 13-9 Parasiticides Used for Control of External Parasites on Swine

<table>
<thead>
<tr>
<th>Drug</th>
<th>Lice</th>
<th>Flies</th>
<th>Mites</th>
<th>Maggots</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coumaphos</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Fenthion</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Malathion</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Methoxychlor</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Permethrin</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Pyrethrins</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>

+, Indicated for use; −, not indicated for use.

### Organophosphates
Organophosphates consist of a group of insecticides that inactivate acetylcholinesterase. Without this enzyme, parasites (especially ectoparasites) are unable to move because these chemicals stop nerve transmission. Many of these pesticides tend to break down when exposed to light, air, soil, and other environmental factors. However, some traces have been known to be residual in drinking water and food. Although they may degrade rather quickly, these substances have a high level of toxicity and may cause problems in people and animals exposed to large doses. SLUDGE is a good mnemonic to use for remembering the effects of toxic doses of these drugs: salivation, lacrimation, urination, defecation, GI upset, and emesis. Atropine may be used as an antidote.

### Clinical Uses
**Organophosphates** are used in the following species:

1. Horses. Effective against bots, roundworms, strongyles, and pinworms but less effective against Strongyloides
2. Cattle, sheep, and goats. Strongyles
3. Dogs and cats. Hookworms, roundworms, whipworms
4. Swine. Ascarids, whipworms, nodule worms, strongyles

### Adverse Side Effects
Adverse side effects include those expected with any organophosphate poisoning: excessive salivation, vomiting, diarrhea, muscle tremors, and miosis.

### Technician’s Notes
1. It is very important that these anthelmintics not be administered concurrently or within a few days of the use of other cholinesterase inhibitors, other organophosphates, succinylcholine, or phenothiazine derivative agents.
2. Atropine and pralidoxime (2-PAM) are antidotal.
3. Read labels carefully regarding use in lactating dairy animals and animals to be slaughtered.

### Tetrahydropyrimidines
**Dosage Forms**
This class includes the following products:

1. Pyrantel pamoate (Nemex, Strongid-T, Anthelban)
2. Pyrantel tartrate (Banminth 48)
3. Morantel tartrate (Nematel, Rumatel)

**Clinical Uses**
Tetrahydropyrimidines are used in the following species:

1. Horses. Ascarids, strongyles, pinworms
2. Cattle, sheep, and goats. Strongyles
3. Dogs and cats. Hookworms, roundworms
4. Swine. Roundworms, strongyles
Hidden page
2. Swine. Gastrointestinal roundworms, lungworms, kidney worms, sucking lice, and mange mites

**Adverse Side Effects**
These are uncommon. Toxic signs include mydriasis, ataxia, tremors, and depression.

---

**Technician's Notes**
1. Although not approved, ivermectin is sometimes used for the treatment of ear mites in cats and scabies in dogs.
2. Because of the small amount of medication in heartworm preventives, crumbing or breaking of the tablets or use of a chewable version is not recommended.
3. Read labels carefully regarding use in lactating dairy animals and animals for slaughter. Moxidectin is approved for use in dairy cattle of all ages and at all stages of lactation, except for veal calves.

**Other Agents**

**Piperazine (Pipa-tabs, Pip-pop 320)**
1. Dogs and cats. Roundworms
2. Used effectively in exotics such as birds and snakes
3. Commonly combined in large-animal dewormers to broaden its spectrum and enhance its efficacy

**Praziquantel/Pyrantel Pamoate/Febantel (Drontal Plus)**
Dogs. It is effective for the removal of tapeworms, hookworms, roundworms, and whipworms.

**Adverse Side Effects**
These are uncommon.

---

**Technician's Notes**
1. Do not use in dogs weighing less than 2 lb or in puppies younger than 3 weeks of age.
2. Do not use in pregnant animals.

---

**Anticestodal**

Drugs used for treating tapeworms have greatly improved over the years. These newer agents are more effective and do not necessitate fasting before their administration.

**Bunamidine (Scolaban)**
1. Dogs. *T. pisiformis*, *D. caninum*, *Echinococcus granulosus*, and *Echinococcus multilocularis*
2. Cats. *D. caninum*, *Taenia taeniaeformis*

**Adverse Side Effects**
These are uncommon but include vomiting, anorexia, diarrhea, and lethargy.

---

**Technician's Notes**
1. No adverse reactions have been reported in pregnant or breeding animals.
2. This product is not for use in puppies younger than 4 weeks or kittens younger than 6 weeks of age.

**Epsiprantel (Cestex)**
1. Dogs. *T. pisiformis* and *D. caninum*
2. Cats. *T. taeniaeformis* and *D. caninum*

**Adverse Side Effects**
These are uncommon.

---

**Technician's Notes**
1. Safety in pregnant or breeding animals has not been established.
2. This product is not for use in puppies or kittens younger than 7 weeks of age.

---

**Antitrematodal**

**Clorsulon (Curatrem)**
1. Cattle. Liver flukes
2. Effective against immature and adult flukes
Adverse Side Effects
These are uncommon.

Technician's Notes
1. This product is not approved for use in female dairy cattle of breeding age.
2. Read label regarding use in animals to be slaughtered.

Albendazole (Valbazen)
1. Cattle. Liver flukes
2. Effective against adult flukes and many intestinal worms

Praziquantel (Droncit)
Praziquantel may be used for lung flukes in dogs and cats.

Topical Solutions
Emodepside/Praziquantel (Profender)
1. A topical solution for the treatment and control of hookworms, roundworms, and tapeworms in cats 8 weeks of age or older
2. Emodepside is a cyclic depsipeptide.
3. Praziquantel is an isoquinoline cestocide.
4. To be applied every 30 days for preventive purposes
5. Some clients may elect to use this product instead of oral meds, which may be difficult for them to administer to their cat.

Antiprotozoal
Protozoa are single-celled organisms found at various body sites that have the ability to replicate rapidly. Coccidia and Giardia are the protozoa that are most commonly associated with diarrhea in many species of animals. Protozoa are most commonly transmitted via contaminated feed and/or water. Prevention of these parasites includes providing uncontaminated food and water and clean housing and avoiding overcrowding. A vaccine is also available for the prevention of giardiasis in dogs. Babesia is a hematozoan (i.e., a protozoan) that is transmitted by ticks and affects many species of animals. An injectable treatment for babesiosis is available for dogs.

Drugs for Treating Coccidia and Other Protozoa
1. Monensin (Coban 60). Turkeys and chickens
2. Amprolium (Corid). Calves
3. Clopidol (Coyden 25). Chickens
4. Diclazuril (Clincox). Horses
5. Maduramicin ammonium (Cygro Type A Medicated Article). Chickens
6. Decoquinate (Deccox). Cattle, calves, and goats
7. Narasin/nicarbazine (Maxiban 72). Chickens
8. Ponazuril (Marquis). Horses
9. Robenidine hydrochloride (Robenz Type A Medicated Article). Chickens
10. Sulfadimethoxine (Albon). Chickens, turkeys, dogs, and cats

Adverse Side Effects
These are uncommon.

Technician's Notes
Read labels carefully regarding use in food-producing animals and animals to be slaughtered.

Drugs for Treating Giardia
1. Metronidazole (Flagyl). Dogs and cats
2. Albendazole (Valbazen). Dogs and cats

Adverse Side Effects
These are uncommon, but vomiting and diarrhea may occur in some animals treated with metronidazole.

Technician's Notes
Metronidazole is not recommended for use in pregnant animals.
**Drugs for Preventing Giardia**

A vaccine for dogs is available as an aid in the prevention of *Giardia* lamblia infection and for a reduction in the duration of cyst shedding. This vaccine is administered subcutaneously, and a booster is given 2 to 4 weeks after the first vaccination. Annual revaccination is recommended.

**Dosage Form**

GiardiaVax

**Adverse Side Effects**

These are uncommon.

---

**Technician’s Notes**

1. May be used in dogs 8 weeks of age or older
2. After exposure to *Giardia*, some vaccinates may shed cysts. Clients should be educated regarding proper hygiene and sanitation practices to prevent zoonotic disease.

**Drugs for Treating Babesia**

Imidocarb dipropionate is available for the treatment of clinical signs of babesiosis and/or evidence of *Babesia* organisms in the blood. This product is indicated for use in dogs, and treatment consists of two injections given over a 2-week interval.

**Dosage Form**

Imizol

**Adverse Side Effects**

These may include injection pain and mild cholinergic signs such as salivation, nasal drip, and vomiting. Other less common side effects include panting, restlessness, diarrhea, and mild injection site inflammation.

---

**Technician’s Notes**

Severe cholinergic signs may be reversed with atropine sulfate.

**HEARTWORM DISEASE**

Heartworm disease is commonly found throughout the United States. This disease primarily affects dogs and wild Canidae, although cats and ferrets also may become infected. *D. immitis* is the filarial nematode that causes heartworm disease. *Acanthocheilonema reconditum* (formerly known as *Dipetalonema reconditum*) (Hendrix, 2006) is a subcutaneous filarial nematode that does not require treatment because it is non-pathogenic. Prevention is the key word for controlling heartworm disease. Dogs not on an approved heartworm disease prevention program should be tested for the presence of adult heartworms before preventive treatment is begun. Clients should be educated about the importance of treating an existing infection if one exists, preventing infection or reinfection, and ensuring periodic testing that may be necessary. (Many veterinarians will not prescribe heartworm prevention without an annual heartworm antigen test.) Over the past several years, the number of cats in which heartworm disease has been diagnosed has increased. The treatment and justification for prevention of heartworms in cats continue to be controversial (Smith, 1999). Products for the prevention of *D. immitis* infection in cats are available. No adulticide products have been approved for use in cats. Table 13-10 provides a comparison of several heartworm preventives that are on the market at this time.

**Adulticides**

**Melarsomine Dihydrochloride (Immiticide)**

1. An arsenic compound administered by deep intramuscular injection in the lumbar region
2. Administration schedule is based on classification of the severity of heartworm disease.
3. Melarsomine appears to be more efficacious than thiacetarsamide (Caparsolate) and less irritating to tissue and does not cause hepatic necrosis (Plumb, 2005).

**Adverse Side Effects**

Some dogs experience reactions such as pain, swelling, and tenderness at the injection site. Firm nodules may form at the injection site. Coughing, gagging,
|-------------------------------------|-----------------------------|-----------------------------------------------|--------------------------------------|---------------------------------------------|--------------------------------------------------|-----------------------------|------------------------------------------|
| Heartgard Plus                      | Chewable tablet given PO on the same day every month | Puppies: 6 weeks Kittens: 6 weeks | Yes | N/A | 15-day grace period (one dose protects against infection up to 45 days) | Not approved for such use; probably won’t cause problems | Dogs: Roundworms Hookworms Cats: Hookworms Roundworms Whipworms | 3rd and 4th stage microfilari 
lanae |
| Interceptor                         | Flavored tablet given PO on the same day every month | Puppies: 8 weeks Cats: Not approved for use in cats | Yes | N/A | Can pick up next dose when mistake is noted but shouldn’t wait longer than 2-3 weeks | Probably safe if microfilaria counts aren’t too high; may be dangerous if microfilaria counts are high | Sarcoptic mangeas, ear mites, fleas, roundworms in cats, and hookworms in dogs | Microfilaria larvae stages, 3rd, 4th and some 5th larvae stages, Microfilaria 4th stage larvae |
| Revolution                          | Topical application on the same day every month | Puppies: 6 weeks Kittens: 6 weeks | Yes | No effect, but pet must be dry when product is applied | Up to 2 months is grace period | Safe because product is FDA-approved for use in heartworm-positive dogs | Hookworms Roundworms Whipworms | Microfilaria 4th stage larvae |
| Sentinel*                           | Flavored tablet given PO on the same day every month | Puppies: 8 weeks Cats: Not approved for use in cats | Yes | N/A | Can pick up next dose when mistake is noted but shouldn’t wait longer than 2-3 weeks | Probably safe if microfilaria counts aren’t too high; may be dangerous if microfilaria counts are high | Hookworms Roundworms Whipworms | Microfilaria 4th stage larvae |
| ProHeart                            | Tablet given PO on the same day every month; injection given by DVM, which lasts 6 months | Puppies: 8 weeks Cats: Not approved for use in cats | Yes | N/A | Up to 84-day grace period | Safe because product is approved by FDA for use in HW* dogs | Tablets: Heartworms only Injectable: Heartworms and hookworms | Microfilaria 3rd stage larvae |

*Sentinel has fenbendazole in it, which breaks down the chitin within the flea’s shell, rendering it harmless.
depression, lethargy, anorexia, fever, lung congestion, and vomiting are common reactions.

**Technician’s Notes**
1. The manufacturer recommends use of a 23-gauge, 1-inch needle for dogs equal to or less than 22 lb and a 22-gauge, 1½-inch needle for dogs larger than 22 lb.
2. Safety in breeding, lactating, or pregnant bitches has not been determined.
3. Melsarsmine is contraindicated in dogs with severe heartworm disease (Class 4, according to manufacturer disease classification).
4. Clients must be informed of the potential of morbidity and mortality associated with heartworm treatment.
5. Exercise in dogs should be restricted after treatment has been provided.

**Microfilaricides**
1. Given 6 weeks after administration of the adulticide
2. Kill circulating *microfilaria*
3. Although not approved as microfilaricides, ivermectin and milbemycin oxime have been used.
4. Levamisole also has been used as a microfilaricide.

**Preventives**

*Imidacloprid + Moxidectin (Advantage multi)*
1. Advantage multi for dogs 7 weeks or older and weighing at least 3 lbs.
2. Advantage multi for cats 9 weeks or older and weighing at least 2 lbs.
3. To be applied topically on a monthly basis (Bayer website, April 2007).

*Ivermectin (Heartgard, Heartgard Plus, Heartgard for Cats)*
1. Dogs. Monthly preventive; the Plus formula contains pyrantel pamoate and is effective against hookworms and roundworms
2. Cats. Monthly preventive for *D. immitis* and for the removal of hookworms
3. Eliminates the tissue stage of heartworm larvae

**Adverse Side Effects**
These are uncommon. Toxic signs include mydriasis, depression, and ataxia.

**Technician’s Notes**
1. If diethylcarbamazine citrate (DEC) is replaced, the first dose should be given within a month after cessation of DEC treatment.
2. This product is safe to use in pregnant and breeding animals.
3. Do not use in puppies or kittens younger than 6 weeks of age.

**Milbemycin Oxime (Interceptor, Sentinel)*
1. Dogs. Monthly preventive; also controls hookworms, roundworms, and whipworms
2. Eliminates the tissue stage of heartworm larvae
3. Sentinel product contains lufenuron for flea control.

**Adverse Side Effects**
These are uncommon.

**Technician’s Notes**
1. If DEC is replaced, the first dose should be given within 1 month after cessation of DEC treatment.
2. This product is safe to use in pregnant and breeding animals.
3. Do not use in puppies younger than 4 weeks of age.

**Moxidectin (ProHeart)**
1. Dogs. Monthly preventive used for *D. immitis* (Fort Dodge website, 2007).
2. Eliminates the tissue stage of heartworm larvae
3. This drug has been taken off the market.

**Adverse Side Effects**
Adverse side effects may include lethargy, vomiting, ataxia, anorexia, diarrhea, nervousness, weakness, polydipsia, and itching.
**Technician's Notes**
1. If DEC is replaced, the first dose should be given within 1 month after cessation of DEC treatment.
2. This product is safe to use in pregnant and breeding animals.
3. Do not use in puppies younger than 8 weeks of age.

**Selamectin (Revolution)**
1. Dogs and cats. Used as a monthly preventive.
2. Available as a solution for topical administration.
3. Indications include prevention of heartworm disease caused by *D. immitis*, prevention and control of flea infestations, treatment and control of ear mites (*Otodectes cynotis*) infestation, treatment and control of sarcoptic (*Sarcoptes scabiei*) mange in dogs, and hookworm and roundworm treatment in cats.

**Adverse Side Effects**
These are uncommon but include transient, localized alopecia at the application site of some treated cats.

**Technician’s Notes**
1. If DEC is replaced, the first dose should be given within 1 month after cessation of DEC treatment.
2. This product is safe to use in pregnant and breeding animals and in avermectin-sensitive collies.
3. Do not use in puppies or kittens younger than 6 weeks of age.
4. This product should not be applied if the haircoat is wet. Bathing the animal 2 or more hours before treatment will not reduce its effectiveness.

**ECTOPARASITES**
Most ectoparasites are ubiquitous in the environment; therefore, control is often difficult. Environmental factors such as housing (indoor or outdoor) and geographic location may affect the incidence of many ectoparasites such as fleas and ticks. When trying to control ectoparasites, the veterinary technician must be familiar with the products used to eradicate these parasites and to educate clients about how to properly combat their pet’s infestation. Not only do ectoparasites cause misery to their host, but many dermatologic problems arise from their infestation. Additionally, increased infestation of fleas may affect humans because fleas are not host specific. Table 13-11 provides a comparison of various topical products on the market at this time.

**Diethylcarbamazine Citrate (Carbam, Filaribits, Filaribits Plus)**
1. Daily preventive; also controls roundworms
2. Filaribits Plus also contains oxibendazole for the control of hookworms, whipworms, and roundworms.
3. Eliminates the tissue stage of heartworm larvae

**Adverse Side Effects**
These include occasional vomiting. Filaribits Plus has been linked with hepatic dysfunction.

**Prediluted Sprays**
1. Consumers like the convenience of sprays.
2. Sprays are available for animal and environmental use.
3. These formulations are available only for the use specified on the label and should be used accordingly.
4. Sprays are available as water-based and alcohol-based formulations.
   a. Water-based sprays do not penetrate oily coats or fabrics as well and do not dry as quickly as alcohol-based sprays.
   b. Alcohol-based sprays may be irritating and drying to the skin. They usually kill ectoparasites quickly.
Hidden page
5. Environmental sprays are usually residual. Most pet sprays require application daily or every 2 to 3 days for adequate parasite control.

Adverse Side Effects
These vary among products. Carefully read warning labels.

Yard and Kennel Sprays
1. These are designed for environmental use and should not be used on animals.
2. These products are residual.

Adverse Side Effects
These vary among products. Directions for application should be followed carefully for the safety of the user and of animals.

Shampoos
1. These products may contain insecticides or medications, or they may be effective only for cleaning the coat.
2. Some shampoos are available as concentrates and require dilution before use.
3. Shampoos are not considered to be residual.
4. Rinse shampoos well; water hardness/softness affects how quickly some shampoos rinse away.

Adverse Side Effects
These vary among products. Shampoos that contain carbamates or organophosphates should not be used with other products of the same origin.

Technician’s Notes
1. Spray the pet from head to tail, including the legs and abdomen. Avoid only the eyes, mouth, and nose. For best results, spray against the natural lay of the hair.
2. Educate clients about environmental control and how to treat the pet.
3. Read labels before applying to young, sick, or pregnant animals. Some products are not safe for certain species (e.g., cats).
4. Water-based flea sprays are best used on young animals because alcohol-based sprays tend to evaporate quickly and may cause loss of body heat. It is best to apply water-based sprays only to the dorsal area and then to spread the spray by combing through the haircoat. In this way, the young animal does not lose body heat.

Emulsifiable Concentrates
Dips
1. Concentrates have to be diluted with water.
2. Dips usually are used after a shampoo.
3. Dips generally are considered residual.

Adverse Side Effects
These vary among products. Read labels carefully for animal and user safety and precautions.

Technician’s Notes
1. Removal of excess water or drying of the coat before dipping is recommended to prevent further dilution of the product.
2. For best results, do not rinse after applying the dip.
3. Organophosphate dips should never be applied to cats.

Dusts
1. Popularity has decreased with the availability of effective sprays.
2. Dusts do not provide a quick kill.

Adverse Side Effects
These include irritation to mucous membranes and drying of the skin and haircoat.

Foggers
1. Foggers work best in large, open rooms.
2. Remind clients that foggers do not go around corners, under couches, or into closets.
Hidden page
Hidden page
Hidden page
Hidden page
3. D-Limonene (VIP Flea Dip, VIP Flea Control Shampoo)
   a. Extract of citrus peel
   b. Found in sprays, shampoos, and dips
   c. Provides a quick kill but is not residual
4. Benzyl benzoate. Effective against many ecto-parasites and may be combined with other agents
5. Petroleum distillate. Usually added to products as the solvent for pyrethrin and pyrethroid products

REFERENCES
Eli Lilly website (2007)

Hendrix CM, editor: Diagnostic veterinary parasitology, ed 2, St. Louis, 2006, Mosby.
REVIEW QUESTIONS

1. Name five types of symbiotic relationships.

2. What is parasitiosis?

3. What is parasitism?

4. What are ectoparasites?

5. What are endoparasites?

6. An animal with endoparasites is said to be __________________, and an animal with ectoparasites is said to be __________________.

7. What is an anthelmintic?

8. __________________ dips should never be used on cats.

9. IGR is an acronym for __________________.

10. Praziquantel is a drug that is used to rid the body of __________________.

11. An example of _________ is the bacterium Moraxella bovis, the etiologic agent of infectious bovine keratoconjunctivitis, or pinkeye, that is mechanically carried from the eyes of one cow to those of another on the sticky footpads of the face fly Musca autumnalis.
   a. predator-prey
   b. commensalism
   c. mutualism
   d. phoresis

12. Ivermectin, moxidectin, and doramectin are in the ______________ class.
   a. avermectins
   b. ivermectins
   c. tetrahydropyrimidines
   d. microfilaricides

13. All the following are monthly heartworm preventives, except ______________.
   a. milbemycin oxime
   b. selamectin
   c. Heartgard Plus
   d. diethylcarbamazine

14. ______ is the most commonly used formamidine in veterinary medicine.
   a. Dichlorvos
   b. Propoxur
   c. Amitraz
   d. Selamectin

15. ______________ is a topical solution that controls ascarids, hookworms, and tape-worms in felines.
   a. Selamectin (Revolution)
   b. Profender (emodepside/praziquantel)
   c. Fipronil (Frontline)
   d. Lufenuron (Program)

16. An arsenic compound administered by deep IM injection in the lumbar region is ______.
   a. caparsolate
   b. clorsulon
   c. melarsomine dihydrochloride
   d. Ivomec

17. Albendazole is the active ingredient found in ________.
   a. Droncit
   b. ProMeris
   c. Synanthic
   d. Valbazen

18. An organophosphate is a substance that can interfere with the function of the nervous system by inhibiting the enzyme cholinesterase.
   a. True
   b. False

19. Advantage has greater efficacy against ____ , and Frontline has greater efficacy against ____.
   a. ticks; fleas
   b. fleas; ticks

20. __________ are parasitic worms, including intestinal roundworms, filarial worms, lungworms, kidney worms, heartworms, and others.
   a. Cestodes
   b. Trematodes
   c. Acanthocephalans
   d. Nematodes
Hidden page
**KEY TERMS**

**ADDISON’S DISEASE** A disease or syndrome characterized by inadequate amounts of corticosteroid hormones.

**ANALGESIA** The absence of the sensation of pain.

**CUSHING’S DISEASE** A disease or syndrome characterized by an overabundance of corticosteroid hormones.

**DEEP PAIN** Pain arising from deep receptors in the periosteum, tendons, and joint structures.

**HISTAMINE** A chemical mediator of the inflammatory response released from mast cells. Histamine may cause dilation and increased permeability of small blood vessels, constriction of small airways, increased secretion of mucus in the airways, and pain.

**IATROGENIC** Caused by the physician (veterinarian).

**MODULATION** The modification of nociceptive transmission.

**NERVE BLOCK** A loss of feeling or sensation produced by injecting an anesthetic agent around a nerve to interfere with its ability to conduct impulses.

**PROSTAGLANDIN** A substance synthesized by cells from arachidonic acid that serves as a mediator of inflammation and has other physiologic functions.

**REGIONAL ANESTHESIA** Loss of feeling or sensation in a large area (region) of the body after injection of an anesthetic agent into the spinal canal or around peripheral nerves.

**TRANSDERMAL APPLICATION** The use of a patch applied to the skin to deliver a drug through an intact cutaneous surface to the systemic circulation.

**TRANSDUCTION** The process that involves translation of noxious stimuli into electrical activity at sensory nerve endings.

---

**INTRODUCTION**

Pain has been defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage.” It may occur alone or in combination with inflammation. Pain sensation arises in free nerve endings called nociceptors, which are located in the skin, joints, blood vessel walls, periosteum, hollow organs (e.g., stomach, intestines, bladder), and parietal surfaces of the thorax and abdomen. These free nerve endings may be activated through mechanical, thermal, and chemical stimulation. Chemical stimulation may be derived from an exogenous source or from endogenous chemicals such as eicosanoids (prostaglandins), bradykinin, serotonin, and others released in response to tissue damage. Pain can have varying degrees of severity and may be acute or chronic.

Pain is sensed in terms of its intensity, duration, location, and quality. Pain that arises in subcutaneous tissue is called superficial pain. **Deep pain** is associated with skeletal muscles, tendons, and bones and joints. Visceral pain arises from hollow abdominal organs, peritoneum, heart, liver, and lungs. Pain can be beneficial in that it can allow the animal to avoid damaging stimuli. It has an emotional content and activates sympathetic stimulation. It can be harmful because it can lead to stress and related problems such as gastrointestinal lesions, immunosuppression, delayed healing, hypertension, and potential dysrhythmias. Pain also has a motivational component and can be used to force behavior and compliance (Kamerling, 2001).

Assessment of pain in animals can be very difficult because of the dependence on nonverbal communication in veterinary medicine. Furthermore, animals differ from people in their pain response. It is important for wild animals to control the expression of pain to avoid predation or abandonment. Response to pain varies among individuals and may include increased heart rate, increased respiratory rate, mydriasis, salivation, vocalization, changes in facial expression, guarding of the painful site, restlessness, unresponsiveness, failure to groom, abnormal gait, abnormal stance, and rolling. A patient that is pain-free will be quiet and calm (Paddleford, 1999).

Drugs used to control pain (analgesics) include nonsteroidal antiinflammatory drugs (NSAIDs)
and narcotics (see Chapter 4). The body is able to produce its own opiate-like analgesic agents called endorphins and enkephalins. Efforts to synthesize these substances for commercial production have been unsuccessful.

Even though some people believe that masking pain with analgesics can interfere with the diagnosis or treatment course of a disease, animals in pain should be treated for humane reasons and to reduce the harmful side effects that accompany it. The treatment regimen may vary according to assessment of the severity and the origin of the pain. For best results, pain management intervention should be preemptive when possible.

Inflammation is a basic process that occurs in the body in response to tissue injury caused by physical, chemical, or biologic trauma. The objectives of this process are (1) to counteract the injury by removing or walling off the cause of the injury and (2) to repair or replace the damaged tissue. Clinical manifestations (cardinal signs) of inflammation include redness, heat, swelling, and pain. Although the process is designed to be protective, it can continue to become a source of further injury or damage (e.g., allergy, shock, “proud flesh”).

Damage to cells from any source results in the release of several chemical mediators that may initiate or prolong the inflammatory response. These chemicals include prostaglandins, leukotrienes, histamine, cytokines, and other mediators. These substances cause helpful responses such as dilation and increased permeability of blood vessels that result in increased blood flow to the injured tissue. Enhanced blood flow brings plasma to dilute the offending agent, fibrin to immobilize it, and phagocytic cells to remove it. Redness, heat, swelling, and, to some extent, the pain of inflammation result from increased amounts of blood in the damaged tissue. The chemical mediators serve other beneficial functions such as attracting phagocytic cells to the area of concern (chemotaxis) and several potentially harmful functions such as initiation of bronchoconstriction (histamine), anaphylactic shock, pain (histamine), cell death, platelet aggregation, and intestinal spasm. The inflammatory process can be acute (anaphylaxis) or chronic (flea allergy and arthritis).

Drugs that are used to minimize the inflammatory process include NSAIDs, glucocorticosteroids, and several miscellaneous agents such as dimethyl sulfoxide (DMSO). Another process mediated by a chemical (or chemicals) released from damaged cells is fever. Fever is an increase in body temperature to above normal; it is an important clinical indicator of disease. The purpose of fever may include destruction of invading microorganisms by heat inactivation and facilitation of biochemical reactions in the body. (Most chemical reactions are speeded up by increased heat.)

Heat is generated by the metabolic activity of muscles and glands and is lost through radiation or conduction loss from the skin, sweat evaporation, and evaporation during panting. A “thermostat” in the hypothalamus regulates these mechanisms, which control body temperature.

A substance that can initiate a fever is called a pyrogen. An exogenous pyrogen is a foreign substance (e.g., bacteria, viruses) that when introduced into the body causes the release of an endogenous pyrogen (a chemical mediator such as prostaglandin) from white blood cells; this endogenous pyrogen causes resetting of the hypothalamic thermostat. The hypothalamus then activates processes to generate or conserve body heat: shivering to generate more heat, constriction of blood vessels in the skin to prevent radiation and conduction loss, and decreased sweating or panting to reduce evaporation loss. Damaged cells in some instances may release endogenous pyrogens in the absence of exogenous pyrogens. Drugs used to control fever are primarily NSAIDs.

ANATOMY AND PHYSIOLOGY

Pain sensation arises by a process called transduction in nociceptors—“naked” nerve endings found in almost every tissue of the body. Pain impulses are carried to the central nervous system (CNS) by two fiber systems: type C unmyelinated fibers are responsible for dull, poorly localized pain (in humans), and type A delta fibers are responsible for sharp, localized pain (Ganong, 2003). Type A and type C fibers carry impulses to the dorsal horn of
Hidden page
antidepressants, NSAIDs, anticonvulsants, and other drugs. Pain perception in the cortex can be inhibited by the use of anesthetics, opioids, benzodiazepines, and alpha-2 agonists.

**Nonsteroidal Antiinflammatory Drugs**

NSAIDs are thought to work by inhibiting an enzyme called cyclooxygenase (COX). Two forms (COX-1 and COX-2) of cyclooxygenase exist. COX-1 maintains physiologic functions such as modulation of renal blood flow and synthesis of gastric mucosa (Paddleford, 1999). COX-2 promotes the formation of prostaglandin from cell membrane arachidonic acid (Figure 14-2). NSAIDs that selectively inhibit COX-2 are thought to produce fewer gastrointestinal side effects. Glucocorticoids exert their effects by blocking phospholipase, an enzyme necessary for the production of both prostaglandins and leukotrienes (intervention is provided earlier in the sequence of the formation of inflammatory mediators). Because the inflammatory reaction is blocked earlier by glucocorticoids, they are more effective antiinflammatory agents than are NSAIDs (Langston and Mercer, 1988). NSAIDs are often preferred, however, because they have fewer side effects and they promote analgesia and fever reduction. At this time, it is not known why glucocorticoids do not induce the analgesic and antipyretic effects of NSAIDs. It is also unknown why some NSAIDs provide relief of only mild pain (aspirin) and others provide relief of moderate to severe pain (flunixin). Some clinicians speculate that NSAIDs may act to varying degrees

![Figure 14-2](image)

*Actions of nonsteroidal antiinflammatory drugs and glucocorticoids to interrupt the inflammatory response.*
centrally to modulate spinal transmission of pain impulses (Paddleford, 1999).

The most common side effects of the NSAIDs are gastrointestinal ulceration and bleeding, which probably result from interference with the normal mucous coating of the stomach. Other side effects may include hepatotoxicity, nephrotoxicity, inhibition of cartilage metabolism, bone marrow suppression, and bleeding tendencies (from reduced platelet aggregation).

All pets should undergo a thorough physical examination and history, as well as appropriate laboratory tests, before NSAIDs are initiated. Clients should be advised to stop the use of these drugs and to contact their veterinarian if they observe side effects in their pets that are receiving NSAIDs. Pets on long-term NSAID use should have periodic evaluations of liver and kidney function performed. Clients should be advised to watch their pets for anorexia, vomiting, changes in bowel movements, bloody or tarry stools, lethargy or other changes in behavior, seizures, jaundice, changes in urination (frequency, color, or smell), or changes in the condition of the skin.

**Technician's Notes**
1. NSAIDs should be used with caution in geriatric animals.
2. Combining NSAIDs or combining NSAIDs with corticosteroids should be done with great caution or avoided.

**Salicylates**
Aspirin, a salicylate, is also known as acetylsalicylic acid. Its actions include the following:

1. Relief of pain (analgesia)
2. Reduction in fever (antipyrexia)
3. Inhibition of inflammation (antiinflammatory)
4. Reduction in platelet aggregation

These effects are thought to occur as a result of the ability of aspirin to inhibit an enzyme (COX) that is responsible for the synthesis of prostaglandin. Prostaglandin is a chemical mediator of the processes that lead to pain, fever, inflammation, and platelet aggregation. Its inhibition results in diminishing of each process.

**Clinical Uses**
Clinical uses of aspirin exist for most animal species and may include the following:

1. Relief of mild to moderate pain caused by musculoskeletal conditions such as arthritis and hip dysplasia
2. Postadulticide treatment for heartworm disease
3. Analgesia/antipyrexia
4. Treatment of cats with cardiomyopathy
5. Treatment of endotoxic shock

**Dosage Forms**
These include plain uncoated tablets, buffered uncoated tablets, enteric-coated forms, and boluses (large-animal applications). Many generic or brand names are available in many different strengths, including the following:

1. Aspirin bolus
2. Aspirin tablets
3. Cortaba (a combination of aspirin and methylprednisolone)

**Adverse Side Effects**
Adverse side effects of aspirin include gastric irritation, which can lead to ulceration and bleeding. Cats are highly susceptible to aspirin overdose because of their inability to metabolize it rapidly; they should receive this drug only under the supervision of a veterinarian.

**Technician's Notes**
1. Enteric-coated aspirin, such as Ecotrin, may be used to prevent gastric irritation.
2. A 1-grain "baby" aspirin contains 65 mg; a 1.25-grain baby aspirin contains 81 mg.
3. Aspirin has no withdrawal time in food animals.

**Pyrazolone Derivatives**
**Phenylbutazone**
Phenylbutazone, a pyrazolone derivative, is an NSAID that is commonly used in veterinary medicine. Its actions include the following:

1. Analgesia for mild to moderate pain
2. Antiinflammatory action
3. Antipyrexia
Clinical Uses
These include relief of inflammatory conditions of the musculoskeletal system of horses and dogs. Phenylbutazone is used extensively in horses for the treatment of lameness and for the relief of pain associated with colic. It sometimes is used in dogs and cattle for its antiinflammatory, analgesic, and antipyretic effects.

Dosage Forms
Dosage forms of phenylbutazone include parenteral injection, tablets, boluses, an oral paste, an oral gel, and powder.

1. Butazolidin Tablets, Boluses, Paste, Injection
2. Phenylzone Paste
3. Equipsalazone Powder
4. Equi-Phar Phenylbutazone Gel, Tablets
5. Phenylbutazone Tablets
6. Pro-Bute
7. Phenylbutazone Injection

Adverse Side Effects
These include gastrointestinal bleeding and bone marrow suppression.

Technician’s Notes
1. Phenylbutazone injection should be administered by the intravenous route only. Subcutaneous and intramuscular injection may lead to sloughing of tissue.
2. Prolonged use or overdose can lead to bone marrow suppression in humans.
3. Prolonged use also may lead to ulcer formation.
4. Because of possible bone marrow suppression and potential ulcer formation, animals that are receiving long-term treatment with phenylbutazone should be monitored carefully.

Flunixin Meglumine (Banamine)
Flunixin is an NSAID that is labeled for use in horses and cattle. It has extralabel uses in other species. Its actions are related to its ability to inhibit COX and include the following:

1. Analgesia
2. Antipyrexia
3. Antiinflammatory

Clinical Uses
Clinical uses of flunixin in horses include alleviation of pain associated with musculoskeletal disorders and colic. (Flunixin apparently has great ability to inhibit visceral pain.) Other uses in horses and other species include treatment of the following:

1. Disk disease
2. Endotoxic shock
3. Calf diarrhea
4. Parvovirus disease
5. Heatstroke
6. Ophthalmic conditions
7. Postsurgical pain

Dosage Forms
Dosage forms of flunixin include injectable, oral paste, and oral granule formulations.

1. Banamine Injection
2. Banamine Oral Paste
3. Banamine Oral Granules
4. Finadyne

Adverse Side Effects
These are limited in horses but may include swelling at the injection site and sweating. In dogs, vomiting, diarrhea, nephrotoxicity, and gastric ulceration may occur with long-term use.

Technician’s Notes
1. Flunixin is labeled for intravenous and intramuscular use in horses.
2. Some equine clinicians believe that flunixin relieves abdominal pain so well in horses that it may cause a sense of false security about the condition of an animal with colic.
3. Small-animal patients receiving flunixin should be well hydrated and should be given intravenous fluids and ulcer prophylaxis (Paddleford, 1999).

Dimethyl Sulfoxide
DMSO is a clear liquid that was originally developed as a commercial solvent. It is noted for its antiinflammatory action and its ability to act as a carrier of other agents through the skin. Its antiinflammatory actions may be related to its ability to trap products
associated with the inflammatory response. DMSO causes vasodilation when applied topically.

**Clinical Uses**
Clinical uses of DMSO are varied; however, the only labeled use for DMSO is for topical application to reduce acute swelling resulting from trauma in dogs and horses. DMSO has reportedly been used as the following:

1. An adjunct to intestinal surgery (intravenously)
2. A treatment for cerebral edema or spinal cord injury (intravenously)
3. A treatment for perivascular injection of chemotherapeutic agents or other irritating substances (topical)
4. A carrier of drugs across the skin

**Dosage Forms**
Dosage forms of DMSO include a solution (90%) and a gel (90%).

1. DMSO Gel and Solution (90%)
2. Synotic (DMSO and a steroid)

**Buscopan Compositum**
Buscopan Compositum is a product that contains butylscopolamimum bromide and metamizole sodium (dipyrone).

**Clinical Uses**
This product is used for the management of abdominal pain associated with equine colic.

**Dosage Form**
1. Buscopan Compositum

**Adverse Side Effects**
Adverse side effects of DMSO are probably minimal with limited use or exposure but may include the following:

1. Garlic taste, which occurs very shortly after the agent is applied to the skin
2. Skin irritation accompanied by a burning sensation
3. Induction of birth defects (teratogenic) in some species

---

**Technician’s Notes**
1. Rubber gloves should be worn while applying DMSO.
2. Bandaging over an application of DMSO may cause skin irritation.
3. DMSO should be used carefully when cholinesterase inhibitors have been used.

**Acetaminophen**
Acetaminophen is an analgesic with limited antipyretic and antiinflammatory activities.

**Clinical Uses**
Clinical uses of acetaminophen are limited in veterinary medicine, and acetaminophen use should be discouraged because of the risk of potential toxicity and the availability of acceptable substitutes.

**Dosage Forms**
Dosage forms of acetaminophen include tablets, caplets, and liquid formulations. Following is a list of some of the human label brand names:

1. TYLENOL
2. Darril
3. Tempra

---

**Technician’s Notes**
1. Acetaminophen should never be given to cats.
2. Over-the-counter products should be checked carefully for the presence of acetaminophen before they are used in cats.

**Adverse Side Effects**
Adverse side effects of acetaminophen use in cats include the formation of methemoglobinemia, cyanosis, anemia, and liver damage. Cats have a limited ability to biotransform acetaminophen and may succumb to a single dose.

**Propionic Acid Derivatives**
**CARPROFEN**
Carprofen is a propionic acid derivative NSAID that has been approved for oral use in dogs. Carprofen has been approved for oral and injectable use in dogs and cats in Europe. It has a half-life of 8 hours...
and is thought to work by inhibiting COX. An injectable form is now available for use in the United States as well.

**Clinical Uses**
Uses include the relief of pain associated with degenerative joint disease and postoperative pain resulting from soft tissue or orthopedic repair.

**Dosage Forms**
2. Carprofen (Novox) Caplets

**Adverse Side Effects**
Side effects such as gastrointestinal ulceration and bleeding are apparently rare with this agent.

**Ketoprofen**
Ketoprofen is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory activities. It is labeled for use in horses in the United States but has been used a great deal in dogs and cats in Europe and Canada.

**Clinical Uses**
In horses, ketoprofen is used for treatment of pain and inflammation associated with musculoskeletal disorders. It has been used for postoperative and chronic pain in dogs and cats.

**Dosage Forms**
1. Ketofen (horses)
2. Orudis (human label)

**Adverse Side Effects**
Side effects may include gastrointestinal bleeding or ulceration, renal dysfunction, and generalized bleeding.

**Naproxen**
Naproxen is a propionic acid derivative that is similar to ketoprofen and ibuprofen. It is labeled for use in horses, although it has been used in dogs.

**Clinical Uses**
Naproxen is labeled for the "relief of pain, inflammation, and lameness associated with myositis and other soft tissue diseases of the musculoskeletal system of horses."

**Dosage Forms**
1. Equispen (horses)
2. Naprosyn (human)

**Adverse Side Effects**
Few side effects are reported in horses. GI ulceration has been reported in dogs.

**Ibuprofen**
Ibuprofen is reported to have the potential for serious side effects in dogs and cats and is not recommended for use in these species.

---

**Other Nonsteroidal Antiinflammatory Drugs**

**Etodolac**
Etodolac is an indole acetic acid derivative NSAID that has been labeled for use in dogs.

**Clinical Use**
This drug is labeled for the management of pain and inflammation associated with osteoarthritis in dogs.

**Dosage Form**
EtoGesic

**Adverse Side Effects**
Side effects include anorexia, vomiting, diarrhea, and lethargy.

**Deracoxib**
Deracoxib is an analgesic and a nonsteroidal anti-inflammatory agent of the coxib class.

**Clinical Use**
Deracoxib is labeled for the control of pain and inflammation associated with orthopedic surgery in dogs with 4 lb body weight or greater, and for the control of pain and inflammation associated with osteoarthritis in dogs weighing 14 lb or more.

**Dosage Form**
Deramaxx
Firocoxib
Firocoxib is an NSAID that belongs to the coxib class.

Clinical Uses
The labeled use is for the treatment of pain and inflammation associated with osteoarthritis in dogs.

Dosage Form
Previcox Chewable Tablets with once-daily dosing

Tepoxalin
Tepoxalin is a nonsteroidal antiinflammatory drug for oral use in dogs only. The manufacturer claims that this product is the only NSAID that blocks both arms of the arachidonic acid cascade (COX and lipooxygenase). It is manufactured as a “rapidly disintegrating” tablet that breaks down quickly upon contact with the moisture of the animal’s mouth and cannot be spit out. This dosage form is designed to improve owner/animal dosage compliance.

Clinical Use
Tepoxalin is labeled for the control of pain and inflammation associated with osteoarthritis in dogs.

Dosage Form
Zubrin

Meloxicam
Meloxicam is a COX-2 receptor NSAID. It has antiinflammatory, analgesic, and antipyretic properties.

Clinical Uses
Meloxicam is used to control pain associated with surgical procedures, arthritis, and other causes. Metacam use in cats is limited to one-time subcutaneous injection for surgical pain.

Dosage Forms
Metacam Oral Suspension, 1.5 mg/ml
Metacam Injection for Cats, 5 mg/ml
Metacam Injection for Dogs, 5 mg/ml

Adverse Side Effects
Similar to other NSAIDs, other agents that are classified as NSAIDs or that have similar activity include those discussed in the following paragraphs

Polysulfated Glycosaminoglycan ( Adequan )
Adequan is a semisynthetic mixture of glycosaminoglycans derived from bovine cartilage. This drug reduces degenerative changes induced by noninfectious or traumatic joint disease and promotes activity in the synovial membrane. It is available in intraarticular and intramuscular forms and is labeled for use in horses and dogs.

Hyaluronate Sodium ( Hyalovet )
Hyalovet is a glycosaminoglycan that is labeled for intraarticular injection. It has activities similar to that of Adequan.

Legend
A solution of hyaluronate that may be given by intravenous or intraarticular injection for synovitis associated with osteoarthritis

Meclofenamic Acid ( Arquel Granules )
This NSAID is labeled for oral treatment of acute or chronic inflammatory disease in horses.

Selenium and Vitamin E ( Seletoc )
Seletoc is labeled for relief of acute symptoms of arthritic conditions in dogs.

Ketorolac
Ketorolac is an NSAID with efficacy similar to that of morphine. It carries a human label and may cause serious side effects.

Orgotein ( Palosein )
Palosein is labeled for acute and chronic inflammatory conditions in horses and dogs.

Opioid Analgesics
Opioids and opioid receptors are discussed in a general fashion in Chapter 4. This section addresses only use of opioids to control pain.
Opioids relieve pain by binding with specific receptor sites in the brain, spinal cord, and peripheral tissue. By altering neurotransmitter release, they alter nerve impulse formation and transmission at many levels within the CNS. The ultimate effect is that the opioids block or inhibit pain impulses to higher CNS centers responsible for the perception of pain.

**Opioid Agonists**

Opioid agonists remain one of the most effective drug classes for relieving moderate to severe pain (Paddleford, 1999). Opioid agonists are drugs that bind with all opioid receptor sites and produce opioid effects and respiratory depression, sedation, and addiction. Opioid agonists include alfentanil, carfentanil, codeine, etorphine, fentanyl, hydromorphone, meperidine, methadone, morphine, oxymorphone, and sufentanil. Even though some of these drugs are considered more potent than morphine, morphine is still considered to be one of the most effective of the opioids. All agonists are C-II controlled substances.

**Clinical Uses**

Opioid agonists are used to control moderate to severe pain in animals.

**Selected Dosage Forms**

1. Morphine sulfate (Infumorph, Astramorph PF) (human labels)
2. Oxymorphone (Numorphan)
3. Meperidine (Demerol)
4. Codeine (codeine phosphate, codeine sulfate, Tylenol with codeine)
5. Fentanyl transdermal (Duragesic)
6. Tramadol (Ultram)—synthetic Mu receptor opiate (noncontrolled)

**Adverse Side Effects**

Side effects can include respiratory depression, sedation, excitement, and addiction. Cats are more sensitive to the excitatory effects of opioid agonists than are other species, and they tolerate low doses well.

**Transdermal Fentanyl Use**

Transdermal application of fentanyl has been successfully used in humans for control of chronic pain. This use has recently been adapted for control of postoperative and chronic pain in dogs and cats (extralabel).

Care must be taken when using transdermal patches to ensure that the animal does not eat or lick the patch (causing possible overdosage), and that accidental exposure to humans (especially children) does not occur. To apply the patch, gloves should be worn; the skin over the dorsum of the neck should be clipped, cleansed, and allowed to dry well; good skin contact with the patch should be achieved; and a snug bandage should be applied to hold the patch in place. The patch should never be cut because this interferes with the rate of release of fentanyl. The patch should be carefully disposed of after use.

**Opioid Agonists-Antagonists**

The opioid agonist-antagonist drugs bind with opioid kappa receptors but antagonize opioid mu receptors. Opioid agonists-antagonists include butorphanol (C-IV), pentazocine (C-IV), and nalbuphine. These drugs are considered effective for mild to moderate pain and have few side effects.

**Clinical Uses**

The primary use is for the relief of mild to moderate pain.

**Dosage Forms**

1. Butorphanol (Torbegesic, Torbutrol, Stadol)
2. Pentazocine (Talwin-V)
3. Nalbuphine (Nubain)

**Adverse Side Effects**

Side effects include sedation, ataxia, and salivation (pentazocine).

**Opioid Partial Agonists**

The opioid partial agonists bind with the mu receptors but only partially activate them. Buprenorphine is the primary drug in this category. Recent studies have shown that buprenorphine may be effectively administered to cats by the sublingual/buccal route (Robertson, 2001).

**Clinical Uses**

Uses include relief of mild to moderate pain in dogs and horses.
Dosage Form
Buprenex (human label)

Adverse Side Effects
Side effects include sedation and respiratory depression.

Other Pain Control Agents
Ketamine, alpha-2-adrenergic agents, lidocaine, benzodiazepines, and tricyclic antidepressants (Elavil) are other agents that are used frequently to modulate pain (see Chapter 4). These agents may be used alone or in combination with others. Some agents are delivered as a constant rate infusion (CRI) for the sustained control of pain. A common CRI for pain control involves the combination of morphine and ketamine (MK) or morphine, lidocaine, and ketamine (MLK).

Antihistamines

Antihistamines are drugs that are used to inhibit the effects or spread of the inflammatory process. These drugs do not inhibit the formation of prostaglandins or other inflammatory mediators. They work by preventing histamine from combining with tissue receptors or by displacing histamine from receptor sites.

Because histamine is a major chemical mediator of the allergic response, antihistamines may be useful in controlling allergic responses.

Histamine is a chemical that is released from mast cells when they are adequately stimulated by immunoglobulin E (IgE) antibodies to allergens (Figure 14-3). Histamine then combines with tissue receptors and causes dilation of small blood vessels, increased permeability of capillaries, smooth muscle spasm, and increased secretion of glands. Two types of antihistamine receptors have been identified: H₁ and H₂.

Antihistamines competitively block the binding of histamine to H₁ receptors, which may block progression of the allergic response. Some antihistamines also block H₁ receptors that may contribute to motion sickness or nausea. Some antihistamines have a high affinity for H₁ receptors in the brain and cause a sedative effect.

Stimulation of H₂ receptors causes increased flow of hydrochloric acid by the gastric mucosa. H₂ blockers reduce the secretion of hydrochloric acid and may be used to treat gastrointestinal irritation and ulceration.

Clinical Uses
Antihistamines are used to treat the following:

1. Pruritus
2. Urticaria and angioedema associated with acute allergic reactions
3. Laminitis in horses and cattle
4. “Downer” cow syndrome
5. Motion sickness
6. “Reverse sneeze” syndrome
7. Anaphylactic shock
8. Upper respiratory tract conditions
Hidden page
Hidden page
stimulate the hypothalamus—through impulses from higher brain centers—to release CRF. The control mechanism then proceeds in the fashion illustrated in Figure 14-4.

One of the major indications for the clinical use of corticosteroids is for their antiinflammatory effects. These effects are brought about by their ability to block the enzyme phospholipase, which promotes the reaction that results in the formation of prostaglandin—a primary mediator of the immune response. Corticosteroids also protect cells from inflammatory trauma by various mechanisms that include but are not limited to the following:

1. Stabilizing cell membranes to help prevent their breakdown
2. Stabilizing lysosomal membranes so they do not release their harmful enzymes
3. Disrupting histamine synthesis
4. Inhibiting interleukin synthesis
5. Reducing exudative processes

Corticosteroids are also used clinically for their immunosuppressive effects. They are used to suppress the immune system in allergic conditions such as flea allergy dermatitis, atopy, autoimmune hemolytic anemia, rheumatoid arthritis, and uveitis. The immunosuppressive effect comes from the ability of corticosteroids to do the following:

1. Inhibit antibody formation
2. Decrease the concentrations of lymphocytes and eosinophils
3. Suppress the migration of neutrophils
4. Inhibit phagocytosis

Although immunosuppressive qualities are very useful clinically, they can also mask the signs of serious infection that are simultaneously present.

Corticosteroids are useful in the treatment of lymphoid tumors because they cause a direct lymphotoxic effect (Barton, 2001).

All steroid compounds are synthesized from a basic parent compound that has been described as resembling three rooms and a bath (Figure 14-5). Steroids are formed in three regions of the adrenal gland. Those regions and their respective products include the following:

1. Zona glomerulosa—mineralocorticoids
2. Zona fasciculata—glucocorticoids
3. Zona reticularis—sex hormones (androgen and estrogen)

**Figure 14-4**
Release of corticosteroids is under the control of the hypothalamic-pituitary-adrenal (HPA) axis.

**Figure 14-5**
The configuration of the parent molecule of all steroid molecules, including corticosteroids.
Hidden page
Hidden page
Hidden page
4. Lidocaine hydrochloride injection
5. Other generic local anesthetics, including tetra-caine and dibucaine

Topical
1. Ophthaine Solution Veterinary
2. Ophthalmic

Adverse Side Effects
Local anesthetics can have adverse side effects if the total maximum dose for the species being treated is exceeded. Side effects may include restlessness, excitement, hypotension, and seizures.

Technician's Notes
1. Lidocaine with epinephrine should never be used if an antiarrhythmic is indicated.
2. Exceeding the total recommended dose of local analgesics may cause toxicity.

REFERENCES
1. Pain sensation arises in free nerve endings called ________________.

2. List some signs associated with pain in animals.

3. NSAIDs that selectively inhibit ________________ are thought to produce fewer gastrointestinal side effects.

4. What is the most common side effect of the NSAIDs? ________________

5. Why are cats so susceptible to aspirin overdose?

6. Phenylbutazone should be administered parenterally by the SQ route only.
   a. True
   b. False

7. What C-II opioid is administered via transdermal patch? ________________

8. Corticosteroid therapy involves treatment of the signs of disease and often cures the disease as well.
   a. True
   b. False

9. What function do mineralocorticoids serve in the body? ________________

10. List some principles that should be followed concerning corticosteroid therapy.

11. What does the term iatrogenic mean?

12. Describe the side effects of short-term and long-term corticosteroid use.

13. What is the mechanism of action of local anesthetic agents?

14. What are some indications for the use of local anesthetics?

15. The body is able to produce its own opiate-like analgesic agents called ________________.
   a. histamine
   b. endorphins
   c. prostaglandins
   d. cytokines

16. A substance that can initiate a fever is called a ________________.
   a. prostaglandin
   b. endorphin
   c. pyrogen
   d. pyometra

17. ________________ is also known as acetylsalicylic acid.
   a. Phenylbutazone
   b. Aspirin
   c. DMSO
   d. Acetaminophen

18. ________________ is a pyrazolone derivative.
   a. Phenylbutazone
   b. Carprofen
   c. Etodolac
   d. Deramaxx

19. Flunixin meglumine is a(an) ________________.
   a. propionic acid derivative
   b. antihistamine
   c. muscle relaxant
   d. NSAID

20. DMSO causes ________________ when applied topically.
   a. vasoconstriction
   b. vasodilation

21. ________________ is considered (even today) to be one of the most effective of the opioids.
   a. Fentanyl
   b. Morphine
   c. Tepoxalin
   d. Carprofen
22. __________ is(are) a major chemical mediator(s) of the allergic response.
   a. Histamine
   b. Prostaglandins
   c. Pyrogens
   d. Hormones

23. All of the following are types of corticosteroids except __________.
   a. dexamethasone
   b. Prednisolone
   c. Vetalog
   d. Ketoprofen

24. A local anesthetic such as lidocaine may be a drug of choice when an epidural is performed to replace a prolapsed uterus in a bovine.
   a. True
   b. False
CHAPTER 15
Therapeutic Nutritional, Fluid, and Electrolyte Replacements

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Define terms related to fluid, electrolyte, and selected therapeutic nutritional preparations.
2. Describe the distribution of water in the body.
3. Describe the composition of body and therapeutic fluids.
4. Define osmotic pressure and tonicity as they apply to fluids.
5. Discuss the basic principles of fluid therapy.
6. Describe fluid equipment and its use.
7. Categorize and provide examples of the fluids used in fluid therapy.
8. List and describe selected fluid additives.
9. List and describe selected oral electrolyte preparations.
10. List and describe selected parenteral vitamin-mineral products.
**KEY TERMS**

**BUFFER** A substance that decreases the change in pH when an acid or base is added.

**COLLOID** A chemical system composed of a continuous medium throughout which small particles are distributed and do not settle out under the influence of gravity.

**DISSOCIATION** The act of separating into ionic components (NaCl → Na and Cl).

**ELECTROLYTE** A substance that dissociates into ions when placed in solution, becoming capable of conducting electricity.

**EMPIRICAL** Based on observation and personal experience.

**HYPERKALEMIA** An excess of potassium in the blood.

**HYPERNATREMIA** An excess of sodium in the blood.

**HYPOKALEMIA** A deficiency of potassium in the blood.

**HYponatremia** A deficiency of sodium in the blood.

**HYPOVOLEMIA** Decreased volume of circulating blood.

**METABOLIC ACIDOSIS** Decreased body pH caused by excess hydrogen ions in the extracellular fluid.

**METABOLIC ALKALOSIS** Increased body pH caused by excess bicarbonate in the extracellular fluid.

**ONCOTIC PRESSURE** The osmotic pressure generated by plasma proteins in the blood.

**SOLUTE** A substance dissolved in a solvent to form a solution.

**TOTAL NUTRIENT ADMIXTURE** A solution used for parenteral administration that contains amino acids, lipids, dextrose, vitamins, and minerals.

**TRANSCELLULAR FLUID** Cerebrospinal fluid, aqueous humor of the eye, synovial fluid, gastrointestinal fluid, lymph, bile, and glandular and respiratory secretions.

**TURGOR** Degree of fullness or congestion; describes the degree of elasticity of the skin.

---

**INTRODUCTION**

Veterinary technicians often have an important role in fluid, electrolyte, and therapeutic nutritional therapy. They administer parenteral or oral fluid or nutritional products and monitor patients’ responses under the direction of a veterinarian. Because the use of these products can be critically important to the outcome of a case, technicians should have a thorough knowledge of the products and their use.

**ANATOMY, PHYSIOLOGY, AND CHEMISTRY**

**Distribution of Body Water and Electrolytes**

Measurements of total body water (TBW) have shown that water represents 50% to 70% of the total body weight in adult animals; 60% is often used as the average figure. As much as 80% of a neonatal animal’s body weight may be water—a factor that makes fluid loss in young animals potentially very serious. An increase in body fat decreases the amount of TBW and makes it important to estimate fluid needs on the basis of lean body mass to avoid overhydration.

TBW is distributed in several compartments within the body (Figure 15-1). Sixty percent of TBW is found within cells and is called **intracellular fluid** (ICF). ICF makes up 40% of total body weight. The other 40% of TBW is found outside the cells and is called **extracellular fluid** (ECF). ECF accounts for 20% of total body weight.

ECF (discounting the relatively small **transcellular fluid** component) distributes itself between the interstitial fluid (15% of body weight) and the intravascular fluid or plasma (5% of body weight).

Body fluid compartments should be thought of as volumes of fluid and electrolytes in dynamic equilibrium, with fluids and electrolytes moving back and forth across semipermeable cell membranes. Changes in the quantity of fluid or electrolytes in one compartment usually result in changes in these quantities in other compartments. Fluids administered intravenously to an animal first enter the intravascular...
space of the ECF, move into the interstitial space, and then enter the ICF (Figure 15-2). In most cases, loss of fluid occurs first from the ECF and then from other compartments.

**Composition of Body and Therapeutic Fluids**

Body water contains an array of solutes that vary in quantity from compartment to compartment. A solute is a substance that dissolves in a solvent; this solvent is usually water in biologic systems. The molecules of substances called electrolytes break down (dissociate) into charged particles called ions. Electrolytes are positively charged (cations) or negatively charged (anions). The number of cations always equals the number of anions in normal animals (Table 15-1). In the ECF, the most abundant cation is sodium, and the most abundant anions are chloride and bicarbonate. In the ICF, the major cations are potassium and magnesium, and the major anions are phosphates and proteins. Therapeutic fluids are described as balanced if they resemble ECF in composition and unbalanced if they do not. Lactated Ringer's solution is an

![Figure 15-2](image)

**Figure 15-2**
Schematic showing movement of fluid between compartments.

<table>
<thead>
<tr>
<th>Table 15-1 Composition of Plasma and Interstitial Fluid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ion</td>
</tr>
<tr>
<td>---------------</td>
</tr>
<tr>
<td>Cations</td>
</tr>
<tr>
<td>Na⁺</td>
</tr>
<tr>
<td>K⁺</td>
</tr>
<tr>
<td>Ca²⁺</td>
</tr>
<tr>
<td>Mg²⁺</td>
</tr>
<tr>
<td><strong>Total</strong></td>
</tr>
<tr>
<td>Anions</td>
</tr>
<tr>
<td>Cl⁻</td>
</tr>
<tr>
<td>HCO₃⁻</td>
</tr>
<tr>
<td>H₂PO₄⁻</td>
</tr>
<tr>
<td>Protein</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Total</strong></td>
</tr>
</tbody>
</table>
Hidden page
### Table 15-2 Composition of Solutions Used in Fluid Therapy

<table>
<thead>
<tr>
<th></th>
<th>Glucose* (g/L)</th>
<th>Na⁺ (mEq/L)</th>
<th>Cl⁻ (mEq/L)</th>
<th>K⁺ (mEq/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dextrose Electrolyte Solution Composition</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5% dextrose</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>10% dextrose</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2.5% dextrose in 0.45% NaCl</td>
<td>25</td>
<td>77</td>
<td>77</td>
<td>0</td>
</tr>
<tr>
<td>5% dextrose in 0.45% NaCl</td>
<td>50</td>
<td>77</td>
<td>77</td>
<td>0</td>
</tr>
<tr>
<td>5% dextrose and 0.9% NaCl</td>
<td>50</td>
<td>154</td>
<td>154</td>
<td>0</td>
</tr>
<tr>
<td>0.45% NaCl</td>
<td>0</td>
<td>77</td>
<td>77</td>
<td>0</td>
</tr>
<tr>
<td>0.85% NaCl (normal saline)</td>
<td>0</td>
<td>145</td>
<td>145</td>
<td>0</td>
</tr>
<tr>
<td>0.9% NaCl</td>
<td>0</td>
<td>154</td>
<td>154</td>
<td>0</td>
</tr>
<tr>
<td>3% NaCl</td>
<td>0</td>
<td>513</td>
<td>513</td>
<td>0</td>
</tr>
<tr>
<td>Ringer’s solution</td>
<td>0</td>
<td>147.5</td>
<td>156</td>
<td>4</td>
</tr>
<tr>
<td>Lactated Ringer’s solution</td>
<td>0</td>
<td>130</td>
<td>109</td>
<td>4</td>
</tr>
<tr>
<td>2.5% dextrose in lactated Ringer’s solution</td>
<td>25</td>
<td>130</td>
<td>109</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>130</td>
<td>109</td>
<td>4</td>
</tr>
<tr>
<td>2.5% dextrose in half-strength lactated Ringer’s solution</td>
<td>25</td>
<td>65.5</td>
<td>55</td>
<td>2</td>
</tr>
<tr>
<td>Normosol-M in 5% dextrose‡</td>
<td>50</td>
<td>40</td>
<td>40</td>
<td>13</td>
</tr>
<tr>
<td>Normosol-R†</td>
<td>0</td>
<td>140</td>
<td>98</td>
<td>5</td>
</tr>
<tr>
<td>Plasma-Lyte§</td>
<td>0</td>
<td>140</td>
<td>103</td>
<td>10</td>
</tr>
<tr>
<td>Plasma-Lyte M in 5% dextrose†</td>
<td>50</td>
<td>40</td>
<td>40</td>
<td>16</td>
</tr>
<tr>
<td>Plasma</td>
<td>1</td>
<td>145</td>
<td>105</td>
<td>5</td>
</tr>
<tr>
<td><strong>Additives and Solutions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20% mannitol</td>
<td>200(M)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>7.5% NaHCO₃</td>
<td>0</td>
<td>893(B)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8.4% NaHCO₃</td>
<td>0</td>
<td>1000(B)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>10% CaCl₂</td>
<td>0</td>
<td>0</td>
<td>2720</td>
<td>0</td>
</tr>
<tr>
<td>14.9% KCl</td>
<td>0</td>
<td>0</td>
<td>2000</td>
<td>2000</td>
</tr>
<tr>
<td>50% dextrose</td>
<td>500</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* All glucose, with one exception: M, mannitol
‡ Buffers used: A, acetate; B, bicarbonate; G, gluconate; L, lactate.
§ CEVA Laboratories.
$§$ Baxter Healthcare

<table>
<thead>
<tr>
<th>$\text{Ca}^{2+}$ (mEq/L)</th>
<th>$\text{Mg}^{2+}$ (mEq/L)</th>
<th>Buffer $^\dagger$ (mEq/L)</th>
<th>Osmolarity (mOsm/L)</th>
<th>kcal/L</th>
<th>pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>252</td>
<td>170</td>
<td>4.0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>505</td>
<td>340</td>
<td>4.0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>280</td>
<td>85</td>
<td>4.5</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>406</td>
<td>170</td>
<td>4.0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>560</td>
<td>170</td>
<td>4.0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>154</td>
<td>0</td>
<td>5.0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>290</td>
<td>0</td>
<td>5.0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>308</td>
<td>0</td>
<td>5.0</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1026</td>
<td>0</td>
<td>5.0</td>
</tr>
<tr>
<td>4.5</td>
<td>0</td>
<td>0</td>
<td>3.10</td>
<td>0</td>
<td>5.5</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>23(L)</td>
<td>272</td>
<td>9</td>
<td>6.5</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>28(L)</td>
<td>398</td>
<td>94</td>
<td>5.0</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>28(L)</td>
<td>524</td>
<td>179</td>
<td>5.0</td>
</tr>
<tr>
<td>1.5</td>
<td>0</td>
<td>14(L)</td>
<td>263</td>
<td>89</td>
<td>5.0</td>
</tr>
<tr>
<td>0</td>
<td>3</td>
<td>16(A)</td>
<td>364</td>
<td>175</td>
<td>5.5</td>
</tr>
<tr>
<td>0</td>
<td>3</td>
<td>27(A)</td>
<td>296</td>
<td>18</td>
<td>6.4</td>
</tr>
<tr>
<td>0</td>
<td>3</td>
<td>23(G)</td>
<td>312</td>
<td>17</td>
<td>5.5</td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>47(A)</td>
<td>178</td>
<td>5.5</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>12(A)</td>
<td>376</td>
<td>5.5</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>12(L)</td>
<td>300</td>
<td>—</td>
<td>7.4</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1099</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>893(B)</td>
<td>1786</td>
<td>0</td>
<td>—</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>1000(B)</td>
<td>2000</td>
<td>0</td>
<td>—</td>
</tr>
<tr>
<td>1360</td>
<td>0</td>
<td>0</td>
<td>4080</td>
<td>0</td>
<td>—</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>4000</td>
<td>0</td>
<td>—</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2780</td>
<td>1700</td>
<td>4.2</td>
</tr>
</tbody>
</table>
Hidden page
**Fluid Balance**

In normal animals, the intake of fluid and electrolytes is adjusted to offset losses that occur. Sources of water intake include (1) water that is drunk, (2) water that is ingested in food, and (3) water that results from the metabolism of food (metabolic water). Normal routes of water loss include (1) urine, (2) fecal water, (3) sweat (horses), and (4) respiration. Respiratory loss potentially can be important in dogs because of panting, and sweating can be important in horses. Fluid losses are frequently characterized as sensible—those that can be measured easily (e.g., urine), and insensible—those that cannot be measured easily (e.g., fecal and respiratory losses).

Decreased fluid intake often accompanies anorexia, and increased fluid loss occurs in disease states that cause polyuria, vomiting, and diarrhea. Third-space shifts of body water occasionally may cause quantities to be taken out of circulation as they are trapped in body cavities or lost through skin lesions (e.g., intestinal obstruction, body cavity effusions, hemorrhage). Extensive burns, which are uncommon in veterinary medicine, also can cause extensive fluid loss.

**History, Physical Examination, and Laboratory Findings**

A patient’s history provides important information about the route and extent of water intake and loss. Knowing the route of loss can aid a clinician in determining the type of fluid to use to correct dehydration and electrolyte imbalances. Table 15-3 lists various causes of dehydration and the fluid indicated for treating each condition. For example, acute vomiting leads to loss of potassium and chloride ions, whereas acute diarrhea causes primarily a potassium loss.

The physical examination provides important information about the extent of fluid loss. The skin turgor test, along with other physical findings, is used to determine the percentage of body weight that has been lost via fluid (Table 15-4). The skin turgor test is performed by pinching up a fold of skin over the thoracic or lumbar area and then determining how long it takes to return to a normal position. If the neck area is used in small animals, the extra skin may cause misleading results. The point of the shoulder should be used in horses because the skin of the neck area can again be misleading. The longer the skin takes to return to normal, the greater the degree of dehydration. Animals with little body fat may appear to be more dehydrated than they really are (slow return to normal skin position) because of low body fat levels, whereas obese animals may appear to be well hydrated when they are not because increased fat increases skin elasticity. The presence of dry mucous membranes; an increased heart rate; weak, thready pulses; reduced jugular distention (especially in horses); and a reduced capillary refill time all may be indicators of dehydration. Because most of the evaluations mentioned earlier are subjective, simple laboratory tests may be performed to aid in assessing hydration status.

Simple laboratory tests that can aid in evaluating hydration status are packed cell volume (PCV), total plasma protein (TPP) determination, and urine specific gravity. Dehydration generally results in an increase in PCV, TPP, and urine specific gravity. Because anemia can make a dehydrated patient appear to be normally hydrated, PCV always should be evaluated with TPP. Readers should consult more advanced references for interpretation of laboratory findings related to hydration status.

**Determining the Amount of Fluid to Administer**

Three values that are calculated to determine the volume of fluid to administer are (1) the hydration deficit, (2) the maintenance requirement, and (3) the contemporary (ongoing) losses.

The hydration deficit, which is the amount of fluid that must be replaced to bring the animal back to a normal hydration status, is calculated by multiplying the percentage of dehydration by the patient’s normal body weight. The percentage of dehydration is estimated from the history, physical examination, and laboratory findings. The saying, “A pint is a pound the world around” can then be applied because a pint is roughly equivalent to 500 ml. For example, if a 22-lb beagle is determined
<table>
<thead>
<tr>
<th>Abnormality</th>
<th>Type of Dehydration</th>
<th>Electrolyte Balance</th>
<th>Acid-Base Status</th>
<th>Fluid Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simple dehydration, stress, exercise</td>
<td>Hypertonic</td>
<td>K⁺ variable Na⁺ variable</td>
<td>Metabolic acidosis</td>
<td>Half-strength or balanced electrolyte solution; 5% dextrose solution</td>
</tr>
<tr>
<td>Heatstroke</td>
<td>Hypertonic</td>
<td></td>
<td>Metabolic acidosis</td>
<td>Health-strength electrolyte solution followed by balanced electrolyte solution</td>
</tr>
<tr>
<td>Anorexia</td>
<td>Isotonic</td>
<td>K⁺ loss</td>
<td>Mild metabolic acidosis</td>
<td>Balanced electrolyte solutions; KCl</td>
</tr>
<tr>
<td>Starvation</td>
<td>Isotonic</td>
<td>K⁺ loss</td>
<td>Mild metabolic acidosis</td>
<td>Half-strength or balanced electrolyte solutions; KCl; calories</td>
</tr>
<tr>
<td>Vomiting</td>
<td>Isotonic or hypertonic</td>
<td>Na⁺, K⁺, and Cl⁻ loss</td>
<td>Metabolic alkalosis; metabolic acidosis chronically</td>
<td>Ringer’s solution; 0.9% saline with KCl supplementation</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Isotonic or hypertonic</td>
<td>Na⁺ loss K⁺ loss chronically</td>
<td>Metabolic acidosis</td>
<td>Balanced electrolyte solution; HCO₃⁻; KCl (if chronic)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Hypertonic</td>
<td>K⁺ loss</td>
<td>Metabolic acidosis</td>
<td>Balanced electrolyte solution; KCl</td>
</tr>
<tr>
<td>Hyperadrenocorticism</td>
<td>Isotonic</td>
<td>K⁺ loss</td>
<td>Occasionally mild metabolic alkalosis</td>
<td>Balanced electrolyte solutions; KCl</td>
</tr>
<tr>
<td>Hypoadrenocorticism</td>
<td>Isotonic or hypertonic</td>
<td>Na⁺ loss K⁺ retention</td>
<td>Metabolic acidosis</td>
<td>Balanced electrolyte solutions; blood</td>
</tr>
<tr>
<td>Urethral obstruction</td>
<td>Isotonic or hypertonic</td>
<td>K⁺ retention Na⁺, Cl⁻ variable</td>
<td>Metabolic acidosis</td>
<td>0.9% saline followed by balanced electrolyte solutions; KCl post-obstruction</td>
</tr>
<tr>
<td>Acute renal failure</td>
<td>Isotonic or hypertonic (with vomiting)</td>
<td>K⁺ retention Na⁺, Cl⁻ variable</td>
<td>Metabolic acidosis</td>
<td>Balanced electrolyte solution; blood</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>Isotonic or hypertonic (with vomiting)</td>
<td>Na⁺, K⁺, Cl⁻ variable</td>
<td>Metabolic acidosis</td>
<td>Balanced electrolyte solutions; blood</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>Plethoric (Na⁺, H₂O retention early); hypotonic chronically</td>
<td>Na⁺ retention (but dilutional hyponatremia)</td>
<td>Metabolic acidosis (chronically)</td>
<td>5% dextrose solution</td>
</tr>
<tr>
<td>Hemorrhagic shock</td>
<td>Isotonic</td>
<td></td>
<td>Metabolic acidosis</td>
<td>Balanced electrolyte solutions; blood</td>
</tr>
<tr>
<td>Endotoxic shock</td>
<td>Isotonic</td>
<td></td>
<td>Metabolic acidosis</td>
<td>Balanced electrolyte solutions; 0.9% saline</td>
</tr>
</tbody>
</table>

Hidden page
that can be administered subcutaneously depends on the size of the animal and the amount of loose skin that it has. Between 50 and 200 ml generally can be infused at a subcutaneous site. Great care should be taken not to administer enough fluid to dissect the skin loose from its blood supply because this can cause sloughing of skin over the site. Hypertonic or irritating fluids should not be given by the subcutaneous route.

The oral route is a practical means of administering fluids as long as an animal has no severe disorders of the gastrointestinal system. This route allows normal physiologic processes to control the amount of fluid and the amount and type of electrolytes absorbed. This route is not satisfactory when large volumes of fluid must be given rapidly.

The intraperitoneal route allows for administration of large volumes of fluid, but absorption is slow. Peritonitis is a potential complication, and this route is not commonly used.

The intraosseous (femur, ilium, or humerus) route is sometimes used in very small animals or in those with poor access to veins. This route allows rapid delivery of fluids and blood but requires greater technical expertise for placing the delivery needle. Careful attention should be paid to sterile technique when this route is used, to avoid causing osteomyelitis.

**Rate of Administration**

Once the volume of fluid needed and the route of administration have been decided, the time frame must be established for delivering the fluids. Rapid
losses of fluid usually call for rapid replacement. In veterinary practice, fluid flow rates often are determined empirically. However, some generalizations are helpful.

For treating patients with shock, fluids should be administered rapidly (40 ml/lb/hr in dogs and 20 to 30 ml/lb/hr in cats). The use of a pressure administration cuff may allow more rapid infusion in these cases (Figure 15-5).

Fluids ideally should be infused continuously during a 24-hour period. One method of determining fluid flow rate is to calculate the hydration deficit, add maintenance and ongoing losses, and set the drip rate to administer the total during a 24-hour period. Some clinicians prefer to administer the hydration deficit during the first few hours and then to give the remainder over a longer period. Some divide the total calculated volume into three equal parts and administer each in an 8-hour period. In many practices, fluid administration can be monitored for a part of the day only. In this case, the total 24-hour fluid volume can be administered during the period that the patient can be monitored. (Common sense and medical judgment, however, must be exercised.) Portions of the total volume may be administered subcutaneously when appropriate.

Fluids are administered from plastic bags or bottles or from glass bottles through intravenous administration sets (Figures 15-6 and 15-7). Two sizes of administration sets that are commonly used in veterinary medicine are the standard macrodrip set (15 drops/ml) and the minidrip/microdrip set (60 drops/ml). Other sizes (10 drops/ml and 20 drops/ml) are also available. Microdrip sets are suited for use in administering fluids to cats and small dogs. The size of the administration set must be known to calculate the drip or flow rate.

To calculate the drip rate, first divide the total number of milliliters to be administered by the total number of minutes for administration to determine the number of milliliters per minute to deliver. Then, multiply the milliliters per minute by the drops per milliliter of the administration set you have chosen to use, to arrive at the number of drops (gtt) per minute (gtt/min). For example, if we wish to give our beagle 1200 ml of fluid during a 24-hour period using a standard (15 gtt/ml) administration set:

\[
\frac{\text{Volume of infusion (ml)}}{\text{Time of infusion (min)}} \times \text{drop factor (gtt/ml)} = \text{gtt/min}
\]

\[
\frac{1200 \text{ ml}}{24 \text{ hours} \times 60 \text{ min/hour}} = \frac{1200 \text{ ml}}{1440 \text{ min}} = 0.83 \text{ ml/min} \times 15 \text{ gtt/ml} = 12.5 \text{ gtt/min}
\]

A rate of 12.5 gtt/min can be thought of as 1 drop approximately every 5 seconds \(\left(\frac{60}{12} = 5\right)\).

When standard gravity flow bags or bottles are used, drip rates are controlled by devices that are placed on the administration sets to adjust the diameter of the line (e.g., roller clamps, slide clamps, screw clamps) (Figure 15-8). The flow rate is simply dialed in on the machine when fluid infusion pumps (ml/hour) or controllers (ml/min) are used.

**Monitoring Fluid Administration**

Fluids administered too rapidly or in too great a volume can be life threatening. Careful monitoring of the physical status of the animal is essential. Lung sounds, skin turgor, and the overall status of the animal should be monitored regularly, along with the PCV and the TPP. When a large volume of fluids is administered rapidly, it is prudent to insert a urinary catheter to monitor urine output and establish that the kidneys are functioning normally. Some clinicians also choose to insert a jugular
catheter to monitor central venous pressure as a way of preventing fluid volume overload.

Signs of overhydration may include restlessness, serous nasal discharge, increased lung sounds (crackles), tachycardia, dyspnea, pitting subcutaneous edema, and an increased “Jello-like” feel in the subcutaneous tissue (Haskins, 2000). Fluid infusion should be slowed or stopped and the veterinarian contacted at the first appearance of these signs.

Labeled adhesive tape should be placed vertically on fluid bottles or bags to allow monitoring of the volume delivered (Figure 15-9). Bottles or bags also should be labeled with all pertinent information, including the presence of any additives. It may be helpful to place a horizontal piece of tape across the fluid container to indicate when fluid delivery is to be stopped.

A volume control system or Buretrol device may be used for administering small volumes of fluid (Figure 15-10). A clamp allows the volume control chamber to be filled with a predetermined amount of fluid from the bag or bottle. The line then is clamped off to prevent entry of additional fluid from the bag. The chamber can be refilled if desired.

**Preparing Fluid Administration Equipment**

When preparing to administer intravenous fluids, you should follow a standard protocol. After gathering your supplies and preparing the injection site,
Figure 15-7
Intravenous administration set.

Figure 15-8
Clamps for controlling fluid flow.

Figure 15-9
Labeling (vertical) of fluid bag.
and the line are patent, the drip rate may be adjusted as required.

If at any time the flow rate slows or stops, check the following: (1) the catheter for correct placement and patency, (2) the position of the patient to determine whether limb position or flexion has occluded the flow, (3) the flow clamp to see whether it is in the open position, (4) the tubing to determine whether it is kinked or crimped, and (5) the fluid level in the bottle.

Two fluid solutions may be administered simultaneously with the use of a piggyback setup of the containers (Figure 15-11). The secondary bag is hung higher than the primary bag, and the secondary administration set line is connected to the Y port of the primary administration set.

It is useful for a technician to understand the use of a three-way valve. The three-way valve permits three-way connections to be made. Flow of fluid through the valve depends on the position at which the control handle is placed. The handle points toward the line that is closed. Figure 15-12 illustrates the operation of a three-way valve.
TYPES OF SOLUTIONS USED IN FLUID THERAPY

Crystalloid Solutions

Crystalloids are solutions that contain electrolyte and non-electrolyte substances capable of passing through cell membranes and therefore entering all body fluid compartments. Administration of crystalloid solutions results in rapid equilibration of fluid between the intravascular and interstitial spaces. Crystalloid solutions are used routinely in veterinary medicine because of their versatility and relatively low cost. Crystalloid solutions can be classified further as replacement or maintenance solutions. Replacement solutions resemble ECF in content, whereas maintenance solutions contain less sodium and more potassium than are found in replacement fluids.

Clinical Uses
Fluids are administered for correction of dehydration, treatment of shock, maintenance of normal hydration, and replacement of electrolytes and nutrients, and as a vehicle for administration of intravenous drugs.

Dosage Forms
Dosage forms are numerous. Fluids are available in glass bottles, plastic bottles, and plastic bags that hold 250, 500, and 1000 ml. Containers that hold 3000 and 6000 ml are available for some solutions (see manufacturer product guides). The following section briefly describes the commonly used crystalloid solutions. See Table 15-3 for a listing of the composition and other characteristics of each.

Adverse Side Effects
Adverse side effects of fluid administration are primarily associated with overhydration. Signs of overhydration may include restlessness, shivering, serous nasal discharge, coughing, and pulmonary edema.

Physiologic Saline
Physiologic saline is a 0.9% solution of NaCl and is also called normal saline. It also may be called isotonic saline because it has an osmolarity of 308 mOsm/L. Saline is used to increase plasma volume or to correct a sodium deficiency (hyponatremia). It also may be used to bathe tissues during surgery to prevent them from drying out. Because of its high sodium content, saline should not be used in animals with known heart disease.

Lactated Ringer’s Solution
Lactated Ringer’s solution is one of the most versatile and commonly used fluids in veterinary medicine. It is a balanced electrolyte replacement solution that can be administered by any route that is available. It contains 28 mEq/L of lactate, which is converted by the liver to bicarbonate to act as a buffer against acidosis. Theoretically, lactated Ringer’s solution should not be administered with blood because the calcium contents could cause clotting to occur. Lactated Ringer’s solution is not currently considered appropriate for use in critical patients (Crowe, 2007).

Dextrose 5% in Water
Dextrose 5% in water (D5W) is a nonbalanced solution that contains only dextrose (50 g/L) and water. Administering dextrose 5% is equivalent to administering pure water because the dextrose is metabolized to carbon dioxide and water. Dextrose 5% provides approximately 170 kcal/L (a quantity that cannot be relied on to meet the daily caloric
Hidden page
plasma volume longer and has fewer side effects than the dextran. It is prepared as a 6% solution in 0.9% saline. The primary disadvantage of hetastarch is its expense.

3. **Oxypolygelatin (Vetaplasma)**. Gelatins are modified animal collagens. These molecules are denser than the dextran and therefore produce greater osmotic action. Coagulopathy is a potential side effect.

**Adverse Side Effects**
Adverse side effects of colloid administration usually are related to clotting deficiencies or allergic reactions.

---

**Technician’s Notes**
1. Colloids are not intended for maintenance or long-term use.
2. References should be checked in determining the appropriate flow rate for colloid solutions.

---

**Hypertonic Solutions**

This discussion is confined to the use of hypertonic saline solutions. These solutions have been advocated by some clinicians for the treatment of hemorrhagic and endotoxic shock, and for patients undergoing major surgical procedures (e.g., gastric dilation, volvulus). Similar to the colloids, hypertonic saline solutions may be useful when brain or pulmonary edema is present or is a potential complication.

**Clinical Uses**

Hypertonic saline solutions are used for the treatment of shock associated with trauma, endotoxemia, burns, pancreatitis, and major surgical procedures.

**Dosage Forms**

Hypertonic saline solutions are available from commercial sources in 3%, 4%, 5%, 7%, and 23.4% preparations.

**Adverse Side Effects**

These may include phlebitis, tissue irritation, re-hemorrhage in traumatic shock, electrolyte imbalances, and—when the administration rate is too fast—hypotension, bronchoconstriction, and bradycardia.

---

**Fluid Additives**

In some instances, special substances may be added to intravenous fluid solutions to enhance the solutions' therapeutic effects. These substances may be added to correct acid-base abnormalities and electrolyte imbalances, to supplement calories, and to provide supplemental vitamins to replace those washed out by fluid therapy.

**Sodium Bicarbonate**

Sodium bicarbonate (baking soda) is an alkalizing agent that may be added to correct metabolic acidosis and certain other conditions. Because lactate or acetate in fluid preparations often cannot correct severe metabolic acidosis, supplementation becomes necessary. Normal serum bicarbonate is 24 mEq/L. Required amounts for supplementation are calculated by measuring a patient's bicarbonate (or carbon dioxide) level and subtracting that value from 24 (normal). The difference is called the bicarbonate deficit. The bicarbonate deficit is multiplied by 0.6 and then by the animal's weight in kilograms to determine the number of milliequivalents of sodium bicarbonate to administer:

\[
\text{Bicarbonate supplementation (mEq) = Bicarbonate deficit} \times 0.6 \times \text{weight (kg)}
\]
When access to laboratory measurement of bicarbonate or carbon dioxide is not available, empirical estimations of supplementation levels are made on the basis of clinical judgment. Bicarbonate concentration in commercial products is measured in milliequivalents per milliliter.

**Clinical Uses**
These include the treatment of metabolic acidosis and as an adjunctive therapy for the treatment of hypercalcemia or hyperkalemia.

**Dosage Forms**
Veterinary-approved forms include the following:

1. An 8% (1 mEq/ml) solution for injection, which is available in 50-, 100-, and 500-ml vials
2. A 5% (0.6 mEq/ml) solution for injection

**Adverse Side Effects**
These may include metabolic alkalosis, hypokalemia, hypocalcemia, and hypernatremia.

**Technician’s Notes**
1. Sodium bicarbonate is incompatible with several solutions and should be mixed only after consulting product inserts or appropriate references.
2. Some references indicate that sodium bicarbonate should not be added to solutions that contain calcium because of the potential for precipitates to form.
3. Replacement of the total number of milliequivalents should be made over several hours.

**Potassium Chloride**
Potassium chloride is a solution that is used to supplement potassium deficits (hypokalemia). Anorexia, diuresis, and diarrhea are some of the common causes of hypokalemia. Normal serum potassium levels are between 3.5 and 5.5 mEq/L. Table 15-5 provides a guide for potassium supplementation that is based on the measured serum level of potassium.

**Clinical Uses**
Potassium chloride is used for the treatment or prevention of potassium deficits.

**Dosage Forms**
Dosage forms for intravenous use include the following:

1. Potassium chloride for injection (2 mEq/ml) in 10- and 20-ml vials (veterinary approved)
2. Potassium chloride for injection (2 mEq/ml) in 5-, 10-, 20-, 30-, 100-, 200-, and 500-ml vials (human approved)

**Adverse Side Effects**
These may include hyperkalemia, which is manifested by muscle weakness, and cardiac conduction disturbances, which can be life threatening.

**Calcium Supplements**
Calcium gluconate and calcium chloride may be diluted (1:1 with saline) and given as an infusion to correct hypocalcemia. This is not a common procedure in practice, however. It is more common to inject the supplement, without diluting, for the treatment of emergency conditions such as eclampsia or milk fever.

**Clinical Uses**
Calcium supplements are used for the treatment of hypocalcemia that may result from various conditions, which may include parathyroid gland disorders, milk fever, eclampsia, and excessive sweating in horses. Calcium in combination with phosphorus, magnesium, potassium, and dextrose is used to treat cattle with conditions such as grass tetany, milk fever, and downer cow syndrome.

**Dosage Forms**
1. Calcium gluconate injection (generic and proprietary) 10%, in ampules, syringes, vials, and bottles (veterinary label)
Hidden page
**Technician's Notes**

Some of the oral electrolyte products for farm animals also contain antibiotics.

---

**PARENTERAL NUTRITION**

The term parenteral indicates the administration of nutrients by a route other than the gastrointestinal tract. Parenteral nutrition (PN) is described in human medicine as total or partial in reference to whether all nutrient requirements are supplied. Diseased and debilitated patients require a daily intake of adequate calories and protein to maintain good immune function, tissue synthesis, and normal metabolic activities. Those patients that are unable or have no desire to eat normally may need PN.

The term total parenteral nutrition (TPN) does not apply to veterinary patients because there is no need to meet the needs for all essential fatty and amino acids, fat- and water-soluble vitamins, and macro and trace minerals, as there is in people (Remillard, Armstrong, and Davenport, 2000). In veterinary medicine, an attempt is made to meet the animal patient's resting energy requirement and most of the requirements for amino and fatty acids, and to provide some of the required vitamins and minerals.

PN solutions must be compounded for the individual patient. A mixture of all required nutrients, called a total nutrient admixture (TNA), can be prepared for the veterinary patient in one fluid bag for convenience. The preparation of these solutions is beyond the scope of most veterinary clinics, but they may be available through human hospitals, veterinary schools, or specialty practices. For a list of products used in the formulation of the TNA, consult an article entitled “Parenteral Nutrition Products” by Miller and Bartges in Kirk’s Current Veterinary Therapy, XIII.

---

**PARENTERAL VITAMIN/MINERAL PRODUCTS**

Parenteral vitamin/mineral products are used to prevent or treat various conditions in veterinary medicine. They are used as therapeutic...
agents in large-animal medicine more often than in small-animal medicine. White muscle
disease, "tying up," polyneuritis, pinkeye, reproductive problems, bracken fern poisoning, and
polioencephalomalacia are only a few of the conditions prevented or treated with vitamin
products in large-animal practice. In small-animal practice, routine vitamin and mineral
supplementation is not considered necessary if the animal receives a balanced diet. Many small-
animal clinicians regard overuse of vitamin/mineral products as a bigger problem than
vitamin/mineral deficiencies. Warfarin poisoning (vitamin K) and certain dermatologic conditions
(zinc) are exceptions.

Oral multiple-vitamin/mineral products are numerous and are not listed here.

Technician's Notes
1. Check the label before giving B complex intravenously.
2. Observe the animal for allergic reactions.
3. B-complex injections may cause pain at the injection site.

Thiamine Hydrochloride (Vitamin B₁)
Thiamine is a water-soluble B-complex vitamin that acts as a coenzyme for biochemical reactions
involved in carbohydrate metabolism. Deficiency of thiamine may occur as a consequence of decreased
intake or synthesis, or from increased destruction, which may result from bracken fern poisoning,
thiamine-destroying factors in the rumen, or thiamaeinase in raw fish. Polioencephalomalacia of
ruminants also has been associated with thiamine deficiency.

Clinical Uses
Thiamine is administered for the treatment of thia-
mine deficiency in all domestic species and as an aid in the treatment of lead poisoning in cattle.

Dosage Forms
1. Vita-Jec Thiamine HCl
2. Thiamine hydrochloride (generic)
3. Vitamin B₁ Powder

Adverse Side Effects
These may include hypersensitivity reactions and
muscle soreness at intramuscular injection sites.

Vitamin B₁₂ (Cyanocobalamin)
Vitamin B₁₂ is a B-complex vitamin that contains
cobalt and is thought to act as a coenzyme in pro-
tein synthesis. Pernicious anemia is a condition
that occurs in humans as the result of a failure to
absorb B₁₂ adequately. A deficiency in any case re-
sults in anemia because red blood cells fail to ma-
ture properly in the absence of B₁₂. B₁₂ deficiencies
are rare in veterinary medicine.

Clinical Uses
Vitamin B₁₂ is administered for the management of
B₁₂ deficiencies.
Hidden page
REFERENCES
REVIEW QUESTIONS

1. Define hyperkalemia.

2. Intravascular fluid makes up approximately ____________________ of body weight.
   a. 2%
   b. 5%
   c. 15%
   d. 40%

3. Explain the concept of a balanced solution for fluid therapy. ___________________

4. What are three units of measurement used for quantifying electrolytes in fluids?

5. Therapeutic fluids with an osmolarity of approximately ____________________ mOsm/L are isotonic.
   a. 100
   b. 200
   c. 300
   d. 500

6. Give examples of sensible and insensible fluid losses. ___________________

7. Underestimation of the degree of dehydration is sometimes a problem in _________________ animals.

8. One pound of fluid is equivalent to ____________________ milliliters, and 1 kg is equivalent to ____________________ milliliters.

9. The three volumes that are calculated to arrive at the total fluid volume are

10. Calculate the fluid needed for a 44-lb dog that is 6% dehydrated and is losing 100 ml of fluid daily through vomiting.

11. What drip rate should be used to deliver (over a 24-hour period) the fluid for the dog in question 10 (using a standard administration set)? ____________________

12. Describe how you would set up the first bag of fluids for the dog in question 10.

13. Tell how you would prepare 500 ml of 5% dextrose from a 50% stock solution.

14. What is the purpose of the lactate in lactated Ringer’s solution?

15. Describe the use of an esophageal feeder.

16. What type of fluid (tonicity) should not be given subcutaneously?

17. Give an example of a balanced solution and an example of an unbalanced solution.

18. ____________________ is a determination of the osmotic pressure of a solution based on the relative number of solute particles in 1 kg of the solution.

19. The osmolarity of dog and cat serum is approximately ____________________ mOsm/L.

20. Commercial fluids with an osmolarity of 300 mOsm/L are ____________________.

21. How often should intravenous catheters be flushed? ____________________

22. What is the longest time an IV catheter should remain in place before it is replaced?

23. What precaution should be observed when fluids are administered subcutaneously?

24. What fluid can be used to bathe tissues during surgery to prevent them from drying out?

25. Any product that contains the electrolyte ____________________ should be given by slow IV administration to prevent cardiac complications.
Hidden page
Hidden page
Hidden page
Hidden page
**Clinical Uses**
This product is labeled for the treatment of anemia in dogs regardless of the cause. It has been used in cats but is not labeled for such use.

**Dosage Form**
Oxyglobin (hemoglobin glutamer-200)

**Adverse Side Effects**
Potential side effects include pulmonary edema, discolored urine, discolored membranes, ventricular arrhythmias, fever, and coagulopathy.

**Technician's Notes**
1. The recommended administration rate should not be exceeded.
2. Do not administer with other fluids or drugs through the same intravenous set.
3. Do not combine with other fluids in the same bag.

**Anticoagulants**

Blood coagulation is an obviously essential process that is designed to inhibit the loss of vital blood constituents from the circulatory system. Two separate systems or pathways may initiate the clotting mechanism—the intrinsic (intravascular) and extrinsic (extravascular) systems.

The intrinsic pathway is activated by injury to the **endothelial layer** of a blood vessel, which disrupts blood flow and causes a chain of chemical reactions leading to a **thrombus**, or clot. This process helps to repair damage to blood vessel walls that occurs from routine wear and from pathologic processes.

The extrinsic pathway is activated by injury to tissue and vessels, which releases tissue thromboplastin. Thromboplastin stimulates the clotting mechanism. Vasoconstriction occurs in damaged blood vessels, causing a slowing of blood flow and facilitating clot formation. Platelet aggregation and adherence are also important steps in the clotting process.

The intrinsic and extrinsic pathways converge into a common pathway in the final steps of clot formation (Figure 16-3). At least 13 clotting factors participate in this series of reactions (called a cascade) in which the product of the preceding reaction promotes the next reaction (Table 16-1). The final step in the process is the conversion of fibrinogen to fibrin by thrombin. If any of the clotting factors in the cascade are deficient or missing, clotting does not occur.

A balance must be maintained in the body between clot formation and clot breakdown. Destruction of clots—fibrinolysis—occurs through the action of an enzyme called **plasmin**. Plasmin digests fibrin threads and other clotting products to cause clot lysis and the release of fibrin degradation products into the circulation.

Anticoagulants inhibit clot formation by tying up or inactivating one of the clotting factors to interrupt the cascade reaction. They are used clinically to prevent coagulation of blood (or other body fluid) samples that are collected for testing, to preserve blood for transfusions, to inhibit clotting in intravenous catheters, and to prevent or treat thromboembolic disorders (e.g., thromboembolic cardiomyopathy in cats).

**Heparin**

Heparin is a natural anticoagulant that is found in many tissues of the body and is thought to be stored in mast cells. It is obtained from pig intestinal mucosa, and its strength is expressed in terms of heparin units. Heparin acts as an anticoagulant by preventing the conversion of prothrombin (factor II) to thrombin. Without thrombin, fibrinogen is not converted to fibrin and a clot does not form. Heparin does not break down clots but can prevent clots from increasing in size. It is administered therapeutically by intravenous or subcutaneous injection.

Heparin has various uses in veterinary medicine. It is used in vitro as an anticoagulant to preserve blood samples for testing by heparinizing (drawing heparin into the syringe and then forcing all visible quantities out) a syringe before the blood sample is drawn. It also is diluted in saline or sterile water for injection to form a flush solution for
preventing clots in intravenous catheters. Heparin is sometimes used to preserve donated blood for transfusions when small quantities are needed (e.g., for cats, small dogs). It is used in vivo to aid in the treatment of DIC and thromboembolism and has been advocated for the treatment of laminitis in horses.

**Clinical Uses**
Clinical uses are listed in the previous paragraph.

**Dosage Forms**
Forms approved for use in humans are used in veterinary medicine:

1. Heparin sodium injection, 1000 U/ml
2. HepLock flush solution (10 or 100 U/ml)

**Adverse Side Effects**
These usually manifest as bleeding or thrombocytopenia.
Table 16-1 The Clotting Factors

<table>
<thead>
<tr>
<th>Coagulation Factor</th>
<th>Synonym</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Fibrinogen</td>
</tr>
<tr>
<td>II</td>
<td>Prothrombin</td>
</tr>
<tr>
<td>III</td>
<td>Tissue factor (thromboplastin)</td>
</tr>
<tr>
<td>IV</td>
<td>Calcium ions</td>
</tr>
<tr>
<td>V</td>
<td>Proaccelerin, labile factor, or accelerator globulin</td>
</tr>
<tr>
<td>VI</td>
<td>Activated factor V</td>
</tr>
<tr>
<td>VII</td>
<td>Serum prothrombin conversion-accelerator (SPCA), stable factor, or proconvertin</td>
</tr>
<tr>
<td>VIII</td>
<td>Antihemophilic factor (AHF), antihemophilic factor A, or antihemophilic globulin factor B</td>
</tr>
<tr>
<td>IX</td>
<td>Christmas factor, plasma thromboplastin component (PTC), or antihemophilic factor B</td>
</tr>
<tr>
<td>X</td>
<td>Stuart-Prower factor, thrombokinase</td>
</tr>
<tr>
<td>XI</td>
<td>Plasma thromboplastin antecedent (PTA) or antihemophilic factor C</td>
</tr>
<tr>
<td>XII</td>
<td>Hageman factor, glass factor, or contact factor</td>
</tr>
<tr>
<td>XIII</td>
<td>Fibrin-stabilizing factor (FSF) or fibrinase</td>
</tr>
</tbody>
</table>

Technician's Notes
1. Heparin should not be used as an anticoagulant when blood is collected for performing a differential count because white blood cell morphology may be adversely affected.
2. A heparin flush solution may be prepared by diluting heparin in saline at a concentration of 5 U/ml (Crow and Walshaw, 1987).
3. Approximately 750 U of heparin should be drawn into a 60-ml syringe to act as an anticoagulant when blood is collected for transfusion (Norsworthy, 1992).
4. Heparin blood collection tubes have a green top.
5. Protamine sulfate is the antidote for heparin overdose.

Ethylenediaminetetraacetic Acid (EDTA)
EDTA is an anticoagulant that prevents clotting by chelation of calcium (factor IV). With calcium ions tied up by EDTA, clotting cannot occur. It is used in vitro to preserve blood samples and is the anticoagulant of choice when a differential count is needed (it preserves white cell morphology well). EDTA is prepared in lavender-topped collection tubes.

The calcium salt of EDTA (calcium disodium versenate) is also used in vivo as a chelating agent to treat lead poisoning. This function does not involve the clotting mechanism (see Chapter 18).

Coumarin Derivatives
Coumarin derivatives such as dicumarol and warfarin are oral anticoagulants that bind vitamin K and therefore inhibit the synthesis of prothrombin (factor II) and factors VII, IX, and X. These compounds are indicated for long-term treatment of thromboembolic conditions. They are used clinically to a greater extent in human medicine than in veterinary medicine.

Dicumarol may be found in moldy sweet clover and has been associated with fatal hemorrhagic disease in cattle. Warfarin and related compounds are used in many rat poisoning products.

Clinical Uses
Coumarin derivatives are used for the long-term management of thromboembolic conditions.

Dosage Form
Coumadin tablets or injection

Adverse Side Effects
Adverse side effects are related to hemorrhage.

Technician's Notes
Vitamin K₁ is the antidote for warfarin or dicumarol toxicity.

Acid Citrate Dextrose (ACD) Solution and Citrate Phosphate Dextrose Adenine (CPDA-1)
ACD solution contains dextrose, sodium citrate, and citric acid and prevents clotting by chelating calcium. It is prepared in bottles or plastic bags for blood collection under both veterinary and human labels. Bottles are available for collecting 250 and 500 ml of blood. ACD solution preserves blood for 3 to 4 weeks.
CPDA-1 solution is available in plastic bags for collection of 450 ml of blood. CPDA-1 also prevents clotting by chelating calcium and preserves blood for as long as 6 weeks.

Eight milliliters of ACD or CPDA-1 can be drawn into a syringe to collect 50 ml of blood when small quantities are needed (Norsworthy, 1992).

**Antiplatelet Drugs**

Antiplatelet drugs such as aspirin appear to impair clotting through inhibition of platelet stickiness and clumping. This activity is thought to be mediated through inhibition of the pro-aggregatory prostaglandin called thromboxane (Pugh, 1991).

Aspirin has been used to prevent thromboembolism associated with heartworm treatment in dogs and to treat cardiomyopathy in cats.

**Hemostatics/Anticoagulant Antagonists**

Substances that promote blood clotting—hemostatics—may be divided into two categories: (1) those applied topically and (2) those given parenterally.

**Topical Agents**

Topical agents act by providing a framework in which a clot may form or by coagulating blood protein to initiate clot formation. Framework substances used in topical hemostatics include gelatins and collagens, whereas styptics, hemostatic powders, and solutions are substances that initiate clotting through coagulation. The framework substances are absorbed after clot formation. Topical hemostatics are used to control capillary bleeding or bleeding from other small vessels.

**Clinical Uses**

These include the control of capillary bleeding at surgical sites or in superficial wounds.

**Dosage Forms**

- 1. Gelfoam absorbable gelatin sponge
- 2. Hemopad Absorbable Collagen Hemostat

3. Surgical Absorbable Hemostat
4. Hemostat Powder (ferrous sulfate powder)
5. Clotisol (ferric sulfate)
6. Silver nitrate sticks
7. Thrombogen topical thrombin solution
8. Celox. Celox granules represent a new generation of hemostatic agent that is being used in military and other trauma situations to control both venous and arterial bleeding in superficial and deep wounds. Celox granules are reported to control bleeding in hyperthermic conditions and in heparinized blood.

**Adverse Side Effects**

These are usually minimal but may include delayed wound healing.

**Parenteral Agents**

Parenterally administered hemostatic agents act as anticoagulant antagonists because they do not directly activate clotting. These substances promote the synthesis of clotting factors that have been depleted through poisoning or disease or tie up (inactivate) anticoagulants that have been overdosed. These drugs are not used to control surgical or traumatic bleeding.

**Protamine Sulfate**

Protamine sulfate is a protein that is produced from the sperm or testes of salmon or related species (Plumb, 2005). Protamine has a strongly basic pH, and heparin has a strongly acidic pH. Protamine combines with heparin to form inactive complexes (salt).

**Clinical Uses**

Protamine sulfate is used for the treatment of heparin overdose. Slow intravenous administration is recommended.

**Dosage Form**

Protamine sulfate injection, USP

**Adverse Side Effects**

Hypotension and bradycardia can occur if given too rapidly.
**Vitamin K₁ (Phytonadione)**

Phytonadione is a synthetic substance that is identical to naturally occurring vitamin K₁. Vitamin K is necessary for the production (in the liver) of active prothrombin (factor II), proconvertin factor (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). It is used clinically for treating cases in which vitamin K has been tied up or destroyed and in bleeding disorders associated with poor formation of vitamin K-dependent clotting factors. Immediate coagulant effect should not be expected after administration of vitamin K because several hours may pass before synthesis of new clotting factors occurs.

**Clinical Uses**

In veterinary medicine, vitamin K₁ is used for the treatment of rodenticide toxicity, for bleeding disorders related to faulty synthesis of vitamin K-dependent clotting factors, and for unknown anticoagulant toxicity.

**Dosage Forms**

Human forms of vitamin K₁ are used:

1. AquaMephyton, phytonadione injection
2. Konakion, phytonadione injection
3. Mephyton, phytonadione tablets

**Adverse Side Effects**

These include anaphylactoid reactions (intravenous use) and bleeding at the injection site.

---

**Technician’s Notes**

Because of the possibility of anaphylactoid reactions, many consider intravenous administration of phytonadione to be contraindicated.

---

**Fibrinolytic (Thrombolytic) Drugs**

Thrombolytic drugs are used to break down or dissolve thrombi. Occlusion of an artery by a thromboembolus can cause necrosis of tissue distal to the blockage if the obstruction is not removed quickly. In humans, damage to heart muscle that occurs when a coronary artery is occluded in a heart attack is a classic example of this process. Pulmonary thromboemboli sometimes occur in dogs after heartworm treatment and may accompany cardiomyopathy in cats.

Thrombolytic agents may help to remove or reduce the size of the occluding thromboembolus and minimize tissue damage. This action is brought about by stimulating conversion of plasminogen to the enzyme plasmin, which lysed the clots. The sooner the therapy is initiated after thromboembolism has occurred, the better the chances of success. Thrombolytic activity of one of the products (alteplase) is activated by the presence of fibrin so that recent clots are targeted.

The expense of these drugs often precludes their use in veterinary medicine.

**Clinical Uses**

1. Treatment of pulmonary embolism
2. Treatment of arterial thrombosis and emboli
3. Treatment of coronary thrombosis
4. Intravenous catheter clearance

**Dosage Forms**

1. Streptase, streptokinase
2. Abbokinase, urokinase
3. Activase, alteplase

**Adverse Side Effects**

These are related to bleeding episodes, especially if anticoagulants have also been used.

---

**Antineoplastic Drugs**

Antineoplastic drugs are administered to animals in an attempt to cure or lessen the effect of neoplasms. Neoplasia is the abnormal growth of tissue into a mass that is not responsive to normal cellular control mechanisms. The term tumor by definition indicates any tissue mass or swelling that may or may not be neoplastic. Tumor is often used broadly in common discussion to indicate a neoplasm. A neoplasm may be benign or malignant. In general, benign tumors (neoplasms) do not cause high mortality because
they grow locally and do not invade adjacent tissue. These tumors may cause morbidity, however, by compressing or occluding organs. The term cancer is used to indicate a malignant neoplasm that is capable of causing destruction of the tissue of origin and is also capable of metastasis to other tissue. Malignant tumors are very damaging to tissue and often lead to the death of the patient if treatment is not provided. A third type of neoplasm is an in situ tumor, which is a small tumor in epithelial tissue that appears to contain cancer cells but does not cross the basement membrane and invade adjacent tissue. Treatment of neoplasia involves several methods, including the use of drugs (chemotherapy), surgery, radiation, and immune modulation. Regardless of the method used, the goals of treatment are to keep the neoplasia under control, increase survival time, and improve the quality of life of the patient.

If one is to understand the use of chemotherapy drugs, a basic understanding of cancer formation is in order. Cancer has been called a "complex mutagenic disease" (Withrow and Vail, 2007) in which genetic mutations give a cell or cells the ability to replicate in an unlimited way (Initiation), form a mass of cells (Promotion), and invade adjacent tissue (Progression). Oncologists speculate that five to six genetic mutations are the minimum number that must occur to give a cell the six fundamental characteristics of cancer. These six characteristics are (1) self-sufficiency in the production of cell growth signals, (2) insensitivity to antigrowth signals, (3) the ability to evade programmed cell death (apoptosis), (4) unlimited potential to replicate, (5) sustained ability to promote angiogenesis (blood vessel formation for the cancer mass), and (6) the capacity to invade tissue and metastasize.

Several mechanisms are thought to be involved in the production of the six hallmarks of cancer. Proto-oncogenes are genetic elements in all normal cells that are capable of causing cancer if they are enhanced through abnormal regulation. The ability of the cancer cell to replicate in an unlimited way may be facilitated by activation or upregulation of an enzyme called telomerase. Defects in suppressor oncogenes or anti-oncogenes like the p53 gene may take away the ability to control the normal cell cycle. Factors that may promote the mechanisms leading to cancer include viruses, as well as chemical, physical, and hormonal influences.

**PRINCIPLES OF CHEMOTHERAPY**

Proliferating cells, whether they are found in normal tissue or in neoplasms, contain resting and dividing cells that are involved in phases of the cell cycle (Figure 16-4). These phases of the cell cycle include the S-phase (DNA synthesis), the M-phase

---

**Figure 16-4**
The cell cycle.
Hidden page
soon after treatment is started because of effects on the chemoreceptor trigger zone (CRTZ), or 3 to 5 days later because of injury to gastrointestinal epithelium. Bone marrow depression (myelosuppression) also may occur, resulting in a moderate to severe reduction in circulating neutrophils and/or platelets. Dogs with continuously growing hair like poodles, terriers, and Old English Sheepdogs may lose their hair as a result of chemotherapy. Cats may lose their whiskers and guard hairs as well. Other side effects may include cystitis, cardiomyopathy, anaphylactic reactions, and tissue damage due to extravasation of the drug/s. Many chemotherapy drugs are vesicants that cause inflammation and potential sloughing of tissue if leakage outside the vein occurs when the agents are administered. Some protocols call for pretreatment of the patient with drugs like antihistamines, steroids, antiemetics, and or analgesics to reduce the severity of side effects.

Great care should be taken to prevent accidental exposure to chemotherapy drugs by technicians, veterinarians, and other employees because of the ability of these drugs to be teratogenic, mutagenic, and carcinogenic at therapeutic doses (Dickenson and Ogilvie, 1995). Box 16-1 provides a list of recommendations for the safe use of antineoplastic agents.

Antineoplastic drugs have been categorized into the following major classes: alkylating agents, anthracyclines, antimetabolites, antitubulin agents, corticosteroids, and miscellaneous agents. Table 16-3 provides a list of the commonly used antineoplastic agents, as well as their indications, toxicities, and dosages.

Cancer chemotherapy can be a long, emotional, costly, and complicated process. Patients may experience periods of relapse and remission, harmful drug reactions can occur, and treatments can fail. Technicians should be prepared to counsel owners about the potential risks and the high level of commitment they will need to see the process through to completion. They should be able to make the animal owner aware that successful treatment can mean a longer and/or a better quality of life for their pet and a strengthening of the human–companion animal bond.

**Alkylating Agents**

Alkylating agents are cell cycle–nonspecific drugs that are able to cross-link strands of DNA to change its structure and inhibit its replication. This brings protein synthesis and cell division to a halt; cell death often follows.

**Clinical Uses**

1. Treatment of various neoplastic disorders, including lymphoproliferative neoplasms, osteosarcoma, hemangiosarcoma, and squamous cell carcinoma
2. Treatment of certain immune-mediated diseases (immunosuppression)

**Dosage Forms**

1. Cytoxan, cyclophosphamide injection
2. Leukerin, chlorambucil tablets
3. Alkeran, melphalan tablets
4. Nitrosoureas, lomustine, and carmustine
5. Dacarbazine
6. Ifex, ifosfamide

**Adverse Side Effects**

Adverse side effects of the alkylating agents may include neutropenia, nephrotoxicity, thrombocytopenia, vomiting, and hemorrhagic cystitis.

**Technician’s Notes**

Cyclophosphamide is also used as an immunosuppressant.

**Anthracyclines**

Many of the anthracycline antineoplastic agents are derived from soil fungi of the Streptomyces genus. They are cell cycle nonspecific and exert their effects by binding with DNA and interfering with RNA and protein synthesis. Doxorubicin is the most commonly used drug in this class in veterinary medicine. It is widely used for various neoplastic conditions.
### BOX 16: Chemotherapy Safety Recommendations

<table>
<thead>
<tr>
<th>Safety Issue</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| To minimize the risk of topical contamination | 1. Wear approved chemotherapy administration gloves. Latex examination gloves are not impermeable to chemotherapeutic agents. If chemotherapy administration gloves are not available, double-glove with latex exam gloves.  
2. Wear a nonabsorbent chemotherapy administration gown or, at minimum, wear a buttoned-up lab coat.  
3. Do not push air bubbles out of the syringe.  
4. The use of commercially available chemotherapy dispensing systems (e.g., PhaSeal) can decrease the risk of exposure.  
5. Use safety goggles or other protective eyewear. |
| To avoid the oral route of contamination | 1. Never eat or drink in the chemotherapy administration room.  
2. Never smoke or apply makeup in the chemotherapy administration room.  
3. Never store chemotherapeutic drugs with food or other drugs.  
4. Caution clients (and veterinary staff) always to wear gloves when administering chemotherapeutic drugs by the oral route. |
| Chemotherapy waste disposal | 1. Separate chemotherapy waste from other sharps and biohazards, including needles, syringes, catheters, gloves, and masks.  
2. Contact a local human hospital for aid in disposal of all chemotherapy-associated waste.  
3. Chemotherapeutic drugs are excreted in feces and urine: wear chemotherapy gloves when cleaning up after patients for 48 hours after drug administration.  
2. No guidelines have been established for the disposal of pet waste; however, caution clients about cleaning up after their pets. If the patient urinates or defecates inside the home within 48 hours of receiving chemotherapy, owners should wear gloves to clean up waste and should double-bag all waste. |


### Clinical Uses
These agents are used for the treatment of lymphoproliferative neoplasms and various carcinomas and sarcomas.

### Dosage Forms
1. Adriamycin, doxorubicin hydrochloride for injection  
2. Bleomycin  
3. Dactinomycin  
4. Mitoxantrone  
5. Idarubicin

### Adverse Side Effects
These include bone marrow suppression, cardiotoxicity (cardiomyopathy), gastroenteritis, and anaphylaxis.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Main Indications</th>
<th>Toxicities</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alkylation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>Lymphoma, carcinoma, sarcoma</td>
<td>Marrow, gastrointestinal (GI) tract, sterile hemorrhagic cystitis</td>
<td>Given orally (PO) or intravenously (IV); many dosing regimens can be used, depending on concurrent anticancer drugs.</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td>Lymphoma, chronic lymphocytic leukemia, mast cell tumor, IgM myeloma Substitute for cyclophosphamide if hemorrhagic cystitis occurs.</td>
<td>Mild marrow toxicity</td>
<td>Given PO only; many dosing regimens can be used, depending on concurrent anticancer drugs.</td>
</tr>
<tr>
<td>CCNU (lomustine)</td>
<td>Relapsed lymphoma or mast cell tumor, brain tumor</td>
<td>Myelosuppression and idiosyncratic, potentially fatal hepatotoxicity</td>
<td>Dogs: 60-90 mg/m² PO every 3 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cats: 50-60 mg/m² PO every 3-6 weeks</td>
</tr>
<tr>
<td>Dacarbazine</td>
<td>Lymphoma</td>
<td>Myelosuppression, vomiting during administration, perivascular irritation upon extravasation</td>
<td>Dogs: 200 mg/m² IV daily for 5 days every 3 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ifosfamide</td>
<td>Lymphoma</td>
<td>Hemorrhagic cystitis, myelosuppression</td>
<td>Dogs: 1000 mg/m² IV every 3 weeks</td>
</tr>
<tr>
<td>Melphalan</td>
<td>Multiple myeloma, anal sac adenocarcinoma</td>
<td>Myelosuppression, potential cumulative thrombocytopenia</td>
<td>Dogs: 275-350 mg/m² IV with saline diuresis and mesna, every 3 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anthracyclines</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dactinomycin</td>
<td>Lymphoma</td>
<td>Myelosuppression, GI upset, perivascular damage with extravasation</td>
<td>Dogs: 0.75-0.8 mg/m² IV every 3 weeks</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>Lymphoma, carcinoma, sarcoma</td>
<td>Myelosuppression, GI upset, hypersensitivity during administration, perivascular damage with extravasation, cumulative (180 mg/m²) myocardial toxicity, nephrotoxicity (cats)</td>
<td>Dogs: ≥10 kg: 30 mg/m² IV every 2-3 weeks</td>
</tr>
<tr>
<td>Doxorubicin HCl liposome</td>
<td>Lymphoma, carcinoma, sarcoma</td>
<td>Mild myelosuppression and/or GI upset, hypersensitivity during administration, perivascular damage with extravasation, palmar plantar erythrodysesthesia (PPES) nephrotoxicity (cats)</td>
<td>Dogs and cats: 1 mg/kg IV every 3 weeks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Main Indications</th>
<th>Toxicities</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idarubicin</td>
<td>Unclear</td>
<td>Mild myelosuppression and/or GI upset, perivascular damage with extravasation</td>
<td>Idarubicin: 2 mg/cat/day for 3 days q 3 wk</td>
</tr>
<tr>
<td>Mitoxantrone</td>
<td>Lymphoma, transitional cell carcinoma</td>
<td>Myelosuppression, GI upset, perivascular damage with extravasation</td>
<td>Dogs: 5-5.5 mg/m² IV every 3 weeks</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td></td>
<td></td>
<td>Cats: 6 mg/m² IV every 3 weeks</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Lymphoma</td>
<td>Mild myelosuppression and/or GI upset</td>
<td>Given PO or IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dogs and cats: 0.8 mg/kg in combination with other chemotherapeutic drugs</td>
</tr>
<tr>
<td>Cytosine arabinoside</td>
<td>Lymphoma (myeloproliferative)</td>
<td>Mild myelosuppression and/or GI upset</td>
<td>Given subcutaneously (SQ), intramuscularly (IM), or IV; several different regimens can be used, depending on concurrent anticancer drugs.</td>
</tr>
<tr>
<td>Antitubulin Agents</td>
<td></td>
<td></td>
<td>Dogs: 132 mg/m² IV every 3 weeks; must premedicate to minimize hypersensitivity</td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>Under investigation</td>
<td>Hypersensitivity during administration</td>
<td>Dogs: 2 mg/m² IV every 1-2 weeks</td>
</tr>
<tr>
<td>Vinblastine</td>
<td>Mast cell tumor</td>
<td>Myelosuppression, perivascular vesicant</td>
<td>Dogs and cats: 0.5-0.7 mg/m² IV weekly or as dictated by concurrent anticancer drugs.</td>
</tr>
<tr>
<td>Vincristine</td>
<td>Lymphoma, mast cell tumor, transmissible venereal tumor, immune-mediated thrombocytopenia</td>
<td>Myelosuppression, perivascular vesicant, peripheral neuropathy, constipation in cats</td>
<td></td>
</tr>
<tr>
<td>Vinorelbine</td>
<td>Primary lung tumor</td>
<td>Myelosuppression, perivascular vesicant</td>
<td>Dogs: 15-18 mg/m² IV every 1-2 weeks</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td></td>
<td></td>
<td>Dogs and cats cytotoxic dose: 2 mg/kg/day, taper according to protocol</td>
</tr>
<tr>
<td>Prednisone</td>
<td>Lymphoma, mast cell tumor, myeloma, chronic lymphocytic leukemia Noncytotoxic indications: brain tumor, insulinoma, appetite stimulant</td>
<td>Polyuria, polyphagia, polydipsia, muscle wasting, behavioral changes</td>
<td>Dogs and cats noncytotoxic dose: 0.5 mg/kg/day</td>
</tr>
<tr>
<td>Miscellaneous Drugs</td>
<td></td>
<td></td>
<td>Dogs and cats: 400 IU/kg SQ or IM, maximum dose of 10,000 IU</td>
</tr>
<tr>
<td>Asparaginase</td>
<td>Lymphoma</td>
<td>Hypersensitivity reaction after administration</td>
<td>Dogs and cats: 300 mg/m³ IV every 3 weeks</td>
</tr>
<tr>
<td>Caroboplatin</td>
<td>Osteosarcoma, carcinoma, sarcoma</td>
<td>Myelosuppression; potentially severe (small dogs) GI effects</td>
<td>Cats: 240-260 mg/m³ IV every 3 weeks</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>Osteosarcoma, carcinoma, sarcoma</td>
<td>Nephrotoxic—must be given with saline-induced diuresis; highly emetogenic; fatal to cats</td>
<td>Cats: Do not use.</td>
</tr>
</tbody>
</table>
### Table 16-3 Commonly Used Chemotherapeutic Drugs—cont’d

<table>
<thead>
<tr>
<th>Drug</th>
<th>Main Indications</th>
<th>Toxicities</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxyurea</td>
<td>Polycythemia vera, myeloproliferative diseases</td>
<td>Myelosuppression</td>
<td>Dogs: 50 mg/kg/day, tapering to every other day with remission</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cats: 10 mg/kg/day, tapering to every other day with remission</td>
</tr>
<tr>
<td>Procarbazine</td>
<td>Lymphoma</td>
<td>GI upset, myelosuppression</td>
<td>Dogs: 50 mg/m² daily for 14 days on and 14 days off as part of mechlorethamine, Oncovin (vincristine), procarbazine, and prednisone (MOPP) protocol</td>
</tr>
</tbody>
</table>

### Technician’s Notes
1. Some clinicians use antihistamines to premedicate animals to be treated with doxorubicin to suppress allergic reactions.
2. Doxorubicin is a strong vesicant. Tissue sloughing can follow extravasation, and skin irritation can result from contact with the drug.
3. Doxorubicin is commonly used in combination with other antineoplastic agents.
4. Dexrazoxane is a drug that may be used to block doxorubicin-induced cardiac toxicity.

### Dosage Forms
1. Methotrexate, oral tablet or injection
2. Cytosar-U, cytosine arabinoside injection
3. 5-Fluorouracil cream or solution

### Adverse Side Effects
These may include anorexia, nausea, vomiting, diarrhea, bone marrow suppression, hepatotoxicity, and neurotoxicity.

### Antimetabolites
The antimetabolites are cell cycle-specific drugs that affect the S-phase (DNA synthesis) of the cycle. These drugs are analogs of purines and pyrimidines—naturally occurring bases in DNA—that may be incorporated into the DNA molecule to inhibit protein and enzyme synthesis. Cellular functions needed for normal activity are thus blocked.

### Clinical Uses
1. Treatment of lymphoproliferative neoplasms
2. Treatment of gastrointestinal and hepatic neoplasms
3. Treatment of central nervous system lymphoma

### Antitubulin Agents
The plant alkaloids are cell cycle specific for the M-phase, inhibiting mitosis and causing cell death. They are thought to bind microtubular proteins and inhibit formation of the mitotic spindle, thus suspending mitosis in metaphase.

The two drugs in this category—vincristine and vinblastine—are natural alkaloids derived from the periwinkle plant (Vinca rosea, Linn). Protective clothing should be worn when these drugs are administered, to prevent possible skin contact irritation.
Hydroxyurea and procarbazine are two other agents in the miscellaneous category. See Table 16-3 for information about these two agents.

**Biologic Response Modifiers**

Biologic response modifiers (BRMs) are agents that alter the relationship between the tumor and the host animal in a way that improves the host's ability to mount an antitumor response (Grant and Shelton, 1989). BRMs are used as an adjunct to conventional chemotherapy protocols, not as the sole agent of treatment.

Cancer develops in many animals because of an immunosuppressed state, and chemotherapy exacerbates the immunosuppression. BRMs may be used to stimulate or restore the compromised immune response of the host.

Examples of BRMs include bacterial agents, chemical agents, interferons, thymosins, cytokines/lymphokines, and monoclonal antibodies.

**Monoclonal Antibodies**

Monoclonal antibodies are identical immunoglobulin molecules formed by a single clone of plasma cells. They are produced by a hybridoma, a fusion of a specific antibody-producing B cell with myeloma cells (Figure 16-5). Hybridomas secrete large quantities of a very specific (for the tumor) antibody. Monoclonal antibodies may have direct cytotoxic effects on tumor cells, or they may be

---

**Figure 16-5**

Hidden page
Hidden page
Hidden page
Hidden page
Hidden page
CHAPTER 17

Immunologic Drugs

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Explain the principles associated with vaccination.
2. Describe the differences between vaccine types.
3. Discuss the advantages and disadvantages of the different types of vaccines.
4. List common diseases that have available vaccines.
5. Describe the different routes of administration of vaccines.
6. List drugs used in immunotherapy.
**PRINCIPLES OF VACCINATION**

Keeping animals healthy through the proper use of immunization programs is an important aspect of veterinary medicine. Veterinary technicians must have knowledge concerning vaccine types and the diseases animals are vaccinated against. Clients ask many questions regarding this area of their pet’s care. It should be remembered that immunization should never take the place of regularly scheduled, routine veterinary checkups (McCurnin and Bassert, 2006). As animals age into their geriatric years, regular laboratory profiles should be done to determine the health of major organ systems. Preventive medicine also includes a good physical examination along with obtaining a complete history on the animal. Therefore, immunization programs are only one aspect of the overall health care that should be afforded companion animals. Livestock should be properly immunized to achieve a healthy herd.

Vaccinations are an important part of the preventive health care program for companion animals and food animals alike. Vaccines are given to lessen the chance for a particular disease to occur. A patient’s response is determined by several factors such as (1) the health and age of the patient, (2) the type of vaccine given, (3) the route of administration, (4) concurrent incubation of infectious disease, (5) exposure to an infectious disease before complete immunity is reached, and (6) drug therapy. The ideal vaccine is safe and effective on challenge and has no undesirable side effects. Immunology is a very complex field of study. This chapter outlines only the basics of common vaccines and immunostimulants. Reference to an immunology textbook may be helpful if further information is desired.

In properly vaccinated females, antibodies are passed to their offspring in the form of maternal antibodies found in colostrum. It is important not to vaccinate very young animals when maternal antibodies are still present. The neonate’s immune system is not capable of producing an immune response when maternal antibodies are blocking this mechanism. (See the charts within this chapter for specific times that various species should be vaccinated.)
COMMON VACCINE TYPES THAT PRODUCE ACTIVE IMMUNITY

**Inactivated**

In the manufacture of inactivated vaccines, organisms are treated most commonly by chemicals that kill the organisms, but very little change occurs in the antigens, which stimulate protective immunity. Inactivated vaccines are also referred to as killed, or dead, vaccines.

**Advantages**
1. Inactivated vaccines are usually very safe.
2. They are stable in storage.
3. They are unlikely to cause disease through residual virulence.

**Disadvantages**
1. Inactivated vaccines require repeated doses to achieve adequate protection.
2. Adjuvants may cause severe local reactions.
3. If repeated doses are required, costs may be higher.
4. Inactivated vaccines contain preservatives such as penicillin, streptomycin, and fungistats.

**Examples**
Leukocell 2: Feline leukemia virus
Duramune Cv-K: Rabies virus
Vibo-5/Somnugen: Campylobacter fetus, leptospirosis, Haemophilus somnus, bacterin

See vaccine charts within this chapter for a more comprehensive listing of the various vaccine types associated with each disease.

**Modified Live**

A live vaccine is prepared from live microorganisms or viruses. These organisms may be fully virulent or avirulent. Few vaccines of this origin are in use, with the exception of several poultry vaccines.

**Advantages**
1. Effective vaccines for many viruses can be developed through attenuation of the causative virus.
2. Immunity is comparable in response and longevity to killed products.
Disadvantages
1. Modified live vaccines may cause abortion when given to pregnant animals.
2. Some vaccines can cause mild immunosuppression.
3. Residual virulence can cause a mild form of the disease.
4. These vaccines contain preservatives such as penicillin, gentamicin, thimerosal, or a fungistat.

Examples
Eclipse 3: Feline rhinotracheitis, calicivirus, and panleukopenia
BoviShield 4: Infectious bovine rhinotracheitis (IBR) virus, bovine virus diarrhea (BVD), para-influenza 3 (PI3) virus, bovine respiratory syncytial virus

See vaccine charts within this chapter for a more comprehensive listing of the various vaccine types associated with each disease.

Recombinant

In recent years, vaccines produced by recombinant DNA technology have become available for veterinary medicine. These vaccines are recognized as being safe, highly specific, potent, pure, and efficacious. These attributes may be the reason why recombinant vaccines are more desirable than any other vaccine type. Recombinant vaccines are divided into three categories:

Type I recombinant (subunit) vaccines—These vaccines are derived by inserting a foreign gene from a specific pathogen into a recombinant organism (e.g., yeast, bacterium, a virus). The recombinant organism multiplies, and the product of the gene is extracted, purified, and prepared for administration as a vaccine.

Type II recombinant (gene-deleted) vaccines—The manufacturing of these vaccines involves deletion of specific genes from a pathogenic organism. This manipulation produces a vaccine that has a low risk of producing disease but can still stimulate a protective immune response.

Type III recombinant (vectored) vaccines—These vaccines are derived from the insertion of specific pathogenic genetic material into a nonpathogenic or gene-deleted organism (e.g., poxvirus). This altered organism then is propagated in vitro and is used to manufacture the vaccine (Van Kampen, 1998).

Advantages
1. These vaccines produce fewer adverse effects.
2. They provide effective immunity.
3. Type I and Type III vaccines cannot revert to virulence because of the way they are manufactured.
4. Some of these vaccines can be administered orally.

Disadvantages
1. Currently, few recombinant vaccines are available.
2. New technology often brings with it a higher cost.

Examples
Type I
RM Recombitek Lyme: Borrelia burgdorferi

Type III
RM Recombitek C4: Canine distemper, adeno-virus type 2, para-influenza, and parvovirus
Raboral V-RG: Oral vaccine for rabies virus (used in baiting devices for wildlife)
Newcastle disease—fowl pox vaccine (recombinant): Newcastle disease and fowl pox
Trovac-AIV H5: Avian influenza subtype H5 and fowl pox

See vaccine charts within this chapter for a more comprehensive listing of the various vaccine types associated with each disease.

Toxoid

A toxoid is a vaccine that is used to produce immunity to a toxin rather than a bacterium or a virus. The toxin is treated with heat or chemicals to destroy its damaging properties without eliminating its ability to stimulate antibody production.
An anaculture combines toxoid and killed bacteria in a single dose prepared from highly toxigenic cultures and culture filtrates.

**Characteristics**
1. Toxoids and anacultures provide protection for up to 1 year.
2. Toxoids may contain adjuvants.
3. Many toxoids contain preservatives such as phenol, thimerosal, and formaldehyde solution.

**Examples**
- Tetanus toxoid: *Clostridium tetani*
- Tettogen: *C. tetani*
- Fermicon CD/T: *Clostridium perfringens* types C and D, and *C. tetani*

**COMMON VACCINE TYPES THAT PRODUCE PASSIVE IMMUNITY**

**Antitoxin**
An antitoxin is a specific antiserum aimed at a toxin that contains a concentration of antibodies extracted from the blood serum or plasma of a hyperimmunized, healthy animal (usually a horse).

**Characteristics**
1. An antitoxin neutralizes toxins produced by microorganisms.
2. It may contain preservatives such as thimerosal, phenol, or oxytetracycline.
3. Antitoxins produce immediate passive immunity.
4. Immunity is short lived (about 7 to 14 days).
5. Biologic products of equine origin may be associated with the development of equine serum hepatitis (Theiler's disease). This link has not been proved, but clients should be made aware of the possible risk before these products are administered.

**Examples**
- Clostratox BCD: *C. perfringens* types C and D
- Tetanus antitoxin: *C. tetani*

**OTHER TYPES OF VACCINES**

**Autogenous Vaccine**
An autogenous vaccine contains organisms isolated from an infected animal on a farm where a disease problem is occurring. This carefully prepared vaccine contains antigens needed for protection at that particular location.

**Mixed Vaccine**
A mixed vaccine contains a mixture of different antigens. It is also referred to as a **polyvalent** vaccine. Each component of a mixed vaccine is required to achieve an immune response comparable...
with that of a vaccine containing a single antigen (monovalent vaccine).

**ADMINISTRATION OF VACCINES**

The intramuscular and subcutaneous routes are by far the most common methods for vaccine administration. These routes are easily accessible and provide systemic immunity, which is important in many diseases. Some diseases also respond well to local immunity. Vaccines against feline rhinotracheitis and calicivirus, canine infectious tracheobronchitis, and infectious bovine rhinotracheitis may be administered intranasally or, in some cases, intraocular administration may be used to provide local immunity. After administration of these vaccines, the animal may experience a slight bout of watery eyes and occasional sneezing for a few days.

All of the previously mentioned routes of vaccine administration necessitate that each animal be handled individually. When a large number of animals require vaccination, these routes may not be feasible. Some vaccines may be mixed with drinking water or feed. Others can be aerosolized and inhaled by the animal. For example, on mink ranches, vaccine for canine distemper and mink enteritis may be administered in this manner, or poultry houses may vaccinate for Newcastle disease by aerosolization. The margin for incomplete vaccination is greater when aerosolization or mixing with feed or water is used. Some animals may not drink or eat enough to acquire adequate protection, or the aerosolized vaccine may not distribute equally throughout the room. Vaccine failure may be implicated if these animals contract the disease, whereas in reality, the animal did not receive enough vaccine to gain adequate immunity.

When conventional measures are used for vaccination, it is very important to carefully read the insert provided with the vaccine. Some vaccines may be administered intramuscularly or subcutaneously, but others may be administered by only one route. For example, some rabies vaccines require administration by an intramuscular route to be most effective. Subcutaneous injections should be given according to the manufacturer's instructions. Care should be used when one is vaccinating a cat to prevent vaccine-induced tumors.

If a vaccine requires reconstitution, this should be done with the diluent provided by the manufacturer. The vaccine should not be reconstituted until just before it is administered (see Chapter 2 for the proper reconstitution procedure). The full recommended dose should be given. Splitting a vaccine dose may cause an animal to fail to develop an adequate immune response and may lower its protection.

Mixing different vaccines to minimize the number of injections the animal receives is not recommended. This procedure can cause antigen blocking, resulting in one component's interfering with the action of another, so that the animal does not receive adequate antigen to attain an effective immune response. Mixing of different vaccines may cause an increased chance of an allergic response. When different types of vaccines are administered, each vaccine should be administered at a separate site. It is also advisable to note the locations of administration and vaccine lot numbers on the patient's medical record. If a reaction or a problem develops later, a reference will be available to aid in evaluation of the problem.

When food animals are vaccinated, several things must be considered. Almost all vaccine labels contain information advising not to vaccinate within 21 days of slaughter. Vaccines such as those for B. abortus are subject to federal limitations and regulations, and complete records are maintained on administration of these vaccines. Brucellosis vaccines are restricted to use by or under the direction of a licensed veterinarian. Carcass destruction is also a factor that involves food animal producers. Injection site lesions may cause damage to muscle tissue, requiring that area to be trimmed and discarded. If a vaccine may be administered intramuscularly or subcutaneously, the subcutaneous route would produce less tissue reaction and would eliminate muscle damage. This is important when one is dealing with animals used for meat consumption. Most vaccines on the market today can be given subcutaneously.
**BIOLOGIC CARE AND VACCINE FAILURE**

Biologics (especially modified live and live vaccines) are sensitive to inactivation by heat or sunlight. Clients purchasing vaccines should be provided with a cold pack if needed and should be warned against leaving such biologics in vehicles or in sunlight, where they may become warm and inactivated. Even the performance of killed products can be altered if proper handling and storage measures are not practiced. When these vaccines are shipped from the manufacturer, cold packs are put in the box to provide some refrigeration during shipment. In some areas, it may be advisable to anticipate how much vaccine may be needed during the hot summer months and to stock up on that amount during early spring to prevent shipments from overheating during summer transportation. Once a shipment is received, it should be quickly unpacked and placed under refrigeration. Vaccines should never be frozen because cells may rupture when the vaccine thaws, releasing toxins that can damage tissue or cause tissue death.

Inappropriate care of vaccines may lead to inactivation of the vaccine and may be perceived as a vaccine failure. Actual vaccine failure is relatively uncommon. If vaccines are purchased from a reputable manufacturer, one can be fairly sure that the vaccine provided is good. Failure usually occurs because of improper handling, storage, or administration.

Live vaccines are especially affected by concurrent antibiotic therapy. Live and modified live vaccines can be inactivated by chemicals used to clean or sterilize syringes and by the use of excessive alcohol or other disinfectants to swab the skin before injection. As was mentioned earlier, the route of administration may affect the ability of an animal to achieve an adequate immune response. Immunosuppressed, parasitized, stressed, or malnourished animals and those incubating disease are not able to mount an adequate immune response to prevent disease. Clients should always be advised that such problems can occur. In most cases, an adequate immune response is not achieved before 10 to 14 days. An 8-week-old puppy may not develop a strong immune response to protect against an infectious disease if challenged by maternal antibodies because it is not feasible to check immune titers to determine the presence of maternal antibodies. Therefore, it is recommended that puppies receive boosters every few weeks until they are about 4 to 5 months of age. Boosters allow vaccines to produce an optimum immune response. Clients often find it difficult to understand why they need to bring their pet in for boosters. If the reasons are explained and if clients are advised about why they should isolate their pet from animals with questionable vaccination histories, many cases of infectious disease would be prevented among young animals. Clients often perceive one vaccine to be enough or do not understand that their animal is not protected immediately after an injection has been received. Technicians should include this information when educating clients on animal and pet care.

**ADVERSE VACCINATION RESPONSES**

The most notable risks involving vaccination include residual virulence and toxicity, allergic reactions resulting from hypersensitivity, disease in immunosuppressed animals, possible effects on a fetus, and abortion. The veterinarian assesses these risks before a vaccine is administered. In most cases, the benefits of vaccination far outweigh the risks, but it may occasionally be necessary to omit or delay vaccination because of some of the factors just mentioned.

One of the most common reactions noted with vaccine administration is the sting felt by the animal after injection. This is most often caused by inactivating agents used in manufacturing the vaccine. Manufacturers are constantly researching ways to decrease these undesirable effects while still producing a quality product. This stinging reaction is short lived and does not usually cause a problem unless the animal reacts violently. Other common but not usually serious reactions include a slight fever, lethargy, and soreness at the injection site. These usually subside within 1 day. Hypersensitivity may be caused by several factors, including
BOX 17-

General Outline of a Preventive Health Program for Dogs

I. First office visit for health program—usually at 6 wk of age
   A. Conduct a general physical examination and record body weight
   B. Check for external parasites and dermatophytes, and initiate appropriate therapy
      1. Fleas, ticks, ear mites (Otodectes cynotis)
      2. Mange mites, especially *Demodex canis* and *Sarcoptes scabiei*
      3. Dermatophytes, particularly *Microsporum* spp. and *Trichophyton mentagrophytes*
   C. Conduct fecal examination including both direct smear and flotation
   D. Initiate administration of heartworm preventive management
   E. Administer an anthelminthic for hookworms and roundworms and, if tapeworms are present, administer praziquantel or eprinprantel
   F. Vaccinate with DA2-PL-PC* and, possibly, with kennel cough vaccine, canine Lyme borreliosis vaccine, and *Giardia* vaccine
   G. Advise on nutrition and routine grooming
   H. Provide owner with client education pamphlets on topics such as the following:
      1. Identification, treatment, and control of fleas, ticks, and ear mites
      2. Benefits of preventive management for canine heartworm disease
      3. Management of normal and abnormal puppy behaviors
      4. Skin, nail, and ear care
      5. "How to" on grooming and nutrition
   I. Fill in the puppy's health record for the owner

II. Second office visit for health program—usually at 9 wk of age
   A. Conduct a general physical examination and record body weight
   B. Check for external parasites and dermatophytes, and initiate appropriate therapy
      1. Fleas, ticks, ear mites (O. cynotis)
      2. Mange mites, especially *D. canis* and *S. scabiei*
      3. Dermatophytes, particularly *Microsporum* spp. and *T. mentagrophytes*
   C. Conduct fecal examination including both direct smear and flotation
   D. Adjust dosage of heartworm preventive according to body weight

III. Third office visit for health program—usually at 12 wk of age
   A. Conduct a general physical examination and record body weight
   B. Check for external parasites and dermatophytes, and initiate appropriate therapy
      1. Fleas, ticks, ear mites (O. cynotis)
      2. Mange mites, especially *D. canis* and *S. scabiei*
      3. Dermatophytes, particularly *Microsporum* spp. and *T. mentagrophytes*
   C. Conduct fecal examination including both direct smear and flotation
   D. Adjust dosage of heartworm preventive according to body weight
   E. Administer an anthelminthic for hookworms and roundworms and, if tapeworms are present, administer praziquantel or eprinprantel
   F. Vaccinate with DA2-PL-PC* and, possibly, with kennel cough vaccine, canine Lyme borreliosis vaccine, and *Giardia* vaccine
   G. Adjust nutrition according to health needs and, if needed, change grooming procedures
   H. Provide owner with client education pamphlets on topics such as the following:
      1. Identification, treatment, and control of fleas, ticks, and ear mites
      2. Dental, skin, nail, and ear care
Hidden page
BOX 17-2 General Outline of a Preventive Health Program for Horses

First Quarter: January-March
All Horses
Deworm at least every 8 wk. Exercise care in choice of anthelmintics for mares in the third trimester. Begin deworming foals at 2 mo of age.
Trim feet every 6 wk; more frequently in foals requiring limb correction.
Dentistry: check twice yearly and float teeth as needed. Remove wolf teeth in 2-yr-olds and retained caps in 2-, 3-, and 4-yr-olds.
Immunize for respiratory disease: influenza, strangles, and rhinopneumonitis.
In southeastern United States immunize for equine encephalitis.
Stallions
Perform complete breeding examination. Maintain stallions under lights if being used for early breeding.
Pregnant Mares
Immunize with tetanus toxoid, and open sutured mares 30 days prepartum. Develop a colostrum bank. Ninth-day breeding only for mares with normal foaling history and normal reproductive tract. Wash udders of foaling mares.
Open Mares
Maintain under lights if being used for early breeding. Perform daily teasing. Perform reproductive tract examination during estrus. Mares should not be too fat but in gaining condition during breeding season.
Newborn Foals
Dip navel in disinfectant. Carefully, give a cleansing enema at birth. Administer tetanus prophylaxis if indicated by history. Perform immunoglobulin test at 12-24 hr.

Second Quarter: April-June
All Horses
Deworm at least every 8 wk.
Trim feet every 6 wk. Do not forget the foals and yearlings.
Dentistry: check teeth and remove or float teeth as needed.
Immunize for equine encephalomyelitis. Administer appropriate vaccine boosters.
Stallions
Maintain an exercise program. Monitor the semen quality.

Broodmares
Palpate at 21, 42, and 60 days after successful breeding.
Foals
Creep-feed the foals and provide free-choice minerals. Immunize at 3 mo of age.
Group foals by gender and size when weaned.

Third Quarter: July-September
All Horses
Deworm at least every 8 wk. Clip and sweep the pastures.
Trim feet every 6 wk. Continue corrective trimming on foals.
Dentistry: check teeth and remove or float teeth as needed.
Stallions
Maintain an exercise program.
Broodmares
Administer rhinopneumonitis boosters to pregnant mares according to manufacturer's labeled directions. Administer appropriate vaccine boosters to foals and yearlings.
Check condition of mare's udder at weaning and reduce amount of feed given until milk flow is reduced.
Foals
Administer all appropriate immunizations. Provide free-choice minerals. Maintain a protein supplement in creep feeders.

Fourth Quarter: October-December
All Horses
Deworm at least every 8 wk. Select anthelmintic appropriate for season.
Trim feet every 6 wk. Continue corrective trimming on foals.
Dentistry: check teeth and remove or float teeth as needed.
Stallions
Continue exercise program. Check immunizations. Perform breeding examination.
Broodmares

BOX 17-3  General Outline of a Preventive Health Program for Cats

I. First office visit for health program (usually at 8-10 wk of age)
   A. Perform a general physical examination and record body weight
   B. Check for external parasites and dermatophytes, and initiate appropriate therapy for the following:
      1. Fleas and ear mites (*Otodectes cynotis*)
      2. Mange mites, especially *Notodredes cati*, *Demodex* spp., and *Cheyletiella* spp.
      3. Dermatophytes, particularly *Microsporum* spp. and *Trichophyton mentagrophytes*
   C. Perform fecal examination, including both direct smear and flotation
   D. Administer anthelmintics, such as pyrantel pamoate for roundworms and hookworms and praziquantel or ivermectin for tapeworms (if present)
   E. Vaccinate with *FVRC-P*,* Chlamydia*,* FIPV* (possibly test for FeLV/FIV before initial FeLV vaccination), FIP,* Bordetella*, and *Giardia* vaccines
   F. Advise on nutrition and routine grooming
   G. Provide owner with client education pamphlets on topics such as the following:
      1. Identification, treatment, and control of fleas, ticks, and ear mites
      2. Benefits of vaccination for FeLV infection
      3. Management of normal and abnormal cat behaviors
      4. Grooming "how to" and nutrition
   H. Fill in kitten’s health record for the owner

II. Second office visit for health program (usually at 12-14 wk of age)
   A. Perform a general physical examination and record body weight
   B. Check for external parasites and dermatophytes, and initiate appropriate therapy for the following:
      1. Fleas and ear mites (*O. cynotis*)
      2. Mange mites, especially *N. cati*, *Demodex* spp., and *Cheyletiella* spp.
      3. Dermatophytes, particularly *Microsporum* spp. and *T. mentagrophytes*
   C. Perform fecal examination, including both direct smear and flotation
   D. Administer anthelmintics, such as pyrantel pamoate for roundworms and hookworms and praziquantel or ivermectin for tapeworms (if present)
   E. Vaccinate with *FVRC-P*, *Chlamydia*,* FIPV*, rabies, FIP,* Bordetella*, and *Giardia* vaccines
   F. Adjust nutrition and grooming procedures
   G. Provide owner with client education pamphlets on topics such as the following:
      1. Identification, treatment, and control of fleas, ticks, and ear mites
      2. Benefits of vaccination for FeLV infection
      3. Dental, skin, nail, and ear care
      4. Management of normal and abnormal cat behaviors
      5. Exercise and its importance
      6. Recommendations for spaying, castration, and declawing
   H. Fill in kitten’s health record for the owner

III. Subsequent visits for health program (usually annual visits)
   A. Perform a general physical examination and record body weight
   B. Check for external parasites and dermatophytes, and initiate appropriate therapy for the following:
      1. Fleas and ear mites (*O. cynotis*)
      2. Mange mites, especially *N. cati*, *Demodex* spp., and *Cheyletiella* spp.
      3. Dermatophytes, particularly *Microsporum* spp. and *T. mentagrophytes*
   C. Perform fecal examination (fecal flotation)
   D. Administer an anthelmintic, according to fecal examination findings
   E. Vaccinate with *FVRC-P*, *Chlamydia*,* FIPV*, rabies, FIP,* Bordetella*, and *Giardia* vaccines
   F. Adjust nutrition and grooming procedures
BOX 17-3  General Outline of a Preventive Health Program for Cats — cont’d

G. Provide owner with client education pamphlets on topics such as the following:
   1. Identification, treatment, and control of fleas, ticks, and ear mites
   2. Benefits of vaccination for FeLV infection
   3. Dental, skin, nails, and ear care

4. Management of normal and abnormal cat behaviors
5. Exercise and its importance
6. Recommendations for spaying, castration, and declawing
H. Fill in the cat’s health record for owner

FeLV, Feline leukemia virus; FIV, feline immunodeficiency virus; FIP, feline infectious peritonitis.
* FVRC-P refers to the use of a vaccine to protect against feline viral rhinotracheitis (FVR); feline calicivirus infection (C); and feline panleukopenia (P).
† Cats being prepared for shipment or entering a boarding kennel, veterinary hospital, or clinic should be vaccinated at least 1-2 wk before admission or shipment.
‡ The vaccine currently available apparently produces effective protection only against Chlamydia psittaci infections. As with other vaccines for respiratory ailments, complete protection is not afforded; however, clinical signs of conjunctivitis or upper respiratory tract disease, if they do occur, can be restricted to short courses and are mild.
§ Refers to the use of a vaccine to protect against FeLV infection. FeLV and FIV vaccines are administered subcutaneously in healthy kittens or older cats as two doses, with the second dose given 3 or 4 wk after the first. Annual revaccination with a single dose is recommended.
‖ The Primucell-FIP Vaccine (Pfizer Animal Health) is administered intranasally to healthy cats. Primary vaccination with two doses should be given with the second dose administered 3-4 wk after the first, and single-dose annual revaccination is recommended.


BOX 17-4  General Outline of a Preventive Health Program for Beef Cattle

Cow-Calf Herd Recommendations*

At Birth
Ingestion of colostrum within the first few hours after birth is an important factor in baby calf survival. Immunize with oral bovine rotavirus and coronavirus enteric disease vaccine if a calf diarrhea problem exists in the herd.

1- to 3-Mo-Old Calves
Immunize with a seven-way clostridial disease product. Deworm with commercial product that is safe for calves.

Preweaning Calves
Deworm with broad-spectrum commercial dewormer, and immunize as follows:

Immunizing Vaccine

Brucella abortus, strain RB-51 (calffood vaccination—replacement heifers only)
Clostridial diseases:
   Clostridium perfringens types C and D, C. chauvoei, C. novyi, C. septicum, C. sordellii
IBR and P1-3 respiratory diseases (inactivated vaccines only)
BVD (inactivated vaccines only)
BRSV

Age for Vaccine Administration
4-12 mo
5-6 mo
5-6 mo, booster at 12-13 mo
5-6 mo, booster at 12-13 mo
5-6 mo, booster at 12-13 mo

Continued
BOX 17-4  General Outline of a Preventive Health Program for Beef Cattle

Weaning Calves
Deworm with broad-spectrum commercial dewormer, and treat for lice and grubs. Castrate the bull calves. Immunize with Pasteurella and Haemophilus (optional) vaccines.

Breeding Replacement Heifers
Deworm with broad-spectrum commercial dewormer and treat for lice. Immunize as follows:

<table>
<thead>
<tr>
<th>Immunizing Vaccine</th>
<th>Time of Vaccine Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBR and P1-3 respiratory diseases</td>
<td>10-12 mo</td>
</tr>
</tbody>
</table>
| Clostridial diseases:
  * C. perfringens types C and D, C. novyi, C. septicum,
  * C. sordelli, C. chauvoei             | 10-12 mo                      |
| BVD                                    | 10-12 mo                      |
| BRSV                                   | 10-12 mo                      |
| Leptospirosis                          | 10-12 mo                      |
| Campylobacteriosis                     | 10-12 mo                      |

Prebreeding Cows
Deworm with broad-spectrum dewormer and treat for lice. Immunize for leptospirosis and campylobacteriosis.

Precalving Cows
Immunize as follows:

<table>
<thead>
<tr>
<th>Immunizing Vaccine</th>
<th>Time of Vaccine Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBR and P1-3 respiratory diseases (inactivated vaccines only)</td>
<td>Before calving</td>
</tr>
<tr>
<td>BVD (inactivated vaccine only)</td>
<td>Before calving</td>
</tr>
<tr>
<td>BRSV</td>
<td>Before calving</td>
</tr>
<tr>
<td>Bovine rotavirus and coronavirus enteric diseases</td>
<td>Before calving</td>
</tr>
<tr>
<td>Escherichia coli enteric diseases</td>
<td>Before calving</td>
</tr>
</tbody>
</table>
| Clostridial diseases:
  * C. perfringens types C and D, C. chauvoei, C. novyi,
  * C. septicum, C. sordelli                    | Before calving |

Bulls
Deworm annually with broad-spectrum dewormer, and treat for lice and grubs. Immunize as recommended for prebreeding replacement heifers annually (see the above section).

Feedlot Recommendations*

On Arrival into the Feedlot
Deworm with a broad-spectrum dewormer and immunize for IBR, P1-3, BVD, BRSV, and clostridial diseases (use seven-way vaccine). Inactivated IBR, P1-3, and BVD vaccines are the safest.

3-4 Wk After Arrival into the Feedlot
Implant a commercial implant product. Treat for lice and grubs. Administer booster immunizations if necessary. Abort the heifers if necessary, Castrate and dehorn if necessary.

* Other optional vaccines that may be incorporated into the immunization program, depending on individual herd needs and diseases endemic to the area, include anthrax and anaplasmosis.
† Other optional vaccines that may be incorporated into the immunization program, depending on individual herd needs and diseases endemic to the area, include Haemophilus somnus, Pasteurella spp., leptospirosis, and anthrax.

BOX 17-5 General Outline

Preventive Health Program for Dairy Cattle

Calves
At Birth
Immunize with bovine rotavirus and coronavirus enteric disease vaccine,† and administer Escherichia coli enteric disease vaccine orally.

Weaning Age (about 2 mo) to Breeding Age (about 15 mo)
Immunizing Vaccine
Brucella abortus, strain RB-51 (calflhood vaccination—replacement heifers only)
Clostridial diseases:
  Clostridium perfringens types C and D,
  C. chauvoei, C. novyi, C. septicum, C. sordellii
IBR and P1-3 respiratory diseases
BVD
BRStV
Leptospirosis
Campylobacteriosis

Age for Vaccine Administration
4-12 mo
2-4 mo, booster in 2 wk
4-6 mo, booster at 12-13 mo
6-8 mo, booster at 12-13 mo
6-8 mo, booster at 12-13 mo
4-6 mo, booster in 2 wk
4-6 mo, booster at 12-13 mo

Fresh Cows and Heifers
Immunizing Vaccine
IBR and P1-3 respiratory diseases (inactivated vaccines only)
BVD (inactivated vaccines only)
BRStV
Leptospirosis
Campylobacteriosis

Time of Vaccine Administration
30 days postpartum
30 days postpartum
30 days postpartum
30 days postpartum
30 days postpartum

Dry Cows and Bred Heifers
The goal of dry cow immunization is to provide optimal protection for the newborn calf.
Immunizing Vaccine
Leptospirosis
Bovine rotavirus and coronavirus enteric diseases†
Escherichia coli enteric disease†
Clostridial diseases:
  C. perfringens types C and D, C. chauvoei,
  C. novyi, C. septicum, C. sordellii

Time of Vaccine Administration
At time of dry-off
At time of dry-off, booster in 2-3 wk
At time of dry-off, booster in 2-3 wk
At time of dry-off, booster in 2-3 wk

BRStV, Bovine respiratory syncytial virus; BVD, bovine virus diarrhea; IBR, infectious bovine rhinotracheitis; PI-3, parainfluenza-3.
* Other vaccines that may be incorporated into the vaccination program, depending on individual herd needs and diseases endemic to the area, include Haemophilus somnus, Pasteurella spp., Salmonella spp., Clostridium haemolyticum, anthrax, and anaplasmosis.
† Use if problem of neonatal calf diarrhea exists on the farm.

BOVINE VACCINES
Bovine respiratory disease complex vaccines
  PI3
  IBR (infectious bovine rhinotracheitis)
  BVD (bovine viral diarrhea)
  Bovine respiratory syncytial virus

Mannheimia haemolytica (formerly known as Pasteurella multocida)
H. somnus
Clostridial vaccines
Leptospirosis
Campylobacteriosis (vibrios)
**BOX 17-6  General Outline of a Preventive Health Program for Swine**

**Prebreeding Recommendations for Boars**
Purchase boars 60 days before intended use. Quarantine new boars for 30 days, then allow fence line contact with gilts and sows for 30 days before breeding. Immunize boars for leptospirosis and erysipelas. Treat for external and internal parasites before breeding.

**Prebreeding Recommendations for Sows and Gilts**
Immunize for leptospirosis, porcine parvovirus infection,* and pseudorabies* 2-4 wk before breeding. Flush gilts by increasing ovulations. Treat for external and internal parasites before breeding.

**Prefarrowing Recommendations for Sows and Gilts**
Limit feed intake to about 4 lb per head per day or feed according to condition to avoid overweight sows or gilts at farrowing. Immunize for colibacillosis,* atrophic rhinitis, erysipelas, transmissible gastroenteritis (TGE), porcine rotavirus infection,* and Clostridium perfringens type C* according to manufacturer's labeled instructions. Treat for external and internal parasites before farrowing with approved products.

**Farrowing Recommendations**
Gradually increase feed intake so lactating swine are receiving full feed at peak milk production. (Rule of thumb: Feed daily 1 lb of feed for every pig being nursed [e.g., a lactating sow with a litter of 12 pigs should receive at least 12 lb of feed daily].)

**General Recommendations for Pigs**

**At Birth**
Perform newborn pig procedures (e.g., clip needle teeth, dock tails, castrate, ear-notch, and inject iron dextran).

**1 Wk of Age**
Immunize for TGE,* rotavirus,* and atrophic rhinitis.

**4-5 Wk of Age**
Wean occurs at this time. Immunize for atrophic rhinitis, erysipelas, and Actinobacillus infection.*

**6-8 Wk of Age**
Treat for external and internal parasites with approved products.

**Older Than 8 Wk of Age**
Repete treatments for external and internal parasites with approved products may need to be done during the growing-finishing period.

---

* Dependent on problems in the individual swine herd.


---

**Brucellosis**
**Trichomoniasis**
**Anthrax**
**Anaplasmosis**
**Enteric diseases**
  - Bovine rotavirus
  - Bovine coronavirus
  - E. coli
  - Moraxella bovis (pinkeye)

**Others**
Vaccines are also available for sheep, poultry, and swine (Box 17-6). These animals may be raised in large numbers on farms, and as for cattle-raising operations, vaccination schedules may vary according to the type of conditions and location. Ferrets have become common household pets and should be vaccinated for canine distemper according to the schedule used for dogs. Some rabies vaccines are approved for use in ferrets. Public health authorities can require a rabies-vaccinated ferret that bites a human to be euthanized and tested for rabies virus.

**Swine Vaccines**
**Erysipelas**
**Leptospirosis**
**TGE (transmissible gastroenteritis)**
**Porcine rotavirus**
**C. perfringens (type C)**
**Neonatal porcine colibacillosis**
**Porcine proliferative enteritis vaccine**
**Bordetella**
**Pasteurella**
**Actinobacillus**
**Mycoplasma**
**Porcine reproductive and respiratory syndrome vaccine (PRRS)**
Hidden page
**Immunostimulants**

**Complex Carbohydrates**

**ACEMANNAN**

This is a complex carbohydrate derived from aloe vera.

**Clinical Uses**

Acemannan is used as an aid in the treatment of fibrosarcoma in cats and dogs. It has also been used for stimulating wound healing and in the treatment of FeLV- and FIV-infected cats.

**Dosage Form**

Acemannan immunostimulant

**Adverse Side Effects**

None

**Immunomodulatory Bacterins**

**STAPHYLOCOCCUS PHAGE LYSATE (SPL)**

This is prepared by lysing *Staphylococcus aureus* with a polyvalent bacteriophage.

**Clinical Uses**

SPL is used in the treatment of canine pyoderma and related skin infections with a staphylococcal component.

**Dosage Form**

Staphage Lysate (SPL)

**Adverse Side Effects**

These include malaise, fever, chills, and injection site irritation.

**Propionibacterium acnes Bacterin**

This is prepared from killed *Propionibacterium acnes*.

**Clinical Uses**

*P. acnes* is used in the treatment of chronic recurrent pyoderma and as an adjunct therapy in the treatment for equine respiratory disease complex. It also has been used as an adjunctive therapy in the treatment of feline retrovirus infection.

**Dosage Forms**

1. Immunoregulin
2. Eqstim

**Adverse Side Effects**

These include malaise, fever, and chills.

**Mycobacterial Cell Wall Fraction**

This is an emulsion of cell wall fractions that are modified to reduce their toxicity and allergic effects.

**Clinical Uses**

These include the treatment of equine sarcoids and bovine ocular squamous cell carcinoma. It is also used in the treatment of mixed mammary tumors and mammary adenocarcinoma in dogs.

**Dosage Forms**

1. Regressin-V
2. Nomagen

**Adverse Side Effects**

These include malaise, fever, and decreased appetite.

---

**Technician's Notes**

The effects of immunotherapy may be decreased with the administration of immunosuppressive drugs.

---

**REFERENCES**


Hidden page
Hidden page
Hidden page
**KEY TERMS**

**Chelating Agent** An agent used in chemotherapy for metal poisoning.

**Methemoglobinemia** The presence of methemoglobin in the blood caused by injury or toxic agents that convert a larger-than-normal proportion of hemoglobin into methemoglobin, which does not function as an oxygen carrier.

**Nutraceutical** Any nontoxic food component that has scientifically proven health benefits.

---

**ALTERNATIVE MEDICINES**

**Chondroprotectives**

Chondroprotectives are substances that are able to decrease the progression of osteoarthritis by providing support to cartilage and promoting its repair.

**Polysulfated Glycosaminoglycans**

Polysulfated glycosaminoglycan (PSGAG) consists of a repeating chain of hexosamine and hexuronic acid (Booth, 2001). The complex nature of the molecule allows water to be trapped in hyaline cartilage to provide resistance to compression and resiliency to the proteoglycan and collagen matrix. PSGAGs are extracted for commercial use from the tracheal tissue of the bovine. After intramuscular (IM) injection, PSGAG is deposited in articular cartilage and is preferentially taken up by osteoarthritic cartilage (Plumb, 2005). When used to treat degenerative joint conditions, these PSGAGs increase synovial fluid viscosity and inhibit enzymes that damage cartilage matrix within joints. PSGAGs also reduce inflammation by inhibiting prostaglandin released in joint injury.

**Clinical Uses**

PSGAG is used in the treatment of noninfectious degenerative or traumatic joint dysfunction and associated lameness of the carpal joints in horses. It also has been used to treat degenerative joint disorders in dogs and lameness in swine.

**Dosage Forms**

1. Adequan I.A., for intraarticular injection
2. Adequan I.M., for intramuscular injection
3. Adequan Canine
4. Legend

**Adverse Side Effects**

Adverse side effects are minimal with use of this product.

---

**Technician’s Notes**

1. Amikacin may be used concurrently with intraarticular use to prevent infection resulting from possible contamination.
2. PSGAG should not be used in horses intended for food.
3. Safety in breeding animals is undetermined.

---

**Nutraceuticals**

The American Veterinary Medical Association defines **nutraceutical** medicine as “the use of micronutrients, macronutrients, and other nutritional supplements as therapeutic agents.” In veterinary medicine, the term is generally used to refer to endogenous substances (not botanicals) that have been prepared or synthesized to support bodily functions. The popularity of these products, which may have characteristics of nutrients and pharmaceuticals, has seen tremendous growth in use by people in recent years. The medical community has acknowledged that some of them may have treatment or preventive effects (Booth, 1997).

As people have become more aware of alternative medical options for themselves, they have come to expect similar options for their pets. Veterinarians and their clients can be expected to use nutraceuticals as treatment options to complement traditional medicine or when traditional treatment options have been exhausted.
Hidden page
Clients should be urged to make use of information regarding nutraceutical quality by making use of the ConsumerLab (www.consumerlab) and USP (www.usp.org) websites.

The following is a partial list of the substances marketed as nutraceuticals. Some of these products may not be “endogenous substances” as defined earlier.

**Glucosamine and Chondroitin Sulfate**

Glucosamine is an amino sugar manufactured by animal cells from glucose and used by the body in the synthesis of glycoproteins and polysulfated glycosaminoglycans. Chondroitin sulfate is a glycosaminoglycan that combines with hyaluronic acid, proteins, and other glycosaminoglycans to form the basic cartilage matrix. Glucosamine and chondroitin sulfate are believed to act synergistically (Davidson, 2000) to exert a positive effect on cartilage metabolism and an inhibition of cartilage breakdown. They have been used extensively in the treatment of osteoarthritis in dogs and horses. Four to six weeks of administration may be necessary for a therapeutic effect to be seen. A common veterinary product that contains these substances is called Cosequin; it is composed of glycosaminoglycan derived from the chitin of crab shell and chondroitin sulfate from bovine trachea. Dasuquin and Dasuquin for Cats are products that contain glucosamine and chondroitin sulfate with avocado/soybean unsaponifiables and decaffeinated tea with claims of enhanced chondroprotection. Glyco-Flex and Syno-Flex derive their glycosaminoglycan from the *Perna canaliculus* mussel.

**Fatty Acids**

The omega-6 and omega-3 fatty acids are the ones most often found in commercial veterinary fatty acid supplements. Omega-6 fatty acids have double-bond 6 carbons from the methyl end, whereas omega-3 fatty acids have double-bond 3 carbons from the methyl end. Fatty acid supplementation has been shown to be useful in treating certain dermatologic conditions in dogs and cats because of their antiinflammatory effects. Omega-3 fatty acids are normally found in low concentrations in the cellular plasma membrane compared with omega-6 fatty acids, but the omega-3 level can be increased by a food or supplement that is enriched in this substance (Roudebush and Freeman, 2000). The breakdown products of the omega-3 acids are apparently less powerful mediators of the inflammatory response than those derived from the omega-6 fatty acids. The omega-3 and omega-6 fatty acids also may be helpful in treating heart disease, cancer, autoimmune disease, and rheumatoid arthritis. The proper ratio of omega-6 to omega-3 fatty acids in a product has apparently not been determined and is often debated. Fish oil and plant oils are common sources of these fatty acids. Side effects may include increased bleeding times and possible decreased immune function.

**S-Adenosylmethionine (SAMe)**

The SAMe SD4 is a molecule produced in the body from methionine and adenosine triphosphate (ATP) by the enzyme SAMe synthetase (Davidson, 2002). It is recommended for veterinary use as a dietary supplement to support normal structure and function of the liver. Some studies have shown that this substance increases levels of glutathione in the liver. Glutathione is an antioxidant that may protect liver cells from injury. Denosyl is a SAMe product manufactured by Nutramax Laboratories.

**Superoxide Dismutase**

Superoxide dismutase from protein sources is an oxygen radical scavenger that has been used as an anti-inflammatory agent for musculoskeletal problems.

**Coenzyme Q**

This substance is an enzyme cofactor of mitochondrial membranes that is important in electron transport and ATP formation. It is used in the treatment of cardiovascular problems.

**Herbal Medicines**

The use of plants to treat veterinary patients is classified by the American Veterinary Medical Association (AVMA) as a modality in the category of complementary and alternative veterinary medicine (CAVM). The AVMA in its policy guidelines states
Hidden page
Table 18-1  Potential Herb-Drug Interactions

<table>
<thead>
<tr>
<th>Herb</th>
<th>Interacting Drugs</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>St. John’s wort</td>
<td>Cyclosporine</td>
<td>Decreased plasma drug concentrations</td>
</tr>
<tr>
<td></td>
<td>Fexofenadine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Midazolam</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Digoxin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tacrolimus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amitriptyline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Warfarin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Theophylline</td>
<td>Serotonin syndrome</td>
</tr>
<tr>
<td></td>
<td>Sertraline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Buspirone</td>
<td></td>
</tr>
<tr>
<td>Gingko</td>
<td>Warfarin</td>
<td>Bleeding</td>
</tr>
<tr>
<td></td>
<td>Heparin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NSAIDs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Omeprazole</td>
<td>Decreased plasma concentrations</td>
</tr>
<tr>
<td>Ginseng</td>
<td>Warfarin</td>
<td>Bleeding</td>
</tr>
<tr>
<td></td>
<td>Heparin</td>
<td>Falsely elevated serum digoxin levels</td>
</tr>
<tr>
<td></td>
<td>NSAIDs</td>
<td>laboratory test interaction with ginseng</td>
</tr>
<tr>
<td></td>
<td>Opioids</td>
<td>Decreased analgesic effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Falsely elevated serum digoxin levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td>laboratory test interaction with ginseng</td>
</tr>
<tr>
<td>Garlic</td>
<td>Warfarin</td>
<td>Bleeding</td>
</tr>
<tr>
<td>Chamomile</td>
<td>Heparin</td>
<td></td>
</tr>
<tr>
<td>Ginger</td>
<td>NSAIDs</td>
<td></td>
</tr>
</tbody>
</table>

Dried extracts: The plant is simmered in water, strained of residue, and sprayed into a vacuum chamber, which produces a powder or granules. A common extract is a 5:1 extract that allows the use of less product because of the concentrated form. Water extracts may exclude plant substances that are alcohol soluble.

Liquid extracts: The ingredients are extracted in alcohol and the residue discarded. Advantages of alcohol extraction are thought to include concentration of the ingredient and improved absorption from the intestinal tract. Alcohol extractions usually taste bad to pets and must be added to another ingredient to improve palatability.

Most of the current dosing of botanicals for animals is extrapolated from human dosage information because few herbal products are produced specifically for animals. Dosage recommendations vary between forms and between extract dilutions (e.g., a 1:1 extract will be dosed differently than a 5:1 extract).

Summary of Herbal Medicines
Herbal medicine has added another dimension outside of conventional therapy to the treatment of veterinary patients. Its practice provides a holistic approach to veterinary health care for those veterinarians and clients who wish to use it as an ancillary method, or when conventional methods have been exhausted. Until strict regulation of the botanical industry is achieved, however, veterinary technicians should counsel clients with judicious information about their use. The following factors
may be useful when one is advising clients about herbal use:

- **The use of herbal medicine should not be started without discussion of the process with the attending veterinarian.**
- **Clients should purchase products from reputable manufacturers approved by the National Animal Supplement Council (NASC).**
- **Clients can find product evaluation information at the ConsumerLab website.**
- **Recommended dosage should be followed closely.**
- **Herbs may cause harmful interactions with conventional drugs.**
- **Herb use may cause bleeding tendencies during surgical procedures.**
- **Adverse side effects of herbs should be reported to the Veterinary Botanical Medicine Association and to the manufacturer.**

Box 18-1 includes a list of useful herbal references.

**Technician’s Notes**

The American Society of Anesthesiology recommends that patients should discontinue all herbal medicines 2 to 3 weeks before elective surgery procedures are performed.

**Aloe**

Aloe vera is a plant native to Africa that was used as early as 1500 B.C. for the treatment of various conditions and as a cathartic (Wynn and Fougere, 2007). Today, it is used primarily for the treatment of burns and skin inflammation. Some herbalists believe that aloe stimulates wound healing.

**Bloodroot**

The rhizome of Sanguinaria canadensis has traditionally been used as an expectorant and to treat respiratory conditions like bronchitis, asthma, and laryngitis. It is also reported to have antiinflammatory and antimicrobial effects.

**Echinacea**

Echinacea purpurea is a commonly used remedy for colds and flu in people in the United States and Europe, where research has been done to show that it is an immunostimulant. It is derived primarily from the American coneflower. No major side effects have been reported other than the occasional allergic reaction (Fascetti, 1998).

**Garlic**

Garlic is a perennial bulb in the lily family (Allium sativum) that is related to the onion. This plant has been used for centuries for its reported medicinal value. People have claimed that it produces disinfectant, diuretic, and/or expectorant effects. Evidence suggests that it does lower cholesterol values in people. No evidence, however, shows that garlic has any value in the treatment of parasites in animals. Garlic can produce Heinz body anemia in cats and possibly in dogs at high dosages.

**Box 18 Useful Herbal References**

| 2. Veterinary Botanical Medicine Association | www.vbma.org |
| 3. Drug Digest | www.drugdigest.org |
| 5. ConsumerLab | www.consumerlab.com |
| 6. Cochrane Collaboration | www.cochrane.org |
| 8. American Association of Feed Control Officials | www.aafco.org |
Hidden page
disodium ethylenediaminetetraacetate, and sodium calcium edetate.

**Clinical Uses**
In veterinary medicine, calcium EDTA is used for the treatment of lead poisoning.

**Dosage Forms**
1. Calcium Disodium Versenate injection (human label)
2. Meta-Dote

**Adverse Side Effects**
These include renal toxicity, depression (dogs), and vomiting/diarrhea (dogs). Zinc deficiency may occur from long-term therapy.

---

**Technician’s Notes**
1. Calcium EDTA should not be used in anemic patients, and caution should be exercised when it is used in patients with renal insufficiency.
2. Calcium EDTA should not be administered orally.
3. Do not confuse with edetate disodium, which may cause severe hypocalcemia.
4. Magnesium sulfate (Epsom salt) or sodium sulfate may be used orally to prevent further intestinal absorption of lead.

---

**Methylene Blue**
Methylene blue is a thiazine dye that appears as dark green crystals or crystalline powder with a bronze-like luster. It is an oxidating agent that helps to convert methemoglobin (a compound formed from hemoglobin by oxidation of the iron atom) from the ferrous (Fe^{2+}) to the ferric (Fe^{3+}) state. It does not function as an oxygen carrier to hemoglobin.

**Clinical Uses**
Methylene blue is used for the treatment of methemoglobinemia caused by oxidative agents (e.g., nitrates, nitrites, chlorates) in ruminants. It may be used for cyanide toxicity in ruminants. It can be used in dogs to intraoperatively stain pancreatic islet cell tumors preferentially and for treatment of acetaminophen poisoning.

**Dosage Forms**
1. Methylene blue injection (generic) (human label)
2. Methylene blue tablets (generic)
3. Methylene blue powder (generic)

**Adverse Side Effects**
These include the development of Heinz body anemia or morphologic changes in red blood cells and decreased red blood cell life span. Methemoglobinemia may occur but is usually dose and species dependent. Tissue necrosis may occur with subcutaneous administration or extravasation during intravenous injection.

---

**Acetylcysteine**
Acetylcysteine is a white crystalline powder that is soluble in water or alcohol. It also may be referred to as N-acetylcysteine or N-acetyl-l-cysteine.

**Clinical Uses**
These include oral therapy for acetaminophen poisoning in dogs and cats. It also may be used as a mucolytic agent for pulmonary (via nebulization) or ophthalmic (via topical application) conditions.

**Dosage Forms**
1. Mucomyst (human label)
2. Mucosil (human label)
3. Acetylcysteine (human label)

**Adverse Side Effects**
These include nausea, vomiting, and occasionally urticaria (hives) when administered orally. Chest tightness, bronchoconstriction, bronchial or tracheal irritation, and acetylcysteine hypersensitivity are rare but possible side effects when administered.
into the pulmonary tract. Acetylcysteine may cause bronchospasm in some patients receiving treatment via the pulmonary tract.

**Technician’s Notes**

1. Acetylcysteine is incompatible with amphotericin B, chlorotetracycline hydrochloride, erythromycin lactobionate, oxytetracycline hydrochloride, ampicillin sodium, tetracycline hydrochloride, iodized oil, hydrogen peroxide, chymotrypsin, and trypsin.
2. Activated charcoal may adsorb acetylcysteine, reducing its effectiveness in treating acetaminophen toxicity.
3. Carefully monitor patients that have bronchospastic diseases and that receive pulmonary treatment.
4. Oral solution has a bad taste, and a masking agent (e.g., colas, juices) may be used.
5. Open vials should be refrigerated and discarded after 96 hours.

**Dimercaprol**

Dimercaprol is a dithiol chelating agent that occurs as a colorless or nearly colorless viscous liquid with a disagreeable odor. The commercial solution may be cloudy or may contain small amounts of flaky material or sediment. This is normal and does not indicate deterioration of the product. It also may be referred to as BAL, British antilewisite, dimercaptopropanol, or dithioglycerol.

**Clinical Uses**

Dimercaprol is used primarily for the treatment of toxicity resulting from arsenic compounds but may be used for lead, mercury, or gold toxicity.

**Dosage Forms**

1. Dimercaprol injection 100 mg/ml (human label)
2. BAL in oil (human label)

**Adverse Side Effects**

Intramuscular injections are painful. Vomiting and seizures may occur with high doses. It is potentially nephrotoxic. Most side effects subside quickly because of rapid elimination of the drug.

**Pralidoxime Chloride**

Pralidoxime chloride is a quaternary ammonium oxime cholinesterase reactivator. It reverses the action of cholinesterase inhibitors such as certain organophosphates. It also may be referred to as a 2-PAM chloride or 2-pyridine aldoxime methyl chloride.

**Clinical Uses**

Pralidoxime chloride is used for oral treatment of organophosphate poisoning. It may be used in conjunction with atropine and supportive therapy.

**Dosage Form**

Protopam injection (human label)

**Adverse Side Effects**

These are uncommon, but rapid intravenous injection may cause tachycardia, muscle rigidity, transient neuromuscular blockade, and laryngospasm.

**Technician’s Notes**

1. Pralidoxime, similar to other anticholinesterases, may potentiate the action of barbiturates.
2. Patients with impaired renal function require a lower dose and careful monitoring.

**Penicillamine**

Penicillamine is a chelating agent of metals such as copper, lead, iron, and mercury. It is a degradation product of penicillins but does not have antimicrobial activity. It also may be referred to as D-penicillamine, B, B-dimethylcysteine, or D,3-mercaptovaline.

**Clinical Uses**

Penicillamine is used for copper-associated hepatopathy and for long-term oral treatment of lead poisoning and cystine urolithiasis.

**Dosage Forms**

1. Depen Titratabs, tablets (human label)
2. Cuprimine capsules (human label)
Adverse Side Effects
These include nausea and vomiting. Other rare side effects include fever, lymphadenopathy, skin hypersensitivity reactions, and immune complex glomerulonephropathy.

Technician’s Notes
Absorption of penicillamine may be reduced by concurrent administration of food, antacids, or iron salts.

Sodium Thiosulfate
Sodium thiosulfate uses the enzyme rhodanese to convert cyanide to a nontoxic thiocyanate ion, which is excreted in urine.

Clinical Uses
Sodium thiosulfate is used in the treatment of cyanide poisoning in horses and ruminants. It may be used in combination with sodium molybdate for the treatment of copper poisoning in ruminants. It also has been used for the treatment of arsenic poisoning. When applied topically, sodium thiosulfate has antifungal properties.

Dosage Forms
1. Cya-dote Injection
2. Sodium Thiosulfate for Injection 25%
   (human label)

Adverse Side Effects
These are uncommon.

Technician’s Notes
When sodium thiosulfate is administered intravenously, it should be given slowly.

Ethanol
Ethanol is an alcohol that is a competitive inhibitor of ethylene glycol metabolism. It also may be referred to as pure grain alcohol, grain alcohol, or ethyl alcohol.

Clinical Uses
Ethanol is used to treat ethylene glycol (antifreeze) poisoning.

Dosage Form
Ethanol

Adverse Side Effects
Ethanol reduces body temperature and overdose can be fatal.

Technician’s Notes
1. A 20% to 50% solution of pure ethanol is administered intravenously until the animal is comatose and does not respond to a toe pinch. Administration is repeated as needed to maintain a comatose state for 3 days.
2. Sodium bicarbonate is usually administered to control metabolic acidosis.

Fomepizole
Fomepizole is a competitive inhibitor of alcohol dehydrogenase. Its action prevents the conversion of ethylene glycol into glycoaldehyde and other toxic metabolites. This allows ethylene glycol to be excreted primarily unchanged. It also may be referred to as 4-methylpyrazole (4-MP).

Clinical Uses
Fomepizole is used to treat ethylene glycol (antifreeze) poisoning in dogs.

Dosage Form
Antizol-Vet

Adverse Side Effects
Clinical signs of possible anaphylaxis include tachypnea, gagging, excessive salivation, and trembling.

Technician’s Notes
1. Fomepizole must be diluted with 0.9% NaCl before intravenous injection.
2. Dogs treated within 8 hours of ingestion have a better prognosis than those treated 10 to 12 hours after ingestion (Plumb, 2005).
Hidden page
Hidden page
Hidden page
1. A 2-year-old beagle has clinical signs of lead toxicity and a history to support the diagnosis. Which agent would be the drug of choice for treating this condition?
   a. Yohimbine HCl
   b. 2-PAM
   c. Calcium EDTA
   d. Methylene blue

2. A client calls and says that she has been giving her cat Tylenol for a limp. Now the cat is breathing fast, its face is swollen, and it is not active. You should tell the client to ______.
   a. give the cat hydrogen peroxide orally
   b. see whether she can get the cat to eat
   c. bring the cat to the hospital to start treatment with hydrogen peroxide
   d. bring the cat to the hospital to start treatment with acetylcysteine

3. Yohimbine HCl is a reversal agent for ______.
   a. rompun
   b. acepromazine
   c. penotthal
   d. oxymorphone

4. Penicillamine should be administered ______.
   a. with food
   b. on an empty stomach
   c. with antacids
   d. with copper

5. Name four drugs that naloxone effectively reverses. ____________________________
   ____________________________

6. BAL has been administered to a 4-year-old mixed-breed dog for arsenic poisoning. Results of which of the following laboratory tests should be monitored closely?
   a. Packed cell volume (PCV)
   b. Blood urea nitrogen (BUN)
   c. White blood cell count (WBC)
   d. Alanine aminotransferase (ALT)

7. Glycosaminoglycans occur naturally in what part(s) of the body?

8. What role do glycosaminoglycans (GAGs) provide in the treatment of degenerative joint conditions?


10. A product usually is determined to be a drug if its label has a claim that indicates a therapeutic or preventive intent.
    a. True
    b. False

11. What Act made dietary supplements as vitamins, minerals, amino acids, herbal products, and substances that supplement the diet by increasing total dietary intake “food” and excluded them from FDA regulation?

12. ____________________________ supplementation has been shown to be useful in treating certain dermatology conditions in dogs and cats.

13. What are two possible side effects for using fatty acids as a dietary supplement?

14. What is activated charcoal used for?

15. In veterinary medicine, calcium EDTA is used primarily for the treatment of ____________________________.

16. Petroleum jelly is not recommended as a lubricant because it is not ____________________________.

17. ____________________________ is a narcotic antagonist used for the treatment, prevention, or control of narcotic depression.

18. Flumazenil is used to reverse the effects of ____________________________.

19. A dietary supplement for support of normal structure and function of the liver is ____________________________.
CHAPTER 19

Inventory: The Veterinary Technician's Role

LEARNING OBJECTIVES

After studying this chapter, you should be able to:

1. Explain why having an inventory control system is important.
2. Describe ways in which inventory control benefits a business.
3. Explain why inventory turnover is important.
4. Discuss ways of becoming an efficient inventory control manager.
5. Describe various inventory record-keeping systems.
6. Describe the differences in vendor types.
7. Describe good communication techniques that can be used with sales representatives.
8. Discuss ways that veterinary management computer software aids in pharmaceutic inventory.
**KEY TERMS**

**Average Cost of Inventory on Hand** Average cost of inventory on hand is determined by adding the year’s beginning inventory to the year’s ending inventory and dividing by 2.

**DEA Form** An official federal government carbon form used for ordering controlled substances.

**Delayed Billing** A benefit that some companies offer the buyer who is purchasing increased amounts of merchandise. The date the statement must be paid is usually longer than 30 to 60 days away.

**FIFO** First in, first out.

**FOB** Acronym for “free on board.”

**FOB Destination** Title of possession passes from the pharmaceutical company to the buyer (i.e., the purchaser) when the shipment is delivered to the buyer’s business destination (i.e., the veterinary facility).

**FOB Shipping Point** Title passes from the pharmaceutical company to the purchaser when the vendor places the goods in the possession of the carrier (e.g., United Parcel Service, Federal Express, Averitt Express).

**Full-Service Company** A pharmaceutical company that offers full service (e.g., the company employs sales representatives [reps] who visit veterinary facilities), usually with a limited number of products.

**Inventory** The quantity of goods or assets that a veterinary facility possesses, requiring proactive control to keep supplies stable and current.

**ICM (Inventory Control Manager)** A person (many times a licensed veterinary medical technician [LVMT]) responsible for monitoring, ordering, and maintaining inventory in a veterinary facility.

**Invoice** A form generated by a company that documents the quantity and price of each item ordered by the inventory control manager.

**Mail Order Discount House** A company that accepts orders from the buyer by telephone; a good source for ordering items such as gauze, cotton, isopropyl alcohol, or paper towels.

**Markup** The amount of money over cost that a product sells for. Markup percentages vary from practice to practice, but all markups reflect a retail value over wholesale value.

**Packing Slip** A document supplied by the vendor that accompanies a purchase. A packing slip generally reflects quantities ordered, not prices.

**Statement** A document generated by the vendor that details the quantity and pricing of all goods purchased (usually in 1 month) by the buyer. The total balance is generally expected to be paid in full within 30 days.

**Turnover** The number of times a product is sold or used up in a veterinary facility. The minimum turnover rate should be established at four times a year.

**Veterinary Supply Distributor** An intermediate company (i.e., not full service, not mail order) that generally stocks a large inventory and employs sales representatives who visit veterinary facilities.

**INTRODUCTION**

Control of inventory is an important concern for companies both large and small, and veterinary businesses are no exception. Proactively maintaining pharmaceutical inventory is an ongoing endeavor for veterinary hospitals (Figure 19-1). Deciding how much trade or generic name product to buy, keeping expired items off the shelves, and performing a physical inventory are all integral parts of keeping a veterinary facility functioning as a healthy business. When a product is depleted before the next order arrives, it is frustrating for both veterinary staff and the clientele. When a product is not available, it cannot be sold and no profit can be made. Deciding which employee to entrust with this responsibility is an important decision for veterinary practice owners that should be made with careful consideration. Therefore, the employee chosen for this job should treat the position with respect and make every effort to be frugal with the employer’s money.

The veterinary technician often is the employee chosen to perform this job. Therefore, knowledge of pharmaceutics and the ability to observe quantities of product used within a month are important talents that the veterinary technician must possess.
at the veterinary facility, and learning about new products. These are only a few of the responsibilities the ICM will meet daily. Inventory should be handled as an ongoing process. Each day, inventory must be visually counted and physical inventory must be done at least once a month for good results.

**INVENTORY**

**Technician’s Notes**
The value of all assets owned by the veterinary facility has important tax and insurance implications.

Accounting of inventory items is very important when one is filing income taxes or in the event of a fire or natural disaster. Veterinary practices providing an accurate inventory of their business assets are assured that their insurance companies will reimburse the business accurately should a disaster occur. The primary goal of inventory is to have sufficient quantities of inventory available to serve clients’ needs, while at the same time minimizing the cost of carrying that inventory. Purchasing too many units of a slow-selling item can cost the practice money, and not purchasing enough of a high-selling item can cause stockouts and frustration (Libby, Libby, and Short, 2004) for the veterinary team.

An accounting system plays three roles in the inventory management process:

1. The system must provide accurate information for preparation of periodic financial statements and tax returns.
2. It must provide up-to-date information on inventory quantities and costs, to facilitate ordering decisions.
3. Since inventories are subject to theft and other forms of misuse, the system also must provide the information needed to protect assets.

So what exactly is the definition of inventory? It is tangible property that is sold in the normal course of a business day. In veterinary medicine, this would include such items as antibiotics, anthelmintics,
shampoos, topical medications, prescription feeds, and even the dispensing bottles used to dispense liquid medication, as well as the syringes sold to clients that they must use to orally medicate their pets at home. Dispensing bottles, syringes, needles, ointment tins, and so forth could be classified as raw materials because they are carriers for the actual medicine that is being prescribed and dispensed. However, raw materials cost the practice money, just as pharmaceutics do. It is just as frustrating to run out of these items as it is to run out of a broad-spectrum antibiotic.

Most veterinary practices use the first in, first out (FIFO) method of inventory. This is not necessarily done by choice, but rather because of the expiration dates on merchandise that the practice sells. Generally speaking, the expiration date that is the earliest should be sold first. A perpetual inventory control system, which is a detailed record for each type of merchandise stocked, shows the following:

- Units and costs of the beginning inventory
- Units and costs of each purchase
- Units and costs of the goods for each sale
- Units and costs of the goods on hand at any point in time

Luckily, most veterinary computer management software programs do the above listed items automatically. In today’s business world, inventory is much easier to keep up with than it was in the days of periodic inventory, when businesses did not have computers (Libby, Libby, and Short, 2004). However, it is better to use a balance between a perpetual inventory control system and a periodic inventory because sometimes the amount of each item listed within the computer system may not be a true reflection of what is actually on hand. Nothing can ever take the place of a periodic inventory and physically counting the amount of each item on hand. The primary disadvantage of a periodic inventory system is the lack of inventory information that is available to the practice owner; that is, veterinary management software makes inventory easier because it shows up-to-date amounts of each item sold, along with trends during the summer or winter months that can help staff in deciding how much inventory needs to be purchased in the coming years.

Inventory is an ongoing process, and trends within the practice must be observed daily. The ICM must be able to recognize the products that each veterinarian in the practice uses and dispenses, to ensure that items are on hand when needed. Nothing is more frustrating than needing a drug or other inventory item to treat a patient with, only to find it is not in stock. Computer software designed for the veterinary business can help tremendously with tracking trends within the practice. Most software has the ability to provide printouts of day-by-day, week-by-week, month-by-month, and yearly sales trends (Figure 19-2).

Through establishment of a workable inventory control system within a realistic budget, expenses can be kept at a minimum.

---

**Technician’s Notes**

For many veterinary practices, inventory represents the second-highest expense. Payroll is usually the highest overhead item.

---

After determination and implementation of a realistic budget that might be based on the mission statement of the facility and practice needs, followed by implementation of that budget, there will be no danger of running out of inventory items because there always will be sufficient quantities of product on hand. An annual inventory evaluation is beneficial when a vision for the practice and its potential growth has been developed.

---

**The Time Equation**

When one is dealing with inventory, no equation is more important than the following:

\[ \text{Time} = \text{Money} \]

Although it is important to have merchandise on hand for retail sale, a fine balance is needed to keep products from sitting too long on pharmacy shelves. Products that stay on the shelf for too long will not make money for the veterinary practice. Instead, this is similar to placing money in a jar and burying
## INVENTORY REPORT

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>UIM</th>
<th>Price</th>
<th>On hand</th>
<th>Avg cost</th>
<th>Stock value</th>
<th>Unit cost</th>
<th>Pkg. cost</th>
<th>Codes</th>
<th>Cis</th>
<th>Last sold</th>
<th>Document</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ANTHelmINTICS

<table>
<thead>
<tr>
<th></th>
<th>0.00</th>
</tr>
</thead>
</table>

#### CANINE VACCINES

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>UIM</th>
<th>Price</th>
<th>On hand</th>
<th>Avg cost</th>
<th>Stock value</th>
<th>Unit cost</th>
<th>Pkg. cost</th>
<th>Codes</th>
<th>Cis</th>
<th>Last sold</th>
<th>Document</th>
</tr>
</thead>
<tbody>
<tr>
<td>1008</td>
<td>Bordetella (Injection)</td>
<td>Ds</td>
<td>0.00</td>
<td>14</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Qty sold, Last 12 Months**

<p>| | | | | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### MISCELLANEOUS ITEMS

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>UIM</th>
<th>Price</th>
<th>On hand</th>
<th>Avg cost</th>
<th>Stock value</th>
<th>Unit cost</th>
<th>Pkg. cost</th>
<th>Codes</th>
<th>Cis</th>
<th>Last sold</th>
<th>Document</th>
</tr>
</thead>
<tbody>
<tr>
<td>1007</td>
<td>Large Garbage Sacks</td>
<td>Box</td>
<td>0.00</td>
<td>0</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Qty sold, Last 12 Months**

<p>| | | | | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>UIM</th>
<th>Price</th>
<th>On hand</th>
<th>Avg cost</th>
<th>Stock value</th>
<th>Unit cost</th>
<th>Pkg. cost</th>
<th>Codes</th>
<th>Cis</th>
<th>Last sold</th>
<th>Document</th>
</tr>
</thead>
<tbody>
<tr>
<td>7022</td>
<td>Small Garbage Sacks</td>
<td>Box</td>
<td>0.00</td>
<td>0</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Qty sold, Last 12 Months**

<p>| | | | | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>UIM</th>
<th>Price</th>
<th>On hand</th>
<th>Avg cost</th>
<th>Stock value</th>
<th>Unit cost</th>
<th>Pkg. cost</th>
<th>Codes</th>
<th>Cis</th>
<th>Last sold</th>
<th>Document</th>
</tr>
</thead>
<tbody>
<tr>
<td>7023</td>
<td>Computer Printer Paper</td>
<td>PACK</td>
<td>0.00</td>
<td>0</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Qty sold, Last 12 Months**

<p>| | | | | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 19-2**

AVI-Mark Veterinary Software Management System.
it in the backyard; the money is there, but it is not earning interest and it is not working for you. So it is with inventory products. A fine inventory balance is crucial to the financial health of a business. Besides, clients do not like to buy products that have been sitting on pharmacy shelves for a long time because the labels become smudged and dusty.

A periodic evaluation of inventory is crucial toward keeping the balance in fine adjustment. Items that are not selling well or are used infrequently within the practice should be deleted from the inventory master list and should not be ordered in the future. This is where turnover becomes an important issue.

The following equation determines the average cost of inventory on hand:

\[
\text{Average cost of inventory on hand} = \frac{\text{Year's beginning inventory} + \text{Year's ending inventory}}{2}
\]

**Example:**

\[
\frac{150,000 + 350,000}{2} = 92,500
\]

**CONTROLLING INVENTORY**

Establishing effective inventory control in a veterinary practice necessitates placing a person in charge of ordering and stocking supplies. An additional person trained as a backup is a must because when the ICM goes on vacation or is sick, someone else must be knowledgeable about the system. These two people can work effectively as a team to keep product supplies on hand.

The duties of the ICM are intense. This person is responsible for keeping an adequate supply of all products used, dispensed, and sold; organizing inventory items for easy location; identifying when products should be reordered; keeping accurate inventory records; ordering, receiving, and inspecting shipments; and maintaining price and price updates for all items. The ICM also is responsible for rotating stock, keeping expired items off the shelves, learning about new products, and keeping the practice owner apprised of the specials that suppliers may offer. This responsibility must be acted upon every day. The veterinary technician who accepts the role of ICM must be able to perform clinical and nursing skills and keep an eye on inventory levels.

**Technician’s Notes**

**Turnover** is the number of times a product is sold or used in-house on an annual basis.

**Calculating Turnover Rate**

The following equation is used to determine turnover rate:

\[
\text{Turnover Rate} = \frac{\text{Yearly inventory expense}}{\text{Average cost of inventory on hand}}
\]

**Example:**

\[
\frac{100,000}{20,000} = 5
\]
Proactive Inventory Control System

For an inventory control system to be workable, it must be easy to use and have a turnover rate of at least four turns per year. It is the inventory control manager's job to make sure that all supplies are on hand when needed. Expenses can be reduced when inventory amounts are ordered properly.

Proper handling of Drug Enforcement Administration (DEA) substances is an important concern.

Technician's Notes

Controlled substances (e.g., Sleepaway, diazepam) must be kept in a locked cabinet that has been bolted to the floor, and all amounts used must be correctly recorded in the controlled substance log.

DEA forms (Figure 19-3) must be filled out properly by including the correct spelling of the substance to be ordered, documenting the exact amount and milligrams, and obtaining the signature of the veterinarian. No liquid paper may be used on these forms, and no strikeouts are allowed. In addition, these forms must be filled out with an ink pen or typewriter.

Each invoice (Figure 19-4) that arrives at the veterinary hospital should be checked to verify amounts ordered and prices the practice is charged. A packing slip (Figure 19-5), an invoice, and a statement (Figure 19-6) are three different forms. Mistakes can be made on these forms unintentionally by the product vendor, but it may fall to the ICM to audit these mistakes and notify the vendor so the account can be adjusted to receive proper credit.

Back-ordered items can present problems. Back-ordered items are those items not on hand at the vendor for any number of reasons. Sometimes, the product may be on back order for manufacturing reasons; another reason may be that the manufacturer is redesigning the product's label. Buyouts of large pharmaceutical corporations also can cause product to be on back order until all minor details are worked out concerning the merger.

Identification of expired items may be one of the most frustrating experiences an ICM may face.

Technician's Notes

Most products have an expiration date on the label, and these must be checked frequently so they can be removed from the pharmacy when they are out of date.

Veterinary practice management systems software can be an invaluable aid in tracking expired items. When products are received, the earliest expiration date should be the one that is recorded in the computer system. Therefore, at the beginning of each month, the computer will reflect those products that expire first, and the ICM can print a list of the old drugs and quickly remove them from the pharmacy. As soon as the old products have been removed from the pharmacy shelves, the next earliest expiration date is recorded in the computer. Some pharmaceutical companies have policies that entitle the practice to free replacement of expired items. However, other vendors do not concur with this arrangement; therefore, the ICM must be able to distinguish which expired product will produce a free product refund and which will not. Some pharmaceutical companies prefer to credit the facility's account instead of sending replacement merchandise; others offer no reimbursement whatsoever for expired items.

It is hoped that pilferage will not occur in the veterinary facility. However, an effective inventory control system will deter employees who may elect to steal because they know that inventory is counted on a regular basis. Likewise, merchandise displayed (e.g., leashes, collars, shampoo, grooming brushes) in the reception area of a veterinary facility can be enticing to some clients who may decide to "pick up" an item instead of paying for it. This is another reason why proper inventory control plays an important role.

Keeping Accurate Records

An orderly way of keeping track of data regarding inventory should be employed. Most veterinary facilities in this age of computer technology use software designed especially for the veterinary business. Remember, when dealing with computers, the old adage—"garbage in, garbage out" ("GIGO")—can detract from the quality of information that a computer contains.
No order form may be issued for Schedules I and II substances unless a completed application form has been received (21 CFR 1305.08).

<table>
<thead>
<tr>
<th>TO: (Name of Supplier)</th>
<th>STREET ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CITY and STATE</td>
<td></td>
</tr>
</tbody>
</table>

**TO BE FILLED IN BY SUPPLIER**

<table>
<thead>
<tr>
<th>SUPPLIERS DEA REGISTRATION No.</th>
</tr>
</thead>
</table>

**TO BE FILLED IN BY PURCHASER**

<table>
<thead>
<tr>
<th>No. of Packages</th>
<th>Size of Package</th>
<th>Name of Item</th>
<th>National Drug Code</th>
<th>Packages Shipped</th>
<th>Date Shipped</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NO. OF LINES COMPLETED**

SIGNATURE OF PURCHASER OR HIS ATTORNEY OR AGENT

Date issued | DEA Registration No. | Name and Address of Registrant |
|-------------|----------------------|------------------------------|

Scheduled: 2, 2N, 3, 3N, 4, 5

Registered as: No. of this Order Form

PRACTITIONER

U.S. OFFICIAL ORDER FORMS - SCHEDULES I & II

DRUG ENFORCEMENT ADMINISTRATION

SUPPLIER’S COPY 1

**FIGURE 19-3**

An example of a U.S. Drug Enforcement Agency (DEA) form.
Hidden page
The Pharmaceutical Warehouse

PACKING LIST

Ship To:
All Pets Veterinary Hospital
1785 Lawrenceville Road
Lawrenceville, Georgia 37965

Bill To:
All Pets Veterinary Hospital
1785 Lawrenceville Road
Lawrenceville, Georgia 37965

<table>
<thead>
<tr>
<th>Customer Account Number</th>
<th>Ship To</th>
</tr>
</thead>
<tbody>
<tr>
<td>198531</td>
<td>Lawrenceville, Georgia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item Code</th>
<th>Unit/Size</th>
<th>Description/Strength</th>
<th>Quantity Ordered</th>
<th>Quantity Shipped</th>
<th>Item Status</th>
<th>Unit Price</th>
<th>Extension</th>
<th>Box No.</th>
<th>REM</th>
</tr>
</thead>
<tbody>
<tr>
<td>15637</td>
<td>18/box</td>
<td>Vetrap</td>
<td>3</td>
<td>3</td>
<td>Sent</td>
<td>$54.95</td>
<td>$164.85</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>15937</td>
<td>9/pack</td>
<td>Gauze bandage rolls</td>
<td>5</td>
<td>5</td>
<td>Sent</td>
<td>$25.65</td>
<td>$128.25</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>13465</td>
<td>Each</td>
<td>Roll Cotton</td>
<td>12</td>
<td>12</td>
<td>Sent</td>
<td>$3.50</td>
<td>$42.00</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 19-5**
A sample packing slip. (Some vendors do not record prices on their packing slips.)

**Inventory Records**

Many types of inventory records may be used in a veterinary facility. At least some of the following should be used, although some practices may elect to use them all.

A reorder log, sometimes called a “want book” (Figure 19-7), is an effective way to track products to be ordered. Each member of the veterinary staff can use this log to record items that should be ordered.

In a busy practice, this habit is of utmost importance because once supplies have been exhausted, obtaining interim product from the neighboring veterinary facility becomes an “emergency.” Afterward, the amounts borrowed must be replaced or paid for.

**Technician’s Notes**

The reorder point is the level reached that necessitates a product reorder.

It is the responsibility of the ICM to set the reorder point. If orders are placed each week, then a minimum of a 3-week supply should be kept in stock. Larger veterinary hospitals, emergency clinics, and colleges of veterinary medicine may require that inventory be ordered via a purchase order. A
Hidden page
Hidden page
An inventory master list provides endless quantities of information. Each veterinary practice should strive to keep a current list of all products in stock. An inventory master list provides information such as name of the product, item number code, usage, order status, and price. Some veterinary management software includes information regarding the seasonal use of products. One category in which this may be important is the area of flea and tick products. Today's computer software designed for veterinary business has the ability to reflect the months during which the greatest amount of product was sold. For instance, it may be that flea and tick shampoo is purchased more frequently during the months of March through September as compared with other times of the year. By using this information, the ICM can better predict how much merchandise should be ordered. The master list also reflects trade names, generic names, unit size, strength, name of the product's manufacturer, phone numbers, addresses, practice account numbers, order information, unit price, and a formula for calculating markup. (Some of these items are optional.)

### Technician's Notes

**Markup** is the amount of money (usually a percentage) over cost that an item is sold for.

There is a difference between cost and retail value. Cost is what the practice pays for an item. **Total cost** is the amount the item costs plus tax. The retail price is the amount the practice charges a client for an item. Retail price usually includes a profit margin (i.e., markup). Each practice has a way of figuring markup, and the percentages used may vary. A common way to figure total cost is to multiply the product's cost by the appropriate tax. When the total cost of an item is obtained and is multiplied by two, a 100% markup (i.e., retail price) is the result. This is illustrated below.

### Example:

Amoxicillin (100 mg, 100-count bottle) cost = $26.75
Tax (@ 10%) = .100
$26.75 × .100 = $2.675
$26.75 + $2.675 = $29.425

### To Find Retail Price @ 100% Markup:

Total cost of the item × 2 = Retail Price @ 100% markup
$29.43 × 2 = $58.86

Then: $58.86 divided by 100 tablets in the bottle = .5886 or $0.59 each

So, each tablet can be retailed for $0.59 (or $0.60 to make accounting easier).

### Reorder Quantity

When the reorder quantity is determined, a good idea is to set the amount equal to a 1-month supply. By ordering a 1-month supply of product, the ICM will not have to micromanage inventory. The reorder quantity can be posted on the computer's master inventory list.

### Rabies Vaccine

Records regarding rabies vaccine are very important. Each rabies certificate reflects the vaccine's expiration date and serial number (Figure 19-8). Therefore, the ICM must ensure that the certificates reflect those numbers by checking that the serial number and expiration date are posted correctly in the computer. This is not optional; it must be done.

### Organizing Inventory

**Pharmacy and ICM Office**

### Technician's Notes

A room in the veterinary facility that is set up to serve as the pharmacy office and the ICM office provides a place to organize catalogs, journals, magazines, and sales lists.
<table>
<thead>
<tr>
<th>Date of rabies vaccination</th>
<th>29 APR 03</th>
</tr>
</thead>
<tbody>
<tr>
<td>Next rabies vaccination on</td>
<td>29 APR 04</td>
</tr>
<tr>
<td>Certificate number</td>
<td>N/A</td>
</tr>
<tr>
<td>Previous rabies vaccination</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Best Veterinary Hospital**

**Taylor Lane, DVM**

621 Banner Street

Camden, Arkansas 71701

501-836-8390

**Owner's name**

**Best Veterinary Client**

**Owner's address**

1313 Schnauzer Lane

Camden, Arkansas 71701

**County of owner's residence**

Ouachita

__This is to certify...__

_That I have vaccinated against rabies the animal described below:_

**Patient Information & Signalment**

<table>
<thead>
<tr>
<th>Patient's name</th>
<th>Tangent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Canine</td>
</tr>
<tr>
<td>Breed</td>
<td>Mix</td>
</tr>
<tr>
<td>Gender</td>
<td>Male/Neutered</td>
</tr>
<tr>
<td>Color and markings</td>
<td>Brindle/White on chest</td>
</tr>
<tr>
<td>Tag number</td>
<td>N/A</td>
</tr>
<tr>
<td>Weight</td>
<td>101.4 lbs.</td>
</tr>
<tr>
<td>Age</td>
<td>2 years</td>
</tr>
</tbody>
</table>

**Signed:**

Taylor Lane, DVM

**Vaccinations administered:**

**Vaccines administered**

RV/DA2PP/CV/Bordetella

**Rabies Vaccine Information**

<table>
<thead>
<tr>
<th>Manufactured by</th>
<th>Pfizer Animal Health</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serial number</td>
<td>A232705A</td>
</tr>
<tr>
<td>Lot expiration date</td>
<td>26 AUG 03</td>
</tr>
<tr>
<td>Administration of vaccine</td>
<td>SC on right side</td>
</tr>
</tbody>
</table>

**Figure 19-8**

A sample rabies certificate.
Other items, such as DEA order records, Occupational Safety and Health Administration (OSHA) manuals, material safety data sheets (MSDSs), and suppliers’ catalogs, also can be stored in the pharmacy office.

**Organizing Inventory in the Veterinary Hospital**

The ideal situation for organizing inventory in the veterinary hospital is to establish a centrally located pharmacy area. In this manner, all pharmaceuticals can be counted easily.

**Technician’s Notes**

Inventory within the pharmacy area can be arranged in a variety of ways. The most common ways to arrange products are alphabetically, by therapeutic use, or by classification of the drug.

An easy way to organize inventory is to print the master inventory list and then stock products on the shelf in the same way that they are listed on the master list. In this way, when it is time to perform inventory, products are arranged on the pharmacy shelves in the same order they appear on the master inventory list—thereby enabling inventory to be carried out in a timely fashion.

**Staff Memos**

**Technician’s Notes**

The ICM should designate a bulletin board for memos to the veterinary staff.

Memos attached to a bulletin board can alert all hospital staff of company buyouts, discontinued items, and back-ordered items. Use of a bulletin board provides the ICM with freedom from frustrating interruptions by office staff concerning inventory questions. Additionally, this bulletin board is a good location for the reorder log (i.e., “want book”).

**Special Conditions**

Some special conditions must be recognized when one is arranging inventory. Products that require refrigeration have only a limited amount of storage space in the refrigerator. Care should be taken to avoid ordering too large a quantity of these items because the available amount of refrigeration may not be able to contain the order amount. DEA substances should be kept in a locked cabinet that has been bolted to the floor. The space within the cabinet should be considered before increased amounts of merchandise are ordered.

### Physical Inventory

**Monthly Inventory versus Rotating Inventory**

Deciding when and how often to perform this necessary function is the question. One effective method is to perform a rotating inventory. A rotating inventory necessitates the division of like products into categories. These categories are given a number of one through four. For example, each category designated as one is counted during the month of January. Each category designated as two is counted during the month of February; three is counted in March, and four in April. During the month of May, the inventory begins again, starting with those categories designated with number one. Thus, each category is counted three times a year (Figure 19-9). Although this may not be acceptable to all veterinary practice owners, it certainly can be an efficient way to perform a physical inventory. Many times, only one person is responsible for inventory control within the veterinary facility, and counting every item stocked in a practice may take a single person 1 to 2 days to complete. If inventory is done on a monthly basis (i.e., all items counted each month), the ICM cannot perform other nursing or technical skills on the day inventory is taken. When a rotating method is used, a smaller amount of inventory is counted each month, thus enabling the ICM to have time available to perform other job duties.

**Technician’s Notes**

Nothing is as effective as performing a physical inventory.
Hidden page
Some practice owners may require a monthly inventory count. However, performing inventory on a rotational 3- to 4-month cycle makes the ICM’s job easier. A veterinary technician may perform many functions in a veterinary practice; use of a rotating inventory ensures an accurate count and good use of the veterinary technician’s nursing skills.

In a busy veterinary facility, an ideal situation is to deal with as few suppliers as possible. The ICM will constantly be involved in an appointment with sales representatives if various vendors are used. Dealing with as few suppliers as possible releases the ICM to perform regular nursing and technical duties required by the facility. If sales reps are asked to make an appointment, the ICM will know when to expect a visit and can better prepare the normal work schedule around this visit. The ICM should ensure that sales representatives are aware of lunch breaks and quitting time; otherwise, they may just “pop in” to make a sale without considering the ICM’s schedule.

In dealing with pharmaceutical and supplier sales representatives, it is advantageous to be aware of several things. (Knowledge of the following information will make the ICM more effective in the responsibility of inventory maintenance.) Quantity and assortment discounts are ways that pharmaceutical companies can offer increased quantities of goods. Usually, the company will offer a discount for buying larger amounts, but several conditions must be considered by the ICM. First, how fast can amounts of the product sold in the practice be increased? Remember, time is money, and product left sitting in the pharmacy for extended periods will end up costing the practice money, even though the merchandise may have been bought at a discounted rate. Also, where will the overstock be stored? Does the practice have sufficient room to store increased quantities of product? Sometimes, quantity discounts are not what they appear to be.

Delayed billing is another feature that some pharmaceutical and supplier companies may offer. When discounts for quantity buying are offered to the veterinary practice, the statement often will reflect a delayed billing option (i.e., the statement does not have to be paid within the usual 30-day span). Instead, the option of paying within a 60- to 90-day period will extend the discount. Usually, no interest is charged the buyer, and the practice owner may be able to purchase increased amounts of stock at a reduced rate without the trial of coming up with funds to pay for it all within a 30-day limit. Consideration must still be given to whether or not there is sufficient room for storage of overstock and how soon the product can be sold.

When an order is placed, many companies waive the shipping fee if the veterinary practice orders a minimum amount of product. For example, if the minimum order amount is $250 per order, the ICM can save the practice shipping fees by ordering the minimum amount. Keep in mind that a shipping fee of $10 when multiplied over 10 orders adds up to $100. Shipping costs multiplied by 12 months could be used to buy other products instead of being spent on shipping fees.

Some pharmaceutical and supplier companies offer discounts for early payment. Veterinary practices can save money by paying the statement early. This too is a way to save the practice money. On the flip side, penalties may be imposed for statements paid after the 30-day time limit. The amount paid in penalties can also buy product instead of being spent on late fees. Every practice should endeavor to pay within 30 days.

The ICM should be familiar with each vendor’s return policy. Items that are expired may have to be returned, along with any item that is not selling well. Some vendors will allow product to be returned and will credit the practice’s account accordingly. Items that have expired may be picked up by a sales representative and replaced. It should be noted that expired controlled substances cannot be picked up by the sales representative for return to the pharmaceutical company.

Incoming Freight
The inventory control manager must be alert to possible damage incurred to freight during shipping.
Technician's Notes
At the time freight is being unloaded at the veterinary facility, the ICM should visually check for damage by noting any boxes that are not intact. Wetness to the cardboard container may indicate breakage of the contents, and boxes should be counted and the number compared with the number of containers listed on the packing slip.

As soon as freight arrives, it should be opened and any damage should be noted. Evidence of damage should be reported to the vendor as soon as possible so that credit can be received and/or damaged items replaced. Some companies have a 24-hour reporting period (i.e., all damaged items must be reported within 24 hours of arrival time). Damaged goods should be returned to the vendor from which they were ordered, in the original shipping carton with the damaged goods inside. In this way, the vendor can assess the damage and correctly apply credit to the veterinary facility's account.

FOB Rules and Shipment Contracts
A vendor delivers freight to the purchaser. The veterinary facility may make an order with a telephone representative, send or fax a purchase order, or make an order with the sales representative during his or her appointment at the veterinary facility. A shipment contract is one in which the seller turns the goods over to a carrier for delivery to the buyer. The seller has no responsibility for seeing that the goods reach their destination. In a shipment contract, both title and risk of loss pass to the buyer when the goods are given to the carrier. Shipment contracts are often designated by the term FOB Place of Shipment (such as FOB Camden, Arkansas). When goods are sent FOB (free on board) followed by place of shipment, they will be delivered free to the place of shipment. The buyer must pay all shipping charges from there to the place of destination. The terms indicate that title to the goods and risk of loss pass at the point of origin. Delivery to the carrier by the seller and acceptance by the carrier complete the transfer of both title and risk of loss. Therefore, the buyer accepts full responsibility during the transit of goods (Brown and Sukys, 2006).

A vendor uses a form of transportation to send required items to the veterinary hospital (e.g., UPS [United Parcel Service], Averitt Express, Federal Express, U.S. Postal Service). Once the vendor releases freight to the carrier, the freight becomes subject to two FOB rules: FOB destination and FOB shipping point.

Technician's Notes
Vendors place different terms of delivery on freight that is leaving a pharmacy/hospital. Basically, FOB rules state which business (vendor or buyer) has the title to freight and who will be responsible in cases of loss of freight when the vendor uses outside transportation companies to deliver goods. FOB destination means that the title of ownership (freight) is being passed from the vendor to the purchaser, and said freight becomes the property of the purchaser when the shipment is delivered to the veterinary hospital. FOB shipping point means that the title of ownership (freight) passes from the vendor to the purchaser when the vendor places the goods in possession of a carrier. FOB shipping point requires the purchaser to determine what responsibility the carrier will take if damage or loss occurs to freight. The ICM should realize that shipments can be refused (not signed for) upon delivery. In such cases, if the ICM deems that damage has or may have occurred because of the condition of the shipping container, the shipment may be refused, in which case the carrier will send the goods back to the vendor.

Receiving Freight

Technician's Notes
It is best to allow the person who placed the order to unpack the freight once the order has been received.

If the order is incorrect, the person who placed the order will know it immediately, whereas a person unpacking freight who did not place the order will not know what is correct. Several important
questions should be asked when one is unpacking an order, such as “Did I get exactly what I ordered?”; “Did I get the right drug form (i.e., capsules, tablets, or powder)?”; “Did I receive the correct size and/or strength?”; “Is the product’s expiration date a long way into the future?”; “Does the invoice list the price I was quoted by the phone rep, or sales rep?”; “Does this order cost more than the last order of the same items?”; “Has everything been ordered, and if so, when will that item be shipped?”; “Is any freight damaged or missing?”; and “Is the order correct, and if so, can the bill be paid?” (Luken and Landau, 1993). By asking all these questions, the ICM is assured that the veterinary facility will be treated fairly by the vendor.

**Stocking Shelves**

When stock is rotated in this manner, the facility is assured that the product is sold or used by the hospital before the expiration date. When stocking shelves, it is good to record expiration dates. The earliest date should be the one recorded in the computer so the software will present an accurate list of expired items when the command is given to print an expired items list. Stocking shelves also presents a convenient time to dust and wipe off labels and lids on products that have been sitting on the shelf for extended periods. It should be noted that after cleaning, products should be replaced in specific locations to facilitate accurate inventory.

**Vendors**

Several different types of vendors may be used. The ICM must have adequate knowledge of these types to correctly place an order. Some vendors allow ordering by phone; others require that the order be given to a sales rep. Still others require a faxed order or an order sent through the mail.

**Full-service companies** are those that send a sales rep to visit the veterinary facility and offer full service. A technical staff, usually made up of veterinarians, is employed. Full-service companies usually carry a limited product line. Some products may be newly developed products that still retain a patent with the federal government and cannot be ordered through a distributorship. A full-service company has sales reps who call on the veterinary hospital and take orders. Most full-service companies will replace outdated product with new or will credit the hospital’s account accordingly.

**Technician’s Notes**

The sales rep may not pick up expired controlled substances; these must be mailed back to the company.

A full-service company may have several “deals” that the ICM must decide to accept or decline. Examples of full-service companies include Pfizer Animal Health, Pharmacia-Upjohn, Schering Animal Health, and Fort Dodge Animal Health. These companies employ veterinarians as technical support staff, and their product lines are often limited as compared with distributorships. However, full-service companies are forerunners in the development of new drugs protected under U.S. patent laws, in which case they may not be sold under a generic name until the patent expires.

**Mail order discount houses** provide a good source for ordering items such as gauze, syringes, needles, paper towels, paper drapes, and even isopropyl alcohol. Ordering from this type of vendor occurs over the telephone because most do not employ sales reps to visit the hospital, although catalogs may be supplied and mailed to the buyer.

**Veterinary supply distributors** provide the most common way of acquiring supplies for the veterinary facility. A distributor is an intermediate between a full-service company and the mail order discount house. If a full-service company gives its approval and a contract is signed between two companies, some products normally sold only through a full-service company may be obtained from a distributor. Many times, products sold by the full-service company to the distributor are those with a patent about to expire.
Hidden page
added to amounts already posted in the computer. Bar coding is available on most pharmaceutic products. Using a device capable of reading bar codes greatly enhances the counting and maintaining of inventory.

Additionally, most software can be used to produce automatic expiration lists from computer files each month. The total amount of money spent on inventory in a day, week, month, or year can be obtained when computer software systems are used.

**The Job of ICM**

It cannot be overemphasized how important inventory control is to the veterinary facility. The veterinary technician who is willing to take on this added responsibility will find himself or herself an invaluable member of the staff. Keeping in mind that inventory is the second-highest expense for the veterinary hospital will enable the ICM to use care when considering sales offers. Understanding the practice’s mission is crucial in inventory control. Remember, time is money, and product left sitting on the shelf for extended periods does not benefit the facility. Keeping a turnover of at least four turns per year is a minimum goal. Training a backup person to monitor inventory during times of vacation or sickness experienced by the ICM is crucial. Reminding employees during staff meetings of the importance of “GIGO” and documenting outages on the reorder log will enable the facility to never run out of needed product. DEA products must be controlled by effective documentation of their use in a log book kept solely for this purpose (e.g., controlled substance log book).

Establishing a formula for markup is critical. The way inventory is arranged within the pharmacy has a great deal to do with the ease of counting it. No better method of counting inventory can replace doing a physical inventory. Keep sales reps abreast of lunch breaks and leaving times. Carefully observe all freight for damage, and report claims as soon as possible after receiving the product. Always rotate product on shelves so that the oldest product is sold first. Be knowledgeable about the different types of vendors. Decide which method of inventory counting is most advantageous to your particular situation by deciding whether to count all inventory monthly or on a rotating basis. Keep a good relationship with a local pharmacy because these businesses serve as a good source of knowledge and enable the veterinarian to order human products not normally sold through veterinary vendors. Decide whether a manual or a computerized system is best for your facility. In this age of technology, it is best to use a computer system to facilitate efficient work flow.

**REFERENCES**

McAllister Software Systems: AVI-Mark Veterinary Software System, Piedmont, Mo: avimark@semo.net
REVIEW QUESTIONS

1. What is inventory?

2. Name the five principles used to control expenses:
   a. ____________________________
   b. ____________________________
   c. ____________________________
   d. ____________________________
   e. ____________________________

3. When dealing with inventory, it is crucial to remember that time is
   ____________________________.

4. What is turnover?

5. Calculate the turnover rate by using the following information: Yearly inventory expense
   = $125,000; average cost of inventory on hand = $31,250.

6. Calculate the average cost of inventory on hand by using the following information:
   Year's beginning inventory = $75,000; year's ending inventory = $130,000.

7. Name two objectives of an inventory control system.
   a. ____________________________
   b. ____________________________

8. What is a packing slip?

9. What is an invoice?

10. What is a statement?

11. What is the reorder point?

12. Why is recording the expiration date and serial number for rabies vaccine so important?

13. Once the reorder point is reached, a basic rule of thumb is to order a
    ____________________________-month supply.

14. Name some materials that may be kept in the pharmacy library.

15. List some rules for filling out a DEA form.
   a. ____________________________
   b. ____________________________
   c. ____________________________
   d. ____________________________
   e. ____________________________
   f. ____________________________

16. Time = Money.
   a. True
   b. False

17. A mean turnover rate of _____ is acceptable for most veterinary practices.
   a. 12
   b. 4
   c. 2
   d. 8

18. Inventory should be placed on pharmacy shelves in such a way so as to ensure _____.
   a. LILO
   b. FIFO
   c. FOB
   d. ICM

19. DEA forms are issued by _____.
   a. state governments
   b. county governments
   c. city governments
   d. the federal government

20. An item may be placed on back order just because the pharmaceutic company is changing
    the color of the drug's label.
   a. True
   b. False

21. The price a veterinary hospital pays for an item is known as _____, and the amount the
    hospital sells the item to a client for is known as _____ price.
   a. retail; cost
   b. cost; retail
22. The expiration date and the serial number of rabies vaccine administered must be recorded on each pet's rabies certificate.
   a. True
   b. False

23. Delayed billing has no perks for a veterinary practice owner.
   a. True
   b. False

24. When a shipment arrives at a veterinary hospital, if the delivery carton appears to be damaged, the ICM does not have to accept the shipment from the carrier.
   a. True
   b. False

25. When a DEA form is used to order a controlled substance, it is acceptable to draw a line through a misspelled word and then write it correctly beside the mistake.
   a. True
   b. False
Hidden page
Hidden page
Hidden page
Hidden page
## Drug Information Resources

<table>
<thead>
<tr>
<th>Subject</th>
<th>Phone Number</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse drug reactions</td>
<td>888-FDA-VETS</td>
<td><a href="http://www.fda.gov/cvm">www.fda.gov/cvm</a></td>
</tr>
<tr>
<td>Associations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>American Academy of Veterinary Consultants</td>
<td></td>
<td><a href="http://tpvec.unl.edu/public/avc.avc.htm">tpvec.unl.edu/public/avc.avc.htm</a></td>
</tr>
<tr>
<td>American Academy of Veterinary Pharmacology and Therapeutics</td>
<td></td>
<td><a href="http://www.aavpt.org">www.aavpt.org</a></td>
</tr>
<tr>
<td>American Animal Hospital Association</td>
<td></td>
<td><a href="http://www.aahanet.org">www.aahanet.org</a></td>
</tr>
<tr>
<td>American College of Veterinary Clinical Pharmacology</td>
<td></td>
<td><a href="http://www.acvcp.org/">www.acvcp.org/</a></td>
</tr>
<tr>
<td>American Veterinary Medical Association</td>
<td>800-248-2862</td>
<td><a href="http://www.avma.org">www.avma.org</a></td>
</tr>
<tr>
<td>Governmental agencies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Enforcement Agency Office of Diversion Control, Registration Section</td>
<td>800-238-7332</td>
<td><a href="http://www.usdoj.gov/dea">www.usdoj.gov/dea</a></td>
</tr>
<tr>
<td>Food and Drug Administration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Center for Veterinary Medicine</td>
<td>301-594-1755</td>
<td><a href="http://www.fda.cvm">www.fda.cvm</a></td>
</tr>
<tr>
<td>Office of Management and Communications</td>
<td>301-594-1752</td>
<td></td>
</tr>
<tr>
<td>Office of New Animal Drug Evaluation</td>
<td>301-594-1620</td>
<td></td>
</tr>
<tr>
<td>Office of Surveillance and Compliance</td>
<td>301-827-6644</td>
<td></td>
</tr>
<tr>
<td>Office of Research</td>
<td>301-827-8010</td>
<td></td>
</tr>
<tr>
<td>Communications Staff</td>
<td>301-827-6514</td>
<td></td>
</tr>
<tr>
<td>United States Department of Agriculture</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal and Plant Health Inspection Service</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Center for Epidemiology and Animal Health</td>
<td>800-545-8732</td>
<td><a href="http://www.aphis.usda.gov">voice response only</a></td>
</tr>
<tr>
<td>Center for Health Monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interstate Shipping</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Center for Animal Health Monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occupational Safety and Health Administration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veterinary Information Network (subscriptions)</td>
<td>800-700-4636</td>
<td></td>
</tr>
<tr>
<td>Compounding and compounding pharmacies</td>
<td>800-331-2498</td>
<td></td>
</tr>
<tr>
<td>Professional Compounding Centers of America</td>
<td></td>
<td><a href="http://www.pccarx.com/">www.pccarx.com/</a></td>
</tr>
<tr>
<td>Formularies and drug databases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibiotics: Medical College of Wisconsin</td>
<td></td>
<td><a href="http://www.intmed.mcw.edu/">www.intmed.mcw.edu/</a> AntibioticGuide.html</td>
</tr>
<tr>
<td>Internet Drug Index RxList</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formulary Medical College of Wisconsin</td>
<td></td>
<td><a href="http://www.mosby.com/Mosby/phyGenRx/">www.mosby.com/Mosby/phyGenRx/</a></td>
</tr>
<tr>
<td>Physicians GenRx (by subscription only)</td>
<td></td>
<td><a href="http://www.meds.com/Dchief.html">www.meds.com/Dchief.html</a></td>
</tr>
<tr>
<td>DoseCalc Online (dose calculations)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health sciences of information gateway sites</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal Health Institute</td>
<td></td>
<td><a href="http://www.ahip.org">www.ahip.org</a></td>
</tr>
<tr>
<td>WWW Virtual Library: Pharmacy</td>
<td></td>
<td><a href="http://www.pharmacy.org/">www.pharmacy.org/</a></td>
</tr>
<tr>
<td>Poisoning antidotes ($50 consultation fee)</td>
<td>888-426-4435</td>
<td><a href="http://www.aspca.org/apcc">www.aspca.org/apcc</a></td>
</tr>
<tr>
<td>Research information</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Appendix C Resource Information

**Veterinary Pharmaceutical Companies, Distributors, and Other Important Numbers**

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Telephone</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories</td>
<td>888-299-7416</td>
<td><a href="http://www.abbott.com">www.abbott.com</a></td>
</tr>
<tr>
<td>AgriPharm/Dealer Distribution of America</td>
<td>901-366-4442</td>
<td></td>
</tr>
<tr>
<td>Alpharma, Inc. Animal Health Division</td>
<td>201-228-5074</td>
<td><a href="http://www.alpharma.com">www.alpharma.com</a></td>
</tr>
<tr>
<td>Animal Blood Bank</td>
<td>800-243-5759</td>
<td></td>
</tr>
<tr>
<td>Aspen Veterinary Resources, Ltd.</td>
<td>816-413-1444</td>
<td></td>
</tr>
<tr>
<td>Bayer Corp. Agriculture Division, Animal Health</td>
<td>800-633-3796</td>
<td><a href="http://www.bayerus.com/ah">www.bayerus.com/ah</a></td>
</tr>
<tr>
<td>Biopure Corp.</td>
<td>617-234-6500</td>
<td><a href="http://www.biopure.com">www.biopure.com</a></td>
</tr>
<tr>
<td>Boehringer Ingelheim Vetmedica, Inc.</td>
<td>800-821-7467</td>
<td><a href="http://www.bi-vetmedica.com">www.bi-vetmedica.com</a></td>
</tr>
<tr>
<td>Bowie Cattle City Calf Jack</td>
<td>800-831-0960</td>
<td></td>
</tr>
<tr>
<td>The Butler Co.</td>
<td>614-761-9095</td>
<td><a href="http://www.wabutler.com">www.wabutler.com</a></td>
</tr>
<tr>
<td>C.E. Kord Animal Disease Laboratory</td>
<td>615-360-0125</td>
<td></td>
</tr>
<tr>
<td>Columbus Serum Co.</td>
<td>800-848-1090</td>
<td><a href="http://www.durvet.com">www.durvet.com</a></td>
</tr>
<tr>
<td>Durvet, Inc.</td>
<td>816-229-9101</td>
<td></td>
</tr>
<tr>
<td>DVM Pharmaceuticals, Inc.</td>
<td>800-367-4902</td>
<td><a href="http://www.DVMPharmaceuticals.com">www.DVMPharmaceuticals.com</a></td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>800-428-4441</td>
<td><a href="http://www.elanco.com">www.elanco.com</a></td>
</tr>
<tr>
<td>EVSCO Pharmaceuticals</td>
<td>856-691-2411</td>
<td><a href="http://www.evscopharm.com">www.evscopharm.com</a></td>
</tr>
<tr>
<td>Fort Dodge Animal Health</td>
<td>800-533-8356</td>
<td><a href="http://www.ahp.com/fortdodge.htm">www.ahp.com/fortdodge.htm</a></td>
</tr>
<tr>
<td>G.C. Hanford Manufacturing Co.</td>
<td>800-234-4263</td>
<td><a href="http://www.hanford.com">www.hanford.com</a></td>
</tr>
<tr>
<td>Halocarbon Laboratories</td>
<td>800-338-5803</td>
<td><a href="http://www.halocarbon.com">www.halocarbon.com</a></td>
</tr>
<tr>
<td>Heska Corp.</td>
<td>800-CO-HESKA</td>
<td><a href="http://www.heska.com">www.heska.com</a></td>
</tr>
<tr>
<td>Hills Pet Nutrition, Inc.</td>
<td>800-354-4557</td>
<td></td>
</tr>
<tr>
<td>IDEXX Laboratories, Inc.</td>
<td>800-248-2483</td>
<td></td>
</tr>
<tr>
<td>Intervet Inc.</td>
<td>800-247-4838</td>
<td></td>
</tr>
<tr>
<td>Lloyd Laboratories, Inc.</td>
<td>800-831-0004</td>
<td><a href="http://www.lloydinc.com">www.lloydinc.com</a></td>
</tr>
<tr>
<td>Luitpold Pharmaceuticals, Inc.</td>
<td>800-458-0163</td>
<td><a href="http://www.luitpold.com">www.luitpold.com</a></td>
</tr>
<tr>
<td>Merial, Ltd.</td>
<td>888-637-4251</td>
<td><a href="http://www.merial.com">www.merial.com</a></td>
</tr>
<tr>
<td>Merritt Veterinary Supplies, Inc.</td>
<td>800-972-4744</td>
<td></td>
</tr>
<tr>
<td>Nasco West</td>
<td>800-558-9595</td>
<td></td>
</tr>
<tr>
<td>Neogen Corp.</td>
<td>800-525-2022</td>
<td><a href="http://www.neogen.com">www.neogen.com</a></td>
</tr>
<tr>
<td>Novartis Animal Health US, Inc.</td>
<td>800-332-2761</td>
<td><a href="http://www.ah.novartis.com">www.ah.novartis.com</a></td>
</tr>
<tr>
<td>Orthopedic Foundation for Animals (OFA)</td>
<td>573-442-0418</td>
<td><a href="http://www.Offa.org">www.Offa.org</a></td>
</tr>
<tr>
<td>Pet-Ag, Inc.</td>
<td>800-323-6878</td>
<td><a href="http://www.petag.com">www.petag.com</a></td>
</tr>
<tr>
<td>Pfizer Animal Health</td>
<td>800-793-0596</td>
<td><a href="http://www.pfizer.com/ah">www.pfizer.com/ah</a></td>
</tr>
<tr>
<td>Phoenix Pharmaceutical, Inc.</td>
<td>800-759-3644</td>
<td><a href="http://www.phoenixpharmaceutical.com">www.phoenixpharmaceutical.com</a></td>
</tr>
<tr>
<td>Phoenix Scientific, Inc.</td>
<td>816-364-3777</td>
<td></td>
</tr>
<tr>
<td>PRN Pharmacal</td>
<td>800-874-9764</td>
<td></td>
</tr>
<tr>
<td>Schering-Plough Animal Health Corp.</td>
<td>800-648-2118</td>
<td><a href="http://www.sp-animalhealth.com">www.sp-animalhealth.com</a></td>
</tr>
<tr>
<td>Sunbelt Veterinary Supply</td>
<td>800-476-4343</td>
<td><a href="http://www.vedco.com/dvmonly/">www.vedco.com/dvmonly/</a></td>
</tr>
<tr>
<td>Vedco, Inc.</td>
<td>816-238-8840</td>
<td><a href="http://www.vedco.com/ldly/">www.vedco.com/ldly/</a></td>
</tr>
<tr>
<td>Vet-A-Mix, a division of Lloyd, Inc.</td>
<td>800-831-0004</td>
<td><a href="http://www.lloydinc.com">www.lloydinc.com</a></td>
</tr>
<tr>
<td>Veterinary Products</td>
<td>800-720-0032</td>
<td><a href="http://www.vpl.com">www.vpl.com</a></td>
</tr>
<tr>
<td>Laboratories</td>
<td>ext. 2158, 2283, or 2284</td>
<td><a href="http://www.burnsvet.com">www.burnsvet.com</a></td>
</tr>
<tr>
<td>Vetus Animal Health</td>
<td>800-92-BURNS</td>
<td></td>
</tr>
<tr>
<td>Vortech Pharmaceuticals, Ltd.</td>
<td>800-521-4686</td>
<td></td>
</tr>
<tr>
<td>Webster Veterinary Supply</td>
<td>800-225-7911</td>
<td></td>
</tr>
<tr>
<td>Wildlife Pharmaceuticals, Inc.</td>
<td>970-484-6267</td>
<td><a href="http://www.wildpharm.com">www.wildpharm.com</a></td>
</tr>
<tr>
<td>Zinpro Corp.</td>
<td>800-445-6145</td>
<td><a href="http://www.zinpro.com">www.zinpro.com</a></td>
</tr>
</tbody>
</table>
Hidden page
APPENDIX D

Controlled Substances Information Summary
Drugs that have been determined to have potential for abuse by people are classified as controlled substances. Controlled substances are regulated through the efforts of the U.S. Drug Enforcement Agency (DEA), which enforces the regulations of the Controlled Substances Act (CSA) and the DEA regulations of Title 21, Code of Federal Regulations (CFR), Parts 1300 to 1316. Much valuable information related to the CSA and the CFR is available online at www.deadiversion.usdoj.gov.

Information that may be found at the DEA Diversion website includes but is not limited to the following:

- Applications and online forms, including Form 106, Report of Theft and Loss of Controlled Substances
- A complete list of controlled substances and the schedule of each
- A list of Drugs and Chemicals of Concern that includes both controlled and noncontrolled drugs (e.g., Tramadol) whose abuse potential concerns the DEA
- Information about proposed or new regulations under the CFR
- Offices and Directories, including a list of DEA offices and officials throughout the United States
- A Practitioner's Manual that summarizes much of the CSA and CFR

### Schedules of Controlled Substances

Drugs that are under the control of the Controlled Substances Act are placed into five schedules, or classes, according to their potential for abuse. This schedule is designated by a “C” with a Roman numeral (I, II, III, IV, or V) inside the C.

Schedule I substances have no (or controversial) accepted medical use and a high potential for abuse. LSD (lysergic acid diethylamide), heroin, crack cocaine, marijuana, and peyote are substances in this class. The use of medicinal marijuana in human medicine is controversial but may be permitted in some states.

Schedule II drugs have accepted medical uses but have a high potential for abuse. A partial list of schedule II drugs includes morphine, meperidine, codeine, cocaine, oxymorphone, amphetamines, and pentobarbital. Orders for schedule II drugs must be made on DEA Form 222 (see Figure 19-3). Schedule III substances have less potential for abuse than those in schedule II and include Hydromorphone, paregoric, barbiturates such as thiamylal or thiopental, and anabolic steroids.

Schedule IV drugs have lower abuse potential than those in schedule III. Included in this class are phenobarbital, diazepam, and pentazocine.

Schedule V drugs are the lowest on the scale of abuse potential and include mostly antidiarrheal and antitussive medications. Lomotil and Robitussin with codeine are in this schedule.

### REGISTRATION REQUIREMENTS

Every person or entity that handles controlled substances must be registered with the DEA or be exempt under the regulations. DEA registration gives practitioners the authority to handle controlled substances. The DEA-registered practitioner may engage only in those activities that are allowed under state law in the state in which the practice is located. In some cases, state law is more stringent than federal law. In all cases, the most stringent regulation takes precedence. To obtain DEA registration, a practitioner must apply using DEA Form 224, which can be submitted as hard copy or online.

A practitioner must be registered with the DEA in each state where controlled substances are prescribed, administered, or dispensed. Also, a separate registration is required for each place of business or practice where controlled substances are stored or dispensed. An exemption is made that allows affiliated (employee) veterinarians to act on behalf of registered veterinarians to administer or dispense controlled substances. The affiliated practitioner cannot write prescriptions under this exemption and may need state registration.

The person who holds the registration must keep the information on the registration certificate current. A letter of request must be made to alter the
name or address, or to approve a change in schedule on the certificate. A DEA modification must be issued before applications related to the request may be carried out by the registrant. Registrations must be renewed every 3 years.

**SECURITY REQUIREMENTS**

CFR regulations require that all registrants provide effective measures and procedures to guard against theft or diversion of controlled substances. The *DEA Practitioner's Manual* lists several factors that may be used to determine the adequacy of security measures. Those factors include the following:

- Location of the premises
- Type of building and its construction
- Type and quantity of controlled substances kept on the premises
- Type of storage container
- Control of public access to the facility
- Adequacy of premise monitoring systems
- Availability of police protection

Regulations require that schedule II through V controlled substances be stored in a "securely locked, substantially constructed cabinet." If the registrant stores carfentanil, etorphine, and/or diprenorphine, a safe or steel cabinet equivalent to a U.S. Government Class V security container (General Services Administration specifications) must be used.

Regulations state that a registrant should limit access to controlled substances according to the following guidelines. Access should be denied to the following:

- Any person convicted of a felony related to a controlled substance
- Any person denied a DEA registration
- Any person who has had a DEA registration revoked
- Any person who has surrendered a DEA license for cause

Registrants must notify the DEA of any theft or "significant loss" of controlled substances using DEA Form 106 as soon as the theft or loss is discovered.

**RECORD-KEEPING REQUIREMENTS**

Registrants under the CSA must maintain specific records. The Practitioner's Manual states that records, inventories, and records of substances in schedules I and II must be maintained separately from all other records. It further states that records of substances in schedules III, IV, and V must be maintained separately or on a form that is readily retrievable from ordinary business records of the practitioner. So, the registrant must have two separate sets of records for controlled substances. The records for schedules III, IV, and V can be kept with records for noncontrolled substances if they can be easily retrieved. Schedule II records are usually kept in a controlled substances log, and schedule III, IV, and V drugs are kept in a controlled substances log and/or in a computer inventory system. The American Animal Hospital Association publishes a controlled substances log for purchase that may avoid pitfalls of hospital/clinic-constructed logs. Entries in the log should be made in ink with great care, and mistakes should be marked through, corrected, and initialed.

Each registrant must maintain a "complete and accurate record of the controlled substances on hand and date the inventory was conducted." This record must be in written, typewritten, or printed form and maintained at the registration location for 2 years. After the first inventory is taken, a new inventory must be carried out every 2 years. Regulations state that each inventory must contain the following information:

- Whether the inventory was taken at the beginning or the end of the business day
- Names of the controlled substances
- Each form of the controlled substances (e.g., 50-mg tablet)
- Number of dosage units in each container (e.g., 100-tablet bottles)
- Number of commercial containers of each form (e.g., two 100-tablet bottles)
- Disposition of the controlled substances
- Name, address, and DEA registration number of the registrant
- Signature of the person performing the inventory
Hidden page
Hidden page
Hidden page
McAllister P: McAllister Software Systems: AVI-Mark Veterinary Software System, Piedmont, Mo, avimark@semo.net.
Shall EA: Psychopharmacology in veterinary behavioral medicine, Annual Conference for Veterinarians and Technicians, Knoxville, Tenn, 1998, UT-CVM.
Tilley LP, Smith WK: The 5-minute veterinary consult canine and feline, ed 2, Baltimore, 2000, Lippincott Williams & Wilkins.
Upson DW: Handbook of clinical veterinary pharmacology, ed 4, Manhattan, Kan, 1988, Dan Upson Enterprises.
Williams BR, Baer C, editors: Essentials of clinical pharmacology in nursing, Springhouse, Pa, 1990, Springhouse Corp.
This page intentionally left blank
Hidden page
ANSWERS TO CHAPTER 1

1. a. An agonist is a drug that has affinity for a receptor and stimulates the receptor to action.
   b. A contraindication is a reason not to use a drug in a particular situation.
   c. Efficacy is the degree to which a drug produces its desired effects in a patient.
   d. An over-the-counter drug is one that may be purchased and used without a prescription from a veterinarian.
   e. A prescription drug is one that must be used under the supervision of a veterinarian.
   f. A receptor is a group of specialized molecules on or in a cell that bind with a drug to produce an effect.
   g. The therapeutic index expresses the relationship between a drug’s therapeutic and harmful effects.
   h. The withdrawal time is the amount of time that must elapse between the end of drug therapy and the elimination of that drug from the patient’s tissues or products.
   i. The veterinarian-client-patient relationship is the relationship that must exist between the veterinarian, his or her patient, and the patient’s owner before prescription drugs may be dispensed.

2. Four sources for veterinary drugs are animal products, plant materials, minerals, and synthetic products.

3. A drug regimen includes the dose, the route of administration, the frequency of administration, and the duration of administration.

4. For a valid veterinarian-client-patient relationship to exist, (1) the veterinarian must assume responsibility for making clinical judgments in relation to the health of the animal, (2) the veterinarian must have recently seen the animal and be acquainted with its care, and (3) the veterinarian must be available for follow-up care of the animal.

5. It is a technician’s responsibility to carry out the veterinarian’s orders correctly. The technician should read the drug label three times to ensure that the proper drug is being administered and should take care to administer the correct dose by the correct route. The technician should also be aware of the expected effects and the potential adverse side effects to be able to monitor the patient in a responsible way. In a large animal practice, the technician should be aware of withdrawal times and potential residue problems.

6. A drug is first absorbed (or directly placed) into the bloodstream. In the blood, the drug may bind with a plasma protein or may exist in the free state. The circulating blood distributes the drug to the capillary level, where the drug leaves the circulation and enters the interstitial fluid. The interstitial fluid bathes the cell and allows the drug to enter the cell or bind with surface receptors. The drug then exits the cell (or its surface), moves back into the interstitial fluid, reenters the circulation, and is transported to the liver for metabolism. After it is metabolized, the metabolite is transported to the kidneys for excretion.

7. (1) The oral route provides a simple route of administration. Many factors may influence the rate of absorption, and the oral route may not be appropriate if the animal is vomiting.
   (2) Subcutaneous administration of drugs is usually a simple procedure. Absorption from subcutaneous sites may be slow, and hypertonic solutions should not be given by this route.
   (3) The intramuscular route produces faster absorption than the subcutaneous route, but care must be taken with many drugs not to inject them into blood vessels.
   (4) The intravenous route allows immediate access to the bloodstream and the dilution of irritating drugs. A toxic or allergic reaction can be a side effect.
   (5) The intraperitoneal route may be used to administer fluids and some other solutions when other routes are not available. Absorption from the peritoneal cavity is slow, however.
   (6) The intraarterial route is a seldom used route that may produce seizures or death.
(7) The intracardiac route is used primarily for administering emergency drugs or for euthanasia.

(8) The intramedullary route may be used to administer fluids or blood to small animals or those with damaged veins.

(9) The inhalation route is used to administer drugs to the respiratory system. Special equipment may be required.

(10) The topical route may be used to place drugs on skin or mucous membranes and may be facilitated by the use of carrier substances in some instances.

(11) The intradermal route is used primarily for allergy testing and for diagnosing tuberculosis.

8. The absorption of a drug may be influenced by (1) the method of absorption, (2) the pH of the drug and its ionization status, (3) the absorptive surface area, (4) the blood supply to the area, (5) the solubility of the drug, (6) the dosage form, (7) the status of the gastrointestinal tract, and (8) interactions with other drugs.

9. b. Liver

10. a. Kidneys

11. Receptors

12. Proprietary/trade

13. The six items that must be on a drug label are the drug names (generic and trade), the drug concentration and quantity, the name and address of the manufacturer, the controlled substance status, the manufacturer's control or lot number, and the drug's expiration date.

14. The government agencies that regulate the development, approval, and use of animal health products are the FDA, EPA, and USDA.

15. Many veterinary clinics dispense rather than prescribe drugs because of the profit earned from selling the products.

16. Veterinary pharmaceuticals may be purchased directly from the manufacturer, from distributors, or from generic mail order companies. In some instances, drugs may be sold under one label to graduate veterinarians and under another as an over-the-counter product.

17. The Green Book

18. FARAD provides resources concerning the avoidance of drug residues in animals.

19. AMDUCA (Animal Medicinal Drug Use Clarification Act)

20. Compounding refers to the diluting or combining of existing drugs.

21. Drug residues in animal products may cause allergic reactions or neoplasia in people, and they may cause the development of antibiotic-resistant strains of bacteria.

22. Pharmacodynamic, pharmacokinetic, and pharmaceutic

23. Liver

24. An "ethical" product is one sold only through veterinarians as a policy of the manufacturer rather than by FDA requirement.

25. Metabolite

26. b. indication

27. a. practical experience

28. b. using a drug in a way not specified by the label

29. a. The veterinarian has seen and treated all the client's pets except a dog for which the owner would like to buy heartworm preventive.

30. c. pharmacokinetics

31. b. by injection

32. b. metabolism (biotransformation)

33. c. efficacy

34. b. false

35. c. AVMA

ANSWERS TO CHAPTER 2

1. Drugs for oral administration, drugs for parenteral administration, drugs for inhalation, drugs for topical administration

2. Large; balling gun

3. Injections, implants

4. Single-, multi-

5. Sharps container

6. Right patient, right drug, right dose, right route, right time and frequency

7. Vomiting

8. Rapid
9. 72
10. Large
11. Date, owner’s name, patient’s name, drug name, amount dispensed or administered, name(s) of personnel administering the drug to the patient
12. The plastic syringe may absorb the drug, which may cause it to be less effective.
13. Luer-lok, slip-tip, eccentric, catheter-tip
14. 1
15. Insulin syringe
16. d. counterirritant
17. c. suspension
18. d. Luer-lok tip
19. b. carotid artery
20. d. 72
21. c. 8; 12
22. b. ear
23. b 15; 30
24. d. 24; 48
25. d. both b and c

ANSWERS TO CHAPTER 3

Ratios
1. 1:4; 0.25
2. 75:100; \(\frac{75}{100}\)
3. 4:1000; \(\frac{4}{1000}\)
4. \(\frac{1}{80}\); 0.0125
5. 9:1000; 0.009
6. \(\frac{1}{32}\); 0.031

Proportions
1. 50
2. 8
3. 2.5
4. 5
5. 200 mg
6. 37.5 mg
7. 31.25 mg
8. 118.25 ml
9. 5 ml
10. 1.25 tablets

Problems Using the Metric System
1. 0.15 g
2. 2000 ml
3. 2.25 g
4. 5000 mg
5. 3 L
6. 2000 g
7. 500 g
8. 0.005 kg
9. 0.00125 g
10. 4 mg
11. 2.05 mg
12. 0.01 g
13. 300 mg
14. 0.75 L
15. 0.3 mg
16. 2500 μg

Problems Using the Apothecary and Household Systems
1. 3 pt
2. 1.5 gal
3. 1 Tbsp
4. 12 cups
5. 6 pints
6. 4 Tbsp
7. 128 oz
8. 16 oz
9. 3 qt

Problems Combining Both Systems
1. 480 ml
2. 30 ml
3. 15 cc
4. 16 oz
5. 0.013 pt
6. 25 tsp
7. 45 ml
8. 33 lb
9. 0.52 pt
10. 150 ml
11. 15.9 kg

Problems Measuring Oral Medications
1. 2 tablets
2. 1.5 tablets
3. 4 tablets
4. 7 tablets
5. 1.5 tablets; 7.5 tablets
6. 20 tablets
7. 200 mg; 100 mg; 50 mg/ml; 4 ml; 2 ml; 44 ml
8. 0.5 tablet each morning and afternoon
9. 60 tablets
10. 0.5 tablet; 4.5 tablets
11. 6.8 kg; 68 mg; 0.75 tablet; 31.5 tablets
12. 4 tubes
13. 100 oz or 3.125 qt (containing 3 oz powder per quart of water)
14. 0.5 tablet; 7 tablets
15. 1.0 ml

Problems Measuring Parenteral Medications
1. 0.4 ml
2. 0.80 ml
3. 17 ml
4. 1.5 ml
5. 2.1 ml
6. 1.95 ml
7. 15 mg
8. 0.74 m\(^2\); 0.37 mg; 0.37 ml
9. 2500 mg; 25 ml; 2.5 bottles
10. 54 mg; 0.54 ml
11. 3.5 ml
12. 0.1 ml
13. 47.5 mg; 1.9 ml
14. 30 ml
15. 1.5 ml
16. 0.18 ml
17. 0.36 ml
18. 1.5 ml
19. 0.35 ml
20. 1.2 ml

Injection Problems
1. 2 ml
2. 5 ml
3. 1.5 ml
4. 3.75 ml
5. 0.25 ml
6. 2 ml
7. 0.75 ml
8. 7.5 ml
9. 0.6 ml
10. 0.22 ml

Preparing Solutions
1. \( V_1 \times C_1 = V_2 \times C_2 \)
   \( V_1 \times 100 = 100 \times 10 \)
   \( V_1 \times 100 = 1000 \)
   \( V_1 = 10 \)
   10 ml 37% formaldehyde + 90 ml water
2. \( V_1 \times C_1 = V_2 \times C_2 \)
   \( V_1 \times 50 = 1000 \times 5 \)
   \( V_1 \times 50 = 5000 \)
   \( V_1 = 100 \)
   100 ml 50% dextrose + 900 ml 0.9% NaCl
3. \( V_1 \times C_1 = V_2 \times C_2 \)
   \( V_1 \times 50 = 100 \times 5 \)
   \( V_1 \times 50 = 500 \)
   \( V_1 = 10 \)
   10 ml 50% dextrose + 90 ml water
4. \( V_1 \times C_1 = V_2 \times C_2 \)
   \( V_1 \times 0.9 = 500 \times 0.45 \)
   \( V_1 \times 0.9 = 225 \)
   \( V_1 = 250 \)
   250 ml 0.9% NaCl + 250 ml 5% dextrose
5. \( V_1 \times C_1 = V_1 \times C_2 \)
   \( V_1 \times 50 = 2000 \times 2.5 \)
   \( V_1 \times 50 = 5000 \)
   \( V_1 = 100 \)
   100 ml 50% dextrose + 1900 ml lactated Ringer's solution
6. \( V_1 \times C_1 = V_2 \times C_2 \)
   \( V_1 \times 50 = 50 \times 5 \)
   \( V_1 \times 50 = 250 \)
   \( V_1 = 5 \)
   5 ml 50% dextrose + 45 ml water
7. \( V_1 \times C_1 = V_2 \times C_2 \)
   \( V_1 \times 50 = 500 \times 2.5 \)
   \( V_1 \times 50 = 1250 \)
   \( V_1 = 25 \)
   25 ml 50% dextrose + 475 ml 0.45% NaCl
8. Remember: 10% solution = 100 mg/ml packets containing 50 g = 50,000 mg
   \( V_1 \times C_1 = V_2 \times C_2 \)
   \( V_1 \times 50,000 = 1000 \times 100 \)
   \( V_1 \times 50,000 = 100,000 \)
   \( V_1 = 2 \)
   2 packets of 50 g GG powder + 1000 ml water
9. Remember: 8% solution = 80 mg/ml
   One 5-g vial contains 5000 mg
   \( V_1 \times C_1 = V_2 \times C_2 \)
1. \(1 \times 5000 = V2 \times 80\)
\(5000 = V2 \times 80\)
\(62.5 = V2\)
62.5 ml needs to be added to one 50-g vial to prepare an 8% solution

10. Remember: 2% solution = 20 mg/ml
\(V_1 \times C_1 = V_2 \times C_2\)
\(V_1 \times 100 = 5 \times 20\)
\(V_1 \times 100 = 100\)
\(V_1 = 1\)
1 ml of Sandimmune (cyclosporine) + 4 ml virgin olive oil

11. Remember: 37% formaldehyde = 100% formalin
\(V_1 \times C_1 = V_2 \times C_2\)
\(V_1 \times 100 = 50 \times 2\)
\(V_1 \times 100 = 100\)
\(V_1 = 1\)
1 ml 37% formaldehyde + 49 ml water

Problems Calculating IV Drop Rates
1. 42 gtt/min or approximately 0.69 gtt/sec
2. 60 gtt/min or 1 gtt/sec
3. 30 gtt/min or 1 gtt/sec
4. 0.15 ml/min or 9 gtt/min
5. 0.5 ml/min or 30 gtt/min
6. 1.52 ml
7. 18 ml/hr
8. 20 ml
9. 1.5 ml
10. 3.3 ml

ANSWERS TO CHAPTER 4

1. An agonist is a drug that combines with a receptor to bring about an action, whereas an antagonist combines with a receptor and blocks the action.

2. A neurotransmitter is a chemical substance released by a nerve ending at the synapse. It acts on the adjacent neuron to stimulate, inhibit, or change its activity.

3. b. Thalamus

4. Interrupting the generation or conduction of nerve impulses; interfering with

5. Epinephrine or norepinephrine

6. Mimicking neurotransmitters, interfering with neurotransmitter release, blocking the attachment of neurotransmitters to receptors, and interfering with the breakdown of neurotransmitters

7. To control vomiting, to treat urinary retention, to stimulate gastrointestinal activity, to treat glaucoma, and to aid in the diagnosis of myasthenia gravis

8. Cholinergic blocking agents (anticholinergic)

9. Adrenergic (sympathomimetic)

10. d. Beta blocker

11. Bradycardia and hypotension may be antagonized by using atropine; respiratory depression or excessive CNS depression may be antagonized by using yohimbine.

12. Thiobarbiturates are very soluble in fat, which acts like a sponge to take the barbiturate out of the circulation and away from the CNS. Thin animals have reduced fat levels, which means that more of the thiobarbiturate remains in the bloodstream and may cause excessive depression of the CNS.

13. Analgesia, increased muscle tone, maintenance of pharyngeal/laryngeal reflexes, muscle tremors, and loss of the blink reflex

14. Respiratory depression, cardiac depression, agitation, excitement, or seizures

15. Naloxone and nalorphine

16. Because of its tendency to precipitate out of solution when stored

17. Doxapram (Dopram) may be administered on or under the tongue, into the umbilical vein, or by intramuscular injection.

18. Some pentobarbital euthanasia agents have a red dye added to distinguish them from pentobarbital agents that may be used for anesthesia. Because these agents are easily identified as euthanasia agents, they have less potential for abuse.

19. Neurotransmitter

20. Burning

21. Propofol

22. GABA

23. Diazepam

24. Clomicalm

25. Anipryl
26. b. endocrine
27. a. somatic
28. d. neuron
29. a. away; toward
30. b. false
31. b. unconscious
32. d. acetylcholine
33. c. communication with stem cells in the bone marrow
34. d. yohimbine
35. a. yohimbine

ANSWERS TO CHAPTER 5

1. Nostrils, nasal cavity, pharynx, larynx, trachea, bronchi, and bronchioles
2. The four functions of the respiratory system are oxygen–carbon dioxide exchange, regulation of acid–base balance, body temperature regulation, and voice production.
3. Structures in the nasal passages filter, warm, and humidify inspired air. The cough, sneeze, and reverse sneeze attempt to remove foreign material that has entered the respiratory system. The mucociliary mechanism also removes foreign material from the respiratory system. Macrophages and immunoglobulins inactivate or destroy invasive organisms.
4. The three important principles of respiratory therapeutics are control of secretions, control of reflexes, and maintenance of normal airflow.
5. Productive
6. Through the breakdown of disulfide chemical bonds
7. Acetylcysteine is administered by nebulization.
8. Through depression of the cough center in the brain
9. Schedule V
10. Release of acetylcholine, release of histamine, and blockade of beta-2-adrenergic receptors
11. Epinephrine and albuterol
12. Phosphodiesterase
13. Treatment of insect bites and treatment of heaves in horses
14. -amine
15. Treatment of respiratory depression associated with anesthesia and stimulation of respiration in newborn animals
16. 22.7 kg × 0.22 mg/kg = 4.9 mg; 5-mg tablets are available. Dispense 14 tablets.
17. 1. As a mucolytic agent. 2. As an antidote for acetaminophen toxicity.
18. E
19. 1 to 5 microns
20. Albuterol
21. c. production of sodium bicarbonate to aid in regulation of the acid-base balance
22. d. expectorants
23. a. antitussives
24. b. butorphanol tartrate
25. d. Class II
26. a. prednisolone
27. c. methylxanthine
28. b. decongestants
29. a. antihistamines
30. c. prednisolone Na succinate

ANSWERS TO CHAPTER 6

1. Kidneys, ureters, bladder, urethra
2. Rompun and Ketaset
3. Prerenal, renal, postrenal
4. Diuretics work by removing excess extracellular fluid, by increasing urine volume and sodium excretion, and by decreasing hypertension
5. Potassium (K)
6. Angiotensin II
7. Struvite
8. Erythropoietin, decrease
9. Loop diuretics inhibit the tubular reabsorption of sodium.
10. Posterior pituitary gland
11. b. originate from the kidneys and connect to the urinary bladder
12. c. hypertension
13. b. extracellular
14. b. posterior
15. d. potassium
16. b. uroliths
17. a. hematuria
ANSWERS TO CHAPTER 7

1. The right atrium and right ventricle serve functionally as one pump for ejecting blood to the lungs, and the left atrium and left ventricle pump blood to the systemic circulation.

2. Syncytium (interconnected mass)

3. Sodium (Na\(^+\)), calcium (Ca\(^{2+}\)), potassium (K\(^+\))

4. Refractory period

5. Chronotropic refers to the rate of contraction, whereas inotropic refers to the force or strength of contraction.

6. Preload is the volume of blood in the ventricles at the end of diastole (the amount of blood that must be pumped out). Afterload is the resistance in the arteries that the ventricle must overcome to pump blood.

7. Increasing the heart rate, increasing the stroke volume, increasing the efficiency of the heart muscle, and heart enlargement

8. Control rhythm disturbances, maintain or increase cardiac output, relieve fluid accumulations, increase the oxygenation of blood, and provide oxygen/sedatives

9. Beneficial effects include improved cardiac contractility, decreased heart rate, antiarrhythmic effect, and decreased signs of dyspnea. A toxic effect is vomiting.

10. Stimulation of cardiac contraction in cardiac arrest

11. Conditions that cause hypoxia; electrolyte imbalances; increased levels or sensitivity to catecholamines; certain drugs such as digitalis, barbiturates, and others; and cardiac trauma or disease

12. Class IA—quinidine; class IB—lidocaine; class IC—flecainide; class II—propranolol; class III—bretylium; class IV—diltiazem

13. Hydralazine—arteriolar dilator; nitroglycerin—venodilator; prazosin—combined; enalapril—combined

14. Lasix is called a loop diuretic because it inhibits reabsorption of sodium in the loops of Henle.

15. Potassium

16. Bronchodilation, oxygen therapy, sedation, aspiration, and centesis

17. Depolarization

18. Cardiac output

19. Congestive heart failure

20. Angiotensin I to angiotensin II

21. Wear gloves; rotate application sites; do not pet the animal at the application site; measure the dosage in inches; and contact the veterinarian if a rash appears at the application site.

22. Lasix

23. An abnormally low potassium level in the blood

24. The primary goals are (1) sodium restriction and (2) maintenance of good body weight and condition (reduction of obesity or cachexia). In some instances, specific nutrient deficiencies, concurrent disease, and/or electrolyte disorders may need to be addressed.

25. (1) Increased force of contraction; (2) an increase in blood pressure; (3) elevated blood glucose levels

26. b. Four

27. c. tachycardia

28. b. arrhythmia

29. a. decreasing heart rate to such an extent that the myocardium is protected from damage caused by the increased workload

30. d. diaphragmatic hernia

31. c. cardiac glycoside

32. a. decreased

33. b. false

34. b. decrease

35. b. hypokalemia

ANSWERS TO CHAPTER 8

1. Entry of food and fluid into the body, absorption of nutrients, and excretion of waste products

2. Dogs, cats, and primates

3. Ruminants have a system of forestomachs, including the reticulum, rumen, and omasum, which allows them to digest coarse plant material, as well as a true stomach (abomasum).
4. Regurgitation is a normal process of ruminants that permits them to bring up partially digested foodstuff for rechewing. Vomiting is the forcible expulsion of gastric contents and is generally considered to be pathologic.
5. Microorganisms in the rumen
6. The autonomic nervous system, hormonal control, and chemical (histamine, prostaglandin, and others) control
7. Bacterial endotoxins may increase the permeability of intestinal blood vessels, resulting in increased fluid loss. They also may induce fever and initiate shock.
8. Chemical substances (digitalis compounds, urea, ketone bodies, and others) and impulses from the inner ear
9. Centrally acting—apomorphine and xylazine; peripherally acting—syrup of ipecac and mustard
10. Antiemetics
11. Reducing the secretion of hydrochloric acid by gastric mucosal cells
12. Cimetidine and ranitidine
13. Peristalsis (a wave of contraction) and segmentation (a mixing action)
14. Withholding of food for 12 to 24 hours
15. Rats and horses
16. By retaining water osmotically in the gut, these agents cause softening of the stool
17. Psyllium
18. By mimicking the effect of acetylcholine
19. Metronidazole
20. C.E.T., Nolvadent, Oral Dent, and Oxydent
21. Peristalsis refers to a wave of contraction that moves contents along, and segmentation refers to intestinal constrictions that mix contents.
22. False
23. 80%
24. By forming a paste-like barrier over the surface of gastric ulcers
25. Felines
26. d. excretion of urine
27. b. equines
28. a. true
29. b. food storage
30. a. ilium
31. d. apomorphine
32. H₂ receptor antagonist
33. d. laxatives
34. c. Epsom salts
35. d. both b and c

**ANSWERS TO CHAPTER 9**

1. Releasing factors (RFs) are messengers made by the hypothalamus in response to its detection of hormone levels in the blood. RFs send messages to the pituitary to stimulate this gland to manufacture trophic hormones. Trophic hormones, in turn, stimulate a specific tissue or gland to produce the hormone in question.
2. The major endocrine glands are the pituitary, the thyroid, the ovaries, the testicles, the adrenals, and the pancreas.
3. To correct a deficiency and to obtain a desired effect
4. In the body; external
5. The pituitary gland is located at the base of the brain ventral to the hypothalamus, and its primary function is to control the activity of the other endocrine glands.
6. A negative feedback mechanism occurs when the hypothalamus senses a high level of a specific hormone in the blood and in response reduces the amount of releasing factor (RF) for this hormone. A reduced amount of RF causes a decreased amount of trophic hormone to be produced by the pituitary; this results in decreased production of the hormone by the target organ.
   A positive feedback mechanism occurs when the hypothalamus senses a low level of the hormone in question and increases its production of RF. Increased RF causes an increase in trophic hormone and a resultant increase in activity of the target organ.
7. Neurohormonal reflex
8. Gonadotropin
9. Progestins
10. Estrus synchronization, to induce abortion, and to induce estrus
11. Pregnant; asthmatics
12. Estrogen and progesterone
13. The reproductive tract has been examined for blockage or torsion, and that the cervix has dilated.
14. Triiodothyronine (T₃) and tetraiodothyronine (T₄)
15. Soloxine and Synthroid
16. Short-acting (regular/lispro/aspart), intermediate-acting (NPH/PZI/Lente), long-acting (Glargine/detemir)
17. Regular
18. NPH/PZI/Lente
19. Weakness, ataxia, shaking, and seizures
20. Breeding purposes
21. Because of the potential for abuse by human athletes
22. Pheromones
23. Wear gloves and/or avoid getting the drug on the skin
24. Residues of DES were shown to have a likely link to cervical cancer in women.
25. Corpus luteum
26. d. uterus
27. c. trophic
28. d. hypothalamus
29. a. estradiol cypionate
30. b. false
31. a. true
32. c. oxytocin
33. b. the adrenal cortex
34. d. odors
35. b. hypothyroidism

ANSWERS TO CHAPTER 10

1. Dilate
2. Glaucoma, keratoconjunctivitis sicca
3. Pupillary
4. Ophthalmic stains are used as diagnostic aids for detecting disease in both the anterior and posterior segments and in the nasolacrimal system.
5. Fluorescein
6. Aural
7. Topical ophthalmics (e.g., ointments, drops)
8. Because the eye secretes tears, the medication may be quickly diluted; thus reapplication becomes necessary.
9. To provide local anesthesia to the eye
10. False
11. c. third eyelid
12. a. dilate
13. b. mydriasis
14. a. closed
15. b. false
16. a. 5; 10
17. b. corneal ulcers
18. c. equines
19. b. false
20. d. Acarexx

ANSWERS TO CHAPTER 11

1. Three, integumentary
2. Proper nutrition
3. Protection, temperature regulation, storage, immunoregulation, secretion, vitamin D production, and sensory perception
4. Five to ten
5. Antiseborrheic
6. Inflammatory, debridement, repair, maturation
7. Has drying and cleansing properties
8. True
9. Systemic
10. To keep the animal from excessive self-licking and/or mutilation
11. b. false
12. c. skin
13. a. true
14. b. false
15. a. true
16. d. 6
17. b. collagen
18. b. false
19. d. granulation
20. c. Kopertox

ANSWERS TO CHAPTER 12

1. Gram
2. Blue
3. Red
4. Naxcel
5. Tetracyclines
6. Tetracycline
7. Oto-, nephro-
8. Dermatophytosis
9. Spectrum
10. True
11. b. false
12. a. true
13. a. fungal
14. b. false
15. a. cephalexin
16. b. false
17. d. a tetracycline
18. b. false
19. c. fluoroquinolone
20. a. true

ANSWERS TO CHAPTER 13

1. Predator-prey, commensalism, mutualism, phoresis, parasitism
2. Parasitiasis occurs when an animal is infected with parasites, but no clinical signs can be observed.
3. Parasitosis occurs when an animal is infected with parasites, and clinical signs can be observed.
4. Ectoparasites infest the outside of the body.
5. Endoparasites infect the inside of the body.
6. Infected; infested
7. An anthelmintic is administered to rid the body of endoparasites.
8. Organophosphate
9. Insect growth regulators
10. Tapeworms
11. d. phoresis
12. a. avermectins
13. d. diethylcarbamazine
14. c. amitraz
15. b. Profender (emodepside/praziquantel)
16. c. melarsomine dihydrochloride
17. d. Valbazen
18. a. true
19. b. fleas; ticks
20. d. nematodes

ANSWERS TO CHAPTER 14

1. Nociceptors
2. Increased heart rate, increased respiratory rate, vocalization, guarding the painful site, restlessness, salivation, failure to groom, unresponsiveness, abnormal gait, abnormal stance, and rolling
3. COX-2
4. Gastrointestinal ulceration and/or bleeding
5. Cats metabolize aspirin very slowly.
6. False
7. Fentanyl
8. False
9. These substances regulate electrolyte and water balance in the body.
10. Alternate day dosing may help prevent iatrogenic hypoadrenocorticism; administration should be tapered off gradually; very large doses may be used in certain emergency situations; corticosteroids should be avoided when corneal ulcers are treated; use aseptic technique when injecting into joints.
11. Caused by the doctor
12. Short-term effects of corticosteroid use include polyuria, polydipsia, polyphagia, and delayed healing. Long-term effects include thinning of the skin, gastric ulcers, osteoporosis, and iatrogenic Cushing’s disease.
13. Local anesthetics prevent generation and conduction of nerve impulses by peripheral nerves.
14. Local anesthetics are used for infiltrating into local areas for suturing wounds, for nerve blocks (lamineness examination), for antiarrhythmic effects, for topical use, and others.
15. b. endorphins
16. c. pyrogen
17. b. aspirin
18. a. phenylbutazone
19. d. NSAID
20. b. vasodilation
21. b. morphine
22. a. histamine
23. d. ketoprofen
24. a. true
Hidden page
12. Treatment of autoimmune hemolytic anemia, treatment of lymphocytic-plasmacytic enteritis, treatment of rheumatoid arthritis, and treatment of lupus erythematosus

13. Because most antineoplastic drugs are very irritating to tissue and may cause sloughing

14. Designate a specific location for handling. Wear nonpermeable latex gloves when handling. Cover work surfaces with a disposable, plastic-backed sheet. Wear an appropriate laboratory coat and mask. Reconstitute all materials carefully to avoid aerosolization. Clean reconstituted material of any contamination, and properly mark and date it. Dispose of contaminated material in leak-proof, puncture-resistant containers. Wash hands thoroughly.

15. In the kidney

16. Epogen (erythropoietin)

17. Plasmin

18. Heparin

19. It may distort the white blood cells, making identification difficult.

20. It chelates (binds with) calcium.

21. Anaphylactic reactions, immunosuppression, vomiting, diarrhea, hair loss, cystitis, pain associated with administration, and tissue damage from extravasation

22. Body surface area

23. Lymphoid neoplasia

24. Interferon

25. Doxorubicin

26. b. bone marrow

27. d. to carry O₂ to the tissues

28. c. Hematinics

29. d. Regu-Mare

30. b. false

31. c. 5 U/ml

32. d. green

33. d. K₁

34. d. EDTA

35. d. felines

**ANSWERS TO CHAPTER 17**

1. Routine checkups

2. Health/age, type of vaccine administered, route of administration, concurrent incubation of infectious disease, exposure to an infectious disease before immunity is reached, drug therapy

3. An inactivated vaccine has organisms commonly treated by chemicals to kill the organism, but very little change occurs in the antigens that stimulate protective immunity.

4. A live vaccine is prepared from live microorganisms or viruses.

5. Modified live vaccine has organisms that have undergone a process (attenuation) to lose their virulence, so that when inoculated into the body, they cause an immune response instead of disease.

6. A toxoid is a vaccine used in producing immunity to a toxin rather than bacterium or virus.

7. An antitoxin is a specific antiserum aimed against a toxin that contains a concentration of antibodies extracted from blood plasma of a hyperimmunized, healthy animal (usually a horse).

8. The contents should be unpacked and placed in the refrigerator.

9. Using drugs to stimulate the body's immune response to disease

10. Acemannan

11. b. false

12. d. administering a medicated bath prior to vaccination to clean the skin's surface

13. c. inactivated (dead)

14. a. live

15. b. modified live

16. b. antitoxin

17. c. both a and b

18. b. blefarospasm

19. e. both b and c

20. c. recombinant

**ANSWERS TO CHAPTER 18**

1. c. calcium EDTA

2. d. Bring the cat to the hospital to start treatment with acetylcysteine.

3. a. Rompun

4. b. on an empty stomach

5. Oxymorphone, Torbugesic, Talwin-V, and Nubain

6. b. blood urea nitrogen (BUN)
7. Articular cartilage and connective tissue
8. GAGs act as chondroprotective agents.
9. A nutraceutical is any nontoxic food component that has scientifically proven health benefits, including disease treatment and prevention. Glucosamine/chondroitin sulfate
10. True
11. The Dietary Supplement Health and Education Act of 1994
12. Omega-6 and omega-3 fatty acids
13. Increased bleeding time and possible decreased immune function
14. To prevent or reduce the systemic absorption of ingested drugs or toxins
15. Lead poisoning
16. Water-soluble
17. Naloxone
18. Benzodiazepines
19. S-adenosylmethionine
20. Ethylene glycol (antifreeze)
21. b. false
22. b. false
23. a. true
24. b. false
25. b. false
26. a. true
27. a. true
28. b. false
29. a. true
30. b. false

ANSWERS TO CHAPTER 19

1. Inventory is the quantity of goods present in the veterinary facility.
2. Develop a budget; keep abreast of expenses on a regular basis; once a system has been put in place, keep it active; budget analysis should mirror the practice's philosophy; analyzing expenses provides a comprehensive view of the condition of the practice and helps shape its future endeavors.
3. Money
4. The number of times a product is used and replenished each year
5. 4 turns
6. $102,500
7. Make sure items are on hand when needed, and minimize the expense of keeping items in stock.
8. A packing slip is found in the carton in which freight is shipped. It documents how many of each item is shipped. It may or may not include the prices of the item(s), although most commonly it does not.
9. An invoice is documentation of an order shipped to the veterinary hospital. It may or may not accompany the packing slip in the shipping carton.
10. A statement is most commonly mailed to the veterinary practice. It documents the items received by the hospital and the amount due on account. Commonly, it must be paid within 30 days so that no late fees are incurred by the business.
11. The point at which a product is allowed to be sold or used in-house before new product is ordered
12. This number is included on the rabies certificate given to the client; also, rabies is a zoonotic disease, and the veterinarian must account for the expiration date of the vaccine and the serial number.
13. 1
14. DEA inventory and usage, OSHA manuals, MSDS sheet, supplier's catalogs
15. All information on the form must be correct, no markouts are allowed, no liquid paper can be used, must have correct spelling, must have correct strength, and the veterinarian must sign the form.
16. a. true
17. d. 8
18. b. FIFO
19. d. the federal government
20. a. true
21. b. cost; retail
22. a. true
23. b. false
24. a. true
25. b. false
Glossary
acetylcholine  A neurotransmitter that allows a nerve impulse to cross the synaptic junction (gap) between two nerve fibers or between a nerve fiber and an organ (e.g., muscle, gland).

acetylcholinesterase  An enzyme that brings about the breakdown of acetylcholine in the synaptic gap.

active immunity  Immunity that occurs by an animal's own immune response after exposure to foreign antigen.

Addison's disease  A disease or syndrome characterized by inadequate amounts of corticosteroid hormones.

adjuvant  A substance given with an antigen to enhance the immune response to the antigen. Adjuvants may form a localized granuloma at the injection site or may produce systemic hypersensitivity. Adjuvants have received much attention as a result of a possible (but not proven) link with the increased incidence of fibrosarcomas in vaccinated cats. Examples of adjuvants are aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate, water in oil, saponin, and diethylaminoethyl (DEAE) dextran.

adrenergic  A term used to describe an action or a receptor that is activated by epinephrine or norepinephrine.

adsorbent  A drug that inhibits GI absorption of drugs, toxins, or chemicals by attracting and holding them to its surface.

adverse drug reaction  An undesirable response to a drug by a patient. It may vary in severity from mild to fatal.

aerosolization  The conversion of a liquid into a fine mist or colloidal suspension in air.

afterload  The resistance (pressure) in arteries that must be overcome to empty blood from the ventricle.

agonist  A drug that brings about a specific action by binding with the appropriate receptor.

alkylation  Formation of a linkage between a substance and DNA that causes irreversible inhibition of the DNA molecule. Alkylating drugs are used in chemotherapy treatment of cancer.

anabolism  The constructive phase of metabolism in which body cells repair and replace tissue.

analgesia  The absence of the sensation of pain.

analog  A chemical compound having a structure similar to another but differing from it in some way.

anaphylaxis  A systemic, severe allergic reaction.

anesthesia  The loss of all sensation. May be described as local (affecting a small area), regional, or surgical (accompanied by unconsciousness).

angiogenesis  The development of blood vessels.

antagonist  A drug that inhibits a specific action by binding with a particular receptor.

anthelmintic  Drug used to eliminate helminth parasites (e.g., roundworms) from a host.

antibacterial  An agent that inhibits bacterial growth, impedes replication of bacteria, or kills bacteria.

antibiotic  An agent produced by a microorganism or semisynthetically that has the ability to inhibit the growth of or kill microorganisms.

antibody  An immunoglobulin molecule that combines with the specific antigen that induced its formation.

anticholinergic  Blocking nerve impulse transmission through the parasympathetic nervous system; also called parasympatholytic. Anticholinergic drugs may be used for the treatment of diarrhea or vomiting.

antigen  Any substance that can induce a specific immune response, such as toxins, foreign proteins, bacteria, and viruses.

antimicrobial  An agent that kills microorganisms or suppresses their multiplication or growth.

antitussive  A drug that inhibits or suppresses the cough reflex.

arrhythmia (dysrhythmia)  A variation from the normal rhythm.

astringent  An agent that causes contraction after application to tissue.

atonal  The absence or lack of normal tone or strength.

automaticity  The ability of cardiac muscle to generate impulses.

autonomic nervous system  That portion of the nervous system that controls involuntary activities.

average cost of inventory on hand  Average cost of inventory on hand is determined by adding the year's beginning inventory to the year's ending inventory and dividing by 2.

avirulent  The inability of an infectious agent to produce pathologic effects.

bacteria  Single-celled microorganisms that usually have a rigid cell wall and a round, rod-like, or spiral shape.

bactericidal  An agent with the capability to kill bacteria.

bacterin  A killed bacterial vaccine.

bacteriostatic  An agent that inhibits the growth or reproduction of bacteria.

beta-lactamase  Enzymes that reduce the effectiveness of certain antibiotics; beta-lactamase I is penicillinase; beta-lactamase II is cephalosporinase.

bots  Larvae of several fly species (e.g., Gastrophilus, horse bot).

bradyarrhythmia  Bradycardia associated with an irregularity of heart rhythm.

bradycardia  A slower-than-normal heart rate.
effector  A gland, organ, or tissue that responds to nerve
stimulation with a specific action.

efficacy  The extent to which a drug causes the intended
effects in a patient.

electrolyte  A substance that dissociates into ions when
placed in solution, becoming capable of conducting
electricity.

elixir  A hydroalcoholic liquid that contains sweeteners,
flavoring, and a medicinal agent.

emesis  The act of vomiting.

empirical  Based on observation and personal experi-
ence.

emulsion  A medicinal agent that consists of oily sub-
stances dispersed in an aqueous medium with an addi-
tive to stabilize the dispersion.

endometrium  The mucous membrane lining of the
uterus.

dioparous  A parasite that lives inside the body of its
host.

endothelial layer  The smooth layer of epithelial cells
that line blood vessels.

entropion  A rolling inward (i.e., toward the cornea) of
the eyelid.

equivalent weight  1 g molecular weight (from periodic
chart) divided by the total positive valence of the
material.

erythema  Redness of the skin caused by congestion of
the capillaries.

erythropoiesis  The formation of erythrocytes.

erythropoietin  A glycoprotein hormone secreted mainly
by the kidney; it acts on stem cells of the bone marrow
to stimulate red blood cell production.

etiology  Anormal thyroid gland.

expectorant  A drug that enhances the expulsion of se-
crations from the respiratory tract.

extralabel use  The use of a drug that is not specifically
listed on the U.S. Food and Drug Administration
(FDA)-approved label.

exudation  Leakage of fluid, cells, or cellular debris
from blood vessels and their deposition in or on the
tissue.

feedback  The return of some of the output product of a
process as input in a way that controls the process.

feed efficiency  The rate at which animals convert feed
into tissue. It is expressed as the number of pounds or
kilograms of feed needed to produce 1 lb or 1 kg of
animal.

fibrinolysis  Fibrin (clot) breakdown through the action
of the enzyme plasmin.

FIFO  First in, first out.

FOB  Acronym for "free on board."

FOB destination  Title of possession passes from the
pharmaceutical company to the buyer (i.e., the pur-
chaser) when the shipment is delivered to the buyer's
business destination (i.e., the veterinary facility).

FOB shipping point  Title passes from the pharmaceutical
company to the purchaser when the vendor places
the goods in the possession of the carrier (e.g., United Par-
cel Service, Federal Express, Averitt Express).

full-service company  A pharmaceutical company that
offers full service (e.g., the company employs sales
representatives [reps] who visit veterinary facilities),
usually with a limited number of products.

ganglionic synapse  The site of the synapse between
neuron one and neuron two of the autonomic nervous
system.

glaucoma  A group of eye diseases characterized by in-
creased intraocular pressure that results in damage to
the retina and the optic nerve.

gonadotropin  A hormone that stimulates the ovaries or
testes.

granulation tissue  New tissue formed in the healing of
wounds of the soft tissue, consisting of connective
tissue cells and ingrown young vessels; it ultimately
forms a scar.

half-life  The amount of time (usually expressed in
hours) that it takes for the quantity of a drug in the
body to be reduced by 50%.

helminths  Parasite worms, including nematodes, cest-
dodes, and trematodes.

hematemesis  Vomiting of blood (the vomitus often
resembles coffee grounds).

hematuria  Blood in the urine.

histamine  A chemical mediator of the inflammatory re-
sponse released from mast cells. Histamine may cause
dilation and increased permeability of small blood
vessels, constriction of small airways, increased secre-
tion of mucus in the airways, and pain.

humidification  Addition of moisture to the air.

hybridoma  A cell culture that consists of a clone of a
hybrid cell formed by fusing cells of different types,
such as stimulated mouse plasma cells and myeloma
cells.

hyperkalemia  An excess of potassium in the blood.

hypertension  Persistently high blood pressure.

hypertonic  The state characterized by an increased
tonicity or tension.

hypokalemia  Abnormally low potassium concentration
in the blood.
hyponatremia A deficiency of sodium in the blood.
hypophyseal portal system This is the portal system of the pituitary gland in which venules from the hypothalamus connect with capillaries of the anterior pituitary.
hypovolemia Decreased volume of circulating blood.
iatrogenic Caused by the physician (veterinarian).
ICM (inventory control manager) A person (many times a licensed veterinary medical technician [LVMT]) responsible for monitoring, ordering, and maintaining inventory in a veterinary facility.
IgA Class of antibody produced on mucous membrane surfaces, such as those of the respiratory tract.
inotropie Affecting the force of cardiac muscle contraction.
inspissated Thickened or dried out.
tegumentary system Pertaining to, or composed of, skin.
inventory The quantity of goods or assets that a veterinary facility possesses, requiring proactive control to keep supplies stable and current.
in vitro Within an artificial environment.
in vivo Within the living body.
invoice A form generated by a company that documents the quantity and price of each item ordered by the inventory control manager.
involution The return of a reproductive organ to normal size after delivery.
iodophor An iodine compound with a longer activity period that results from the combination of iodine and a carrier molecule that releases iodine over time.
keratitis Inflammation of the cornea.
keratolytic An agent that promotes loosening or separation of the horny layer of the epidermis.
keratoplastie An agent that promotes normalization of the development of keratin.
levo isomer Left-sided arrangement of a molecule that may exist in a left- or a right-sided configuration. Levo and dextro isomers have the same molecular formula.
liment A medicine in an oily, soapy, or alcoholic vehicle to be rubbed on the skin to relieve pain or to act as a counterirritant.
lower motor neurons Peripheral neurons whose cell bodies lie in the central gray columns of the spinal cord and whose terminations lie in skeletal muscle. A sufficient number of lesions of lower motor neurons cause muscles supplied by the nerve to atrophy, resulting in weak reflexes and flaccid paralysis.
mail order discount house A company that accepts orders from the buyer by telephone; a good source for ordering items such as gauze, cotton, isopropyl alcohol, or paper towels.
manufaCturing The bulk production of drugs for resale outside of the veterinarian-client-patient relationship.
makup The amount of money over cost that a product sells for. Markup percentages vary from practice to practice, but all markups reflect a retail value over wholesale value.
melena Dark or black stools that result from blood staining. Bleeding has occurred in the anterior part of the GI tract.
metabolic acidosis Decreased body pH caused by excess hydrogen ions in the extracellular fluid.
metabolic alkalosis Increased body pH caused by excess bicarbonate in the extracellular fluid.
metabolism (biotransformation) The biochemical process that alters a drug from an active form to a form that is inactive or that can be eliminated from the body.
metastasis Generally refers to the transfer of cancer cells from one site to another.
methemoglobinemia The presence of methemoglobin in the blood caused by injury or toxic agents that convert a larger-than-normal proportion of hemoglobin into methemoglobin, which does not function as an oxygen carrier.
microfilaria A prelarval stage of a filarial worm transmitted to the biting insect from the principal host (e.g., filarial stage of Dirofilaria immitis).
microorganism An organism that is microscopic (e.g., bacterium, protozoan, Rickettsia, virus, and fungus).
milliequivalent 1/1000 of an equivalent weight. A term used to express the concentration of electrolytes in a solution.
miosis Contraction of the pupil.
modulation The modification of nociceptive transmission.
monovalent A vaccine, antiserum, or antitoxin developed specifically for a single antigen or organism.
motilin A hormone secreted by cells in the duodenal mucosa that causes contraction of intestinal smooth muscle.
mucolytic Having the ability to break down mucus.
muscarinic receptors Receptors activated by acetylcholine and muscarine that are found in glands, the heart, and smooth muscle. An acronym for remembering muscarinic effects is "SLUD": S = salivation; L = lacrimation; U = urination; D = defecation.
mydriasis Dilation of the pupil.
myeloma A malignant neoplasm of plasma cells (B-lymphocytes).
myelosuppression  Inhibiting bone marrow activity that results in decreased production of blood cells and platelets.

myofibril  A muscle fibril composed of numerous myofilaments.

nebulization  The process of converting liquid medications into a spray that can be carried into the respiratory system by inhaled air.

nematodes  Parasitic worms, including intestinal roundworms, filarial worms, lungworms, kidney worms, heartworms, and others.

nephrology  The study of the urinary (renal) system.

ephron  The basic functional unit of the kidney.

nerve block  A loss of feeling or sensation produced by injecting an anesthetic agent around a nerve to interfere with its ability to conduct impulses.

nicotinic receptors  Receptors activated by acetylcholine and nicotine found at the neuromuscular junction of the skeletal muscle and at the ganglionic synapses.

nitrogen balance  The condition of the body as it relates to protein intake and use. Positive nitrogen balance implies a net gain in body protein.

nonproductive cough  A cough that does not result in coughing up of mucus, secretions, or debris (a dry cough).

nutraceutical  Any nontoxic food component that has scientifically proven health benefits.

ointment  A semisolid preparation that contains medicinal agents for application to the skin or eyes.

oncotic pressure  The osmotic pressure generated by plasma proteins in the blood.

open-angle glaucoma  A type of primary glaucoma of the eye in which the angle of the anterior chamber remains open, but filtration of the aqueous humor is gradually reduced, causing an increase in intraocular pressure.

organophosphate  A substance that can interfere with the function of the nervous system by inhibiting the enzyme cholinesterase.

packing slip  A document supplied by the vendor that accompanies a purchase. A packing slip generally reflects quantities ordered, not prices.

parasitiasis  A condition in which an animal harbors an endoparasite or an ectoparasite, but no clinical signs of infection or infestation are evident.

parasitosis  A condition in which an animal harbors an endoparasite or an ectoparasite, and clinical signs of infection or infestation are evident.

parasympathetic nervous system  That portion of the autonomic nervous system that arises from the craniosacral portion of the spinal cord, is mediated by the neurotransmitter acetylcholine, and is concerned primarily with conserving and restoring a steady state in the body.

parasympathomimetic  A drug that mimics the effects of stimulating the parasympathetic nervous system.

parenteral  The route of administration of injectable drugs.

parietal cell  A cell located in the gastric mucosa that secretes hydrochloric acid.

partition coefficient  The ratio of the solubility of substances (e.g., gas anesthetics) between two states in which they may be found (e.g., blood and gas, gas and rubber goods).

passive immunity  Immunity that occurs by administration of antibody produced in another individual.

peristalsis  A wave of smooth muscle contraction that passes along a tubular structure (GI or other) and moves the contents of that structure forward.

polydipsia  Excessive thirst manifested by increased water consumption.

polyuria  Excessive urination.

polyvalent  A vaccine, antiserum, or antitoxin active against multiple antigens or organisms; mixed vaccine.

preload  The volume of blood in the ventricles at the end of diastole.

premature ventricular contraction (PVC)  Contraction of the ventricles without a corresponding contraction of the atria. PVCs arise from an irritable focus or foci in the ventricles.

prescription (legend) drug  A drug that is limited to use under the supervision of a veterinarian because of potential danger, difficulty of administration, or other considerations. The legend that designates a prescription drug states the following: “Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.”

preservative  A substance, such as an antibiotic, antiinfective, or fungistat, that is added to a product to destroy or inhibit multiplication of microorganisms.

primary hypothyroidism  Hypothyroidism resulting from a pathologic condition in the thyroid.

productive cough  A cough that results in coughing up of mucus, secretions, or debris.

prostaglandin  A substance synthesized by cells from arachidonic acid that serves as a mediator of inflammation and has other physiologic functions.

pruritus  Itching.

pyoderma  Any skin disease characterized by the presence or formation of pus.

recombinant DNA technology  A process that removes a gene from one organism or pathogen and inserts it
Hidden page
Hidden page
<table>
<thead>
<tr>
<th>Index</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>2-PAM (pralidoxime), 79, 378</td>
</tr>
<tr>
<td></td>
<td>2.5X Flea and Tick Powder, 275</td>
</tr>
<tr>
<td></td>
<td>50% dextrose solution, 317-318</td>
</tr>
<tr>
<td></td>
<td>concentration of dextrose in, 318TN</td>
</tr>
<tr>
<td></td>
<td>A fibers, 73, 279-280</td>
</tr>
<tr>
<td></td>
<td>A-H (doxylamine), 110</td>
</tr>
<tr>
<td></td>
<td>Abbokinase (urokinase), 333</td>
</tr>
<tr>
<td></td>
<td>Abbreviations, medical and pharmacologic, 48, 410</td>
</tr>
<tr>
<td></td>
<td>Abdominocentesis, 145</td>
</tr>
<tr>
<td></td>
<td>Absorbine Veterinary Liniment, 222</td>
</tr>
<tr>
<td></td>
<td>Absorption, drug, 8-10</td>
</tr>
<tr>
<td></td>
<td>and administration route, 7-8, 9</td>
</tr>
<tr>
<td></td>
<td>factors affecting, 8-10</td>
</tr>
<tr>
<td></td>
<td>and lipid solubility of drug, 9-10</td>
</tr>
<tr>
<td></td>
<td>Acarex (0.1% ivermectin), 207</td>
</tr>
<tr>
<td></td>
<td>ACE (angiotensin-converting enzyme) inhibitors, 123, 143</td>
</tr>
<tr>
<td></td>
<td>Ace-Oric Cleanser, 207</td>
</tr>
<tr>
<td></td>
<td>Accemannan, 343, 366</td>
</tr>
<tr>
<td></td>
<td>Accemannan Immunostimulant, 365t</td>
</tr>
<tr>
<td></td>
<td>Acpromazine, 81, 89</td>
</tr>
<tr>
<td></td>
<td>Acpromazine maleate, 82</td>
</tr>
<tr>
<td></td>
<td>Aetaminophen, 284</td>
</tr>
<tr>
<td></td>
<td>acetylcysteine antidote to, 106, 377-378, 378TN</td>
</tr>
<tr>
<td></td>
<td>contraindications to, for cats, 108TN, 284TN</td>
</tr>
<tr>
<td></td>
<td>Acetazolamide, 121</td>
</tr>
<tr>
<td></td>
<td>for treatment of glaucoma, 199</td>
</tr>
<tr>
<td></td>
<td>Acetic acid, as topical antiseptic, 218</td>
</tr>
<tr>
<td></td>
<td>Acetylcholine, 70, 75</td>
</tr>
<tr>
<td></td>
<td>action of, 77, 78, 108</td>
</tr>
<tr>
<td></td>
<td>and behavioral pharmacotherapy, 95</td>
</tr>
<tr>
<td></td>
<td>Acetylcholinesterase, 70, 78</td>
</tr>
<tr>
<td></td>
<td>Acetylcholinesterase inhibitors, as gastrointestinal prokinetics, 166</td>
</tr>
<tr>
<td></td>
<td>Acetylcysteine</td>
</tr>
<tr>
<td></td>
<td>as antidote to acetaminophen poisoning, 377-378, 378TN</td>
</tr>
<tr>
<td></td>
<td>as mucolytic, 106, 377</td>
</tr>
<tr>
<td></td>
<td>Acetylcysteine ophthalmic, 204</td>
</tr>
<tr>
<td></td>
<td>Acid-base balance, regulation of, 104</td>
</tr>
<tr>
<td></td>
<td>Acid citrate dextrose (ACD) solution, 331-332</td>
</tr>
<tr>
<td></td>
<td>Acidified Copper Sulfate, 223</td>
</tr>
<tr>
<td></td>
<td>Acidifying diets, client education about, 124TN</td>
</tr>
<tr>
<td></td>
<td>Acleral lick dermatitis, canine, 220, 223</td>
</tr>
<tr>
<td></td>
<td>ACTH. See Adrenocorticotropic hormone.</td>
</tr>
<tr>
<td></td>
<td>Acimmune injection (recombinant interferon), 343</td>
</tr>
<tr>
<td></td>
<td>Activase (alteplase), 333</td>
</tr>
<tr>
<td></td>
<td>Activated charcoal, 162-163, 376, 376TN</td>
</tr>
<tr>
<td></td>
<td>Active immunity, 349</td>
</tr>
<tr>
<td></td>
<td>vaccines that produce, 351-353</td>
</tr>
<tr>
<td></td>
<td>Acular (ketorolac tromethamine), 203</td>
</tr>
<tr>
<td></td>
<td>Acyclovir, 202, 244</td>
</tr>
<tr>
<td></td>
<td>Acyclovir ophthalmic solution, 202</td>
</tr>
<tr>
<td></td>
<td>Adalat (nifedipine), 141</td>
</tr>
<tr>
<td></td>
<td>Adams Flea and Tick preparations, 273</td>
</tr>
<tr>
<td></td>
<td>Addison’s disease, 278, 292, 293</td>
</tr>
<tr>
<td></td>
<td>Additives, 3, 4t, 10, 35. See also</td>
</tr>
<tr>
<td></td>
<td>Inactive (inert) ingredients; Preservatives</td>
</tr>
<tr>
<td></td>
<td>in fluids for therapy, 315-318</td>
</tr>
<tr>
<td></td>
<td>Adequan preparations (polysulfated glycaminoglycans), 286, 370</td>
</tr>
<tr>
<td></td>
<td>Adjuvant, immunologic, 349</td>
</tr>
<tr>
<td></td>
<td>responses to, 356</td>
</tr>
<tr>
<td></td>
<td>Administration of drug. See Drug administration.</td>
</tr>
<tr>
<td></td>
<td>Adrenalin (epinephrine), 80</td>
</tr>
<tr>
<td></td>
<td>Adrenalin Chloride (epinephrine HCl), 137</td>
</tr>
<tr>
<td></td>
<td>Adrenergic, definition of, 70</td>
</tr>
<tr>
<td></td>
<td>Adrenergic agonists, 70, 80. See also</td>
</tr>
<tr>
<td></td>
<td>Catecholamine(s); Noncatecholamines.</td>
</tr>
<tr>
<td></td>
<td>for cardiovascular disorders, 136-137</td>
</tr>
<tr>
<td></td>
<td>for glaucoma, 200</td>
</tr>
<tr>
<td></td>
<td>inhibition of, by beta adrenergic antagonists, 122</td>
</tr>
<tr>
<td></td>
<td>for pain treatment, 288</td>
</tr>
<tr>
<td></td>
<td>Adrenergic antagonists (adrenergic blocking agents), 80-81, 122</td>
</tr>
<tr>
<td></td>
<td>Adrenergic nervous system. See</td>
</tr>
<tr>
<td></td>
<td>Sympathetic (adrenergic) nervous system.</td>
</tr>
<tr>
<td></td>
<td>Adrenergic receptor(s), 75, 77f</td>
</tr>
<tr>
<td></td>
<td>responses of, 77, 78f</td>
</tr>
<tr>
<td></td>
<td>Adrenocorticotropic hormone (ACTH), 174, 290</td>
</tr>
<tr>
<td></td>
<td>for fetal production of, 177</td>
</tr>
<tr>
<td></td>
<td>Adrenocorticotropic hormone. See</td>
</tr>
<tr>
<td></td>
<td>Adrivamycin, 337</td>
</tr>
<tr>
<td></td>
<td>Adsorbent agent(s), 150</td>
</tr>
<tr>
<td></td>
<td>Adverse effects, 14-15</td>
</tr>
<tr>
<td></td>
<td>information resources on, 414t</td>
</tr>
<tr>
<td></td>
<td>reporting, to veterinarian, 5</td>
</tr>
<tr>
<td></td>
<td>Aero-Chamber, 105</td>
</tr>
<tr>
<td></td>
<td>Aero-Mask, 105</td>
</tr>
<tr>
<td></td>
<td>Aerosol formulation, 35</td>
</tr>
<tr>
<td></td>
<td>Aerosol therapy, 105</td>
</tr>
<tr>
<td></td>
<td>Aerosolization, 102</td>
</tr>
<tr>
<td></td>
<td>Affinity, of drug and receptor, 13, 15f</td>
</tr>
<tr>
<td></td>
<td>Afnir (oxymetazoline), 110</td>
</tr>
<tr>
<td></td>
<td>Afterload, 130, 133</td>
</tr>
<tr>
<td></td>
<td>increased, in heart failure, 141</td>
</tr>
<tr>
<td></td>
<td>Agonist, 14, 121</td>
</tr>
<tr>
<td></td>
<td>combination of, with receptor, 15f</td>
</tr>
<tr>
<td></td>
<td>definition of, 2, 115</td>
</tr>
<tr>
<td></td>
<td>Akarpine (piloarpine), 78</td>
</tr>
<tr>
<td></td>
<td>Albendazole, 253</td>
</tr>
<tr>
<td></td>
<td>for treating Giardia infection, 264</td>
</tr>
<tr>
<td></td>
<td>Albon (sulfadimethoxine) preparations, 241, 264</td>
</tr>
<tr>
<td></td>
<td>Albuterol, 80</td>
</tr>
<tr>
<td></td>
<td>as bronchodilator, 109</td>
</tr>
<tr>
<td></td>
<td>Alcohol(s)</td>
</tr>
<tr>
<td></td>
<td>as disinfecting agent, 244-245, 245t</td>
</tr>
<tr>
<td></td>
<td>increasing sporidial and antiviral activity of, 245TN</td>
</tr>
<tr>
<td></td>
<td>precautions in using, on skin, 245TN</td>
</tr>
<tr>
<td></td>
<td>as topical antiseptic, 217</td>
</tr>
<tr>
<td></td>
<td>Aldactone (spironolactone), 121, 144</td>
</tr>
<tr>
<td></td>
<td>Aldosterone, 141</td>
</tr>
<tr>
<td></td>
<td>Aldosterone antagonists, 121</td>
</tr>
<tr>
<td></td>
<td>Alleron N (leukocyte derived interferon), 343</td>
</tr>
<tr>
<td></td>
<td>Alkaban-AQ (vinblastine), 341</td>
</tr>
<tr>
<td></td>
<td>Alkalai, as disinfectants, 248</td>
</tr>
<tr>
<td></td>
<td>Alkylating agents, 336</td>
</tr>
<tr>
<td></td>
<td>commonly used, 338t</td>
</tr>
<tr>
<td></td>
<td>Alkylolation, 326</td>
</tr>
<tr>
<td></td>
<td>Alkylphenol derivative, 92-93</td>
</tr>
<tr>
<td></td>
<td>Allergic conditions</td>
</tr>
<tr>
<td></td>
<td>antihistamines for treatment of, 288-289</td>
</tr>
</tbody>
</table>
Aminoglycosides (Continued)
precautions in use of, with other
drug therapies, 237TN
preparations of (including
indications and antagonists),
236t
Aminopentamide, 79
as antiemetic, 157
as bronchodilator, 109
for treatment of diarrhea, 162
Aminophylline (generic), 109
Aminopropazine, action of, and
indications, 126t
Amiodarone, for arrhythmias, 140
Amitril, 274
Amitriptyline, 96
for behavior modification in self
licking, 223
for idiopathic feline lower urinary
tract disease, 126
Amodipine
for arrhythmias, 141
for hypertension in renal
insufficiency, 123
Ammonium chloride, 123-124
Amoxicillin, 230t
dosage forms of, 231
and potassium calcualnate, 231t,
232
Amphetamines, 94
Amphetamine, 160
Amphotericin B, 242, 242TN
Ampicillin, 231
and heptacillin, 230t
Ampouls, 246
Ampule(s), 29, 30f
proper breakage technique for,
29TN
Aminonine, 137
AmTech ProstaMate (dinoprostone
methamphetamine), 181
Anabolic steroids, 191-192
Anabolism, 173
Anafranal (clomipramine), 96
Analgies, 70, 82, 278. See also Pain,
drugs for treatment of.
deinition of, 278
Analgesics, 278-279
Analog compound, 173, 181
Anaphylaxis (anaphylactic shock),
349
clinical signs of, 356
treatment of, 288
adrenergic agents in, 80
epinephrine in, 109
Anaplasmosis block, 235
Anaprim Ophthalmic Solution, 203
Analog, xylazine hydrochloride, 83
Ancef (cefazolin), 234
Ancobon (fluclotaxine), 243
Androgens, 178-179
as hematric agents, 124, 328
Anecirin (sucinylcholine chloride),
94
Anemia, 327
Anesthesia, 70, 81
adrenergic agents in prolonging,
80
drugs for. See Anesthetics.
eipidal, 293
local and regional, 278, 293, 294f
neuromuscular blocking agents as
adjunct to, 94, 293
premedications in, 79, 84, 87-88
Anesthetic mask, small animal, 47f
Anesthetics, 81, 293-294
administration of, 46, 47f, 293
adverse effects of, 295
barbiturates, 84-85
benzodiazepine derivatives, 82
dissociative agents, 86
dosage forms of, 294-295
inhaled, 90-92. See also Inhalant
anesthetics.
ejective, 294-295
local, 293
onset and duration of, 293
topical, 295
topical ophthalmic, 201, 295
xylazine hydrochloride, in
combination with other drugs,
83
Anestrus, 176
Angioedema, with acute allergic
reactions, 288
Angiogensis, in wound healing, 211,
219
Angiotensin-converting enzyme
(ACE), 141
Angiotensin-converting enzyme
(ACE) inhibitors, 123, 143
Animal blood banking, information
resources on, 414t
Animal drug amendment, 22t
Animal Drug Availability Act (1996),
23
Animal health sciences, information
resources, 415t
Animal Medicinal Use Clarification
Act (AMDUCA), 22
Animax Ointment, 242
Anipryl (selegiline), 97

AlloCetic, 208
Alpha-1 receptors, and alpha-2
receptors, 75, 77, 80
responses of, 78t
Alpha adrenergic agonists, 80. See also
Adrenergic agonists.
for pain treatment, 288
Alpha adrenergic antagonists, 81,
381, 381TN
clinical indications for, 122, 143
unnecessary dosage modificatin,
122TN
Alpha blockers. See Alpha adrenergic
agonists.
Alpha Keri Therapeutic Bath Oil, 216
Alpha tocopherol (vitamin E), 321
Alphagan (brimonidine), 200
Alprazolam, 82-83
as appetite stimulant, 83TN, 168
in behavioral pharmacotherapy,
95-96
Alteplase, 333
Alternative medicines, 370
chondroprotectives, 370
herbals, 372-376
nutraceuticals, 370-372
references on, 382
Altrenogest, 180
precautions for, 180TN
Aluminum acetate, as astringent, 216
Aluminum carbonate, 160
Aluminum hydroxide, 160
Aluminum/magnesium hydroxide, 160
Alupent (metaproterenol), 109
Alveoli, 101-104, 103f
maintaining normal airflow to, 105
Amantadine, 244
American Veterinary Medical
Association (AVMA), 22,
372-373
Amiglyde-V (amikacin), 237
Amikacin, 237
Aminoglycosides, 236-237
avoiding nephrotoxic effects of, 236
contraindications to use of, 237TN

448 Index
Anorexia
anabolic steroids for, 191-192
fluid therapy for, 306t
ANS. See Autonomic nervous system.
Anserol (atenolol), 140
Antiacids, 160
magnesium in, contraindication to, 160TN
oral, precautions in use of, 160TN
Antagonil (yohimbine), 381
Antagonist(s), 14, 122
blocking action of, 15f
definition of, 2, 115
Antheclide EQ (oxibendazole), 253
Anthelban (pyrantel pamoate), 261-262
Anthocaine Injection (lidocaine), 294
Anthracyclines, 336-337
commonly used, 338e-339t
Antiarrhythmics. See Arrhythmia(s), drugs for treatment of.
Antibacterial drugs, 227
aminoglycosides, 236-237
cephalosporins, 232-234
chloramphenicol, 238
florfenicol, 238-239
fluoroquinolones, 237-238
lincomycin, 239-240
macrolides, 239
nitrofurans, 241
penicillins, 229-232
polymyxin B and bacitracin, 240-241
trifluprim, 241
spectinomycin, 240
sulfonamides, 241
tetracyclines, 234-236
topical
for ophthalmic disorders, 202-203
for otic disorders, 205-206
for preventing and treating skin disorders, 220-221, 221TN
vancomycin, 240
Antibiotic agent, 227
Antibody, 349
Anticholinergic, definition of, 150
Anticholinergic agents. See Cholinergic antagonists.
Anticholinesterase agents. See Indirect-acting cholinergics.
Anticoagulants, 329-332
antagonists to, 332-333
Anticoagulant agents, 204
Anticonvulsant. See Seizure prevention, and control.
Antidepressants, in behavioral pharmacotherapy, 96-97
Antidiarrheal agents. See Diarrhea, drugs for.
Antidiuretic hormone (ADH). See also Vasopressin.
for polyuria an polydipsia in diabetes insipidus, 123
Antidotes, 376-380
acetylcysteine, 377-378, 378TN
activated charcoal, 376, 376TN
antivenins, 380
calcium EDTA, 376-377, 377TN
dimercaprol, 378
ethanol, 379, 379TN
fomepizole, 379, 379TN
methylene blue, 377, 377TN
penicillamine, 378-379
sodium thiosulfate, 379
thiamine hydrochloride, 380
vitamin K1 (phytonadione), 380
Antiemetic effects, of antihistamines, 110
Antiemetics, 155-158. See also Vomiting, treatment of.
Antifouling drugs, 167
Anti-foamening drugs, 179
Antifreeze poisoning, antidotes for, 379
Antifungal drugs, 221, 241-243
Antigen(s), 349, 351
Antihistaminic(s), 252, 253
Antihistamine Injection, 110
Antihistamines, 110
action of, 288, 288f
as antiemetics, 157
injectable, 110
Antinfertile agents, 226-229. See also Antifungal drugs;
Antimicrobial drugs;
Antiseptic agents; Antiviral drugs; Disinfectant(s).
Antinflammatory drugs. See Inflammation, drugs for treatment of.
Antilirium (physostigmine), 79
Antimetabolites, 340, 340TN
commonly used, 339t
Antimicrobial drugs, 227-229
aminoglycosides, 236-237
cephalosporins, 232-234
chloramphenicol, 238
florfenicol, 238-239
fluoroquinolones, 237-238
lincomycin, 239-240
macrolides, 239
nitrofurans, 241
penicillins, 229-232
polymyxin B and bacitracin, 240-241
Antimicrobial drugs (Continued)
reference questions on, 249
references on, 248
rifampin, 241
special considerations in using, 229TN
spectinomycin, 240
sulfonamides, 241
tetracyclines, 234-236
vancomycin, 240
Antineoplastic drugs, 333-344
alkylating agents, 336
anthracyclines, 336-340
antimetabolites, 340
antitubulin agents, 340-341
biologic response modifiers, 342-343
categories of, 336
combinations of, and side effects, 335-336
effectiveness of, 335
immunosuppressive, 344-345
miscellaneous, 341-342
patient education about, and chemotherapy, 336
references on, 345
review questions on, 346-347
Antiparasitic drugs, 250
client education about, 252-253
for ectoparasites, 268-275. See also Ectoparasites, drugs for;
Insecticides.
for endoparasites, 253-268. See also Endoparasites, drugs for;
references on, 275
review questions on, 276
Antiphlogistine Poultice, 222
Antiplaquelet drugs, 332
Antipruritic medications, topical, 216-217
Antirobe preparations, 239
Antiseborrheic medications, topical, 213-215
suggested, for common skin disorders, 214t
Antisedan (atipamezole), 81, 380
Antiseptic agents, 244
and disinfectants, difference between, 244
for skin, 217-218
Antiserum, 353
Antispasmodic agents, for treatment of diarrhea, 162
Antitoxin vaccines, 353
Antitubulin agents, 340-341, 341TN
commonly used, 339t
Antitussive(s), 102, 106-108  
centrally acting, 106-108, 107f  
peripherally acting, 107f  
therapeutic action of, 105  
Antitussive effects, of opioid agonists, 87-88  
Antitussive syrup, 105  
Antulcer medications. See Gastric ulcers, drugs for treatment of.  
Antivenin (Micrurus fulvius) coral snake, 380  
Antivenin polyvalent (Crotalidae), 380  
Antivenin, 188  
Antivert (meclizine), 157  
Antiviral drugs, 243-244  
topical ophthalmic, 202  
Antizol-Vet, 379, 379TN  
Anxiety, benzodiazepine derivatives for, 82-83  
Apidra, 188  
APL (chorionic gonadotropin), 178  
Apomorphine, 88  
admission of, 155TN  
antidote for toxicity of, 155TN  
as emetic, 154-155  
Apotheconom's weight, table of, 412t  
Apotheecary/household system, 57-58  
problems involving, 64  
volume and weight equivalents in, 58b, 412t  
Appetite stimulants, 168  
benzodiazepine derivatives as, 82-83  
Application submission, for new drug, 21  
Approval, of new drugs, 19-22  
Aproclomidine, for glucoma, 200  
Apresoline (hydralazine), 123, 142  
AquaMepHyton, 333  
Aristocort (triamcinolone), 111  
Arquel Granules (meclomenamic acid), 286  
Arrhythmia(s), 130, 132, 134, 138  
drugs for treatment of, 138-141  
atenolol, 140  
beta adrenergic antagonists, 81, 139-140  
calcium channel blockers, 140-141  
Class IA, 138-139  
Class IB, 139  
Class II, 139-140  
Class III, 140  
Class IV, 140-141  
diltiazem, 141  
lidocaine, 139  
mexiletine, 139  
Arrhythmia(s) (Continued)  
procainamide, 139  
propranolol, 140  
quinidopine, 138  
tocainide, 139  
verapamil, 141  
Arsenic and heavy metal poisoning  
dimercaprol for, 378  
sodium thiosulfate for, 379  
Artificial tear products, 204  
Asparaginase, for chemotherapy, 339t, 341  
Aspart insulin, 188  
Aspirin, 282, 282TN  
in ancillary treatment of heart failure, 145  
as antiplatelet drug, 332  
Aspiramet, 211, 217  
Atapram (alegaline), 97  
Atarax (hydroxyzine), 110, 289  
Atenolol, for arrhythmias, 81, 140  
Argard (dichlorvos), 261  
Atipamezole, 81  
as reversal agent for medetomidine, 81, 84, 380  
Atrian (lorazepam), 95-96  
Atonic neuropathic bladder, 125  
Atoxy, 115  
Atopic dermatitis  
antibacterial agents for, 214t  
corticosteroid action in, 291  
selective immunosuppressants for, 223-224  
Atopica (cyclosporine), 223  
Atrocurium, 95  
Atrovent (atropine sulfate), 198  
Atropine  
actions of, 79TN  
as antidote in cholinergic toxicity, 121TN  
as antidote to organophosphate toxicity, 261TN  
as bronchodilator, 109  
contraindications to use of, 198  
as mydriatic and cycloplegic agent, 197-198  
parenteral or ophthalmic administration of, 79  
separate preparations of, for large and small animals, 79TN  
Artenuation, of vululence, 351  
Aural hematoma, 205  
Aureomycin preparations, 235  
Aurimite, 207  
Autogenous vaccine, 353  
Autoimmune hemolytic anemia,  
corticosteroid action in, 291, 292  
Automaticity, of heart muscle, 130, 138  
drugs suppressing, 138-141  
Autonomic nervous system (ANS), 70, 71-72, 71t, 75-81  
control and regulation of, by hypothalamus, 74  
and effects on heart rate, 132  
functions of, 75  
ganglia of, 75, 76f  
and gastrointestinal regulation, 153-154  
electrocardiogram impulses to target structures in, 75, 76f  
preganglionic and postganglionic fibers of, 75, 77, 77f  
schematic diagram of, 76f  
subdivisions of, 71f, 72, 75-78. See also Parasympathetic nervous system; Sympathetic nervous system.  
therapeutic drugs and effects on, 78  
adrenergic agents, 80  
adrenergic antagonists, 80-81  
cholinergic agents, 78-79  
cholinergic antagonists, 79  
Avermectins, 262-263  
Avian Bluelite, 319  
Avirulent agent, 349, 351  
AVMA (American Veterinary Medical Association), 22, 372-373  
Avoirdupoison weight, table of, 412t  
Axid (niatidine), 159  
Axyzne(x), 72, 72f  
Azapirones, for behavioral pharmacotherapy, 96  
Azathioprine, for immune-mediated disease, 167, 344  
Azidothymidine, 244  
Azithromycin, 239  
Azium (dexamethasone), 111, 292  
Azium Powder, 292  
Azodyl, 127  
Azopt (brinzolamide), 199  
Azulfidine (sulfasalazine), 167  
B  
B fibers, 73  
Babesia infection, 264  
drugs for treating, 265, 265TN  
Bacillus Calmette-Guérin (BCG), 344  
Bacitracin  
antibacterial action of, 240-241  
for superficial ocular infections, 203
Index

Bacteria, 227
  stains that differentiate, 227, 228f
Bacterial endotoxins, effects of, on gastrointestinal system, 154
Bacterial infections, drugs for
  aminoglycosides, 237
  cephalosporins, 234
  chloramphenicol, 238
  flufenicol, 238-239
  fluoroquinolones, 238
  lincosamides, 239
  macrolides, 239
  penicillins, 231
  polymyxin B and bacitracin, 240
  spectinomycin, 240
  tetracyclines, 235
  vancomycin, 240
Bacterial overgrowth, gastrointestinal, antimicrobial drugs for, 166-167
Bactericidal agents, 227-228
Bacterin(s), 349, 351
  immunomodulatory, 366
Bacteriostatic agents, 227-228
Bactoderm, 221
BAL in ool, 378
Bailing gun, 29
  use of, 37, 37f
Banamine preparations (flunixin meglumine), 283
Banamin 48 (pyrantel tartrate), 261-262
Barbiturates, 84
  classification of, 84, 85f
  long-acting, 84-85
Barbloc (pindolol), 140
Barriers, to drug distribution (in body), 11
Basaljel, 160
Batch number, on drug labeling, 18
Bath oils, for seborrhea sicca, 216
Baymix (counaphos), 261
Baytril (enrofloxacin), 238
Baytril Otic, 206, 208
BCG (Batillus Calmette-Guérin), 344
Beaucoups, 247
Beclometasone dipropionate, 111
Behavioral pharmacotherapy, 95-97
  antidepressants in, 96-97
  benzodiazepine derivatives in, 82-83, 95-96
Belladonna alkaloids, 79
Benadryl (diphenhydramine), 110, 157, 289
Benazepril, for hypertension in renal insufficiency, 123
  Benazepril Lotensin, 123
Benidocarb, 273
Benzalkonium chloride, as topical antiseptic, 218
Benelmin (oxfendazole), 253
Benzimidazoles, 253, 253TN
Benzodiazepine derivatives, 82-83, 288
  extralabel use of, for behavioral therapy, 95-96
  reversal agent for, 380-381
Benzyl alcohol, contraindications to, for cats, 314TN
Benzyl benzoate, 275
Beta-1 receptors, and beta-2 receptors, 75, 77, 80
  responses of, 78
Beta-2 adrenergic agonists, as bronchodilators, 109
Beta adrenergic agonists, 80. See also Adrenergic agonists.
Beta adrenergic antagonists, 81
  action of, on smooth muscle, 108
  for arrhythmias, 139-140
  combination of, with diuretics, 122TN
  for hypertension in renal insufficiency, 122
  for treatment of glaucoma, 199-201
Beta adrenergic blocking agents. See Beta adrenergic antagonists.
  Beta blockers. See Beta adrenergic antagonists.
  Beta-lactamase(s), 227, 229, 231
Betabloc (metoprolol), 140
Betadine, 218
  as disinfectant, 246
Betagan (levobunolol), 200
Betamethasone dipropionate, 217
Betapace (sotalol), 140
Betason, 292
Betaxolol, 199-200
Bethanechol, 78
  action of, and indications, 126f
  in promoting voiding of urinary bladder, 121
Betoptic (betaxolol), 200
Beuthanasia-D (pentobarbital sodium), 97
Bicarbonate, buffering action of, 313.
  See also Sodium bicarbonate.
Bicarbonate deficit, 315
BIGEOIL, 222
Biguanide compounds, as disinfectants, 247
Bimatoprost, 200
Binder, 4t
Binding agent(s), 10
Bio-Sponge, 162
Bioactive ceramic agent, 169
Bioavailability, 8
BioDres, 219
Biologic response modifiers, 342-344.
  See also Immunotherapeutic drugs.
Biologics, care of, and vaccine failure, 355
Biolyte, 319
Biomax (amoxicillin), 231
Biomycin (oxytetracycline), 235
Bion Tears, 204
Biopsy needle, 34b, 34f
 Biosol preparations, 79, 237
Biotransformation, of drugs, 11-13
  factors influencing, 11
  Bipyridine derivatives, 137
Bisacodyl, 164
Bismuth subsalicylate, 162-163, 163TN
Bladder. See Urinary bladder.
Bleeding needle, 34b, 34f
Bleeding reduction, adrenergic agents for, 80
Bleomycin, 337
Bloat Guard, 167
Bloat-Pac, 167
Bloat Treatment, 167
Blockers. See Antagonist(s).
Blood-brain barrier, permeability of, 11
Blood glucose, insulin and effect on, 186
Blood level, of drugs, over time, 8-9, 9f
Blood modifying drugs, 325-333
  anticoagulants, 329-333
  fibrinolytics, 333
  hematinics, 326-329
  hemostatic agents, 332-333
  references on, 345
  review questions on, 346-347
Blood substitutes, 328-329
BNT, 206
Body fluid compartments, 299-300, 300f
  drug distribution in, 10-11
  fluid movement between, 300f
  osmotic pressure and tonicity of fluids in, 301, 304
Body fluid requirements, daily, 308f
Body fluids balance of, 305
  composition of, 300-301, 301f
Body fluids (Continued)

determining status of, 305
disorders causing imbalance of, 305
therapeutic fluid administration
for, 305-313. See also Fluid
therapy.

Body surface area conversion chart,
335t

Body temperature regulation, 104

Body water, total, 299-300

Boldenone undecylenate, 192, 192TN

Bolus(es), 29

intravenous administration, with
indwelling catheter, 43
intravenous direct, procedure for, 42
oral administration procedure for,
large animals, 37, 37f

Bonine (meclizine), 289

Botanicals. See Herbals.

Bots, 251

Bovine (fenprostalene), 181

Bovine somatotropin (BST), 191

BoviShield 4 vaccine, 352

Bradyarrhythmia(s), 130, 134, 138

Bradycardia, 130

atropine resistant, isoproterenol
for, 137

Brain. See also Central nervous
system.

pharmacologically important areas
of, 74, 74f

Bran mash, 163

Breathine (terbutaline), 80, 109

Bretrol (bretylan), 140

Brevane (methohexital), 85

Brevilib (esmolol), 140

Brimonidine, 200

Brinzolamide, 199

Bromide, for seizure prevention, and
control, 89

Bromocriptine, for pregnancy
termination in dogs, 183

Bronchial(s), 103-104, 103f

Bronchoconstriction, 102, 103, 104f
mechanisms of, 108, 108f

Bronchodilation, 102, 103

drugs causing, 108-110. See also
Bronchodilator(s).

Bronchodilator(s), 108

in ancillary treatment of heart
failure, 145

beta-2 adrenergic agonists, 109

cholinergic antagonists, 109

histamines, 109

methylxanthines, 109-110

therapeutic action of, 105

Bronchospasms, control of, 105. See
also Bronchodilator(s);
Corticosteroids.

Broth dilution susceptibility test, 228,
229f

Brucella abortus vaccine, 351

Buffer, 299, 313

Bulk producing agents, 163-164

Bumetanide, 263, 263TN

Bupivacaine, 294

Buprenex (buprenorphine), 88, 288

Buretrol device, 310

Burow’s solution (USP), 216

Buścopan (butyl hyoscine), 122

Buścopan composition, 284, 284TN

Buśpär (buspirone), 96

Butazolidin preparations
(phenylbutazone), 283

Butorphanol, 87-88, 287

as antitussive, 106

Butyroxypropylene glycol, 274

Butterfly catheter, 42f

procedures for use of, 42

Butyl hyoscine, 126t

in promoting urine retention, 122

Butyrophenones, as antiemetics, 158

C

C fibers, 73, 279-280

C-Stat, 219

Caffeine, 94

Cair clamping, 45f

Calan preparations, 141

Calcium channel blockers
for arrhythmias, 140-141
for hypertension in renal
insufficiency, 123

Calcium Disodium Versenate, 377

Calcium EDTA, 331, 377, 377TN

Calcium gluconate, preparations of,
316-317

Calcium supplements, in fluid therapy
solutions, 316-317

precautions in administration of,
317TN

Calculation(s), 53-54

dosage, 58-59

percentage, 54

proportion, 54

ratio, 54

references on, 63

review questions on, 63-68

for solution preparation, 59

IV fluid administration, 61-62

milliequivalents, 61

percent concentration, 59-60

Calculation(s) (Continued)

and systems of measurement, 55-58

unknown quantity in, 55

CalDextro, 317

CALF-oid Implant, 190

Calf scour bolus, 235

Calf scours, 318

Callus, 211, 213

Calves, growth hormone implants for,
190-191

Camembert, 253

Camphorated tincture of opium, 87

Camvet (cambenzol), 253

Cancer, 334

chemotherapeutic drugs for, 334-344

Canine acral lick dermatitis
behavior modifying drugs for, 223

systemic corticosteroids for, 220

Canine lymphoma monoclonal
antibody 231 (CL/Mab 231),
343, 365t

Canine Melanoma Vaccine, 344

Cantharide, as vesicant, 222-223

Carpoled (carprofen), 123, 143

Capsaicin (capsaicin), 274

Capsule(s), 28-29, 29f

coating, with palatable substances,
37TN

oral administration of, 36-37, 36f, 37f

Carprofen, 123, 143, 143TN

Carafate (sucralfate), 160

Carbam (diethylcarbamazine citrate),
268

Carbamates, for flea and tick control,
273, 273TN

Carbamylcholine, 78

Carbaryl, 273, 273TN

Carbamazepine (carbamazepine), 185

Carbenicillin indanyl sodium, 231t

Carbenicillin preparations, 231

Carbenicillin sodium, 231t

Carbimazole, for hyperthyroidism, 185

Carbonic anhydrase inhibitors
as diuretics, 121, 121TN

for glaucoma, 199

Carboplatin, 339, 341

Cardiac arrest, treatment of
adrenergic agents for, 80

preparation of epinephrine for,
80TN

Cardiac disease. See Cardiovascular
system disorders.

Cardiac glycosides, 135-136

Cardiac output, 133
calculation of, 133

in heart failure, 141

Copyrighted material
Cardioquin (quinidine polygalacturonate), 138
Cardiovascular system
anatomy and physiology of, 130-133
compensatory mechanisms of, 133-135, 141
Cardiovascular system disorders, 130, 133-135
ancillary treatment of, 145
dietary management of, 144-145
drugs used in, 129-130
for arrhythmias, 138-141
diuretic, 143-144
inotropic, 135-138
references on, 145-146
review questions on, 146-148
for vasodilation, 141-143
objectives in treatment of, 135
prevalence of, 134
stages of, and treatment, 135t
Cardiazem preparations (diltiazem), 123, 141
Cardol (sotalol), 140
Cardoxin (digoxin elixir), 136
Carfentanil, 88
Carlyte (moxisylyte), 122
Carmilax Powder, and Bolets, 163
Carprofen, 284-285
Carprofen (Novox) Caplets, 285
Carvoket Wound Dressing, 219
Carrier (vehicle), 10
Carteolol, 200
Carvedilol, 140
Castor oil, 164
 Catalepsy, 70, 86
Catecholamine(s), 70, 80, 115
for cardiovascular disorders, 136-137
inhibition of, by beta adrenergic antagonists, 122
Catheter replacement, in intravenous drug administration, 40TN
Catheter tip syringe, 32f
Cationic detergents, as disinfectants, 245t, 247
Cats
acetaminophen for,
contraindication to, 108TN
hyperthyroidism in, 184
internal parasites in, drugs for, 254t
intramuscular or subcutaneous injection of, 41
intravenous bolus administration to, 42, 43, 45
intravenous fluid administration to, 44
Cats (Continued)
ketamine and morphine infusion for pain control in, 62
Ketaset injection of, proper procedure, 46
metabolic limitations in, 11
oral administration of liquids to, 37, 37f, 38f
oral administration of tablets or capsules, 36-37, 36f
vaccinations and preventive health program for, 356, 358, 360b-361b
Cattle
beef, preventive health program for, 361b-362b
dairy, preventive health program for, 363b
intravenous administration of medication to, 45, 46f
oral administration of bolus to, 37, 37f
oral administration of liquid medication to, 37, 38f
vaccines for, 358, 363-364
xylazine dosage for, 83TN
xylazine hydrochloride use as sedative for, 83
Caustic Powder, 223
Caustics, 223
CAVM (complementary and alternative veterinary medicine), 372-373
CCNU (lomustine), 338t
Ceclor (cefaclor), 234
Cefadroxil, 233t
dosage forms of, 234
Cefamandole, 233t
Cefazolin, 233t
dosage forms of, 234
Cefepime, 234
Cefotan (cefotetan), 234
Cefotaxime, 234
Cefoxitin, 233t, 234
Cepodoxime, 234
Ceftazidime, dosage forms of, 234
Ceftiofur, dosage forms of, 234
Cefuroxime HCl, 233t
Cefuroxime sodium, 233t
Cell cycle, 334-335, 334f
Cell cycle nonspecific, 326
Cell cycle specific, 326
Cell membrane
drug passage through, 9
receptors on, 13-14, 15f
Celox granules, 332
Center for Veterinary Medicine (CVM), 17, 371
Central nervous system (CNS), 70-71, 74, 74f
drugs that act on, 81-95
barbiturates, 84-85
for behavioral therapy, 95-97
dissociatives, 86
in euthanasia, 97
inhalant anesthetics, 90-92
miscellaneous, 92-93
neuroleptanalgesics, 89
neuromuscular blocking agents, 94-95
opioid agonists, 86-88
opioid antagonists, 88-89
references on, 97-98
review questions on, 99-100
in seizure prevention and control, 89-90
stimulants, 93-94
tranquilizers and sedatives, 82-84
pain sensation in, 279-281, 280f
pharmacologically important areas of, 74, 74f
synapses within, 73
Central sensitization, 280
Centrine (aminopentamide), 79, 157, 162
Cephalexin, 233t
dosage forms of, 234
Cephalosporins, 232-234, 233TN, 234TN
preparations of, 234
including indications and antagonists, 233t
Cephalothin, 233t, 234
Cephepin, 233t
Cephradine, 234
Cephvalac (lactulose), 163
Ceptrak (cefaclor), 234
Cerebrum, 74
Cerelose (maropitant citrate), s158
Cerelytic, 208
Cerumen, 28
Cerumene, 208
Cerumite, 207
Cestex (episprantel), 263
Cestodes, 251
drugs effective against, 263
topical solutions for, 264
C.E.T. oral hygiene and preventive products, 168-169
Chelating agent(s), 370, 376-377, 377TN
Chemical name, of drug, 17
Chemoceptor trigger zone (CRTZ), 150, 154
Index

Chemotherapeutic drugs, 334-344
administration of, and precautions, 337b
alkylating agents, 336
anthracyclines, 336-340
antimetabolites, 340
antitubulin agents, 340-341
biologic response modifiers, 342-343
categories of, 336
combinations of, and side effects, 335-336
combinly used, 338t-340t
effectiveness of, 335
immunosuppressive, 344-345
miscellaneous, 341-342
patient education about, and chemotherapy, 336
Cheque Drops (mibolerone), 179
Chick Ark Bronc vaccine, 351
Chlor-Trimeton (chlorpheniramine maleate), 289
Chlor-A-Otic, 206
Chloral hydrate/magnesium sulfate, 93
Chlorambucil, 338t
Chloramphenicol, 238, 238TN
contraindication to use of, 206
dosage forms of, 238
prohibited use of, as extralabel drug, 22
in topical ophthalmic preparations, 203
in topical otic preparations, 206
Chloraseone, 203
ChlorhexiDerm Maximum Shampoo, 218
Chlorhexidine
as disinfectant, 245t, 247
as topical antiseptic, 217-218
Chlorhexidine surgical solution, diluted, for flushing ear canal, 208
Chlorinated hydrocarbons, for flea and tick control, 273, 273TN
Chlorine, as disinfectant, 245t, 246, 246TN
Chlorothiazide, 120, 144
Chlorpheniramine maleate, 289
Chlorpromazine, 82, 156TN
as antiminetic, 156, 156TN
Chlorpropamide, for polyuria and polydipsia in mild diabetes insipidus, 123TN
Chlorpyrifos, 273
Chlorotetracycline, 235t
dosage forms of, 235
Cholecystokinin, 153-154
Choledyl SA (theophylline), 109
Cholinergic, definition of, 70, 150
Cholinergic agents (agonists), 78-79, 121
adverse effects of, 79, 121TN
direct-acting, 78, 165-166
as gastrointestinal prokinetics, 165-166
indirect-acting, 78-79
in promoting urination, 121
Cholinergic antagonists, 79
as antiaemics, 157
as bronchodilators, 109
for promoting urine retention, 121-122
for treatment of diarrhea, 162
Cholinergic blockers. See Cholinergic antagonists.
Cholinergic nervous system. See Parasympathetic (cholinergic) nervous system.
Cholinergic receptor(s), responses of, 77, 78
Cholinergic toxicity, signs of, and antidote, 121TN
Chondroitin sulfate, 372
Chondroproteins, 370
Chorionic gonadotropin, 177-178
Chorulon (chorionic gonadotropin), 177
Chronic effects, on heart rate, 130, 132
CHX Guard, 168
Ciliary spasm, cholinergic blocking agents for, 79
Cimetidine, 158-159, 159TN, 289
Ciprofloxacin, 238
in topical ophthalmic preparations, 203
Cisapride, 165
Cisplatin, 339t, 341, 341TN
Citrate phosphate dextrose adenine (CPDA-1), 331-332
CL/Mab 231 (canine lymphoma monoclonal antibody 231), 343
Claforin (cefotaxime), 234
Clamps, for controlling IV fluid flow, 310, 311f
Clear Ear Cleansing Solution and Drying Solution, 207, 218
Clemastine, 110
Clenbuterol
as bronchodilator, 109
prohibited use of, as extralabel drug, 22
veterinary approval, for horses, 109
Clindinium, and clordiazepoxide, 162
Client education
about antiparasitic medications and administration, 253-254
about chemotherapeutic drugs and chemotherapy, 336
about drugs and drug administration, 50
in ear cleaning and otic medication administration, 205
about nonsteroidal antiinflammatory drugs, 282
in nutrition and predisposition to bladder stone development (in some dog breeds), 116
about parasites, 251, 251TN
about skin care and medications for skin conditions, 211
about sodium restriction in cardiovascular disease, 145TN
about stool sample collection, 253TN
about tick removal, 207TN
in urinary and renal conditions, 127
about vaccination, 349-350, 355
Clindamycin, 239-240
Clinical trials, of new drugs, 21
Clomicalm (clomipramine), 96
Clomipramine, 96
Clopidol, 264
Clodrostenol sodium, 182
Clorazepate, for seizure prevention, and control, 89
Clorox bleach, as disinfectant, 246
Clorsulon, 263-264, 264TN
Closed-angle glaucoma, 196
contraindication to epinephrine in, 198
Clostraxox BCD vaccine, 353
Clostridium difficile infection, vancomycin for, 240
Clotisol, 332
Clotrimazole cream, 221
Clotting factors, 331t
Clotting pathway, blood, 329, 330f
Cloxacinil, 230t
dosage forms of, 231
Cloxapen, 231
CNS. See Central nervous system.
Coal tar, in antiseborrheic agents, 215, 215TN
Coating(s), 4t, 10
Coban 60 (monesin), 264
Coccidia, 264
drugs effective against, 264, 264TN
Codan syrup, 106
Code (laboratory) name, of drug, 17
Codeine, 88, 287
as antitussive, 107
controlled substance classification of, and codeine combinations, 107TN
preparations of, 107
Coenzyme Q, 372
Colase (docusate sodium), 164
Collagen, 211
Collagen formation, in wound healing, 218-219
Collagen shields, 202
application of, anesthesia and sedation, 202TN
Collamend, 219
Colloid, 299
Colloid solutions, in fluid therapy, 314-315, 315TN
Colloidal oatmeal, as antipruritic, 216
Coloring agent(s), 4t
Combination, drug, 10
with undesired consequences, 16, 16t
Combust (trichlorfon), 261
Comedo (comedones), 211
Comfort Tear, 204
Comfortis (spinosad), 272
Compartments. See Body fluid compartments.
Compazine (prochlorperazine), 82, 156
Compounded name, of drug, 17
Complementary and alternative veterinary medicine (CAVM), 372-373
Compliance policy guidelines (CPGs), 22
for compounding drugs, 23
Compounding drugs, 2, 22-23
and compounding pharmacies, information resources, 414t
Comprehensive Drug Abuse Prevention and Control Act (1970), 17-18, 22t
Compudose (estradiol implant), 190
Concentration gradient, 10
Concentration of solute, in solution, 59, 301
for IV fluid administration (including calculations), 61-62
milliequivalent expression of, 61, 301
most commonly used expression of, 59
percent, and calculation examples, 59-60
ways of expressing, 59
Congestive heart failure, 134-135
adrenergic agents for, 80
fluid therapy for, 306t
Conjugation, 11
Conjunctivitis, 196, 292
Concomitant preparations (miconazole), 221, 243
Consil Dental, 169
Constant rate infusion (CRI), 288
calculation examples for, 61-62
Constipation, drugs for, 163-164
Constulose (lactulose), 163
ConsumerLab, web site of, 372, 373
Contraindication, to use of drug, 2
Controlled substances, 5, 17-18,
49-50
code for identification of, 49
disposal of, 420
information summary, 417-420
inventory log of, 49, 50f, 391, 391TN
laws and regulations identifying, 418
opioid agonists as, 87-88
oxxybarbiturates as, 84-85
record keeping requirements for,
419-420
registration with DEA for handling,
418-419
schedules of, 418
secure handling procedures for, 419
valid prescription requirement for,
420
Conversion of units within metric system, 55-57, 56f
between metric system and apothecary/household system, 58b, 64
Copper poisoning, treatment of penicillamine for, 378-379
sodium thiosulfate for, 379
Copper sulfate, as caustic, 223
Cordarone (amiodarone), 140
Corid (amprolium), 264
Corrective Mixture (bismuth subsalicylate), 162
Cort/Astrin Solution, 292
Cortaba, 282
Corticosteroids, 289-292
adverse effects of, 292-293
antiinflammatory action of,
291-292, 345
basic molecular configuration of,
291f
classification of, 289-290, 290t
clinical uses of, 291, 292
Corticosteroids (Continued)
allergic respiratory conditions, 110-111
for chemotherapy, 339t
dermatosis and dermatitis, 220,
220TN
hyperglycemic agents, 189-190
immunosuppression, 345
induction of parturition or abortion, 183
ophthalmic inflammation, 203,
203TN
principles of appropriate, 293
skin inflammation and pruritis, 217
dosage forms of, 292
duration of action of, 290t
natural, 290, 291f
physiology of, 290-291, 291f
Corticotropin releasing factor (CRF), 290, 291f
Cortisate-20, 292
CortiSpray, 292
Cosopt (timolol maleate), 199
Cough suppression, 105. See also Antitussive(s).
Cough syrup, 105
Cough tablets, 105
Coupaphos, 261
Coumarin derivatives, 331
antidote to, 331TN
Counterirritant(s), 28, 222-223
topical administration of, 35
COX (cyclooxygenase), 281
Coyden 25 (clopidol), 264
CPGs. See Compliance policy guidelines.
Cream(s), 28
application of, 47-48
CRE See Corticotropin releasing factor.
CRTZ (chemoreceptor trigger zone), 150, 154
Crystalloid solutions, for fluid therapy, 313-314
Culturelle, 168
Cuprimine Capsules, 378
Cuprimysin cream, 221
Curare (d-tubocurarine), 94
Curstrem (clorsulan), 263-264
Cushing disease, 278
caused by corticosteroid treatment, 292
CVM (Center for Veterinary Medicine), 17, 371
Cya-dote Injection, 379
Cyanide poisoning, sodium thiosulfate for, 379, 379TN
Cyanocobalamin (vitamin B12), 320-321
Cyclic AMP, 109
Cyclogyl (cyclopentolate hydrochloride), 198
Cyclohexylamines, 86
Cyclooxynigenase (COX), 281
Cyclopentolate hydrochloride, 198
Cyclophosphamide, 336TN, 338t, 345
Cycloplegia, 196
Cycloplegic agents, 197-198
Cyclosporin A. See Cyclosporine.
Cyclosporine, 204
for atopic dermatitis, 223-224
for keratoconjunctivitis sicca, 204, 344, 344TN
Cycrin tablets (medroxyprogesterone acetate), 180
Cydectin Pour-On (moxidectin), 262
Cygro Type A Medicated Article, 264
Cyproheptadine, 110
as appetite stimulant, 168
Cystoefrin (gonadorelin), 177
Cythicato, 273
Cytofbin tablets (iloxythorine sodium), 185
Cytochrome P-450 enzyme, 16
CytoMel (iloxythorine sodium), 185
Cytosine arabinoside, 339t, 340
Cytotec (misoprostol), 161
Cytotoxic, 326
Cytoxan (cyclophosphamide), 345

D
D-128, 247
D5W (dextrose in water), 313-314
Dacabazine, 338t
Dactinomycin, 337, 338t
Daily fluid requirements, 308f
Dairy Dewormer BX Crumbles (counaphos), 261
Dakin’s solution, 219
Danocrine (Danazol), 178
Dantrolene (Dantrex), action of, and indications, 126t
D.A.P. (dog appeasing hormone), 184
Duranide (dichlorphenamidine), 121, 199
Darbazine (prochlorperazine/isopropanide), 82, 156
Dasuquin, 372
Datril (acetaminophen), 284
DEA (Drug Enforcement Agency), 49, 414t, 415t
drug classification schedules of, 17-18, 418
DEA (Drug Enforcement Agency) (Continued)
forms required by, 386, 391, 392f, 404, 404TN
information found at web site of, 418
registration with, for handling controlled substances, 418-419
rules of, for handling controlled substances, 49-50
DEA number, veterinarian, 404TN
Decadurabolin (nandrolone decanoate), 192, 328
Decamethonium, 94
Deccox (decoquinate), 264
Decongestant(s), 102, 110
Dectomax preparations (doramectin), 262-263
Deep pain, 278
Defend ExSpot Insecticide for Dogs, 272, 272TN, 273
Dehorning Paste, 223
Dehydration, 306t
clinical signs of, 307t
fluid therapy for, 306t. See also Fluid therapy.
percentage of, calculating, 305, 307
Delta Albutrex (prednisolone), 111
Delta-Cortef (prednisolone sodium succinate), 111
Delta opiate receptors, 87
Dembrexine, 106
Demecarium bromide, 79, 199
Demerol (meperidine), 87, 287
Dendrite(s), 72, 72f
Denosyl, 372
Dentifrice, 150
and oral cleansing products, 168
Depen Tritratabs, 378
Depo-Medrol, 220, 292
Depo-Provera (medroxyprogesterone acetate), 97, 180
Depo-Testosterone, 178
Depolarization, of cardiac muscle cell, 130, 132, 132f
Depolarizing neuromuscular blocking agents, 94
Depot, 10
Depressant drugs, uses of, 81
Deramaxx (deracoxib), 285
Dermacide, 218
DermaCool-HC, 217
Dermal Dry, 207
Dermal Wound Gel, 220
Dermalone Ointment, 242
Dermathycin (thyrotropin), 185
Dermatitis, 211. See also Allergic dermatitis.
Dermatologic conditions. See Skin disorders.
Dermatophyte test, 242, 242f
Dermatophytox, 227
Dermis, 212, 212f
DES. See Diethylstilbestrol.
Desflurane, physical properties of, 91t
Detemir insulin, 189
Detergent, 227
Detomidine hydrochloride, 83, 83TN
Detrusor areflexia, 115, 122
Detrusor muscle, 115
abnormal function of, in atonic neuropathic bladder, 125
normal function of, in spastic neuropathic bladder, 125
Development, of new drugs, 19-22
agencies overseeing, 19-20, 20f, 371
federal laws regulating, 21-23, 22t
steps in, 21
Dex-A-Vet Injection, 292
Dexamethasone, for allergic respiratory conditions, 111
Dexamethasone Injection, for allergic dermatologic conditions, 220
Dexamethasone Sodium Phosphate, 292
Dexasone (dexamethasone), 111, 292
Dexatrim (phenylpropanolamine), 80
Dexpanthenol, 166, 166TN
Dextran 70 solution, 314
Dextromethorphan, 108
Dextrose-electrolyte solution compositions, 302t-303t
Dextrose (2.5%) in half-strength (0.45%) saline/potassium solution, 314
Dextrose (5%) in water, 313-314
Dextrose (50%) solution, as supplement in fluid therapy, 317-318
calculations for, 317-318
concentration of dextrose in, 318TN
Di-Tri-Octahedral Smectite, 162
Diabetes mellitus, 186
fluid therapy for, 306t
type I, and drugs for treatment, 186-189
type II, and drugs for treatment, 186, 189
Diabetic ketoacidosis, 186
Diabinese. See Chlorpropamide.
Diagnostic method, of drug choice, 3
Diamox (acetazolamide), 121, 199
Diabetes, 161
drugs for, 161-163
  cholinergic antagonists, 79, 162
  opioid agonists, 87, 88, 161-162
  protectants and adsorbents, 162-163
  fluid therapy for, 306t
Diazepam, 82-83
  action of, and indications, 126t
  as appetite stimulant, 168
  for behavior modification in self
  licking, 223
  in behavioral pharmacotherapy, 95-96
  as injectable anesthetic, 82
  metabolism of, 83TN
  for seizures prevention, and control, 89
  storage precautions for, 83TN
Diazide (trihamsterene), 121
Diazinon, 273
Diazoxide, 189-190
Dibenzyline (phenoxybenzamine), 81, 122
Dibucaine, 295
DIC. See Disseminated intravascular
  coagulation.
Dichlorphenamide, 121
  for treatment of glaucoma, 199
Dichlorvos, 261, 273
Diclazuril (Clnix), 264
Diclofenac sodium, 203
Dicurol (diflucin), 238
Dicumarol, 331
Didoxacillin, and floxacillin, 230t
Diestrus, 176
Dietary management, in cardiovascular
  disorders, 144-145
Dietary Supplement Health and
  Education Act (1994), 371
Diethylcarbamazine citrate, 268, 268TN
Diethylestibostrol (DES), 178
  action of, and indications, 126t
  prohibited use of, as extralabel
  drug, 22
Diffusion, of solutes, 301
Diflucin, 238
Digestive enzyme(s), 166
Digestive system. See Gastrointestinal
  system.
Digitalis, 135-136
  effects of, on sodium-
  potassium-ATPase pump, 136f
Digoxin, 136
  bioavailability of, 136TN
  client education about, 136TN
  Digoxin elixir, 136
  Dihydropyrazystrol, 124
  Dilacor XR (diltiazem), 141
  Dilantin (phenytoin sodium), 89
  Dilatrend (carvedilol), 140
  Diltiazem
    for arrhythmias, 141
    for hypertension in renal
    insufficiency, 123
  Dimenhydrinate, as antiemetic in
  motion sickness, 157
  Dimecaprol, for arsenic and heavy
  metal poisoning, 378
  Dimetapp DM, 108
  Dimethylsulfoxide (DMSO), 283-284
  Dimetridazole, prohibited use of, as
  extralabel drug, 22
  Dinoprostone methamethamine, 181, 181TN
  Dioctyl sodium sulfosuccinate, 164
  Dipentum (olsalazine), 167
  Diphenhydramine, 110, 289
    as antiemetic in motion sickness, 157
  Diphenoxylate, for diarrhea, 88, 162
  Dipivalyl epinephrine, 198
  Diprenorphine, as antagonist to
  etorphine, 88
  Dipirvan (propofol), 93
  Diprolea (betamethasone
  dipropionate), 217
  Diprosone (betamethasone
  dipropionate), 217
  Direct-acting hormones, 175
  Dilrotapide, 167-168
  Disal (furosemide), 120
  Disclosing solution, 169
  Disease processes, and drug
  distribution, 11
  Disinfectant(s), 227, 244, 244f
    and antiSeptic, difference between,
    244
    preparations of, and activity, 245t
  Disintegrant(s), 4t
  Disk susceptibility test, 228, 228f
  Dispensing drugs, versus prescribing
  drugs, 23
  Disposable Enema, 164
  Disseminated intravascular coagulation
  (DIC), 326, 329
    treatment of, 329-330
  Dissociation, of ions, 299, 301
  Dissociative agents, 86
  Distribution process (in body), drug, 10-11
    equilibrium of, 10, 10f
  Diuretics, 120-121
    use of, in heart failure, 143-144
  Diurete (furosemide), 120
  Diuril (chlorothiazide), 120, 144
  DMSO (dimethylsulfoxide), 283-284
  Dobutamine (Dobutrex), 80
    for inotropic effect on heart, 137
  Docusate Calcium, 164
  Docusate Sodium, 164
  Dog appeasing hormone (D.A.P), 184
  Dog's ear cleaning process in, proper,
  204-205
  hypothyroidism in, 184
  internal parasites in, drugs for
  specific, 254t
  intramuscular or subcutaneous
  injection of, 41
  intravenous bolus administration
  to, 42, 43, 45
  intravenous fluid administration
  to, 44
  ketamine and morphine infusion
  for pain control in, 62
  medetomidine use in, age
  restrictions, 84
  oral administration of liquids to, 37-38, 37f, 37f
  oral administration of tablets or
  capsules, 36-37, 36f, 37f
  predisposition to bladder stones, in
  some breeds, 116
  vaccinations and preventive health
  program for, 356, 357b-358b
  xylazine use in, precautions for, 83TN
  Dolophine (methadone), 88
  Domeboro powder, and tablets, 216
  Domitor (medetomidine), 84
  reversal agent for, 380
  Domperidone, as gastrointestinal
  prokinetic, 165
  Donnagel, 162
  Donnutil, 162
  Dopamine, 75, 77, 80
    for adjunctive use in heart failure, 137
    and behavioral pharmacotherapy, 95
    for hypertension in renal
    insufficiency, 123
  Dopamine hydrochloride, 137
  Dopaminergic antagonists, as
  gastrointestinal prokinetics, 165
  Dopaminergic receptors, 75
    responses of, 78t
  Dopram preparations (doxapram), 94
  Doramectin, 262-263
Dormosedan (detomidine), 83
Dorzolamide, 199
Dosage, and patient response, 5-6, 6f
Dosage calculations, 58-59
units most commonly used in, 55
Dosage form(s), 28-35
bolus, 29
implants, 35
liquid preparations, 29
microencapsulation, 35
oral, 29
parenteral, 29-35
preservatives and solvents in, 35
tablets and capsules, 28-29
topical, 28-35
Dose. See also dosage entries.
definition of, 58
Dose-respons curve, 14
DoseCalc Online, 415t
Downer cow syndrome, 288
Doxapram, 94, 94TN, 111
Doxirobe, 169
Doxorubicin, 337, 338a, 340TN
Doxycaps (doxycycline), 235
Doxycycline, 235t
dosage forms of, 235
as perioperative agent, 169
Doxylamine, 110
Drancamine (dimenhydrinate), 157
Draxxin (tulathromycin), 239
Drip rate, of fluid therapy, calculating, 309
Droncit (praziquantel), 264
Drontal Plus, 263
Dropertol, 81
and fentanyl, 89, 158
Drops, application of, 47-48
Drug(s), 2
absorption of. See Absorption.
adomination of, 2, 5-8. See also
Drug administration.
affinity of, to cell membrane
receptor, 13-14, 15f
combination of, 10
with undesired consequences, 16, 16t
compounding, 22-23
development and approval of new, 19-22
dispensing versus prescribing, 23
distribution of, in body. See
Distribution process.
efficacy of, 14
extralabel use of, 4
federal laws related to new drugs
and drug use, 21-23
Drug(s) (Continued)
formulation of, 10. See also Dosage
form(s).
half-life of, 13, 14f
information resources about,
414t-416t
interaction among, 15-16,
16TN, 16t. See also Drug
interaction(s).
label of, information found on,
17-19, 18f-19f
marketing of, 23-24
multiple effects of, 14
names of, 16-17
new, development and approval of,
19-22
object, 16, 16t
over-the-counter, 4-5
pharmacodynamics of, 13-15
pharmacokinetics of, 5-13. See also
Pharmacokinetics.
potency of, 14
precipitant, 16, 16t
prescription, 3-4
routes of administration of, 6-8
solubility of, 9-10
sources of, 3
storage of, appropriate, 50TN
Drug administration, 2, 5-8, 27-52
avoiding drug mixtures in, 16TN
client education about, 50
controlled substances in, 49-50
documentation of, in medical
record, 48, 48f
dosage forms in, 28-35. See also
Dosage form(s).
five Rights of, 35-36
medication orders for, 48
microencapsulation of drugs for, 35
procedures and techniques of,
35-47
oral medications, 36-38
parenteral medications, 38-47
reconstitution of medication in, 29,
31f, 35TN
references on, 50
review questions on, 51-52
routes of, 6-8
oral, 7, 28-29, 36-38. See also
Oral medications.
parenteral, 2, 7-8, 28, 29, 38-40,
46-47. See also Parenteral
medications.
topical, 8, 35, 47-48. See also
Topical medications.
transdermal, 278
Drug Enforcement Agency (DEA).
See DEA (Drug Enforcement
Agency).
Drug interaction(s), 15-16, 16TN, 16t
Dry Eye Therapy, 204
Drying agents, otic, 207
ear cleaning before administration
of, 207TN
Dulcolax (bisacodyl), 164
Duo 128 Disclosing Solution, 169
Duocide Spray, 273
Durabolin, 124
Duragesic (fentanyl transdermal), 287
Dureakl Pet Spray and Shampoo
(resmethrin), 273
Duramorph (morphine sulfate), 87
Duramune CV-K vaccine, 351
Duramycin powder (tetracycline), 235
Dusts, for flea and tick control, 270
Dynapen (dicloxacillin), 231
Dyrenium (triamide), 121
Dyrex T.F. (trichlorfon), 261
Dyshomia. See Arrhythmia.
Dystocia, 173
oxytocin use in, 182, 182TN

E
Ear
anatomy of, 205, 205f
correct cleaning of, 204-205
topical medications for, 205-208
Ear canal, flushing procedure for, 208
Ear mite infestation, 204-205. See also
Ectoparasites.
preparations for, 206-207
selamectin preparations for, 266t,
268, 268TN, 269t
Ear Miticide, 207
Ear ticks, preparations for, 207. See also
Ticks.
Eccentric tip syringe, 32f
Eclipse 3 vaccine, 352
Ectoxyl IGR preparations
(tetramethrin), 273
Ectoparasites, 251, 252, 268. See also
Fleas; Ticks.
drugs for, 268-272, 269t
on cattle/sheep/goats, 260t
on dogs and cats, 259t
on horses, 259t
on swine, 261t
insecticides for, 272-275
references on, 275
Ectopic focus, 138
Ectopic ureter, 125
Ectropion, 196
ED 50, 14
Edecrin (ethacrynic acid), 120
Edetate disodium ophthalmic, 204
Edrophonium, 78
as antagonist to nondepolarizing neuromuscular blocking agents, 94
EDTA (ethylenediaminetetraacetic acid), 331
Education. See Client education; Veterinary technician.
Effective osmoses, 301
Effect or organs, 70, 73
receptors in, 77, 77f
of sympathetic and parasympathetic nervous systems, 75, 77f
Efficacy, drug, 2, 14
Elavil (amitriptyline), 96, 125
for pain relief, 288
Elderyl (selegiline), 97
Electrical impulse transmission, through neuron, 72-73, 72f
Electrolyte(s), 299
in body fluid, 300-301, 300t
in therapeutic solutions, 61. See also Fluid therapy.
Electrolyte imbalance, evaluation of, 300-301. See also Fluid and electrolyte disorders.
Elixir(s), 28, 29
Elmiron (pentosan polysulfate sodium), 126
Elpak-G Electrolyte Gel, 319
Elspar (asparaginase), 341
Emesis, 150
Emetics, 154-155. See also Vomiting, induction of.
centrally acting, 154-155
locally acting, 155-156
Emodepside/praziquantel, 264
Emodin, 164
Empirical determinations, 299, 309
Empirical estimation, of supplemental additives, 316
Empirical method, of drug choice, 3
Empirin with codeine, 107
Emulsifier(s), 4t
Emulsion(s), 28, 29
Enacard (enalapril), 123, 143
Enalapril, 123, 124, 143, 143TN
Endocrine disorders, 172-173
Endocrine system, 173. See also Hormones.
anatomy and physiology of, 173-177
hormone regulation in, 175-177
pituitary gland in, 173-174
Endocrine system (Continued)
feedback mechanisms in, 175-177, 177f
and nervous system, interaction of, 173-174, 174f
Endogenous hormones, 173
Endometriosis, 173
Endoparasites, 251, 252, 253. See also Cestodes; Heartworm disease; Nematodes; Protozoal infections; Trematodes.
drugs for, 253-268
in cattle/sheep/goats, 256t
in dogs and cats, 254t
in horses, 255t
in reptiles, 258t
in swine, 257f
topical, 264
references on, 275
Endorphins, 279
Endothelial layer, 326
injury to, and clotting mechanism, 329
Endotoxin shock, fluid therapy for, 306t
Endotracheal intubation, neuromuscular blocking agents for, 94-95
Endotracheal tube, with cuff, 47f
Enemas. See Laxatives.
Enkephalins, 279
Enrofloxacin, 238
in topical otic antiinfectives, 206
Enteric nervous system, 153
EnteroLYSE, 319
Entropion, 196
Enulose (lactulose), 163
Enuresis, 115
Environmental Protection Agency (EPA), U.S., regulation of animal health products, 19-20, 20f
Epakitin, 126
Epinephrine, 80, 110
Epi-Otic ear cleanser, 208
Epi-Soothe Bath Treatment, 216
Epi-Soothe Shampoo, 216
Epidermis, 212, 212f
Epidermal administration, of drug, 7, 8
Epidermal anesthesia, 293
Epidermal Injection (procaine HCl), 294
Epiphren (epinephrine), 198
Epinal (epinephrine), 198
Epinephrine, 77, 80
after cardiac arrest, 136-137
as bronchodilator, 109
as hyperglycemic agent, 189-190
as mydriatic agent, 198
Epinephrine (Continued)
preparation notes for, 137TN
storage notes for, 137TN
Epoetin alpha, 124, 328
Epogen (erythropoietin), 328
Espiritantel, 263, 263TN
Epsom Salts (magnesium sulfate), 163, 216
Eqtim, 366
Equ-Lin, 222
Equi-Phar Phenybutazone Gel/Tablets, 283
Equi-Phar Proud Blue Liquid, 223
Equi-Phar Sweet Psyllium, 163
Equibot TC (trichlorfon), 261
Equidone (domperidone), 165
Equimate (fluoprostenol), 181
Equine BlueLette, 319
Equine Luxavite, 163
Equine Psyllium, 163
Equine Thyroid Supplement (levothyroxine sodium), 184
Equivalazone (phenylbutazone), 283
Equipoise (boldenone undecylenate), 192, 328
Equiproxen (naproxen), 285
Equivalent weight, definition of, 54
Equivole (thiabendazole), 253
Eqvalan (ivermectin), 262
Ergonovine maleate, 183
Erygabobrix thuripathiae antiserum, 353
Erythema, 211
Erythromycin (erythromycin), 165, 239
Erythromycin, as gastrointestinal prokinetic, 165
Erythropeosis, 115, 118-119
Erythrophoistetin, 326
administration of, in renal failure, 124
clinical uses, dosage forms and adverse effects of, 328
stimulation of bone marrow by, 326, 327f
Escherichia-Colcin-B antiserum, 353
Escort, 273
Escort Plus, 273
Eserine (physostigmine), 79
Esmolol, for arrhythmias, 140
Esophageal feeder, 318, 319f
Esophagitis, treatment of, 160
Estradiol cypionate, 178
Estradiol implants, 190-191
Estrogen(s), 178
and anemia, association of, 178TN
contraindication to, in pregnancy, 178TN
Estrogen(s) (Continued)
in promoting weight gain in
ruminants, 190-191
synthetic, 178TN
Estrumate (cloprostenol sodium), 182
Estrus, 176
Estrus cycle, 176, 176f
Ethacrynic acid, 120
Ethanol, as antidote to antifreeze
poisoning, 379, 379TN
Ethyl alcohol, 244-245
70%, 217
Ethylene oxide, as disinfectant,
245-246, 246TN
Ethylene diaminetetraacetic acid
(EDTA), 331
EtoCesic (etodolac), 285
Etorphine, 88
Euthanasia-6 (pentobarbital), 97
Euthanasia agents, 97
barbiturates as, 84-85
Euthasol-C III, 97
Euthyroid, 173, 184
Excenel (ceftiofur), 234
Exogenous hormones, 173
Expectorant(s), 102, 105
therapeutic action of, 104-105
Expiration date, on drug label, 18
Expired air, excretion of metabolites
in, 13
Extracellular fluid (ECF), 299-300,
300f
Extralabel use, of drugs, 2, 4
guideline legislation for, 22
prohibited, 22
Exudation, 211
Eye, external structures of, 197f
Eye disorders. See Ophthalmic
disorders.
Eye examination, agents facilitating,
197-198
Eye medications. See Ophthalmic
preparations.
Eyeball, internal structure of, 197f
F
Factrel (gonadorelin), 177
Famotidine, for gastric ulcers, 159
FARAD (Food Animal Residue
Avoidance Databank), 20-21
Fat-soluble vitamins, 321
Fatal-Plus (pentobarbital sodium), 97
Fatty acid supplements, 221, 222
Fatty acids, 372
FDA. See Food and Drug
Administration.
Febantel, 262
Fecal centrifugation techniques,
diagnostic, 252
Feces, excretion of metabolites in,
13, 13f
Federal laws, regulating animal health
drugs, 21-23, 22t
Feed efficiency, 173, 190
Feedback, 173
Feedback mechanisms, of hormonal
control, 175-177, 175f
Felafin (petrolatum), 164
Felbamate, for seizure prevention, and
control, 89
Feline herpes virus infection, antiviral
agents for, 244
Feline psychogenic alopecia, behavior
modifying drugs for, 223
Feliway, 183
Fenbendazole, 253
Fenoxycarb, 274
Fenprostalene, 181, 181TN
Fentanyl, 88, 287
and droperidol (Innovar-Vet)
as anxiolytic, 158
as neuroleptanalgesic, 89
Fentanyl transdermal patches, for
chronic pain, 88, 287
application of, and precautions, 287
Fenthion, 273
Fenimum, 235
Fertagyl (gonadorelin), 177
Fibrinolysis, 326
Fibrinolytic drugs, 333
Flick speculum, oral liquid
administration with, 37, 38f
Filaribits (diethylcarbamazine citrate),
268
Filgrastim, 343-344
Fillers/diluents, 4t
Finadyn (flunixin meglumine), 283
Finaplix H (trenbolone implant), 190
Finaplix S (trenbolone implant), 190
Fipronil, 269t, 271, 271TN
Fipronil methoprene, 269t
Firocoxib, 286
Flagyl (metronidazole), 167, 264, 345
Flavor agents, 4t
Flaxedil (gallamine), 94
Flea dips, 270, 270TN
Fleas, 268
environmental control products for,
270-271
insecticides effective against,
272-275
monthly application products for,
271-272
Fleas (Continued)
prediluted sprays for, 268, 270,
270TN
products for, and comparisons, 269t
Fleet Enema, 163
Florfenicol, 238-239
contraindications to use of, 239TN
intramuscular injection of, 239TN
FloVent (fluticasone propionate), 111
Flow agents, 4t
Flucort Solution, 292
Flucytosine, 243
Fluid and electrolyte disorders, 306t
clinical evaluation of, 305, 307, 307f
fluid therapy for, 306t. See also Fluid
therapy.
Fluid compartments. See Body fluid
compartments.
Fluid requirements, daily, 308f
Fluid therapy, 304-312. See also
Solute(s); Solution(s).
administration of, 305-312
determining fluid amount, 305, 307
equipment preparation, 311-312
intravenous (IV), 40, 42-46,
298-318
monitoring, 309-310
oral, 318-319
rate of, 308-309
routes of, 307-308
two fluid, 312, 312f
body water content and electrolyte
balance in, 299-304. See also
Body fluid compartments;
Body fluids.
fat-soluble vitamins in, 321
indications for, 304
oral preparations for, 318-319
parenteral nutrition in, 319
parenteral vitamin/mineral
products in, 319-320
references on, 322
review questions on, 323-324
solutions used in, 302t-303t,
313-321
additives to, 315-318
collidal, 314-315
composition of, 302t-303t
crystallloid, 313-314
hypertonic, 315
preservatives in, contraindications
to, 314TN
water-soluble vitamins in, 320-321
Flukes. See Trematodes.
Flumazenil, for reversal of
benzodiazepine action, 380-381
Flunixin meglumine, administration precautions for, 283TN
Fluocinolone acetonide cream, 217
Fluorescein ophthalmic stain, 201-202, 202TN
Fluoride products, 168
Fluorofolam, 168
Fluoroquinolones, 237-238
  dosage forms of, 238
  prohibited use of, as extralabel drug, 22
  safety of, 238TN
  in topical, for Gram-negative corneal infection, 203
  withdrawal periods for animals on, 238TN
5-Fluorouracil, 340, 340TN
Fluoxetine, 96
  for behavior modification in self-licking, 223
Fluprostrenol, 181, 181TN
Flurbiprofen sodium, 203
Flushing solution, 43
  syringe changes in using, 43TN
Fluticasone propionate, for allergic respiratory conditions, 111
Fluvaxamine, 96
Foggers, for flea and tick control, 270-271
Follicle stimulating hormone (FSH), 174
  role of, in estrus cycle, 176, 176f
  target and actions of, 175T
Follicle stimulating hormone-pituitary (FSH-P), 178
Folliculitis, superficial, antiseborrheic agents for, 214t, 215
Folutein (chorionic gonadotropin), 177
Fomepizole, as antidote to antifreeze poisoning, 379, 379TN
Food additives amendment, 22t
Food and Drug Administration (FDA), U.S., 414t
  and drug information on labels, 17-19, 18f-19f
  and regulation of animal health products, 19-20, 20f
  and regulation of neutraceuticals, 371
  review of new drug application by, 21
Food Animal Residue Avoidance Databank (FARAD), 20-21
Foraminidines, 274
Forane (isoflurane), 92
Formaldehyde, as disinfectant, 246, 246TN
Formula 911, 319
Formularies, and drug databases, resources of, 415t
Fortaz (ceftazidime), 234
Forto-Topical, 221, 240
Fortekor (benazapril), 123
FortiFlora, 168
Fresh Eat, 208, 218
Friskies Cheweez Beefhide treats, 168
Friskies Feline Dental Diet, 168
Frontline, 269t
  Frontline Plus, 269t
Frontline Top Spot for Cats, 271, 271TN
Frontline Top Spot for Dogs, 271, 271TN
FSH. See Follicle stimulating hormone.
FSH-P (follicle stimulating hormone-pituitary), 178
Full service companies, for veterinary products, 403
Fulvicin, dosage forms of, 243
Fungal infections, drugs for, 241-243
  Fungicidal agent, 227, 242
  Fungistatic agent, 227, 242
  Fungizone, 242
Furazolidone, 241
  prohibited use of, as extralabel drug, 22
  Furazolidone spray, 221
Furosemide, 120
  administration of, and client education, 144TN
  use of, in heart failure, 144
G
G. I. Conditioner, 168
Gallamine, 94
Gallimycin (erythromycin), 239
Gamma aminobutyric acid (GABA), 75
  and behavioral pharmacotherapy, 95
Ganciclovir, 244
Ganglia, of autonomic nervous system, 75, 76f
Ganglionic blockers, 81
Ganglionic synapse, 70
Gasric ulcers, 158
  drugs for treatment of, 158-161
  antacids, 160
  gastromucosal protectants, 160-161
  H₂ receptor antagonists, 158-159
  prostaglandin E₁ analogs, 161
  proton pump inhibitors, 160
Gastrin, 153-154
Gastroguard (omeprazole), 160
Gastrointestinal system, 150
  anatomy and physiology of, 150-153
  birds, 151, 153f
  carnivorous species, 150-151, 151f
  monogastric herbivores, 151, 152f
  ruminant species, 151, 152f
  function of, 150
  monogastric, 150-151, 151f
  regulation of, 153-154
Gastrointestinal system disorders, and therapies, 149-150
  appetite stimulation, 168
  bloating, 167
  constipation and impaction, 163-164
  diarrhea, 161-163
  digestion, 166
  gastric ulcers, 158-161
  induction of vomiting, 154-155
  infection inhibition, 168
  infections, 166-167
  inflammation, 167
  motility, 164-166
  obesity, 167-168
  references on, 169
  review questions on, 170-171
  vomiting and nausea control, 154-158
Gastrointestinal ulcers, treatment of, 160-161
Gastrumucosal protectants, 160-161
Gecolate (guaifenesin), 93
Gelfoam sponge, 332
Gemini (xylazine hydrochloride), 83
Generic name, of drug, and location on label, 17
Genesis, 217
Gent-L-Tip Enema, 163
Gentamicin, 236l, 237
  in topical preparation for conjunctivitis, 203
Gentamicin sulfate, 205-206
  ototoxicity with use of, 206TN
Gentamicin sulfate/betamethasone valerate, in ointment and spray, 221
Gentamicin sulfate/betamethasone valerate/clotrimazole ointment, 221
GentaVed Otic Solution, 206
Gentocin Durafilm solution, 203
Index

Gentocin Otic Solution, 206
Gentocin preparations, 237
Gentocin Topical Spray, 217
Gentran 70 solution, 314
Geopen (carbenicillin), 231
GH. See Growth hormone.
Giardia infection, 264
drugs for treatment of, 264, 264TN
drugs preventing, 265, 265TN
Giardia Vax, 265, 265TN
Glargine insulin, 189
Glaucoma, 196
closed angle, contraindication to
epinephrine in, 198
contraindication to atropine sulfate
in, 198
drugs for treatment of
adrenergic agents, 80
beta blockers, 81
cholinergic agents, 78
miotics, 198-199
Glaucon (epinephrine), 198
Glipizide, 189
Glomerular filtration, 12, 12f,
116-118, 117f
direction of, 117f
Glucamide. See Chloropropamide.
Glucocorticoids, 290, 290t
as chemotherapy agents, 341-342
inhibitory action of, in
inflammation, 281f
Glucophage XR (metformin), 189
Glucosamine, 372
Glucose, as diuretic, 120
Glucotrol (glipizide), 189
Glutaraldehyde, as disinfectant, 245t,
248
Glycerol, 201
Glyceryl guaiacolate, 93, 105
Glyco-Flex, 372
Glycols, and enhancement of drug
solubility, 35
Glycopeptides, prohibited use of, as
extralabel drug, 22
p-Glycoprotein drug transport, dog
breeds with deficiency in, 11
Glycopyrrolate, 79
as bronchodilator, 109
Glycosaminoglycans (GAGs), 126.
See also Polysulfated
glycosaminoglycans.
Goiter, 184
Gonadorelin, 177
Gonadotropin(s), 173
and gonadal hormones, 177-180
Gonadotropin releasing hormone
(GnRH), 176-177. See also
Gonadorelin.
in estrus cycle, 176f
Government agencies, regulating
veterinary medicine and animal
health, 414t, 415t
Gram (g), 55
Gram stain, 227, 228f
Granulomatous tissue, 211, 218-219
caustic use for excessive, 223
Granulocyte-macrophage colony
stimulating factor (G-CSF), 343-344
Gravity IV set, 45, 46f
Green Book, 21, 415t
Griseofulvin, 243, 243TN
Growth hormone (GH), 174, 191
target and actions of, 175f
Growth hormones, insect, 274
Growth promoting hormones
(implants), 190-191, 191TN
implantation site for, 190, 190f
Guaifenesin, 93, 93TN, 105
as expectorant, 105
for extension of anesthesia, 105
precautions in incremental
administration, 93TN
Guilaxin (guaifenesin), 93
Guallaxin. See Guaifenesin.

H
H1 blockers. See Histamine-1 receptor
antagonists.
H1 receptor. See Histamine-1 (H1)
receptor.
H2 blockers. See Histamine-2 receptor
antagonists.
Hair follicles, 212-213, 212f
Half-life, of drugs, 2, 13, 14f
Haloperidol (Haldol), as antiemetic,
158
Halothane, 92
physical properties of, 91f
Haloxon, 261
Happy Jack Kernel Dip, 273, 273TN
Hartz. Flavor Infused Oral Chews, 168
Healing stimulators, 219, 219TN
Heart, anatomy and physiology of,
130-133
blood pressure in arterial conduc-
tion system, 132-133
conduction system, 131-132, 132f
control of heart rate, 132
direction of blood flow, 130-131,
131f
pumping action, 130-131
Heart beat, phases of, 131
events during, on
electrocardiogram, 133f
Heart disease, 130, 133-135. See also
Cardiovascular system disorders.
Heart failure
ancillary treatment of, 145
compensatory physiology in, 133,
141
Heart rate
control of, 132
increasing, as compensatory
mechanism, 133, 141
Heartgard (ivermectin), 262, 267,
267TN
Heartgard for Cats (ivermectin), 262,
267, 267TN
Heartgard Plus (ivermectin), 262,
266t, 267, 267TN
Heartworm disease, 265
adulticides used in, 265, 267,
267TN
microfilaricides for, 267
preventive drugs for, 267-268
preventive products for, comparison
of, 266t
Heatstroke, fluid therapy for, 306t
Heavy metal poisoning
dimercaprol for, 378
penicillamine for, 378-379, 379TN
Heifers, growth hormone implants for,
190-191
Helminths, 251
Hematemesis, 150
Hematin agents, 326
action of, on blood oxygen carrying
capacity, 327
androgens, 328
blood substitutes, 328-329, 329TN
erthropoietin, 328
iron compounds, 327-328
Hematuria, 115, 116
Hemoglobin, 326, 327f
Hemopad Absorbable Collagen
Hemostat, 332
Hemorrhagic shock, fluid therapy for,
306t
Hemostat Powder, 332
Hemostatic agents, 332-333
parenteral, 332
topical, 332
Heparin, 329-330, 331TN
Herbals, 372-376
Aloe vera, 375
bloodroot (Sanguinaria canadensis),
375
Hormones, and endocrine agents (Continued)
indirect-acting, 174
pancreatic, for treatment of diabetes mellitus, 186-189
production of, in hypothalamus and pituitary gland, 174-175
references on, 192
reproductive, 177-184
drugs affecting uterine contractility, 182-183
gonadotropins and gonadal hormones, 177-180
pheromones, 183-184
prostaglandins, 180-182
review questions on, 193-194
sources of, and target actions, 175t
thyroid, 184-186
Horses
detomidine hydrochloride for sedation/tranquilization of, 83
inhalation therapy units for, 105
intravenous administration of, 45, 46f
oral administration of bolus to, 37, 37f
oral administration of liquid medication to, 37, 38f
vaccinations and preventive health program for, 356, 359b
xylazine hydrochloride use as sedative for, 83, 83TN
Hot spots. See Mois dermatosis.
Household system, of measurement. See Apothecary/household system.
Humalog, 188
Humecutans, 4t
Humidification, of inspired air, 102 of inspired air, 103
Humilac, 216
Humorsol (dexamethasone sodium), 79, 199
Humulin N, 188-189, 188t
Humulin R, 188, 188r
Hyalomel (hydroxyuridine sodium), 286
Hyaluronidase, 7
Hybridoma, 326, 342
Hycoan (hydrocodone bitartrate), 88, 106-107
Hydralazine for hypertension in renal insufficiency, 123
as vasodilator in heart failure, 142
Hydration deficit, 305, 307
Hydrochlorothiazide, 120
Hydrocodone, and homatropine, for nonproductive cough, 106
Hydrocodone bitartrate, 88
as antitussive, 106-107
Hydrocodone syrup, generic, 106
HydroDIURIL (hydrochlorothiazide), 120
Hydrogen peroxide, as disinfectant, 248
Hydrolysis, 11
HydroPlus, 292
Hydroxyurea, for chemotherapy, 340t, 342
Hydroxyxine, 110, 289
HyLyte eta Bath Oolr Coat Conditioner, 216
Hyoscyamine, 162
and phenobarbital, for treatment of diarrhea, 162
Hyperadrenocorticism, fluid therapy for, 306t
Hyperalgesia, 280
Hypercalcemia, treatment of, 316
Hyperglycemic agents, 189-190
Hyperkalemia, 299
treatment of, 316
Hypernatremia, 299
Hyperpigmentation, 211
Hypertension, 115
associated with heart failure, 141
drugs for, 141-143
associated with renal dysfunction, 120
drugs for, 120-121, 122-123
Hyperthyroidism
drugs for, 185-186
feline, 184
Hypertonic solutions, 304
in fluid therapy, 315, 315TN
Hypertonus, 122
definition of, 115
Hypertrophic cardiomyopathy, beta blockers in treatment of, 81
Hypoadrenocorticism, 292-293
Hypocalcemia, treatment of, 316-317
Hypodermis, 212, 212f
Hypodermoclysis, 7
Hypoglycemic agents injectable, 186-189. See also Insulin.
oral, 189
Hypokalemia, 115, 299
as adverse effect of loop diuretics, 120
as adverse effect of thiazide diuretics, 120TN
prevention of, 120TN
treatment of, 316, 318
Hyponatremia, 299
Hypophyseal portal system, 173, 174, 174f
Hypotension
  adrenergic agents for treatment of, 80
  adrenergic blocking agents in promoting, 81
Hypothalamic-pituitary-adrenal axis, 290-291, 291f
Hypothalamus, 74, 74f, 173-174, 174f
  control of reproductive system by, 176-177, 176f
Hypothyroidism, 184-185
  primary, diagnosis of, 185
Hypotonic solutions, 304
Hypotonus, definition of, 115
Hypovolemia, 299
Hypovolemic shock, colloid solutions for, 314-315
Hytakerol. See Dihydrotachysterol.
I
I-131, for hyperthyroidism, 186
Iatrogenic, definition of, 278
Ibufrofen, 285
ICM (inventory control manager), 386. See also Inventory control manager.
Idarubicin, 337, 339t
Idiopathic feline lower urinary tract disease, amitriptyline for, 125-126
Idiosyncratic drug reaction, 15
Idoxuridine, 202, 244
Ifosfamide, 338t
IgA, 102
  in mucociliary defense mechanisms, 104
IgE release, from mast cells, 288
IGR. See Insect growth regulators.
Ilottycin, 239
Ilopen injection (dexpanthenol), 166
Imidacloprid, 269t, 271, 271TN
Imidacloprid/moxidectin, 267
Imidacloprid/permethrin, 269t, 271, 271TN
Imidazoles, 242-243
Imidazothiazoles, 262, 262TN
Imipramine, 96
Immiscible substance, 59
Immibicid (melarsomine dihydrochloride), 265, 267
Immunity, active and passive, 349
Immunologic drugs, 348-365. See also Vaccination(s); Vaccine(s).
Immunoregulin, 344, 365t, 366
Immunostimulants, 342-344, 365-366, 365t
Immunosuppressive drugs, 344-345, 365
corticosteroids as, 291
and effects on immunotherapy, 366TN
for skin disorders, 223-224
Immunotherapeutic drugs, 342-344, 365-366. See also Biologic response modifiers, indications for use of, 365t
references on, 366
review questions on, 367-368
Imodium (loperamide), 162
Implants, 35
growth hormone, 190-191
Implus H (estradiol/testosterone implant), 190
Implus S (estradiol/progesterone implant), 190
Imuran (azathioprine), 167, 344
In Synch (dinoprost tromethamine), 181
in vitro, and in vivo, effectiveness of antimicrobial agent, 227, 228
Inactivated vaccines, 351
Inactive (inert) ingredients, 3, 4t, 10, 35
Inderal (propranolol), 81, 122, 140, 186
Inderal LA (propranolol extended release capsules), 140
Indications, for using drug, 2
Indirect-acting cholinergics, 78-79
Indirect-acting hormones, 174
Induction chamber, small animal, 47t
Indwelling catheter, 44f
Ineffective osmotes, 301
Inflammation, 279, 281-282, 281f
acute and chronic, 279
drugs for treatment of, 167, 279
antihistamines, 288-289
antihypertensives, 288-289
corticosteroids, 289-293
muscle relaxants, 289
nonsteroidal antiinflammatory drugs, 281-286
references on, 295
review questions on, 296-297
topical ophthalmic, 203
inhibitory action of NSAIDs on, 281-282, 281f
Information, veterinary and animal health, resources for, 414t-416t
Infumorph (morphine sulfate), 287
Inhalant anesthetics, 90-92
alveolar concentration of, 90
MAC value of, 90
Inhalant anesthetics (Continued)
  partition coefficient of, 90
  physical properties of currently used, 91t
  vapor pressure of, 90
  veterinary technician exposure to, 90
Inhalation therapy
  administration of, 8, 46, 47f
  for respiratory disease, 105
  units for small animals, 105
Injection(s), 7, 38-41, 45, 46. See also Intramuscular (IM) injection; Subcutaneous (SC) injection.
Injection calculations, practice problems involving, 65-66
Innovar-Vet (fentanyl and droperidol), 89, 158
Inotropic drugs, for cardiovascular disorders, 135-137
Inotropic effect, on heart rate, 130
parasympathetic nervous system and, 132
Insect growth regulators (IGRs), 274
Insect repellants, 274
Insecticides, 272-275
Inspirated air, distribution and diffusion of, 104
Inspissated, definition of, 102
Inspissated respiratory mucus, 106
Insulin
  administration routes for, 186. See also Insulin syringe(s).
  classification of, 187-188
  intermediate acting insulin, 188-189
  long acting insulin, 189
  short acting insulin, 188
  client education about products and use, 189, 189TN
  concentration of, in units per milliliter, 187
  discontinued products containing, 189TN
  hypersecretion of, in beta cell tumors, 189-190
  products commonly used for dogs and cats, 188t
  sources of therapeutic, 186
  synthetic production of, 186-187
  Insulin dependent diabetes mellitus, 186
  Insulin syringe(s), 187t
  manufacturers of, 187t
  with needle attached, 33b, 33f
  types of, and needle size, needle gauge, and packaging, 187t
Insulinosmas, 189-190
Integumentary system, 211-213
Intensol (propranolol oral solution), 140
Interceptor (milbemycin oxime), 266t, 267, 267TN
Interferon, 343
recombinant, 244, 343
Interleukins, as immunostimulants, 343, 365
Intermediate acting insulin, 187, 188-189, 189TN
Interneurons, 73
Interstitial fluid, 299, 300f
composition of, 300-301, 300t
drug level in, 11
Intraarterial (IA) administration, 7, 8
Intraarticular administration, 7, 8
Intracardiac administration, 7, 8
Intracell, 219
Intracellular fluid (ICF), 299-300, 300f
Intradermal (ID) administration, 7
Intramedullary administration, of drug, 7, 8
Intramuscular (IM) injection, 7, 38
avoiding sciatic nerve in, 39f
common complications after, 40
negative syringe pressure in, 40
procedure for, 41, 46
Intraocular pressure. See Glaucoma.
Intravenous route, of fluid therapy administration, 308
Intraperitoneal (IP) administration, 7-8
of therapeutic fluids, 308
Intrathecal administration, 8
Intravascular fluid. See Plasma.
Intravenous (IV) administration sets, 309, 311f
Intravenous (IV) fluid administration, 7, 29, 40, 42-46, 307. See also Fluid therapy.
bolus using Y-injection site, 45
bolus with indwelling intravenous catheter, 43
calculations for, 58-62, 67-68, 305, 307
catheter replacement in, 40TN
direct bolus, 42
duration and drip rate calculations for, 308-309
equipment preparation for, 311-312
with indwelling catheter, 44, 44f, 44TN
with infusion pump, 46
Intravenous (IV) fluid administration (Continued)
by injection with syringe, 38, 40, 40f
to large animals, 45, 46f
large volume bottle or bag in, 29, 39f
monitoring patient in, 46, 46TN, 309-310
to pediatric animals, and exotics, 45
to small animals, 40-45
Intron A (recombinant interferon), 343
Intropin (dopamine), 80, 123
Inventory, 385-388
accounting systems for, 387-388, 389f, 404-405
controlling objectives in, 390, 390TN
veterinary technician role in, 386-387, 387TN, 390, 405.
See also Inventory control manager.
definition of, 386, 387-388
expense of, in veterinary operation, 388TN
FIFO method of, 386, 388
human pharmacy, 404
markup of, 386, 397, 397TN
monthly versus rotating, 399-401
ordering, 395, 397
organizing, 397, 399, 399TN
purchasing, 401-404
delayed billing in, 386, 401
return policies in, 401
statement payment in, 401
vendors used in, 403-404
rabies vaccine records in, 397
receiving shipment of, 401-403, 402TN
FOB rules and contracts in, 402, 402TN
references on, 405
reorder log in, 394, 394TN, 396f
reorder point for, 394TN
reorder quantity for, 397
review questions on, 406-407
shelf stocking, and product rotation, 403
special ordering, 404
time equation in managing, 388, 390
turnover of products in, 386, 390, 390TN
rate of, 390
vendors of products for, 403-404
Inventory control manager (ICM), 386, 387TN
responsibilities of, 386-387, 387TN, 390, 405
back-ordering, 391
controlled substances handling and storage, 391, 391TN.
See also Controlled substances.
DEA forms, 391, 392f, 404
expiration date checking, 391, 391TN
FOB rules and shipment contract, 402, 402TN
inventory taking, 399-401
invoice checking, 391, 393f
ordering, 395, 397, 403-404
organizing, 397, 399
packing slip checking, 391, 394f, 402, 402TN
pilferage checking, 391
purchasing, 401-402
rabies vaccine recording, 397, 398f
receiving shipment, 402-403, 402TN
recording accuracy, 391
reorder point setting, 394-395, 394TN
sale representative communications, 404
staff memo, 399, 399TN
statement checking, 386, 391, 395f
turnover rate, 391, 391TN
Invoice, 386, 391, 393f
Involuntary control of nervous system, 71-72
Involution, 173, 182
Iodine
as disinfectant, 245f, 246, 246TN
as topical antiseptic, 218
Iodine-131, in treatment of hyperthyroidism, 186
Iodine Shampoo, 221
Iodine tincture, 218
as disinfectant, 246
Iodophor(s), 227, 246
Iopidine (aprazolam), 200
Ipecac oral syrup, 155
Ipodate, 186
Iproniazide, prohibited use of, as extralabel drug, 22
Iron compounds, 327-328, 328TN
Irritants, for gastrointestinal stimulation, 164
Isoflorane (isoflorane), 92
Isoflorane, 92
physical properties of, 91t
Isopropyl alcohol, 244-245
70% to 90%, 217
as counterirritant, 222
Isoproterenol, 80
for atropine resistant bradycardia, 137
as bronchodilator, 109
Isopin (verapamil), 123, 141
Isopin SR (verapamil), 141
Isopto Carpine (pilocarpine), 78, 199
Isopropyl Homatropine (homatropine hydrobromide), 198
Isotonic solutions, 304
Isuprel (isoproterenol), 80, 109
Itching. See also Pruritis.
topical medications for, 216-217
Itraconazole, 243
topical, for ophthalmic fungal infections, 202
Ivermectin, 262
administration of, 263TN as insecticide, 274
as microfilaricidal agent, 267
precautions in use of, 263TN
as preventive agent against heartworm disease, 267
unapproved uses of, 263TN
Ivermectin/milbemycin, for ear mites, 207
Ivomec (ivermectin), 262
Ivomec 1% Injectable for Cattle, 274
Ivomec 1% Sterile Solution for Swine, 274

J
Jenotone (aminopropazine), 126t
K
K-Pek (kaolin/pectin), 162
K-Y Jelly, 381
K9 Advantix, 269t, 271, 271TN
Kanamycin, 236t, 237
Kantrisin (kanamycin), 237
Kao-Forte (kaolin/pectin), 162
Kaolin/pectin, 162-163
Kaopectol (kaolin/pectin), 162
Kappa opiate receptors, 87
Kat-A-Lax (petrolatum), 164
Kefauver-Harris amendment, 22t
Keflex (cephalexin), 234
Keflin (cephalothin), 234
Kefox (cefazolin), 234
Kernel sprays, for flea and tick control, 270
Kerasolv Gel, 213
Keratinized structures, of skin, 212-213
Keratitis, 196
caused by herpes simplex, 202
mycotic, 202
Kerateconjunctivitis sicca, treatment of, 204
Keratolytic drugs, 211, 213-215
Keratoplasty drugs, 211, 213-215
Ketalar (Ketamine HCl), 86
Ketamine HCl, 86, 288
contraindications to, and precautions, 86TN
intramuscular injection of, 46
and morphine, 62, 288
Ketanest (Ketamine HCl), 86
KetoChlor, 218
Ketocazone, 242-243
infertility in male dogs, 243TN
Ketofen (ketoprofen), 285
Ketone bodies, 186
Ketoprofen, 285
Ketorolac, 286
Ketorolac tromethamine, 203
Kidneys. See also Renal system, and urinary tract.
decreased function of, and resulting conditions, 118-119.
See also Renal insufficiency.
in drug metabolite excretion, 12, 12f
failure of, 119-120
function of, 116-119, 117f
Kilogram (kg), 55
Kirby-Bauer procedure, 228
Konakion, 333
Kopertex, 221
L
Label(s), drug, 186-19f
information found on, 17-19, 371
Labeling, of IV bag, for volume control, 310, 311f
Lacri-Lube, 204
Lactated Ringer's solution, 313
Lactulose, 163
Lambs, growth hormone implants for, 191
Lameness, in horses, local anesthesia in diagnosis of, 293, 294f
Laminitis
antiinflammatories for, 288
corticosteroids for, 292
Lanoxicaps (digeoxin capsules), 136
Lanoxin preparations, 136
Lansoprazole, 160
Lantus (glargine insulin), 188t, 189
Large-volume bottle(s), or bags, 29, 30f
Lasix (furosemide), 120, 144
Latanoprost, 200
Laudanum (10% opium), 87
Laxatives, 163
bulk producing, 163-164
lubricant, 164
saline and hyperosmotic, 163
Laxatone (petrolatum), 164
LD₃₀, 14
Lead poisoning, treatment of
calcium EDTA for, 376-377,
377TN
dimercaprol for, 378
penicillamine for, 378-379, 379TN
Legend, 286, 370
Legend drug. See Prescription drug.
Length units, in metric system, 55t
Lente insulin, 188-189
Leukocell 2 vaccine, 351
Leuprolide, for endocrine disorder therapies, 183
Levamisole, 262
as immunostimulant, 344
Levasole (levamisole), 262
Levemir (detemir insulin), 189
Leventa (levothyroixine sodium), 184
Levo isomer(s), 173, 184
Levobunolol, 200
Levophed (norepinephrine), 80
Levotyroxine sodium (T₄), 184-185
Levson (lyoscyamine), 162
LH. See Luteinizing hormone.
Librax (clidinium/chlordiazepoxide), 162
Lidocaine, 288
for arrhythmias, 139, 139TN
effects of, on sodium ion channels, 139f
with epinephrine, contraindication to, in arrhythmias, 295TN
injectable preparations of, 294, 295
for pain relief, 288
LIFECARE flexible fluid therapy bags, 310f
D-Limonene, 275
Lin-O-Gel, 222
Lincomycine, dosage forms of, 239
Lincomycin, 239-240, 240TN
Lindane, 273, 273TN
Liniment(s), 28
for topical administration of, 35
Liothyrone sodium (T₃), 185
Lipid solubility, of drug, 9-10
Liquamycin-LA 200
(oxtetracycline), 235
Methigel (methionine), 123
Methimazole, for hyperthyroidism, 185
Methio Tabs (methionine), 123
Methionine, 123-124
Methocarbamol, 289
Methohexital, 85
Methoprene, 274
Methotrexate, 339t, 340
Methoxychlor, 273
Methoxyflurane, 92
physical properties of, 91t
Methscopolamine, 79
for treatment of diarrhea, 162
Methylene blue, as antide, 377, 377TN
Methylprednisolone Tablets, 292
Methylxanthines, as bronchodilators, 109-110
Meticorten, 292
Metipranolol, 200
Metoclopramide, 78
antagonists to action of, 157TN
as antiemetic, 156-157
contraindication to, in GI
obstruction, 157TN
as gastrointestinal prokinetic, 165
Metofane (methoxyflurane), 92
Metoprolol, for arrhythmias, 140
Metronidazole (pentylenetetrazol), 94
Metric system, 55-57
conversion of units within, 55-57,
56f
problems using, 63-64
units of, 55t
weights and measures, and equivalent
apothecary values, 412t
Metronidazole, 167, 167TN, 345,
345TN
for Giardia infection, 264, 264TN
immunosuppressive action of, 345
Mexiletine, for arrhythmias, 139
MGK 11 (2,3,4,5-bis
(2-butylene)tetrahydro-
2-furaldehyde), 274
MGK 236 (di-n-propyl
isocinohemeronate), 274
Mibolerone, 179
contraindication to, in cats, 179TN
Miconazole, 221, 242-243
Miconazole solution, as ophthalmic
antifungal agent, 202
Micotil, 239, 239TN
Micro Pearls Advantage Seba-
Moist-Shampoo, 213
Micro Pearls Benzoyl Plus Shampoo,
215
Microdrip IV administration set, 309
Microencapsulation, 35
Microfloria, 251
Microorganism(s), 227
Micturition, 115
Midazolam, 82-83
Midbrain, 74f
Milbemite (0.1% Milbemycin), 207
Milbemycin oxide
as microfilaricidal agent, 267
as preventive agent against
heartworm disease, 267, 267TN
Milk of magnesia, 160, 163
Milliequivalent(s) (mEq), and
calculations, 61, 301
Milliequivalent weight, definition
of, 54
Milligram (mg), 55
Milliliter (ml), 55
Milliosmole (mOsm), 301
Milrinone, 137
Mineral oil, as intestinal lubricant,
164, 164TN
Mineralocorticoids, 290, 290t
Minidrip IV administration set, 309
Minipress (prazosin), 81, 122, 143
Minocin (minocycline), 235, 235t
Minor Use and Minor Species Animal
Health Act (2001), 23
Miosis, 196
Miotic agents, 198-199
Muscible substance, 59
Misoprostol
contraindication to use of, in
pregnant animals, 161TN
for gastric ulcers associated with use
of NSAIDs, 161
Mita-Clear, 207
Mitaban (amitraz), 274
Mitaplex-R, 207
Mites. See Ear mite infestation;
Insecticides.
Mitoxantrone, 337, 339t
Mixed vaccine, 353-354
Mixing drugs
avoiding, 16TN
interactions when, 16, 16t
Mixture(s), 29
MK (morphine and ketamine), 288
MLK (morphine, lidocaine, and
ketamine), 288
Modified live vaccines, 351-352, 355
Modulation, of nociceptive
transmission, 278
Moist dermatosis
antiseborrheic agents for, 214t, 215
Moist dermatosis (Continued)
 systemic corticosteroids for, 220
topical corticosteroids for, 217
Mometamax, 206
Monesin, 264
Monisstat (miconazole), 243
Monoamine neurotransmitters, 95
Monoamine oxidase-B inhibitors, 96-97
Monoclonal antibodies, 342-343, 342f
Monodox (doxycycline), 235
Monovalent vaccine, 354
Morantel tartrate, 261-262
Morphine sulfate, 87, 287
and ketamine, for pain control,
62, 288
Motilin, 150
Motilin-like drugs, 165
Motility disorders, gastrointestinal.
See Constipation; Diarrhea;
Prokinetics and stimulants.
Motilium (domperidone), 165
Motion sickness, 288
Motor neuron, 73
Moxidectin, 262, 267, 268TN
Moxifloxacin, in topical ophthalmic
preparations, 203
Moxisylyte
action of, and indications, 126t
for urinary retention treatment, 122
MPA. See Medroxyprogesterone
acetate.
MTD (maximum tolerated dose), 335,
335t
Mu opiate receptors, 87
Mucociliary clearance, 104
Mucolytic(s), 102, 106
therapeutic action of, 104-105
Mucomyst (acetylcysteine), 106, 377
Mucosil preparations (acetylcysteine),
106, 377
Mucus membrane congestion,
adrenergic agents in reducing, 80
Mucus secretion and movement, in
upper respiratory tract, 103-104
Multidose syringe, 33h, 33f
Multidose vial(s), 29, 30f
easing liquid withdrawal from,
41TN
Multisol-R, 314
Muscarinic receptor(s), 70, 77, 78
Muscle relaxants. See Skeletal muscle
relaxant(s).
Musculoskeletal inflammation,
corticosteroids for, 289-292
Myasthenia gravis, cholinergic agents
in diagnosis of, 78
Mycitracin Sterile Ointment, 240
Mycobacterial cell wall fraction, 365f, 366
MycoDEX Minifog (D-Phenothrin), 273
MycoDEX Pet Shampoo (D-trans allethrin), 273
MycoDEX Pet Shampoo with Carbaryl, 273
MycoDEX Tar and Sulfur Shampoo, 215
MycoPhenolate mofetil, 345
Mydfrin (phenylephrine), 197
Mydriacyl (tropicamide), 198
Mydriasis, 196
Mydriatic agents, 197-198
Myelin sheath, 72, 72f, 73
Myeloma, 326, 342
Myelosuppression, 326
Myelanta, 160
Myelopain (primidone), 89
Myocardial disease, 134
MyoFibril(s), 173
contractility of uterine, 182
Myosan Cream, 218
Myotol, 289
N
Nalbuphine, 287
Nalorphine (Nalline), 88
adverse effects of, 89
Naloxone, 88, 89
for behavior modification in self licking, 223
for respiratory stimulation in narcotic overdose, 111
in reversal of apomorphine overdose, 155TN
in reversal of narcotic overdose, 88, 89, 381, 381TN
Naloxone HCl injection, 88
Naltrexone, for behavior modification in self licking, 223
Names, of drugs, 16-17
Nandrolone, 124
Nandrolone decanoate, 192
Naproxen, 285
Naproxyn (naproxen), 285
Narasin/nicarbazine, 264
Narcam (naloxone), 89, 381
Narcotics. See Opioid agonists.
Nasal cavity, defense mechanisms within, 104
Natacyn (natamycin), 202
National Animal Supplement Council logo of, 371f
and quality control of herbal, 373
Navelbine (vinorelbine), 341
Naxel (ceftiofur sodium), 234
approval for use in dairy animals, 233TN
NDC (National Drug Code) number, on drug labeling, 18
Nebulization, 102, 105
of mucolytics, 105
Needle(s), 34h, 34f
for biopsy, 34f
for bleeding, 34f
common gauges for specific animal species, 30t
hub, shaft, and bevel of, 34f
proper discarding of, 35TN
Nematem (morante tartrate), 261-262
Nematodes, 251
drugs effective against, 253-263
topical solutions for, 264
Nembutal (pentobarbital sodium), 85, 85t
Nemex (pyrantel pamoate), 261-262
Neo-Carbazole (carbimazole), 185
Neo-Predef, 203
Neo-Synephrine (phenylephrine), 80, 197
Neobacimyx Ophthalmic Solution, 240
Neomycin, 236t, 237
ototoxicity of, 206TN
in topical ophthalmic preparations, 203
in topical oitic preparations, 206
Neoplasms
benign and malignant, difference between, 333-334
drug therapy for, 333-344. See also Chemotherapeutic drugs.
Neoral (cyclosporine), 204
Neostigmine, 78-79
as antagonist to nondepolarizing neuromuscular blocking agents, 94
as gastrointestinal prokinetic, 166
Nephrology, 115
Nephron, 12, 12f, 115
function of, 115
Neptazane (methazolamide), 199
Nerve block, 278, 293
Nerve fiber(s), 73
diameters of, 73
myelin sheath of, 72f, 73
in pain sensation, 279-280, 280f
preganglionic and postganglionic, in autonomic nervous system, 75, 76f
Nervous system, 70
anatomy and physiology of, 70-75
autonomic, 71-72. See also Autonomic nervous system.
therapeutic drugs and effects on, 78-81
central, 70-71. See also Central nervous system.
drugs that act on, 81-97
and endocrine system, interaction of, 173-174, 174f
function of, 70
impulse conduction through, 73-75, 74f
neurotransmitters in, 72-73, 73f, 75
organization of, 70-72, 71f
parasympathetic, 72
peripheral, 70-71. See also Peripheral nervous system.
physiologic unit of, 72-73. See also Neuron(s).
sympathetic, 72
Neurogenic disorder(s), urinary incontinence as, 125
Neurohormonal reflex, 176
Neuroleptanalgesics, 89
Neuromuscular blocking agents, 94-95
avoiding use of aminoglycosides with, 237TN
cholinergics as antidotes to, 78
Neuron(s), 72, 72f
impulse transmission through, 72-73, 72f
Neurotransmitter(s), 72-73, 72f, 75
in behavioral disorders, 95
blocking of, 73f
monoamine, 95
physiological activity of, 73f
Neuterosol, 183
Neutraceutical(s)
definition of, 371
evaluation of, for veterinary use, 371
labeling regulation for, 371
Newcastle disease vaccine, 352
Nexaband, 220
NFZ Puffer, 241
Nicerogoloneaction of, and indications, 126f
for urinary retention treatment, 122
Nicotinic receptor(s), 70, 77, 78
Nifedipine, for arrhythmias, 141
Nitenpyram, 274
Nitro-Bid (nitroglycerin ointment), 142-143
Nitrofurans, 241, 241TN
Nitrofurantoin, 241
Index

Nitrofurazone preparations, 241
Nitrogen balance, 173
positive, 191
Nitroglycerin ointment, 142-143, 143TN
Nitroimidazoles, prohibited use of, as
extralabel drug, 22
Nitrol (nitroglycerin ointment), 142-143
Nitrous oxide, 92
physical properties of, 91t
Nizatidine, as gastrointestinal
prokinetic, 159
Nizoral (ketocanazole) preparations, 242
NK-1 receptor antagonists, as
antiemetics, 158
No String Barrier Film, 220
Nociceptors, 278, 279-280, 280f
Nocturia, 115
Novaldent oral cleansing solution, 168, 247
Novamide, 207
Novasyn Antiseptic Ointment, 218
Novasyn preparations, 247
Nomagen, 365t, 366
Noncatecholamines, 80
Nondepolarizing neuromuscular
blocking agents, 94
Noninsulin dependent diabetes
mellitus, 186
Nonneoplastic feline leukemia,
antiviral agents for, 244
Nonproductive cough, 102, 105
antitussives for, 106-108
Nonsteroidal antiinflammatory drugs
(NSAIDs), 281-286
acetaminophen, 284, 284TN
action of, in analgesia and fever
reduction, 281-282
buscopan compositum, 284
client education about, 282
deracoxib, 285
dimethylsulfoxide, 283-284
erodolac, 285
firocoxib, 286
flunixin meglumine, 283, 283TN
hyaluronate sodium, 286
inhibitory action of, in
inflammation, 281f
ketorolac, 286
meloxicam acid, 286
meloxicam, 286
ongotein, 286
polysulfated glycosaminoglycan, 286
precautions in use of, 282TN
Nonsteroidal antiinflammatory drugs
(NSAIDs) (Continued)
propionic acid derivatives, 284-285
pyrazolone derivatives, 282-283,
283TN
salicylates, 282, 282TN
selenium and vitamin E, 286
side effects of, 282
tepoxalin, 286
topical, for ophthalmic
inflammation, 203
Nonsteroidal antiinflammatory medications,
216-217
Noradrenaline (norepinephrine), 80
Norcalciphos, 317
Norcuron (vecuronium bromide), 95
Norepinephrine, 75, 77, 80
and behavioral pharmacotherapy, 95
Norflaxacin, 238
in topical ophthalmic preparations,
203
Norgestomet, 180
Normal saline solution, 313
Normosol-M in 5% dextrose, 314
Normosol-R, 314
Noroxin (norflaxacin), 238
Norvase (amlodipine), 123, 141
Novolin N, 188-189, 188t
Novolin R, 188, 188t
NovoLog, 188
NPH (Neutral Protamine Hagedorn)
insulin, 188-189
NSAIDs. See Nonsteroidal
antiinflammatory drugs.
Nubain (nalbuphine), 287
Nuflox identifiable solution
(flofenicol), 239
Numorphan (oxymorphone), 87, 287
NuSal-T Shampoo, 213
Nutracertical(s), 370-372
definition of, 370
Nutrient replacement, with fluid
therapy, 313-314
NutriVed T-4 Chewables
(levothryroxine sodium), 184
Nylar, 274
Nystatin, 242
O
Obesity, canine, darlatapipide for, 167-168
Object drug(s), 16, 16t
Octreotide, 189-190
N-Octyl bicyclohexetene
dicarboximide, 274
Ocufer (flurbiprofen sodium), 203
Ocular lubricants, 204
Ocupress (cartelol), 200
Official name, of drug, 17
Ofloxacin, in topical ophthalmic
preparations, 203
Ointment(s), 28
application of, 35, 47-48
ophthalmic, application of, 47-48, 48f
Olsalazine, 167
Omeprazole, 160
Omnizole (thiabendazole), 253
Onocitic pressure, 299
Onccovin (vincristine), 341
Ondansetron, as antiemetic, 158
Ongoing fluid loss, 305, 307
Open-angle glaucoma, 196
drugs for, 198-199
Ophthalmic parapropacaine
hydrochloride), 201
Ophthalmic Solution Veterinary, 295
Ophthalmic disorders, 195-197
Ophthalmic preparations
for anesthesia, 201, 295
application of, 47-48, 48f
patient education about, 196
preventing contamination in,
241TN
for artificial tears, 204
choice of, considerations in, 196
for collagen shields, 202
for inflammation, 203, 292
for keratoconjunctivitis sicca, 204
miotic, 198-199
miscellaneous, 204
mydriatic and cycloplegic, 197-198
references on, 208
review questions on, 209
for stains, 201-202
for superficial infection, 202-203
Ophthalmic stains, administration of,
202TN
Ophthalmic, 295
Opiate receptors, 87
Opioid agonists, 86-88, 286-288
action of, in pain relief, 287
adverse effects of, 88
antagonists to action of, 88-89
combined with antagonists, 287
for diarrhea, 161-162
naturally occurring, 87
partial, 287-288
synthetic, 87-88
Opioid antagonists, 88-89, 287
Opium, 87
Opti-Chamber, 105
Opticyl (tropicamide), 198
Optimmune Ophthalmic Ointment
(cyclosporine), 204
Pain (Continued)
perception of, 280
sensation of, anatomy and physiology, 279-281
Palosein (orgotein), 256
Pamime (methscopolamine), 162
Panacure (fenbendazole), 253
Panalog, 206, 221
Panalog Cream, 242
Pancreatic enzymes, 166
Pancreatic hormones, 186
in diabetes mellitus therapy, 186-189
Pancrelipase, 166, 166TN
Pancrenzmy powder (pancrelipase), 166
Pancurium bromide, 94
Pantamycin (tetracycline), 235
Pantec Cleanser, 247
d-Panthenol preparations (dexpantrol), 166
Parmite Dip for Dogs, 273
Parapactol, 162
Paraplatin (carboplatin), 341
Parapox ovis virus immunomodulator, 344
Parasites
external, 252, 268-275. See also Ectoparasites.
internal, 252, 253-268. See also Endoparasites.
life cycles of, 252
otic, topical medications for, 206-207
zoontic, 252
Parasitiasis, 251, 252
Parasitosis, 251, 252
Parasympathetic (cholinergic) nervous system, 70, 72, 75
drugs acting on, 78-79
drugs blocking action in, 79
effector organs of, 75, 76f, 77f
functions of, 75
neurotransmitters of, 78
preganglionic and postganglionic fibers of, 75, 77f
receptors of, 77, 78
Parasympathomimetic agents, 70, 78-79
Paravertebral block, 293
Paregoric, for treatment of diarrhea, 87, 162
Parenteral hemostatic agents, 332-333
Parenteral medications, 2, 7-8, 28, 29
administration of, 2, 7-8, 28, 29,
38-40
calculations for, 58-62, 65-68
common complications after, 40
Parenteral medications (Continued)
needle gauge in, for specific species, 30t
procedures for, 40-47
bolus using indwelling intravenous line, 43
bolus using Y-injection site, 45
inhaled medication, 46
intramuscular or subcutaneous injection, 41, 46
intravenous direct bolus, 42
intravenous fluids, 44
syringe and needle use in, 29, 32b-34b
causing tissue irritation, 46TN
components settling out in, 46TN
dosage containers for, 29, 30f
preservatives in, purpose of, 35
Parenteral nutrition, 319
Parenteral vitamin/mineral products, 319-320
Parietal cell(s), 150
activation of, 158
Paroxetine, 96
Partition coefficient, 2
of anesthetic gas, 90
Parts, expression of concentration in, 59
Parts per million (ppm), 59
Passive immunity, 349
vaccines that produce, 353
Pavulon (pancuronium bromide), 94
Paxil (paroxetine), 96
Penicillinamine, as antidote to copper and lead poisoning, 378-379, 379TN
Penicillin binding proteins, 229
Penicillin G
avoiding subcutaneous injection of, 232TN
dosage forms of, 231-232
Penicillin G benzathine, 230t
avoiding subcutaneous injection of, 232TN
Penicillin G potassium, 230t
Penicillin G procaine, 230t
Penicillin G sodium, 230t
Penicillin V, 230t
Penicillins, 229-231, 229-232
adverse effects of, 232
beta-lactamase resistant, 229, 230t
broad spectrum, 230t-231t
contraindication to use of, 232TN
dosage forms of, 231-232
narrow spectrum, 230t
pharmacodynamics of, 229, 231
Penicillins (Continued)
pharmacokinetics of, 229
potentiated, 231t
precautions in using, in allergic animals, 232TN
preparations of (including indications and antagonists), 233c-231t
tubular secretion of, inhibitor of, 231t
withdrawal times for, 231-232, 232TN
Pentazocine, 88, 287
Pentobarbital sodium, 85
classification of, and duration of action, 85t
as euthanasia agent, 97
recovery from, 85TN
for seizure prevention, and control, 89
Pentolair (cyclpentolate hydrochloride), 198
Pentosan polysulfate sodium, 126
Pentothal (thiopental), 85, 85t
Pentyleneetetrazol, 94
Pepcid (famotidine), 159
Pepcid AC (famotidine), 159
Pepcid IV (famotidine), 159
Pepto-Bismol (bismuth subsalicylate), 162
Percent, calculation of, 54
Percent concentration, in solution, 59-60
calculation examples of, 59-60
Pericorten-V, 292
Perfusion, 104
Periactin (cyproheptadine), 110
Perioctic agents, 169
Peripheral nervous system, 70-71
subdivisions of, 71-72
Peristalsis, 150, 152, 153f
Permeet, 273
Permethrin, 272, 272TN, 273
Pet-Derm III, 292
Petrolatum, as intestinal lubricant, 164
Petroleum distillate, as solvent for pyrethrins and pyrethroids, 275
Petroleum jelly
contraindication to, around vesicant, 23
contraindication to, as lubricant, 382TN
P.G. 600 (chorionic gonadotropin), 177
Pharmaceutical aids. See Inactive (inert) ingredients.
Pharmaceutical companies, for veterinary drugs, 416t
Pharmacodynamic drug interaction, 16
Pharmacodynamic drug interaction, 16
Pharmacodynamic information resources, 414t
Pharmacodynamics, 13-15
Pharmakokinetic drug interaction, 15-16
Pharmakokinetic information resources, 414t
Pharmakokinetics, 5-13, 5f
biotransformation in, 11-13
dosage and patient response in, 5-6, 6f
drug absorption in, 8-10
drug administration routes in, 6-8
drug distribution in, 10-11
Pharmacology, 1-2
calculations in, 53-68. See also Calculation(s).
drug interactions in, 15-16
drug sources and ingredients of pharmaceuticals in, 3
pharmacodynamics in, 13-15
pharmakokinetics in, 5-13
pharmacotherapeutics in, 3-5
references on, 24
review questions on, 25-26
Pharmacotherapeutics, 3-5
Phenazopyridine, 125
Phenergan (promethazine), 108, 157, 289
Phenobarbital, 84-85
for behavior modification in self-lacking, 223
classification of, and duration of action, 85t
for seizure prevention, and control, 89
Phenol Red Thread (PRT) test, 202
Phenolics, as disinfectants, 245t,
246-247
Phenothiazine derivatives, 82
as antiemetic drugs, 156
contraindication to, within 30 days of organophosphate treatment, 82TN
tranquilizing effect of, in excited animal, 82TN
D-Phenothrin, 273
Phenoxybendrine action of, and indications, 126t
for urinary retention treatment, 122
Phenylbutazone, 282-283, 283TN
preparations of, 283
prohibited use of, as extralabel drug, 22
Phencyclidine, 86
Phenylephrine, 80
as decongestant, 110
as mydriatic agent, 196
Phenylpropanolamine, 80
action of, and indications, 126t
as decongestant, 110
Phenylone Paste (phenylbutazone), 283
Phenytin sodium, for seizure prevention, and control, 89
Pheromones, 183-184
Phosmet, 273
Phosphodiesterase inhibitors, 109
Phospholipase, 291
Photosensitivity, 15
Physicians GenRx, web site, 415t
Physiologic saline, 313
Physostigmine, 79
Phytomadione, 333, 333TN, 380
Pilling difficult animals, 37TN
Pilling gun, small animal, 36f
procedure for use, 36
Pilocar (pilocarpine), 78
Pilocarpine, 78, 198-199
Ploptic (pilocarpine), 199
Pilostrat (pilocarpine), 199
Pimobendan, 137
Pimozide, as antemetic, 158
Pindolol, for arrhythmias, 140
Pip-Pop 320, 263
Pipa-Tabs, 263
Piperacillin, 231t
Piperazine, 263
Piperonyl butoxide, 274, 274TN
Pitressin (vasopressin), 123
Pituitary gland, 173-174
hormones secreted by, 174-175, 175t
lobes of, 174f
Plasma, 299, 300f
composition of, 300-301, 300t
drug level in, 10-11
Plasma-Lyte, 314
Plasma-Lyte M in 5% dextrose, 314
Plasma volume expansion, colloid solutions for, 314-315
Platinol (cisplatin), 341
Platinum drugs, 341
Poisoning antidotes, online resource, 415t
Polishing paste, 169
Poly Ox II Bolus, 163
Polydipsia, 115
in diabetes insipidus, antidiuretic hormone for, 123
Polyene antifungal agents, 242
Polymin B and bacitracin, 240
in topical ophthalmic preparations, 203, 240
Polysulfated glycosaminoglycans, 286, 370, 370TN
Polyuria, 115
in diabetes insipidus, antidiuretic hormone for, 123
Polyvalent vaccines, 349, 353-354
Ponazuril, 264
Pentocaine (tetracaine), 201
Pentocaine hydrochloride (tetracaine hydrochloride), 201
Posilac (bovine somatotropin), 191
Postanesthetics, opioids as, 87
Postganglionic axon (nerve fiber), 75, 76f, 77f
Potassium chloride, as supplement in fluid therapy solutions, 316, 316TN, 317t
Potassium citrate, 124
Potassium-sparing diuretics for hypertension associated with renal dysfunction, 120-121
use of, in combination with other diuretics, 121TN
Potassium supplementation guide, 317t
Potency, drug, 14
Poultry, vaccinations and preventive health program for, 364
Povidone iodine solution as disinfectant, 246
as ophthalmic antifungal agent, 202
Powder formulation, 35
Pralidoxime, as antidote to organophosphates, 79, 261TN, 378, 378TN
Pramoxide HCl, as antipruritic, 216
Prasiquantel, 264
Prasiquantel/pyrantel pamoate/fenbantel, 263, 263TN
Prazosin, 81, 122, 143
combination of, with diuretics, 122TN
Preanesthetics
cholinergic blocking agents as, 79
opioid agonists as, 87-88
romifidine as, 84
Precipitant agent(s), 16, 16t
Preclinical (animal safety) trials of new drugs, 21
Pred Forte prednisolone, 203
Predef, 292
Prednisolone
for allergic respiratory conditions, 111
for chemotherapy, 341
in combination, as antitussive, 108
for inflammatory bowel disease, 167
Prednisolone acetate drops, 203
Prednisolone generic tablets, 292
Prednisolone sodium phosphate drops, 203
Prednisolone sodium succinate, 111
Prednisone
for allergic dermatologic conditions, 220
for chemotherapy, 339t, 341
Prednisone generic tablets, 292
Preganglionic axon (nerve fiber), 75, 76f, 77f
Preliminary trials of new drugs, 21
Preload, 130, 133
increased, in heart failure, 141
Premature ventricular contractions (PVCs), 130
treatment of, 139
Prescribing drugs, versus dispensing drugs, 23
Prescription(s), for medication, 48, 49f
Prescription diets, for sodium restricted patients, 145
Prescription drug, 2, 3-4
Preservatives, in drug formulations, 4t, 35
contraindications to, in fluid therapy for cats or dogs, 314TN
for vaccines, 35TN, 349
Pressure administration cuff, 309, 309f
Prevacid (lansoprazole), 160
Preventic Tick Collar for Dogs, 274
Preventive health programs. See Vaccination(s).
Previcox Chewable Tablets (firocoxib), 286
Prilosec (omeprazole), 160
Primary hypothyroidism, 173, 185
Primaterne (ephedrine), 110
Primidone, for seizure prevention, and control, 89
Primor Tablets, 241
Pro-Banthine (propantheline), 79, 122, 157, 162
Pro-Bute (phenylbutazone), 283
Probanicid, 231
Probiotics, 168
Procainamide, 139
Procainamide derivatives, as antiemetics, 139, 275
Procaaine HCl, 294
Procarbazone, for chemotherapy, 340t, 342
Prochlorperazine as antiemetic, 156
and isopropamide, 82, 156
Procrit (epoetin alpha), 124, 328
Prodine solution, 221
Productive cough, 102, 105
as indication for expectorant, 105
Proestrous, 176
Profenital (suprofen), 203
Profender (emodepside/praziquantel), 264
Progestosterone as hyperglycemic agent, 189-190
in promoting weight gain in ruminants, 190-191
Progestrone/estradiol implant, 190-191
Progestins, 179-180, 180TN
Propylhexil (diazoxide), 189-190
Program 6 Month Injectable for Cats, 271
Program Suspension, 271
Program Tablets, 271
ProHeart (moxidectin), 266t, 267, 268TN
Prokinetics and stimulants, gastrointestinal, 164-165
acetylcholinesterase inhibitors, 166
cholinergics, 78, 165-166
dopaminergic antagonists, 165
motilin-like drugs, 165
serotonergic agents, 165
Prolacis Paste, 168
Prolactin (LTH), 174
Prolamine (phenylpropanolamine), 80
Promace (acepromazine maleate), 82
Promazine HCl, 82
ProMeris (metllumizone), 272
ProMeris Duo (metllumizone/amitraz), 272
Promethazine, 289
as antiemetic in motion sickness, 157
with dextromethorphan, 108
Pronestyl (procainamide hydrochloride), 139
Propanion, 168
Propantheline, 79
action of, and indications, 126t
as antiemetic, 157
in promoting urine retention, 122
for treatment of diarrhea, 162
Proparacaine hydrochloride, 201, 201TN
Propionibacterium acnes, 344, 365t, 366
Propionic acid derivatives, 284-285
Propoflo (propofol), 93
Propofol, 92-93, 93TN
Proportion(s) calculations involving, 54
problems using, 63
Propoxur, 273
Propranolol, 81
for cardiac arrhythmias, 140
contraindication to, in overt heart failure, 140TN
for hypertension in renal insufficiency, 122
precautions in discontinuation of therapy with, 140TN
preoperative administration of, to cats, 186
Proprietary name of drug, 17
Propulsid (cisapride), 165
Propylene glycol, as topical antiseptic, 217
Propylthiouracil, 186
Prostaglandin(s), 180-182, 278, 279, 291
and influence on gastrointestinal system, 154
for stimulation of uterine contractions, 183
topical, for treatment of glaucoma, 200
Prostaglandin E-1 analogs, 161
ProstaMate (dinoprostone tromethamine), 181
Prostigmine (neostigmine), 78-79
Protamine sulfate, 332
Protectants gastrointestinal, 162-163
in wound dressing, 220, 220TN
Protective reflexes, of upper respiratory tract, 104
Protease-Bb vaccine, 351
Proton pump inhibitors, 160
Protomox (praladoxime), 79, 378
Protozoal infections, 264
drugs effective against, 167, 264-265
Proudfoot, 223
Proventil (albuterol), 80, 109
Provera tablets (medroxyprogesterone acetate), 180
Prozac (fluoxetine), 96
PRT (Phenol Red Thread) test, 202
Pruritis, 211, 288
antihistamines for, 288-289, 289TN
fatty acid supplements for, 221-222
phenothiazine derivatives for, 82
topical medications for, 216-217
Pseudoephedrine, as decongestant, 110
Psyllium preparations, 163-164
Pupil dilation, cholinergic blocking agents for, 79
Purina Cattle Dust, 273
Purina Veterinary Diets DH, 168
Pustular dermatitis, superficial, antiseborrheic agents for, 214t, 215
Pybem Gel and Shampoo, 215
Pyoderma, 211
deep, antiseborrheic agents for, 214t, 215
Pyopen (carbenicillin), 231
Pyramet pamoate, 261-262
Pyranter tetract, 261-262
Pyrazolone derivatives, 282-283, 283TN
Pyrethrins for flea and tick control, 272
for ectoparasites, 207
synergists with, 274, 274TN
Pyrethroids, synthetic, for flea and tick control, 273, 274TN
synergists with, 274, 274TN
Pyridostigmine, 79
Pyrilamine maleate, preparations of, 110, 289
Pyrogen, 279
PZI (Protamine Zinc Insulin), 188-189
PZI Vet, 188-189, 188t
Q
Q-Cide, 247
Quarternary ammonium compounds, disinfectants, 245t, 247
Quest 2% Equine Oral Gel (moxidectin), 262
Quinaglute DuraTabs (quinidine gluconate), 138
Quinindex Extentabs (quinidine sulfate), 138
Quinidine, 138
dosage reduction, in animals being treated with digoxin, 138TN
Quinora (quinidine sulfate), 138
Rabies control, information resource on, 415f
Rabies vaccine, and vaccination certificate of, 398f
record keeping of, 397
Raboral V-RG vaccine, 352
Radioactive iodine, in treatment of hyperthyroidism, 186
Ralgro beef cattle implant (zeralol), 191
Ralgro feedlot lamb implant (zeralol), 191
Ranitidine, 159, 166, 289
advantage of, over cimetidine, 159TN
Rapinovet (propofol), 93
Ratio(s)
calculations involving, 54
problems using, 63
Re-Sorb, 319
Receptor(s), 73
on cell membrane, 13-14, 15f
in effector organs, 77-78
Recombinant DNA technology, 349, 352
Recombinant interferon, 244, 343
Recombinant vaccines, 352
Reconcile (fluoxetine), 96
Reconstitution, of medication with preservatives, precautions in,
35TN
procedure for, 29, 31f
ReCovr (tripelennamine HCl), 110, 289
Reduction, chemical, 11
Reflex arc, 73-75, 74f
Regimen, 2
details of, 3
Regional anesthesia, 278
Reglan (metoclopramide), 78, 156-157, 165
Regressin-V, 366
Rega-Mate (altronegest), 180
Regular insulin, 188
Regulatory agencies
for animal health products, 19-20, 20f
veterinary and animal health, 114t
Regurgitation, 150
Releasing hormones, 173, 174
Relief brand preparations, 216
Renal and urinary tract disorders, 118-120
client education about, 127
drugs used for, 114-116
Renal and urinary tract disorders (Continued)
adrenergic antagonists, 122
amitriptyline, 125-126
angiotensin converting enzyme inhibitors, 123
anticholinergic agents, 121-122
antidiuretic hormone, 123 azothy, 127
calcium channel blockers, 123
cholinergic agonists, 121
diuretics, 120-121
epikinin, 126
pentosan polysulfate sodium, 126
phenazopyridine, 125
references on, 127
review questions on, 127-128
urinary acidifiers, 123-124
urinary alkalizers, 124
vasodilators, 123
xanthine oxidase inhibitors, 124
Renal failure, 119-120
acute, fluid therapy for, 306t
chronic, fluid therapy for, 306t
pharmacotherapy for complications of, 124
Renal insufficiency, 118-119. See also Renal and urinary tract disorders.
drugs contraindicated in, 119b
drugs for therapy in, 114-116
for hypertension, 120-121, 122-123
drugs not contraindicated in, 119b
drugs requiring dosage modifications in, 119b
Renal system, and urinary tract, anatomy and physiology of,
115-119
Renin-angiotensin system, 141, 142f
Reorder log, 394, 394TN, 396f
Repellants, insect, 274
Reropolarization, of cardiac muscle cell, 130, 132, 132f
Reproduction, hormonal drugs associated with, 177-184
drugs affecting uterine contractility, 182-183
gonadotropins and gonadal hormones, 177-180
pheromones, 183-184
prostaglandins, 180-182
Reproductive system, hormonal control mechanisms of, 176-177, 176f
Research information, resources, 415t
ResiCHLOR, 218
Residue(s), 2, 13
ResiHIST, 217
ResiPROX, 217
ResiSOOTHE, 216
Resmethrin, 273
Respiratory depression, stimulant agents for, 93-94
Respiratory secretions, control of, 104-105
Respiratory system, 102-104, 103f
Respiratory system disorders. See also Respiratory therapeutics.
drugs used in, 101-102
antihistamines, 110, 288-289
antitussives, 106-108
bronchodilators, 108-110
corticosteroids, 110-111
decongestants, 110
expectorants, 105
mucolytics, 106
references on, 111
review questions on, 112-113
stimulants, 110
inhalation therapy for, 105
Respiratory therapeutics, 104-105
Restraint facilitation, 81
dissociative agents for, 86
romifidine for, 84
tranquilizers in, 82-83
xylazine hydrochloride in, 83
Reticular activating system, 74-75
Reticular formation, 74-75, 74f
Revalor S (trenbolone estradiol implant), 191
Reversal agent(s)
for alpha adrenergic agonists, 381, 381TN
for benzodiazepine overdose, flumazenil, 380-381
for medetomidine, atipamezole, 81, 84, 380, 380TN
for narcotic overdose, naloxone, 88, 89, 155TN, 381, 381TN
for xylazine overdose, 81, 381, 381TN
Reverse sneeze, 102, 104, 288
Revolution (selamectin)
for flea control, 269t, 272, 272TN
for preventing nematode infection, 266t, 268, 268TN
Rheumatoid arthritis, corticosteroid action in, 291
Rickettsial infections, tetracyclines for, 235
Rifadin Powder, 241
Rifampin, 241
Rifampin Capsules, 241
RigiCare fluid therapy bottles, 310f
Rimadyl (carprofen), 285
Ringer’s solution, 314
Ritalin (lebanet), 262
Ritrol, 319
RM Recombitek C4 vaccine, 352
RM Recombitek Lyme vaccine, 352
Robamox (amoxicillin), 231
Robaxin-V (methocarbamol), 289
Rohedine hydrochloride, 264
Robenz Type A Medicated Article, 264
Robinal-V (glycopyrrolate), 79
Robitussin-AC (guaifenesin), 105
Robitussin-DM (dextromethorphan and guaifenesin), 108
Rocaltrol, 124
Roccal-D Plus, 247
Rodenticide poisoning (anticoagulant), Vitamin K1 antidote to, 380
Roferon-A, 343
Rommicon (flumazenil), 381
Romifidine, 84
Rompun (xylazine hydrochloride), 83
Rose bengal ophthalmic stain, 202
Rotenone, 274
for ear mites, 207, 274
Round worms. See Nematodes.
Royal Canin Veterinary Diet, 168
Rubella Virus Immunomodulator, 365t
Rulox II, 160
Rumate (ramonel tetrates), 261-262
Rumen acidosis, treatment of, 160
Ruminants. See also Cattle; Sheep. hormones increasing weight gain in, 190-191
S
S-Adenosylmethionine (SAMe), 372
Safeguard (fenbendazole), 253
Salicylates, 282, 282TN
Salicylic acid, in antiseborrheic products, 213, 215TN
Saline solution compositions, 302t-303t, 313-314, 315
Saliva, excretion of metabolites in, 13
Salmetrol, as bronchodilator, 109
SAMe (S-adenosylmethionine), 372
Sandimmune (cyclosporine), 204
Sandostatin (octreotide), 189
Sapontized cresol, as disinfectant, 245t, 246-247
Sarcotic mange, selamectin in prevention of, 266t, 268, 268TN, 269t
Saturated solution, 59
Scar tissue, formation of, 218-219
Sclare Oil, 219
Schirmer Tear Test, 202
Schonauer comedo syndrome, antiseborrheic agents for, 214t, 215
Sciatic nerve, avoiding, in intramuscular injection, 39f
Scolaban (bunanudine), 263
Scopolamine, 79
SebaLyt Shampoo, 213
Sebavax Shampoo, 213
Seboretive, 211, 215
Seboretive oleosa, 211
antiseborrheic agents for, 214t, 215
Seboretive siccata, 211
antiseborrheic agents for, 214t sulfur in medications for, 213
Seboretive dermatitis, 211
systemic corticosteroids for, 220
Secretin, 153-154
Sedation, 81
in ancillary treatment of heart failure, 145
barbiturates for, 84-85
dissociative agents for, 86
opioids for, 87
tranquilizers for, 82-84
Sedazine (xylazine hydrochloride), 83
Sedivet (romifidine), 84
Segmentation, 150, 152, 153f
Seizure prevention, and control, 81
barbiturates for, 84-85, 89-90
benzodiazepine derivatives for, 82-83, 89-90
client noncompliance in failure of, 90TN
contraindicated drugs in, 90TN treatment of, 89-90
Selamectin for flea control, 269t, 272, 272TN for preventing nematode infection, 266t, 268, 268TN
Seldane (terfenadine), 110, 289
Seele Plus Medicated Shampoo, 215
Selegiline, 97
Selenium, and vitamin E, 286
Selenium sulfate, in antiseborrheic medications, 215, 215TN
Seltrol solution (diltiazem), 168
Selset (selenium and vitamin E), 286
Self licking. See Canine acral lick dermatitis; Feline psychogenic alopecia.
Selsun Blue Shampoo, 215
Selsun Shampoo, 215
Sensory neuron(s), 73
Sentinel (milbemycin oxime), 266t, 267, 267TN, 271, 271TN
Septum-Serum, 353
Septic shock, colloid solutions for, 314-315
Serevent (salmeterol), 109
Sermon (nicergoline), 122
Sernylan (phenylcyclicidine), 86
Serotonergic drugs, as gastrointestinal prokinetics, 165
Serotonin, 75
and behavioral pharmacotherapy, 95
influence of, on gastrointestinal system, 154
Serotonin receptor antagonists, as antiepileptics, 158
Serotonin reuptake inhibitors, 96
Sertraline, 96
Sevin Dust, 273
Sevoflurane (SevoFlo), 92
physical properties of, 91t
SFO4 Stannous Fluoride Gel, 168
Shampoos, for flea and tick control, 270, 270TN
Sheep, vaccinations and preventive health program for, 364-365
Shin-O-Gel, 222
Shock
hemorrhagic or endotoxic corticosteroids for, 289-292
fluid therapy for, 313-314, 315
hypovolemic or septic, colloid solutions for, 314-315
Short acting barbiturates, 84, 85
Short acting insulin, 187-188, 188TN
Sigma opiate receptors, 87
Silvadene, 208
Silver nitrate, as caustic, 223
Silver nitrate sticks, 332
Silver sulfadiazine, antibacterial and antifungal action of, 208
Simplex IV set, 45, 46f
Similic (cetodiazomine), 234
Single-dose vial, 29, 30f
Sinus bradycardia, cholinergic blocking agents for, 79
Sirolimus, 345
Skeletal muscle relaxant(s), 289
guaifenesin as, 93
methocarbamol as, 289
neuromuscular blocking agents as, 94-95
Skin, anatomy and physiology of, 211-213, 212f
Stimuli and impulse formation, in sensory neuron, 73
Stomach tube, large animal, oral administration of liquid medication, 37, 38f
Stool softeners, 164
Storage instructions, on drug labeling, 18, 50TN
Storage of drugs, appropriate, 50TN, 399
Stoxil (sidouridine), 202
Streptase (streptokinase), 333
Streptokinase, 333
Streptomycin, 236f
Stress response, 290-291
Stroke volume, of left ventricle, 130, 133
increased, as compensatory mechanism, 133
Strongid-T (pyrantel pamoate), 261-262
Struvite urolith prevention, 123-124
SU-PER Poultec, 222
SU-PER Sweat, 222
Subcutaneous (SC) injection, 7, 38, 40f
of fluid therapy, 307-308
procedure for, 41, 46
Subdural administration, 7, 8
Sublingual, 88
Succinylcholine chloride, 94
Sucrostrin (succinylcholine chloride), 94
Sucralfate, as gastromucosal protectant, 160-161, 161TN
Sudafed (pseudoephedrine), 110
Sulfd/OxyDex Shampoo, 215
Sulfabromomethazine, prohibited use of, as extralabel drug, 22
Sulfacetamide, in topical ophthalmic preparations, 203
Sulfadimethoxine, 264
prohibited use of, as extralabel drug, 22
Sulfaphthoxypyridazine, prohibited use of, as extralabel drug, 22
Sulfasalazine, for inflammatory bowel disease, 167
Sulfonamides, 241, 241TN
prohibited use of, for lactating dairy cattle, 22
Sulfur, in shampoos and ointments, 213, 213TN
SuperChar-Vet Powder and Liquid, 162
Superoxide dismutase, 372
Index

Supersaturated solution, 59
Suprofen, 203
Surfact (docusate sodium), 164
Surfactant(s), 102, 103-104
as stool softeners, 164
Surgical Absorbable Hemostate, 332
Suspension(s), 28, 29
definition of, 59
Sustain III Cattle Bolus, 241
Sweat, excretion of metabolites in, 13
Sweetening agents, 4t
Swine, vaccinations and preventive
health programs for, 364-365, 364b
Symbiosis, 251
Symbiotic relationships, 251-252
Sympathetic (adrenergic) nervous
system, 70, 72, 75
drugs acting on, 80
drugs blocking action in, 80-81
effector organs of, 75, 76f, 77f
functions of, 75
neurotransmitters of, 77
preganglionic and postganglionic
fibers of, 75, 77f
receptors of, 75, 77, 77f, 78
Sympathomimetic agents. See
Adrenergic agonists.
Symptomatic method, of drug choice, 3
Synalar Cream, 292
Synalar Otic Solution, 292
Synanthic (ofendazol), 253
Synapse(s)
in central nervous system, 73
ganglionic, 70
between neurons, 72-73, 72f
Syncro-Mate-B (noregestomet), 180
Syncurine (decamethonium), 94
Synergists, with pyrethrins, 274, 274TN
Syno-Flex, 372
Synotic (DMSO and steroid), 284
Synovex C (estradiol/progesterone
implant), 190-191
Synovex H (estradiol/testosterone
implant), 190
Synovex S (estradiol/testosterone
implant), 190-191
Synthetic progestins, in behavioral
pharmacotherapy, 97
Synthroid (levothyroxine sodium), 184
Syringe(s), 32b-33b
needle attached to, 32f
reading medication amount in, 33b,
33f-34f
tips available on, 32f
Syrup(s), 29
Syrup of ipecac, 155, 155TN
T
T-61 (euthanasia agent), 97
T3 (lethynorine sodium), 185
T4 (levothyroxine sodium), 184-185
Tablet(s), 28-29, 29f
coating, with palatable substances,
37TN
oral administration, to dogs and
cats, 36-37, 36f, 37f
scored or unscored, 28, 29f
Tachyarrhythmia(s), 130, 134, 138
Tachycardia, 130
Tacrolimus, 345
Tagamet (cimetidine), 159
Tail gland hyperplasia, 215
Tactic, 274
Talwin (pentazocine), 88
Talwin-V (pentazocine), 88, 287
Tamisol, 217
Tanni-Gel, 217
Tapazole (methimazole), 185
Tapeworms. See Cestodes.
Task (dichlorvos), 261
Tavist (clemastine), 110
Tazicel (ceftazidime), 234
Tazidime (ceftazidime), 234
TBW (total body water), 299-300
TBZ (thiabendazole), 235
T.D.N. MiniRockets, 168
T.D.N. Rockets, 168
Teat Infusion Cannula, for oral
administration of liquid
medication, 38TN
Tegopen (cloxacillin), 231
Telazol (tiletamine HCl), 86
Telmin (mebendazole), 253
Telminic (mebendazole), 253
Telodendra, 72, 72f
Temaril-P (trimetrazine and
prednisolone), 108, 111
Temaril-P Tablets, 292
Temperature equivalents, Fahrenheit/
Celsius, 412T
Tempra (acetaminophen), 284
Tenormin (atenolol), 140
Tensilon (edrophonium), 78
Tepoxalin, 286
Terbutaline, 80
as bronchodilator, 109
Terfenadine, 110, 289
Terminal bronchioles, 103f
Terminator, 273
Terramycin dosage forms, 235
Testosterone
for weight gain in ruminants,
190-191
in weight gain products,
classification as controlled
substance, 179TN
Testosterone cypionate, 178-179
action of, and indications, 126t
Testosterone enanthate, 124, 178-179
Testosterone propionate, 178-179
action of, and indications, 126t
Tetanus antitoxin, 353
Tetracaine, and tetracaine
hydrochloride
antimicrobial activity of, 201TN
injectable preparations of, 295
as topical ophthalmic anesthetics,
201
Tetracycline, 235, 235t
Tetracycline preparations, 234-236,
235t
administration notes on, 236TN
adverse effects of, 235, 236TN
clinical uses of, 235
contraindication to, in horses,
236TN
pharmacodynamics of, 234-235
pharmacokinetics of, 234
Tetrahydropryrimidines, 261-262,
262TN
Tetrathrombin, 273
Thalamus, 74, 74f
Theo-Dur (theophylline), 109
Theophylline, 109-110
interaction of, with other
commonly used drugs, 110TN
Therabloat, 167
Therapeutic drug monitoring, 6
information resources for, 414t
Therapeutic index, of drug, 14
Thiabendazole, 235
Thiamine hydrochloride (vitamin
B1), 320, 380
Thiazide diuretics, 144
for hypertension associated with
renal dysfunction, 120
precaution in use, in crossing
placental barrier, 120TN
Thickening agents, 4t
Thimerosal, 248
Thiobarbiturates, 84-85, 85TN
Thiola (tiopronin tablets), 124
Thiopental, 85
classification of, and duration of
action, 85t
Thoracocentesis, in ancillary treatment of heart failure, 145
Thorazine (chlorpromazine), 82, 156
Thorazine Sapsule, 156
Three-way valves, operation of, 312, 313f
Thrombocytopenia, 326, 330
Thromboembolism, 326, 330
Thrombogen Topical Thrombin Solution, 332
Thrombolytic drugs, 333
Thromoxane, 332
Thrombus, 326
Thuja-Zinc Oxide Ointment, 220
Thyro-Form (levothyroxine sodium), 184
Thyro-L (levothyroxine sodium), 184
Thyro-Tab (levothyroxine sodium), 184
Thyroid hormones, 184-186
for hyperthyroidism, 185-186
for hypothyroidism, 184-185
regulatory actions of, 184
Thyroid stimulating hormone (TSH), 174-175, 185
target and actions of, 175t
Thyrotropin, 185
Thyroxyne, 184
Thyroxine Tablets (levothyroxine sodium), 184
Thytopar (thytropin), 185
Ticarcillin, 231t
dosage forms of, 232
Ticks, 268
ear, medications for, 207
environmental control products for, 270-271
insecticides effective against, 272-275
monthly application products for controlling, 271-272
prediluted sprays for, 268, 270, 270TN
products for, comparison of, 269t
removing, client education about, 207TN
Tigan (trimethobenzamide HCI), 157
Tiletamine HCI, 86, 86TN
Timolol maleate, 81
contraindications to use of, 199TN
for treatment of glaucoma, 199
Timoptic (timolol maleate), 81, 199
Triprostin tablets, 124
Tissuemend, 220
Tobramycin, 236f
in topical preparation for conjunctivitis, 203
Tocainide, for arrhythmias, 139
Tofranil (imipramine), 96
Tolazoline, 381, 381TN
Tolnaftate cream, 221
Tonicity, of body fluids, 301, 304
Topical anesthetics, ophthalmic, 201
Topical corticosteroids, 292
Topical hemostatic agents, 332
Topical medications application of, 8, 47-48
formulations for, 35
Topical wound spray, 218
Torbugesic (butorphanol), 87-88, 106, 287
Torbutrol (butorphanol), 87-88, 106, 287
Total body water (TBW), 299-300, 300f
Total nutrient admixture (TNA), 299, 319
Total parenteral nutrition (TPN), 319
Toxican preparations, 162, 376
Toxoid vaccines, 352-353
Trachea. See Respiratory system.
Tracrium (atracurium), 95
Trade name, of drug, and location on label, 17
Traditional Chinese Medicine (TCM), 373
Tramadol, 287
Tramisol (levamisole), 262
Tranquillizer(s), 82-84
as alpha blockers, 81
benzodiazepine derivative, 82-83
detomidine, 83
medetomidine, 84
phenothiazine derivative, 82
romifidine, 84
xylazine, 83
D-trans allethrin, 273
Transcellular fluid, 299
Transdermal administration, of drug, 278
Transduction, of noxious stimuli, 278, 279-280, 280f
Travoprost (Travatan), 200
Trematodes, 251
drugs effective against, 263-264
Trenbolone estradiol implant, 190-191
Trenbolone implant, 190-191
Tresaderm, 206, 207
Tri-Otic, 206
Triamcinolone, for allergic respiratory conditions, 111
Triamcinolone Tablets, 292
Triamino Expectorant (guaifenesin), 105
Triamterene, 121
Tribrissen 48% Injection, 241
Trichlorfon, 261
Tricyclic antidepressants, 96
for behavior modification aids in skin disorders, 223
for pain relief, 288
Trifluridine, 202
Trimeprazine tartrate, and corticosteroid, 108
Trimethobenzamide HCI, as antihemotic in motion sickness, 157
Tripelennamine HCI, 110, 289
Tris-EDTA, 208
Triton, 206
Trophic hormones, 173, 174
Tropicacyl (tropicamide), 198
Tropicamide, as mydriatic agent, 198
Trovac-AIV H5 vaccine, 352
Trusopt (dorzolamide), 199
TSH. See Thyroid stimulating hormone.
Tuberculin syringe, 32b-33b
with needle attached, 32f
d-Tubocurarine chloride, 94
Tubular reabsorption, 12, 116, 118, 118f
Tubular secretion, 116, 118, 118f
of drug metabolites, 12, 12f, 118
Tulathromycin, 239
Tunil-K, 319
Tumor, definition of, 333
Turgor, 299
Tussigon (hydrocodone bitartrate), 88
Tylan, 239
Tylenol (acetaminophen), 284
Tylenol with Codeine, 287
Tylocine, 239
Tyllosin, 239
Tyloxin, for chronic colitis, 167TN
Type I recombinant vaccines, 352
Type II recombinant vaccines, 352
Type III recombinant vaccines, 352
U
U/ml (units of insulin per milliliter), 187
Ulcers. See Gastric ulcers.
Ultrasound acting barbiturates, 85
United States Pharmacopeia (USP) logo of, 371f
web site of, 372
Unknown quantity (X), 55
Upper motor neurons, 115
lesions of, in spastic neuropathic bladder, 125
Upper respiratory system, 102-103
Upper respiratory tract, physiology of, 103
Urecholine (berthanelchol), 78, 121
Uremia, 115, 119
Urethral obstruction, fluid therapy for, 306t
Urethral sphincter, hypertonus of, 122
Urinary acidifiers, 123-124
and acidifying diets, precautions for clients about, 124TN
Urinary alkalizers, 124
Urinary bladder. See also Renal system, and urinary tract:
neurogenic and nonneurogenic disorders of, 125
Urinary incontinence, 115, 125
drugs for management of, 125, 126t
anticholinergic, 121-122
neurogenic and nonneurogenic causes of, 125
Urinary obstruction, functional alpha adrenergic agents for, 122,
125
feline, phenoxybenzamine for, 81, 122
Urinary output, agents increasing, 121
Urinary retention, 125
alpha adrenergic agents for, 122
cholinergic agents for, 78, 121
Urinary tract analgesics, 125
Urinary tract infection, 115
ruling out, in urinary incontinence, 125
Urine, formation of, 116-119, 117f
Uroct K (potassium citrate), 124
Uroeez (ammonium chloride), 123
Urogenital system
of bull, 116f
of female dog, 115f
of male cat, 116f
of male dog, 116f
Urokinase, 333
Urolithiasis, drugs for management of, 123-124
Urticaria, with acute allergic reactions, 288
U.S. Dept. of Agriculture (USDA), 414t
and regulation of animal health products, 19-20, 20f
review of new drug application by, 21
Uterine contractility, drugs affecting, 182-183
Uvea, 196
Uveitis, 196
corticosteroid action in, 291
homatropine hydrobromide for, 198
V
Vaccination(s), 349-350, 350f
administration of vaccine in, 46, 350, 350f, 354
adverse responses to, 355-356
client education about, 349, 355
of food animals, 350, 354
information resources on, 415t
in preventive health programs, 356-365
beef cattle, 361b-362b
bovine, 358, 363-364
canine, 356, 357b-358b
dairy cattle, 363b
equine, 356, 359b
feline, 356, 358, 360b-361b
poultry, 364
sheep, 364
small ruminants, 364-365
swine, 364-365, 364b
protocols for, 350
purposes of, 349
references on, 366
review questions on, 367-368
sarcomas associated with, 350
and transfer of antibodies to offspring, 349
Vaccine(s), 349
for active immunity, 351-353
administration of, 46, 350, 350f, 354
antitoxin, 353
appropriate handling and storage of, 355
autogenous, 353
inactivated, 351
live, 351
mixed, 353-354
modified live, 351-352
for passive immunity, 353
recombinant, 352
reconstitution of, 354
references on, 366
review questions on, 367-368
toxoid, 352-353
Vaccines
information resources about, 415t
Valacyclovir, 244
Valbazen (albendazole), 253, 264
Valium (diazepam), 82-83, 89, 95-96
Valvular disease, of heart, 133-134
Vancill (beclomethasone dipropionate), 111
Vancomycin, 240
Vapona (dichlorvos), 273
Vapor pressure, of anesthetic gas, 90
Vasoconstriction, adrenergic agents promoting, 80
Vasodilators, 81
action of, in heart failure, 141
for hypertension in cardiovascular disease, 141-143
for hypertension in renal insufficiency, 123
Vasopressin, 175
for polydipsia and polyuria in diabetes insipidus, 123
target and actions of, 175t
Vasotec injection, for IV use, 143
Vasotec tablets, 143
Vatrolon (ephedrine), 80
Vazepam (diazepam), 82-83
VCPR. See Veterinarian-client-patient relationship.
Vecuronium bromide, 95
Vedalyte 8X, 319
Velosef (cephradine), 234
Ventilation, 104
intermittent positive pressure, 105
Ventipulmin syrup (clenbuterol), 109
Ventolin (albuterol), 109
Venpamyl
for arrhythmias, 141
for hypertension in renal insufficiency, 123
Versed (midazolam), 82
Vesicant(s), 222-223, 326
Vesication, 222-223
Vet-Shield 72, 202
Vetalog (Ketamine HCl), 86
Vetalog, 111, 220
Vetalog Cream, 217, 292
Vetalog Oral Powder/Tablets, 292
Vetalog Parenteral, 292
Vetaplasma (oxytocin gelatin), 315
Veterinarian-client-patient relationship (VCPR), 2
conditions of, 4
educational aspects of, 50. See also Client education.
validity of, in prescribing controlled substances, 420
Veterinary associations, 414t
<table>
<thead>
<tr>
<th>Index</th>
<th>481</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veterinary Feed Directive, 23</td>
<td>Volume control system, in fluid therapy administration, 310, 311f, 312f</td>
</tr>
<tr>
<td>Veterinary pharmaceutic companies, 416t</td>
<td>Volume equivalents, metric-apothecary, 58h, 412t</td>
</tr>
<tr>
<td>Veterinary supply distributors, 403-404</td>
<td>Volume-per-volume (v/v) expression, of drug concentration, 59</td>
</tr>
<tr>
<td>Veterinary technician</td>
<td>Volume units, in metric system, 55t</td>
</tr>
<tr>
<td>drug administration by, 5</td>
<td>Voluntary control, of nervous system, 71</td>
</tr>
<tr>
<td>education of about drugs and drug administration, 50</td>
<td>Vernicrinine, 339t, 341</td>
</tr>
<tr>
<td>resources for, 414t</td>
<td>Vio okase -V powder (pancrelipase), 166</td>
</tr>
<tr>
<td>importance of, in veterinary medicine, 2. See also Client education.</td>
<td>VIP Flea Control Shampoo, 275</td>
</tr>
<tr>
<td>Vetmedin Chewable Tablets (pimobendan), 137</td>
<td>VIP Flea Dip, 275</td>
</tr>
<tr>
<td>Vetropolyvin (verapamil), 203</td>
<td>VIPPS, 24</td>
</tr>
<tr>
<td>Vetsulin, 188-189, 188et</td>
<td>Viroptic ophthalmic solution (trifluridine), 202</td>
</tr>
<tr>
<td>Vial(s), single dose and multidose, 29, 30f</td>
<td>Virosol solution, 247</td>
</tr>
<tr>
<td>Vibiben, 339t, 341</td>
<td>Virulence, of infectious agent, 349, 351</td>
</tr>
<tr>
<td>Vibramycin (doxycycline), 235</td>
<td>Viscidility, of secretion, 102, 105</td>
</tr>
<tr>
<td>Vinblastine, 339t, 341</td>
<td>Vitamin(s)</td>
</tr>
<tr>
<td>Vincristine, 339t, 341</td>
<td>fat-soluble, 321</td>
</tr>
<tr>
<td>Vinorelbine, 339t, 341</td>
<td>water-soluble, 320-321</td>
</tr>
<tr>
<td>Viookase -V powder (pancrelipase), 166</td>
<td>Vitamin B complex, 320, 320TN</td>
</tr>
<tr>
<td>VIP Flea Control Shampoo, 275</td>
<td>Vitamin B1, 320</td>
</tr>
<tr>
<td>VIP Flea Dip, 275</td>
<td>Vitamin B12, 320-321</td>
</tr>
<tr>
<td>VIPPS, 24</td>
<td>Vitamin D, 321</td>
</tr>
<tr>
<td>Viroptic ophthalmic solution (trifluridine), 202</td>
<td>Vitamin D supplements, 124</td>
</tr>
<tr>
<td>Virosol solution, 247</td>
<td>Vitamin E, 321</td>
</tr>
<tr>
<td>Virulence, of infectious agent, 349, 351</td>
<td>Vitamin K, 321</td>
</tr>
<tr>
<td>Viscidility, of secretion, 102, 105</td>
<td>Vitamin K1, 333, 333TN</td>
</tr>
<tr>
<td>Vitamin(s)</td>
<td>as antidote to anticoagulant rodenticide poisoning, 380</td>
</tr>
<tr>
<td>fat-soluble, 321</td>
<td>as antidote to coumarin derivatives, 331TN</td>
</tr>
<tr>
<td>water-soluble, 320-321</td>
<td>Vitamin/mineral products, parenteral, 319-320</td>
</tr>
<tr>
<td>Vitamin B complex, 320, 320TN</td>
<td>Voice production, 104</td>
</tr>
<tr>
<td>Vitamin B1, 320</td>
<td>Voltaren (diclofenac sodium), 203</td>
</tr>
<tr>
<td>Vitamin B12, 320-321</td>
<td>Wildnil (carfentanil), 88</td>
</tr>
<tr>
<td>Vitamin D, 321</td>
<td>WinGel, 160</td>
</tr>
<tr>
<td>Vitamin D supplements, 124</td>
<td>Winstrol-V (stanozolol), 191, 328</td>
</tr>
<tr>
<td>Vitamin E, 321</td>
<td>Withdrawal time, 2</td>
</tr>
<tr>
<td>Vitamin K, 321</td>
<td>Wound cleansers, 219-220</td>
</tr>
<tr>
<td>Vitamin K1, 333, 333TN</td>
<td>precautions in administration of, 220TN</td>
</tr>
<tr>
<td>as antidote to anticoagulant rodenticide poisoning, 380</td>
<td>Wound dressings, topical, 219</td>
</tr>
<tr>
<td>as antidote to coumarin derivatives, 331TN</td>
<td>Wound healing, 218-219</td>
</tr>
<tr>
<td>as antidote to anticoagulant rodenticide poisoning, 380</td>
<td>Xanxan (alprazolam), 82-83, 95-96</td>
</tr>
<tr>
<td>as antidote to coumarin derivatives, 331TN</td>
<td>Xanthine oxidase inhibitors, 124</td>
</tr>
<tr>
<td>as antidote to coumarin derivatives, 331TN</td>
<td>Xenodine Spray, 218</td>
</tr>
<tr>
<td>as antidote to anticoagulant rodenticide poisoning, 380</td>
<td>Xenodyne, 208</td>
</tr>
<tr>
<td>as antidote to anticoagulant rodenticide poisoning, 380</td>
<td>Xylazine, and butorphanol, as neuroleptanalgesic, 89</td>
</tr>
<tr>
<td>Xylazine hydrochloride, 83</td>
<td>Xylazine hydrochloride, 83</td>
</tr>
<tr>
<td>concentrations of, for large and small animals, 83TN</td>
<td>as emetic, 83, 155</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>extralabel use of, 83</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>tolazoline as antidote to, 381, 381TN</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>yohimbine as antidote to, 81, 381, 381TN</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Z</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zanact (ranitidine), 159</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zeniquin (marbofloxacin), 238</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zeranol, for weight gain in ruminants, 190-191</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zeranol implant, 190-191</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zinc Oxide, and healing stimulus, 219</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zithromax (azithromycin), 239</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zofran (ondansetron), 158</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zoloft (sertraline), 96</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zoonotic parasites, 252</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zovirax (acyclovir), 244</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zubrin (trexoxalin), 286</td>
</tr>
<tr>
<td>as emetic, 83, 155</td>
<td>Zyloprim (allopurinol), 124</td>
</tr>
</tbody>
</table>
This page intentionally left blank